<SEC-DOCUMENT>0001829126-25-007608.txt : 20250923
<SEC-HEADER>0001829126-25-007608.hdr.sgml : 20250923
<ACCEPTANCE-DATETIME>20250923163057
ACCESSION NUMBER:		0001829126-25-007608
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		22
CONFORMED PERIOD OF REPORT:	20251016
FILED AS OF DATE:		20250923
DATE AS OF CHANGE:		20250923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NovaBay Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001389545
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				680454536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33678
		FILM NUMBER:		251334000

	BUSINESS ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 899-8800

	MAIL ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>novabay_def14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CIK0001389545="http://CIK0001389545/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_ECD%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_CIK0001389545_CIK0001389545_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001389545 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:EntityCentralIndexKey">0001389545</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0010" name="dei:DocumentType">DEF 14A</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cik0001389545-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PEOAddEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PEOAddEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PEOAddEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NEOAddEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NEOAddEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NEOAddEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PEOTotalEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PEOTotalEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PEOTotalEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NEOTotalEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NEOTotalEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NEOTotalEquityAwardAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_90A_edei--DocumentType_dxL_c20240101__20241231_zBls0Nu6vZv3" title="::XDX::DEF%2014A"><span style="-sec-ix-hidden: xdx2ixbrl0010">SCHEDULE 14A</span></span> INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Proxy Statement Pursuant to Section&#160;14(a) of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Amendment No.&#160;&#160;&#160;&#160;&#160;&#160;)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Filed by the Registrant &#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Filed by a Party other than the Registrant &#9744; </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&#9744;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Preliminary Proxy Statement</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&#9744;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Confidential, For Use of the Commission Only (as permitted by Rule&#160;14a-6(e)(2))</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&#9746;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Definitive Proxy Statement</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&#9744;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Definitive Additional Materials</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&#9744;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Soliciting Material Pursuant to &#167; 240.14a-12</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20240101__20241231_zDi4AbwAZgB8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000011" name="dei:EntityRegistrantName">NOVABAY PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name of Registrant as Specified in Its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Payment of Filing Fee (Check the appropriate box):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&#9746;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">No fee required</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&#9744;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Fee paid previously with preliminary materials</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&#9744;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules&#160;14a-6(i)(1) and 0-11</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img src="img_001.jpg" alt="" style="height: 66px; width: 350px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2000 Powell Street, Suite 1150</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Emeryville, California 94608</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: small-caps 14pt Times New Roman, Times, Serif"><b>Notice of 2025 Annual Meeting of Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 25%; vertical-align: bottom"><b><span style="text-decoration: underline">Date</span>:</b></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 25%; vertical-align: bottom"><b><span style="text-decoration: underline">Time</span>:</b></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; vertical-align: bottom"><b><span style="text-decoration: underline">Place</span>:</b></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>October&#160;16, 2025</b></p> </td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><b>11:00 a.m. PDT</b></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><b>Virtual meeting at:<br/> </b>www.virtualshareholdermeeting.com/NBY2025</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Stockholders of NovaBay Pharmaceuticals, Inc.:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You are cordially invited to attend the 2025 Annual Meeting of Stockholders (the &#8220;<b><i>Annual Meeting</i></b>&#8221;) of NovaBay Pharmaceuticals, Inc., a Delaware corporation (&#8220;<b><i>NovaBay</i></b>,&#8221; the &#8220;<b><i>Company</i></b>&#8221;, &#8220;<b><i>we</i></b>,&#8221; &#8220;<b><i>our</i></b>&#8221; and &#8220;<b><i>us</i></b>&#8221;). Stockholders will be able to participate in the Annual Meeting and to vote and submit questions during the virtual meeting by visiting www.virtualshareholdermeeting.com/NBY2025. The Annual Meeting will be held for the purpose of stockholders voting upon the following proposals, each of which are described in the accompanying proxy statement (&#8220;<b><i>Proxy Statement</i></b>&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(1)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To elect three (3) Class III directors nominated by our Board of Directors to hold office for a term of three (3) years or until their respective successors are elected and qualified or until their earlier resignation (including upon the Resignation Event, as defined and described in the Proxy Statement, occurring) or removal. The nominees for election are Dr. Paul E. Freiman, Mr.&#160;David E. Lazar and Ms. Swan Sit (&#8220;<b><i>Proposal One</i></b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(2)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement (&#8220;<b><i>Proposal Two</i></b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(3)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers (&#8220;<b><i>Proposal Three</i></b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(4)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To ratify the appointment by our Audit Committee of WithumSmith+Brown, PC as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2025 (&#8220;<b><i>Proposal Four</i></b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(5)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To approve, as required by, and in accordance with, Sections&#160;713(a) and 713(b) of the NYSE American Company Guide, both (i) the issuance of an aggregate of 77,000,000 shares of common stock, par value $0.01 per share (&#8220;<b><i>Common Stock</i></b>&#8221;), upon the conversion of the 481,250 shares of our Series D Preferred Stock that were issued in the First Closing of the Investment Transaction and (ii) the issuance of an aggregate of 43,000,000 shares of Common Stock upon conversion of the 268,750 shares of our Series E Preferred Stock that are expected to be issued in the Final Closing of the Investment Transaction (with terms defined below and in the accompanying Proxy Statement), both issuances subject to the potential increase in the number of underlying conversion shares due to applicable anti-dilution adjustments (&#8220;<b><i>Proposal Five</i></b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(6)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To amend the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (the &#8220;<b><i>2017 Omnibus Plan</i></b>&#8221;) to increase the shares authorized under the 2017 Omnibus Plan by 1,000,000 shares of Common Stock resulting in a maximum number of shares currently available for issuance of 1,021,332 shares of Common Stock and to make corresponding changes to the share grant limitations in the 2017 Omnibus Plan (&#8220;<b><i>Proposal Six</i></b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(7)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To approve the issuance and payment of the Equity Consideration, comprised of newly-issued shares of restricted Common Stock with an aggregate value of $40,000, at a price per share which may be below the market price (as reported by the NYSE American) on the date of issuance, to each of the Resigning Non-Employee Directors as contemplated by the Release Agreements (as discussed and terms defined in the Proxy Statement) (the &#8220;<b><i>Proposal Seven</i></b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(8)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To approve an amendment to our Certificate of Incorporation that will effect a reverse stock split of all of our Common Stock issued and outstanding, or held in treasury, at a ratio of not less than 1-for-2 and not more than 1-for-10 (the &#8220;<b><i>Reverse Stock Split</i></b>&#8221;), and to grant authorization to our Board of Directors to determine, in its sole discretion, the specific ratio at any whole number within such share range and the timing of the Reverse Stock Split becoming effective or to otherwise decide to abandon the Reverse Stock Split (&#8220;<b><i>Proposal Eight</i></b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(9)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the &#8220;<b><i>Certificate of Incorporation</i></b>&#8221;), to increase the number of authorized shares of our Common Stock from 150,000,000 to 1,500,000,000 (&#8220;<b><i>Proposal Nine</i></b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(10)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our preferred stock, par value $0.01, from 5,000,000 to 10,000,000 (&#8220;<b><i>Proposal Ten</i></b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(11)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To grant discretionary authority to the Board of Directors to adjourn the Annual Meeting from time to time, if necessary or appropriate, to establish a quorum or, even if a quorum is present, to permit further solicitation of proxies if there are not sufficient votes cast at the time of the Annual Meeting or after any adjournment in favor of any of the Proposals (as defined below) (&#8220;<b><i>Proposal Eleven</i></b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in; text-align: left; text-indent: 0in; vertical-align: top">(12)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">To transact any other business that may properly come before the Annual Meeting.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Proposal One (Election of Directors), Proposal Two (Say-on-Pay), Proposal Three (Say-on-Frequency), Proposal Four (Ratification of the Selection of the Independent Registered Public Accounting Firm), Proposal Five (NYSE American Proposal), Proposal Six (2017 Omnibus Plan Proposal), Proposal Seven (Director Equity Consideration Proposal), Proposal Eight (Reverse Stock Split Proposal), Proposal Nine (Common Stock Authorization Proposal), Proposal Ten (Preferred Stock Authorization Proposal) and Proposal Eleven (Adjournment) are collectively referred to as the &#8220;<b><i>Proposals</i></b>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August&#160;19, 2025, we entered into a Securities Purchase Agreement (the &#8220;<b><i>Purchase Agreement</i></b>&#8221;) with David E. Lazar (&#8220;<b><i>Mr.&#160;Lazar</i></b>&#8221;) that provides for an investment by Mr.&#160;Lazar in two separate closings of up to $6.0 million in the aggregate in exchange for newly issued shares of Company preferred stock (the &#8220;<b><i>Investment Transaction</i></b>&#8221;). On the date the Purchase Agreement was entered into, Mr.&#160;Lazar completed the purchase of 481,250 shares of the Company&#8217;s Series D non-voting convertible preferred stock, par value $0.01 per share (the &#8220;<b><i>Series D Preferred Stock</i></b>&#8221;), resulting in aggregate gross proceeds to us of $3.85 million (the &#8220;<b><i>First Closing</i></b>&#8221;). The Purchase Agreement contemplates that Mr.&#160;Lazar will separately purchase 268,750 shares of the Company&#8217;s Series E non-voting convertible preferred stock, par value $0.01 per share (the &#8220;<b><i>Series E Preferred Stock</i></b>&#8221;), resulting in additional aggregate gross proceeds of $2.15 million, which are contemplated to be issued in a second closing that is subject to receiving approval of Proposal Five (NYSE American Proposal) and the satisfaction of certain other closing conditions (the &#8220;<b><i>Final Closing</i></b>&#8221;). In addition to the Proposals customarily included by the Company for its Annual Meetings of Stockholders, there are several other Proposals (Proposals Five through Eleven) that are also being presented at this Annual Meeting for stockholders to vote upon that relate to the Investment Transaction, which we agreed to present pursuant to the Purchase Agreement, as further described in the accompanying Proxy Statement. Approval of these Proposals will be important in order for the Company to complete the Final Closing and to pursue the growth of its business, including pursuing a Post-Investment Transaction, as further described in the accompanying Proxy Statement. We have included certain material information regarding the Investment Transaction and the related transactions in the accompanying Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We encourage you to read the Proxy Statement in its entirety and the other documents to which we have referred you to in the Proxy Statement before voting. <b>After careful consideration, the NovaBay Board of Directors has determined that all eleven of the Proposals are advisable and in the best interests of NovaBay and its stockholders and recommends that the holders of Common Stock and the Series F Voting Retractable Preferred Stock entitled to vote with respect to each of the Proposals, vote or give instruction to vote &#8220;FOR&#8221; each of the director nominees in Proposal One, &#8220;FOR&#8221; Proposal Two, &#8220;THREE YEARS&#8221; for Proposal Three and &#8220;FOR&#8221; Proposal Four through Proposal Eleven.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You may attend the Annual Meeting online, vote your shares electronically, and submit questions during the Annual Meeting by visiting www.virtualshareholdermeeting.com/NBY2025 and entering the 16-digit control number included in your proxy card or the voting information form provided by your bank or broker. Prior to the Annual Meeting, you can vote at www.proxyvote.com using your 16-digit control number or by the other methods described in the Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The record date for the Annual Meeting is September&#160;22, 2025. Only stockholders of record at the close of business on that date are entitled to notice of, and may vote at, the virtual Annual Meeting or any adjournment or postponement thereof. This Notice of Annual Meeting and the Proxy Statement are being distributed and made available on or about September&#160;23, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A list of stockholders entitled to vote at the Annual Meeting will be available at NovaBay Pharmaceuticals, Inc., 2000 Powell Street, Suite 1150, Emeryville, California 94608, for a period of ten (10) days prior to the Annual Meeting. If you would like to inspect the stockholder list, please contact our Corporate Secretary at (510) 899-8800. The stockholder list will also be available during the virtual Annual Meeting through the following secure link www.virtualshareholdermeeting.com/NBY2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 50%">September&#160;23, 2025</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 50%">By Order of the Board of Directors,</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"/> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">/s/ Paul E. Freiman</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Paul E. Freiman</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><i>Chair of the Board of Directors</i></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 100%; text-align: center; vertical-align: middle"><span style="font: small-caps 14pt Times New Roman, Times, Serif; color: #1F4E79"><b>Table of Contents</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Page</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; width: 90%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS</a></span></td>
    <td style="padding-bottom: 1pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">SUMMARY OF THE PROXY STATEMENT</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">About NovaBay</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Recent Developments&#8212;NovaBay Strategic Direction</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Corporate Governance Highlights</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Corporate Governance Policies</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Compensation Highlights</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Proposals at this Annual Meeting Which Require Your Vote</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Voting Generally</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Proposals for Stockholders at the Annual Meeting</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">RISK FACTORS</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Overview</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">General Risks Related to the Investment Transaction</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Risks Related to the Our Securities and Control of Our Company</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">General Risks Related to the Reverse Stock Split Proposal</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">THE ANNUAL MEETING</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">Purpose of Meeting</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">Attendance at the Annual Meeting</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Voting; Quorum</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Voting Commitments</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Required Votes and Effects of Abstentions and Broker Non-Votes</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Effect of Not Voting</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024">Voting Methods</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">Revoking Proxies</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">Solicitation</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_027">Other Matters</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_028">Results of the Voting at the Annual Meeting</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_029">MATTERS TO BE CONSIDERED AT THE ANNUAL MEETING</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_030">PROPOSAL ONE: ELECTION OF DIRECTORS</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_031">Current Directors and Nominees</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><a href="#a_032">Class III Directors &#8211; Terms Expiring at the 2025 Annual Meeting</a></i></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_033">Stockholder Approval</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><a href="#a_034">Class I Directors &#8211; Terms Expiring at the 2026 Annual Meeting</a></i></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><a href="#a_035">Class II Directors &#8211; Terms Expiring at the 2027 Annual Meeting</a></i></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_036">Family Relationships</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_037">CORPORATE GOVERNANCE</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_038">Code of Ethics and Business Conduct</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_039">Director Independence</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_040">Board Committees and Meetings</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_041">Other Board Matters</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_042">Communications to the Board</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_043">EXECUTIVE COMPENSATION AND OTHER INFORMATION</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_044">Executive Officers</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_045">Summary Compensation Table</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_046">Outstanding Equity Awards at Fiscal Year End</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_047">Employment-Related Agreements and Potential Payments upon Termination or Change in Control</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_048">Director Compensation</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_049">PAY-VERSUS-PERFORMANCE</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_050">PROPOSAL TWO: ADVISORY, NON-BINDING VOTE TO APPROVE EXECUTIVE COMPENSATION</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_051">Stockholder Approval</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_052">PROPOSAL THREE: ADVISORY, NON-BINDING VOTE ON THE FREQUENCY OF SOLICITATION OF ADVISORY STOCKHOLDER APPROVAL OF EXECUTIVE COMPENSATION</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_053">Stockholder Approval</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_054">PROPOSAL FOUR: ADVISORY, NON-BINDING VOTE TO RATIFY THE SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_055">Fees Paid to Independent Registered Public Accounting Firm</a></span></td>
    <td style="padding-bottom: 1pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_056">Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_057">Stockholder Approval</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_058">Audit Committee Report</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_059">DESCRIPTION OF THE INVESTMENT TRANSACTION AND PREFERRED STOCK</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_060">Investment Transaction and Related Transactions</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_061">The Purchase Agreement and Related Transaction Documents</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_062">Description of the Preferred Stock and Lazar Investor Rights</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_063">PROPOSAL FIVE: APPROVAL OF ISSUANCE OF COMMON STOCK UPON CONVERSION OF SERIES D PREFERRED STOCK AND SERIES E PREFERRED STOCK</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_064">Overview of Investment Transaction</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_065">Reasons for this Proposal Five</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_066">Effect and Consequences of the Investment Transaction</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_067">Risk Factors</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_068">Additional Information</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_069">Stockholder Approval</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_070">PROPOSAL SIX: APPROVAL TO INCREASE SHARES AVAILABLE FOR ISSUANCE UNDER THE 2017 OMNIBUS PLAN</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_071">Amendment Language</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_072">Summary of the 2017 Omnibus Plan</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_073">Certain Federal Income Tax Consequences</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_074">Award Issuances under the 2017 Omnibus Plan</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_075">Risk Factors</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_076">Additional Information</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_077">Stockholder Approval</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_078">PROPOSAL SEVEN: APPROVAL OF THE PAYMENT OF THE EQUITY CONSIDERATION TO RESIGNING NON-EMPLOYEE DIRECTORS</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_079">Overview of the Release Agreement and Equity Consideration</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_080">Certain United States Federal Income Tax Consequences</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_081">Risk Factors</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_082">Stockholder Approval</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_083">PROPOSAL EIGHT: THE REVERSE STOCK SPLIT PROPOSAL</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_084">Overview</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_085">Effective Date</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_086">Reasons for the Reverse Stock Split</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_087">Principal Effects of the Reverse Stock Split</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_088">Fractional Shares</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_089">No Dissenters&#8217; Rights</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_090">Certain United States Federal Income Tax Consequences</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_091">Accounting Consequences</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_092">Stock Certificates</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_093">Book-Entry Shares</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_094">Risk Factors</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_095">Stockholder Approval</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_096">PROPOSAL NINE: APPROVAL TO INCREASE AUTHORIZED COMMON STOCK</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_097">Background of the Charter Amendment to Increase Authorized Common Stock</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_098">Reasons for Stockholder Approval</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_099">Effect and Consequences of the Amendment</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_100">Risk Factors</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_101">Additional Information</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_102">Stockholder Approval</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_103">PROPOSAL TEN: APPROVAL TO INCREASE AUTHORIZED PREFERRED STOCK</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_104">Background of the Charter Amendment to Increase Authorized Preferred Stock</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_105">Reasons for Stockholder Approval</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_106">Preferred Stock Generally</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_107">Effect and Consequences of the Amendment</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_108">Risk Factors</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_109">Additional Information</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_110">Stockholder Approval</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_111">PROPOSAL ELEVEN: THE ADJOURNMENT PROPOSAL</a></span></td>
    <td style="padding-bottom: 1pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_112">Stockholder Approval</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_113">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_114">EQUITY COMPENSATION PLAN INFORMATION</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_115">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_116">OTHER PROXY MATTERS</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_117">Delinquent Section 16(a) Reports</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_118">Deadlines for Receipt of Stockholder Proposals and Nominations</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_119">Householding of Proxy Materials</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_120">Method of Proxy Solicitation</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_121">Where You Can Find More Information</a></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_122">Other Business</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="img_001.jpg" alt="" style="height: 66px; width: 350px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2000 Powell Street, Suite 1150</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Emeryville, California 94608</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 7in; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: small-caps 14pt Times New Roman, Times, Serif; color: #1F4E79"><b><span id="a_001"></span>Proxy Statement</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: small-caps 14pt Times New Roman, Times, Serif; color: #1F4E79"><b>For The 2025 Annual Meeting of Stockholders</b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This proxy statement (the &#8220;<b><i>Proxy Statement</i></b>&#8221;), our Notice of 2025 Annual Meeting of Stockholders (the &#8220;<b><i>Notice</i></b>&#8221;) and our proxy card are being furnished in connection with the solicitation of proxies by the Board of Directors (the &#8220;<b><i>Board</i></b>&#8221;) of NovaBay Pharmaceuticals, Inc., a Delaware corporation (&#8220;<b><i>NovaBay</i></b><i>,</i>&#8221; the &#8220;<b><i>Company</i></b><i>,</i>&#8221; &#8220;<b><i>we</i></b><i>,</i>&#8221; &#8220;<b><i>our</i></b><i>,</i>&#8221; or &#8220;<b><i>us</i></b>&#8221;), to be voted at the 2025 Annual Meeting of Stockholders to be held on Thursday, October&#160;16, 2025 (the &#8220;<b><i>Annual Meeting</i></b>&#8221;), and at any adjournment or postponement of the Annual Meeting. The Annual Meeting will be held at 11:00 a.m. Pacific Time and will be a virtual meeting of stockholders. You will be able to participate in the Annual Meeting, vote, and submit your questions during the meeting via live webcast by visiting www.virtualshareholdermeeting.com/NBY2025. You must have your 16-digit control number on your proxy card to enter and participate in the virtual meeting. This Proxy Statement, the proxy card and our Annual Report on Form 10-K, as amended, for the year ended December&#160;31, 2024 (the &#8220;<b><i>Annual Report</i></b>&#8221;) are being delivered by mail on or about September&#160;23, 2025 to stockholders of record as of September&#160;22, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">If you have any questions in voting your shares, please contact:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Sodali &amp; Co.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">333 Ludlow Street &#8211; 5th Floor</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">South Tower</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Stamford, CT 06902</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">nby.info@investor.morrowsodali.com</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">800-662-5200</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; width: 100%; font-size: 10pt; text-align: center"><span style="font: small-caps 14pt Times New Roman, Times, Serif; color: #1F4E79"><b><span id="a_002"></span>Summary of the Proxy Statement</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The following is a summary of selected information contained in this Proxy Statement and does not contain all the information that is important to you. We urge you to carefully read this Proxy Statement, the annexes to this Proxy Statement and the documents referred to or incorporated by reference in this Proxy Statement in their entirety before you decide whether to vote to approve each of the proposals described below. The below summary includes page references directing you to a more complete description of the related topic within this Proxy Statement.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: #1F4E79"><b><span id="a_003"></span>About NovaBay</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We historically focused on the development and sale of scientifically-created and clinically-proven eyecare, wound care, and skin care products. We have undergone significant changes to our business and operations as a result of completing the following transactions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The sale of our eyecare products sold under the Avenova brand and related assets to PRN Physician Recommended Nutriceuticals, LLC (&#8220;<b><i>PRN</i></b>&#8221;) on January 17, 2025, which constituted substantially all of our revenue generating and operating assets (the &#8220;<b><i>Avenova Asset Divestiture</i></b>&#8221;);</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The sale of a significant portion of our wound care business, including two of the Company&#8217;s wound care trademarks, to our distributor, Phase One Health LLC on January 3, 2025 (the &#8220;<b><i>PhaseOne Divestiture</i></b>); and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The sale of 100% of the membership units of our former wholly-owned subsidiary, DERMAdoctor, LLC, which operated our primary skin care business, on March 12, 2024 (the &#8220;<b><i>DERMAdoctor Divestiture</i></b>&#8221;).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the closing of these transactions, we significantly reduced the Company&#8217;s assets and operations and significantly reduced our current and expected revenue. We do, however, continue to manufacture our wound care products domestically in the United States and export finished goods to China. Additionally, as further discussed below, in connection with the Investment Transaction, we expect to identify and pursue a potential Post-Investment Transaction (each as defined below) to provide a future growth opportunity for our Company and our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NovaBay was originally incorporated as a California corporation on January 19, 2000, and converted to a Delaware corporation in June 2010. Our common stock is listed on the NYSE American under the ticker symbol &#8220;NBY.&#8221; NovaBay&#8217;s principal executive offices are located at 2000 Powell Street, Suite 1150, Emeryville, California 94608, and our telephone number is (510) 899-8800. Our website address is www.novabay.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 30, 2024, the Company effected a reverse stock split. Except as otherwise specifically noted, all share numbers, share prices, exercise/conversion prices and per share amounts have been adjusted, on a retroactive basis, to reflect such reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: #1F4E79"><b><span id="a_004"></span>Recent Developments&#8212;NovaBay Strategic Direction</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Investment Transaction Background</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After the Avenova Asset Divestiture, PhaseOne Divestiture and DERMAdoctor Divestiture, the Board evaluated the strategic options available to the Company and unanimously determined that the best opportunity available to maximize the remaining value for our Company and to our stockholders was to potentially pursue a voluntary liquidation and dissolution under Delaware law (the &#8220;<b><i>Dissolution</i></b>&#8221;). Stockholders approved the Dissolution at a special meeting of stockholders that was held on April 16, 2025 (the &#8220;<b><i>2025 Special Meeting</i></b>&#8221;). Although stockholder approval of the Dissolution was received, the Board (as part of the approval received at the 2025 Special Meeting) was also authorized to subsequently determine, in its discretion, whether or not to proceed with the Dissolution. Accordingly, the Board retained complete discretion to evaluate and determine if and when the Dissolution should be effected or if another strategic option would instead be available to us that would be a better opportunity to maximize our remaining value for our Company and stockholders and be in the best interests of our Company and stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the period that the Company was seeking stockholder approval of the Dissolution proposal at the 2025 Special Meeting, we continued to explore and evaluate strategic options available to the Company to maximize its value, including mergers, reverse mergers, strategic partnerships, investments, licensing and sub-licensing transactions. Following the Company&#8217;s review of its strategic options, the Board determined that pursuing the Investment Transaction that provides for our stockholders to receive a Special Dividend and the opportunity for our Company to enter into a Post-Investment Transaction (each as defined and discussed below), instead of pursuing the Dissolution at this time, is a better opportunity to maximize the value of the Company for stockholders and is in the best interest of the Company and its stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Description of the Investment Transaction</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 19, 2025, we entered into a Securities Purchase Agreement (the &#8220;<b><i>Purchase Agreement</i></b>&#8221;) with David E. Lazar, an Israeli and E.U. citizen residing in Panama (&#8220;<b><i>Mr. Lazar</i></b>&#8221;), that provides for an investment by Mr. Lazar in two separate closings of up to $6.0 million in the aggregate in exchange for newly issued shares of Company preferred stock (the &#8220;<b><i>Investment Transaction</i></b>&#8221;). On the date the Purchase Agreement was entered into, Mr. Lazar completed the purchase of 481,250 shares of the Company&#8217;s Series D non-voting convertible preferred stock, par value $0.01 per share (the &#8220;<b><i>Series D Preferred Stock</i></b>&#8221;), convertible into 77.0 million shares of our common stock, par value $0.01 (&#8220;<b><i>Common Stock</i></b>&#8221;), at a price of $8.00 per share resulting in aggregate gross proceeds to us of $3.85 million (the &#8220;<b><i>First Closing</i></b>&#8221;). The Purchase Agreement contemplates that Mr. Lazar will separately purchase 268,750 shares of the Company&#8217;s Series E non-voting convertible preferred stock, par value $0.01 per share (the &#8220;<b><i>Series E Preferred Stock</i></b>&#8221;), convertible into 43.0 million shares of Common Stock, on substantially the same terms as the Series D Preferred Stock resulting in additional aggregate gross proceeds of $2.15 million at the second and final closing of the Investment Transaction that is expected to occur by the end of the fourth quarter of 2025, subject to the satisfaction of certain conditions to closing, including receiving stockholder approval in accordance with the NYSE American Company Guide (the &#8220;<b><i>Company Guide</i></b>&#8221;) Rule 713(a) and Rule 713(b) for Mr. Lazar to be able to convert the Series D Preferred Stock and the Series E Preferred Stock (the &#8220;<b><i>Conversion Approval</i></b>&#8221;), as provided in the Purchase Agreement (the &#8220;<b><i>Final Closing</i></b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consummation of the First Closing was subject to the satisfaction of customary closing conditions, including the accuracy of the representations and warranties in the Purchase Agreement, as well as the delivery of certain transaction documents, including the Series F Agreements, the Voting Agreement and the Release Agreements (each as discussed and defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the First Closing of the Investment Transaction, Mr. Lazar was appointed as a director to our Board and began serving as our Chief Executive Officer. Additionally, pursuant to the Purchase Agreement, Mr.&#160;Lazar received one-time contractual rights involving the Board, which include: (i) a right to recommend one (1) individual to be nominated for election at this Annual Meeting, which right Mr. Lazar exercised with his nomination for election to the Board as a Class III director at this Annual Meeting; (ii) subject to the Conversion Approval and the Final Closing occurring, a right to nominate up to three (3) individuals (the &#8220;<b><i>Additional Purchaser Nominee(s)</i></b>&#8221;) to be qualified and appointed to serve as directors on the Board after the resignation of the Resigning Non-Employee Directors pursuant to their respective Release Agreements (both as discussed and defined below); and (iii) subject to receipt of the Conversion Approval and the Final Closing occurring, a right to be appointed as the Chair of the Board. See &#8220;<i>Description of the Investment Transaction and Preferred Stock&#8212;Description of the Preferred Stock and Lazar Investor Rights&#8212;Lazar Investor Rights&#8212;Board Rights</i>&#8221; in the Proxy Statement for additional information regarding these investor rights. These one-time investor rights provided to Mr. Lazar are also discussed below in this Proxy Statement as they relate to the management and governance of our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Series F Agreements with Certain Series F Warrant Holders</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneous with the First Closing, on August 19, 2025, we entered into Warrant Exchange Agreements (collectively, the &#8220;<b><i>Series F Agreements</i></b>&#8221;) with the three largest remaining holders (collectively, the &#8220;<b><i>Remaining Warrant Holders</i></b>&#8221;) of our Series F-1 Common Stock warrants (the &#8220;<b><i>Series F Warrants</i></b>&#8221;). Pursuant to the Series F Agreements, each Remaining Warrant Holder surrendered all of their respective Series F Warrants and any additional Common Stock purchase warrants owned, if any, in exchange for (i) the Company issuing an aggregate of 1,986,565 shares of a new series of Series F voting retractable preferred stock, par value $0.01 (the &#8220;<b><i>Series F Preferred Stock</i></b>&#8221;), to the Remaining Warrant Holders and (ii) a cash payment of $175,000 to each of the Remaining Warrant Holders. Each share of Series F Preferred Stock has the right to vote the equivalent to approximately 0.424 shares of Common Stock, or in the aggregate the right to vote 842,832 shares of Common Stock, which will represent approximately 12.3% of the voting power as of the record date of this Annual Meeting on September 22, 2025. Further, the Series F Agreements provide for each of the Remaining Warrant Holders to exercise their voting rights by voting all of their Series F Preferred Stock in favor of the proposals that have been presented to stockholders at this Annual Meeting. See &#8220;<i>Description of the Investment Transaction and Preferred Stock&#8212;The Purchase Agreement and Related Transaction Documents&#8212;First Closing Conditions and Transactions&#8212;Series F Agreements</i>&#8221; in the Proxy Statement for additional information on the Series F Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Voting Agreement</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the First Closing, the Company and Mr.&#160;Lazar entered into a voting agreement on August 19, 2025 (the &#8220;<b><i>Voting Agreement</i></b>&#8221;) with Jad Fakhry and his controlled entities Poplar Point Capital Management LLC, Poplar Point Capital Partners LP, and Poplar Point Capital GP LLC (together, the &#8220;<b><i>Poplar Entities</i></b>&#8221;). The Poplar Entities reported owning approximately 17.5% of outstanding Common Stock in their Schedule 13D filed with the Securities and Exchange Commission (the &#8220;<b><i>SEC</i></b>&#8221;) on June&#160;4, 2025. Pursuant to the Voting Agreement, the Poplar Entities agreed to, among other terms, vote all of their shares of Common Stock at the Annual Meeting in favor of the proposals, as recommended by the Board and appoint the Company as an irrevocable proxy for the Poplar Entities for the duration of the Voting Agreement, which has a term of two years. In connection with the Poplar Entities entering into the Voting Agreement, we agreed to use commercially reasonable efforts to issue a special cash dividend that equals or exceeds $0.80 per share, which we will satisfy as a result of having declared the Special Dividend (as discussed and defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Special Dividend </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Investment Transaction, the Company and Mr. Lazar agreed to provide for the Company to declare and pay a special cash dividend to our stockholders following the First Closing as a way to maximize the value of the Company for stockholders following the Avenova Asset Divestiture. Pursuant to the Purchase Agreement, the Company segregated in a separate bank account an amount comprised of the Company&#8217;s cash, including from the Investment Transaction, at the First Closing (the &#8220;<b><i>Aggregate Cash Distribution Amount</i></b>&#8221;) to fund the Special Dividend. On August 26, 2025, in connection with receiving the proceeds from the Investment Transaction, the Special Transaction Committee of the Board declared a special cash dividend of $0.80 per share for the Common Stock (the &#8220;<b><i>Special Dividend</i></b>&#8221;), which will be payable on September 29, 2025 to stockholders of record of Common Stock at the close of business on September 15, 2025. Neither the Series D Preferred Stock nor the Series E Preferred Stock will participate in the Special Dividend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Pursuit of a Post-Investment Transaction</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the Investment Transaction, it is contemplated that the Company will seek to consummate a strategic transaction that would involve an investment and/or acquisition (the &#8220;<b><i>Post-Investment Transaction</i></b>&#8221;) of an operating going concern and solvent company (&#8220;<b><i>Target Company</i></b>&#8221;). Pursuant to the Purchase Agreement, the Company, after the First Closing and subject to approval by the Board, intends to use a portion of the net proceeds from the Investment Transaction to pursue a Post-Investment Transaction. If and when a Post-Investment Transaction is entered into and consummated after receiving required approvals, we expect that by combining with a new operating and revenue generating Target Company that such combination will result in a future growth opportunity for our Company and our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_005"></span>Corporate Governance Highlights</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NovaBay has a longstanding commitment to effective governance of its business and affairs for the benefit of stockholders, including through the below highlighted measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Board Leadership Structure</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board leadership structure currently consists of an independent Chair of the Board (the &#8220;<b><i>Chair</i></b>&#8221;) and independent committees. The Chair performs all duties and has all powers commonly incident to the office of Chair of the Board, including presiding at all meetings of the Board. In March 2019, the Board nominated Dr. Paul E. Freiman (&#8220;<b><i>Dr. Freiman</i></b>&#8221;) to serve as Chair due to his service on the Company&#8217;s Board since May 2002 and his prior position as the Board&#8217;s Lead Independent Director. Since this date, Dr. Freiman has and continues to serve as our Chair.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning on August 19, 2025, the Board appointed Mr. Lazar as a Class III director immediately prior to the First Closing and as Chief Executive Officer upon the effectiveness of the First Closing, with the Company&#8217;s former Chief Executive Officer, Mr. Justin M. Hall (&#8220;<b><i>Mr. Hall</i></b>&#8221;), continuing with the Company as its Vice President of Business Development, General Counsel and Corporate Secretary and as a director on the Board. In his executive officer role, Mr. Lazar has, and Mr. Hall prior to Mr. Lazar&#8217;s appointment had, responsibility for the management and control of the day-to-day business and affairs of the Company, as well as general supervision of the Company&#8217;s executives, employees and agents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Purchase Agreement, Mr. Lazar has a one-time contractual right to serve as the Chair of the Board subject to the Conversion Approval and the Final Closing occurring. See &#8220;<i>Description of the Investment Transaction and Preferred Stock&#8212;Description of the Preferred Stock and Lazar Investor Rights&#8212;Lazar Investor Rights&#8212;Board Rights</i>&#8221; in the Proxy Statement for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board believes that until the Final Closing, the Board is best served by continuing to separate the roles of Chair and Chief Executive Officer to enhance both the independence of the Board and its effectiveness in discharging its responsibilities. After the Final Closing and as a result of the Investment Transaction, the Board believes that NovaBay will be best served by combining the roles of Chair and Chief Executive Officer in order for Mr. Lazar to lead the Company in pursuing a Post-Investment Transaction. At such time, the Board may evaluate and nominate a Lead Independent Director in its discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Board Refreshment After the Final Closing and Payment of Equity Consideration</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the First Closing, the Company entered into a Settlement Agreement and General and Mutual Release (collectively, the &#8220;<b><i>Release Agreements</i></b>&#8221;) on August 19, 2025 with Mr. Hall and with five (5) of the six (6) non-employee directors serving on the Board (Dr. Paul Freiman, Ms. Julie Garlikov, Ms. Swan Sit, Mr. Mijia (Bob) Wu and Mr. Yongxiang (Sean) Zheng) (collectively, the &#8220;<b><i>Resigning Non-Employee Directors</i></b>&#8221;). Under the terms of the Release Agreements with Mr. Hall and the Resigning Non-Employee Directors, these directors agreed to resign from the Board effective upon the following having occurred: (i) the Conversion Approval having been received; (ii) the Final Closing having occurred; and (iii) up to three (3) Additional Purchaser Nominee(s) nominated by Mr. Lazar being qualified and appointed to serve on the Board; <i>provided</i>, <i>however</i>, the resignations of the Resigning Non-Employee Directors are also conditioned upon (A) the Special Dividend having been declared and paid and (B) Proposal Seven (Director Equity Consideration Proposal) being approved (with the time at which all applicable resignation conditions set forth in subparagraphs (i) through (iii) for Mr. Hall, and subparagraphs (i) through (iii) and (A) and (B) for the Resigning Non-Employee Directors, being the &#8220;<b><i>Resignation Event</i></b>&#8221;). Dr. Yenyou (Jeff) Zheng, currently serving on our Board, is not a Resigning Non-Employee Director and did not enter into a Release Agreement. Dr. Jeff Zheng will continue to serve on the Board as a continuing director following the Resignation Event. See &#8220;<i>Description of the Investment Transaction and Preferred Stock&#8212;The Purchase Agreement and Related Transaction Documents&#8212;First Closing Conditions and Transactions&#8212;Release Agreements</i>&#8221; in the Proxy Statement for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Board Committees</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The three (3) standing committees established by the Board meet on a regular basis and operate under written charters approved by the Board. Each committee performs an annual self-evaluation to determine whether the committee is functioning effectively and fulfilling its duties as prescribed by its charter. All directors serving on the Board&#8217;s Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee (the &#8220;<b><i>N&amp;CG Committee</i></b>&#8221;) are independent, and each committee has the ability to hire and terminate its own outside advisors. A copy of each committee&#8217;s charter is available on the Corporate Governance section of our website at <span style="text-decoration: underline">www.novabay.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the Board&#8217;s approval of the Investment Transaction, the Board established the Special Transaction Committee and empowered it with the exclusive authority, among other powers, to: (i) direct and control the payment of the Special Dividend; (ii) authorize and direct all matters related to the Investment Transaction, including the Release Agreements and other ancillary agreements to the Investment Transaction; (iii) enforce the Company&#8217;s rights under the Purchase Agreement and other Investment Transaction documents; and (iv) approve this Proxy Statement and the Investment Transaction related proposals in this Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Board Composition </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board seeks directors with a broad diversity of experience, professions, skills, geographic representation and backgrounds that will enhance the quality of the Board&#8217;s governance. Our directors&#8217; expertise combines to provide a broad mix of skills, qualifications and proven leadership abilities. The N&amp;CG Committee regularly identifies individuals who have expertise that would complement and enhance the current Board&#8217;s skills and experience. In addition, as part of our stockholder engagement dialogue, we routinely ask our investors for input regarding director recommendations. Our current Board composition as of September 22, 2025 includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="img_002.jpg" alt="" style="height: 184px; width: 450px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Other Governance Practices</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board of eight (8) directors reflects a range of talents, ages, skills, and expertise.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board established a Special Transaction Committee as part of the Board&#8217;s approval of the Investment Transaction to provide independent oversight to the distribution of the Special Dividend and other Investment Transaction related matters.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each director during his or her service attended over 75% of applicable Board/Committee meetings in fiscal year 2024.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board conducts an annual evaluation of the Chief Executive Officer (the &#8220;<b><i>CEO</i></b>&#8221;).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors participate in an annual evaluation of the full Board and each committee on which they serve in order to assess the performance and effectiveness of the Board and its committees. The responses and comments are presented to, and discussed with, the Board and each committee of the Board.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 13, 2023, the Board approved an amendment to the Company&#8217;s Bylaws, as amended and restated, changing the Company&#8217;s stockholders&#8217; meeting quorum requirement from &#8220;the holders of a majority of the voting power of all of the outstanding shares of stock entitled to vote&#8221; to &#8220;the holders of 1/3 of the voting power of all of the outstanding shares of stock entitled to vote&#8221;.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No stockholder rights plan or &#8220;poison pill&#8221; has been adopted.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_006"></span>Corporate Governance Policies</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NovaBay has established Corporate Governance Guidelines, as routinely reviewed and updated by the N&amp;CG Committee, to maintain effective and appropriate standards of corporate governance. We have also established a Code of Ethics and Business Conduct (the &#8220;<b><i>Code of Ethics</i></b>&#8221;) that establishes standards of conduct and expectations for our employees and the overall manner in which we conduct business. The Code of Ethics, along with our other policies and business standards and our overall risk and compliance programs, are components of mitigating the risks associated with the operation of our business. The full text of our Code of Ethics is available on the Corporate Governance section of our website at <span style="text-decoration: underline">www.novabay.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NovaBay also maintains an <span id="xdx_90E_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20240101__20241231_zKA7W15qJiFi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000012" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">Insider</ix:nonNumeric></span> Trading Policy governing the purchase, sale, and/or other dispositions of our securities by NovaBay and our directors, officers and employees, that we believe is reasonably designed to promote compliance with insider trading laws, rules and regulations, and any listing standards applicable to NovaBay. The Company considers it improper and inappropriate for any employee, officer or director of the Company to engage in short-term or speculative transactions in the Company&#8217;s securities. The Insider Trading Policy specifically prohibits directors, officers and other employees from engaging in short sales, margin accounts, pledging or hedging transactions of the Company&#8217;s securities. A copy of the Insider Trading Policy was filed as Exhibit 19 to our Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_007"></span>Compensation Highlights</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Overview</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2024, the Compensation Committee (the &#8220;<b><i>Compensation Committee</i></b>&#8221;) of the Board continued its historic practice of an annual performance incentive program, pursuant to which each Company executive could earn an annual performance bonus, tied to a percentage of his or her base salary. The Compensation Committee has the sole discretion to pay any portion of, or the entire, annual performance bonus in the form of equity compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Recent Compensation Developments </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Investment Transaction and following approval by the Board and the Compensation Committee, we entered into the following new employment arrangements with Mr. Hall and Tommy Law (&#8220;<b><i>Mr. Law</i></b>&#8221;) at the First Closing:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><i>Amended and Restated Employment Agreement with Justin Hall</i></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. At the First Closing, the Company entered into an amended and restated employment agreement with Mr.&#160;Hall (&#8220;<b><i>New Hall Employment Agreement</i></b>&#8221;) that provided for his continued service as the Company&#8217;s Vice President of Business Development, General Counsel and Corporate Secretary, which entirely amended and restated the Employment Agreement, dated January&#160;31, 2020, as amended, between the Company and Mr.&#160;Hall (the &#8220;<b><i>Prior Hall Employment Agreement</i></b>&#8221;). The New Hall Employment Agreement provides for an employment term commencing on the date of the First Closing and ending on October&#160;31, 2025 and an annual base salary of $175,000. </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><i>Employment Agreement with Tommy Law</i></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company at the First Closing also entered into an employment agreement with Mr. Law to serve as the Company&#8217;s Chief Financial Officer and Treasurer (the &#8220;<b><i>Law Employment Agreement</i></b>&#8221;). Mr. Law previously served as the Interim Chief Financial Officer and Treasurer and did not previously have an employment agreement in place. The Law Employment Agreement provides for at-will employment with a term commencing on the date of the First Closing that continues until the first anniversary of the date of commencement and an annual base salary of $170,000. Mr. Law will also be (i) entitled to a retention bonus of $170,000 to the extent he remains employed through the Company&#8217;s filing of its quarterly report on Form 10-Q with the SEC for the quarter ended September 30, 2025 (the &#8220;<b><i>Retention Date</i></b>&#8221;) and has not resigned or been terminated for cause (as defined in the Law Employment Agreement) prior to the Retention Date and (ii) eligible for any bonus plan that is deemed appropriate by the Board. </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also, in connection with the Investment Transaction and as consideration for the Release Agreement, each Resigning Non-Employee Director is entitled to (i) a settlement payment of newly-issued shares of restricted Common Stock, with an aggregate value of $40,000 to be issued upon the Resignation Event (the &#8220;<b><i>Equity Consideration</i></b>&#8221;), subject to stockholders approving Proposal Seven (Director Equity Consideration Proposal), plus (ii) any accrued and unpaid director&#8217;s fees. To the extent that Proposal Seven is not approved and the Equity Consideration is not issued to the Resigning Non-Employee Directors, then the Release Agreements with the Resigning Non-Employee Directors will terminate and be of no further force and effect. Separately, pursuant to Mr. Hall&#8217;s Release Agreement, he received a cash settlement payment of $481,250 plus any unpaid wages and $8,778 in payments pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<b><i>COBRA</i></b>&#8221;) in connection with the First Closing. Further, Mr. Hall will receive a second cash settlement payment of $481,250 plus any unpaid wages and $8,778 in COBRA payments by October 31, 2025. Mr. Hall&#8217;s payment amounts comprise his earned severance under the Prior Hall Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Compensation Related Advisory Votes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We implemented a stockholder advisory vote on executive compensation (commonly referred to as the &#8220;<b><i>Say-on-Pay</i></b>&#8221; proposal) beginning at our 2013 Annual Meeting and every three years thereafter, which gives stockholders the opportunity to endorse or not endorse the Company&#8217;s named executive compensation program. At the Company&#8217;s 2019 Annual Meeting, our stockholders voted to continue conducting its Say-on-Pay vote every three years, and stockholders approved the most recent Say-on-Pay proposal at the Company&#8217;s 2022 Annual Meeting. At this Annual Meeting, we are conducting our next vote on both our Say-on-Pay proposal (Proposal Two) and the frequency of the Say-on-Pay proposal (Proposal Three).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><br/> </p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_008"></span>Proposals at this Annual Meeting Which Require Your Vote</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders are being asked to consider and vote on the following proposals (collectively, the &#8220;<b><i>Proposals</i></b>&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>More <br/> Information</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Recommendation</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote Required for Approval</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Proposal One</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Election of the three (3) following director nominees:</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.35pt; text-align: justify; text-indent: -15.35pt"><span style="font-family: Wingdings; font-size: 10pt">&#216; </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul E. Freiman</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.35pt; text-align: justify; text-indent: -15.35pt"><span style="font-family: Wingdings; font-size: 10pt">&#216; </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David E. Lazar</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.35pt; text-align: justify; text-indent: -15.35pt"><span style="font-family: Wingdings; font-size: 10pt">&#216; </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Swan Sit</span></p></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 24</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR each nominee</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plurality with the three director candidates who receive the highest number of &#8220;FOR&#8221; votes being elected</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Proposal Two</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approve, on an advisory non-binding basis, the compensation of NovaBay&#8217;s named executive officers, as disclosed in this Proxy Statement</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 50</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Proposal Three</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote, on an advisory non-binding basis, on the frequency of solicitation of stockholder approval of executive compensation</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 51</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THREE YEARS</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The frequency that receives the greatest number of votes will be considered the selection by stockholders</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Proposal Four</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ratification, on an advisory non-binding basis, of the selection of WithumSmith+Brown, PC as our independent registered public accounting firm for the fiscal year ending December 31, 2025</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 52</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Proposal Five</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approve, as required by, and in accordance with, Sections 713(a) and 713(b) of the Company Guide, both: (i) the issuance of an aggregate of 77,000,000 shares of Common Stock upon the exercise of the Series D Preferred Stock that were issued in the First Closing and</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 62</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 12%">&#160;</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: left; width: 2%">&#160;</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> (ii) the issuance of an aggregate of 43,000,000 shares of Common Stock upon the exercise of the Series E Preferred Stock expected to be issued in the Final Closing </span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: left; width: 2%">&#160;</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 15%">&#160;</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: left; width: 2%">&#160;</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 15%">&#160;</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: left; width: 1%">&#160;</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> represented by proxy and entitled to vote at the Annual Meeting</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Proposal Six</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approve an amendment to our 2017 Omnibus Plan to increase the shares authorized under the 2017 Omnibus Plan by 1,000,000 shares of Common Stock resulting in a maximum number of shares currently available for issuance of 1,021,332 shares of Common Stock and to make corresponding changes to the share grant limitations in the 2017 Omnibus Plan </span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 67</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Proposal Seven</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approve the issuance and payment of the Equity Consideration, with an aggregate value of $40,000, at a price per share which may be below the market price (as reported by the NYSE American) on the date of issuance, to each of the Resigning Non-Employee Directors as contemplated by the Release Agreements</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 74</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Proposal Eight</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approve an amendment to the Certificate of Incorporation to effect the Reverse Stock Split, and to grant authorization to the Board to determine, in its sole discretion, the specific split ratio and the effective time (if at all)</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 77</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221; votes of a majority of the votes cast at the Annual Meeting</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Proposal Nine</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our Common Stock from 150,000,000 to 1,500,000,000</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 84</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221; votes of a majority of the votes cast at the Annual Meeting</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Proposal Ten</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our preferred stock, par value $0.01, from 5,000,000 to 10,000,000</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 88</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221; votes of a majority of our outstanding shares entitled to vote at the Annual Meeting</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Proposal Eleven</b></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approve the adjournment of the Annual Meeting</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 92</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_009"></span>Voting Generally</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The record date for determining those stockholders who are entitled to notice of, and to vote at, the Annual Meeting has been fixed as September 22, 2025 (&#8220;<b><i>Record Date</i></b>&#8221;). Only the holders of Common Stock and the holders of Series F Preferred Stock of record at the close of business on the Record Date are entitled to notice of, and to vote at, the Annual Meeting and any adjournment or postponement thereof. Each stockholder of Common Stock is entitled to one (1) vote for each share of our Common Stock held by such stockholder as of the Record Date. Each holder of Series F Preferred</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock is entitled to the voting equivalent of approximately 0.424 shares of Common Stock for each share of Series F Preferred Stock held. See &#8220;<i>The Annual Meeting</i>&#8221; in the Proxy Statement for additional information about voting, including the required votes an effects of abstentions and broker non-votes on the Proposals at this Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Series F Agreements, the Remaining Warrant Holders agreed to vote all of their Series F Preferred Stock, which represents approximately 12.3% of the voting power as of the Record Date, in favor of each of the Proposals. Separately, pursuant to the Voting Agreement, Jad Fakhry and the Poplar Entities agreed to vote all of their shares of Common Stock, which owned approximately 17.5% of outstanding Common Stock as of June 4, 2025, at the Annual Meeting in favor of each of the Proposals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_010"></span>Proposals for Stockholders at the Annual Meeting</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Election of Directors (Proposal One) (page 24)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You will find important information in the Proxy Statement about the qualifications and experience of each of the three (3) director nominees listed below whom you are being asked to elect at the Annual Meeting. The N&amp;CG Committee performs an annual assessment to evaluate whether each of NovaBay&#8217;s directors has the skills and experience to oversee the Company effectively. All of our directors, including the director nominees listed below, have demonstrated that they have proven leadership ability, sound judgment, integrity and a commitment to the success of our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="3" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="color: rgb(31,78,121); vertical-align: bottom">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: center">Director Nominees</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: center">Director Since</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: center">Age</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: center">Independent</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: center">Principal Occupation</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: center">NovaBay Board <br/> Committees</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; width: 16%; text-align: left">Paul E. Freiman</td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 8%; text-align: center">2002</td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 8%; text-align: center">91</td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 8%; text-align: center">Yes</td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 28%; text-align: left">Independent Pharmaceutical Professional and Consultant</td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center">Audit, Compensation and N&amp;CG</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">David E. Lazar</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">2025</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">35</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">No</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: left">Chief Executive Officer of NovaBay</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">None</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-align: left">Swan Sit</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">2019</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">48</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">Yes</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: left">Independent Business Consultant</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">Audit, Compensation and N&amp;CG</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board recommends unanimously that you vote &#8220;FOR&#8221; all of the three (3) Class III director nominees listed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Approval of Executive Compensation (Proposal Two) (page 50)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board is requesting stockholder approval of an advisory, non-binding resolution to approve the Company&#8217;s historic executive compensation as described in this Proxy Statement. The Board and the Compensation Committee value the opinions of the Company&#8217;s stockholders and, based on the outcome of this vote, will consider stockholders&#8217; concerns regarding executive compensation, if any, and evaluate whether any action is necessary to address those concerns. Our Board recommends unanimously that you vote &#8220;FOR&#8221; Proposal Two.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Vote on Frequency of Solicitation of Stockholder Approval of Executive Compensation (Proposal Three) (page 51)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board is requesting that stockholders vote on an advisory, non-binding basis on the frequency with which they would prefer to cast an advisory, non-binding vote on executive compensation. Stockholders may indicate whether they prefer we seek an advisory vote every one, two or three years with the option that receives the votes of a majority of shares present in person or represented by proxy being deemed the preferred frequency. Though advisory and non-binding, the Company intends to adopt whichever frequency is approved by the stockholders. Our Board recommends unanimously that you vote &#8220;THREE YEARS&#8221; for Proposal Three.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Ratification of the Selection of the Independent Registered Public Accounting Firm (Proposal Four) (page 52)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Audit Committee has appointed WithumSmith+Brown, PC (&#8220;<b><i>Withum</i></b>&#8221;) as the Company&#8217;s independent registered public accounting firm for 2025. While we are not required to have stockholders ratify the selection of Withum as the Company&#8217;s independent auditor, we are doing so because we believe it is good corporate practice. If our stockholders do not ratify the selection, the Audit Committee will reconsider the appointment, but may nevertheless retain Withum as the Company&#8217;s independent auditor. Even if the selection is ratified, the Audit Committee may, at its discretion, direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such change is in the best interests of the Company and its stockholders. Our Board recommends unanimously that you vote &#8220;FOR&#8221; Proposal Four.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Approval of the Issuance of Shares Upon Conversion of Series D Preferred Stock and Series E Preferred Stock (Proposal Five) (page 62)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You will find important information in the &#8220;<i>Description of the Investment Transaction and Preferred Stock</i>&#8221; and in &#8220;<i>Proposal Five: Approval of Issuance of Common Stock Upon Conversion of Series D Preferred Stock and Series E Preferred Stock</i>&#8221; in the Proxy Statement about the Investment Transaction entered into on August 19, 2025 and the Series D Preferred Stock that were issued in the First Closing and the Series E Preferred Stock expected to be issued in the Final Closing. The Series D Preferred Stock is convertible into an aggregate of 77.0 million shares of Common Stock, which represents approximately 61% of the Company&#8217;s issued and outstanding Common Stock on a fully diluted basis anticipated to be outstanding as of the Final Closing; however, Mr. Lazar may only convert the Series D Preferred Stock up to 19.99% of the Common Stock outstanding as of the date of the Purchase Agreement or such lower amount as may be required by the NYSE American until the Conversion Approval is approved by stockholders (the &#8220;<b><i>Share Issuance Limitation</i></b>&#8221;). The Series E Preferred Stock, if and when issued, will be convertible into an aggregate of 43.0 million shares of Common Stock, which represents approximately 34% of the Company&#8217;s issued and outstanding Common Stock on a fully diluted basis anticipated to be outstanding as of the Final Closing. Collectively, the Series D Preferred Stock and the Series E Preferred Stock are convertible into an aggregate of 120.0 million shares of Common Stock, which represents approximately 95% in the aggregate (based on the number of shares of Common Stock anticipated to be outstanding as of the Final Closing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Common Stock is listed on the NYSE American, and, as such, is subject to the applicable rules of the NYSE American as set forth in the Company Guide, including Section 713(a) and Section 713(b) of the Company Guide. Accordingly, we are seeking stockholder approval of Proposal Five (NYSE American Approval) at the Annual Meeting in order to both satisfy the requirements of Section 713(a) and Section 713(b) of the Company Guide and the Purchase Agreement effecting the Investment Transaction, which require our stockholders to approve the aggregate issuance of up to 120.0 million shares of Common Stock upon the conversion of the Series D Preferred Stock that was issued to Mr. Lazar in the First Closing and the Series E Preferred Stock that the Company intends to issue to Mr. Lazar in the Final Closing. While approval of our stockholders was not required to issue the Series D Preferred Stock, and is not required to issue the Series E Preferred Stock, the approval of our stockholders is required to authorize the conversion of the Series D Preferred Stock and the Series E Preferred Stock above the Share Issuance Limitation. Our Board recommends unanimously that you vote &#8220;FOR&#8221; Proposal Five.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Approval to Increase Shares Available for Issuance Under the 2017 Omnibus Plan (Proposal Six) (page 67)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board is requesting that stockholders vote on an amendment to the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (the &#8220;<b><i>2017 Omnibus Plan</i></b>&#8221;) to: (i) increase the number of authorized shares thereunder by 1,000,000 shares of Common Stock resulting in a maximum number of shares currently available for issuance of 1,021,332 shares of Common Stock and (ii) make corresponding changes to the share grant limitations in the 2017 Omnibus Plan for Incentive Stock Options, Restricted Stock and Restricted Stock Units (as each term is defined under the 2017 Omnibus Plan). The Board believes such amendment is in the best interests of our stockholders in order to provide flexibility to use the 2017 Omnibus Plan in the future, including as may relate to a potential Post-Investment Transaction. Our Board recommends unanimously that you vote &#8220;FOR&#8221; Proposal Six.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Approval of the Equity Consideration (Proposal Seven) (page 74)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board is requesting that stockholders vote to approve the issuance and payment of the Equity Consideration, comprised of newly-issued shares of restricted Common Stock with an aggregate value of $40,000, at a price per share which may be below the market price (as reported by the NYSE American) on the date of issuance, to each of the Resigning Non-Employee Directors as consideration for entering into the Release Agreements. The execution and delivery of the Release Agreements by the Resigning Non-Employee Directors was a required closing deliverable under the terms of the Purchase Agreement for consummation by Mr. Lazar of his initial investment at the First Closing. The Equity Consideration contemplated to be issued to each Resigning Non-Employee Director will be shares of restricted Common Stock that will be newly issued from our authorized and unissued shares of Common Stock and will not be issued from the 2017 Omnibus Plan or any other NovaBay equity compensation plan that has been approved by our stockholders. Accordingly, before we are able to issue and pay the Equity Consideration to the Resigning Non-Employee Directors, we are required under Section 711 of the Company Guide to first obtain stockholder approval of this arrangement. Our Board recommends unanimously that you vote &#8220;FOR&#8221; Proposal Seven.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Approval of the Reverse Stock Split (Proposal Eight) (page 77)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are also seeking stockholder approval of Proposal Eight in order to effect a reverse stock split of all of our Common Stock issued and outstanding at a ratio of not less than 1-for-2 and not more than 1-for-10 (the &#8220;<b><i>Reverse Stock Split</i></b>&#8221;). The Board expects that the Reverse Stock Split will increase the market price of our Common Stock, which will improve the marketability and liquidity of our Common Stock and will encourage interest and trading in our Common Stock. Further, if the Board determines to effect the Reverse Stock Split, the number of authorized shares of Company capital stock will remain unchanged, and, as a result, the number of authorized shares of Common Stock that will be available for future issuance will increase significantly. This will provide further flexibility to use our Common Stock for business and financial purposes in the future, including for a potential Post-Investment Transaction and capital raise transactions. Accordingly, approval of this Proposal Eight is important in order to improve the marketability and liquidity of our Common Stock and to provide further flexibility to use our Common Stock in the future. Our Board recommends unanimously that you vote &#8220;FOR&#8221; Proposal Eight.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Approval to Increase Authorized Common Stock (Proposal Nine) (page 84)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board is requesting that stockholders approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the &#8220;<b><i>Certificate of Incorporation</i></b>&#8221;) to increase the number of authorized shares of our Common Stock from 150,000,000 shares to 1,500,000,000 shares in order to provide flexibility to use our Common Stock for business and financial purposes in the future, including for a potential Post-Investment Transaction and capital raise transactions. Of the 150,000,000 shares of our Common Stock currently authorized, as of the close of business on September 22, 2025, there were 23,750,495 authorized shares of Common Stock that remain available for issuance by us (including to account for shares reserved for issuance under our equity compensation plans or for our outstanding Series B Non-Voting Convertible Preferred Stock (&#8220;<b><i>Series B Preferred Stock</i></b>&#8221;), Series D Preferred Stock, Unsecured Convertible Notes, warrants, options or restricted stock units as well as the shares we expect to reserve after issuing our Series E Preferred Stock in the Final Closing). If our stockholders approve the proposed amendment to our Certificate of Incorporation contemplated by Proposal Nine, then the number of authorized shares of Common Stock available for issuance will increase to approximately 1,373,750,495. Further, such change will become effective upon filing with the Secretary of State of the State of Delaware (the &#8220;<b><i>Delaware Secretary of State</i></b>&#8221;), which we anticipate doing as soon as practicable following stockholder approval. However, even if our stockholders approve the proposed amendment, our Board retains discretion under Delaware law not to implement the proposed amendment. If our Board were to exercise such discretion or our stockholders did not approve the proposed amendment to the Certificate of Incorporation, the number of authorized shares of Common Stock would remain at the current level. Our Board recommends unanimously that you vote &#8220;FOR&#8221; Proposal Nine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Approval to Increase Authorized Preferred Stock (Proposal Ten) (page 88)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board is requesting that stockholders approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our preferred stock, par value $0.01 (&#8220;<b><i>preferred stock</i></b>&#8221;), from 5,000,000 shares to 10,000,000 shares in order to provide flexibility to use our preferred stock for business and financial purposes in the future, including for a potential Post-Investment Transaction and capital raise transactions. Of the 5,000,000 shares of our preferred stock currently authorized, as of the close of business on September 22, 2025, there were 2,263,304 authorized shares of preferred stock that remain available for issuance by us (as a result of our Series B Non-Voting Convertible Preferred Stock, Series D Preferred Stock and Series F Preferred Stock currently outstanding as well as accounting for the shares of Series E Preferred Stock that we expect to issue in the Final Closing). If our stockholders approve the proposed amendment to our Certificate of Incorporation contemplated by Proposal Ten, then the number of authorized shares of preferred stock available for issuance will increase to approximately 7,263,304. Further, such change will become effective upon filing with the Delaware Secretary of State, which we anticipate doing as soon as practicable following stockholder approval. However, even if our stockholders approve the proposed amendment, our Board retains discretion under Delaware law not to implement the proposed amendment. If our Board were to exercise such discretion or our stockholders did not approve the proposed amendment to the Certificate of Incorporation, the number of authorized preferred shares would remain at the current level. Our Board recommends unanimously that you vote &#8220;FOR&#8221; Proposal Ten.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: rgb(31,78,121) 2pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79"><b><i><span style="text-decoration: underline">Approval of the Adjournment Proposal (Proposal Eleven) (page 92)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the Annual Meeting, we are asking our stockholders to grant discretionary authority to the Board to adjourn this Annual Meeting, from time to time, if necessary or appropriate, to establish a quorum or, even if a quorum is present, to permit further solicitation of proxies if there are not sufficient votes cast at the time of the Annual Meeting or after any adjournment in favor of any of the Proposals at the Annual Meeting. Proposal Eleven for the vote regarding adjournment of the Annual Meeting will be disregarded if there are sufficient votes to approve the Proposals at the Annual Meeting. The Board unanimously recommends that you vote &#8220;FOR&#8221; Proposal Eleven.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 6.75in; text-align: center; vertical-align: middle"><span style="font: small-caps 14pt Times New Roman, Times, Serif; color: #1F4E79"><b><span id="a_011"></span>Cautionary Note Regarding Forward-Looking Statements</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">This Proxy Statement and the documents referenced herein contain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities and Exchange Act of 1933, as amended (the &#8220;<b><i>Securities Act</i></b>&#8221;) and Section&#160;21E of the Securities and Exchange Act of 1933, as amended (the &#8220;<b><i>Exchange Act</i></b>&#8221;). Forward-looking statements are predictions based on expectations and projections about future events, are not statements of historical fact, are subject to risks, uncertainties and assumptions that are difficult to predict and involve risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The use of words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;likely,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would&#8221; and similar words or expressions are intended to identify forward-looking statements. These statements and related risks, uncertainties, factors and assumptions, include, but are not limited to: statements regarding the Investment Transaction, the expected completion of the Final Closing, the impact of not obtaining stockholder approval for Proposal Five (NYSE American Proposal) and certain of the other Proposals at this Annual Meeting, our ability to successfully pursue our business strategy, including identifying and completing a Post-Investment Transaction, and the Company&#8217;s financial condition and results of operations, including the financial impact of the Investment Transaction, the Special Dividend, and related transactions and matters. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in, or implied by, these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to our business, ownership of our securities, the continued listing of our Common Stock on the NYSE American, and other matters, including risks that could cause results to differ materially from those projected in the forward-looking statements in this Proxy Statement, are detailed in this Proxy Statement as well as in our Annual Report, and subsequent Quarterly Reports on Form 10-Q and/or Current Reports on Form 8-K filings with the SEC, especially under the heading &#8220;Risk Factors.&#8221; The forward-looking statements in this Proxy Statement and the documents referenced herein represent our current beliefs, estimates and assumptions as of the date of this Proxy Statement, and we disclaim any intent or obligation to revise or update publicly any forward-looking statement contained in this Proxy Statement, except as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 6.75in; text-align: center; vertical-align: middle"><span style="font: small-caps 14pt Times New Roman, Times, Serif; color: #1F4E79"><b><span id="a_012"></span>Risk Factors</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Before you make a decision regarding how you will vote on the Proposals as set forth in this Proxy Statement, you should carefully consider each of the risk factors described below in addition to the other information contained in this Proxy Statement and the annexes attached to this Proxy Statement. The risk factors described below relate to the Investment Transaction, including our planned issuance of the Series E Preferred Stock at the Final Closing and the Post-Investment Transaction, as well as the risks relating to NovaBay and its business. The risks discussed below also include forward-looking statements and actual results may differ substantially from those discussed in these forward-looking statements. See the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; The risks and uncertainties described below and in this Proxy Statement are not the only risks and uncertainties that we face. We encourage you to also carefully read the risk factors generally associated with our Company and our business contained in our Annual Report, and our subsequent SEC filings. Additional risks and uncertainties not currently known to us may also materially and adversely affect our business operations and financial condition or the price of our Common Stock.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6.75in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_013"></span>Overview</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As described in this Proxy Statement, we recently completed the Investment Transaction, which is material to us and resulted in significant changes to NovaBay&#8217;s business, operations and strategic direction, as well as to our overall capital structure. Accordingly, as a result of these changes, there will be new and additional risks and uncertainties that we may encounter and have to face in the future, as well as those risks that we already had prior to completing these transactions. These risks and uncertainties have been presented and summarized below to provide stockholders with important information in connection with their own evaluation of each of the Proposals being considered at the Annual Meeting. We urge all stockholders to fully and carefully read each of these risk factors listed below in their entirety and in this Proxy Statement in connection with their voting decision on the Proposals at the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6.75in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_014"></span>General Risks Related to the Investment Transaction</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>As a result of the Series D Preferred Stock that we issued and the Series E Preferred Stock to be issued in the Final Closing, whether or not the Conversion Approval is received, our stockholders will experience significant dilution as a result of the issuance of shares of our Common Stock upon future conversion of the Series D Preferred Stock and/or the Series E Preferred Stock.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Regardless of whether we receive the Conversion Approval, Mr.&#160;Lazar is entitled to convert a portion of his Series D Preferred Stock into Common Stock at any time, provided that upon conversion, the aggregate number of shares of Series D Preferred Stock converted by him does not exceed the Share Issuance Limitation (e.g. 19.99% of our issued and outstanding shares of Common Stock as of the date of the Purchase Agreement or a lower percentage as may be required by the NYSE American). If the Conversion Approval, however, is received at the Annual Meeting, (i) all of the shares of Series D Preferred Stock will be convertible either by Mr.&#160;Lazar or will automatically convert within the third business day after the Conversion Approval is received into 77.0 million shares of Common Stock and (ii) all of the Series E Preferred Stock to be issued in the Final Closing will also be immediately convertible following issuance (either by Mr.&#160;Lazar or converted automatically) into 43.0 million shares of Common Stock. As a result of the full conversion of the Series D Preferred Stock and the Series E Preferred Stock, 120.0 million shares of Common Stock will be issued, which collectively will represent approximately 95% of the total number of shares of Common Stock expected to be outstanding immediately after the Final Closing. Upon the conversions of the Series D Preferred Stock and/or the Series E Preferred Stock after the Conversion Approval, the existing stockholders of the Company will experience significant dilution in their ownership percentage and their voting power, with Mr.&#160;Lazar receiving effective voting control over matters presented to stockholders in the future relating to our Company. Further, as part of the Investment Transaction, Mr.&#160;Lazar agreed to ensure that the Company will have sufficient capital to identify and complete a Post-Investment Transaction and fund operations for at least twelve (12) months after completing a Post-Investment Transaction, which may result in additional equity being issued to Mr.&#160;Lazar that may result in further dilution to stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>If stockholders do not provide the Conversion Approval, then we will not be able to complete the Final Closing and receive the proceeds from this additional investment.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we do not receive stockholder approval of the Conversion Approval at this Annual Meeting or at a Second Meeting (as defined in the Proxy Statement), then Mr.&#160;Lazar will not be obligated to make the additional $2.15 million investment in the Series E Preferred Stock, even if we satisfy all of the other closing conditions. The availability of the proceeds from the</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">sale of the Series E Preferred Stock at the Final Closing will be important to us to continue funding our operations and expenses, the pursuit of a Post-Investment Transaction, and to satisfy our other obligations, including the retirement of the outstanding shares of Series F Preferred Stock that is contemplated to occur following the Conversion Approval or after December&#160;31, 2025. Additionally, until the Conversion Approval is obtained, the conditions to the Release Agreements will not be satisfied, Mr.&#160;Lazar will not be able to exercise certain of his one-time Board rights, including the right to nominate Additional Purchaser Nominee(s) to the Board and to be appointed as Chair of the Board and we may not be able to further pursue and/or consummate a Post-Investment Transaction. Accordingly, the failure to receive the Conversion Approval will have a material and adverse effect upon our ability to complete the transactions contemplated by the Investment Transaction and to pursue our business strategy of growing our business and creating value for our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>We may fail to realize the anticipated benefits of the Investment Transaction if we are not able to identify and/or pursue a Post-Investment Transaction.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The success of the Investment Transaction and the pursuit of our business strategy to grow our Company will depend on, among other things, our ability to identify, pursue and consummate a Post-Investment Transaction with a Target Company. We may not be able to identify a suitable operating and revenue generating Target Company to acquire or ultimately enter into and consummate a Post-Investment Transaction within the necessary timing before our capital resources are depleted. If we do enter into and consummate a Post-Investment Transaction with a Target Company, there is no assurance that the transaction will be successful or that we will be able to achieve the anticipated revenues, efficiencies, cost savings and/or realize other expected benefits of the Post-Investment Transaction. As a result, the Board may determine it is in the best interests of the stockholders to alternatively proceed with the Dissolution of our Company under Delaware law, as previously approved by stockholders at our 2025 Special Meeting held on April&#160;16, 2025, or otherwise seek bankruptcy protection or protection under other insolvency laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In pursuing a Post-Investment Transaction, it is possible that we may need additional capital to fund the acquisition of a Target Company and/or we may issue Common Stock or other equity securities as consideration to acquire the Target Company. The number of shares and/or the value of the additional shares of Common Stock or other equity securities, if any, that we may issue in connection with a Post-Investment Transaction is not currently known and any such issuance would be subject to required corporate and/or stockholder approvals that may be applicable under law or the NYSE American Company Guide. To the extent we raise additional capital by issuing equity securities or issue equity securities as consideration in a Post-Investment Transaction, our stockholders may experience substantial dilution (in addition to the dilution in connection with the Investment Transaction) and the new equity securities may have greater rights, preferences or privileges than our existing Common Stock and/or our preferred stock issued, as the case maybe. In addition, the new equity securities may be offered in the future at a price that is below the then in effect conversion price of the Series D Preferred Stock, which, unless an exception was available, would result in the lowering of the conversion price of the Preferred Stock and a greater number of shares of Common Stock being issuable upon conversion of the Series D Preferred Stock for no additional consideration, causing even greater dilution to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Our Board and management team will significantly change in connection with the Investment Transaction and if we consummate a Post-Investment Transaction.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the Investment Transaction, there are material changes to the management of our Company that have occurred with Mr.&#160;Lazar being appointed as Chief Executive Officer and as a director at the First Closing, and that are expected to occur in connection with the resignation of Mr.&#160;Hall and the five (5) Resigning Non-Employee Directors and the appointment of up to three (3) Additional Purchaser Nominee(s) to the Board, provided that we receive approval for the issuance of the Equity Consideration and the Conversion Approval, as well as complete the Final Closing. Additionally, there may be further changes to our executive management team and Board that possibly occur in the future in connection with our Company pursuing and potentially consummating a Post-Investment Transaction. The identity of the Additional Purchaser Nominee(s) and/or other changes that may occur in the future to our executive management team and/or Board are not currently known to us; however, such persons will be subject to our review, qualification and approval. Accordingly, we expect that our Company will have significant changes and turnover to our executive management team and the Board, who would lead our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>If the Conversion Approval and the other Proposals are not approved by stockholders at this time, pursuant to the terms of the Purchase Agreement, we will be required to use our reasonable best efforts to call another stockholder meeting, which will be costly and delay our ability to complete the Final Closing and pursue the Post-Investment Transaction.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the Conversion Approval and approval of the other Proposals contemplated by the Purchase Agreement are not received at this Annual Meeting, then we will be required to use our reasonable best efforts to call a Second Meeting within seventy (70) days of the date of the Annual Meeting. The failure to obtain stockholder approval at this Annual Meeting and/or the Second Meeting will result in additional cost and expense to us to hold an additional stockholder meeting, delay our ability to pursue and consummate a Post-Investment Transaction and complete the Final Closing and certain other transactions contemplated by the Investment Transaction (as discussed in the risk factor above).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>If stockholders approve the amendments to our Certificate of Incorporation to increase the number of authorized Common Stock and preferred stock, then the availability of these additional authorized shares may result in greater dilution to our stockholders and/or affect the market price of our Common Stock.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, if stockholders approve Proposal Nine that provides for an increase to our authorized Common Stock from 150,000,000 shares to 1,500,000,000 shares and/or Proposal Ten, which provides for an increase to our authorized preferred stock from 5,000,000 shares to 10,000,000 shares, then we will significantly increase the number of authorized shares of Common Stock and preferred stock that NovaBay may issue in the future, which our Board will have discretion to issue in the future, including, without limitation, in connection with future capital raise transactions and financings. Stockholders will not have a right to approve any such issuances or transactions, unless required by our governing documents, NYSE American rules or applicable law, and any such issuance of our Common Stock or preferred stock in the future may have a dilutive effect, including on earnings per share, on stockholders&#8217; equity and/or voting rights. Furthermore, future sales of substantial amounts of our Common Stock, or the perception that these sales might occur, could adversely affect the prevailing market price of our Common Stock or limit our ability to raise additional capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>We may be limited in our financing and business development activities if we are not able to increase the authorized shares of Common Stock</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If Proposal Nine that provides for an increase to the authorized Common Stock is not approved by our stockholders at this Annual Meeting, we may not have sufficient shares of Common Stock to be able to access the capital markets, complete a Post-Investment Transaction, other strategic investment and/or acquisition, pursue corporate collaborations or partnerships, and/or pursue other business opportunities that are integral to executing our business strategy and our growth and success. After the Final Closing, to the extent completed, we would only have 23,750,495 shares of Common Stock that remain available for issuance. Even if our stockholders approve Proposal Nine to increase the authorized shares of Common Stock, there is no assurance that we will be successful in completing a Post-Investment Transaction or other strategic investment and/or acquisition, raising additional funds or pursuing other business opportunities to the extent needed in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6.75in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_015"></span>Risks Related to the Our Securities and Control of Our Company</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The market price of our Common Stock may decline in the future as a result of the Investment Transaction and we may not regain compliance under the Company Guide.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The market price of our Common Stock may decline in the future as a result of completing the Investment Transaction and the related transactions, for a number of reasons, including the substantial dilutive impact of the issuance of 120.0 million shares of Common Stock upon conversion of all of the shares of Series D Preferred Stock and, after issuance at the Final Closing, the Series E Preferred Stock. The issuance of Common Stock will likely have a depressive effect on the market price of our Common Stock at the time of conversion by increasing the number of shares of Common Stock then outstanding. Such downward pressure could encourage short sales by certain investors, which could place further downward pressure on the price of the Common Stock. Further, if we fail to achieve the perceived benefits of the Investment Transaction, including consummating a Post-Investment Transaction or pursuing another strategic opportunity, as rapidly as, or to the extent anticipated by, financial or industry analysts, the market price of our Common Stock may further decline. Some of these factors are beyond our control. Further, we cannot assure you that we will be able to once again regain compliance with the NYSE American continued listing requirements relating to our stockholders&#8217; equity under the Company Guide or otherwise maintain the listing of our Common Stock. Our failure to regain compliance with those stockholders&#8217; equity requirements or to comply with other requirements of the Company Guide, including upon completion of a Post-Closing Transaction, could result in our Common Stock being delisted from the NYSE American.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Our stockholders will have significantly reduced ownership and voting power as a result of the conversion of the shares of Series D Preferred Stock and, upon issuance at the Final Closing, Series E Preferred Stock.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the Conversion Approval is received at the Annual Meeting, then stockholders who owned shares of Common Stock prior to the conversion of the Series D Preferred Stock and, after the Final Closing, the Series E Preferred Stock into Common Stock will have a significantly lower percentage of ownership and correspondingly reduced voting power than they held immediately prior to the conversion. The shares of Series D Preferred Stock issued at the First Closing, upon conversion, will represent approximately 61% of the Company&#8217;s issued and outstanding Common Stock on a fully diluted basis, and the Series E Preferred Stock to be issued, upon conversion, will represent approximately 34% of the Company&#8217;s issued and outstanding Common Stock on a fully diluted basis as of the Final Closing, or collectively approximately 95% in the aggregate (based on the number of shares of Common Stock anticipated to be outstanding as of the Final Closing). Therefore, assuming the completion of the Final Closing and without taking into account future issuances of our securities (including pursuant to a Post-Investment Transaction), our stockholders prior to the conversion of the Series D Preferred Stock and the Series E Preferred Stock will have significantly less ownership of our Company and voting power, and, therefore, they will have a substantially reduced ability to influence significant corporation decisions that require approval of holders of the outstanding Common Stock with Mr.&#160;Lazar, and/or transferee who subsequently owns such securities upon exercise of Mr.&#160;Lazar&#8217;s Securities Purchase Rights, owning approximately 95% of the issued and outstanding shares as of the Final Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Mr.&#160;Lazar will have significant control and influence over our Company and corporate matters.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to the ownership that will result in connection with the conversion the Series D Preferred Stock and the Series E Preferred Stock to be issued in the Final Closing (as described in the risk above), Mr.&#160;Lazar was appointed as a director to our Board and began serving as our Chief Executive Officer in connection with the First Closing. Additionally, pursuant to the Purchase Agreement, Mr.&#160;Lazar received certain one-time contractual rights involving the Board, which include: (i) a contractual right to recommend one (1) individual to be nominated for election at this Annual Meeting, which right was exercised with Mr.&#160;Lazar&#8217;s nomination for election to the Board at this Annual Meeting; (ii) provided that the Conversion Approval is received and the Final Closing occurs, a contractual right to nominate and have appointed up to three (3) Additional Purchaser Nominee(s) depending on Mr.&#160;Lazar&#8217;s percentage ownership of our Common Stock at the time of appointment; and (iii) subject to the Conversion Approval and the Final Closing occurring, a one-time contractual right to be appointed as the Chair of the Board. As a result of Mr.&#160;Lazar&#8217;s one-time contractual Board rights and his positions as Chief Executive Officer and a director, Mr.&#160;Lazar will have input on all matters before our Board (excluding the matters delegated to the Board committees, including the Special Transaction Committee). Separately, due to his potential significant ownership of Common Stock, Mr.&#160;Lazar would also have the ability to exercise significant influence and control over the outcome of all matters requiring Board and stockholder approval, including the election of directors. As a result of Mr.&#160;Lazar&#8217;s voting power (and assuming he does not exercise his Securities Purchase Rights or otherwise sell the Conversion Shares), we may determine that we are a &#8220;controlled company&#8221; as defined in the Company Guide and, therefore, are not subject to the NYSE American&#8217;s requirements that would otherwise require us to have (a) a majority of independent directors; (b) director nominees selected, or recommended for the Board selection, either by a majority of the independent directors or a nominating committee composed solely of independent directors; (c) a nominating committee composed solely of independent directors; (d) compensation of our chief executive officer and all other officers determined by a majority of the independent directors or a compensation committee composed solely of independent directors; and/or (e) a compensation committee charter which provides the compensation committee with the authority and funding to retain compensation consultants and other advisors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The shares of Series D Preferred Stock, Series E Preferred Stock and/or the Conversion Shares acquired or to be acquired by Mr.&#160;Lazar may be sold to another unknown person if Mr.&#160;Lazar decides to exercise his Securities Purchase Rights.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement expressly provides for Mr.&#160;Lazar to have the Securities Purchase Rights that permits the assignment, transfer and/or sale of the Series D Preferred Stock, the Series E Preferred Stock, the Conversion Shares and/or his right to acquire such securities, which may occur at any time after the First Closing, including having such rights exercised at the time or in connection with a Post-Investment Transaction. If Mr.&#160;Lazar were to properly exercise the Securities Purchase Rights with respect to all of his shares of Series D Preferred Stock and the right to acquire the shares of Series E Preferred Stock at the Final Closing, then the ownership of such preferred stock and related rights will transfer to a third party who is unknown to us and such third party will then have the right to exercise significant influence and control over the outcome of all other matters requiring Board and stockholder approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6.75in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_016"></span>General Risks Related to the Reverse Stock Split Proposal</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The proposed Reverse Stock Split, if effected, may not increase our stock price, and could lead to a decrease in our overall market capitalization.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September&#160;22, 2025, the closing sale price of our Common Stock on the NYSE American was $2.11 per share of Common Stock. We expect that the Reverse Stock Split, if effected, will increase the per share trading price of our Common Stock. However, the market price per share of our Common Stock after the Reverse Stock Split may not rise (or remain constant) in proportion to the reduction in the number of shares of Common Stock outstanding before the Reverse Stock Split. We cannot predict the effect of the Reverse Stock Split on the per share trading price of our Common Stock, and the history of reverse stock splits for our Company and other companies is varied, particularly since some investors may view a reverse stock split negatively. In many cases, the market price of a company&#8217;s shares declines after a reverse stock split, or the market price of a company&#8217;s shares immediately after a reverse stock split does not reflect a proportionate or mathematical adjustment to the market price based on the ratio of the reverse stock split (which happened to the Company after its 1-for-35 reverse stock split effective November&#160;15, 2022 and its 1-for-35 reverse stock split effective May&#160;30, 2024). Accordingly, our total market capitalization after a Reverse Stock Split may be lower than our total market capitalization before the Reverse Stock Split, and it is possible that a Reverse Stock Split may not result in a per share trading price that would attract investors who do not trade in lower priced stocks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if we implement the Reverse Stock Split, the per share trading price of our Common Stock may decrease due to factors unrelated to the Reverse Stock Split. Other factors, such as our financial results, market conditions and the market perception of our business, may adversely affect the per share trading price of our Common Stock. As a result, we cannot assure you that the Reverse Stock Split, if completed, will result in the benefits that we anticipate, that the per share trading price of our Common Stock will increase following the Reverse Stock Split or that the per share trading price of our Common Stock will not decrease in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The proposed Reverse Stock Split, if effected, may decrease the liquidity of our Common Stock.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The liquidity of our Common Stock may be harmed by the proposed Reverse Stock Split, given the reduced number of shares that would be outstanding after the Reverse Stock Split, particularly if the per share trading price does not increase proportionately as a result of the Reverse Stock Split. While the Board believes that a higher stock price may help generate the interest of new investors, the Reverse Stock Split may not result in a per share price that will attract certain types of investors, such as institutional investors or investment funds, and such share price may not satisfy the investing guidelines of institutional investors or investment funds. As a result, the trading liquidity of our Common Stock may not improve as a result of a Reverse Stock Split and could be adversely affected by a higher per share price. Accordingly, the Reverse Stock Split may not increase marketability of our Common Stock. In addition, investors might consider the increased proportion of unissued authorized shares to issued shares to have an anti-takeover effect under certain circumstances, because the proportion allows for dilutive issuances that could prevent certain stockholders from changing the composition of the Board or render tender offers for a combination with another entity more difficult.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The proposed Reverse Stock Split, if effected, may result in some stockholders owning</i> &#8220;<i>odd lots</i>&#8221; <i>that may be more difficult to sell or require greater transaction costs per share to sell.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the proposed Reverse Stock Split is implemented, it will increase the number of stockholders who own &#8220;odd lots&#8221; of less than 100 shares of Common Stock. A purchase or sale of less than 100 shares of Common Stock may result in incrementally higher trading costs through certain brokers, particularly &#8220;full service&#8221; brokers. Therefore, those stockholders who own less than 100 shares of our Common Stock following the Reverse Stock Split may be required to pay higher transaction costs if they sell their shares of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The proposed Reverse Stock Split, if effected, will result in a significant increase in our authorized Common Stock and may result in future dilution to our stockholders.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Reverse Stock Split will reduce the number of outstanding shares of our Common Stock without a proportionate reduction in the number of shares of authorized but unissued Common Stock in our Certificate of Incorporation (either currently 150,000,000 shares of Common Stock or 1,500,000,000 shares of Common Stock if stockholders approve Proposal Nine providing for an increase in the authorized shares of Common Stock), which will give the Company a significantly larger number of authorized shares, as a percentage of total outstanding shares, available for future issuance without further stockholder action, except as may be required by applicable laws or the rules of any stock exchange on which our Common Stock is listed. Accordingly, as a result of our Company having available a significantly greater number of shares of Common Stock for future issuance due to the authorized but unissued shares in our Certificate of Incorporation not proportionately adjusting as a result of the Reverse Stock Split, the ability to issue an even greater number of newly issued shares of Common Stock in the future may have a further dilutive effect on the ownership of existing stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 6.75in; text-align: center; vertical-align: middle"><span style="font: small-caps 14pt Times New Roman, Times, Serif; color: #1F4E79"><b><span id="a_017"></span>The Annual Meeting</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6.75in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_018"></span>Purpose of Meeting</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The specific Proposals to be considered and acted upon at the Annual Meeting are summarized in the Notice and &#8220;<i>Summary of the Proxy Statement</i>&#8221; above and are described in more detail in this Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_019"></span>Attendance at the Annual Meeting</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As permitted by Delaware law and our Bylaws, as amended and restated effective June&#160;13, 2023 (the &#8220;<b><i>Bylaws</i></b>&#8221;), the Annual Meeting will be held as a virtual meeting live via the Internet. As an owner of Common Stock and/or Series F Preferred Stock, you will be able to attend the Annual Meeting via live webcast by visiting NovaBay&#8217;s virtual meeting website (www.virtualshareholdermeeting.com/NBY2025) at the meeting time. Upon visiting the meeting website, you will be prompted to enter your 16-digit control number provided on your proxy card. Your unique control number allows us to identify you as a stockholder and will enable you to securely log on, vote and submit questions during the Annual Meeting on the meeting website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Shares of Common Stock which you are the beneficial owner, but not the stockholder of record, also may be voted electronically during the Annual Meeting if you have a 16-digit control number. If there is no 16-digit control number included on your instructions, please refer to the information provided by your broker, bank or other holder of record for voting information and/or instruction on how to attend the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if you plan to attend the Annual Meeting virtually, NovaBay recommends that you vote your shares in advance, so that your vote will be counted if you later decide not to attend the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_020"></span>Voting; Quorum</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The record date for determining those stockholders who are entitled to notice of, and to vote at, the Annual Meeting has been fixed as September&#160;22, 2025 (&#8220;<b><i>Record Date</i></b>&#8221;). Only holders of Common Stock and holders of Series F Preferred Stock of record at the close of business on the Record Date are entitled to notice of, and to vote at, the Annual Meeting and any adjournment or postponement thereof. Each stockholder of Common Stock is entitled to one (1) vote for each share of our Common Stock held by such stockholder as of the Record Date. Each holder of Series F Preferred Stock is entitled to the voting equivalent of approximately 0.424 shares of Common Stock for each outstanding share of Series F Preferred Stock held. Holders of Common Stock and Series F Preferred Stock will vote together as a single class.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the Record Date, 6,005,749 shares of our Common Stock and 1,986,565 shares of Series F Preferred Stock (having the voting equivalent of an aggregate of 842,832 shares of Common Stock) were outstanding. There were also 131 shares of our Series B Preferred Stock and 481,250 shares of our Series D Preferred Stock outstanding as of the Record Date. Neither the Series B Preferred Stock nor the Series D Preferred Stock have voting rights for any of the Proposals, and, therefore, cannot be voted at the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The presence at the Annual Meeting, either in person or by duly authorized proxy, of holders of one-third (1/3) of the voting power of all the outstanding shares of our stock entitled to vote will constitute a quorum for the transaction of business at the Annual Meeting, in line with the Bylaws. Stockholders who log on and vote at our virtual meeting of stockholders with their 16-digit control number (which is provided on your proxy card) are considered present in person at the Annual Meeting. Abstentions are counted as present for purposes of determining the presence of a quorum. If a quorum is not present, we expect that the Annual Meeting will be adjourned or postponed in order to permit further solicitation of proxies until a quorum is obtained. If a quorum is not present, the Annual Meeting will be adjourned or postponed in order to permit further solicitation of proxies until a quorum is obtained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_021"></span>Voting Commitments</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Pursuant to the Series F Agreements that we entered into in connection with the Investment Transaction, the Remaining Warrant Holders agreed to vote all of their Series F Preferred Stock, which represents approximately 12.3% of the voting power as of the Record Date, in favor of each of the Proposals presented to stockholders at this Annual Meeting. Also in connection with the Investment Transaction, we and Mr.&#160;Lazar separately entered into the Voting Agreement with Jad Fakhry and the Poplar Entities pursuant to which the Poplar Entities agreed to vote all of their shares of Common Stock,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> approximately 17.5% of outstanding Common Stock as of June&#160;4, 2025, at the Annual Meeting in favor of each of the Proposals presented to stockholders at this Annual Meeting. As a result of these voting commitments by the Remaining Warrant Holders and the Poplar Entities, we expect that approximately 29.8% of the voting power at this Annual Meeting will be present at the Annual Meeting for purposes of establishing a quorum and will vote to approve each of the director nominees, for three years in relation to the Say-on-Frequency proposal and to approve the remaining Proposals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_022"></span>Required Votes and Effects of Abstentions and Broker Non-Votes</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Votes Generally</i></b></span>. Votes will be counted by the inspector of election appointed for the Annual Meeting, who will separately count, for each proposal, votes &#8220;FOR&#8221; and &#8220;Against,&#8221; abstentions, and, if applicable, broker non-votes (as well as &#8220;ONE YEAR&#8221;, &#8220;TWO YEARS&#8221; AND &#8220;THREE YEARS&#8221; votes with respect to Proposal Three (Say-on-Frequency)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Abstentions and Broker Non-Votes</i></b></span>. Abstentions and broker non-votes will be counted towards the quorum requirement. A broker non-vote occurs when a broker, bank or other agent has not received voting instructions from the beneficial owner of the shares and the broker, bank or other agent cannot vote the shares because the matter is considered &#8220;non-routine&#8221; under NYSE rules. Proposals 1, 2, 3, 5, 6, 7 and 10 are considered to be &#8220;non-routine&#8221; under NYSE rules such that your broker, bank or other agent may not vote your shares on those Proposals in the absence of your voting instructions. As also provided in the chart below, Proposals 4, 8, 9 and 11 are considered to be &#8220;routine&#8221; under NYSE rules and thus if you do not return voting instructions to your broker, your shares may be voted by your broker in its discretion for these Proposals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Required Vote</i></b></span>. The following table summarizes the proposals and the minimum vote needed to approve each proposal and the effect of abstentions and broker non-votes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; width: 12%; text-align: left; vertical-align: bottom"><span style="color: #1F4E79"><b>Proposal No. </b></span></td>
    <td style="text-align: left; width: 2%"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 29%; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>Proposal Description</b></span></td>
    <td style="text-align: left; width: 2%"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>Vote Required for Approval</b></span></td>
    <td style="text-align: left; width: 2%"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>Effect of Abstentions</b></span></td>
    <td style="text-align: left; width: 1%"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>Effect of Broker Non-Votes</b></span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; vertical-align: top; text-align: left">One</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; text-align: justify">Election of the three (3) following director nominees:</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.35pt; text-align: justify; text-indent: -15.35pt">&#9679;&#160;&#160;&#160;&#160;Paul E. Freiman</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.35pt; text-align: justify; text-indent: -15.35pt">&#9679;&#160;&#160;&#160;&#160;David E. Lazar</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.35pt; text-align: justify; text-indent: -15.35pt">&#9679;&#160;&#160;&#160;&#160;Swan Sit </p> </td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Plurality with the three director candidates who receive the highest number of &#8220;FOR&#8221; votes being elected</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">No effect</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">No effect</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; vertical-align: top; text-align: left">Two</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Approve, on an advisory and non-binding basis, the compensation of NovaBay&#8217;s named executive officers, as disclosed in this Proxy Statement</p> </td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Against</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">No effect</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; vertical-align: top; text-align: left">Three</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">Vote, on an advisory and non-binding basis, on the frequency of solicitation of stockholder approval of executive compensation</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">The frequency that receives the greatest number of votes will be considered the selection by stockholders</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">No effect</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">No effect</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; vertical-align: top; text-align: left">Four</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">Ratification, on an advisory and non-binding basis, of the selection of WithumSmith+Brown, PC as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2025</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Against</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Not applicable as a routine matter brokers may vote on</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; vertical-align: top; text-align: left">Five </td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">Approve, as required by, and in accordance with, Sections&#160;713(a) and 713(b) of the Company Guide, both: (i) the issuance of an aggregate of 77,000,000 shares of Common Stock upon the exercise of the Series D Preferred Stock that were issued in the First Closing and</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Against</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">No effect</td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> (ii) the issuance of an aggregate of 43,000,000 shares of Common Stock upon the exercise of the Series E Preferred Stock expected to be issued in the Final Closing</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 12%">&#160;</td>
    <td style="text-align: left; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 29%">&#160;</td>
    <td style="text-align: left; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 28%">&#160;</td>
    <td style="text-align: left; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 12%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 12%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Six</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">Approve an amendment to our 2017 Omnibus Plan to increase the shares authorized under the 2017 Omnibus Plan by 1,000,000 shares of Common Stock resulting in a maximum number of shares currently available for issuance of 1,021,332 shares of Common Stock and to make corresponding changes to the share grant limitations in the 2017 Omnibus Plan</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Against</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">No effect</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Seven</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">Approve the issuance and payment of the Equity Consideration, with an aggregate value of $40,000, at a price per share which may be below the market price (as reported by the NYSE American) on the date of issuance, to each of the Resigning Non-Employee Directors as contemplated by the Release Agreements</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Against</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">No effect</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Eight</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">Approve an amendment to the Certificate of Incorporation to effect the Reverse Stock Split, and to grant authorization to the Board to determine, in its sole discretion, the specific split ratio and the effective time (if at all)</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#8220;FOR&#8221; votes of a majority of the votes cast at the Annual Meeting</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">No effect</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Not applicable as a routine matter brokers may vote on </td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Nine</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">Approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our Common Stock from 150,000,000 to 1,500,000,000</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#8220;FOR&#8221; votes of a majority of the votes cast at the Annual Meeting</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">No effect</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Not applicable as a routine matter brokers may vote on</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Ten</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">Approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our preferred stock, par value $0.01, from 5,000,000 to 10,000,000</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#8220;FOR&#8221; votes of a majority of our outstanding shares entitled to vote at the Annual Meeting</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Against</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Against</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Eleven</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">Approve the adjournment of the Annual Meeting</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#8220;FOR&#8221; votes of the majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Against</td>
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Not applicable as a routine matter brokers may vote on </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is important to understand that we are not seeking stockholder approval of, and you are <span style="text-decoration: underline">not</span> being asked to vote on, the Investment Transaction (with the First Closing having already been completed), the issuance of the Series D Preferred Stock (which have already been issued) or the issuance of the Series E Preferred Stock at the Final Closing (which has yet to occur and is subject to the satisfaction of closing conditions as described in this Proxy Statement). Instead, pursuant to Proposal Five (NYSE American Proposal), we are seeking your approval of the issuance of shares of Common Stock to be issued upon conversion of the shares of Series D Preferred Stock and, if issued at the Final Closing, the shares of Series E Preferred Stock, as well as the other Proposals Six through Ten that are matters being submitted in connection with the Investment Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_023"></span>Effect of Not Voting</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Stockholder of Record; Shares Registered in Your Name</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you are a stockholder of record and do not vote by telephone or over the Internet or by completing and returning your proxy card, your shares will not be voted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Beneficial Owner; Shares Registered in the Name of a Broker, Bank or Other Nominee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you are a beneficial owner and do not instruct your broker, bank or other nominee on how to vote your shares, the question of whether your broker, bank or other nominee will still be able to vote your shares depends on whether the NYSE American deems the particular proposal to be a &#8220;routine&#8221; matter. Brokers, banks or other nominees can use their discretion to vote &#8220;uninstructed&#8221; shares with respect to matters that are considered to be &#8220;routine,&#8221; but not with respect to &#8220;non-routine&#8221; matters. Under the rules and interpretations of NYSE American, &#8220;non-routine&#8221; matters are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation (including any advisory stockholder votes on executive compensation and on the frequency of stockholder votes on executive compensation), and certain corporate governance proposals, even if management supported. Accordingly, your broker, bank or other nominee may not vote your shares on Proposals 1, 2, 3, 5, 6, 7 and 10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_024"></span>Voting Methods</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you were a registered stockholder on the Record Date, you may vote your shares at the virtual Annual Meeting, www.virtualshareholdermeeting.com/NBY2025, which contains voting instructions. You may also vote your shares by telephone by calling (toll free within the U.S. and Canada) 1-800-690-6903 and following the voting instructions read to you by the automated operator. Upon visiting the meeting website or calling the call-in telephone line, you will be prompted to enter your 16-digit control number provided to you on your proxy card. Your unique control number allows us to identify you as a stockholder and will enable you to securely cast votes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Internet and telephone voting facilities for stockholders of record will be available 24 hours a day beginning at 12:01 a.m. Pacific Time on September&#160;23, 2025. Internet and telephone voting will close promptly at 11:59 p.m. Eastern Time on Wednesday, October&#160;15, 2025. After internet and telephone voting closes, you will only be able to vote by attending the Annual Meeting via live webcast and voting at the Annual Meeting. The Annual Meeting starts at 11:00 a.m. (Pacific Time) on October&#160;16, 2025. After voting is closed during the Annual Meeting, you will no longer have the ability to vote your shares for the specific Proposals considered at the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you are a registered stockholder as of the Record Date and hold your shares in more than one fund or other affiliated investment vehicle, you will receive separate voting credentials for each such entity that is a record holder of shares of our Common Stock. Please be sure to log on separately for each fund in order to cast all votes that you are entitled to cast at the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you receive proxy materials by mail or if you request paper copies of the proxy materials, you can vote by mail by marking, dating, signing and returning your proxy card in the postage-paid envelope. Further instructions on how to vote by mail are included on the proxy card. Only proxy cards that have been signed, dated, and timely returned will be counted towards the quorum and entitled to vote.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you submit your proxy card and it does not specify how the shares represented thereby are to be voted, then the proxy will be voted &#8220;FOR&#8221; the election of the directors proposed by the Board under Proposal One, &#8220;FOR&#8221; the approval of Proposal Two, &#8220;THREE YEARS&#8221; for Proposal Three, and &#8220;FOR&#8221; Proposal Four through Proposal Eleven described in this Proxy Statement. The proxy card also grants the proxy holder discretionary authority to vote on any other business that may properly come before the Annual Meeting. We have not been notified by any stockholder of his or her intent to present a stockholder proposal at the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_025"></span>Revoking Proxies</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If your shares are held in your name, you may revoke or change your vote at any time before the Annual Meeting by (i) submitting another proxy on a later date on the Internet or by telephone (only your latest Internet or telephone proxy submitted prior to the Annual Meeting will be counted); (ii) attending the Annual Meeting live via webcast and voting during the meeting (simply attending the virtual meeting will not, by itself, revoke your proxy);</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> or (iii) by filing a notice of revocation or submitting another signed proxy card with a later date with our Corporate Secretary, Mr.&#160;Justin M. Hall, Esq., at our principal executive offices at 2000 Powell Street, Suite 1150, Emeryville, California 94608. Unless so revoked, the shares represented by such proxies or voting instructions will be voted at the Annual Meeting and all adjournments or postponements of the Annual Meeting. Proxies solicited on behalf of the Board will be voted in accordance with the directions given.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_026"></span>Solicitation</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NovaBay will bear the entire cost of proxy solicitation, including the costs of preparing, assembling, printing and mailing this Proxy Statement, the Notice, the proxy card and any additional solicitation materials furnished to the stockholders. Copies of these materials will be furnished to brokers, banks or other nominees holding shares in their names that are beneficially owned by others so they may forward these materials to such beneficial owners. In addition, we may reimburse such persons for their reasonable expenses in forwarding the solicitation materials to the beneficial owners. The original solicitation of proxies by mail may be supplemented by a solicitation by personal contact, telephone, facsimile, email or any other means by our directors, officers or employees. No additional compensation will be paid to these individuals for any such services. In addition, we have engaged Sodali &amp; Co., to assist in the solicitation of proxies and provide related advice and informational support. For additional information about this engagement, please see &#8220;Method of Proxy Solicitation&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_027"></span>Other Matters</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other than the Proposals described in the Proxy Statement, the Board is not aware of any other business that will be presented for consideration at the Annual Meeting. If any other matters should be properly presented at the Annual Meeting or any adjournments or postponements of the Annual Meeting for action by stockholders, the person named in the form of proxy will vote the proxy, pursuant to the authority provided to him or her, in accordance with his or her best judgment on that matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_028"></span>Results of the Voting at the Annual Meeting</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four (4) business days after the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 7in; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: small-caps 14pt Times New Roman, Times, Serif; color: #1F4E79"><b><span id="a_029"></span>Matters to be Considered at the Annual Meeting</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="font-variant: small-caps">&#160;</span></b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: small-caps 14pt Times New Roman, Times, Serif; color: #1F4E79"><b><span id="a_030"></span>Proposal One:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: small-caps 14pt Times New Roman, Times, Serif; color: #1F4E79"><b>Election of Directors</b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation provides for a classified Board consisting of three (3) classes of directors, Class I, Class II and Class III, each with staggered three (3)-year terms. As a result, a portion of our Board will be elected at each annual meeting. In connection with the Investment Transaction and the appointment of Mr.&#160;Lazar as a director in connection with the First Closing, the size of our Board was increased from seven (7) directors to eight (8) directors. At this year&#8217;s Annual Meeting, the current term of the Class III directors will expire and our stockholders will vote on the three Class III director nominees identified below. Pursuant to the Purchase Agreement, Mr.&#160;Lazar received certain investor rights relating to the Board, which included a one-time contractual right to recommend one (1) individual to be nominated for election at this Annual Meeting, which right was exercised by Mr.&#160;Lazar recommending himself for nomination to the Board at this Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon the recommendation of the N&amp;CG Committee of the Board, our Board selected and approved Dr. Paul E. Freiman (&#8220;<b><i>Dr. Freiman</i></b>&#8221;), Mr.&#160;Lazar and Ms. Swan Sit (&#8220;<b><i>Ms. Sit</i></b>&#8221;) as nominees for election as Class III directors at this Annual Meeting to serve for a term of three (3) years, expiring at the 2028 Annual Meeting of Stockholders, until their respective successors are duly elected and qualified or until their earlier resignation or removal. Each nominee has agreed to serve if elected. Management has no reason to believe any of the nominees herein will be unable to serve. In the event any of the nominees named is unable to serve or declines to serve at the time of the Annual Meeting, the proxy holders will exercise discretionary authority to vote for substitutes. Unless otherwise instructed, the proxy holders will vote the proxies received by them &#8220;FOR&#8221; the nominees named above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Mijia (Bob) Wu (&#8220;<b><i>Mr.&#160;Wu</i></b>&#8221;) and Dr. Yenyou (Jeff) Zheng (&#8220;<b><i>Dr. Jeff Zheng</i></b>&#8221;) have been designated as Class I directors whose terms expire at the 2026 Annual Meeting of Stockholders. Further, Ms. Julie Garlikov (&#8220;<b><i>Ms. Garlikov</i></b>&#8221;), Mr.&#160;Justin M. Hall, Esq. (&#8220;<b><i>Mr.&#160;Hall</i></b>&#8221;), and Mr.&#160;Yongxiang (Sean) Zheng (&#8220;<b><i>Mr.&#160;Sean Zheng</i></b>&#8221;) have been designated as Class II directors whose terms expire at the 2027 Annual Meeting of Stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the First Closing and pursuant to the terms of the Release Agreements, Mr.&#160;Hall and the Resigning Non-Employee Directors (Dr. Freiman, Ms. Garlikov, Ms. Sit, Mr.&#160;Wu and Mr.&#160;Sean Zheng) agreed to resign after the Annual Meeting and upon the Resignation Event, including the Final Closing occurring which the Company expects to occur by the end of the fourth quarter of 2025. Dr. Jeff Zheng is not a Resigning Non-Employee Director and did not enter into a Release Agreement. Dr. Jeff Zheng is expected to continue to serve on the Board after the Resignation Event until his earlier resignation or removal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_031"></span>Current Directors and Nominees</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The names of our director nominees and other current directors, as well as their ages (as of September&#160;22, 2025) and biographical information about them are as follows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: Black"><b><i><span id="a_032"></span>Class III Directors &#8211; Terms Expiring at the 2025 Annual Meeting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: gainsboro">
    <td colspan="4" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"><span style="font-variant: small-caps"><b>Paul E. Freiman, Ph.D. </b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: rgb(31,78,121) 2pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Chair &amp; Independent Director</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Age: </b>91</p></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director since: </b>May&#160;2002</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees: </b>Compensation (Chair), Audit, N&amp;CG and Special Transaction (Chair)</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Current Occupation: </b>Independent Pharmaceutical Professional &amp; Consultant</p></td></tr>
  <tr style="vertical-align: top">
    <td colspan="4"><b>Selected Director Qualifications:</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="text-align: justify">Extensive historical knowledge about NovaBay, having served over 20 years as one of our directors, providing valuable Board continuity</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="text-align: justify">Valuable operational and industry expertise and leadership skills from prior experiences as a chief executive officer as well as a board member of various pharmaceutical companies</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid"><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 2pt solid; text-align: justify">Experience in multiple acquisitions, for example guiding Syntex Corporation (&#8220;<b><i>Syntex</i></b>&#8221;) through an acquisition by Roche for $5.3 billion</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0pt; padding-bottom: 0pt; width: 0.2in">&#160;</td>
    <td style="padding-top: 0pt; padding-bottom: 0pt; width: 0.25in">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; padding-bottom: 0pt; width: 18%">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&#160;</td></tr>
  </table>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Dr. Freiman has been an independent pharmaceutical professional and consultant since January&#160;2009. He was also a board member of Chronix Biomedical Inc., a private molecular diagnosis company, from 2009 until its acquisition by Oncocyte Corporation in April&#160;2021. Dr. Freiman&#8217;s prior experience includes serving as the president and chief executive officer of Neurobiological Technologies, Inc. (OTC: NTII) and a member of its board of directors from April&#160;1997 until 2009. Dr. Freiman&#8217;s prior experience also includes serving as the former chairman and chief executive officer of Syntex from 1989 to 1994. He is credited with much of the marketing success of Syntex&#8217;s lead product, Naprosyn, and was responsible for moving the product to over-the-counter status, marketed as Aleve. Dr. Freiman served as chairman of the board of Neurotrope, Inc. (OTCBB: BLFL) from 2013 until August&#160;2016. Dr. Freiman served as chairman of Penwest Pharmaceutical Co. until 2010 and served on the board of directors of Otsuka American Pharmaceuticals, Inc. and Otsuka America, Inc. until 2011, NeoPharm, Inc. until 2010 and Calypte Biomedical Corporation until September&#160;2009. Dr. Freiman also served on the board (including as chairman) of the Pharmaceutical Research and Manufacturers Association of America. He has also served on a number of industry task forces both domestically and internationally. Dr. Freiman received a B.S. in pharmacy from Fordham University and an honorary doctorate from the Arnold &amp; Marie Schwartz College of Pharmacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: gainsboro">
    <td colspan="4" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"><span style="font-variant: small-caps"><b>David E. Lazar</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: rgb(31,78,121) 2pt solid">
        <p style="margin-top: 0; margin-bottom: 0"><b>Director</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>Age:</b> 35</p></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: justify">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Director since: </b>August&#160;2025</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Committees: </b>None</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Current Occupation: </b>Chief Executive Officer of NovaBay</p></td></tr>
  <tr style="vertical-align: top">
    <td colspan="4"><b>Selected Director Qualifications:</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="text-align: justify">Valuable expertise and leadership skills from prior experiences as a chief executive officer, as well as a board member of various publicly-traded companies, including in the pharmaceutical industry</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid"><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 2pt solid; text-align: justify">Experience in transformative transactions by publicly-traded companies</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0pt; width: 0.2in; padding-bottom: 0pt">&#160;</td>
    <td style="padding-top: 0pt; width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; width: 18%; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Lazar currently serves as NovaBay&#8217;s Chief Executive Officer, and has served as Chief Executive Officer since August&#160;2025 upon the First Closing occurring. Mr.&#160;Lazar previously served as director on the board of directors of FiEE, Inc. (formerly Minim, Inc.) (NASDAQ: FIEE) where he also previously served as the Chief Executive Officer and Chief Financial Officer from December&#160;2023 to February&#160;2025. Mr.&#160;Lazar served as interim Chief Executive Officer and principal financial officer of Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), from January&#160;2, 2025 through February&#160;26, 2025. Mr.&#160;Lazar served as the Chief Executive Officer of Titan Pharmaceuticals Inc. listed on Nasdaq (NASDAQ: TTNP) from August&#160;2022 to April&#160;2024, where he also served as a director and board chairman from August&#160;2022 until October&#160;2023. Mr.&#160;Lazar also served as the chief executive officer and chairman of the board of directors of OpGen, Inc. (OTC: OPGN) from March&#160;2024 to August&#160;2024. Mr.&#160;Lazar also served as the president and a member of the board of directors of LQR House Inc. (NASDAQ: YHC) from October&#160;2024 to April&#160;2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: gainsboro">
    <td colspan="4" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"><span style="font-variant: small-caps"><b>Swan Sit</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: rgb(31,78,121) 2pt solid">
        <p style="margin-top: 0; margin-bottom: 0"><b>Independent Director</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>Age:</b> 48</p></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: justify">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Director since: </b>December 2019</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Committees: </b>Audit, Compensation and N&amp;CG</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Current Occupation: </b>Independent Business Consultant</p></td></tr>
  <tr style="vertical-align: top">
    <td colspan="4"><b>Selected Director Qualifications:</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="text-align: justify">Experience in brand management and advertising</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid"><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 2pt solid; text-align: justify">Expertise in the digital transformation of companies through ecommerce</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0pt; width: 0.2in; padding-bottom: 0pt">&#160;</td>
    <td style="padding-top: 0pt; width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; width: 18%; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Ms. Sit currently acts as an independent business consultant to various public and private companies. Ms. Sit also serves as a director of Edgewell Personal Care Company (NYSE: EPC) since September&#160;2020. She previously served as the Vice President of NA Digital Commerce Capabilities, Business Operations and Service and the Vice President of Global Digital Marketing of Nike, Inc. from 2018 to 2019. Prior to such position, Ms. Sit served as the Vice President of Global Digital of Revlon and Elizabeth Arden, Inc. from 2015 to 2017 and the Executive Director of Strategy and Planning, Online of The Est&#233;e Lauder Companies, Inc. Ms. Sit brings business experience including digital transformation experience supplemented by management consulting, brand management and advertising. Ms. Sit has built front-end consumer experiences across ecommerce, omnichannel, mobile, media, social, apps and innovation as well as integrated back-end operations. Ms. Sit received an MBA from Columbia Business School and a B.A. in Economics from Harvard University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6.5in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_033"></span>Stockholder Approval </b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A plurality of the votes entitled to be cast at the Annual Meeting is required for approval of each of the director nominees. Unless otherwise instructed in the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted &#8220;FOR&#8221; this proposal. Abstentions and broker non-votes, if any, with respect to this Proposal One, will have no effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 7in; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79"><b><span style="text-decoration: underline">Recommendation of Our Board</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79">Our Board unanimously recommends that you vote &#8220;FOR&#8221; each of the Class III director nominees listed above.</span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="a_034"></span>Class I Directors &#8211; Terms Expiring at the 2026 Annual Meeting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: gainsboro">
    <td colspan="4" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"><span style="font-variant: small-caps"><b>Mijia (Bob) Wu, M.B.A. </b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: rgb(31,78,121) 2pt solid">
        <p style="margin-top: 0; margin-bottom: 0"><b> Director</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>Age:</b> 50</p></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: justify">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Director since: </b>January 2016</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Committees: </b>Special Transaction</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Current Occupation: </b>Managing Director of China Kington Investment Co. Ltd. and Managing Director of Shanghai Ceton Investment Management Co. Ltd.</p></td></tr>
  <tr style="vertical-align: top">
    <td colspan="4"><b>Selected Director Qualifications:</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="text-align: justify">Over 15 years of valuable experience in finance and investments</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid"><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 2pt solid; text-align: justify">Expertise in the international market</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0pt; width: 0.2in; padding-bottom: 0pt">&#160;</td>
    <td style="padding-top: 0pt; width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; width: 18%; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since June&#160;2008, Mr.&#160;Wu has been the Managing Director of China Kington Investment Co. Ltd. (an affiliated entity of China Kington Asset Management, which has a long-standing relationship with NovaBay). Certain related-party historic transactions between the Company and China Kington are described in the Company&#8217;s prior filings with the SEC. Concurrently, he has served as the Managing Director of Shanghai Ceton Investment Management Co. Ltd. From October&#160;2013 to January&#160;2022, he also served as the Non-Executive Director of Pioneer. Previously, he served as a Director of UBS AG, Hong Kong Branch in 2007 and Vice President of BNP Paribas Hong Kong from 2005 to 2006. He was also the Assistant Vice President at ABN AMRO Bank (China) Co., Ltd. from 2002 to 2005. He holds an M.B.A. from Manchester Business School, University of Manchester, and an Executive M.B.A. from Cheung Kong Graduate School of Business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: gainsboro">
    <td colspan="4" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"><span style="font-variant: small-caps"><b>Yenyou (Jeff) Zheng, Ph.D. </b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: rgb(31,78,121) 2pt solid">
        <p style="margin-top: 0; margin-bottom: 0"><b> Independent Director</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>Age:</b> 69</p></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: justify">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Director since: </b>September 2019</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Committees: </b>N&amp;CG (Chair), Audit (Chair), Compensation and Special Transaction</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Current Occupation: </b>Director of Business Development of Craft Capital Management LLC</p></td></tr>
  <tr style="vertical-align: top">
    <td colspan="4"><b>Selected Director Qualifications:</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="text-align: justify">Significant strategic experience in corporate financing solutions from his current experience at both Craft Capital Management LLC and Spartan Securities Group, Ltd.</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid"><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 2pt solid; text-align: justify">Extensive network of contacts related to financing, partnering and support services</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0pt; width: 0.2in; padding-bottom: 0pt">&#160;</td>
    <td style="padding-top: 0pt; width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; width: 18%; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Dr. Jeff Zheng has served as the Director of Business Development of, and as a broker with, Craft Capital Management LLC since September&#160;2019. Dr. Jeff Zheng is also currently an independent director with Mars Acquisition Corp. Prior to that, Dr. Jeff Zheng served as the Director of Business Development of Spartan Securities Group, Ltd. from 2014 to August&#160;2019. Dr. Jeff Zheng&#8217;s experience includes providing innovative financial solutions and consulting services for initial public offering underwriting and investment banking as well as corporate financing solutions with a particular focus on Chinese companies listed overseas. Dr. Jeff Zheng previously served as a financial advisor for various Canadian public companies including: P &amp; P Ventures Inc. (TSX-V: PPV.H) where he served as president and a director; Damon Capital Corp (TSX-V: DAM.H) where he served as Chief Financial Officer and a director; and Cantronic Systems Inc. (TSX-V: CTS) where he served as a director and chair of the audit committee. Dr. Jeff Zheng received a Ph.D. in physics from Flinders University of South Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="a_035"></span>Class II Directors &#8211; Terms Expiring at the 2027 Annual Meeting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: gainsboro">
    <td colspan="4" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"><span style="font-variant: small-caps"><b>Julie Garlikov </b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: rgb(31,78,121) 2pt solid">
        <p style="margin-top: 0; margin-bottom: 0"><b> Independent Director</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>Age:</b> 54</p></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: justify">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Director since: </b>January 2022</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Committees: </b>None</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Current Occupation: </b>Vice President of Global Marketing of CareDx</p></td></tr>
  <tr style="vertical-align: top">
    <td colspan="4"><b>Selected Director Qualifications:</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="text-align: justify">Over 25 years of experience in consumer marketing</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="text-align: justify">Extensive expertise in health, beauty and eyecare products, as well as in direct to consumer advertising and digital demand generation</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid"><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 2pt solid; text-align: justify">Leadership of NovaBay through the DERMAdoctor Divestiture and Avenova Asset Divestiture</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0pt; width: 0.2in; padding-bottom: 0pt">&#160;</td>
    <td style="padding-top: 0pt; width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; width: 18%; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Ms. Garlikov currently serves as the Vice President of Global Marketing of CareDx, a leading precision medicine solutions company focused on clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. She previously served as the Chief Commercial Officer of Sherlock Biosciences, a biotechnology CRISPR diagnostic company from 2022 to 2024 and was the Vice President of Marketing of Grail, LLC, a biotechnology and pharmaceutical company focused on early cancer detection from 2020 to 2022. Ms. Garlikov has over 25 years of experience in marketing, which includes serving as the Chief Marketing Officer or Leader at GRAIL, New Age and Shaklee, as well as senior marketing positions at Rodan &amp; Fields, Obagi Medical, Nuvesse Skin Therapies and Allergan. She is a classically trained consumer packaged goods sales and marketing leader who gained her consumer experience at Procter &amp; Gamble, Johnson &amp; Johnson and PepsiCo and has deep expertise in both health, beauty and eyecare products, as well as in direct to consumer advertising and digital demand generation. Ms. Garlikov has a Bachelor&#8217;s degree from the University of California, Berkley and a Master&#8217;s degree in Business Administration from Columbia University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: gainsboro">
    <td colspan="4" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"><span style="font-variant: small-caps"><b>Justin M. Hall, Esq. </b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: rgb(31,78,121) 2pt solid">
        <p style="margin-top: 0; margin-bottom: 0"><b>Director</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>Age:</b> 48</p></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: justify">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Director since: </b>August 2020</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Committees: </b>None</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Current Occupation: </b>Vice President of Business Development, General Counsel and Corporate Secretary of NovaBay</p></td></tr>
  <tr style="vertical-align: top">
    <td colspan="4"><b>Selected Director Qualifications:</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="text-align: justify">Extensive knowledge of NovaBay&#8217;s historic operations and employees due to his tenure and continuing leadership of the Company</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid"><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 2pt solid; text-align: justify">Expertise in the pharmaceutical industry and legal issues surrounding NovaBay&#8217;s historic business</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0pt; width: 0.2in; padding-bottom: 0pt">&#160;</td>
    <td style="padding-top: 0pt; width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; width: 18%; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Hall currently serves as NovaBay&#8217;s Vice President of Business Development, General Counsel and Corporate Secretary of NovaBay. Mr.&#160;Hall has served as NovaBay&#8217;s Vice President of Business Development since August&#160;2025 and as General Counsel and Corporate Secretary since June&#160;2019. He previously served as NovaBay&#8217;s Chief Executive Officer from June&#160;2019 until his resignation effective at the First Closing. Mr.&#160;Hall served as the Company&#8217;s Interim President and Chief Executive Officer from March&#160;2019 to June&#160;2019 and as the Company&#8217;s Senior Vice President and General Counsel beginning in December&#160;2015. Prior to this, he served as the Company&#8217;s lead in-house counsel beginning in February&#160;2013. Prior to joining the Company, Mr.&#160;Hall worked as Corporate Counsel at Accuray Incorporated, a radiation oncology company, which he joined in October&#160;2006, where he provided substantive legal advice on a broad range of complex legal matters with a focus on employment, corporate compliance, and corporate governance. Mr.&#160;Hall&#8217;s prior experience also includes serving as an investment advisor at Sagemark Consulting from 2000 to 2006, and a stockbroker at First Security Van Kasper from 1998 to 2001. Mr.&#160;Hall received a B.A. in Business Administration and Management from the University of California, San Diego, and a J.D. from the University of San Diego, School of Law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: gainsboro">
    <td colspan="4" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"><span style="font-variant: small-caps"><b>Yongxiang (Sean) Zheng </b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: rgb(31,78,121) 2pt solid">
        <p style="margin-top: 0; margin-bottom: 0"><b>Director</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>Age:</b> 56</p></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: justify">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Director since: </b>January 2022</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Committees: </b>None</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><b>Current Occupation: </b>General Manager of the Investment Department of Pioneer</p></td></tr>
  <tr style="vertical-align: top">
    <td colspan="4"><b>Selected Director Qualifications:</b></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid"><span style="font-family: Wingdings; color: #1F4E79">&#175;</span></td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 2pt solid; text-align: justify">More than 27 years&#8217; experience in mergers and acquisitions, fund management and import/export businesses</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0pt; width: 0.2in; padding-bottom: 0pt">&#160;</td>
    <td style="padding-top: 0pt; width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; width: 18%; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Sean Zheng has served as the General Manager of the Investment Department of China Pioneer Pharma Holding Ltd. since January&#160;1, 2024. Prior to joining China Pioneer Pharma Holding Ltd., he served as the Managing Director of Q3 Medical Devices (Shanghai) Co. Ltd. from November&#160;2021 to December&#160;2023. Prior to joining Q3 Medical, Mr.&#160;Sean Zheng held several leadership positions, including Managing Director of Boill Fund Management (HK) Co., Ltd. and Managing Director and Chief Executive Officer of Sprott- Zijin Mining fund, a joint venture fund between Zijin Mining Group and Sprott Asset Management LP. From 2007 to 2011, Mr.&#160;Sean Zheng served as a director of Dingtian Asset Management. Mr.&#160;Sean Zheng has also been a CFA chartered holder since 2006. Mr.&#160;Sean Zheng graduated from Renmin University of China in 1992 and holds a B.S. degree in Commodity Science. He received his MBA from the University of New South Wales in 2002 and earned a master&#8217;s degree of EMBA from China Europe International Business School (CEIBS) in 2010.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_036"></span>Family Relationships</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are no family relationships among any of our directors, director nominees or executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 7in; text-align: center; vertical-align: middle"><span style="font: small-caps 14pt Times New Roman, Times, Serif; color: #1F4E79"><b><span id="a_037"></span>Corporate Governance</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6.5in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_038"></span>Code of Ethics and Business Conduct</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board has adopted a Code of Ethics and Business Conduct (the &#8220;<b><i>Code of Ethics</i></b>&#8221;) which applies to all directors, officers (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) and employees. The full text of our Code of Ethics is available on the Corporate Governance section of our website at <span style="text-decoration: underline">www.novabay.com</span>. We intend to disclose future amendments to certain provisions of the Code of Ethics, and any waivers of provisions of the Code of Ethics required to be disclosed under the rules of the SEC, at the same location on our website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6.5in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_039"></span>Director Independence</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board has determined that each of Dr. Freiman, Ms. Garlikov, Ms. Sit and Dr. Jeff Zheng satisfies the requirements for &#8220;independence&#8221; as defined in the NYSE American Company Guide. The remaining directors, who are not independent, do not and will not serve on any committees of the Board as long as they are not independent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: #1F4E79"><b><span id="a_040"></span>Board Committees and Meetings</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board has three (3) standing committees, including an Audit Committee, a Compensation Committee and an N&amp;CG Committee. As part of the Board&#8217;s approval of the Investment Transaction, the Board established a Special Transaction Committee of the Board. Each of the Board&#8217;s three (3) standing committees has a written charter that is reviewed annually and revised as appropriate. A copy of each standing committee&#8217;s charter is available on the Corporate Governance section of our website at <span style="text-decoration: underline">www.novabay.com</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121)">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); width: 40%; text-align: center; vertical-align: bottom"><b>Name</b></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); vertical-align: bottom; width: 15%; text-align: center"><b>Audit <br/> Committee</b></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); vertical-align: bottom; width: 15%; text-align: center"><b>Compensation <br/> Committee</b></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); vertical-align: bottom; width: 15%; text-align: center"><b>N&amp;CG <br/> Committee</b></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); vertical-align: bottom; width: 15%; text-align: center"><b>Special <br/> Transaction<br/> Committee</b></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E7E6E6; text-align: justify">Paul E. Freiman, Ph.D.*</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#9679;</span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">C</span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E7E6E6; text-align: center"><span style="color: #1F4E79">&#9679;</span></td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">C</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Julie Garlikov</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E7E6E6; text-align: justify">Justin M. Hall, Esq.</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E7E6E6; text-align: center">&#160;</td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">David E. Lazar</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E7E6E6; text-align: justify">Swan Sit</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#9679;</span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#9679;</span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E7E6E6; text-align: center"><span style="color: #1F4E79">&#9679;</span></td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Mijia (Bob) Wu, M.B.A.</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#9679;</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E7E6E6; text-align: justify">Yenyou (Jeff) Zheng, Ph.D. +</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">C</span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#9679;</span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E7E6E6; text-align: center"><span style="color: #1F4E79">C</span></td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #E7E6E6; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#9679;</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Yongxiang (Sean) Zheng</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; vertical-align: bottom">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: #1F4E79">&#9679;</span></td>
    <td style="text-align: justify">Member</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: #1F4E79">C</span></td>
    <td style="text-align: justify">Chair</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: #1F4E79">+</span></td>
    <td style="text-align: justify">Audit Committee Financial Expert</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: #1F4E79">*</span></td>
    <td style="text-align: justify">Chair of the Board</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The table below shows the number of Board and Committee meetings held in 2024. The Special Transaction Committee was formed in June&#160;2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); font-weight: bold; text-align: center">Number&#160;of<br/> Meetings Held</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; width: 40%; text-align: left">Board of Directors</td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; width: 20%; text-align: center">8</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: left">Audit Committee</td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: center">4</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: left">Compensation Committee</td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: Black 1pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: left; padding-bottom: 1pt">N&amp;CG Committee</td>
    <td style="border-right: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 2pt solid; text-align: center">1</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Directors are expected to attend Board meetings, our annual stockholders&#8217; meeting and the meetings of the committees on which they serve. In 2024, no director attended fewer than 75% of the aggregate number of Board and Committee meetings of the Board and committees on which he or she served. Following all of the regularly scheduled 2024 Board meetings, the independent directors met in an executive session. During 2024, Dr. Freiman served as Chair of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 3pt; padding-top: 3pt; text-align: left; padding-bottom: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committee</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 1pt solid; padding-top: 3pt; padding-bottom: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-right: 3pt; padding-top: 3pt; text-align: justify; padding-bottom: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committee Function</b></span></td></tr>
  <tr style="vertical-align: top">
    <td rowspan="15" style="padding-left: 3pt; padding-top: 3pt; text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yenyou (Jeff) Zheng, Ph.D., Chair</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul E. Freiman, Ph.D.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Swan Sit</span></p></td>
    <td style="border-left: rgb(31,78,121) 1pt solid; padding-top: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="padding-right: 3pt; padding-top: 3pt; text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board has determined that each member of the Audit Committee is independent, as defined in the Company Guide and Rule 10A-3 under the Exchange Act. Dr. Jeff Zheng qualifies as an &#8220;audit committee financial expert&#8221; as that term is defined in the rules and regulations established by the SEC.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The functions of this committee include, but are not limited to:</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting with our management and our independent registered public accounting firm periodically to consider the adequacy and effectiveness of our disclosure controls and procedures and our internal controls;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting findings regularly to the Board, including any issues that arise with respect to the quality or integrity of our financial statements, our compliance with legal or regulatory requirements, and the performance and independence of our independent registered public accounting firm;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering and pre-approving all audit and non-audit services to be rendered by our independent registered public accounting firm;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing, evaluating, engaging and determining the compensation of, overseeing the work of, and, when appropriate, dismissing our independent registered public accounting firm;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with management and our independent registered public accounting firm, prior to public release, our financial statements (including annual and quarterly financial statements in periodic reports to be filed with the SEC);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with our independent registered public accounting firm all of its significant findings during the year, including the status of previous audit recommendations, and any significant unadjusted audit differences;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; padding-bottom: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 3pt; text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; padding-bottom: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and discussing with management and our independent registered public accounting firm the accounting policies that may be viewed as critical, and reviewing and discussing any significant changes in our accounting policies and any accounting and financial reporting proposals that may have a significant impact on our financial reports;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 3pt; text-align: left; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 3pt; padding-top: 3pt; text-align: left; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 1pt solid; padding-top: 3pt; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-top: 3pt; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-top: 3pt; text-align: justify; width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-right: 3pt; padding-top: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">resolving disagreements between management and our independent registered public accounting firm regarding financial reporting;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 3pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 3pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inquiring of management, the Chief Financial Officer and/or the Controller, and our independent registered public accounting firm, about significant risks or exposures and assessing the steps management has taken to minimize such risks; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 3pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 3pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls and auditing matters.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 3pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 3pt; padding-bottom: 3pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-left: rgb(31,78,121) 1pt solid; padding-bottom: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="padding-right: 3pt; padding-bottom: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both our independent registered public accounting firm and internal financial personnel regularly meet privately with the Audit Committee and have unrestricted access to this committee.</span></td></tr>
  <tr style="vertical-align: top">
    <td rowspan="9" style="border-top: rgb(31,78,121) 2pt solid; padding-left: 3pt; padding-top: 3pt; text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul E. Freiman, Ph.D., Chair</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Swan Sit</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yenyou (Jeff) Zheng, Ph.D.</span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 1pt solid; padding-top: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-top: rgb(31,78,121) 2pt solid; padding-right: 3pt; padding-top: 3pt; text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board has determined that each member of the Compensation Committee is independent, as defined in the Company Guide.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The functions and scope of authority of the Compensation Committee include, but are not limited to:</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing, approving and reviewing the overall corporate policies, goals and objectives for the compensation of our CEO and other executive officers, as well as annually evaluating the performance of our CEO and other executive officers in light of the corporate goals and objectives, and determining and approving the compensation of our CEO and other executive officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically reviewing and making recommendations to the Board concerning our equity and other incentive compensation plans, including the need to amend existing plans or adopt new plans or arrangements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting the Board in the administration of our stock option plans and any equity or incentive compensation plans, and making recommendations to the Board as to stock option grants and other discretionary awards under such plans as to the executive officers; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing, at least annually, our pension and retirement plans, including any supplemental executive retirement plans, and making recommendations to the Board regarding the need to amend existing plans or adopt new ones for the purpose of implementing the Compensation Committee&#8217;s strategy regarding pension and retirement benefits.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 3pt; padding-bottom: 3pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 1pt solid; padding-bottom: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 3pt; padding-bottom: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decisions regarding executive compensation are ultimately determined by the Board upon recommendations of the Compensation Committee, which reviews a number of factors in its decisions, including market information about the compensation of executive officers at similarly-sized companies in our industry and geographic region, or peer group companies, and</span></td></tr>
  </table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 3pt; padding-bottom: 3pt; padding-top: 3pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 1pt solid; padding-bottom: 3pt; padding-top: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-right: 3pt; padding-bottom: 3pt; padding-top: 3pt; text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommendations from our CEO and Chief Financial Officer (&#8220;<b><i>CFO</i></b>&#8221;). The CEO and CFO attend meetings, and participate in discussions of the Compensation Committee, to the extent requested by the Compensation Committee. Neither the CEO nor CFO attend when their respective compensation package is being discussed.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future decisions regarding executive compensation will continue to be the responsibility of our Compensation Committee. Outside director compensation is determined by the entire Board after review and approval by the Compensation Committee. Director compensation is discussed further under the caption &#8220;<i>Director Compensation</i>&#8221; below.</span></p></td></tr>
  <tr style="vertical-align: top">
    <td rowspan="17" style="border-top: black 1pt solid; padding-left: 3pt; padding-top: 3pt; text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating and Corporate Governance:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yenyou (Jeff) Zheng, Ph.D., Chair</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul E. Freiman, Ph.D.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Swan Sit</span></p></td>
    <td style="border-top: black 1pt solid; border-left: rgb(31,78,121) 1pt solid; padding-top: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-top: black 1pt solid; padding-right: 3pt; padding-top: 3pt; text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board has determined that each member of the N&amp;CG Committee is independent, as defined in the Company Guide.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The functions of the N&amp;CG Committee include, but are not limited to:</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting the Board in establishing the minimum qualifications for a director nominee, including the qualities and skills that Board members are expected to possess;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">leading the search for and identifying qualified candidates to become members of our Board;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting nominees for election of directors at the next annual meeting of stockholders (or special meeting of stockholders at which directors are to be elected);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting candidates to fill vacancies on our Board;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the Board a determination with respect to each director&#8217;s &#8220;independence&#8221; under the listing standards, the rules and regulations of the SEC and any other laws applicable to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receiving, reviewing and responding to director nominations submitted in writing by our stockholders, including the proposed Additional Purchaser Nominee(s) that Mr. Lazar has a one-time contractual right to nominate after the Final Closing and in connection with the resignation of the Resigning Non-Employee Directors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and assisting the Board in developing a succession plan for the CEO;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing, assessing annually, and making recommendations to the Board concerning appropriate corporate governance policies, including our Code of Ethics, and monitoring compliance with our Code of Ethics and other corporate governance policies; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-bottom: 3pt; padding-left: 3pt; text-align: left; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 1pt solid; padding-bottom: 3pt; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-bottom: 3pt; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-bottom: 3pt; text-align: justify; width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-bottom: 3pt; padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing an annual review of the performance of the full Board and management and overseeing the annual self-evaluation process of each Board committee.</span></td></tr>
  </table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td rowspan="9" style="border-top: rgb(31,78,121) 2pt solid; padding-top: 3pt; padding-left: 3pt; text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Special Transaction:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul E. Freiman, Ph.D., Chair</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yenyou (Jeff) Zheng, Ph.D.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mija (Bob) Wu</span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 1pt solid; padding-top: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-top: rgb(31,78,121) 2pt solid; padding-right: 3pt; padding-top: 3pt; text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board has determined that each member of the Special Transaction Committee does not have a material personal interest and is not otherwise affiliated with Mr. Lazar or the Investment Transaction.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The functions of the Special Transaction Committee include, but are not limited to:</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorizing and directing all matters related to the Investment Transaction pursuant to the Purchase Agreement and the transactions contemplated thereby, including, without limitation, the New Hall Employment Agreement (as defined in this Proxy Statement), the Release Agreements and the Series F Agreements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and evaluating the Special Dividend (as was approved on August 26, 2025) as well as overseeing the segregation of the Aggregate Cash Distribution Amount for the payment of the Special Dividend;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving and filing this Proxy Statement for the Annual Meeting, including the ability to amend or supplement this Proxy Statement;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving the Proposals to be voted on at the Annual Meeting that relate to the Investment Transaction and are pursuant to the Purchase Agreement; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-left: rgb(31,78,121) 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F4E79">&#160;</span></td>
    <td style="padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-bottom: 3pt; padding-left: 3pt; text-align: left; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; border-left: rgb(31,78,121) 1pt solid; padding-bottom: 3pt; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-bottom: 3pt; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-bottom: 3pt; text-align: justify; width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 3pt; padding-bottom: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcing the Company&#8217;s rights under the Purchaser Agreement, the Series F Agreements and the other Investment Transaction documents.</span></td></tr>
  </table>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7in"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_041"></span>Other Board Matters</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Board&#8217;s Leadership Structure</i></b></span><i>. </i>Dr. Freiman has served as the Board&#8217;s independent Chair since March&#160;2019. Pursuant to the Purchase Agreement, Mr.&#160;Lazar has a one-time contractual right to serve as the Chair of the Board subject to the Conversion Approval and the Final Closing occurring. The Board believes that until the Final Closing that the Board is best served by separating the roles of Chair and Chief Executive Officer to enhance both the independence of the Board and its effectiveness in discharging its responsibilities. As a result of the Investment Transaction and Mr.&#160;Lazar&#8217;s one-time contractual right to serve as Chair of the Board after the Final Closing, the Board believes that NovaBay will be served by combining the roles of Chair and Chief Executive Officer to lead the Company in pursuing a Post-Investment Transaction. At such time as the roles of Chair and Chief Executive Officer are combined, the Board may evaluate and nominate a Lead Independent Director in its discretion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Board Changes in Connection with the Investment Transaction</i></b></span>. Pursuant to the Purchase Agreement, Mr.&#160;Lazar obtained certain one-time contractual rights involving the Board, including the right to nominate one director at this Annual Meeting (Mr.&#160;Lazar nominated himself), and a right for Mr.&#160;Lazar to later be appointed as Chair of the Board and to nominate up to three (3) Additional Purchaser Nominee(s) to the Board. The rights to serve as Chair and nominate the Additional Purchaser Nominee(s) to the Board are subject to the Conversion Approval and the Final Closing occurring.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the First Closing, the Company entered into the Release Agreements on August&#160;19, 2025 with Mr.&#160;Hall and the five (5) Resigning Non-Employee Directors. Under the terms of the Release Agreements with Mr.&#160;Hall and the Resigning Non-Employee Directors, these directors agreed to, among other terms, resign from the Board effective on the Resignation Event, which requires the following to have occurred: (i) the Conversion Approving having been received; (ii) the Final Closing having occurred; and (iii) up to three (3) Additional Purchaser Nominee(s) nominated by Mr.&#160;Lazar being qualified and appointed to serve on the Board; <i>provided</i>, <i>however</i>, the resignations of the Resigning Non-Employee Directors are also conditioned upon (A) the Special Dividend having been declared and paid and (B) Proposal Seven (Director Equity Consideration Proposal) being approved. Dr. Jeff Zheng is not a Resigning Non-Employee Director and did not enter into a Release Agreement. Dr. Jeff Zheng will continue to serve on the Board as a continuing director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the anticipated changes to the composition and management of our Board described above and changes to our business, including as a result of a Post-Investment Transaction being completed, as described in this Proxy Statement, our Board management, priorities and other aspects of our governance may change as a result.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Board&#8217;s Role in Risk Oversight</i></b></span>. One of the Board&#8217;s key functions is informed oversight of NovaBay&#8217;s risk management process. The Board does not have a formal risk management committee, but rather administers this oversight function through various standing committees of the Board that address risks inherent in their respective areas of oversight. Our Audit Committee is responsible for considering and discussing financial and enterprise risk exposures, including internal controls, and discusses with management, and the independent registered public accountants, our policies with respect to risk assessment and risk management, including risks related to fraud, liquidity, credit operations and regulatory compliance. In addition, under our whistleblower policy, employees wishing to report concerns or complaints they have related to accounting, auditing and internal controls submit such concerns in confidence, or anonymously if desired, to an outside administrator who forwards such complaints to our Audit Committee Chair. Our Audit Committee monitors the effectiveness of the whistleblower policy. Our N&amp;CG Committee monitors the effectiveness of our compliance and ethics policies, including whether they are successful in preventing illegal or improper liability-creating conduct, and our compliance with legal and regulatory requirements. Our Compensation Committee monitors NovaBay&#8217;s compensation policies to ensure that the compensation packages offered to our executive officers do not present such individuals with the potential to engage in excessive or inappropriate risk-taking activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management is responsible for the day-to-day management of the risks that we face, while our Board, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, the Board is responsible for satisfying itself that our risk management processes are adequate and functioning as designed. Our Board&#8217;s involvement in risk oversight includes receiving regular reports from members of management and evaluating areas of material risk, including operational, financial, legal, regulatory, strategic and reputational risks. As a smaller reporting company with a reasonably-sized Board, we believe it is appropriate to have the involvement and input of all of our directors in risk oversight matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Annual Meeting Attendance</i></b></span><i>. </i>We do not have a formal policy regarding attendance by members of our Board at the annual meetings of stockholders; however, directors are encouraged to attend all such meetings. In 2024, all seven (7) of our directors then serving attended our 2024 Annual Meeting of Stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Director Selection</i></b></span>. The N&amp;CG Committee reviews the appropriate qualities and skills required of directors in the context of the current Board composition. This includes an assessment of each candidate&#8217;s independence, personal and professional integrity, financial literacy or other professional or business experience, ability to think and act independently and with sound judgment, and ability to serve our stockholders&#8217; interests. These factors, and others deemed appropriate by the N&amp;CG Committee in contributing to our Board&#8217;s heterogeneity, are reviewed in the context of an assessment of the perceived needs of the Board at a particular point in time. As a result, the priorities and emphasis of the N&amp;CG Committee and of the Board may change from time to time to take into account changes in business and other trends, rules and laws related to board criteria, and the portfolio of skills and experience of current and prospective directors. The N&amp;CG Committee has historically led the search for and selected, or recommended that the Board select, candidates for election to the Board. Consideration of new director candidates typically involves a series of committee discussions, review of information concerning candidates and interviews with selected candidates. Other than the director candidates nominated or to be nominated by Mr.&#160;Lazar in connection with this Investment Transaction, candidates for nomination to our Board typically have been suggested by other members of the Board or by our executive officers or by our large stockholders or investment partners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time, the N&amp;CG Committee may engage the services of a third-party search firm to identify director candidates. The Board strives to achieve a membership of qualified individuals with a combination of qualities that best serves the Company&#8217;s needs. The N&amp;CG Committee consults with the Board to determine the most appropriate mix of characteristics, skills and experiences for the Board as a whole to possess at any given time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To identify the best candidates for the Board&#8217;s needs, the N&amp;CG Committee considers the following as the minimum qualifications a nominee must have:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">experience at a strategic or policymaking level in a business, government, non-profit or academic organization;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">be highly accomplished in his or her respective field, with superior credentials and recognition;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">be well regarded in the community and possess a long-term reputation for the highest ethical and moral standards;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">sufficient time and availability to devote to the affairs of the Company, particularly in light of the number of boards on which the nominee may serve; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><span style="font-family: Wingdings; font-size: 10pt; color: #1F4E79">&#216;</span></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">to the extent such nominee serves or has previously served on other boards, a demonstrated history of actively contributing at board meetings.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The N&amp;CG Committee also considers industry experience or qualifications, such as generic, brand or biotech experience, general management or financial experience, and diverse experience in business, education, government, law, technology, regulatory compliance, medicine and science. When considering candidates for election (or re-election) to the Board, the N&amp;CG Committee considers the entirety of a candidate&#8217;s credentials and background in addition to the specific minimum qualifications outlined above. Moreover, the members of the N&amp;CG Committee believe that each member of the Board should have the highest character and integrity, a reputation for working constructively with others, and minimal conflicts of interest that might interfere with his or her performance as a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The N&amp;CG Committee will consider candidates for director recommended by our stockholders who meet the eligibility requirements for submitting stockholder proposals for inclusion in our next proxy statement, as described in the Bylaws and provided that such recommendations are received within the timeframe required under</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">the caption &#8220;<i>Deadline for Receipt of Stockholder Proposals or Nominations</i>&#8221; below. Such stockholder&#8217;s notice shall set forth: (A) as to each nominee such stockholder proposes to nominate at the meeting: (i) the name, age, business address and residence address of such nominee, (ii) the principal occupation or employment of such nominee, (iii) the class and number of shares of each class of capital stock of the Company which are owned of record and beneficially by such nominee, (iv) the date(s) on which such shares were acquired and the investment intent of such acquisition, (v) a statement of whether such nominee, if elected, intends to tender, promptly following such person&#8217;s failure to receive the required vote for election or re-election at the next meeting at which such person would face election or re-election, his or her resignation, and (vi) such other information concerning such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest is not involved), or that is otherwise required to be disclosed pursuant to &#167; 14 of the Exchange Act and the rules and regulations promulgated thereunder (including such person&#8217;s written consent to being named as a nominee and to serving as a director if elected); and (B) as of the date of the notice and as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (each, a &#8220;<b><i>Proponent</i></b>&#8221; and collectively, the &#8220;<b><i>Proponents</i></b>&#8221;): (i) the name and address of each Proponent, as they appear on the Company&#8217;s books; (ii) the class, series and number of shares of the Company that are owned beneficially and of record by each Proponent; (iii) a description of any agreement, arrangement or understanding (whether oral or in writing) with respect to such nomination or proposal between or among any Proponent and any of its affiliates or associates, and any others (including their names) acting in concert, or otherwise under the agreement, arrangement or understanding, with any of the foregoing; (iv) a representation that the Proponent(s) are holders of record or beneficial owners, as the case may be, of shares of the Company entitled to vote at the meeting and intend to appear in person or by proxy duly authorized at the meeting to nominate the person(s) specified in the notice; (v) a representation as to whether the Proponent(s) intend to deliver a proxy statement and form of proxy to holders of a sufficient number of holders of the Company&#8217;s voting shares to elect such nominee or nominees; (vi) to the extent known by any Proponent, the name and address of any other stockholder supporting the proposal on the date of such stockholder&#8217;s notice; and (vii) a description of any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proponent or any of its affiliates or associates, whether record or beneficial (each, a &#8220;<b><i>Derivative Transaction</i></b>&#8221;) by each Proponent during the previous 12-month period, including the date of the transactions and the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The N&amp;CG Committee evaluates each candidate, including Board incumbents, based on the same criteria. After a candidate has been contacted and agrees to be considered as a nominee, the N&amp;CG Committee will review the candidate&#8217;s resume and other credentials and evaluate the expertise and experience that the candidate would provide to the Board and the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any potential candidates for director nominee, including candidates recommended by stockholders, are reviewed in the context of the current composition of the Board, our operating requirements, and the interests of stockholders. In conducting this assessment, the N&amp;CG Committee considers such factors as it deems appropriate given our current needs and those of our Board to maintain a balance of knowledge, experience and capability. The N&amp;CG Committee reviews directors&#8217; overall service during their term, including the number of meetings attended, level of participation and quality of performance. The N&amp;CG Committee also determines whether the nominee would be independent, which determination is based upon the Company Guide and applicable SEC rules and regulations. The N&amp;CG Committee then compiles a list of potential candidates from suggestions it may receive. The N&amp;CG Committee conducts any appropriate and necessary inquiries into the background and qualifications of possible candidates as it deems appropriate, then meets to discuss and consider such candidates&#8217; qualifications, and then selects a nominee for recommendation to the Board by majority vote.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other than the nomination of Mr.&#160;Lazar in connection with the Investment Transaction, no other candidates for director nominations were submitted to the N&amp;CG Committee by any stockholder in connection with the election of directors at the Annual Meeting. All three of the director nominees standing for election at this Annual Meeting are current directors of NovaBay.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With respect to Mr.&#160;Lazar&#8217;s one-time contractual right to nominate up to three (3) Additional Purchaser Nominee(s) subject to the Final Closing occurring and the Conversion Approval being received, pursuant to the Purchase Agreement, each Additional Purchaser Nominee nominated shall be qualified and approved by the N&amp;CG Committee, which shall include an assessment of their respective qualifications and experience, personal and professional integrity, financial literacy and other factors and criteria customarily reviewed and assessed as discussed above. Additionally, a sufficient number of Additional Purchaser Nominee(s) shall be nominated in order for us to continue to satisfy the &#8220;independence&#8221; requirements as set forth in the Company Guide and under the federal securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_042"></span>Communications to the Board</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board has implemented a process by which stockholders or other interested parties may send written communications directly to the attention of the Board, any committee of the Board or any individual Board member, care of our Corporate Secretary, Mr.&#160;Justin M. Hall, Esq., at 2000 Powell Street, Suite 1150, Emeryville, California 94608. The name of any specific intended Board recipient should be noted in the communication. Our Corporate Secretary will be responsible for collecting, organizing and monitoring communications from stockholders and, where appropriate depending on the facts and circumstances outlined in the communication, providing copies of such communications to the intended recipients. Communications will be forwarded to directors if they relate to appropriate and important substantive corporate or Board matters. Communications that are primarily commercial in nature or related to an improper or irrelevant topic will not be forwarded to the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: center; width: 100%"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_043"></span>Executive Compensation and Other Information</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated, all per share numbers have been retroactively adjusted to account for the 1-for-35 reverse stock split, effective May&#160;30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_044"></span>Executive Officers</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The table below sets forth certain information regarding our executive officers. Our executive officers are elected by, and serve at the discretion of, our Board. The following provides the biographical information regarding our Chief Financial Officer. Information concerning the business experience of Mr.&#160;Lazar and Mr.&#160;Hall is provided in &#8220;<i>Class III Directors</i>&#8221; and &#8220;<i>Class II Directors</i>&#8221; above, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; background-color: #FFFFFF; text-align: left; vertical-align: bottom"><span style="color: #1F4E79"><b>Name</b></span></td>
    <td style="background-color: #FFFFFF; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; background-color: #FFFFFF; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>Age</b></span></td>
    <td style="white-space: nowrap; background-color: #FFFFFF; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left; background-color: #FFFFFF; vertical-align: bottom"><span style="color: #1F4E79"><b>Current
    Position(s)<sup>(1)</sup></b></span></td> </tr>
  <tr style="background-color: Gainsboro">
    <td style="text-align: left; vertical-align: top; width: 30%">David E. Lazar</td>
    <td style="width: 1%; text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; width: 9%; text-align: center; vertical-align: bottom">35</td>
    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; width: 59%; vertical-align: top">Chief Executive Officer</td> </tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">Justin M. Hall, Esq.</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">48</td>
    <td style="white-space: nowrap; text-align: left; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top">Vice President of Business Development, General Counsel and Corporate Secretary</td> </tr>
  <tr style="background-color: Gainsboro">
    <td style="text-align: left; vertical-align: top">Tommy Law</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">39</td>
    <td style="white-space: nowrap; text-align: left; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top">Chief Financial Officer and Treasurer</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><sup>(1)</sup></td>
    <td style="text-align: justify">Effective August&#160;19, 2025, (i) Mr.&#160;Lazar was appointed to serve as the Company&#8217;s Chief Executive Officer, (ii) Mr.&#160;Hall, who formerly served as the Company&#8217;s Chief Executive Officer, resigned from such position and was appointed to serve as the Company&#8217;s Vice President of Business Development, General Counsel and Corporate Secretary, and (iii) Mr.&#160;Law, who formerly served as the Company&#8217;s Interim Chief Financial Officer and Treasurer, was appointed to serve as the Company&#8217;s Chief Financial Officer and Treasurer.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Tommy Law</i></b></span> (&#8220;<b><i>Mr.&#160;Law</i></b>&#8221;), prior to his appointment as Chief Financial Officer and Treasurer of the Company in August&#160;2025, served as the Company&#8217;s Interim Chief Financial Officer and Treasurer since February&#160;2023. Prior to that, he served the Company since December&#160;2019 in a variety of positions, including as the Corporate Controller from September&#160;2022 to January&#160;2023. As the Corporate Controller, Mr.&#160;Law was responsible for quarterly filings with the SEC, as well as managing the periodic financial close process. Prior to serving as the Corporate Controller, Mr.&#160;Law served the Company as an Assistant Controller (April&#160;2022 to September&#160;2022), Accounting Manager (June&#160;2020 to April&#160;2022) and Senior Accountant (December&#160;2019 to June&#160;2020). Prior to joining the Company, Mr.&#160;Law was a Senior Accountant at KP LLC, a marketing solutions company, from January&#160;2017 to December&#160;2019. Previously, he served as Accounting Manager at Hitachi Solutions America, Ltd., an information technology company, from 2012 to 2015. Mr.&#160;Law received a B.S. in Business Administration, Accounting from San Jose State University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no arrangement or understanding between any director or executive officer and any other person pursuant to which he or she was or is to be selected as a director, nominee or officer, other than the Purchase Agreement, the New Hall Employment Agreement, the Law Employment Agreement and the Release Agreements (each as described elsewhere in this Proxy Statement). There are no family relationships among any of our officers or directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_045"></span>Summary Compensation Table</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table shows information regarding the compensation earned during the fiscal years ended December&#160;31, 2024 and December&#160;31, 2023 for Mr.&#160;Hall and Mr.&#160;Law (collectively, the &#8220;<b><i>NEOs</i></b>&#8221;). The current and former titles of each of the NEOs is as indicated in the following Summary Compensation Table.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Lazar did not begin his service as our Chief Executive Officer until August&#160;2025, and therefore, was not a NEO during the fiscal years ended December&#160;31, 2024 and 2023. Mr.&#160;Lazar is currently not party to an employment agreement with the Company and is not currently receiving any compensation for assuming and serving in the role of Chief Executive Officer. Mr.&#160;Lazar is also not receiving any compensation for his service as a director on the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="color: rgb(31,78,121); vertical-align: bottom">
    <td style="border-bottom: rgb(31,78,121) 1pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: left">Name and principal position(s)</td>
    <td style="color: rgb(31,78,121); padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 1pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: center">Fiscal<br/> year</td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="color: rgb(31,78,121); padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 1pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); text-align: center; margin-top: 0; margin-bottom: 0"><b>Salary<br/> ($)</b></p></td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="color: rgb(31,78,121); padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 1pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); text-align: center; margin-top: 0; margin-bottom: 0"><b>Bonus</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); text-align: center; margin-top: 0; margin-bottom: 0"><b>($)</b></p></td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="color: rgb(31,78,121); padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 1pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); text-align: center; margin-top: 0; margin-bottom: 0"><b>All other<br/> Compensation</b><sup><b>(1)(2)</b></sup></p>
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); text-align: center; margin-top: 0; margin-bottom: 0"><b>($)</b></p></td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="color: rgb(31,78,121); padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(31,78,121) 1pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); text-align: center; margin-top: 0; margin-bottom: 0"><b>Total<br/> ($)</b></p></td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; width: 40%; text-align: left">Justin M. Hall, Esq.</td>
    <td style="text-align: right; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 10%; text-align: center">2024</td>
    <td style="padding-left: 0pt; vertical-align: top; width: 1%; text-align: right">&#160;</td>
    <td style="text-align: right; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; vertical-align: top; width: 9%; text-align: right">350,000</td>
    <td style="padding-left: 0pt; vertical-align: top; width: 1%; text-align: right">&#160;</td>
    <td style="text-align: right; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; vertical-align: top; width: 9%; text-align: right">-</td>
    <td style="padding-left: 0pt; vertical-align: top; width: 1%; text-align: right">&#160;</td>
    <td style="text-align: right; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; vertical-align: top; width: 9%; text-align: right">15,177</td>
    <td style="padding-left: 0pt; vertical-align: top; width: 1%; text-align: right">&#160;</td>
    <td style="text-align: right; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; vertical-align: top; width: 9%; text-align: right">365,177</td>
    <td style="padding-left: 0pt; vertical-align: top; width: 1%; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-style: italic; text-align: left">Former CEO, GC and Chief Compliance Officer and Current VP of Business Development, GC and Chief Compliance Officer</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">2023</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">350,000</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">-</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">14,146</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">364,146</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">Tommy Law</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">2024</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">170,000</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">42,500</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">7,696</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">220,196</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-style: italic; text-align: left">Former Interim CFO and Treasurer and Current CFO and Treasurer</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">2023</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">170,000</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">-</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">7,696</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; vertical-align: top; text-align: right">177,696</td>
    <td style="padding-left: 0pt; vertical-align: top; text-align: right">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(1)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">In 2024, the amounts included: (a) individual life insurance premiums paid for by the Company for Mr.&#160;Hall and Mr.&#160;Law of $1,854 and $896, respectively; and (b) 401(k) plan matching contributions paid for by the Company for Mr.&#160;Hall and Mr.&#160;Law of $13,323 and $6,800, respectively.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">In 2023, the amounts included: (a) individual life insurance premiums paid for by the Company for Mr.&#160;Hall and Mr.&#160;Law of $1,854 and $896, respectively; and (b) 401(k) plan matching contributions paid for by the Company for Mr.&#160;Hall and Mr.&#160;Law of $12,292 and $6,800, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(2)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">In connection with the closing of the Avenova Asset Divestiture, we entered into a Transition Services Agreement, dated January&#160;17, 2025, with PRN, pursuant to which we agreed to provide services to PRN with respect to specified accounting, marketing, sales, customer service, regulatory and operational support for a period of four (4) months after the closing of the Avenova Asset Divestiture in exchange for agreed upon service fees to be paid to us. In relation to such Transition Services Agreement, PRN entered into a consulting agreement with Mr.&#160;Law, then our Interim Chief Financial Officer, for certain services with a one-time payment of $85,000 to be made by PRN to Mr.&#160;Law when all such services were complete.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Base Salaries and Target Bonus Amounts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Compensation Committee did not recommend any increases to executive salaries or target bonus amounts for 2024 or 2023; they remained the same as 2022. For Mr.&#160;Hall, this was a 2024 base salary of $350,000 and a target bonus percentage of base salary of 50%. For Mr.&#160;Law, this was a 2024 base salary of $170,000 and a target bonus percentage of base salary of 25%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As further described below, in connection with the Investment Transaction and the New Hall Employment Agreement or Law Employment Agreement, as applicable, Mr.&#160;Hall&#8217;s base salary was reduced to $175,000 and Mr.&#160;Law&#8217;s base salary was maintained at $170,000, which changes were both effective at the First Closing on August&#160;19, 2025. Neither the New Hall Employment Agreement nor the Law Employment Agreement provides for a target bonus percentage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Cash Bonuses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board, upon the recommendation of the Compensation Committee, determined not to award any bonuses to Mr.&#160;Hall for fiscal year 2024 performance or fiscal year 2023 performance. Mr.&#160;Law did not receive a bonus for fiscal year 2024 performance and received a cash bonus of $42,500 for fiscal year 2023 performance (as paid to Mr. Law in 2024).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to his Release Agreement in connection with the Investment Transaction and as further described below, Mr.&#160;Hall is entitled to a cash settlement payment of $481,250 plus any unpaid wages and $8,778 in payments pursuant to COBRA, which he received in connection with the First Closing, as well as a second cash settlement payment of $481,250 plus any unpaid wages and $8,778 in COBRA payments by October&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Separately, as further described below, in connection with the Investment Transaction and the Law Employment Agreement, Mr.&#160;Law is entitled to receive a retention bonus of $170,000 to the extent he remains employed by the Retention Date and has not resigned or been terminated for cause. Mr.&#160;Law will also be eligible for any bonus plan that is deemed appropriate by the Board. Additionally, as a result of Mr.&#160;Law&#8217;s appointment as the Chief Financial Officer and Treasurer of the Company, Mr.&#160;Law also received a one-time signing bonus of $89,250 that was paid in cash, which payment was separate from the terms of the Law Employment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Equity Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div id="xdx_988_eecd--AwardTmgMnpiDiscTextBlock_c20240101__20241231_zT01FEWcgczh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000013" name="ecd:AwardTmgMnpiDiscTextBlock">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_901_eecd--AwardTmgMethodTextBlock_c20240101__20241231_zkumahoDFW6g" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000014" name="ecd:AwardTmgMethodTextBlock">The Board, upon the recommendation of the Compensation Committee, determined not to grant any equity awards for the 2024 fiscal year or 2023 fiscal year to any of its NEOs.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_906_eecd--AwardTmgHowMnpiCnsdrdTextBlock_c20240101__20241231_zMaUyqNiQDwb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000015" name="ecd:AwardTmgHowMnpiCnsdrdTextBlock">In connection with the Investment Transaction, <span id="xdx_90A_eecd--AwardTmgPredtrmndFlag_dbF_c20240101__20241231_zTaXnd4h7ZB4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><span id="xdx_90A_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20240101__20241231_z6V9AxSHXQNc" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><span id="xdx_90E_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_zDo4dVZl1X6h" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000016" name="ecd:AwardTmgPredtrmndFlag"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000017" name="ecd:AwardTmgMnpiCnsdrdFlag"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000018" name="ecd:MnpiDiscTimedForCompValFlag">no</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span> equity awards were granted to any NEOs; however, as consideration for the Release Agreements, each Resigning Non-Employee Director is entitled to certain Equity Consideration subject to stockholders approving Proposal Seven (Director Equity Consideration Proposal) at this Annual Meeting, as further described below.</ix:nonNumeric></span></p> </ix:nonNumeric></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Federal Income Tax Law</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Federal income tax law prohibits publicly-held companies, such as the Company, from deducting compensation paid to a NEO that exceeds $1 million during the tax year. Prior to the adoption of the Tax Cuts and Jobs Act of 2017 (&#8220;<b><i>Tax Act</i></b>&#8221;), to the extent that compensation was based upon the attainment of performance goals set by the Compensation Committee pursuant to plans approved by the stockholders, the compensation was exempted from the $1 million deduction limit. The Tax Act repealed this exemption, and now compensation paid to NEOs in excess of $1 million is no longer deductible, even if performance-based. The Compensation Committee intends to continue to use performance metrics in compensation when it is in the best interests of the Company and its stockholders even if such compensation is not deductible for tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_046"></span>Outstanding Equity Awards at Fiscal Year End</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table presents the outstanding equity awards held by each of our NEOs as of December&#160;31, 2024. Stock options were granted pursuant to our 2007 Omnibus Incentive Plan (&#8220;<b><i>2007 Omnibus Plan</i></b>&#8221;) thereafter until its expiration in March&#160;2017, and all awards since then have been granted pursuant to our 2017 Omnibus Plan. The options granted under our 2007 Omnibus Plan and 2017 Omnibus Plan are not exercisable until they have vested. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="color: rgb(31,78,121); vertical-align: bottom">
    <td style="color: rgb(31,78,121); padding-bottom: 1pt; vertical-align: top; text-align: left">&#160;</td>
    <td style="color: rgb(31,78,121); padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="color: rgb(31,78,121); padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="color: rgb(31,78,121); padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); font-weight: bold; text-align: center">Option Awards</td>
    <td style="padding-left: 0pt; padding-bottom: 1pt; color: rgb(31,78,121); font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; color: rgb(31,78,121); font-weight: bold; text-align: center">&#160;</td>
    <td style="color: rgb(31,78,121); padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="color: rgb(31,78,121); padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); font-weight: bold; text-align: center">Stock Awards</td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="color: rgb(31,78,121); vertical-align: bottom">
    <td style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: left"><b>Name</b></td>
    <td style="color: rgb(31,78,121); text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: center"><b>Grant
    date</b></td>
    <td style="color: rgb(31,78,121); text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Number
                                            of<br/> securities underlying unexercised options</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(#)</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>exercisable<sup>(1)</sup></b></p></td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); white-space: nowrap; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td style="color: rgb(31,78,121); text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Number
                                            of<br/> securities underlying unexercised options</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(#)</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>unexercisable</b></p></td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td style="color: rgb(31,78,121); text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Option<br/>
                                            exercise price</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>($)</b></p></td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td style="color: rgb(31,78,121); text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: center"><b>Option<br/>
    expiration date</b></td>
    <td style="color: rgb(31,78,121); text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: center"><p style="color: rgb(31,78,121); text-align: center; margin-top: 0; margin-bottom: 0"><b>Number
                                            of<br/> shares or<br/> units of stock<br/> that have<br/> not vested<br/> (#)</b></p></td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><b>&#160;</b></td>
    <td style="color: rgb(31,78,121); text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: center"><b>Market
    value<br/> of shares or<br/> units of stock<br/> that have<br/> not vested<br/> ($)</b></td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><b>&#160;</b></td>
    <td style="color: rgb(31,78,121); text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Equity
                                            incentive<br/> plan awards: number<br/> of unearned shares, units or other<br/> rights
                                            that have<br/> not vested</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(#)</b></p></td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td style="color: rgb(31,78,121); text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Equity
                                            incentive<br/> plan awards: market<br/> or payout value<br/> of unearned shares,<br/>
                                            units or other<br/> rights that have<br/>
                                            not vested</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; color: rgb(31,78,121); margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>($)</b></p></td>
    <td style="padding-left: 0pt; color: rgb(31,78,121); text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; width: 10%; text-align: left">Justin M. Hall, Esq.</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">08/20/20</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">232</td>
    <td style="padding-left: 0pt; white-space: nowrap; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">1,212.75</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">08/20/30</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">05/31/18</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">155</td>
    <td style="padding-left: 0pt; white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">2,695.00</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">05/31/28</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">01/25/17</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">18</td>
    <td style="padding-left: 0pt; white-space: nowrap; text-align: left"><sup>(2)</sup>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">4,410.00</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">01/25/27</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">06/06/16</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">106</td>
    <td style="padding-left: 0pt; white-space: nowrap; text-align: left"><sup>(3)</sup>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">3,405.50</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">06/06/26</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">10/01/15</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">2</td>
    <td style="padding-left: 0pt; white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">8,268.75</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">10/01/25</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-align: left">Tommy Law</td>
    <td>&#160;</td>
    <td style="text-align: center">08/20/20</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">21</td>
    <td style="padding-left: 0pt; white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">1,212.75</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">08/20/2030</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.165in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">06/08/20</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">5</td>
    <td style="padding-left: 0pt; white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">1,097.25</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">06/08/2030</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(1)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Unless otherwise noted, each option vested as to 25% of the shares underlying the option on the first anniversary of the grant date, with the remainder vesting every three months in 12 equal installments thereafter. Options expire ten (10) years from the date of grant.</td> </tr>
  </table>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(</sup><sup>2</sup><sup>)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Mr.&#160;Hall was granted 117 stock options to vest on January&#160;31, 2018, in direct proportion to the percentage achievement of the stated 2017 corporate goals, as approved and determined by the Board. Such determination resulted in a 15% payout, or 18 shares vesting.</td> </tr>
  </table>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(</sup><sup>3</sup><sup>)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Mr.&#160;Hall was granted 106 stock options to vest on January&#160;31, 2017, in direct proportion to the percentage achievement of the stated 2016 corporate goals, as approved and determined by the Board, which was 100%.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_047"></span>Employment-Related Agreements and Potential Payments upon Termination or Change in Control</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As noted above, effective August&#160;19, 2025, (i) Mr.&#160;Lazar was appointed to serve as the Company&#8217;s Chief Executive Officer, (ii) Mr.&#160;Hall resigned as the Company&#8217;s Chief Executive Officer and was appointed to serve as the Company&#8217;s Vice President of Business Development, General Counsel and Corporate Secretary, and (iii) Mr.&#160;Law, who formerly served as the Company&#8217;s Interim Chief Financial Officer and Treasurer, was appointed to serve as the Company&#8217;s Chief Financial Officer and Treasurer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The principal terms of Mr.&#160;Hall&#8217;s and Mr.&#160;Law&#8217;s respective employment agreements and the Hall Release Agreement are each summarized below. Mr.&#160;Lazar is not currently party to an employment agreement with the Company and is not currently receiving any compensation for assuming and serving in the role of Chief Executive Officer. Mr.&#160;Lazar is also not receiving any compensation for his service as a director on the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Justin Hall</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January&#160;31, 2020, the Company entered into an employment agreement with Mr.&#160;Hall in connection with his appointment to serve as an executive officer. Mr.&#160;Hall&#8217;s employment agreement was subsequently amended by a first amendment on January&#160;26, 2022, a second amendment effective on December&#160;31, 2023, and a third amendment effective on December&#160;31, 2024 (as amended, the Prior Hall Employment Agreement). Mr.&#160;Hall&#8217;s employment agreement, as amended by the third amendment, provided for at-will employment and a term commencing on January&#160;31, 2020 and ending on December&#160;31, 2025, unless earlier terminated in accordance with the terms of the employment agreement. For the fiscal year ended December&#160;31, 2024, pursuant to the Prior Hall Employment Agreement, Mr.&#160;Hall&#8217;s annual base salary was three hundred fifty thousand dollars ($350,000), subject to annual review and increases determined by the Compensation Committee and/or Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August&#160;19, 2025, the Company entered into the New Hall Employment Agreement with Mr.&#160;Hall for his service as the Company&#8217;s Vice President of Business Development, General Counsel and Corporate Secretary, which entirely amended and restated the Prior Hall Employment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The New Hall Employment Agreement provides for employment with a term commencing on the date of the First Closing on August&#160;19, 2025 and ending on October&#160;31, 2025 (the &#8220;<b><i>Hall Employment Term</i></b>&#8221;). The New Hall Employment Agreement provides for an amended annual base salary of one hundred seventy-five thousand dollars ($175,000) (the &#8220;<b><i>Hall Base Salary</i></b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The New Hall Employment Agreement is guaranteed through the Hall Employment Term. If the Company terminates Mr.&#160;Hall prior to the end of the Hall Employment Term, the Company is required to pay the Hall Base Salary from the date of termination through the end of the Hall Employment Term (the &#8220;<b><i>Hall Severance Amount</i></b>&#8221;). The Hall Severance Amount is required to be paid in a lump sum within sixty (60) days following the executive&#8217;s separation from service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Also on August&#160;19, 2025, the Company entered into a Release Agreement with Mr.&#160;Hall (the &#8220;<b><i>Hall Release Agreement</i></b>&#8221;). The Hall Release Agreement provides for (i) Mr.&#160;Hall to generally release the Company from any claims, actions, or losses that such person may have against the Company and (ii) the Company to similarly release Mr.&#160;Hall from any claims, actions or losses that the Company may have against such person, provided that the Company shall remain obligated pursuant to the indemnification agreements with each person and to maintain D&amp;O insurance coverage, or a D&amp;O tail policy. Pursuant to the Hall Release Agreement, he agreed to resign from the Board effective on the Resignation Event, which includes the Conversion Approval being received, the Final Closing having occurred, and up to three (3) Additional Purchaser Nominee(s) being appointed to the Board. Mr.&#160;Hall further agreed to resign, and did resign, as the Company&#8217;s Chief Executive Officer as of the First Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Hall received a cash settlement payment of $481,250 plus any unpaid wages and $8,778 in payments pursuant to COBRA in accordance with the Hall Release Agreement in connection with the First Closing. Further, Mr.&#160;Hall will receive a second cash settlement payment of $481,250 plus any unpaid wages and $8,778 in COBRA payments by October&#160;31, 2025. Mr.&#160;Hall&#8217;s payment amounts comprise his earned severance under the Prior Hall Employment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Tommy Law</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August&#160;19, 2025, the Company entered into the Law Employment Agreement with Mr.&#160;Law for his service as the Company&#8217;s Chief Financial Officer and Treasurer. Mr.&#160;Law did not previously have an employment agreement in place. As a result of Mr.&#160;Law&#8217;s appointment as the Chief Financial Officer and Treasurer of the Company, Mr.&#160;Law also received a one-time signing bonus of $89,250, to be paid in cash, separate from the terms of the Law Employment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Law Employment Agreement provides for at-will employment with a term commencing on the date of the First Closing and continuing until the first anniversary of the date of commencement. The Law Employment Agreement provides for an annual base salary of one hundred seventy thousand dollars ($170,000) (the &#8220;<b><i>Law Base Salary</i></b>&#8221;). In addition, Mr.&#160;Law shall be eligible for any bonus plan that is deemed appropriate by the Board. The bonus amount shall be determined by the Board, in its sole discretion, based upon, among others, the following factors: (i) the fulfillment, during the relevant year, of specific milestones and tasks delegated, for such year, to the executive as set by the Company&#8217;s Chief Executive Officer and/or the Board, before the end of the first calendar quarter; (ii) the evaluation of the executive by the Company&#8217;s Chief Executive Officer and/or the Board; (iii) the Company&#8217;s financial, product and expected progress; and (iv) other pertinent matters relating to the Company&#8217;s business and valuation. Any bonus will be payable within two and a half (2 &#189;) months following the end of the year for which the bonus was earned. The Compensation Committee of the Board shall have the sole discretion to pay any or all of the annual bonus in the form of equity compensation. Any such equity compensation shall be issued from the Company&#8217;s 2017 Omnibus Plan and shall be fully vested upon payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, Mr.&#160;Law is entitled to a retention bonus of $170,000 to the extent he remains employed through the Company&#8217;s filing of its quarterly report on Form 10-Q with the SEC for the quarter ended September&#160;30, 2025 (the &#8220;<b><i>Retention Date</i></b>&#8221;) and he has not otherwise resigned or been terminated for cause (as defined in the Law Employment Agreement) prior to the Retention Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the event the Company terminates Mr.&#160;Law without cause (including death, disability or for constructive termination), or his employment term otherwise expires at the end of the term, he shall be entitled to an amount equal to the Law Base Salary in effect on the date of separation from service (the &#8220;<b><i>Law Severance Amount</i></b>&#8221;). The Law Severance Amount will be paid in a lump sum within sixty (60) days following the executive&#8217;s separation from service. The Law Severance Amount shall be in addition to Mr.&#160;Law&#8217;s earned wages and other compensation (including reimbursements of his outstanding expenses and unused vacation) through the date his employment is terminated from the Company as provided in the preceding sentence. In the event the Company terminates Mr.&#160;Law for cause, he shall be entitled to any earned but unpaid wages or other compensation (including reimbursements of his outstanding expenses and unused vacation) earned through the termination date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, all outstanding equity awards held by Mr.&#160;Law will be subject to full accelerated vesting on the date of termination without cause or at the expiration of the employment term, and the exercise period shall be extended to three (3) years from the date of termination. In order to terminate Mr.&#160;Law for cause (or for Mr.&#160;Law to resign for constructive termination), the acting party shall give notice to the other party specifying the reason for termination and providing a period of thirty (30) days to cure the reason specified. If there is no cure within thirty (30) days or the notified party earlier refuses to effect the cure, the termination shall then be deemed effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_048"></span>Director Compensation</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The compensation and benefits for service as non-employee members of our Board is determined by the Board. Directors employed by the Company, such as Mr.&#160;Lazar and Mr.&#160;Hall, are not compensated for service on the Board or any committee of the Board; however, the Company reimburses all directors for any out-of-pocket expenses incurred in connection with attending meetings of the Board and committees of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board, upon the recommendation of the Compensation Committee, approved the Non-Employee Director Compensation Program, effective January&#160;1, 2024 (the &#8220;<b><i>2024 Non-Employee Director Compensation Plan</i></b>&#8221;). Under the 2024 Non-Employee Director Compensation Plan, each director received his or her annual retainer compensation in cash and an annual grant of 858 restricted stock units. All cash compensation is payable quarterly on the first (1st) business day of the quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Approved non-employee director compensation for 2024 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="color: rgb(31,78,121); background-color: White">
    <td style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); width: 32%; text-align: center; vertical-align: bottom"><b>Board Meetings</b></td>
    <td style="color: rgb(31,78,121); width: 2%; text-align: center; vertical-align: bottom"><span style="text-transform: lowercase; color: rgb(31,78,121)">&#160;</span></td>
    <td style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); width: 32%; text-align: center; vertical-align: bottom"><b>Committee Chairs</b></td>
    <td style="color: rgb(31,78,121); width: 2%; text-align: center; vertical-align: bottom"><span style="text-transform: lowercase; color: rgb(31,78,121)">&#160;</span></td>
    <td style="border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); width: 32%; text-align: center; vertical-align: bottom"><b>Non-Chair Committee Members</b></td> </tr>
  <tr>
    <td style="background-color: Gainsboro; text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Chair of the Board</i>: Annual cash compensation of $52,000 per year.</p> </td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Chair of the Audit Committee</i>: Annual cash compensation of $17,500 per year.</p> </td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="background-color: Gainsboro; text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Member of the Audit Committee</i>: Annual cash compensation of $7,500 per year.</p> </td> </tr>
  <tr>
    <td style="padding-top: 0pt; background-color: Gainsboro; text-align: justify; vertical-align: top; padding-bottom: 0pt">&#160;</td>
    <td style="padding-top: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt">&#160;</td>
    <td style="padding-top: 0pt; text-align: justify; vertical-align: top; padding-bottom: 0pt">&#160;</td>
    <td style="padding-top: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt">&#160;</td>
    <td style="padding-top: 0pt; background-color: Gainsboro; text-align: justify; vertical-align: top; padding-bottom: 0pt">&#160;</td></tr>
  <tr>
    <td style="background-color: Gainsboro; text-align: justify; vertical-align: top"><i>Member of the Board</i>: The annual fee consists of: (i) $40,000 in cash and (ii) 858 restricted stock units granted. The restricted stock units are granted at the Company&#8217;s Annual Meeting of Stockholders, and vest on the one year anniversary of the grant date.</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><i>Chair of the Compensation Committee</i>: Annual cash compensation of $13,000 per year.</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><i>Chair of the N&amp;CG Committee</i>: Annual cash compensation of $10,000 per year.</p></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="background-color: Gainsboro; text-align: justify; vertical-align: top">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><i>Member of the Compensation Committee</i>: Annual cash compensation of $6,000 per year.</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><i>Member of the N&amp;CG Committee</i>: Annual cash compensation of $5,000 per year.</p></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Non-employee directors also may be granted additional awards under our equity incentive plans at the discretion of our Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The compensation received during 2024 by each non-employee director is set forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="color: rgb(31,78,121)">Name</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: rgb(31,78,121)">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0"><span style="color: rgb(31,78,121)">Fees Earned</span></p>
        <p style="margin-top: 0; margin-bottom: 0"><span style="color: rgb(31,78,121)">or Paid in<br/> Cash<br/> ($)</span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: rgb(31,78,121)">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: rgb(31,78,121)">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: rgb(31,78,121)"><b>Stock<br/> Awards<sup>(1)</sup></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: rgb(31,78,121)"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: rgb(31,78,121)">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: rgb(31,78,121)">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: rgb(31,78,121)"><b>Total</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: rgb(31,78,121)"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: rgb(31,78,121)">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; width: 64%; text-align: left">Paul E. Freiman, Ph.D.</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 9%; text-align: right">77,500</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 9%; text-align: right">4,234</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 9%; text-align: right">81,734</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">Julie Garlikov</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">40,000</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">4,234</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">44,234</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">Swan Sit</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">58,500</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">4,234</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">62,734</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">Mijia (Bob) Wu, M.B.A.</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">40,000</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">4,234</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">44,234</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">Sean Zheng</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">40,000</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">4,234</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">44,234</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">Yenyou (Jeff) Zheng, Ph.D.</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">73,500</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">4,234</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">77,734</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><sup>(1)</sup></td>
    <td style="text-align: justify">These amounts represent the aggregate grant date fair value of $4.94 per share for the 858 restricted stock awards granted to each director as part of his or her annual fee in fiscal year 2024. The assumptions used to determine the value of restricted stock units are described in Note 15 &#8220;Equity-Based Compensation&#8221; to the Company&#8217;s consolidated financial statements in the Annual Report. At December&#160;31, 2024, each of Dr. Freiman, Ms. Garlikov, Ms. Sit, Mr.&#160;Wu, Mr.&#160;Sean Zheng and Dr. Jeff Zheng had an aggregate of 858 unvested restricted stock units. At December&#160;31, 2024, the aggregate number of vested stock options for each of the non-employee directors who served in 2024 and held stock options was as follows (with no such director holding any unvested stock options at such time): Dr. Freiman, 99; Ms. Sit, 17; Mr.&#160;Wu, 47; and Dr. Jeff Zheng, 17.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify"><span style="color: #1F4E79"><b><i>Release Agreements with the Resigning Non-Employee Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August&#160;19, 2025 at the First Closing of the Investment Transaction, the Company entered into Release Agreement with Mr.&#160;Hall and each of the Resigning Non-Employee Directors (Dr. Freiman, Ms. Garlikov, Ms. Sit, Mr.&#160;Wu and Mr.&#160;Sean Zheng). The remaining non-employee director, Dr. Jeff Zheng, will continue to serve on the Board as a continuing director and, therefore, he did not enter into a Release Agreement. Please see &#8220;<i>Executive Compensation and Other Information&#8212;Employment-Related Agreements and Potential Payments upon Termination or Change in Control&#8212;Justin Hall</i>&#8221; for a description of the Hall Release Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Release Agreements provide for (i) the Resigning Non-Employee Directors to generally release the Company from any claims, actions, or losses that such person may have against the Company and (ii) the Company to similarly release each of the Resigning Non-Employee Directors from any claims, action or losses that the Company may have against such person, provided that the Company shall remain obligated pursuant to the indemnification agreements with each person and to maintain D&amp;O insurance coverage, or a D&amp;O tail policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the terms of the Release Agreements with the Resigning Non-Employee Directors, these directors agreed to resign from the Board effective on the Resignation Event, which includes the Conversion Approval being received, the Final Closing having occurred, and up to three (3) Additional Purchaser Nominee(s) being appointed to the Board as well as the Special Dividend having been declared and paid and Proposal Seven being approved. Pursuant to, and as consideration for, the Release Agreements with the Resigning Non-Employee Directors, each Resigning Non-Employee Director shall receive the Equity Consideration of a settlement payment of newly-issued shares of restricted Common Stock, with an aggregate value of $40,000 (determined based on the closing price of Common Stock on the trading day that immediately precedes the date of the Resignation Event) to be issued on the date of the Resignation Event, as well as any accrued and unpaid director&#8217;s fees. To the extent that Proposal Seven (Director Equity Consideration Approval) is not obtained and the Equity Consideration is not issued to the Resigning Non-Employee Director, then the Release Agreements with the Resigning Non-Employee Directors will terminate and be of no further force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; width: 100%; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_049"></span>Pay-Versus-Performance</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As required by Section&#160;953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, the Company is providing the following disclosure about the relationship between executive pay actually paid (as defined by SEC rules) and the Company&#8217;s financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000020" name="ecd:PvpTableTextBlock"><p id="xdx_80D_eecd--PvpTableTextBlock_dU_zVK71DJ6giP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Pay-Versus-Performance Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In accordance with the SEC&#8217;s rules, the below table sets forth the following information for the fiscal years ended December&#160;31, 2024, 2023 and 2022: (i) the total compensation paid to the Company&#8217;s principal executive officer, the Chief Executive Officer (or &#8220;<b><i>CEO</i></b>&#8221;), and the non-CEO NEOs, as provided on the &#8220;Summary Compensation Table&#8221; provided in this Proxy Statement (and, as relates to the fiscal year ended December&#160;31, 2022, the &#8220;Summary Compensation Table&#8221; provided in the Company&#8217;s 2024 Proxy Statement filed with the SEC on April&#160;18, 2024 (the &#8220;<b><i>2024 Proxy Statement</i></b>&#8221;)); (ii) the compensation &#8220;actually paid&#8221; to the CEO and the non-CEO NEOs, which reflects certain adjustments based on SEC rules and as described in the footnotes below; (iii) the Company&#8217;s total stockholder return (&#8220;<b><i>TSR</i></b>&#8221;); and (iv) the Company&#8217;s net loss. The &#8220;Summary Compensation Table&#8221; and the compensation actually paid amounts do not reflect the actual amounts of compensation earned by, or paid to, our NEOs during the applicable years, but rather are amounts determined in accordance with Item 401(v) of Regulation S-K. The Compensation Committee did not consider the pay-versus-performance disclosure when making its incentive compensation decisions for 2024. For information regarding the decisions made by the Compensation Committee with respect to compensation for 2024, please see the &#8220;Compensation Discussion &amp; Analysis&#8221; provided elsewhere in this Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" id="xdx_30D_zheUtsSgpCRk" summary="xdx: Disclosure - Pay vs Performance Disclosure" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="color: #1F4E79">Fiscal Year</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="color: #1F4E79"><b>Summary<br/> Compensation<br/> Table Total -<br/>CEO<sup>(1)</sup></b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Compensation<br/> &#8220;Actually Paid&#8221;<br/> Total -<br/>CEO<sup>(2)</sup></b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Summary<br/> Compensation<br/> Table Total -<br/>Non-CEO</b></span></p>
        <p style="margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>NEO Average<sup>(3)</sup></b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Compensation<br/> &#8220;Actually Paid&#8221;<br/> Total - Non-CEO<br/>NEOs<sup>(4)</sup></b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>NBY TSR<sup>(5)</sup></b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Fiscal Year</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Net Loss</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>(in thousands)<sup>(6)</sup></b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; width: 28%; text-align: left">2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98A_eecd--PeoTotalCompAmt_c20240101__20241231_zJ6vdCxufyJ4" style="padding-right: 0pt; width: 9%; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,177</ix:nonFraction></td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_980_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_zpRSHvfe2j9h" style="padding-right: 0pt; width: 9%; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,461</ix:nonFraction></td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_zMPRL4EDpmJk" style="padding-right: 0pt; width: 9%; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,196</ix:nonFraction></td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_zDT6vn4AmlOb" style="padding-right: 0pt; width: 9%; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,295</ix:nonFraction></td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98B_eecd--TotalShareholderRtnAmt_pp2p0_c20240101__20241231_z20OrPK2GR1c" style="padding-right: 0pt; width: 9%; text-align: right"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000025" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">0.13</ix:nonFraction></td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231_z7f8Gca9NlIh" style="padding-right: 0pt; width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000026" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,223</ix:nonFraction></td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_989_eecd--PeoTotalCompAmt_c20230101__20231231_zTgkfwAXnSY2" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,146</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_982_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_zAB2JBikIvC" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000028" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,857</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98F_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_zFion8p2wFR8" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,840</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_983_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_zm1HBvnVBCPd" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2023-01-012023-12-31" id="Fact000030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,734</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_988_eecd--TotalShareholderRtnAmt_pp2p0_c20230101__20231231_zLfXdsLmYs02" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2023-01-012023-12-31" id="Fact000031" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">0.84</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231_z4XtUCUnjFo8" style="padding-right: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000032" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,640</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">2022</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_984_eecd--PeoTotalCompAmt_c20220101__20221231_zxzEfROoczb5" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000033" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,954</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_984_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_zdJlkvkoL43j" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,489</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_989_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_zUWcFU6a7df" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000035" format="ixt:numdotdecimal" decimals="0" unitRef="USD">259,285</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_98F_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_zvlPcLzB31dj" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2022-01-012022-12-31" id="Fact000036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,806</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_988_eecd--TotalShareholderRtnAmt_pp2p0_c20220101__20221231_zFewj2blZiUj" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2022-01-012022-12-31" id="Fact000037" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">7.99</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_98B_eus-gaap--NetIncomeLoss_pn3n3_c20220101__20221231_z1MkfTqtxoIg" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000038" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,608</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(1)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Reflects compensation amounts reported in the &#8220;Summary Compensation Table&#8221; provided in this Proxy Statement and, as relates to the fiscal year ended December&#160;31, 2022, the 2024 Proxy Statement for our CEO, Mr.&#160;Hall.</td> </tr>
  </table>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(2)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Compensation actually paid (as defined by SEC rules) to the CEO for each period presented reflects the amount set forth in column (1), adjusted as set forth below in the Reconciliation of Compensation Actually Paid Table.</td> </tr>
  </table>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(3)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Mr.&#160;Law, our Interim Chief Financial Officer during such fiscal year was our only non-CEO NEO in fiscal year 2024. Mr.&#160;Law, our Interim Chief Financial Officer during such fiscal year, Dr. Kunin, our former Chief Product Officer, and Mr.&#160;Jones, our former Chief Financial Officer, were our non-CEO NEOs in fiscal year 2023. Dr. Kunin and Mr.&#160;Jones were our non-CEO NEOs in fiscal year 2022. Mr.&#160;Law was appointed our Interim Chief Financial Officer effective February&#160;16, 2023 (and subsequently our Chief Financial Officer effective August&#160;19, 2025) after Mr.&#160;Jones resigned as Chief Financial Officer effective February&#160;15, 2023. Since his resignation, Mr.&#160;Jones has continued to serve as a consultant to the Company pursuant to a consulting agreement. Dr. Kunin was appointed our Chief Product Officer effective November&#160;5, 2021 and resigned effective November&#160;5, 2023. Amounts in 2023 and 2022 for the NEOs other than the CEO are weighted-averages based on the number of days applicable NEOs served.</td> </tr>
  </table>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(4)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Average compensation actually paid (as defined by SEC rules) to the Company&#8217;s NEOs (except the CEO) for each period presented reflects the amount set forth in column (3), adjusted as set forth below in the Reconciliation of Compensation Actually Paid Table.</td> </tr>
  </table>



<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(5)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Reflects the TSR of a $100 investment in the Company from the beginning of fiscal year 2022 through each of the fiscal years ended December&#160;31, 2024, 2023 and 2022. The Company&#8217;s TSR includes share price depreciation, but does not include dividend reinvestment as the Company did not pay any dividends in the 2024, 2023 or 2022 fiscal years.</td> </tr>
  </table>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(6)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Reflects &#8220;Net loss&#8221; in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss included in the Company&#8217;s Annual Reports on Form 10-K for the fiscal years ended December&#160;31, 2024, 2023 and 2022.</td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_81A_zKugcc786Ejh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000040" name="ecd:AdjToPeoCompFnTextBlock"><p id="xdx_84F_eecd--AdjToPeoCompFnTextBlock_dU_zLX3LaMsXai7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Reconciliation of Compensation Actually Paid Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table details the applicable adjustments that were made to determine compensation actually paid (amounts are weighted-averages for the NEOs other than the CEO in 2023 and 2022 based on the number of days served):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" id="xdx_30F_zwDGAMaCsm51" summary="xdx: Disclosure - Pay vs Performance Disclosure" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="color: #1F4E79"><b>Reporting Period</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Reported Summary<br/> Compensation<br/> Table Total</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>($) </b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="color: #1F4E79"><b>Deduct: Reported<br/> value of equity<br/> awards</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="color: #1F4E79"><b>($)(a)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Add: Equity award</b></span></p>
        <p style="margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>adjustments<br/> ($)(b)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="color: #1F4E79"><b>Deduct: Reported<br/> change in the<br/> actuarial present value<br/> of pension benefits</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="color: #1F4E79"><b>($)(c)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center"><span style="color: #1F4E79"><b>Add: Pension<br/> benefit adjustments<br/> ($)(c)</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center"><span style="color: #1F4E79"><b>Compensation<br/> actually paid<br/> ($)</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td colspan="9" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"><i>CEO</i></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 34%; text-align: left">2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_989_eecd--PeoTotalCompAmt_c20240101__20241231_zbGJVPU2tWZ" style="padding-right: 0pt; width: 8%; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,177</ix:nonFraction></td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 8%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--PEOAddEquityAwardAdjustmentsMember_zqTAdmBGRjAf" style="padding-right: 0pt; width: 8%; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_PEOAddEquityAwardAdjustmentsMember" id="Fact000042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,284</ix:nonFraction></td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 8%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 8%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_zEzH0bzp5ysk" style="padding-right: 0pt; width: 8%; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,461</ix:nonFraction></td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eecd--PeoTotalCompAmt_c20230101__20231231_zb6BD0UGmu41" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,146</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98D_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOAddEquityAwardAdjustmentsMember_z8YfLYHU56Ve" style="padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_custom_PEOAddEquityAwardAdjustmentsMember" id="Fact000045" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,289</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_zdg4jM5klEEe" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,857</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2022</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_987_eecd--PeoTotalCompAmt_c20220101__20221231_zf21MH2Ehqzc" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,954</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_984_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOAddEquityAwardAdjustmentsMember_zlpFhXVcWVV3" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_PEOAddEquityAwardAdjustmentsMember" id="Fact000048" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">253,465</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_988_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_zEnH7X0Xgnpb" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,489</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td colspan="19" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"><i>NEOs (except the Chief Executive Officer)</i></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2024</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_z852ZOUARH0f" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,196</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98E_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--NEOAddEquityAwardAdjustmentsMember_zw2GPfpQ7mf9" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_NEOAddEquityAwardAdjustmentsMember" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98D_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_zsYMwFmHDqrd" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,295</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_z9D9wnn5Pywd" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,840</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98E_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOAddEquityAwardAdjustmentsMember_z7LtCpKsyzv4" style="padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_custom_NEOAddEquityAwardAdjustmentsMember" id="Fact000054" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,106</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_988_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_zyAX1Gvdve25" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2023-01-012023-12-31" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,734</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2022</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_zyV2SflyV4N2" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">259,285</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_98E_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOAddEquityAwardAdjustmentsMember_zuYVTguDNjV3" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_NEOAddEquityAwardAdjustmentsMember" id="Fact000057" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">150,479</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_z3phWdgUELs9" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2022-01-012022-12-31" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,806</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(a)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">As provided in the &#8220;Summary Compensation Table&#8221; provided in this Proxy Statement and, as relates to the fiscal year ended December&#160;31, 2022, the 2024 Proxy Statement. No equity awards were granted to any NEO in the 2024 or 2023 fiscal years.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 54; Value: 1 -->
    <div id="xdx_233_z7MHskW4guWi" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> -</p></div>
    <div id="xdx_234_z82pJP9MxvZa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zOambdmowvQ5" style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:exclude>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(b)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">The equity award adjustments for each applicable period include the subtraction of the following (amounts are weighted-averages for the NEOs other than the CEO in 2023 and 2022 based on the number of days served):</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" id="xdx_30F_zQ1JJDczYUCa" summary="xdx: Disclosure - Pay vs Performance Disclosure" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="color: #1F4E79">Reporting Period</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Period-end fair<br/> value of equity<br/> awards granted<br/> during the period</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Changes in value<br/> of prior years&#8217;<br/> awards unvested at<br/> fiscal year end</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Fair value as<br/> of vesting date<br/> of equity awards granted and vested<br/> in the period</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Change in value<br/> of prior years&#8217;<br/> awards that vested<br/> in year reported</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Fair value at<br/> the end of<br/> the prior period<br/> of equity awards<br/> that failed to meet<br/> vesting conditions<br/> in the period</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Value of dividends<br/> or other earnings<br/> paid on stock or<br/> option awards not<br/> otherwise reflected<br/> in fair value or<br/> total compensation</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Total equity award adjustments</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td colspan="8" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"><span style="font-size: 10pt"><i>CEO</i></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 30%; text-align: left">2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_981_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zLAEag9WlLml" style="padding-right: 0pt; width: 7%; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,284</ix:nonFraction></td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98F_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--PEOTotalEquityAwardAdjustmentsMember_zdHkWb9fRMI8" style="padding-right: 0pt; width: 7%; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_PEOTotalEquityAwardAdjustmentsMember" id="Fact000061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,284</ix:nonFraction></td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_zzufJCWS94Ea" style="padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" id="Fact000062" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,974</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98F_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zoBlt3R53zh" style="padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" id="Fact000063" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,315</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_984_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOTotalEquityAwardAdjustmentsMember_zlyDt8wZHzF6" style="padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_custom_PEOTotalEquityAwardAdjustmentsMember" id="Fact000064" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,289</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2022</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_zgbLfrvl1M5" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" id="Fact000065" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">236,113</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_980_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_z1tMKdp6DQPl" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" id="Fact000066" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,352</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_986_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOTotalEquityAwardAdjustmentsMember_z7aCWywn4v95" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_PEOTotalEquityAwardAdjustmentsMember" id="Fact000067" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">253,465</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td colspan="18" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"><span style="font-size: 10pt"><i>NEOs (except the Chief Executive Officer)</i></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2024</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zEwIfdRqd8Gg" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_986_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--NEOTotalEquityAwardAdjustmentsMember_z9F3sGC5wqw6" style="padding-right: 0pt; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_NEOTotalEquityAwardAdjustmentsMember" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_z09B9dZovWOh" style="padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" id="Fact000070" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_984_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zIbf4Gs9mizg" style="padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" id="Fact000071" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,023</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_987_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOTotalEquityAwardAdjustmentsMember_zWgAdfI9kx5d" style="padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_custom_NEOTotalEquityAwardAdjustmentsMember" id="Fact000072" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,106</ix:nonFraction></td>
    <td style="padding-left: 0pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2022</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_98A_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_zGEBBUQOJdvb" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" id="Fact000073" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">134,736</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zsxtw1BaC56i" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" id="Fact000074" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,743</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_98F_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOTotalEquityAwardAdjustmentsMember_zWBWYRKTtyY3" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_NEOTotalEquityAwardAdjustmentsMember" id="Fact000075" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">150,479</ix:nonFraction></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(c)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">In the periods presented and consistent with the &#8220;Summary Compensation Table&#8221; provided in this Proxy Statement and, as relates to the fiscal year ended December&#160;31, 2022, the 2024 Proxy Statement, the Company did not have: (i) a change in the actuarial present value of the accumulated benefit under any defined benefit or actuarial pension plans or (ii) any service cost or prior service cost related to any defined benefit or actuarial pension plans.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000077" name="ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock"><p id="xdx_844_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zO74glgJuvp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Pay-Versus-Performance Relationship</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company believes the table above shows the alignment between compensation actually paid to the CEO and our other non-CEO NEOs and the Company&#8217;s performance. The charts below show, for the past three years, the relationship of the CEO and the other non-CEO NEOs compensation &#8220;actually paid&#8221; and (i) the Company&#8217;s TSR and (ii) the Company&#8217;s net loss.</p>

<ix:exclude><p id="xdx_23C_zE8iv1KNHrqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 55; Value: 1 -->
    <div id="xdx_235_zvZrLdcZLpyf" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> -</p></div>
    <div id="xdx_236_z97h1isQPxK6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zobTcgSNZkld" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img src="img_003.jpg" alt="" style="height: 300px; width: 550px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000081" name="ecd:CompActuallyPaidVsNetIncomeTextBlock"><p id="xdx_84D_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zqmvdVCgeie" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img src="img_004.jpg" alt="" style="height: 309px; width: 550px"/></p>

</ix:nonNumeric><p id="xdx_85B_zpxyo8b8zI9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_81B_zKAb59upwkoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 6.5in; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_050"></span>Proposal Two:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>Advisory, Non-Binding Vote to Approve Executive Compensation</b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In accordance with Section&#160;14(a) of the Exchange Act, stockholders are being given the opportunity to vote on an advisory (non-binding) resolution to approve the compensation of the Company&#8217;s executive officers or NEOs, as described above under &#8220;Executive Compensation and Other Information,&#8221; which includes compensation tables and narrative discussions of the NEOs&#8217; compensation in this Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are asking our stockholders to indicate their support for our NEO compensation as set forth in this Proxy Statement. This proposal, commonly known as a &#8220;Say-on-Pay&#8221; proposal, gives our stockholders the opportunity to express their views on our NEOs&#8217; compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our NEOs and the philosophies, policies and practices described in this Proxy Statement. We are asking our stockholders to vote &#8220;FOR&#8221; the following non-binding resolution at the Annual Meeting:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;RESOLVED, that the compensation of NovaBay Pharmaceuticals, Inc.&#8217;s named executive officers, as disclosed in NovaBay&#8217;s Proxy Statement for the 2025 Annual Meeting of Stockholders pursuant to Item 402 of Regulation S-K, including the &#8220;Executive Compensation and Other Information,&#8221; the compensation tables and related narrative disclosures, is hereby approved.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Say-on-Pay vote is advisory, and therefore not binding on NovaBay, the Compensation Committee or the Board. The Board and the Compensation Committee value the opinions of NovaBay&#8217;s stockholders and, to the extent there is any significant vote against the NEO compensation as disclosed in this Proxy Statement, the Board and the Compensation Committee will consider stockholders&#8217; concerns and evaluate whether any actions are necessary to address those concerns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_051"></span>Stockholder Approval</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting is required for the approval of this Proposal Two. Unless otherwise instructed in the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted &#8220;FOR&#8221; this proposal. Abstentions, if any, with respect to this proposal will have the effect of a vote &#8220;AGAINST&#8221; this Proposal Two. Broker non-votes, if any, with respect to this Proposal Two, will have no effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 6.5in; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79"><b><span style="text-decoration: underline">Recommendation of Our Board</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79">Our Board recommends unanimously that you vote &#8220;FOR&#8221; the approval of the compensation of our executive officers.</span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 6.5in; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_052"></span>Proposal Three:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>Advisory, Non-Binding Vote on the Frequency of</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>Solicitation of Advisory Stockholder Approval of</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>Executive Compensation</b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under Section&#160;14(a) of the Exchange Act, the Company&#8217;s stockholders are required to vote, on an advisory, non-binding bases, on the frequency with which they would prefer to cast an advisory, non-binding Say-on-Pay vote on executive compensation, commonly referred to as the &#8220;Say-on-Frequency vote,&#8221; at least every six (6) years. By voting on this proposal, stockholders may indicate whether they prefer that we seek an advisory vote every one, two or three years. At our 2019 Annual Meeting, our stockholders expressed a preference that the non-binding advisory Say-on-Pay vote on executive compensation be held every three years, which the Company has done for the last six (6) years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After careful consideration of the frequency alternatives, the Board believes that continuing to conduct a triennial advisory (non-binding) Say-on-Pay vote on executive compensation is appropriate for the Company and its stockholders at this time. In making its determination to recommend that our stockholders vote for a frequency of every three years, the Board determined that such advisory vote on executive compensation will provide our stockholders with sufficient time to evaluate the effectiveness of our executive compensation philosophy, policies, and practices in the context of long-term business results and strategy, while avoiding over-emphasis on short-term variations in compensation and business results; and that an advisory vote every three years will also permit our stockholders to observe and evaluate the impact of any changes in our executive compensation policies and practices which have occurred since the last advisory vote on executive compensation, including changes made in response to the outcome of a prior advisory vote on executive compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accordingly, the Board is asking stockholders to indicate their preferred voting frequency by voting for one, two or three years (which vote will also be a vote to approve the resolution) or abstaining from voting on the resolution below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;RESOLVED, that the alternative of soliciting advisory stockholder approval of the compensation of NovaBay&#8217;s named executive officers once every one, two or three calendar years that receives the greatest number of votes of shares present in person or represented by proxy and voting on this proposal at the Annual Meeting shall be considered the frequency preferred by the stockholders.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although the vote of the stockholders is non-binding on the Board and NovaBay, the Board and the Compensation Committee value the opinions of NovaBay&#8217;s stockholders in this matter and the Board intends to adopt whichever frequency receives the greatest number of votes of shares present in person or represented by proxy and entitled to vote on this proposal at the Annual Meeting. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_053"></span>Stockholder Approval</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The frequency that receives the greatest number of votes by holders of the voting power of shares present in person or represented by proxy and entitled to vote at the Annual Meeting will be considered the non-binding selection of stockholders for this Proposal Three. Unless otherwise instructed in the proxy or unless authority to vote is withheld, shares represented by executed proxies will vote &#8220;THREE YEARS&#8221; for this proposal. Abstentions and broker non-votes, if any, with respect to this Proposal Three, will have no effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 6.5in; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79"><b><span style="text-decoration: underline">Recommendation of Our Board</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79">Our Board recommends unanimously that you cast your vote for once every &#8220;THREE YEARS&#8221; as the frequency of advisory votes on executive compensation.</span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 6.5in; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_054"></span>Proposal Four:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>Advisory, Non-Binding Vote to Ratify the Selection of</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>the Independent Registered Public Accounting Firm</b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Audit Committee of our Board has selected WithumSmith+Brown, PC (&#8220;<b><i>Withum</i></b>&#8221;) as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2025. Withum is registered with the Public Company Accounting Oversight Board (&#8220;<b><i>PCAOB</i></b>&#8221;) and the Center for Audit Quality and has over twenty (20) years of experience representing public companies with over 200 SEC registrants for which it performs public company audits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are asking our stockholders to ratify the selection by the Audit Committee of Withum as our independent registered public accounting firm to audit our consolidated financial statements for the fiscal year ending December&#160;31, 2025, and to perform other appropriate services. Stockholder ratification of the selection of Withum as our independent registered public accounting firm is not required by the Bylaws or otherwise. In the event that stockholders fail to ratify the appointment, the Audit Committee will reconsider its selection. Even if the selection is ratified, the Audit Committee, in its sole discretion, may direct the appointment of a different independent registered public accounting firm at any time during the year if the Audit Committee feels that such a change would be in the Company&#8217;s best interests and our stockholders&#8217; best interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A representative of Withum is expected to be present at the Annual Meeting, will have the opportunity to make a brief presentation to the stockholders if he or she so desires and is expected to be available to respond to appropriate questions from stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_055"></span>Fees Paid to Independent Registered Public Accounting Firm</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets forth the fees billed to us for the fiscal years ended December&#160;31, 2024 and 2023 by Withum for such years: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; vertical-align: bottom; padding-left: 0.165in; text-align: center"><span style="color: rgb(31,78,121)">&#160;</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="color: rgb(31,78,121)">&#160;</span></td>
    <td colspan="2" style="border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="color: rgb(31,78,121)">2024</span></td>
    <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="color: rgb(31,78,121)">&#160;</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="color: rgb(31,78,121)">&#160;</span></td>
    <td colspan="2" style="border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="color: rgb(31,78,121)">2023</span></td>
    <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="color: rgb(31,78,121)">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; width: 76%; text-align: left">Audit Fees</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 9%; text-align: right">474,000</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 9%; text-align: right">370,000</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">Audit-Related Fees</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">18,960</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">14,800</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">Tax Fees</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left; padding-bottom: 1pt">All Other Fees</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">Total Fees</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; padding-right: 0pt; text-align: right">492,960</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; padding-right: 0pt; text-align: right">384,800</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Audit Fees</i></b></span><i>.</i> Audit fees consisted of fees billed by Withum for professional services rendered in connection with the audit and quarterly reviews of our consolidated financial statements and other engagements, such as review of documents filed with the SEC, including fees associated with the review of registration statements, comfort letters and consents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Audit-Related Fees</i></b></span>. Audit-related fees comprise fees for professional services rendered by Withum that are reasonably related to the performance of the audit or review of our consolidated financial statements that are not reported in &#8220;Audit Fees.&#8221; In 2024 and 2023, such audit-related fees were related to out-of-pocket expenses incurred in conjunction with the performance of audits and reviews.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Tax Fees</i></b></span>. These are fees for professional services with respect to tax compliance, tax advice and tax planning. There were no such services rendered by Withum in 2024 or 2023 that meet this category description.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>All Other Fees</i></b></span><i>.</i> All other fees are the fees for products and services other than those in the above three categories. There were no such services rendered by Withum in 2024 or 2023 that meet this category description.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_056"></span>Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All engagements for services by Withum or other independent registered public accounting firms are subject to prior approval by the Audit Committee; however, <i>de minimis</i> non-audit services may be approved in accordance with applicable SEC rules. The Audit Committee approved all services provided by Withum for the fiscal years ended December&#160;31, 2024 and December&#160;31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_057"></span>Stockholder Approval</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting is required for ratification of this Proposal Four. Unless otherwise instructed in the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted &#8220;FOR&#8221; this proposal. Abstentions, if any, with respect to this proposal will have the effect of a vote &#8220;AGAINST&#8221; this Proposal Four. We do not expect to receive any broker non-votes on this Proposal Four.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 6.5in; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79"><b><span style="text-decoration: underline">Recommendation of Our Board</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79">Our Board recommends unanimously that you vote &#8220;FOR&#8221; the ratification of the selection of Withum as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2025.</span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_058"></span>Audit Committee Report</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is the report of the Audit Committee with respect to the audited consolidated financial statements of NovaBay Pharmaceuticals, Inc. for the fiscal year ended December&#160;31, 2024, included in the Annual Report on Form 10-K for that year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Audit Committee has reviewed and discussed the audited financial statements of NovaBay for the fiscal year ended December&#160;31, 2024 with NovaBay&#8217;s management. The Audit Committee has discussed with NovaBay&#8217;s independent registered public accounting firm, Withum, the matters required to be discussed by Auditing Standard No. 61, <i>Communications with Audit Committees</i>, as adopted by the Public Company Accounting Oversight Board (&#8220;<b><i>PCAOB</i></b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Audit Committee has received the written disclosures and the letter from Withum required by applicable requirements of the PCAOB regarding Withum&#8217;s communications with the Audit Committee concerning independence and has discussed with Withum the independence of Withum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based on the review and discussions referred to above in this report, the Audit Committee recommended to NovaBay&#8217;s Board that the audited financial statements be included in NovaBay&#8217;s Annual Report for filing with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%">&#160;</td>
    <td style="text-align: left; vertical-align: top; width: 50%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Submitted by the Audit Committee of the Board of Directors:</p> </td> </tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Dr. Yenyou (Jeff) Zheng, Chair</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Dr. Paul E. Freiman</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Ms. Swan Sit</p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 6.5in; text-align: center; vertical-align: middle"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_059"></span>Description of the Investment Transaction and Preferred Stock</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>The following is a summary of the material provisions of the Purchase Agreement, the Series D Preferred Stock, the Series E Preferred Stock and other related transaction documents summarized below, but does not purport to describe all of the terms and conditions and may not contain all of the information about these documents identified below that are important to you. The following summary is qualified in its entirety by reference to the complete text of the Purchase Agreement, the Series D Certificate of Designation (as defined below), the Series E Certificate of Designation (as defined below) and other related transaction documents, which are publicly available and attached as exhibits to our Current Report on Form 8-K as filed with the SEC on August&#160;19, 2025 (the &#8220;</i><b><i>Investment Transaction Form 8-K</i></b><i>&#8221;). You should refer to the full text of the Purchase Agreement, the Series D Certificate of Designation, the Series E Certificate of Designation and other related transaction documents referred to below and elsewhere in this Proxy Statement for details about the Investment Transaction, and carefully read this entire Proxy Statement and the other documents to which we have referred you under the section &#8220;Where You Can Find More Information&#8221; in this Proxy Statement.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_060"></span>Investment Transaction and Related Transactions</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Private Placement of Series D Preferred Stock and Expected Private Placement of Series E Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August&#160;19, 2025, we entered into the Purchase Agreement that provided for the Company to sell to Mr.&#160;Lazar in a private placement an aggregate of 481,250 shares of Series D Preferred Stock convertible into an aggregate of 77.0 million shares of Common Stock and an aggregate of 268,750 shares of Series E Preferred Stock convertible into an aggregate of 43.0 million shares of Common Stock. At the First Closing simultaneously with entering into the Purchase Agreement, Mr.&#160;Lazar purchased the shares of Series D Preferred Stock at a price of $8.00 per share for aggregate gross proceeds to us of $3.85 million. Pursuant to the Purchase Agreement, at the Final Closing, Mr.&#160;Lazar will separately purchase the shares of Series E Preferred Stock at a price of $8.00 per share for aggregate gross proceeds to us of $2.15 million. The consummation of the Final Closing by us and Mr.&#160;Lazar is subject to the satisfaction or waiver of, among other customary closing conditions, (i) receiving the Conversion Approval, as is being solicited by Proposal Five (NYSE American Proposal), (ii) the accuracy of the representations and warranties of each of the parties in the Purchase Agreement, (iii) compliance by the parties with the covenants in the Purchase Agreement, and (iv) no permanent suspension or other trading suspension for more than three consecutive trading days of our Common Stock by the SEC, the NYSE American or as reported by Bloomberg L.P. having occurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The shares of Series D Preferred Stock issued at the First Closing, upon conversion, will represent approximately 61% of the Company&#8217;s issued and outstanding Common Stock on a fully diluted basis, and the Series E Preferred Stock to be issued at the Final Closing, upon conversion, will represent approximately 34% of the Company&#8217;s issued and outstanding Common Stock on a fully diluted basis as of the Final Closing, or collectively approximately 95% in the aggregate (based on the number of shares of Common Stock anticipated to be outstanding as of the Final Closing). As a result of our Common Stock being listed on the NYSE American, we are required to comply with the continued listing rules set forth in Section&#160;713(a) and Section&#160;713(b) of the Company Guide and obtain the Conversion Approval of our stockholders in order for Mr.&#160;Lazar to be able to fully convert the Series D Preferred Stock and convert the Series E Preferred Stock, which approval, pursuant to Proposal Five (NYSE American Proposal) is being sought at this Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Use of Proceeds</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase Agreement, the net proceeds received from the Investment Transaction have been and will be used for the Company&#8217;s operations, including for general corporate and working capital purposes, for payment of the Special Dividend, for expenses related to the Investment Transaction and the Post-Investment Transaction (as discussed below) and to satisfy other agreed upon Company obligations that include the payments to the Remaining Warrant Holders pursuant to the Series F Agreements and severance and other payments pursuant to the Release Agreements (as discussed below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>One-Time Special Cash Dividend to Stockholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of receiving the proceeds from the Investment Transaction and pursuant to the Purchase Agreement, the Company committed to declaring and paying a one-time Special Dividend to stockholders funded by the Aggregate Cash Distribution Amount that was segregated at the First Closing for payment of the Special Dividend. Further, pursuant to the Voting Agreement with the Poplar Entities, the Company agreed to use commercially reasonable efforts to issue a special cash dividend that equals or exceeds $0.80 per share. To satisfy this important commitment, on August&#160;26, 2025, the Company announced that it declared this one-time Special Dividend payable on September&#160;29, 2025 to stockholders of record as of the close of business on September&#160;15, 2025 in the amount of $0.80 per share of Common Stock. Pursuant to the Purchase Agreement, in addition to other conversion limitations, Mr.&#160;Lazar is restricted from converting any shares of Series D Preferred Stock until after the Special Dividend is declared and paid to our stockholders. The payment of the Special Dividend is under the direction and control of the Special Transaction Committee, comprised of directors that our Board has determined do not have a material personal interest and are not otherwise affiliated with Mr.&#160;Lazar or the Investment Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Post-Investment Transaction</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, after the Final Closing and subject to approval by the Board, the Company intends to use the net proceeds from the Investment Transaction to pursue and consummate the Post-Investment Transaction, which is contemplated to be a strategic transaction involving an investment and/or acquisition of an operating going concern and solvent company (&#8220;<b><i>Target Company</i></b>&#8221;). If and when a Post-Investment Transaction is entered into and consummated after receiving required approvals, we expect that, by combining with a new operating and revenue generating Target Company, such combination will result in a future growth opportunity for our Company and our stockholders. In connection with a Post-Investment Transaction being consummated, our stockholders may experience dilution to the extent that we issue additional shares of our Common Stock or other securities as consideration to acquire the Target Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_061"></span>The Purchase Agreement and Related Transaction Documents</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement entered into by us and Mr.&#160;Lazar provides for the transactions and agreements described below and contains customary representations, warranties, and covenants by us and Mr.&#160;Lazar, as well as indemnification rights, and other obligations of the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>First Closing Conditions and Transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The consummation of the First Closing on August&#160;19, 2025 was subject to the satisfaction of customary closing conditions, including the accuracy of the representations and warranties in the Purchase Agreement and the execution and delivery of certain transaction documents, which included the Series F Agreements with the Remaining Warrant Holders and the Voting Agreement with the Poplar Entities, as well as the Release Agreements with Mr.&#160;Hall and each of the Resigning Non-Employee Directors, the New Hall Employment Agreement and the Law Employment Agreement, each as further described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Series F Agreements</span></i></span>. On August&#160;19, 2025, simultaneous with the First Closing, the Company entered into the Series F Agreements with each of the Remaining Warrant Holders, comprised of Anson Investments Master Fund LP, Hudson Bay Capital Management LP and Armistice Capital, LLC, as the three largest remaining holders of the Company&#8217;s Series F Warrants. Pursuant to the Series F Agreements, each Remaining Warrant Holder surrendered all of their respective Series F Warrants and any additional Common Stock purchase warrants that each Remaining Warrant Holder owned, if any, in exchange for (i) the Company issuing an aggregate of 1,986,565 shares of Series F Preferred Stock to the Remaining Warrant Holders and (ii) a cash payment of $175,000 to each of the Remaining Warrant Holders. The Series F Preferred Stock issued has the powers, preferences, rights, qualifications, limitations and restrictions as set forth in the Certificate of Designation of Preferences, Rights and Limitations for the Series F Voting Retractable Preferred Stock (the &#8220;<b><i>Series F Certificate of Designation</i></b>&#8221;). Among these rights, each share of Series F Preferred Stock that we issued has the right to vote the equivalent of approximately 0.424 shares of Common Stock, or in the aggregate the right to vote 842,832 shares of Common Stock, which will represent an aggregate of approximately 12.3% of the voting power as of the Record Date. The Series F Agreements provide for each of the Remaining Warrant Holders to exercise their voting rights by voting all of their Series F Preferred Stock in favor of the Proposals that have been presented to stockholders at this Annual Meeting, including the Conversion Approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> The terms of the Series F Preferred Stock provide the Remaining Warrant Holders with the right to require that we retire their shares of Series F Preferred Stock and convertible securities beginning after the earlier of the Conversion Approval and December&#160;31, 2025 in exchange for $175,000 to each Remaining Warrant Holder, or an aggregate of $525,000. We also have the right to retire the Series F Preferred Stock for the same amount after December&#160;31, 2025 if such shares have not been retired. The Series F Agreements include a standstill provision pursuant to which the Remaining Warrant Holders agree not to initiate any claims against the Company, including claims that relate to the transactions contemplated by the Purchase Agreement and the Special Dividend, as well as a &#8220;most favored nations&#8221; provision that provides for transaction terms of the Remaining Warrant Holders to be materially consistent. For additional information about the Series F Agreements and the Series F Preferred Stock, see the Investment Transaction Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Voting Agreement</span>.</i></span> In connection with the First Closing of the Investment Transaction, the Company and Mr.&#160;Lazar entered into the Voting Agreement with Jad Fakhry and the Poplar Entities, which reported owning approximately 17.5% of outstanding Common Stock in their Schedule&#160;13D filed with the SEC on June&#160;4, 2025. In connection with the Poplar Entities entering into the Voting Agreement, we agreed to use commercially reasonable efforts for the contemplated Special Dividend to equal or exceed $0.80 per share (prior to any stock split, share consolidation, recapitalization or similar transaction). Pursuant to the Voting Agreement, the Poplar Entities agreed to, among other terms, vote all of their shares of Common Stock at the Annual Meeting in favor of the Proposals recommended by the Board and appoint the Company as an irrevocable proxy for the Poplar Entities for the duration of the Voting Agreement, which has a term of two years. The Poplar Entities also agreed to a standstill provision that ensures they will, among other terms, (i) not effect, offer or propose to purchase any additional securities or assets of the Company (including derivative rights), engage in any tender, merger, recapitalization, liquidation, or other business combination transaction, solicit proxies or otherwise act to control or influence the management of the Board or take any action that may force us to make a public announcement of such matters and (ii) not dispose of any shares of our Company until the Poplar Entities have voted their shares of Common Stock at the Annual Meeting in favor of all Proposals recommended by the Board at the Annual Meeting and such proposals have passed. Notwithstanding the standstill provision, the Poplar Entities can make proposals to the Board or Special Transaction Committee, the Chairman, and/or the Chief Executive Officer on a confidential, non-public basis for pursuit of a proposed transaction between the Company, Mr.&#160;Lazar and the Poplar Entities, so long as the Company would not reasonably be expected to publicly disclose such a proposal and a waiver of the standstill provision.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Release Agreements</span></i>.</span> As a condition to the First Closing, we entered into Release Agreements with Mr.&#160;Hall and the Resigning Non-Employee Directors, comprised of five (5) of the six (6) non-employee directors serving on the Board (Dr. Freiman, Ms. Garlikov, Ms. Sit, Mr.&#160;Wu and Mr.&#160;Sean Zheng). The remaining non-employee director, Dr. Jeff Zheng (who satisfies the &#8220;independence&#8221; requirements set forth in the Company Guide and under federal securities laws) will continue to serve on the Board, and, therefore, he did not enter into a Release Agreement. The Release Agreements provide for (i) Mr.&#160;Hall and the Resigning Non-Employee Directors to generally release the Company from any claims, actions, or losses that such person may have against the Company and (ii) the Company to similarly release Mr.&#160;Hall and each of the Resigning Non-Employee Directors from any claims, actions or losses that the Company may have against such person, provided that the Company shall remain obligated pursuant to the indemnification agreements with each person and to maintain D&amp;O insurance coverage, or a D&amp;O tail policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Hall Release Agreement, he agreed to resign from the Board effective on the date and at the time that each of the following have occurred: (i) receipt of the Conversion Approval; (ii) the completion of the Final Closing; and (iii) the Additional Purchaser Nominee(s) (as further discussed below) being qualified and appointed to serve on the Board. Mr.&#160;Hall further agreed to resign, and did resign, as the Company&#8217;s Chief Executive Officer as of the First Closing. Under the terms of the Release Agreements with the Resigning Non-Employee Directors, each of these directors agreed to resign from the Board effective upon the Resignation Event or on the date and at the time that each of the following have occurred: (a) receipt of the Conversion Approval; (b) the Final Closing; (c) the Additional Purchaser Nominee(s) being qualified and appointed to serve on the Board; (d) the Special Dividend having been declared and paid; and (e) Proposal Seven (Director Equity Consideration Proposal) having been approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to, and as consideration for, the Release Agreements with the Resigning Non-Employee Directors, each Resigning Non-Employee Director shall receive (i) a settlement payment of newly-issued shares of restricted Common Stock, with an aggregate value of $40,000 (determined based on the closing price of Common Stock on the trading day that immediately precedes the date of the Resignation Event) to be issued on the date of the Resignation Event (the &#8220;<b><i>Equity Consideration</i></b>&#8221;), subject to stockholders approving Proposal Seven (Director Equity Consideration Proposal), plus (ii) any accrued and unpaid directors&#8217; fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">To the extent that Proposal Seven (Director Equity Consideration Proposal) is not obtained and the Equity Consideration is not issued to the Resigning Non-Employee Directors, then the Release Agreements with the Resigning Non-Employee Directors will terminate and be of no further force and effect. The Hall Release Agreement provides for Mr.&#160;Hall to receive a cash settlement payment of $481,250 plus any unpaid wages and $8,778 in payments pursuant to COBRA in connection with the First Closing, which Mr.&#160;Hall received at such time. Further, Mr.&#160;Hall will receive a second cash settlement payment of $481,250 plus any unpaid wages and $8,778 in COBRA payments by October&#160;31, 2025. Mr.&#160;Hall&#8217;s payment amounts comprise his earned severance under the Prior Hall Employment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">New Hall Employment Agreement</span>.</i></span><i> </i>At the First Closing, the Company entered into the New Hall Employment Agreement that provides for his continued service as the Company&#8217;s Vice President of Business Development, General Counsel and Corporate Secretary, which entirely amended and restated the Prior Hall Employment Agreement. The New Hall Employment Agreement provides for an employment term commencing on the date of the First Closing and ending on October&#160;31, 2025 (the &#8220;<b><i>Hall Employment Term</i></b>&#8221;) and an annual base salary of $175,000. The Hall Employment Agreement is guaranteed through the Hall Employment Term. See &#8220;<i>Executive Compensation and Other Information&#8212;Employment-Related Agreements and Potential Payments upon Termination or Change in Control&#8212;Justin Hall</i>&#8221; for a further description of the New Hall Employment Agreement and the Prior Hall Employment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Law Employment Agreement</span><b>.</b></i></span> The Company at the First Closing also entered into the Law Employment Agreement with Mr.&#160;Law to serve as the Company&#8217;s Chief Financial Officer and Treasurer. Mr.&#160;Law previously served as the Interim Chief Financial Officer and Treasurer and did not have an employment agreement in place. The Law Employment Agreement provides for at-will employment with a term commencing on the date of the First Closing that continues until August&#160;19, 2026 with an annual base salary of $170,000. Mr.&#160;Law will also be (i) entitled to a retention bonus of $170,000 to the extent he remains employed through the Company&#8217;s filing of its quarterly report on Form 10-Q with the SEC for the quarter ended September&#160;30, 2025 and has not resigned or been terminated for cause (as defined in the Law Employment Agreement) prior to such date and (ii) eligible for any bonus plan that is deemed appropriate by the Board as provided in the Law Employment Agreement. The Law Employment Agreement also provides for the termination of Mr.&#160;Law&#8217;s employment and compensation that he may be entitled to receive, including a severance payment, depending on the circumstances of his termination. See &#8220;<i>Executive Compensation and Other Information&#8212;Employment-Related Agreements and Potential Payments upon Termination or Change in Control&#8212;Tommy Law</i>&#8221; for a further description of the Law Employment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Post-First Closing Covenants of Mr.&#160;Lazar and Our Company</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase Agreement, we and Mr.&#160;Lazar each agreed to be bound by certain covenants after the First Closing, which include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">We agreed to maintain a reserve of Common Stock from our authorized shares in order to complete the Investment Transaction and related transactions pursuant to the Purchase Agreement, except to the extent limited by our authorized shares of Common Stock at the time.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">We agreed that until the Annual Meeting, without Mr.&#160;Lazar&#8217;s consent, we would not, except as contemplated to occur pursuant to the Purchase Agreement: (i) change the number of directors constituting the Board from eight (8) or fill any vacancy on the Board; (ii) change the nature of our operations; (iii) incur any debt outside of the ordinary course of business; (iv) guarantee any obligation of any third party; (v) issue any capital stock or Common Stock equivalent, other than pursuant to certain limited exceptions such as those related to the 2017 Omnibus Plan; or (vi) amend our Certificate of Incorporation or Bylaws.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0">Mr.&#160;Lazar agreed to ensure that the Company will have sufficient capital to identify, conduct due diligence and complete a Post-Investment Transaction in a timely manner and fund operations and pursue the growth opportunity and business strategy of a Target Company for at least twelve (12) months after completing a Post-Investment Transaction (the &#8220;<b><i>Post-Investment Available Capital</i></b>&#8221;). Further, after both the First Closing and the Final Closing, Mr.&#160;Lazar agreed that the Company will maintain a cash balance sufficient to fund the</p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; vertical-align: top; width: 0.25in"/>
    <td style="vertical-align: top; text-align: left; text-indent: 0in; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#8220;Minimum Company Operating Capital&#8221; (as defined in the Purchase Agreement that generally means capital equivalent to at least three (3) months of the Company&#8217;s operations), the Post-Investment Available Capital and the Other Company Liabilities (as defined in the Purchase Agreement) or that he, or other institutional investors known to him, will otherwise provide the necessary additional cash through private placement investments on commercially reasonable terms.</p></td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Mr.&#160;Lazar agreed, upon receipt of written notice from the Company that the Remaining Warrant Holders have exercised their right to retire the Series F Preferred Stock in exchange for a cash payment, to cause the Company to pay the full amount of such payment including through the proceeds of the Investment Transaction.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Mr.&#160;Lazar agreed that he will not offer, sell, dispose of, or otherwise transfer the Series D Preferred Stock, the Series E Preferred Stock or the Conversion Shares (as defined below) to a U.S. person within six (6) months from the date of purchase, subject to certain exceptions (including the &#8220;Securities Purchase Rights,&#8221; as defined in the Purchase Agreement), or engage in any hedging transactions in compliance with Regulation S promulgated under the Securities and Exchange Act of 1933, as amended.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Stockholder Proposals and Meeting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase Agreement, we agreed to hold this Annual Meeting to obtain the Conversion Approval contemplated by Proposal Five, as well as obtain stockholder approval of (i) an increase in the Company&#8217;s authorized shares of Common Stock to 300.0 million shares from 150.0 million shares, as contemplated by Proposal Nine, although such increase is proposed to be 1.5 billion shares, (ii) an increase in the Company&#8217;s authorized shares of preferred stock to 10.0 million shares from 5.0 million shares, as contemplated by Proposal Ten, (iii) the election of Company directors to the Board, including Mr.&#160;Lazar, as contemplated by Proposal One, (iv) an increase in shares available under the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Plan to up to one (1) million shares, as contemplated by Proposal Six, (v) the issuance and payment of the Equity Consideration, comprised of newly-issued shares of restricted Common Stock with an aggregate value of $40,000, to each of the Resigning Non-Employee Directors as contemplated by the Release Agreements, as contemplated by Proposal Seven, and (vi) a reverse stock split of the Common Stock in the range of not less than 1-for-2 and not more than 1-for-10, with the specific ratio to be determined and implemented in the sole and absolute discretion of the Board, as contemplated by Proposal Eight<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To the extent that the above proposals are not obtained, then we are required to use our reasonable best efforts to call a second stockholder meeting within seventy (70) days of the date of the Annual Meeting (the &#8220;<b><i>Second Meeting</i></b>&#8221;). If the Conversion Approval is not received at the Second Meeting, then we agreed to issue and sell to Mr.&#160;Lazar in the Additional Private Placement (as defined below) up to 19.99% of the Common Stock outstanding as of the date of the Purchase Agreement at a price per share equal to the closing stock price of the Common Stock on the date of the Second Meeting plus $0.02. The number of shares of Common Stock that Mr.&#160;Lazar will be entitled to purchase in the Additional Private Placement is limited and subject to automatic reduction to a number of shares of Common Stock where Mr.&#160;Lazar, together with his affiliates, will not own shares of Common Stock in excess of 19.99% of Common Stock outstanding as of the date of the Purchase Agreement. As a result of the Share Issuance Limitation in the Series D Preferred Stock, if the Additional Private Placement is completed by Mr.&#160;Lazar, he will no longer be able to convert any Series D Preferred Stock until after the Conversion Approval is received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_062"></span>Description of the Preferred Stock and Lazar Investor Rights</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Description of Series D Preferred Stock and Series E Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The powers, preferences, rights, qualifications, limitations and restrictions applicable to the Series D Preferred Stock and the Series E Preferred Stock to be issued in the Investment are set forth in the Company&#8217;s Certificate of Designation of Preferences, Rights and Limitations of the Series D Non-Voting Convertible Preferred Stock (the &#8220;<b><i>Series D Certificate of Designation</i></b>&#8221;) and the form of Certificate of Designation of Preferences, Rights and Limitations of the Series E Non-Voting Convertible Preferred Stock (the &#8220;<b><i>Series E Certificate of Designation</i></b>&#8221;). The Series D Certificate of Designation was filed with the Delaware Secretary of State on August&#160;19, 2025 and is attached as Exhibit 3.1 to the Investment Transaction Form 8-K. The Series E Certificate of Designation will be filed</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: Black">with the Delaware Secretary of State prior to the Final Closing occurring, with the form of such Series E Certificate of Designation attached as Exhibit 3.2 to the Investment Transaction Form 8-K. As summarized below, the powers, preferences, rights, qualifications, limitations and restrictions applicable to the Series D Preferred Stock and the Series E Preferred Stock are substantially similar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Voting Rights</span></i></span><i><span style="color: Black">.</span></i><span style="color: Black"> The holders of the shares of the Series D Preferred Stock and Series E Preferred Stock generally will have no voting rights, except as required by law, with the exception that the consent of the majority of holders of the outstanding Series D Preferred Stock or Series E Preferred Stock, as applicable, would be required to: (i) alter or change adversely the powers, preferences or rights given to the Series D Preferred Stock or Series E Preferred Stock or alter or amend the Series D Certificate of Designation or Series E Certificate of Designation, as applicable; (ii) amend the Certificate of Incorporation or other charter documents in any manner that adversely affects any rights of the holders of the Series D Preferred Stock or Series E Preferred Stock, as applicable; (iii) increase the number of authorized shares of Series D Preferred Stock or Series E Preferred Stock, as applicable; and (iv) enter into any agreement with respect to any of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Dividends</span></i></span><i><span style="color: Black">. </span></i><span style="color: Black">The holders of the Series D Preferred Stock and the Series E Preferred Stock will be entitled to receive, and the Company will be required to pay, dividends on shares of the Series D Preferred Stock and the Series E Preferred Stock equal (on an as if converted to Common Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock; <i>provided</i>, <i>however</i>, that no dividends will be paid to the holders of the Series D Preferred Stock or the Series E Preferred Stock prior to the declaration and payment of the Special Dividend and the Company receiving the Conversion Approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Conversion and Limitations</span></i></span><i><span style="color: Black">.</span></i><span style="color: Black"> Pursuant to the Series D Certificate of Designation and the Series E Certificate of Designation, the Series D Preferred Stock and the Series E Preferred Stock are each generally subject to the Share Issuance Limitation. After issuance by the Company, (i) each share of Series D Preferred Stock will be convertible into 160 shares of Common Stock per share of Series D Preferred Stock, or an aggregate of 77.0 million shares of Common Stock, and (ii) each share of Series E Preferred Stock will be convertible into 160 shares of Common Stock, or an aggregate of 43.0 million shares of Common Stock (as may be adjusted from time to time as a result of certain corporate actions such as a reverse stock split), in each case, subject to the Share Issuance Limitation and receipt of the Conversion Approval. Thereafter, on the third business day after the Company receives the Conversion Approval, each outstanding share of the Series D Preferred Stock will automatically convert into 160 shares of Common Stock (or an aggregate of up to 77.0 million shares of Common Stock), which conversion, as a result of having received the Conversion Approval, shall not be subject to the Share Issuance Limitation. Effective on the 30<sup>th</sup> business day after the Conversion Approval is received and the issuance of the Series E Preferred Stock, each outstanding share of the Series E Preferred Stock will automatically convert into 160 shares of Common Stock (or an aggregate of up to 43.0 million shares of Common Stock), which conversion, as a result of having received the Conversion Approval, shall also not be subject to the Share Issuance Limitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Dilution Protection</span></i></span><i><span style="color: Black">.</span></i><span style="color: Black"> In the event the Company, at any time that any shares of Series D Preferred Stock or Series E Preferred Stock are outstanding: (i) pays a dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, a dividend or other distribution shall not include any shares of Common Stock issued by the Company upon conversion of the Series D Preferred Stock and Series E Preferred Stock); (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the number of shares of Common Stock underlying each share of Series D Preferred Stock and Series E Preferred Stock shall be adjusted as provided in the respective Series D Certificate of Designation or Series E Certificate of Designation. Any adjustment made pursuant to the respective Series D Certificate of Designation or Series E Certificate of Designation shall become effective immediately after the effective date of the applicable event described in subsections (i) through (iv) above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: Black">In addition, if the Company issues shares of Common Stock (or other shares of capital stock or other securities convertible into Common Stock) at any time while the Series D Preferred Stock and Series E Preferred Stock are outstanding and the consideration per share payable to the Company reflects a pre-money imputed equity value of the Company less than $10.0 million, then the value of the Series D Preferred Stock or the Series E Preferred Stock will</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: Black">&#160;</span></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: Black">be reduced to such lower price, which is referred to as a &#8220;full-ratchet&#8221; anti-dilution protection. This full-ratchet anti-dilution protection is subject to the reduced value only being reduced to the extent such reduction will not require further stockholder approval. Additionally, these dilution protections are not applicable to the Investment Transaction, the Additional Private Placement, the Equity Consideration and other transactions pursuant to the Purchase Agreement or any Post-Investment Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Rank</span></i></span><i><span style="color: Black">. </span></i><span style="color: Black">Based upon the rights and preferences as provided in the Series D Certificate of Designation and the Series E Certificate of Designation, each of the Series D Preferred Stock and the Series E Preferred Stock, respectively, will rank as to dividends or distributions of assets upon the Company&#8217;s liquidation, dissolution or winding up, whether voluntarily or involuntarily, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><span style="color: Black">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in"><span style="color: Black">on par with the Series D Preferred Stock and the Series E Preferred Stock, as applicable, and any class or series of capital stock hereafter created specifically ranking by its terms to be on parity with the Series D Preferred Stock and the Series E Preferred Stock, as applicable;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><span style="color: Black">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in"><span style="color: Black">senior to the Common Stock and any class or series of the Company&#8217;s capital stock that is currently or hereafter created specifically ranking by its terms junior to the Series D Preferred Stock and the Series E Preferred Stock; and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><span style="color: Black">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in"><span style="color: Black">junior to any class or series of the Company&#8217;s capital stock hereafter created specifically ranking by its terms senior to the Series D Preferred Stock and the Series E Preferred Stock.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Liquidation Preference</span></i></span><span style="color: Black">. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of Series D Preferred Stock and Series E Preferred Stock will be entitled to receive an amount equal to $8.00 per share, the stated value of the Series D Preferred Stock and the Series E Preferred Stock (as may be increased from time to time pursuant to the terms of the Series D Certificate of Designation or Series E Certificate of Designation, as applicable) plus any declared but unpaid dividends that such holders are entitled to at such time. Next, the remaining assets of the Company will be distributed to the holders of Common Stock and any other junior securities until such holders receive a return of their capital originally contributed. Following this distribution, any remaining assets will be distributed to all holders of Common Stock, junior securities, Series D Preferred Stock, Series E Preferred Stock and any other parity securities pro rata based on the number of shares held on an as-converted basis. Pursuant to the terms of the Series D Certificate of Designation and the Series E Certificate of Designation, a liquidation event includes an acquisition or merger of the Company (not including transactions where stockholders maintain 50% or more voting power) or a sale of substantially all of the assets of the Company. The Series D Certificate of Designation and Series E Certificate of Designation each expressly provide that a liquidation event will not be triggered by a Post-Investment Transaction, or any other transaction contemplated by the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Lazar Investor Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Board Rights</span></i></span><span style="color: Black">. In connection with the First Closing of the Investment Transaction, Mr.&#160;Lazar was appointed as a director to our Board and began serving as our Chief Executive Officer, with our former Chief Executive Officer, Mr.&#160;Hall, continuing with the Company as its Vice President of Business Development, General Counsel and Corporate Secretary. Additionally, pursuant to the Purchase Agreement, Mr.&#160;Lazar received one-time contractual rights involving the Board, which include: (i) a contractual right to recommend one (1) individual to be nominated for election at this Annual Meeting, which right was exercised with Mr.&#160;Lazar&#8217;s nomination for election to the Board at this Annual Meeting; (ii) subject to the Conversion Approval and the Final Closing occurring, a contractual right to nominate up to three (3) Additional Purchaser Nominee(s) to be qualified (including satisfying director &#8220;independence&#8221; requirements under the Company Guide) and appointed to serve as directors on the Board after the resignation of the Resigning Non-Employee Directors pursuant to their respective Release Agreements; and (iii) subject to the Conversion Approval and the Final Closing occurring, a contractual right to be appointed as the Chair of the Board. Pursuant to the Purchase Agreement, when exercising his one-time right to appoint Additional Purchaser Nominee(s), Mr.&#160;Lazar will be entitled to nominate up to three (3) Additional Purchaser Nominee(s) to the Board based on his beneficial ownership of Common Stock (including through his ownership of Preferred Stock convertible into Common Stock) at the time of such nomination as follows: (a) one (1) Additional Purchaser Nominee when Mr.&#160;Lazar beneficially owns 20% but less than 40% of the outstanding Common Stock; (b) two (2) Additional Purchaser Nominee(s) when Mr.&#160;Lazar beneficially owns at least 40% of the outstanding Common Stock but less than 60% of the outstanding Common Stock; and (c) three (3) Additional Purchaser Nominee(s) when Mr.&#160;Lazar beneficially owns 60% or more of the outstanding Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: Black">&#160;</span></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Participation in Future Offerings</span></i></span>. In connection with the Investment Transaction, the Company granted Mr.&#160;Lazar a right to participate in subsequent financing transactions where we issue Common Stock or Common Stock equivalents for cash consideration, indebtedness or a combination thereof until the earlier of closing a Post-Investment Transaction or February&#160;19, 2026 (i.e. the six (6) month anniversary of the First Closing), in an amount up to 25% of the subsequent financing transaction or a lesser amount to the extent that Mr.&#160;Lazar no longer holds at the time at least 25% of the issued and outstanding shares of Common Stock, including on an as converted basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Share Transfer Rights</span></i></span>. Pursuant to the Purchase Agreement, Mr.&#160;Lazar has the right to assign and transfer the Series D Preferred Stock, the Series E Preferred Stock and the Conversion Shares and/or his right to acquire such securities (collectively, the &#8220;<b><i>Securities Purchase Rights</i></b>&#8221;), or the option to sell the Securities Purchase Rights, subject to Mr.&#160;Lazar and the transferee satisfying certain requirements pursuant to the Purchase Agreement. In connection with any such assignment or transfer of the Securities Purchase Rights, (i) such assignee or transferee must agree to be bound with respect to the transferred Securities Purchase Rights and/or transferred securities, by the representations and warranties and other applicable provisions of the Purchase Agreement and other transaction documents applicable to Mr.&#160;Lazar acquiring such securities, (ii) the exemption relied upon by us in connection with the issuance of the securities in the Investment Transaction shall continue to be in full force and effect and the transfer will be in compliance with all applicable laws, and (iii) upon request, Mr.&#160;Lazar shall certify to us regarding compliance with these obligations. Mr.&#160;Lazar&#8217;s indemnification obligations and covenants set forth in Article 4 of the Purchase Agreement shall be performed by Mr.&#160;Lazar and not be assignable in connection with the Securities Purchase Rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 6.5in; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_063"></span>Proposal Five:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>Approval of Issuance of Common Stock Upon Conversion</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>of Series D Preferred Stock and Series E Preferred Stock</b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At the Annual Meeting, we are asking stockholders to approve this Proposal Five, and thereby provide the Conversion Approval, in accordance with Sections&#160;713(a) and 713(b) of the Company Guide for both:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in"><i><span style="text-decoration: underline">Series D Conversion Shares</span></i>. The issuance of 77.0 million shares of Common Stock (the &#8220;<b><i>Series D Conversion Shares</i></b>&#8221;) upon conversion of 481,250 shares of Series D Preferred Stock already issued at the First Closing of the Investment Transaction, subject to the potential increase in the number of Series D Conversion Shares due to applicable anti-dilution adjustments; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in"><i><span style="text-decoration: underline">Series E Conversion Shares</span></i>. The issuance of 43.0 million shares of Common Stock (the &#8220;<b><i>Series E Conversion Shares</i></b>&#8221; and together with the Series D Conversion Shares, the &#8220;<b><i>Conversion Shares</i></b>&#8221;) for an additional $2.15 million upon conversion of 268,750 shares of Series E Preferred Stock are contemplated to be issued at the Final Closing of the Investment Transaction, subject to the potential increase in the number of Series E Conversion Shares due to applicable anti-dilution adjustments.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Series D Preferred Stock that were issued at the First Closing, upon conversion will represent approximately 61% of the Company&#8217;s issued and outstanding Common Stock on a fully diluted basis, and the Series E Preferred Stock to be issued, upon conversion, will represent approximately 34% of the Company&#8217;s issued and outstanding Common Stock on a fully diluted basis as of the Final Closing, or collectively approximately 95% in the aggregate (based on the number of shares of Common Stock anticipated to be outstanding as of the Final Closing). Accordingly, as a result of the significant number of shares of Common Stock and controlling ownership of NovaBay that Mr.&#160;Lazar will have upon conversion of the Series D Preferred Stock into the Series D Conversion Shares and the Series E Preferred Stock into the Series E Conversion Shares, our stockholders at this Annual Meeting are being asked to authorize and approve the full conversion of all of the shares of Series D Preferred Stock and all of the shares of Series E Preferred Stock to be issued in the Final Closing into the Conversion Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since our Common Stock is currently listed on the NYSE American, we are required to comply with the continued listing rules of the Company Guide. Section&#160;713(a) of the Company Guide requires stockholder approval in connection with any transaction, other than a public offering, involving the sale, issuance, or potential issuance, of Common Stock or securities convertible into Common Stock, equal to 20.0% or more of presently outstanding stock for less than the greater of book or market value. Section&#160;713(b) of the Company Guide requires stockholder approval of a transaction, other than a public offering, involving the sale, issuance or potential issuance by an issuer of Common Stock (or securities convertible into or exercisable for Common Stock) when the issuance or potential issuance of additional shares may result in a change of control of the issuer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Company Guide, derivative securities representing in excess of 20% of shares of Common Stock currently outstanding on an as-converted basis or that will result in a change of control upon conversion, such as the Series D Preferred Stock issued in the Investment Transaction, may be issued prior to obtaining stockholder approval; however, such derivative securities, such as the Series D Conversion Shares, may not be converted into or exercised for shares of Common Stock above the Share Issuance Limitation until such time, if ever, that stockholder approval for such conversion or exercise, is obtained. Accordingly, until this Proposal Five is approved by stockholders, Mr.&#160;Lazar, as the current holder of the Series D Preferred Stock, may convert his shares only up to an aggregate of 19.99% of the outstanding shares of Common Stock as of the signing of the Purchase Agreement or such lower percentage of outstanding shares of Common Stock as may be required by the NYSE American or due to the issuance of Common Stock in the Additional Private Placement (the &#8220;<b><i>Share Issuance Limitation</i></b>&#8221;). Therefore, if stockholder approval is not obtained for the issuance of the Conversion Shares, the Series D Preferred Stock may not be converted into the Series D Conversion Shares in excess of the Share Issuance Limitation and even if we were to issue the Series E Preferred Stock in the Final Closing, the Series E Preferred Stock would not be convertible for the Series E Conversion Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%; background-color: #FFFFFF; text-align: justify"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_064"></span>Overview of Investment Transaction</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Strategic Direction of NovaBay</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NovaBay has continued to explore and evaluate strategic options available to the Company during 2024 and 2025 to maximize its value following the Avenova Asset Divestiture that closed on January&#160;17, 2025, the PhaseOne Divestiture that closed on January&#160;8, 2025, and the DERMAdoctor Divestiture that closed on March&#160;12, 2024. Among these strategic options, we pursued potential strategic transactions, such as this Investment Transaction, as well as the Dissolution that stockholders approved at the 2025 Special Meeting held on April&#160;16, 2025. Specifically, the stockholder approval of the Dissolution gave the Board authorization from stockholders to subsequently determine, in its discretion, whether or not to proceed with the Dissolution. Following the Company&#8217;s review of its strategic options, the Company determined that pursuing the Investment Transaction that provides for a Special Dividend and a Post-Investment Transaction, instead of pursuing the Dissolution at this time, is a better opportunity to maximize the value of the Company for stockholders following the divestiture transactions and is in the best interest of the Company and its stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Investment Transaction</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August&#160;19, 2025, we entered into the Purchase Agreement with Mr.&#160;Lazar that provides for the Company to issue and sell to Mr.&#160;Lazar in a private placement (i) an aggregate of 481,250 shares of Series D Preferred Stock convertible into the Series D Conversion Shares for $3.85 million and (ii) an aggregate of 268,750 shares of Series E Preferred Stock convertible into the Series E Conversion Shares for an additional $2.15 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Simultaneously with entering into the Purchase Agreement on August&#160;19, 2025, we completed the First Closing where Mr.&#160;Lazar purchased the Series D Preferred Stock from the Company at a price of $8.00 per share for aggregate gross proceeds to the Company of $3.85 million. The Purchase Agreement also contemplates that Mr.&#160;Lazar will separately purchase and acquire the Series E Preferred Stock as soon as practicable at the Final Closing after the Company receives the Conversion Approval at a price of $8.00 per share for aggregate gross proceeds to us of $2.15 million, subject to the satisfaction of certain closing conditions that include: (i) the receipt of the Conversion Approval, and (ii) the continued listing of our Common Stock on the NYSE American. Pursuant to the Purchase Agreement, the net proceeds from the Investment Transaction have been and will be used for the Company&#8217;s operations, including for general corporate and working capital purposes, for payment of the Special Dividend, for expenses related to the Investment Transaction and the Post-Investment Transaction and to satisfy other agreed upon Company obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As part of the Investment Transaction, Mr.&#160;Lazar was appointed as the Chief Executive Officer of NovaBay and was appointed to serve as a director of the Company. Mr.&#160;Lazar also received certain one-time contractual rights involving the Board, including: (i) nominating one (1) director at this Annual Meeting (which right was exercised with Mr.&#160;Lazar&#8217;s nomination at this Annual Meeting) and (ii) subject to receipt of the Conversion Approval and the Final Closing occurring, Mr.&#160;Lazar being appointed as Chair of the Board and his right to nominate up to three (3) Additional Purchaser Nominee(s) to the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">See &#8220;<i>Description of the Investment Transaction and Preferred Stock</i>&#8221; for a more fulsome description of the Investment Transaction and the rights Mr.&#160;Lazar received with respect to the Board and management of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Special Dividend to Stockholders (excluding Mr.&#160;Lazar)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of receiving the proceeds from the Investment Transaction, the Purchase Agreement contemplated the Company declaring a one-time special dividend to NovaBay stockholders under the direction and control of our Special Transaction Committee. On August&#160;26, 2025, the Company announced that it declared this one-time Special Dividend to stockholders of record on September&#160;15, 2025 in the amount of $0.80 per share of Common Stock and payable on September&#160;29, 2025. Neither the Series D Preferred Stock nor the Series E Preferred Stock will participate in the Special Dividend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Post-Investment Transaction</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After the Final Closing and subject to approval by the Board, the Company intends to use the net proceeds from the Investment Transaction to pursue and consummate a Post-Investment Transaction (i.e., a potential strategic transaction that would involve an investment and/or acquisition of a Target Company). If and when a Post-Investment Transaction is entered into and consummated after receiving required approvals, we expect that by combining with a new operating and revenue generating Target Company that such combination will result in a future growth opportunity for our Company and our stockholders. In connection with a Post-Investment Transaction being consummated, our stockholders may experience dilution to the extent that we issue shares of our Common Stock or other securities as consideration to acquire the Target Company, which would be in addition to the dilution that will result if stockholders approve this Proposal Five.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%; background-color: #FFFFFF"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_065"></span>Reasons for this Proposal Five</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Significant Ownership and Control Upon Conversion of the Series D Preferred Stock and Series E Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As summarized in this Proposal Five and further detailed in the section of this Proxy Statement titled &#8220;<i>Description of the Investment Transaction and Preferred Stock</i>&#8221;, as a result of to the conversion of all of the shares of Series D Preferred Stock into shares of Common Stock representing approximately 61% of the Company&#8217;s issued and outstanding Common Stock on a fully diluted basis as of the Record Date, and the full conversion of all shares of Series E Preferred Stock to be issued at the Final Closing into shares of Common Stock representing approximately an additional 34% of the Company&#8217;s issued and outstanding Common Stock on a fully diluted basis as of the Final Closing, or collectively approximately 95% in the aggregate, we are seeking approval of stockholders under both Section&#160;713(a) and Section&#160;713(b) of the Company Guide. Stockholder approval of this Proposal Five will constitute stockholder approval for purposes of both Section&#160;713(a) and 713(b) of the Company Guide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Approval of this Proposal Five will remove the conversion limitations upon the Series D Preferred Stock and there will not be any conversion limitations upon the Series E Preferred Stock to be issued, which upon conversion will result in Mr.&#160;Lazar having significant ownership of our Common Stock. Further, pursuant to the Purchase Agreement, Mr.&#160;Lazar has the right to assign and transfer his Securities Purchase Rights (i.e., the Series D Preferred Stock, the Series E Preferred Stock and the Conversion Shares and/or his right to acquire such securities), or the option to sell the Securities Purchase Rights, subject to certain requirements. Accordingly, if Mr.&#160;Lazar exercises this right partially or in full, it is possible that Mr.&#160;Lazar would not continue to be the controlling stockholder of our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board approved the Investment Transaction and the Purchase Agreement and believes that satisfying our contractual obligations in the Investment Transaction by submitting this Proposal Five to stockholders for their approval at this Annual Meeting is in the best interests of our Company and our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Satisfaction of a Condition to the Final Closing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase Agreement, the issuance of the Series E Preferred Stock to Mr.&#160;Lazar and our receipt of gross proceeds of $2.15 million is conditioned upon us receiving the Conversion Approval, as is being proposed by this Proposal Five, that will allow for the Series E Preferred Stock to be converted into Common Stock, as well as the satisfaction of certain other closing conditions that include no permanent suspension or other trading suspension for more than three consecutive trading days of our Common Stock by the SEC, the NYSE American or as reported by Bloomberg L.P. These additional proceeds will be important to us to fund our continuing operations and expenses, our pursuit of a potential Post-Investment Transaction, and our other obligations, including the retirement of the outstanding shares of Series F Preferred Stock that is contemplated to occur following the Conversion Approval or any time after December&#160;31, 2025. If we do not receive stockholder approval of this Proposal Five, then Mr.&#160;Lazar will not be obligated to make the additional investment in the Series E Preferred Stock, even if we satisfy all of the other closing conditions, until the Conversion Approval is received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_066"></span>Effect and Consequences of the Investment Transaction</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Dilutive Effect and Control After Issuance of Conversion Shares</i></b>.</span> If this Proposal Five is approved by stockholders, all of the shares of Series D Preferred Stock will be convertible by Mr.&#160;Lazar or converted automatically within the third business day after this Proposal Five is approved into 77.0 million shares of Common Stock and the Series E Preferred Stock to be issued in the Final Closing will be immediately convertible following issuance by Mr.&#160;Lazar or converted automatically within 30 business days after this Proposal Five is approved into 43.0 million shares of Common Stock. As a result of the full conversion of the Series D Preferred Stock and the Series E Preferred Stock, it will result in the aggregate issuance of up to 120.0 million shares of Common Stock, which collectively will represent 95% of shares of Common Stock anticipated to be outstanding as of the Final Closing. Upon the conversions of the Series D Preferred Stock and the Series E Preferred Stock, the existing stockholders of the Company will suffer significant dilution in their ownership interests and their voting rights, with Mr.&#160;Lazar receiving effective voting control over matters presented to stockholders in the future relating to our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Rights as a Holder of Common Stock</i></b>.</span> If stockholder approval of this Proposal Five is received at this Annual Meeting, then the shares of Common Stock issuable upon the conversion of the Series D Preferred Stock and the Series E Preferred Stock, when issued, shall have the same privileges and rights as all other shares of our Common Stock that are currently issued and outstanding, including the right to vote on all matters presented to the holders of our Common Stock. However, as discussed above, Mr.&#160;Lazar&#8217;s ownership of our Common Stock will result in him having the ability to control the outcome of votes presented to stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Obligations Upon Failure of Stockholder Approval.</i></b></span><b><i> </i></b>Pursuant to the Purchase Agreement, to the extent that this Proposal Five and approval of Proposals One, Six, Seven, Eight, Nine and Ten are not obtained at this Annual Meeting, then we will be required to use our reasonable best efforts to call a Second Meeting within seventy (70) days of the date of the Annual Meeting. If the Conversion Approval is not received at the Second Meeting, the Company agreed to enter into the Additional Private Placement with Mr.&#160;Lazar and issue him shares of Common Stock equal to up to 19.99% of the Common Stock outstanding as of the date of the Purchase Agreement (as may be adjusted down) at a price per share equal to the closing stock price of the Common Stock on the date of the Second Meeting plus $0.02. The Company calling a Second Meeting and/or completing the Additional Private Placement would create additional expenses for the Company and divert management&#8217;s attention from its strategy, including completing a Post-Investment Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_067"></span>Risk Factors</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please refer to &#8220;<i>Risk Factors</i>&#8221; in this Proxy Statement above for certain material risks related to the Investment Transaction and the approval of this Proposal Five.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_068"></span>Additional Information</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Proposal Five and the Section of this Proxy Statement titled &#8220;<i>Description of the Investment Transaction and Preferred Stock</i>&#8221; provides a description of the Investment Transaction and the material terms of the Purchase Agreement, the Series D Preferred Stock as set forth in the Series D Certificate of Designation, the Series E Preferred Stock as set forth in the Series E Certificate of Designation, as well as the related transaction documents. Additionally, disclosure of the Investment Transaction, as well as forms of the Purchase Agreement, the Series D Certificate of Designation, the Series E Certificate of Designation and the other transaction documents referred to in this Proposal Five and in other Proposals in this Proxy Statement can be found as exhibits to the Investment Transaction Form 8-K. See &#8220;<i>Where You Can Find More Information</i>&#8221; in this Proxy Statement below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
approved by the stockholders, Mr.&#160;Lazar or any transferee (if Mr.&#160;Lazar were to transfer his shares as described in this Proxy
Statement) will be entitled to convert all of the shares of Series D Preferred Stock and Series E Preferred Stock after being issued
in the Final Closing into Common Stock. <b>By approving this Proposal Five you are not being asked to vote on the Investment Transaction
(with the First Closing already been completed), the issuance of the Series D Preferred Stock (which has already been issued) or the
issuance of the Series E Preferred Stock at the Final Closing (which has yet to occur and is subject to satisfaction of closing conditions).
Instead, pursuant to this Proposal Five, we are seeking your approval of the issuance of shares of Common Stock to be issued upon conversion
of the shares of Series D Preferred Stock and, if issued at the Final Closing, the shares of Series E Preferred Stock.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 6.5in"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_069"></span>Stockholder Approval</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting is required for the approval of this Proposal Five. Unless otherwise instructed in the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted &#8220;FOR&#8221; this proposal. Abstentions, if any, with respect to this proposal will have the effect of a vote &#8220;AGAINST&#8221; this Proposal Five. Broker non-votes, if any, with respect to this Proposal Five, will have no effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 6.5in; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79"><b><span style="text-decoration: underline">Recommendation of Our Board</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79">Our Board recommends unanimously that you vote &#8220;FOR&#8221; the approval of the issuance of Common Stock upon conversion of the Series D Preferred Stock outstanding and Series E Preferred Stock contemplated to be issued to comply with Section&#160;713(a) and (b) of the Company Guide.</span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-variant: small-caps; color: #1F4E79"><b><span id="a_070"></span>Proposal Six:</b></span></p>
        <p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-variant: small-caps; color: #1F4E79"><b>Approval to Increase Shares Available for Issuance under the 2017 Omnibus Plan</b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At this Annual Meeting, we are asking our stockholders to approve an amendment (the &#8220;<b><i>Omnibus Plan Amendment</i></b>&#8221;) to our 2017 Omnibus Plan to (i) increase the shares authorized under the 2017 Omnibus Plan by 1,000,000 shares of Common Stock resulting in a maximum number of shares currently available for issuance of 1,021,332 shares of Common Stock, subject to an annual increase in the Board&#8217;s discretion pursuant to the Evergreen Provision (as defined and described below) and (ii) make corresponding changes to the share grant limitations in the 2017 Omnibus Plan for Incentive Stock Options, Restricted Stock and Restricted Stock Units (as each term is defined under the 2017 Omnibus Plan). On September&#160;5, 2025, upon recommendation of the Compensation Committee, the Board approved the adoption of the Omnibus Plan Amendment, subject to approval by NovaBay&#8217;s stockholders at the Annual Meeting. The Omnibus Plan Amendment will not make any other changes to the 2017 Omnibus Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our stockholders originally approved the 2017 Omnibus Plan at the 2017 Annual Meeting of Stockholders, and, at that time, the 2017 Omnibus Plan initially authorized the issuance of an aggregate of 1,892 shares of Common Stock under the 2017 Omnibus Plan, and the Board further authorized an additional 19,440 aggregate shares of Common Stock under the 2017 Omnibus Plan pursuant to its Evergreen Provision (as defined and discussed below). We currently have approximately 14,332 shares of Common Stock available for issuance under the 2017 Omnibus Plan, which number reflects the adjustments made as a result of the 1-for-35 reverse stock split of our Common Stock on November&#160;15, 2022 and the 1-for-35 reverse stock split of the our Common Stock on May&#160;30, 2024, as well as the additional shares added over the years with the automatic adjustments in accordance with the Evergreen Provision (as defined and described below) of the 2017 Omnibus Plan. With the proposed 1,000,000 share increase under the Omnibus Plan Amendment, 1,021,332 will be available for issuance under the 2017 Omnibus Plan, which will represent approximately 17.0% of our 6,005,749 shares outstanding as of the Record Date of September&#160;22, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the increase in authorized shares under the 2017 Omnibus Plan that will occur if stockholders approve this Proposal Six, the Omnibus Plan Amendment will also adjust the amounts of the share grant limitations for Incentive Stock Options, Restricted Stock and Restricted Stock Units (as each are defined in the 2017 Omnibus Plan) to provide for these limitations to not exceed the number of authorized shares under the 2017 Omnibus Incentive Plan. Accordingly, if stockholders approve this Proposal Six that will increase the authorized shares under the 2017 Omnibus Plan to 1,021,332 shares, then stockholders will also be approving an amendment to the share grant limitation amounts under the 2017 Omnibus Plan (as provided below) whereby the number of shares that will be available for grant for (i) Incentive Stock Options shall not exceed 1,021,332 shares, plus the automatic annual increase contemplated by Evergreen Provision (as defined below), subject to adjustment as provided in the 2017 Omnibus Plan and (ii) Restricted Stock and Restricted Stock Units shall not exceed 1,021,332 shares, plus the automatic annual increase contemplated by Evergreen Provision and subject to adjustment as provided in the 2017 Omnibus Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase Agreement, we agreed to seek stockholder approval as provided in this Proposal Six at the Annual Meeting to increase the authorized shares of Common Stock available for issuance under the 2017 Omnibus Plan to up to 1,000,000 shares. If the Omnibus Plan Amendment is approved, we intend to utilize the increased amount of shares authorized under the Omnibus Plan Amendment to attract officers, directors, employees and others who perform services for us and incentivize key individuals through annual equity grants in the future, including as we execute upon our business strategy, including pursuing a Post-Investment Transaction as discussed in this Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_071"></span>Amendment Language</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The amendment to the 2017 Omnibus Plan that is being presented to stockholders for approval at this Annual Meeting that provides for the increase in authorized shares and amends the share grant limitations for Incentive Stock Options, Restricted Stock and Restricted Stock Units reads as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section&#160;4(a) of the 2017 Omnibus Plan states as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <span style="text-decoration: underline">Shares Available</span>. Subject to adjustment as provided in Section&#160;4(c) of the Plan, the aggregate number of Shares that may be issued under the Plan shall be 1,021,332, plus an automatic annual increase on the first day of each of the Company&#8217;s fiscal years beginning January&#160;1, 2018 through January&#160;1, 2027 equal to (i) four percent (4%) of the number of shares of Common Stock outstanding on the last day of the immediately preceding fiscal year or (ii) such lesser number of shares of Common Stock than provided for in Section&#160;4(a)(i) as determined by the Board. Shares to be issued under the Plan may be either authorized but unissued Shares or Shares re-acquired and held in treasury. Any Shares that are used by a Participant as full or partial payment to the Company of the purchase price relating to an Award, or in connection with the satisfaction of tax obligations relating to an Award, shall again be available for granting Awards (other than Incentive Stock Options) under the Plan. In addition, if any Shares covered by an Award or to which an Award relates are not purchased or are forfeited, or if an Award otherwise terminates without delivery of any Shares, then the number of Shares counted against the aggregate number of Shares available under the Plan with respect to such Award, to the extent of any such forfeiture or termination, shall again be available for granting Awards under the Plan. Notwithstanding the foregoing, (i) the number of Shares available for granting Incentive Stock Options under the Plan shall not exceed 1,021,332, plus the automatic annual increase described above, subject to adjustment as provided in Section&#160;4(c) of the Plan and subject to the provisions of Section&#160;422 or 424 of the Code or any successor provision and (ii) the number of Shares available for granting Restricted Stock and Restricted Stock Units shall not exceed 1,021,332, plus the automatic annual increase described above, subject to adjustment as provided in Section&#160;4(c) of the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_072"></span>Summary of the 2017 Omnibus Plan</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The material features and provisions of the 2017 Omnibus Plan are summarized below. The full text of the 2017 Omnibus Plan is attached as <span style="text-decoration: underline">Annex A</span> and the proposed Omnibus Plan Amendment is attached as <span style="text-decoration: underline">Annex B</span> to this Proxy Statement. The summary of the 2017 Omnibus Plan set forth below also assumes the approval of the Omnibus Plan Amendment. The following description is not complete and is qualified in its entirety by reference to <span style="text-decoration: underline">Annex A</span> and <span style="text-decoration: underline">Annex B</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Administration</i></b></span><i>. </i>The Compensation Committee is the committee of the Board that will administer the 2017 Omnibus Plan, and has full power and authority to determine when and to whom awards will be granted, and the type, amount, form of payment and other terms and conditions of each award, consistent with the provisions of the 2017 Omnibus Plan (<span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that awards to Committee members are required to be authorized by a disinterested majority of the Board). Subject to the provisions of the 2017 Omnibus Plan, the Compensation Committee may amend or waive the terms and conditions, or accelerate the exercisability, of an outstanding award. The Compensation Committee has authority to interpret the 2017 Omnibus Plan, and establish rules and regulations for the administration of the 2017 Omnibus Plan. In addition, the Board may exercise the powers of the Compensation Committee at any time, but only to the extent it would not cause a loss of any benefits under &#167; 162(m) of the Internal Revenue Code of 1986, as amended (the &#8220;<b><i>Code</i></b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Eligible Participants</i></b></span><i>.</i> Any employee, officer, consultant, independent contractor or director providing services to us or any of our affiliates (including our current and future subsidiaries), who is selected by the Compensation Committee, is eligible to receive an award under the 2017 Omnibus Plan. Accordingly, each of our executive officers, directors and nominees for election as a director is eligible to receive awards under the 2017 Omnibus Plan. However, any such grants will be made by the Compensation Committee at its discretion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Shares Available For Awards</i></b></span><i>.</i> Prior to the contemplated Omnibus Plan Amendment, an aggregate of 14,332 shares of our Common Stock are currently reserved for issuance over the term of the 2017 Omnibus Plan. Every year (beginning on each January&#160;1<sup>st </sup>from January&#160;1, 2018 through January&#160;1, 2027), the number of shares reserved for issuance under the 2017 Omnibus Plan is able to increase by an amount equal to the lesser of: (a) four percent (4%) of the total number of shares of our Common Stock outstanding on the last day of the preceding year, or (b) such lesser number as determined by our Board (the &#8220;<b><i>Evergreen Provision</i></b>&#8221;). To date, since the 2017 Omnibus Plan was established, the total number of shares available for issuance has increased from 1,892 to 21,332 with the 19,440 increase in shares occurring pursuant to the Evergreen Provision. Awards of incentive stock options (&#8220;<b><i>ISOs</i></b>&#8221;) under the 2017 Omnibus Plan may be made for shares of our Common Stock with an aggregate fair market value of up to $100,000 on the grant date and exercisable for the first time by any Participant during any calendar year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The shares of Common Stock issuable under the 2017 Omnibus Plan may be drawn from shares of authorized but unissued Common Stock or from shares of Common Stock that we re-acquire and hold in treasury. The Compensation Committee may adjust the number of shares and share limits described above in the case of a stock dividend or other distribution, including a stock split, merger or other similar corporate transaction or event, in order to prevent dilution or enlargement of the benefits or potential benefits intended to be provided under the 2017 Omnibus Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If any shares of our Common Stock subject to any award or to which an award relates are forfeited or are reacquired by us, or if any award terminates without the delivery of any shares, the shares previously set aside for such awards will be available for future awards under the 2017 Omnibus Plan. In addition, shares used by award recipients as payment of the exercise price of an award or in satisfaction of the tax obligations relating to an award other than an ISO will be available again for award grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Types of Awards and Terms and Conditions</i></b></span>. The 2017 Omnibus Plan permits the granting of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">stock options (including both ISOs and non-qualified stock options (&#8220;<b><i>NQSOs</i></b>&#8221;));</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">stock appreciate rights (&#8220;<b><i>SARs</i></b>&#8221;);</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">restricted stock and restricted stock units (&#8220;<b><i>RSUs</i></b>&#8221;);</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">performance awards of cash, stock or property;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">dividend equivalents;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">other stock grants; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">other stock-based awards.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Awards may be granted alone, in addition to, in combination with or in substitution for, any other award granted under the 2017 Omnibus Plan or any other compensation plan. Awards can be granted for no cash consideration or for cash or other consideration as determined by the Compensation Committee or as required by applicable law. Awards may provide that upon the grant or exercise thereof, the holder will receive cash, shares of our Common Stock, promissory notes, other securities, other awards or property, or any combination of these, in a single payment, installments or on a deferred basis. The exercise price per share under any stock option and the grant price of any SAR will be determined by the Compensation Committee and may not be less than the fair market value on the date of grant of such option or SAR, or less than 110% of fair market value for incentive stock options granted to holders of more than ten percent (10%) of our Common Stock. Determinations of fair market value under the 2017 Omnibus Plan will be made in accordance with methods and procedures established by the Compensation Committee. The term of awards will not be longer than ten (10) years, or in the case of incentive stock options, longer than five (5) years with respect to holders of more than ten percent (10%) of our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Stock Options and SARs</i></b></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Limitations</span></i>. No holder may be granted, during any one (1) calendar year period, options and SARs with respect to more than 1,000,000 shares in the aggregate, subject to the number of shares being adjusted as provided for in the 2017 Omnibus Plan).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Stock Options</span>.</i> The holder of an option will be entitled to purchase a number of shares of our Common Stock at a specified exercise price during a specified time period, all as determined by the Compensation Committee. The option exercise price may be payable either in cash or, at the discretion of the Compensation Committee, in other securities or other property having a fair market value on the exercise date equal to the exercise price. The shares subject to each option will generally vest in one (1) or more installments over a specified period of service measured from the grant date. We receive no payment for the grant of an option. Upon cessation of service, we have the right to repurchase any or all unvested shares at a price per share determined by the Compensation Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">SARs</span>.</i> The holder of a SAR is entitled to receive the excess of the fair market value (calculated as of the exercise date or, at the Compensation Committee&#8217;s discretion, as of any time during a specified period before or after the exercise date) of a specified number of shares of our Common Stock over the grant price of the SAR, as determined by the Compensation Committee, paid solely in shares of Common Stock. SARs vest and become exercisable in accordance with a vesting schedule established by the Compensation Committee. This type of SAR is sometimes described as a &#8220;stock-settled stock appreciation right.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Restricted Stock</span></i>. The holder of restricted stock will own shares of our Common Stock subject to restrictions imposed by the Compensation Committee (including, for example, restrictions on transferability or on the right to vote the restricted shares or to receive any dividends with respect to the shares) for a specified time period determined by the Compensation Committee. The restrictions, if any, may lapse or be waived separately or collectively, in installments or otherwise, as the Compensation Committee may determine. If the participant&#8217;s employment or service as a director terminates during the vesting period for any other reason, the restricted stock shall be forfeited, unless the Compensation Committee determines that it would be in our best interest to waive the remaining restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">RSUs</span>.</i> The holder of RSUs will have the right, subject to any restrictions imposed by the Compensation Committee, to receive shares of our Common Stock at some future date determined by the Compensation Committee. If the participant&#8217;s employment or service as a director terminates during the vesting period for any other reason, the RSUs will be forfeited, unless the Compensation Committee determines that it would be in our best interest to waive the remaining restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Performance Awards</span>.</i> Prior to the effective date of the Tax Cuts and Jobs Act of 2017, performance awards granted under the 2017 Omnibus Plan are intended to qualify as &#8220;performance-based compensation&#8221; within the meaning of &#167; 162(m) of the Code. Performance awards give participants the right to receive payments in stock or property based solely upon the achievement of certain performance goals during a specified performance period. The Compensation Committee must designate all participants for each performance period, and establish performance goals and target awards for each participant No later than 90 days after the beginning of each performance period. Performance goals must be based solely on one or more of the following business criteria: (i) revenue; (ii) cash flow; (iii) gross profit; (iv) earnings before interest and taxes; (v) earnings before interest, taxes, depreciation and amortization; (vi) net earnings; (vii) earnings per Share; (viii) margins (including one (1) or more of gross, operating and net income margins); (ix) returns (including one or more of return on assets, equity, investment, capital and revenue and total stockholder return); (x) Share price; (xi) economic value added; (xii) working capital; (xiii) market share; (xiv) cost reductions; (xv) workforce satisfaction and diversity goals; (xvi) employee retention; (xvii) customer satisfaction; (xviii) completion of key projects; and (xix) strategic plan development and implementation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Dividend Equivalents</span>.</i> The holder of a dividend equivalent will be entitled to receive payments in cash, shares of our Common Stock, other securities or other property equivalent to the amount of cash dividends paid by us to our stockholders, with respect to the number of shares determined by the Compensation Committee. Dividend equivalents will be subject to other terms and conditions determined by the Compensation Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration: underline"><i>Other Stock Awards</i></span><i>.</i> The Compensation Committee may grant unrestricted shares of our Common Stock, subject to terms and conditions determined by the Compensation Committee and the 2017 Omnibus Plan limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration: underline"><i>Other Stock-Based Awards</i></span><i>.</i> The Compensation Committee may grant awards denominated or payable in shares of our Common Stock, including securities convertible into such shares, consistent with the purpose of the 2017 Omnibus Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Duration, Termination and Amendment</span>.</i> Unless earlier discontinued or terminated by the Board, the 2017 Omnibus Plan will expire on June&#160;2, 2027. No awards may be made after that date. However, unless otherwise expressly provided in an applicable award agreement, any award granted under the 2017 Omnibus Plan prior to expiration may extend beyond the end of such period through the award&#8217;s normal expiration date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board and, pursuant to the delegation of its authority, the Compensation Committee, may amend, alter or discontinue the 2017 Omnibus Plan at any time, although stockholder approval must be obtained for any action that would, absent such approval, (i) violate the rules and regulations of the NYSE American or any other securities exchange applicable to us, (ii) cause Rule&#160;16b-3 of the Exchange Act to become unavailable with respect to the 2017 Omnibus Plan, or (iii) cause us to be unable under the Code to grant incentive stock options under the 2017 Omnibus Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Transferability of Awards</span>.</i> With the exception of NQSOs, unless otherwise provided by the Compensation Committee, awards under the 2017 Omnibus Plan may only be transferred by will or by the laws of descent and distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Acceleration</span>.</i> The Compensation Committee may accelerate the exercisability of any option award. The ability to accelerate vesting in the event of a change in the ownership or control may be seen as an anti-takeover provision and may have the effect of discouraging a merger proposal, a takeover attempt or other efforts to gain control of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Delivery of Shares for Tax Obligation</span>.</i> Under the 2017 Omnibus Plan, the Compensation Committee may permit participants receiving or exercising awards, subject to the discretion of the Compensation Committee and upon such terms and conditions as it may impose, to deliver shares of our Common Stock (either shares received upon the receipt or exercise of the award or shares previously owned by the holder of the option) to us to satisfy federal and state income tax obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Governing Law</span></i>. The validity, construction and effect of the 2017 Omnibus Plan or any award, and any rules and regulations relating to the 2017 Omnibus Plan or any award, will be determined in accordance with the laws of the State of Delaware.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_073"></span>Certain Federal Income Tax Consequences </b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of the principal U.S. federal income tax consequences generally applicable to awards under the 2017 Omnibus Plan and does not purport to be complete. This summary is based upon current U.S. federal income tax rules and therefore is subject to change when those rules change. Because the tax consequences to any recipient may depend on his or her particular situation, each recipient should consult his or her tax adviser regarding the federal, state, local, and other tax consequences of the grant or exercise of an award or the disposition of shares acquired pursuant to an award. Our ability to realize the benefit of any income tax deductions described below depends on our generation of taxable income as well as the requirement of reasonableness, the provisions of &#167; 162(m) of the Code and the satisfaction of our tax reporting obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Grant of Options and SARs</i></b></span><i>.</i> The grant of a stock option or SAR is not expected to result in any taxable income for the recipient, and we will not be entitled to an income tax deduction upon such grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Exercise of Options and SARs</i></b></span><i>.</i> Upon exercising an NQSO, the optionee will recognize ordinary income equal to the excess, if any, of the fair market value of the shares of our Common Stock acquired on the date of exercise over the exercise price, and we will generally be entitled at that time to an income tax deduction for the same amount. Upon exercising an incentive stock option, the optionee generally will not recognize taxable income (except that an alternative minimum tax liability may arise), and we will not be entitled to an income tax deduction. Upon exercising a SAR, the recipient of the SAR will recognize ordinary income in an amount equal to the fair market value on the exercise date of any shares of our Common Stock received, and we will generally be entitled at that time to an income tax deduction for the same amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Disposition of Shares Acquired Upon Exercise of Options and SARs</i></b></span><i>.</i> The tax consequence upon a disposition of shares acquired through the exercise of an option or SAR will depend on how long the shares have been held and whether the shares were acquired by exercising an NQSO or SAR or by exercising an incentive stock option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Generally, there will be no tax consequence to us in connection with the disposition of shares acquired under an NQSO or SAR. The optionee&#8217;s or recipient&#8217;s tax basis in those shares will be equal to the fair market value of the shares on the date of exercise, and the optionee&#8217;s or recipient&#8217;s capital gain holding period for those shares will begin on that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If an optionee holds a share acquired upon exercise of an incentive stock option for more than two (2) years following the date the option was granted and more than one (1) year following the date the option was exercised, which is referred to as the required holding period, the difference, if any, between the amount realized on a sale or other taxable disposition of that share and the holder&#8217;s tax basis in that share will be long-term capital gain or loss. If, however, an optionee disposes of a share acquired upon exercise of an incentive stock option before the end of the</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">required holding period, which is referred to as a disqualifying disposition, the optionee generally will recognize ordinary income in the year of the disqualifying disposition equal to the excess, if any, of the fair market value of the share on the date the option was exercised over the exercise price. However, if the sales proceeds are less than the fair market value of the share on the date the option was exercised, the amount of ordinary income recognized by the optionee will not exceed the gain, if any, realized on the sale. If the amount realized on a disqualifying disposition exceeds the fair market value of the share on the date the option was exercised, that excess will be short-term or long-term capital gain, depending on whether the holding period for the share exceeds one year. The Company will not be entitled to an income tax deduction on the disposition of a share acquired upon exercise of an incentive stock option after the required holding period. If there is a disqualifying disposition of a share, however, we will generally be entitled to an income tax deduction in an amount equal to the ordinary income includible in income by the optionee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Awards Other than Options and SARs</i></b></span><i>.</i> As to other awards granted under the 2017 Omnibus Plan that are payable in either cash or shares of our Common Stock that are either transferable or not subject to substantial risk of forfeiture, the holder of the award must recognize ordinary income equal to (a) the amount of cash received or, as applicable, (b) the excess of (i) the fair market value of the shares received (determined as of the date of receipt) over (ii) the amount (if any) paid for the shares by the holder of the award. We will generally be entitled at that time to an income tax deduction for the same amount. The holder&#8217;s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from such an award will be the amount (if any) paid for such shares plus any ordinary income recognized when the shares are received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As to an award that is payable in shares of our Common Stock that are restricted from transfer and subject to substantial risk of forfeiture, unless a special election is made by the holder of the award under the Code, the holder must recognize ordinary income equal to the excess of (i) the fair market value of the shares received (determined as of the first time the shares become transferable or not subject to substantial risk of forfeiture, whichever occurs earlier) over (ii) the amount (if any) paid for the shares by the holder of the award. We will generally be entitled at that time to an income tax deduction for the same amount. The holder&#8217;s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from such an award will be the amount (if any) paid for such shares plus any ordinary income recognized when the shares become transferable or not subject to substantial risk of forfeiture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To conform to the requirements of &#167; 409A of the Code, the shares subject to an RSU award may generally only be delivered upon one of the following events: a fixed calendar date (or dates), separation from service, death, disability or a change in control. If delivery occurs on another date, unless the award otherwise complies with or qualifies for an exception to the requirements of &#167; 409A of the Code, in addition to the tax treatment described above, the recipient will owe an additional 20% federal tax and interest on any taxes owed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Deductibility of Executive Compensation Under Code &#167; 162(m)</i></b></span><i>.</i> Section&#160;162(m) of the Code generally limits to $1,000,000 the amount that a publicly-held corporation is allowed each year to deduct for the compensation paid to (i) each of the company&#8217;s principal executive officer and principal financial officer, (ii) each of the company&#8217;s three (3) most highly compensated officers (excluding the principal executive officer and principal financial officer) whose compensation for the taxable year is required to be reported to stockholders under the SEC&#8217;s executive compensation disclosure rules, and (iii) each employee or former employee who was a &#8220;covered employee&#8221; for purposes of Section&#160;162(m) of the Code for any taxable year of the company beginning after December&#160;31, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_074"></span>Award Issuances under the 2017 Omnibus Plan</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In 2024, we made grants of 5,148 shares of restricted stock to our non-employee directors, and have not made any grants under the 2017 Omnibus Plan in 2025 through the date of this Proxy Statement. As we execute on our business strategy, including pursuing a Post-Investment Transaction, and seek to grow and expand our business, we expect to make future grants under the 2017 Omnibus Plan as determined by the Board and the Compensation Committee to support these efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot currently determine the benefits or number of shares subject to awards that may be granted to participants under the 2017 Omnibus Plan, as amended by the Omnibus Plan Amendment, during the remainder of the 2025 fiscal year or in future periods due to the discretionary nature of the 2017 Omnibus Plan, as amended by the Omnibus Plan Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">See &#8220;<i>Equity Compensation Plan Information</i>&#8221; in this Proxy Statement for NovaBay&#8217;s equity compensation plan information as of December&#160;31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_075"></span>Risk Factors</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please refer to &#8220;<i>Risk Factors</i>&#8221; in this Proxy Statement above for certain material risks related to the Investment Transaction and the approval of this Proposal Six, as one of the Proposals required as part of the Investment Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_076"></span>Additional Information</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Registration</i></b></span>. We intend to file a Registration Statement on Form S-8 relating to the issuance of additional shares of Common Stock under the Omnibus Plan Amendment with the SEC pursuant to the Securities Act, as soon as practicable after approval of the Omnibus Plan Amendment by our stockholders pursuant to this Proposal Six.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Effect of the Reverse Stock Split</i></b></span>. If stockholders also approve Proposal Eight that provides for the Reverse Stock Split and it is effected by the Board, the outstanding shares of our Common Stock will adjust downward pursuant to the ratio determined by the Board. Pursuant to the 2017 Omnibus Plan, the Compensation Committee may, and consistent with historic practice would likely, adjust the number of shares and share limits described above if the Reverse Stock Split is effected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Compensation Committee may adjust the number of shares and share limits described above in the case of a stock dividend or other distribution, including a stock split, merger or other similar corporate transaction or event, in order to prevent dilution or enlargement of the benefits or potential benefits intended to be provided under the 2017 Omnibus Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_077"></span>Stockholder Approval</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting is required for the approval of this Proposal Six. Unless otherwise instructed in the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted &#8220;FOR&#8221; this proposal. Abstentions, if any, with respect to this proposal will have the effect of a vote &#8220;AGAINST&#8221; this Proposal Six. Broker non-votes, if any, with respect to this Proposal Six, will have no effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; background-color: Gainsboro; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79"><b><span style="text-decoration: underline">Recommendation of Our Board</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79">Our Board recommends unanimously that you vote &#8220;FOR&#8221; the approval of the Omnibus Plan Amendment to increase the shares authorized under the 2017 Omnibus Plan by 1,000,000 shares of Common Stock and to amend the share grant limitations under the 2017 Omnibus Plan.</span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_078"></span>Proposal Seven:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>Approval of the Payment of the Equity Consideration to</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>Resigning Non-Employee Directors</b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At the Annual Meeting, we are submitting this Proposal Seven for our stockholders to approve the issuance and payment of the Equity Consideration, which is comprised of newly-issued shares of restricted Common Stock with an aggregate value of $40,000, at a price per share which may be below the market price (as reported by the NYSE American) on the date of issuance, to each of the following Resigning Non-Employee Directors: Dr. Freiman, Ms. Garlikov, Ms. Sit, Mr.&#160;Wu and Mr.&#160;Sean Zheng, as consideration for each of the Resigning Non-Employee Directors agreeing to enter into a Release Agreement. The execution and delivery of the Release Agreements by the Resigning Non-Employee Directors was required under the terms of the Purchase Agreement for consummation by Mr.&#160;Lazar of his initial investment at the First Closing. By entering into the Release Agreements with the Resigning Non-Employee Directors, it will provide us with reduced risk and certainty with respect to the timely and coordinated resignations of the Resigning Non-Employee Directors from the Board upon the Resignation Event occurring (including approval of this Proposal Seven), which will pave the way for us to execute upon the business strategy of pursuing a Post-Investment Transaction (as discussed in this Proxy Statement). As summarized below and in &#8220;<i>Description of the Investment Transaction and Preferred Stock&#8212;Release Agreements</i>&#8221;, each Release Agreement that we entered into with each of the Resigning Non-Employee Directors has identical terms and provides for the issuance and payment by us of the Equity Consideration having a value of $40,000 (or $200,000 in the aggregate to all Resigning Non-Employee Directors). In addition to the information contained in this Proposal Seven and the Proxy Statement, we also encourage you to carefully read the Release Agreement entered into by each Resigning Non-Employee Director that has been filed with the SEC and is attached as Exhibit 10.9 to the Investment Transaction Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Special Transaction Committee unanimously approved the Release Agreements to be entered into with each of the Resigning Non-Employee Directors and the Special Transaction Committee and the Board approved the issuance and payment of the Equity Consideration to the Resigning Non-Employee Directors. The Equity Consideration contemplated to be issued to each Resigning Non-Employee Director will be shares of restricted Common Stock that will be newly issued from our authorized and unissued shares of Common Stock and will not be issued from our 2017 Omnibus Plan or any other NovaBay equity compensation plan that has been approved by our stockholders. Accordingly, before we are able to issue and pay the Equity Consideration to the Resigning Non-Employee Directors pursuant to the Release Agreements, we are required under Section&#160;711 of the Company Guide to first obtain stockholder approval, which approval we are seeking by submitting this Proposal Seven at the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Equity Compensation will be calculated and determined based on the future closing market price of our Common Stock on the trading day immediately prior to the Resignation Event (as described below). As a result, the actual number of shares of restricted Common Stock to be issued, if stockholders approve this Proposal Seven, is not currently known and will not be known at the time stockholders vote at the Annual Meeting on this Proposal Seven.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_079"></span>Overview of the Release Agreement and Equity Consideration</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>General Terms</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Release Agreement that we entered into with each Resigning Non-Employee Director, each of the Resigning Non-Employee Directors agreed to resign from the Board upon the Resignation Event occurring, which is on the date and at the time that each of the following have occurred: (i) the Conversion Approval; (ii) the Final Closing; (iii) the Additional Purchaser Nominee(s) are qualified and appointed to serve on the Board; (iv) the Special Dividend has been declared and paid; and (v) approval of this Proposal Seven. Dr. Jeff Zheng did not enter into a Release Agreement, as he is expected to continue to serve on the Board after the Resignation Event. In addition, the terms of the Release Agreements provide for (a) each of the Resigning Non-Employee Directors to generally release the Company from any claims, actions, or losses that such person may have against the Company and (b) us to similarly release each of the Resigning Non-Employee Directors from any claims, action or losses that we may have against such person, provided that we shall remain obligated pursuant to the indemnification agreements with each person and to maintain D&amp;O insurance coverage or a D&amp;O tail policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As consideration for the Resigning Non-Employee Directors agreeing to the terms and obligations and executing the Release Agreements, each Resigning Non-Employee Director shall be entitled to receive the following consideration:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Equity Consideration</span></i></span>. The Equity Consideration, which is a settlement payment of newly-issued shares of restricted Common Stock that has an aggregate value of $40,000 to be issued on the date of the Resignation Event, subject to our stockholders approving the payment of the Equity Consideration as proposed by this Proposal Seven. The number of shares to be issued to each Resigning Non-Employee Director will be determined based on the closing market price of our Common Stock on the trading day that immediately precedes the date of the Resignation Event, which may be below the market price (as reported by the NYSE American) on the date of issuance; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in"><span style="color: #1F4E79"><i><span style="text-decoration: underline">Unpaid Board Fees</span></i></span>. The payment of any accrued and unpaid director&#8217;s fees that we owe to each Resigning Non-Employee Director.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Unregistered Issuance and Registration Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The offer and issuance of the Equity Consideration will not be registered at the time of issuance by the Company under the Securities Act, and the Equity Consideration may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Company is relying on the private placement exemption from registration provided by Section&#160;4(a)(2) of the Securities Act, and in reliance on similar exemptions under applicable state laws. The Equity Consideration that will be issued will contain restrictive legends preventing the sale, transfer, or other disposition of such securities, unless registered under the Securities Act, or pursuant to an exemption therefrom.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Release Agreement, we agreed to provide each Resigning Non-Employee Director with a contractual piggyback registration right to include any the shares of restricted Common Stock received as Equity Consideration on each registration statement that we file with the SEC, subject to customary pro rata reductions of the shares to be registered either as required by an underwriter (equally applied to all classes of Company stock) or otherwise pursuant to comments received from the SEC staff. If the shares of restricted Common Stock become eligible for sale or transfer pursuant to Rule&#160;144 of the Securities Act, then we agreed to cooperate with the Resigning Non-Employee Director to facilitate such sale and/or transfer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Termination of the Release Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To the extent that stockholders do not approve the issuance and payment of the Equity Consideration to the Resigning Non-Employee Director, including at this Annual Meeting or another meeting of stockholders, then the Release Agreements with the Resigning Non-Employee Directors will terminate and be of no further force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_080"></span>Certain United States Federal Income Tax Consequences</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of the United States federal income and employment tax consequences that generally will arise with respect to the Equity Consideration issued and paid to the Resigning Non-Employee Directors. This summary is based on the federal tax laws in effect as of the date of this Proxy Statement. Changes to these laws could alter the tax consequences described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Tax Consequences to the Resigning Non-Employee Director</i></b></span>. A Resigning Non-Employee Director that receives the shares of restricted Common Stock as contemplated by the Release Agreements will recognize ordinary income equal to the fair market value of the shares on the date the shares are issued by us to the Resigning Non-Employee Director. Upon the sale of shares acquired pursuant to a restricted stock award, any gain or loss, based on the difference between the sale price and the fair market value on the date the ordinary income tax event occurs, will be taxed as capital gain or loss, with the gain or loss being long-term if the participant held the shares for more than one year after issuance and otherwise will be short-term. In addition to income tax, any capital gain recognized may be subject to the net investment income tax, if the participant&#8217;s income exceeds certain thresholds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Tax Consequences to the Company</i></b></span><b>. </b>When the Equity Consideration is issued, the Company will be entitled to an income tax deduction equal to the fair market value of the shares on such date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_081"></span>Risk Factors</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please refer to &#8220;<i>Risk Factors</i>&#8221; in this Proxy Statement above for certain material risks related to the Investment Transaction and the approval of this Proposal Seven, as one of the Proposals required as part of the Investment Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_082"></span>Stockholder Approval</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting is required for the approval of this Proposal Seven. Unless otherwise instructed in the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted &#8220;FOR&#8221; this proposal. Abstentions, if any, with respect to this proposal will have the effect of a vote &#8220;AGAINST&#8221; this Proposal Seven. Broker non-votes, if any, with respect to this Proposal Seven, will have no effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; background-color: Gainsboro; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79"><b><span style="text-decoration: underline">Recommendation of Our Board</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79">Our Board recommends unanimously that you vote &#8220;FOR&#8221; the approval of the issuance and payment of the Equity Consideration, comprised of newly-issued shares of restricted Common Stock with an aggregate value of $40,000 at a price per share which may be below the market price (as reported by the NYSE American) on the date of issuance, to each of the Resigning Non-Employee Directors, as contemplated by the Release Agreements.</span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_083"></span>Proposal Eight:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>The Reverse Stock Split Proposal</b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_084"></span>Overview</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board has unanimously approved the Reverse Stock Split by approving resolutions to (i) effect a reverse split of all of our outstanding (or held in treasury) shares of Common Stock by a ratio of not less than 1-for-2 and not more than 1-for-10 (each 2 to 10 shares of Common Stock, as the case may be, shall be combined to become 1 share of Common Stock) that will be effected by amending our Certificate of Incorporation and (ii) direct that a proposal be submitted to our stockholders at the Annual Meeting for the prior approval of the Reverse Stock Split. The primary purpose of this Reverse Stock Split is to increase the value per share of Common Stock in order to improve the marketability and liquidity of our Common Stock as well as to comply with our covenant to seek stockholder approval of the Reverse Stock Split pursuant to the Purchase Agreement and for the other reasons detailed below under &#8220;<i>&#8212; Reasons for the Reverse Stock Split</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If this Proposal Eight is approved by our stockholders, the Board will have sole discretion pursuant to Section&#160;242(c) of the Delaware General Corporation Law to elect, as it determines to be in the Company&#8217;s best interests and without further action by our stockholders, whether or not and when to effect the Reverse Stock Split, or to abandon it. The Company reserves the right to abandon the Reverse Stock Split without further action by our stockholders at any time before the effectiveness of the filing with the Secretary of the State of Delaware of the Reverse Stock Split Certificate of Amendment (as defined below), even if the authority to effect the Reverse Stock Split has been approved by our stockholders. By voting in favor of Proposal Eight, you are expressly also authorizing the Board to delay, not to proceed with, and/or abandon, the Reverse Stock Split if it should so decide, in its sole discretion, that it is in the stockholders&#8217; best interests to do so. No further action on the part of stockholders will be required to either implement or abandon the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If this Proposal Eight is approved by stockholders and if the Reverse Stock Split is made effective, the number of authorized shares of Company capital stock, currently consisting of 150,000,000 authorized shares of Common Stock and 5,000,000 authorized shares of preferred stock (or 1,500,000,000 authorized shares of Common Stock and 10,000,000 shares of preferred stock if Proposals Nine and Ten are approved at the Annual Meeting and the Board effects the Common Stock Certificate of Amendment and the Preferred Stock Certificate of Amendment), will remain unchanged, which will result in the number of authorized shares of Common Stock that will be available for future issuance to increase significantly. If Proposal Eight is approved by our stockholders and the Reverse Stock Split is effective, then these additional authorized shares of Common Stock will be available for issuance for any proper corporate purpose as determined by the Board, without further approval by the stockholders, except as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Should the Board proceed with the Reverse Stock Split, the exact ratio will be set at a whole number within the above range as determined by the Board in its sole discretion without further action by our stockholders. If the Board elects to effect the Reverse Stock Split with a ratio of 1-for-2 (the low end of the range set forth above), each 2 shares of Common Stock will be combined to become 1 share of Common Stock. Following a 1-for-2 Reverse Stock Split, the Company would continue to have 150,000,000 authorized shares of Common Stock (or 1,500,000,000 authorized shares of Common Stock if Proposal Nine is approved at the Annual Meeting and the Board effects the Common Stock Certificate of Amendment), but would only have approximately 63,124,753 shares of Common Stock outstanding or reserved for issuance (as compared to 126,249,505 shares outstanding or reserved for issuance as of the Record Date), both amounts additionally accounting for the Series E Conversion Shares underlying Series E Preferred Stock. If the Board elects to effect a Reverse Stock Split with a ratio of 1-for-10 (the high end of the range set forth above), each 10 shares of Common Stock will be combined to become one share of Common Stock. Following a 1-for-10 Reverse Stock Split, the Company would similarly continue to have 150,000,000 authorized shares of Common Stock (or 1,500,000,000 authorized shares of Common Stock if Proposal Nine is approved at the Annual Meeting and the Board effects the Common Stock Certificate of Amendment), but would only have approximately 12,624,951 shares of Common Stock outstanding or reserved for issuance (as compared to 126,249,505 shares outstanding as of the Record Date), both amounts additionally accounting for the Series E</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Conversion Shares underlying Series E Preferred Stock. As a result of effecting the Reverse Stock Split, the outstanding shares of our Common Stock will adjust downward pursuant to the ratio determined by the Board; however, there will not be any corresponding adjustment to the number of authorized shares of Common Stock, which effectively will result in a greater number of authorized shares of Common Stock that will be available for future issuance by us. The foregoing numbers of shares of Common Stock outstanding will be subject to adjustments that may result from the treatment of fractional shares as described below under the heading &#8220;<i>&#8212; Fractional Shares</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board believes that the availability of alternative Reverse Stock Split ratios will provide it with the flexibility to implement the Reverse Stock Split in a manner designed to maximize the anticipated benefits for the Company and its stockholders. In determining the specific Reverse Stock Split ratio, the Board may consider, among other things, factors such as:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">the historical trading price and trading volume of our Common Stock;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">the then prevailing trading price and trading volume of our Common Stock and the anticipated impact of the Reverse Stock Split on the trading market for our Common Stock;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">compliance with the NYSE American continued listing rules under the Company Guide with respect to minimum share price requirements for our Common Stock;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">the anticipated impact of the Reverse Stock Split on our ability to raise additional financing and/or consummate a Post-Investment Transaction; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">prevailing general market and economic conditions.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the Board determines that effecting the Reverse Stock Split is in our stockholders&#8217; best interest, the Reverse Stock Split will become effective as provided in the Reverse Stock Split Certificate of Amendment, which will set forth the number of shares to be combined into one share of Common Stock within the limits set forth in this proposal. The Reverse Stock Split, if effected, would affect holders of Common Stock and holders of Series B Preferred Stock, Series D Preferred Stock, and, to the extent issued, Series E Preferred Stock, which are convertible into shares of Common Stock, uniformly, as described below under the heading &#8220;<i>&#8212;Principal Effects of the Reverse Stock Split</i>&#8221;. Except for adjustments that may result from the treatment of fractional shares as described below under the heading &#8220;<i>&#8212;Fractional Shares</i>&#8221;, each stockholder will hold the same percentage of our outstanding Common Stock immediately following the Reverse Stock Split as such stockholder held immediately prior to the Reverse Stock Split. The following description of the proposed Reverse Stock Split and the Reverse Stock Split Certificate of Amendment is a summary and is subject to the full text of the proposed the Reverse Stock Split Certificate of Amendment, which is attached to this Proxy Statement as <span style="text-decoration: underline">Annex C</span> (the &#8220;<b><i>Reverse Stock Split Certificate of Amendment</i></b>&#8221;). The text of the form of Reverse Stock Split Certificate of Amendment accompanying this Proxy Statement is, however, subject to revision to reflect the exact ratio for the Reverse Stock Split and any changes that may be required by the office of the Delaware Secretary of State or that the Board may determine to be necessary or advisable to comply with applicable law and to effect the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_085"></span>Effective Date</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our stockholders approve this Proposal Eight, we expect our Board to determine a reverse stock split ratio within the range approved by stockholders and then file the Reverse Stock Split Certificate of Amendment with the Delaware Secretary of State, substantially in the form as attached in <span style="text-decoration: underline">Annex C</span> hereto. The Reverse Stock Split Certificate of Amendment will become effective after filing with the Delaware Secretary of State and on the date and time set forth therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If this Proposal Eight is approved and the Board determines to proceed with the Reverse Stock Split, the exact timing of the filing of the Reverse Stock Split Certificate of Amendment will be determined by the Board. We refer to this time and date as the &#8220;<b><i>Effective Date</i></b>.&#8221; Except as explained below with respect to fractional shares, each issued share of Common Stock immediately prior to the Effective Date will automatically be changed, as of the Effective Date, into a fraction of a share of Common Stock based on the exchange ratio within the approved range determined by the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_086"></span>Reasons for the Reverse Stock Split</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board currently believes that a Reverse Stock Split is desirable and in the best interest of the Company and its stockholders for the primary reasons listed and described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Improve the Marketability and Liquidity of the Common Stock and Appeal to a Broader Range of Investors and Generate Greater Investor Interest</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that the expected increased market price of our Common Stock resulting from the Reverse Stock Split will improve the marketability and liquidity of our Common Stock and will encourage interest and trading in our Common Stock. A Reverse Stock Split could allow a broader range of institutions to invest in our Common Stock (namely, funds that are prohibited or discouraged by internal policies and practices from buying stocks whose price is below a certain threshold), potentially increasing the liquidity of our Common Stock. We believe that improved marketability and liquidity of our Common Stock may aid in our strategic goals, including the completion of a Post-Investment Transaction. Additionally, because brokers&#8217; commissions on low-priced stocks generally represent a higher percentage of the stock price than commissions on higher-priced stocks, the current average price per share of our Common Stock can result in individual stockholders paying transaction costs representing a higher percentage of their total share value than would be the case if the share price were substantially higher.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Additional Authorized Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If this Proposal Eight is approved by stockholders and the Board determines to effect the Reverse Stock Split, the number of authorized shares of Company capital stock, consisting of 150,000,000 authorized shares of Common Stock and 5,000,000 authorized shares of preferred stock, will remain unchanged (or 1,500,000,000 authorized shares of Common Stock and 10,000,000 shares of preferred stock if Proposals Nine and Ten are approved and the Board effects the Common Stock Certificate of Amendment and the Preferred Stock Certificate of Amendment). As a result of there being no change to the number of shares of our authorized capital stock in connection with the Reverse Stock Split, the number of authorized shares of Common Stock that will be available for future issuance will increase significantly. Therefore, the Reverse Stock Split will provide for additional shares of Common Stock that may be issued in any future offerings or potential strategic transactions that we may pursue. We plan to use the additional authorized shares resulting from the Reverse Stock Split to continue to pursue our strategic goals, including completing a Post-Investment Transaction, as well as raising additional capital in order to fund our operations and meet our ongoing obligations. While we do not have any current and/or definite plans, agreements or arrangements, whether written or oral, to issue any newly authorized shares in connection with a capital raising transaction, such a transaction could arise at any time following the date of this Proxy Statement, either prior to or after the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Maintain Compliance with NYSE American Continued Listing Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Common Stock is listed on the NYSE American under the symbol &#8220;NBY.&#8221; In order to maintain listing on the NYSE American, among other requirements, our Common Stock must maintain an average minimum closing stock price of $0.20 over any 30-day consecutive trading period, with $0.20 being the current NYSE American internal precedent threshold of what the NYSE American considers to be a &#8220;low price per share&#8221; and constitute &#8220;low selling price issues&#8221; of the issuer pursuant to Section&#160;1003(f)(v) of the Company Guide. As of September&#160;22, 2025, our 30-trading day average closing stock price was $1.75 per share, which is above the $0.20 &#8220;low price per share&#8221; minimum threshold; however, the trading price of our Common Stock has historically been volatile and there is no guarantee on the future trading price. To the extent our stock price is below the minimum threshold, there is a potential that the NYSE American could initiate delisting procedures against the Company. The Board expects that the Reverse Stock Split will increase the market price of Common Stock, which may help the Company satisfy the continued listing requirements of the NYSE American to the extent needed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_087"></span>Principal Effects of the Reverse Stock Split</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Common Stock and Preferred Stock</i></b></span><i>.</i> If the Reverse Stock Split is approved by the stockholders at the Annual Meeting and the Board determines to proceed with the Reverse Stock Split, we expect the Board to establish the Reverse Stock Split ratio and proceed to effect the Reverse Stock Split, including the filing of the Reverse Stock Split</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Certificate of Amendment with the Delaware Secretary of State. Except for adjustments that may result from the treatment of fractional shares as described below, each issued share of Common Stock immediately prior to the Effective Date will automatically be changed, as of the Effective Date, into a fraction of a share of Common Stock based on the exchange ratio within the approved range determined by the Board. In addition, proportional adjustments (i.e., in proportion to the Reverse Stock Split ratio determined by the Board) will be made to any convertible or exchangeable securities entitling the holders thereof to purchase, exchange for, or convert into shares of Common Stock (including, but not limited to, warrants, convertible notes and convertible preferred stock). The Reverse Stock Split, if effected, would affect holders of Common Stock and holders of Series B Preferred Stock, Series D Preferred Stock, and, to the extent issued, Series E Preferred Stock, which are convertible into shares of Common Stock and have not converted at the time into Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Voting Rights</i></b></span><i>.</i> Except for adjustments that may result from the treatment of fractional shares as described below, because the Reverse Stock Split would apply to all issued shares of our Common Stock, the proposed Reverse Stock Split would not alter the relative rights and preferences of existing stockholders nor affect any stockholder&#8217;s proportionate equity interest in the Company. For example, a holder of 2% of the voting power of the outstanding shares of Common Stock immediately prior to the effectiveness of the Reverse Stock Split will generally continue to hold 2% of the voting power of the outstanding shares of Common Stock immediately after the Reverse Stock Split, and the number of stockholders of record will also remain unaffected by the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Stock-Based Plans</i></b></span><i>.</i> Proportional adjustments (i.e., in proportion to the Reverse Stock Split ratio) will be made to the maximum number of shares issuable under, outstanding awards under, and other terms of our 2007 Omnibus Plan and 2017 Omnibus Plan (collectively, the &#8220;<b><i>Plans</i></b>&#8221;), including adjustments (based upon the Reverse Stock Split ratio) by the Board or a committee thereof, as applicable, to the number of shares available for future grant under the Plans, the number of shares underlying outstanding awards, the exercise price per share of outstanding stock options, and other terms of outstanding awards issued pursuant to the Plans to equitably reflect the effects of the Reverse Stock Split, so as to avoid the effect of increasing the value of awards previously granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Listing</i></b></span><i>. </i>Our Common Stock currently trades on the NYSE American. The Reverse Stock Split will not directly affect the listing of our Common Stock on the NYSE American, although we believe that a Reverse Stock Split could potentially increase our stock price, thereby facilitating continued compliance with the NYSE American&#8217;s continued listing standards. Following the Reverse Stock Split, we expect that our Common Stock will continue to be listed on the NYSE American under the symbol &#8220;NBY&#8221;, although our Common Stock would have a new committee on uniform securities identification procedures (or &#8220;<b><i>CUSIP</i></b>&#8221;) number (which is a number used to identify our Common Stock). Any stock certificates with the older CUSIP number will need to be exchanged for stock certificates with the new CUSIP number by following the procedures described below &#8220;<i>&#8212; Stock Certificates</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Authorized but Unissued Shares; Potential Anti-Takeover Effects</i></b></span><i>.</i> Our Certificate of Incorporation currently authorizes 150,000,000 shares of Common Stock and 5,000,000 shares of preferred stock (and may authorize 1,500,000,000 shares of Common Stock and 10,000,000 shares of preferred stock if Proposals Nine and Ten are approved and the Board effects the Common Stock Certificate of Amendment and the Preferred Stock Certificate of Amendment), and the Reverse Stock Split would not change those numbers. Therefore, the number of issued and outstanding shares of Common Stock would decrease, and the number of shares remaining available for issuance by us in the future would increase. These additional shares would be available for issuance from time to time for corporate purposes, such as issuances of Common Stock in connection with capital-raising transactions and acquisitions of companies or other assets (including a Post-Investment Transaction), as well as for issuance upon conversion or exercise of securities such as convertible preferred stock, convertible debt, warrants or options convertible into or exercisable for Common Stock. We believe that the availability of the additional shares will provide us with the flexibility to meet business needs as they arise, to take advantage of favorable opportunities and to respond effectively in a changing corporate environment. For example, we may elect to issue shares of Common Stock to raise equity capital, to make acquisitions through the use of stock, to establish strategic relationships with other companies, to adopt additional employee benefit plans or reserve additional shares for issuance under such plans, where the Board determines it advisable to do so, without the necessity of soliciting further stockholder approval, subject to applicable stockholder vote requirements under Delaware General Corporation Law and the Company Guide rules. If we issue additional shares for any of these purposes, the aggregate ownership interest of our current stockholders, and the interest of each such existing stockholder, would be diluted, possibly substantially.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_088"></span>Fractional Shares</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will not issue fractional shares in connection with the Reverse Stock Split. To the extent any holders of pre-Reverse Stock Split Shares are entitled to fractional shares as a result of the Reverse Stock Split, we will instead issue one whole share of Common Stock to all holders that would otherwise receive a fractional share of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_089"></span>No Dissenters&#8217; Rights</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under Delaware law, our stockholders will not be entitled to dissenters&#8217; rights or rights of appraisal in connection with the implementation of the Reverse Stock Split, and we will not independently provide our stockholders with any such rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_090"></span>Certain United States Federal Income Tax Consequences</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of certain United States federal income tax consequences of the Reverse Stock Split. It does not address any state, local or foreign income or other tax consequences, which, depending upon the jurisdiction and the status of the stockholder/taxpayer, may vary from the United States federal income tax consequences. It applies to you only if you held shares of pre-reverse stock split Common Stock as capital assets for United States federal income tax purposes. This discussion does not apply to you if you are a member of a class of holders subject to special rules, such as (a) a dealer in securities or currencies, (b) a trader in securities that elects to use a mark-to-market method of accounting for your securities holdings, (c) a bank, (d) a life insurance company, (e) a tax-exempt organization, (f) a person that owns shares of Common Stock that are a hedge, or that are hedged, against interest rate risks, (g) a person who owns shares of Common Stock as part of a straddle or conversion transaction for tax purposes or (h) a person whose functional currency for tax purposes is not the U.S. dollar. This summary does not address all tax considerations that may be relevant to a particular holder in light of the holder&#8217;s circumstances. This summary does not address all aspects of U.S. federal income taxes, such as consequences under the Medicare contribution tax or the alternative minimum tax. Further, this summary does not address the consequences under any U.S. federal tax laws other than the U.S. federal income tax laws, such as U.S. federal estate or gift tax laws. The discussion is based on the Internal Revenue Code of 1986, as amended (the &#8220;<b><i>Internal Revenue Code</i></b>&#8221;), its legislative history, existing, temporary and proposed regulations under the Internal Revenue Code, published rulings and court decisions, all as of the date hereof. These laws, regulations and other guidance are subject to change or differing interpretations, possibly on a retroactive basis, which could result in United States federal income tax consequences that differ from those summarized below. We have not sought, and will not seek, an opinion of counsel or a ruling from the Internal Revenue Service regarding the United States federal income tax consequences of a reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">PLEASE CONSULT YOUR OWN TAX ADVISOR CONCERNING THE CONSEQUENCES OF THE REVERSE STOCK SPLIT IN YOUR PARTICULAR CIRCUMSTANCES UNDER THE INTERNAL REVENUE CODE AND THE LAWS OF ANY OTHER TAXING JURISDICTION.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Tax Consequences to United States Holders of Common Stock</i></b></span><i>.</i> A United States holder, as used herein, is a stockholder who or that is, for United States federal income tax purposes: (a) a citizen or individual resident of the United States, (b) a domestic corporation, (c) an estate whose income is subject to United States federal income tax regardless of its source, or (d) a trust that (i) is subject to the primary supervision of a U.S. court and the control of one or more U.S. persons or (ii) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. This discussion applies only to United States holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Reverse Stock Split is intended to be treated as a &#8220;recapitalization&#8221; for U.S. federal income tax purposes and, therefore, a reorganization within the meaning of Section&#160;368(a)(1)(E) of the Internal Revenue Code. Assuming that the Reverse Stock Split is so treated, a stockholder should not recognize gain or loss upon the Reverse Stock Split. A stockholder&#8217;s aggregate tax basis in the shares of Common Stock received pursuant to the Reverse Stock Split should equal the aggregate tax basis of the shares of Common Stock surrendered. The stockholder&#8217;s holding period in the shares of the Common Stock received should include the holding period in the shares of Common Stock surrendered. Treasury regulations promulgated under the Internal Revenue Code provide detailed rules for allocating</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">the tax basis and holding period of the shares of Common Stock surrendered to the shares of Common Stock received pursuant to the Reverse Stock Split. Stockholders who acquired their shares of Common Stock on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As noted above, we will not issue fractional shares in connection with the Reverse Stock Split. To the extent any holders of pre-reverse stock split shares would be entitled to fractional shares as a result of the Reverse Stock Split, we will instead issue to each such holder an additional fraction of a share of Common Stock to round up to the next whole share of Common Stock. The U.S. federal income tax consequences of the receipt of such an additional fraction of a share of Common Stock are not clear.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_091"></span>Accounting Consequences</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following the Effective Date of any Reverse Stock Split, if any, the net income or loss and net book value per share of Common Stock will be increased because there will be fewer shares of Common Stock outstanding. We do not anticipate that any other accounting consequences would arise as a result of the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_092"></span>Stock Certificates</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the Effective Date, each certificate representing shares of Common Stock outstanding before the Reverse Stock Split will be deemed, for all corporate purposes, to evidence ownership of the reduced number of shares of Common Stock resulting from the Reverse Stock Split. All options, warrants and other securities exchangeable or exercisable for, or convertible into, Common Stock also automatically will be adjusted on the Effective Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our transfer agent, Equinti Trust Company, LLC, will act as the exchange agent for purposes of exchanging stock certificates subsequent to the Reverse Stock Split. Shortly after the Effective Date, stockholders of record will receive written instructions requesting them to complete and return a letter of transmittal and surrender their old stock certificates for new stock certificates reflecting the adjusted number of shares as a result of the Reverse Stock Split. Certificates representing shares of Common Stock issued in connection with the Reverse Stock Split will continue to bear the same restrictive legends, if any, that were borne by the surrendered certificates representing the shares of Common Stock outstanding prior to the Reverse Stock Split. No new certificates will be issued until such stockholder has surrendered any outstanding certificates, together with the properly completed and executed letter of transmittal, to the exchange agent. Until surrendered, each certificate representing shares of Common Stock outstanding before the Reverse Stock Split would continue to be valid and would represent the adjusted number of shares, based on the ratio of the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any stockholder whose stock certificates are lost, destroyed or stolen will be entitled to a new certificate or certificates representing post-reverse stock split shares upon compliance with the requirements that we and our transfer agent customarily apply in connection with lost, destroyed or stolen certificates. Instructions as to lost, destroyed or stolen certificates will be included in the letter of instructions from the exchange agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon the Reverse Stock Split, we intend to treat stockholders holding Common Stock in &#8220;street name,&#8221; through a broker, bank, or other nominee, in the same manner as registered stockholders whose shares are registered in their names. Brokers, banks, and other nominees will be instructed to effect the Reverse Stock Split for their beneficial holders holding Common Stock in &#8220;street name.&#8221; However, such brokers, banks, and other nominees may have different procedures than registered stockholders for processing the Reverse Stock Split. If you hold your shares in &#8220;street name&#8221; with a bank, broker or other nominee, and if you have any questions in this regard, we encourage you to contact your broker, bank, or nominee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">YOU SHOULD NOT DESTROY YOUR STOCK CERTIFICATES AND YOU SHOULD NOT SEND THEM NOW. YOU SHOULD SEND YOUR STOCK CERTIFICATES ONLY AFTER YOU HAVE RECEIVED INSTRUCTIONS FROM THE EXCHANGE AGENT AND IN ACCORDANCE WITH THOSE INSTRUCTIONS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If any certificates for shares of Common Stock are to be issued in a name other than that in which the certificates for shares of Common Stock surrendered are registered, the stockholder requesting the reissuance will be required to pay to us any transfer taxes or establish to our satisfaction that such taxes have been paid or are not payable and, in addition, (i) the transfer must comply with all applicable federal and state securities laws, and (ii) the surrendered certificate must be properly endorsed and otherwise be in proper form for transfer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_093"></span>Book-Entry Shares </b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Registered stockholders are stockholders who hold some or all of their shares electronically in book-entry form with our transfer agent and do not have stock certificates evidencing their ownership of Common Stock. They are, however, provided with a statement reflecting the number of shares of Common Stock registered in their accounts. If you hold registered shares of Common Stock in book-entry form, you do not need to take any action to receive your post-Reverse Stock Split shares of Common Stock in registered book-entry form. If you are entitled to post-Reverse Stock Split shares of Common Stock, a transaction statement will automatically be sent to your address of record by our transfer agent as soon as practicable after the Effective Date indicating the number of shares of Common Stock you hold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_094"></span>Risk Factors</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please refer to &#8220;<i>Risk Factors</i>&#8221; in this Proxy Statement above for certain material risks related to the Investment Transaction and the approval of this Proposal Eight, as one of the Proposals required as part of the Investment Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_095"></span>Stockholder Approval </b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stockholder approval of Proposal Eight requires a &#8220;FOR&#8221; vote from a majority of the votes cast at the Annual Meeting. Unless otherwise instructed in the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted &#8220;FOR&#8221; this proposal. Abstentions, if any, with respect to this proposal will have no effect. We do not expect to receive any broker non-votes on this Proposal Eight.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our stockholders approve this Proposal Eight, we expect the Board to determine a Reverse Stock Split ratio within the range approved by stockholders and then file the Reverse Stock Split Certificate of Amendment with the Delaware Secretary of State to affect the Reverse Stock Split, as soon as practicable following stockholder approval of Proposal Eight. The Reverse Stock Split Certificate of Amendment will become effective after filing with the Delaware Secretary of State and on the date and time set forth therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79"><b><span style="text-decoration: underline">Recommendation of Our Board</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79">Our Board recommends unanimously that you vote &#8220;FOR&#8221; the approval of an amendment to the Certificate of Incorporation, as amended, that will effect a Reverse Stock Split of all of our Common Stock issued and outstanding shares or held in treasury at a ratio of not less than 1-for-2 and not more than 1-for-10, and to grant authorization to the Board to determine, in its sole discretion, the specific ratio at any whole number within the above share range and the timing of the Reverse Stock Split becoming effective or to otherwise decide to abandon the Reverse Stock Split.</span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_096"></span>Proposal Nine:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>Approval to Increase Authorized Common Stock</b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September&#160;5, 2025, the Board approved and adopted, subject to stockholder approval at the Annual Meeting, an amendment to our Certificate of Incorporation to increase our authorized shares of Common Stock from 150,000,000 shares to 1,500,000,000 shares. The text of the proposed amendment to the Certificate of Incorporation approved by the Board is set forth in the form of Certificate of Amendment to the Certificate of Incorporation, which is set forth below and a form of which is attached as <span style="text-decoration: underline">Annex D</span> to this Proxy Statement (the &#8220;<b><i>Common Stock Certificate of Amendment</i></b>&#8221;). Accordingly, our Board is requesting stockholder approval of this Proposal Nine to approve the Common Stock Certificate of Amendment that will provide for an increase in the number of authorized shares of Common Stock from 150,000,000 shares to 1,500,000,000 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_097"></span>Background of the Charter Amendment to Increase Authorized Common Stock </b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation currently authorizes the issuance of up to 155,000,000 shares of capital stock, consisting of 150,000,000 shares of Common Stock with a par value $0.01 per share, and 5,000,000 shares of preferred stock with par value $0.01 per share. An increase in the number of authorized shares of Common Stock to 1,500,000,000 shares will increase our total authorized capitalization to 1,505,000,000 shares of capital stock, which includes our previously authorized 5,000,000 shares of preferred stock. If the stockholders also approve Proposal Ten in this Proxy Statement, which is a proposal to approve the Preferred Stock Certificate of Amendment that provides for an increase in the number of authorized shares of Preferred Stock from 5,000,000 shares to 10,000,000, then our total authorized capitalization will instead be 1,510,000,000 shares of capital stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The additional Common Stock to be authorized by stockholder approval of this Proposal Nine would be identical to the currently outstanding shares of our Common Stock. Approval of this Proposal Nine and issuance of the additional authorized shares of Common Stock would not affect the rights of the holders of currently outstanding shares of our Common Stock; however, increasing the number of shares of our Common Stock outstanding through future issuances of our Common Stock would significantly affect the holders in terms of dilution of any earnings per share and the voting rights of current holders of Common Stock. Under our Certificate of Incorporation, stockholders do not have preemptive rights to subscribe for additional securities that we may issue, which means that current stockholders under our governing documents do not have a prior right thereunder to purchase any new issue of Common Stock in order to maintain their proportionate ownership interests in NovaBay. In connection with the Investment Transaction, we granted Mr.&#160;Lazar a contractual right to participate in subsequent financing transactions where we issue Common Stock or Common Stock equivalents for cash consideration, indebtedness or a combination thereof until the earlier of closing a Post-Investment Transaction or February&#160;19, 2026. See &#8220;<i>Description of the Investment Transaction and Preferred Stock&#8212;Description of the Preferred Stock and Lazar Investor Rights&#8212;Lazar Investor Rights&#8212;Participation in Future Offerings</i>&#8221; in the Proxy Statement for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Common Stock Certificate of Amendment, if approved by our stockholders, would become effective upon the filing of the Common Stock Certificate of Amendment with the Delaware Secretary of State as set forth below and attached as <span style="text-decoration: underline">Annex D</span> to this Proxy Statement. The Board reserves the right, notwithstanding stockholder approval and without further action by stockholders, to abandon and elect not to proceed with the Common Stock Certificate of Amendment if the Board determines that the Common Stock Certificate of Amendment is no longer in the Company&#8217;s best interests and the best interests of NovaBay&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_098"></span>Reasons for Stockholder Approval</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Of the 150,000,000 shares of Common Stock currently authorized, as of the close of business on the Record Date, there were 6,005,749 shares of Common Stock outstanding. In addition to the shares of Common Stock outstanding on the Record Date, we had (i) 14,332 shares of Common Stock reserved for future grant under our equity compensation plans; (ii) 1,022 shares of Common Stock reserved for future issuance for outstanding stock options; (iii) 106,191 shares of Common Stock for outstanding warrants reserved for future issuance; (iv) 15,065 shares of Common Stock for our outstanding Series B Preferred Stock reserved for future issuance;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(v) 77,000,000 shares of Common Stock for issuance upon conversion of the Series D Preferred Stock; and (vi) 107,146 shares of Common Stock for our outstanding Unsecured Convertible Notes reserved for future issuance. In addition, as of the First Closing, we will reserve 43,000,000 shares of Common Stock for issuance upon conversion of the Series E Preferred Stock, following the issuance of the Series E Preferred Stock at the Final Closing. Accordingly, we will have only 23,750,495 authorized shares of Common Stock that remain available for further issuance by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the Investment Transaction, under the terms of the Purchase Agreement, we agreed to seek stockholder approval at this Annual Meeting to increase the number of authorized shares of Common Stock to 300,000,000 shares of Common Stock. In order to provide us with a greater number of options and flexibility to identify and successfully pursue a Target Company for a Post-Closing Transaction, we determined to seek stockholder approval at this Annual Meeting to increase the number of authorized shares of Common Stock to 1,500,000,000 as provided in this Proposal Nine. If our stockholders approve the Common Stock Certificate of Amendment, then the number of authorized shares of Common Stock available for issuance will increase to approximately 1,373,750,495.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to satisfying NovaBay&#8217;s obligation to seek stockholder approval to increase its authorized shares of Common Stock under the terms of the Purchase Agreement, the Board also approved the proposed increase in authorized Common Stock to provide flexibility to issue additional shares of our Common Stock and/or and securities or equity awards which may be convertible, exercisable or otherwise settleable in Common Stock for business and financial purposes in the future. These purposes may include, among others: (i) pursuing a strategic investment transaction and/or acquisition following the Final Closing, including a Post-Investment Transaction (as discussed above); (ii) exploring other strategic relationships and opportunities; (iii) raising additional capital; (iv) equity incentive compensation and awards raising capital and other financing transactions; and (v) other corporate purposes. Other than conversions or exercises of outstanding securities convertible or exercisable into Common Stock, including the Series D Preferred Stock we issued and the Series E Preferred Stock we expect to issue, the potential Additional Private Placement to Mr.&#160;Lazar if we do not receive stockholder approval of Proposal Five (NYSE American Proposal) at this Annual Meeting (or subsequently called meeting of stockholders) and future issuance under 2017 Omnibus Plan, we do not currently have any specific plans, proposals or arrangements, written or oral, to issue any of the proposed additional authorized shares of Common Stock. However, in connection with the Company pursuing a Post-Investment Transaction, shares of Common Stock, preferred stock and/or other Company securities may be issued as part of any such transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_099"></span>Effect and Consequences of the Amendment </b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Limited Financing and Business Development Activities</i></b></span>. If this Proposal Nine is not approved by our stockholders, our strategic investment and/or acquisition, financing and business development prospects may be limited. In short, if our stockholders do not approve this Proposal Nine, we may not be able to: (i) access the capital markets; (ii) complete a Post-Investment Transaction or other strategic investment, and/or acquisition; (iii) pursue corporate collaborations or partnerships; and/or (iv) pursue other business opportunities that are integral to executing our business strategy and our growth and success. Even if this Proposal Nine is approved by our stockholders, there is no assurance that we will be successful in completing a Post-Investment Transaction or other strategic investment and/or acquisition, raising additional funds or pursuing other business opportunities to the extent needed in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Obligations of NovaBay Upon Failure of Stockholder Approval</i></b></span>. If this Proposal Nine is not approved by our stockholders, then pursuant to the terms of the Purchase Agreement, NovaBay shall use its reasonable best efforts to call a Second Meeting within seventy (70) days of the Annual Meeting for the purpose of obtaining approval with the recommendation of the Board that such proposal is approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Potential Dilution</i></b></span>. The issuance of additional shares of Common Stock may, among other things, have a dilutive effect on earnings per share and on stockholders&#8217; equity and voting rights. Furthermore, future sales of substantial amounts of our Common Stock, or the perception that these sales might occur, could adversely affect the prevailing market price of our Common Stock or limit our ability to raise additional capital. Stockholders should recognize that, as a result of this Proposal Nine and the potential future issuance of Common Stock, they could own a smaller percentage of shares relative to the total authorized shares of the Company than they presently own.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Effect of the Reverse Stock Split</i></b></span>. In addition to the number of authorized shares of Common Stock increasing to 1.5 billion if stockholders approve this Proposal Nine and the Common Stock Certificate of Amendment is filed and becomes effective, the number of authorized shares available for issuance is subject to further increase if stockholders also approve Proposal Eight that provides for the Reverse Stock Split and it is effected by the Board. In connection with the Reverse Stock Split being effected, the outstanding shares of our Common Stock will adjust downward pursuant to the ratio determined by the Board; however, there will not be any corresponding adjustment to the number of authorized shares of Common Stock, which effectively will result in a greater number of authorized shares of Common Stock that will be available for future issuance by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_100"></span>Risk Factors</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please refer to &#8220;<i>Risk Factors</i>&#8221; in this Proxy Statement above for certain material risks related to the impact of the Common Stock Certificate of Amendment and the approval of this Proposal Nine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_101"></span>Additional Information</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our stockholders approve this Proposal Nine, then we expect to file the Common Stock Certificate of Amendment with the Delaware Secretary of State, substantially in the form as attached in <span style="text-decoration: underline">Annex D</span> hereto, as soon as practicable. Upon filing of the Common Stock Certificate of Amendment with the Delaware Secretary of State, Article IV.A. of our Certificate of Incorporation will be amended to read in its entirety as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;A. This Corporation is authorized to issue two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock.&#8221; The total number of shares which the Corporation is authorized to issue is One Billion Five Hundred Five Million (1,505,000,000) shares. One Billion Five Hundred Million (1,500,000,000) shares shall be Common Stock, each having a par value of one cent ($0.01) per share. Five Million (5,000,000) shares shall be Preferred Stock, each having a par value of one cent ($0.01) per share.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our stockholders approve this Proposal Nine and also approve Proposal Ten that provides for approval of the Preferred Stock Certificate of Amendment, then we expect to combine both the Common Stock Certificate of Amendment and the Preferred Stock Certificate of Amendment into one Certificate of Amendment to the Certificate of Incorporation (the &#8220;<b><i>Combined Certificate of Amendment</i></b>&#8221;) that we will file with the Delaware Secretary of State, substantially in the form as attached in <span style="text-decoration: underline">Annex F</span> hereto, as soon as practicable. Upon filing of the Combined Certificate of Amendment with the Delaware Secretary of State, Article IV.A. of our Certificate of Incorporation will be amended to read in its entirety as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;A. This Corporation is authorized to issue two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock.&#8221; The total number of shares which the Corporation is authorized to issue is One Billion Five Hundred Ten Million (1,510,000,000) shares. One Billion Five Hundred Million (1,500,000,000) shares shall be Common Stock, each having a par value of one cent ($0.01) per share. Ten Million (10,000,000) shares shall be Preferred Stock, each having a par value of one cent ($0.01) per share.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">However, even if our stockholders approve the proposed Common Stock Certificate of Amendment in this Proposal Nine and/or the Preferred Stock Certificate of Amendment in Proposal Ten, our Board retains discretion under Delaware law not to implement either one or both of these proposed amendments to our Certificate of Incorporation. If our Board were to exercise such discretion, the number of authorized shares would remain at the current level until such time as stockholders were to approve an increase in authorized shares of Common Stock and/or preferred stock in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_102"></span>Stockholder Approval</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stockholder approval of this Proposal Nine requires a &#8220;FOR&#8221; vote from a majority of the votes cast at the Annual Meeting. Unless otherwise instructed in the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted &#8220;FOR&#8221; this proposal. Abstentions, if any, with respect to this proposal will have no effect. We do not expect to receive any broker non-votes on this Proposal Nine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79"><b><span style="text-decoration: underline">Recommendation of Our Board</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79">Our Board recommends unanimously that you vote &#8220;FOR&#8221; the approval of the Common Stock Certificate of Amendment to increase the number of authorized shares of Common Stock from 150.0 million to 1.5 billion.</span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_103"></span>Proposal Ten:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>Approval to Increase Authorized Preferred Stock</b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September&#160;5, 2025, the Board approved and adopted, subject to stockholder approval at the Annual Meeting, an amendment to our Certificate of Incorporation to increase our authorized shares of preferred stock from 5,000,000 shares to 10,000,000 shares. The text of the proposed amendment to the Certificate of Incorporation approved by the Board is set forth in the form of Certificate of Amendment to the Certificate of Incorporation, which is set forth below and a form of which is attached as <span style="text-decoration: underline">Annex E</span> to this Proxy Statement (the &#8220;<b><i>Preferred Stock Certificate of Amendment</i></b>&#8221;). Accordingly, our Board is requesting stockholder approval of this Proposal Ten to approve the Preferred Stock Certificate of Amendment that will provide for an increase in the number of authorized shares of Preferred Stock from 5,000,000 shares to 10,000,000 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_104"></span>Background of the Charter Amendment to Increase Authorized Preferred Stock </b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation currently authorizes the issuance of up to 155,000,000 shares of capital stock, consisting of 150,000,000 shares of Common Stock with a par value $0.01 per share, and 5,000,000 shares of preferred stock with par value $0.01 per share. An increase in the number of authorized shares of preferred stock to 10,000,000 shares will increase our total authorized capitalization to 160,000,000 shares of capital stock, which includes our previously authorized 150,000,000 shares of Common Stock. If the stockholders also approve Proposal Nine, which is a proposal to approve the Common Stock Certificate of Amendment that provides for an increase in the number of authorized shares of Common Stock from 150,000,000 shares to 1,500,000,000, then our total authorized capitalization will be 1,510,000,000 shares of capital stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under our Certificate of Incorporation, stockholders do not have preemptive rights to subscribe for additional securities that we may issue, which means that current stockholders under our governing documents do not have a prior right thereunder to purchase any new issue of preferred stock or Common Stock in order to maintain their proportionate ownership interests in NovaBay. In connection with the Investment Transaction, we granted Mr.&#160;Lazar a contractual right to participate in subsequent financing transactions where we issue Common Stock or Common Stock equivalents for cash consideration, indebtedness or a combination thereof until the earlier of closing a Post-Investment Transaction or February&#160;19, 2026. See &#8220;<i>Description of the Investment Transaction and Preferred Stock&#8212;Description of the Preferred Stock and Lazar Investor Rights&#8212;Lazar Investor Rights&#8212;Participation in Future Offerings</i>&#8221; in the Proxy Statement for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Preferred Stock Certificate of Amendment, if approved by our stockholders, would become effective upon the filing of the Preferred Stock Certificate of Amendment with the Delaware Secretary of State as set forth below and attached as <span style="text-decoration: underline">Annex E</span> to this Proxy Statement. The Board reserves the right, notwithstanding stockholder approval and without further action by stockholders, to abandon and elect not to proceed with the Preferred Stock Certificate of Amendment if the Board determines that the Preferred Stock Certificate of Amendment is no longer in our best interests and the best interests of our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_105"></span>Reasons for Stockholder Approval</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Of the 5,000,000 shares of preferred stock currently authorized, as of the close of business on the Record Date, there were 2,467,946 shares of preferred stock that are outstanding, which includes 131 shares of Series B Preferred Stock, 481,250 shares of Series D Preferred Stock, and 1,986,565 shares of Series F Preferred Stock. There will remain 2,532,054 authorized shares of preferred stock available for issuance by us, which number is expected to be reduced by 268,750 shares in connection with the issuance of the Series E Preferred Stock in the Final Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the Investment Transaction, under the terms of the Purchase Agreement we agreed to seek stockholder approval at this Annual Meeting to increase the number of authorized shares of preferred stock to 10,000,000 shares of preferred stock as provided in this Proposal Ten. If our stockholders approve the Preferred Stock Certificate of Amendment and after the effect of issuing the Series E Preferred Stock at the Final Closing, then there would be approximately 7,263,304 authorized shares of Preferred Stock available for issuance by us in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to satisfying NovaBay&#8217;s obligation to seek stockholder approval to increase its authorized shares of preferred stock under the terms of the Purchase Agreement, the Board also approved the proposed increase in authorized preferred stock to provide flexibility to issue additional shares of our preferred stock and/or and securities or equity awards which may be convertible, exercisable or otherwise settleable in preferred stock for business and financial purposes in the future. These purposes may include, among others: (i) pursuing a strategic investment and/or acquisition following the Final Closing, including a Post-Investment Transaction; (ii) exploring other strategic relationships and opportunities; (iii) equity incentive compensation and awards raising capital and other financing transactions; and (iv) other corporate purposes. Other than the Series E Preferred Stock that we expect to issue at the Final Closing, we do not currently have any specific plans, proposals or arrangements, written or oral, to issue any of the proposed additional authorized shares of preferred stock. However, in connection with the Company pursuing a Post-Investment Transaction, shares of preferred stock, Common Stock and/or other Company securities may be issued as part of any such transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_106"></span>Preferred Stock Generally</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Board Right to Designate Rights and Preferences of Preferred Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under our Certificate of Incorporation, we are authorized to issue &#8220;blank check&#8221; preferred stock, which may be issued in one or more series upon authorization of the Board. The preferred stock that would be authorized by the Preferred Stock Certificate of Amendment would also be &#8220;blank check&#8221; preferred stock. The Board is authorized to fix the designations, powers, preferences and the relative, participating, optional or other special rights and any qualifications, limitations and restrictions of the shares of each series of preferred stock. The authorized shares of our preferred stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. If the approval of our stockholders is not required for the issuance of shares of our preferred stock, the Board may determine not to seek stockholder approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Possible Anti-Takeover Effects</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A series of preferred stock could, depending on the terms of such series, impede the completion of a merger, tender offer or other takeover attempt. The Board will make any determination to issue preferred stock based upon its judgment as to the best interests of our stockholders. The Board, in so acting, could issue preferred stock having terms that could discourage an acquisition attempt through which an acquirer may be able to change the composition of the Board, including a tender offer or other transaction that some, or a majority, of our stockholders might believe to be in their best interests or in which stockholders might receive a premium for their stock over the then-current market price of the stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Specifically, if in the due exercise of its fiduciary obligations, the Board were to determine that a takeover proposal was not in our stockholders&#8217; best interests, shares could be issued by the Board without stockholder approval in one or more transactions that might prevent or render more difficult or costly the completion of the takeover by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">financing transactions, such as public or private offerings of Preferred Stock;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">diluting the voting or other rights of the proposed acquirer or insurgent stockholder group;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">putting a substantial voting block in institutional or other hands that might undertake to support the incumbent Board; or</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">effecting an acquisition that might complicate or preclude the takeover.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board is not aware of any attempt, or contemplated attempt, to acquire control of the Company (apart from Mr.&#160;Lazar&#8217;s potential ownership control in connection with the Investment Transaction), nor is this proposal being presented with the intent that it be used to prevent or discourage any acquisition attempt. However, nothing would prevent the Board from taking any such actions that it deems to be consistent with its fiduciary duties</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_107"></span>Effect and Consequences of the Amendment </b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Limited Financing and Business Development Activities</i></b></span>. If this Proposal Ten is not approved by our stockholders, our strategic investment and/or acquisition, financing and business development prospects will be</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">limited. In short, if our stockholders do not approve this Proposal Ten, we may not be able to: (i) access the capital markets; (ii) complete a Post-Investment Transaction or other strategic investment and/or acquisition; (iii) pursue corporate collaborations or partnerships; and/or (iv) pursue other business opportunities that are integral to executing our business strategy and our growth and success. Even if this Proposal Ten is approved by our stockholders, there is no assurance that we will be successful in completing a Post-Investment Transaction or other strategic investment and/or acquisition, raising additional funds or pursuing other business opportunities to the extent needed in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Obligations of NovaBay Upon Failure of Stockholder Approval</i></b></span>. If this Proposal Ten is not approved by our stockholders, then pursuant to the terms of the Purchase Agreement, NovaBay shall use its reasonable best efforts to call a Second Meeting within seventy (70) days of the Annual Meeting for the purpose of obtaining approval with the recommendation of the Board that such proposal is approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #1F4E79"><b><i>Potential Dilution</i></b></span>. The issuance of additional shares of preferred stock, depending on the rights, preferences, privileges and other terms, may, among other things, have a dilutive effect on earnings per share and on stockholders&#8217; equity and voting rights. Furthermore, future sales of substantial amounts of our preferred stock, or the perception that these sales might occur, could adversely affect the prevailing market price of our Common Stock or limit our ability to raise additional capital. Stockholders should recognize that, as a result of this proposal and the potential future issuance of preferred stock, they could own a smaller percentage of shares relative to the total authorized shares of the Company than they presently own.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_108"></span>Risk Factors</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please refer to &#8220;<i>Risk Factors</i>&#8221; in this Proxy Statement above for certain material risks related to the impact of the Preferred Stock Certificate of Amendment and the approval of this Proposal Ten.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_109"></span>Additional Information</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our stockholders approve this Proposal Ten, we expect to file a Certificate of Amendment to the Certificate of Incorporation with the Delaware Secretary of State, substantially in the form as attached in <span style="text-decoration: underline">Annex E</span> hereto, as soon as practicable. Upon filing the Preferred Stock Certificate of Amendment with the Delaware Secretary of State, Article IV.A. of our Certificate of Incorporation will be amended to read in its entirety as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;A. This Corporation is authorized to issue two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock.&#8221; The total number of shares which the Corporation is authorized to issue is One Hundred Sixty Million (160,000,000) shares. One Hundred Fifty Million (150,000,000) shares shall be Common Stock, each having a par value of one cent ($0.01) per share. Ten Million (10,000,000) shares shall be Preferred Stock, each having a par value of one cent ($0.01) per share.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our stockholders approve this Proposal Ten and also approve Proposal Nine that provides for approval of the Common Stock Certificate of Amendment, then we expect to combine both the Preferred Stock Certificate of Amendment and the Common Stock Certificate of Amendment into the Combined Certificate of Amendment that we will file with the Delaware Secretary of State, substantially in the form as attached in <span style="text-decoration: underline">Annex F</span> hereto, as soon as practicable. Upon filing the Combined Certificate of Amendment with the Delaware Secretary of State, Article IV.A. of our Certificate of Incorporation will be amended to read in its entirety as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;A. This Corporation is authorized to issue two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock.&#8221; The total number of shares which the Corporation is authorized to issue is One Billion Five Hundred Ten Million (1,510,000,000) shares. One Billion Five Hundred Million (1,500,000,000) shares shall be Common Stock, each having a par value of one cent ($0.01) per share. Ten Million (10,000,000) shares shall be Preferred Stock, each having a par value of one cent ($0.01) per share.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">However, even if our stockholders approve the proposed Preferred Stock Certificate of Amendment in this Proposal Ten and/or the Common Stock Certificate of Amendment in Proposal Nine, our Board retains discretion under Delaware law not to implement either one or both of these proposed amendments to our Certificate of Incorporation. If our Board were to exercise such discretion, the number of authorized shares would remain at the current level until such time as stockholders were to approve an increase in authorized shares of Common Stock and/or Preferred Stock in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_110"></span>Stockholder Approval</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a majority of our outstanding shares entitled to vote at the Annual Meeting is required for the approval of this Proposal Ten. Unless otherwise instructed in the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted &#8220;FOR&#8221; this proposal. Abstentions and broker non-votes, if any, with respect to this proposal will have the effect of a vote &#8220;AGAINST&#8221; this Proposal Ten.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79"><b><span style="text-decoration: underline">Recommendation of Our Board</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79">Our Board recommends unanimously that you vote &#8220;FOR&#8221; the approval of the Preferred Stock Certificate of Amendment to increase the number of authorized shares of preferred stock from 5.0 million to 10.0 million.</span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_111"></span>Proposal Eleven:</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b>The Adjournment Proposal </b></span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A proposal will be submitted to the stockholders at the Annual Meeting to grant discretionary authority to the Board to adjourn the Annual Meeting from time to time, if necessary or appropriate, to establish a quorum or, even if a quorum is present, to permit further solicitation of proxies if there are not sufficient votes cast at the time of the Annual Meeting or after any adjournment in favor of any of the Proposals presented for stockholder approval at this Annual Meeting. Any adjournment of the Annual Meeting may be made by an announcement made at the Annual Meeting. Any adjournment of the Annual Meeting for the purpose of soliciting additional proxies will allow stockholders who have already sent in their proxies to revoke them at any time prior to the time that the proxies are used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt, any proxy authorizing the adjournment of the Annual Meeting shall also authorize successive adjournments thereof, at any meeting so adjourned, to the extent necessary for us to solicit additional proxies in favor of the adoption of any such proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_112"></span>Stockholder Approval</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting is required for the approval of this Proposal Eleven. Unless otherwise instructed in the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted &#8220;FOR&#8221; this proposal. Abstentions, if any, with respect to this proposal will have the effect of a vote &#8220;AGAINST&#8221; this Proposal Eleven. Broker non-votes, if any, with respect to this Proposal Eleven, will have no effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: Gainsboro">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; vertical-align: middle">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79"><b><span style="text-decoration: underline">Recommendation of Our Board</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: #1F4E79">Our Board recommends unanimously that you vote &#8220;FOR&#8221; the approval of the adjournment of the Annual Meeting, if necessary or appropriate, to establish a quorum or to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting or after any adjournment to approve any of the Proposals.</span></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; width: 100%; text-align: center; vertical-align: bottom"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_113"></span>Security Ownership of Certain Beneficial Owners and Management</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table indicates information as of September&#160;22, 2025 (or the most recent practical date noted in the footnotes below) regarding the beneficial ownership of our securities by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">each person who is known by us to beneficially own more than five percent (5%) of our securities;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">our current executive officers;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">each of our directors; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">all of our directors and executive officers as a group.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The percentage of shares beneficially owned is based on 6,005,749 shares of Common Stock outstanding as of September&#160;22, 2025. Except as indicated in the footnotes to this table, and as affected by applicable community property laws, all persons listed have sole voting and investment power for all shares shown as beneficially owned by them and no shares are pledged. None of the below entities or individuals own Series F Preferred Stock and have the associated voting rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="color: #1F4E79"><b>Name and Address of Beneficial Owner<sup>(1)</sup></b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; font-weight: bold"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; font-weight: bold; text-align: center"><span style="color: #1F4E79">Number of<br/>Shares<br/>Beneficially<br/>Owned</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; font-weight: bold"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; font-weight: bold"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; font-weight: bold; text-align: center"><span style="color: #1F4E79">Percent<br/>of Class</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; font-weight: bold"><span style="color: #1F4E79">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; width: 76%; text-align: left">
        <p style="margin-top: 0; margin-bottom: 0">Poplar Point Capital Management LLC</p>
        <p style="margin-top: 0; margin-bottom: 0">330 Primrose Road, Suite 400</p>
        <p style="margin-top: 0; margin-bottom: 0">Burlingame, CA 94010<sup>(2)</sup></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; width: 9%; text-align: right">1,020,300</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; width: 9%; text-align: right">17.5</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="text-decoration: underline; text-indent: -0.125in; padding-left: 0.165in; vertical-align: top; text-align: left">Executive Officers and Directors</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">&#160;</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.165in; vertical-align: top; text-align: left">David E. Lazar<sup>(3)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">1,200,048</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">20.0</td>
    <td style="padding-left: 0pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="text-indent: -0.125in; padding-left: 0.165in; vertical-align: top; text-align: left">Justin M. Hall, Esq.<sup>(4)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">580</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">*</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.165in; vertical-align: top; text-align: left">Tommy Law<sup>(5)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">26</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">*</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="text-indent: -0.125in; padding-left: 0.165in; vertical-align: top; text-align: left">Paul E. Freiman, Ph.D.<sup>(6)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">1,030</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">*</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.165in; vertical-align: top; text-align: left">Julie Garlikov<sup>(7)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">908</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">*</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="text-indent: -0.125in; padding-left: 0.165in; vertical-align: top; text-align: left">Swan Sit<sup>(8)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">950</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">*</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.165in; vertical-align: top; text-align: left">Mijia (Bob) Wu, M.B.A.<sup>(9)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">980</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">*</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="text-indent: -0.125in; padding-left: 0.165in; vertical-align: top; text-align: left">Yenyou (Jeff) Zheng, Ph.D.<sup>(10)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">950</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">*</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.165in; vertical-align: top; text-align: left">Yongxiang (Sean) Zheng<sup>(11)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">908</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">*</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-indent: -0.125in; padding-left: 0.165in; vertical-align: top; text-align: left">All directors and executive officers as a group (9 persons)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">1,206,380</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">20.1</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">*</td>
    <td style="text-align: justify">Less than one percent (1%).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><sup>(1)</sup></td>
    <td style="text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The address for each director and executive officer of NovaBay listed is c/o NovaBay Pharmaceuticals, Inc., 2000 Powell Street, Suite 1150, Emeryville, CA 94608. The number of shares beneficially owned and percent of class is calculated in accordance with SEC rules. A beneficial owner is deemed to beneficially own shares the beneficial owner has the right to acquire within sixty (60) days of September&#160;22, 2025. For purposes of calculating the percent of class held by a single beneficial owner, the shares that such beneficial owner has the right to acquire within sixty (60) days of September&#160;22, 2025 are also deemed to be outstanding; however, such shares are not deemed to be outstanding for purposes of calculating the percentage ownership of any other beneficial owner.</p> </td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><sup>(2)</sup></td>
    <td style="text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based upon information contained in the Schedule&#160;13D/A jointly filed by the Poplar Entities, comprised of Poplar Point Capital Management LLC, a Delaware limited liability company, Poplar Point Capital Partners LP, a Delaware limited partnership, Poplar Point Capital GP LLC, a Delaware limited liability company, and Jad Fakhry, a United States citizen, with the SEC on September&#160;4, 2025, with shared voting and dispositive power of all shares and sole voting and dispositive power of no shares. Pursuant to the Voting Agreement, the Poplar Entities have shared voting power with Mr.&#160;Lazar over all of the shares owned by the Poplar Entities.</p> </td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0.25in"><sup>(3)</sup></td>
    <td style="text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based upon information contained in the Schedule&#160;13D filed by Mr.&#160;Lazar with the SEC on August&#160;26, 2025, with sole voting and dispositive power over 179,748 shares (as a portion of the shares underlying the Series D Preferred Stock) and shared voting and dispositive power of 1,020,300 shares (as shares Mr.&#160;Lazar has shared voting power with the Poplar Entities pursuant to the Voting Agreement). As described in this Proxy Statement, Mr.&#160;Lazar&#8217;s participation in the Investment Transaction may, as of a subsequent date, result in a change of control of NovaBay. The shares and percentage in the above table are based on shares that have not been issued to Mr.&#160;Lazar and are not outstanding. The Share Issuance Limitation will apply to Mr.&#160;Lazar&#8217;s ownership of our Common Stock until the Conversion Approval is received, and, therefore, his ownership of Common Stock will be limited to no more than 19.99% of shares of Common Stock outstanding on the date of the Purchase Agreement (or such lower ownership as may be required by the NYSE American).</p> </td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><sup>(4)</sup></td>
    <td style="text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Consists of (i) 67 shares of Common Stock held directly by Mr.&#160;Hall and (ii) 513 shares issuable upon the exercise of outstanding options that are exercisable as of September&#160;22, 2025 or within 60 days after such date.</p> </td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><sup>(5)</sup></td>
    <td style="text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Consists of 26 shares of Common Stock issuable upon exercise of outstanding stock options that are exercisable as of September&#160;22, 2025 or within 60 days after such date.</p> </td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><sup>(6)</sup></td>
    <td style="text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Consists of (i) 933 shares of Common Stock held directly by Dr. Freiman; (ii) 2 shares of Common Stock held by the Paul Freiman and Anna Mazzuchi Freiman Trust, of which Dr. Freiman and his spouse are trustees (with sole voting power over 1 share, shared voting power over 1 share, sole investment power over no shares and shared investment power over 2 shares); and (iii) 95 shares of Common Stock issuable upon exercise of outstanding stock options that are exercisable as of September&#160;22, 2025 or within 60 days after such date.</p> </td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><sup>(7)</sup></td>
    <td style="text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Consists of 908 shares of Common Stock held directly by Ms. Garlikov as of September&#160;22, 2025.</p> </td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><sup>(8)</sup></td>
    <td style="text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Consists of (i) 933 shares of Common Stock held directly by Ms. Sit and (ii) 17 shares issuable upon exercise of outstanding stock options that are exercisable as of September&#160;22, 2025 or within 60 days after such date.</p> </td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><sup>(9)</sup></td>
    <td style="vertical-align: top; text-align: justify">Consists of (i) 933 shares of Common Stock held directly by Mr.&#160;Wu and (ii) 47 shares issuable upon exercise of outstanding stock options that are exercisable as of September&#160;22, 2025 or within 60 days after such date.</td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><sup>(10)</sup></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Consists of (i) 933 shares of Common Stock held directly by Dr. Jeff Zheng and (ii) 17 shares issuable upon exercise of outstanding stock options that are exercisable as of September&#160;22, 2025 or within 60 days after such date.</p> </td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><sup>(11)</sup></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Consists of 908 shares of Common Stock held directly by Mr.&#160;Sean Zheng as of September&#160;22, 2025.</p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; text-align: center; vertical-align: middle"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_114"></span>Equity Compensation Plan Information</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table provides information as of December&#160;31, 2024, with respect to shares of our Common Stock that may be issued under existing equity compensation plans. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="color: rgb(31,78,121); vertical-align: bottom">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); vertical-align: bottom; font-weight: bold; text-align: left">Plan category</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); font-weight: bold; text-align: center">Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); font-weight: bold">&#160;</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); font-weight: bold; text-align: center">Weighted Average Exercise Price of Outstanding Options and Rights</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); font-weight: bold">&#160;</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; color: rgb(31,78,121); font-weight: bold; text-align: center">Number of Securities Remaining Available For Future Issuance under Equity Compensation Plans (excluding securities reflected in first column)</td>
    <td style="border-top: rgb(31,78,121) 2pt solid; color: rgb(31,78,121); font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; width: 64%; text-align: left">Equity compensation plans approved by security holders<sup>(1)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; width: 9%; text-align: right">6,855</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 9%; text-align: right">471.64</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="padding-right: 0pt; width: 9%; text-align: right">13,668</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">Equity compensation plans not approved by security holders</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">Total</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">6,855</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">471.64</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">13,668</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"/>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(1)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Consists of the 2007 Omnibus Plan and 2017 Omnibus Plan. No additional option grants are being made under the 2002 Stock Option Plan, 2005 Stock Option Plan or 2007 Omnibus Plan. The 2017 Omnibus Plan became effective on June&#160;2, 2017, and 13,668 shares were reserved for issuance under that plan at December&#160;31, 2024.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; text-align: center; vertical-align: middle"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_115"></span>Certain Relationships and Related Party Transactions</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NovaBay&#8217;s Audit Committee has the responsibility of reviewing possible related party transactions. In conducting its review, the Audit Committee applies the principles of the Code of Ethics and its Conflict of Interest Policy to: (i) the relationship of the related persons to the transaction; (ii) the relationship between the Company and the related persons; (iii) the importance of the interest to the related persons; and (iv) the amount involved in the transaction. Additionally, in connection with the Investment Transaction, the Special Transaction Committee may also review possible related party transactions in connection with the exercise of its exclusive authority to authorize and direct all matters related to the Investment Transaction, including the Release Agreements with Mr.&#160;Hall and the Resigning Non-Employee Directors and other ancillary agreements to the Investment Transaction and enforce our rights under the Purchase Agreement and other Investment Transaction documents. Accordingly, other than as described below, since January&#160;1, 2023, there has not been any transaction, nor is there any proposed transaction, in which NovaBay was a participant, and in which a &#8220;related party&#8221; of NovaBay had or is expected to have a direct or indirect material interest, in which the amount involved exceeded or will exceed the lesser of $120,000 or one percent (1%) of the average of NovaBay&#8217;s total assets at the end of the last two (2) completed fiscal years, that would require disclosure, except as follows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Investment Transaction</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August&#160;19, 2025, we entered into the Investment Transaction that provides for an investment by Mr.&#160;Lazar in two separate closings of up to $6.0 million in the aggregate in exchange for newly issued shares of Series D Preferred Stock, which were issued in the First Closing and shares of Series E Preferred Stock to be issued in the Final Closing, subject to Proposal Five (NYSE American Proposal) being approved and the satisfaction of other closing conditions. As a result of the Investment Transaction, Mr.&#160;Lazar is currently a beneficial owner of approximately 19.9% of Common Stock (as a result of his ownership of the Series D Preferred Stock that is convertible up to the Share Issuance Limitation) with his beneficial ownership expected to increase to approximately 95% of outstanding Common Stock if Proposal Five (NYSE American Proposal) is approved and the Share Issuance Limitation on the Series D Preferred Stock is lifted and Mr.&#160;Lazar received the issuance of the Series E Preferred Stock in the Final Closing. As part of the Investment Transaction, Mr.&#160;Lazar and the Company made various covenants, including, among others, Mr.&#160;Lazar agreeing that we shall maintain an amount of cash for the Minimum Company Operating Capital (as defined in the Purchase Agreement that generally means capital equivalent to at least three (3) months of the Company&#8217;s operations), the Post-Investment Available Capital and the Other Company Liabilities (as defined in the Purchase Agreement) or that he, or other institutional investors known to him, will otherwise provide the necessary additional cash through private placement investments on commercially reasonable terms. Mr.&#160;Lazar also obtained the right to participate in our subsequent financing transactions (until February&#160;19, 2026), to assign and/or transfer the Series D Preferred Stock, the Series E Preferred Stock and the Conversion Shares and/or his right to acquire such securities pursuant to the Securities Purchase Rights, and certain one-time contractual rights related to the Board, including for his nomination at this Annual Meeting as well as, subject to the Conversion Approval and the Final Closing, a right to nominate up to three (3) Additional Purchaser Nominee(s) and be appointed as the Chair of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the Investment Transaction, we appointed Mr.&#160;Lazar as our Chief Executive Officer and as a director of the Board. Separately, Mr.&#160;Hall resigned as Chief Executive Officer and entered into the New Hall Employment Agreement with the Company for his service as Vice President of Business Development, General Counsel and Corporate Secretary, and Mr.&#160;Law was appointed as Chief Financial Officer and Treasurer and entered into the Law Employment Agreement with the Company. The employment agreements provide for: (i) for Mr.&#160;Hall, a term until October&#160;31, 2025 with an annual base salary of $175,000 and (ii) for Mr.&#160;Law, a term until August&#160;19, 2026 with an annual base salary of $170,000 and a retention bonus of $170,000 subject to certain conditions. Mr.&#160;Hall also entered into the Hall Release Agreement, which provides for two cash settlement payments of an aggregate of $490,028&#8212;one that was paid on August&#160;19, 2025 and one scheduled to be paid on October&#160;31, 2025. Mr.&#160;Law also received a one-time signing bonus of $89,250 for entering into the Law Employment Agreement. Also, in connection with the Investment Transaction and as consideration for the Release Agreement, each Resigning Non-Employee Director (Dr. Freiman, Ms. Garlikov, Ms. Sit, Mr.&#160;Wu and Mr.&#160;Sean Zheng) is entitled to (a) the Equity Consideration, which is a settlement payment of newly-issued shares of restricted Common Stock, with an aggregate value of $40,000 to be issued upon the Resignation Event, subject to stockholders approving Proposal Seven (Director Equity Consideration Proposal), plus (b) any accrued and unpaid director&#8217;s fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For additional information regarding the above transactions and agreements, see &#8220;<i>Description of the Investment Transaction and Preferred Stock</i>&#8221; in this Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>2023 Private Placement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April&#160;27, 2023, the Company entered into the 2023 Private Placement. As a result of the significant number of shares of common stock that may be issued upon the future conversion or redemption of the Secured Convertible Notes and exercise of the May&#160;2023 Warrants compared to the currently issued and outstanding shares of Common Stock, the Company was required to obtain stockholder approval in accordance with the Company Guide Rule&#160;713(a) and Rule&#160;713(b), which was obtained on June&#160;9, 2023. In connection with the closing of the Private Placement, the Company was required to obtain voting commitments from the Company&#8217;s executive officers, directors, more than 10% stockholders, Mr.&#160;Fu and Pioneer Hong Kong to support the Company in obtaining the required stockholder approval. As a condition for Mr.&#160;Fu and Pioneer Hong Kong delivering their voting commitments to the Company, the Company entered into warrant amendment agreements with certain other existing Company investors that held previously-issued Company common stock purchase warrants that reduced the exercise price of these warrants to $1.30 per share. Mr.&#160;Sean Zheng currently serves as the Head of Investment Department of Pioneer (an affiliate of Pioneer Hong Kong), and Mr.&#160;Wu historically served as the Non-Executive Director of Pioneer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: middle; width: 100%; text-align: center; vertical-align: middle"><span style="font-size: 14pt; font-variant: small-caps; color: #1F4E79"><b><span id="a_116"></span>Other Proxy Matters</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_117"></span>Delinquent Section&#160;16(a) Reports</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the federal securities laws, our directors and officers and any persons holding more than ten percent (10%) of our Common Stock are required to report their ownership of our Common Stock and any changes in that ownership to the SEC. Specific due dates for these reports have been established, and we are required to report in this Proxy Statement any failure to file by these dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In making this statement, we have relied upon examination of the copies of Forms 3, 4 and 5, and amendments to these forms, provided to us and the written representations of our directors, executive officers and ten percent (10%) stockholders. Based solely on our review of copies of the reports on the Section&#160;16(a) forms filed with the SEC with respect to the fiscal year ended December&#160;31, 2024, and the written representations received from the reporting persons that no other reports were required, we believe that all directors, executive officers and persons who own more than ten percent (10%) of our Common Stock have complied with the reporting requirements of Section&#160;16(a) and have filed all reports required by such section.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_118"></span>Deadlines for Receipt of Stockholder Proposals and Nominations</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Deadline for submitting stockholder proposals for inclusion in the Company&#8217;s 2026 Annual Meeting of Stockholders Proxy Statement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company anticipates that its 2026 Annual Meeting of Stockholders (the &#8220;<b><i>2026 Annual Meeting</i></b>&#8221;) will be held on or about May&#160;28, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stockholder proposals submitted for inclusion in the proxy statement for our 2026 Annual Meeting must comply with applicable requirements and conditions established by the SEC pursuant to Rule&#160;14a-8 of the Exchange Act. Under Rule&#160;14a-8 of the Exchange Act, the deadline for submitting a stockholder proposal for inclusion in the proxy statement for our 2026 Annual Meeting is 120 calendar days before the date of this Proxy Statement for the Annual Meeting; provided, that if the date of the 2026 Annual Meeting is changed by more than 30 days from the date of the Annual Meeting, then the deadline will be a reasonable time before the Company begins to print and send its proxy materials to stockholders for the 2026 Annual Meeting. Given that the Company anticipates its 2026 Annual Meeting will be held on or about May&#160;28, 2026, the date of the 2026 Annual Meeting will differ by more than 30 days from the anniversary date of this Annual Meeting. Therefore, stockholder proposals submitted pursuant to Rule&#160;14a-8 of the Exchange Act for inclusion in our proxy statement for the 2026 Annual Meeting must be received by our Corporate Secretary no later than the close of business on December&#160;19, 2025, which the Company has determined is a reasonable time before it plans to begin to print and send its proxy materials to stockholders for the 2026 Annual Meeting. If notice is received after December&#160;19, 2025, it will be considered untimely, and we will not be required to present the matter at the 2026 Annual Meeting. All stockholder proposals must comply with applicable rules and regulations adopted by the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Due Date for Receipt of Advance Notice of Stockholder Nominations and Proposals for 2026 Annual Meeting of Stockholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to our Bylaws, if you wish to bring certain business or nominate a director, you must comply with the advance notice provisions in our Bylaws and do so no earlier than the close of business on the 120<sup>th</sup> day, and not later than the close of business on the 90<sup>th</sup> day, prior to the first anniversary of the preceding year&#8217;s annual meeting; <span style="text-decoration: underline">provided</span>, that if the date of the 2026 Annual Meeting is changed by more than 30 days from the date of the Annual Meeting, your notice must be received (i) no earlier than the close of business on the 120<sup>th</sup> day prior to the 2026 Annual Meeting and (ii) not later than the close of business on the later of (y) the 90<sup>th</sup> day prior to the 2026 Annual Meeting or (z) the tenth 10<sup>th</sup> day following the day on which public announcement of the date of the 2026 Annual Meeting of Stockholders is first made. Given that the Company anticipates its 2026 Annual Meeting will be held on or about May&#160;28, 2026, the date of the 2026 Annual Meeting will be more than 30 days before the anniversary date of this Annual Meeting, and September&#160;23, 2025, the date this Proxy Statement is first filed with the SEC, constitutes</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">the public announcement of the date of the 2026 Annual Meeting of Stockholders. Accordingly, if you wish to bring certain business or nominate a director, you must comply with the advance notice provisions in our Bylaws and do so no earlier than the close of business on January&#160;28, 2026, and no later than the close of business on February&#160;27, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stockholders are also advised to review the Bylaws, which contain additional requirements with respect to the advance notice of stockholder proposals and director nominations. Our advance notice Bylaw provisions do not apply to stockholder proposals made in compliance with SEC Rule&#160;14a-8.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Deadline for Providing Notice of a Solicitation of Proxies in Support of Director Nominees Other than the Company&#8217;s Nominees for the 2026 Annual Meeting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To comply with the SEC&#8217;s universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company&#8217;s nominees at the 2026 Annual Meeting must provide notice that sets forth the information required by the SEC no later than 60 days prior to the first anniversary of this Annual Meeting, except that if the date of the 2026 Annual Meeting has changed by more than 30 calendar days from the previous year, then notice must be provided by the later of 60 calendar days prior to the date of the 2026 Annual Meeting or the 10th calendar day following the day on which public announcement of the date of the 2026 Annual Meeting is first made by the Company. Given that the Company anticipates its 2026 Annual Meeting will be held on or about May&#160;28, 2026, the date of the 2026 Annual Meeting will differ by more than 30 days from the anniversary date of this Annual Meeting, and September&#160;23, 2025, the date this Proxy Statement is first filed with the SEC, constitutes the public announcement of the date of the 2026 Annual Meeting of Stockholders. Therefore, stockholders who intend to solicit proxies in support of director nominees other than the Company&#8217;s nominees at the 2026 Annual Meeting must provide notice that sets forth the information required by the SEC no later than March&#160;29, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>General Administration</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stockholder proposals must be in writing and should be addressed to our Corporate Secretary, at our principal executive offices at 2000 Powell Street, Suite 1150, Emeryville, California 94608. It is recommended that stockholders submitting proposals direct them to our Corporate Secretary and utilize certified mail, return receipt requested, to provide proof of timely receipt. The presiding officer of the Annual Meeting reserves the right to reject, rule out of order, or take other appropriate action with respect to any proposal that does not comply with these and other applicable requirements, including conditions set forth in our Bylaws and conditions established by the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_119"></span>Householding of Proxy Materials</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The SEC has adopted rules that permit companies and intermediaries (<i>e.g.</i>, brokers, banks or other nominees) to satisfy the delivery requirements for proxy statements and annual reports with respect to two (2) or more stockholders sharing the same address (and who do not receive electronic delivery of proxy materials) by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For those who receive proxy materials by mail, a single proxy statement may be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker, bank or other nominee or NovaBay that it will be &#8220;householding&#8221; communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you notify your broker, bank or other nominee or NovaBay that you no longer wish to participate in &#8220;householding.&#8221; If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate proxy statement and annual report in the future, you may (i) notify your broker, bank or other nominee or (ii) direct your written request to our Corporate Secretary, NovaBay Pharmaceuticals, Inc., 2000 Powell Street, Suite 1150, Emeryville, California 94608, (510) 899-8800. Stockholders who currently receive multiple copies of the proxy statement at their address and would like to request &#8220;householding&#8221; of their communications should likewise contact their broker, bank or other nominee or NovaBay using the above information. In addition, NovaBay will promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of the Annual Report and this Proxy Statement to a stockholder at a shared address to which a single copy of the documents was delivered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_120"></span>Method of Proxy Solicitation</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will pay all costs of preparing, assembling, printing and distributing the proxy materials. NovaBay has engaged Sodali &amp; Co., to assist in the solicitation of proxies and provide related advice and informational support, for a services fee, plus customary disbursements, which are not expected to exceed $15,000 in total. No fees will be paid for solicitation of any stockholder to vote in favor of one of the Proposals. Our employees may solicit proxies on behalf of the Board through the mail, in person, by telephone or by other forms of electronic communication, without additional compensation. We will reimburse brokers, banks and other nominees who hold shares of Common Stock in their names for the expenses of furnishing proxy materials to beneficial owners of the shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_121"></span>Where You Can Find More Information</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NovaBay files reports, proxy statements and other information with the SEC as required by the Exchange Act. You may read and copy reports, proxy statements and other information filed by NovaBay with the SEC at the SEC&#8217;s website, which contains reports, proxy statements and other information, at: <span style="text-decoration: underline">http://www.sec.gov</span>. This Proxy Statement refers to certain documents that are not attached or delivered with this Proxy Statement, but have been filed by NovaBay with the SEC, including the Investment Transaction Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Company&#8217;s Internet address, located at <span style="text-decoration: underline">www.novabay.com</span>, includes electronic files of this Proxy Statement and our Annual Report, as well as our other SEC filings. Further, this Proxy Statement and other documents referred to in this Proxy Statement are available without charge to stockholders of NovaBay upon written or oral request. If you would like additional copies of this Proxy Statement, such other documents referred to herein that are filed by us with the SEC or if you have questions about the Proposals to be presented at the Annual Meeting, you should contact NovaBay in writing at NovaBay Pharmaceuticals, Inc., 2000 Powell Street, Suite 1550, Emeryville, CA 94608 or by telephone at (510) 899-8800.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; width: 100%"><span style="font-size: 12pt; color: rgb(31,78,121)"><b><span id="a_122"></span>Other Business</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board is not aware of any other matter which will be presented for action at the Annual Meeting other than the matters set forth in this Proxy Statement. If any other matter requiring a vote of the stockholders arises, it is intended that the proxy holders will vote the shares they represent as the Board may recommend. The proxy grants the proxy holders discretionary authority to vote on any such other matters properly brought before the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: left; vertical-align: top; width: 50%">September&#160;23, 2025</td>
    <td style="text-align: left; vertical-align: top; width: 50%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">By Order of the Board of Directors,</p> </td> </tr>
  <tr>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: top">/s/ Paul E. Freiman</td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Paul E. Freiman, Ph.D.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Chairman of the Board</p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Annex A</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2017 OMNIBUS INCENTIVE PLAN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purpose</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The purpose of the Plan is to promote the interests of the Company and its shareholders by aiding the Company in attracting and retaining employees, officers, consultants, independent contractors and directors capable of assuring the future success of the Company, to offer such persons incentives to continue in the Company&#8217;s employ or service and to afford such persons an opportunity to acquire a proprietary interest, or otherwise increase their proprietary interest, in the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Definitions</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As used in the Plan, the following terms shall have the meanings set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#8220;<i>Affiliate</i>&#8221; shall mean (i) any entity that, directly or indirectly through one or more intermediaries, is controlled by the Company and (ii) any entity in which the Company has a significant equity interest, in each case as determined by the Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#8220;<i>Award</i>&#8221; shall mean any Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, Performance Award, Dividend Equivalent, Other Stock Grant or Other Stock-Based Award granted under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#8220;<i>Award Agreement</i>&#8221; shall mean any written agreement, contract or other instrument or document evidencing an Award granted under the Plan which may, but is not required to be, transmitted electronically to any Participant. Each Award Agreement shall be subject to the applicable terms and conditions of the Plan and any other terms and conditions (not inconsistent with the Plan) determined by the Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#8220;<i>Board</i>&#8221; shall mean the Board of Directors of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#8220;<i>Code</i>&#8221; shall mean the Internal Revenue Code of 1986, as amended from time to time, and any regulations promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#8220;<i>Committee</i>&#8221; shall mean a committee of Directors designated by the Board to administer the Plan, which shall initially be the Company&#8217;s compensation committee. The Committee shall be comprised of not less than such number of Directors as shall be required to permit Awards granted under the Plan to qualify under Rule&#160;16b-3 and Section&#160;162(m) of the Code, and each member of the Committee shall be a &#8220;Non-Employee Director&#8221; and an &#8220;Outside Director.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;&#8220;<i>Company</i>&#8221; shall mean NovaBay Pharmaceuticals, Inc., a Delaware corporation, and any successor corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#160;&#8220;<i>Covered Employee</i>&#8221; means an employee who is, or could be, a &#8220;covered employee&#8221; within the meaning of Section&#160;162(m) of the Code, as interpreted by Internal Revenue Service Notice 2007-49.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#8220;<i>Director</i>&#8221; shall mean a member of the Board, including any Non-Employee Director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#160;&#8220;<i>Dividend Equivalent</i>&#8221; shall mean any right granted under Section&#160;6(e) of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#160;&#8220;<i>Eligible Person</i>&#8221; shall mean any employee, officer, consultant, independent contractor or Director providing services to the Company or any Affiliate who the Committee determines to be an Eligible Person. An Eligible Person must be a natural person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&#160;&#8220;<i>Exchange Act</i>&#8221; shall mean the Securities Exchange Act of 1934, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 108; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#160;&#8220;<i>Effective Date</i>&#8221; shall mean the date the Plan is approved by the Company&#8217;s shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&#160;&#8220;<i>Fair Market Value</i>&#8221; shall mean, with respect to any property (including, without limitation, any Shares or other securities), the fair market value of such property determined by such methods or procedures as shall be established from time to time by the Committee. Notwithstanding the foregoing and unless otherwise determined by the Committee, the Fair Market Value of a Share as of a given date shall be, if the Shares are then listed on an established stock exchange, the closing price of one Share as reported on such exchange on such date or, if such exchange is not open for trading on such date, on the most recent preceding date when it is open for trading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&#160;&#8220;<i>Incentive Stock Option</i>&#8221; shall mean an option granted under Section&#160;6(a) of the Plan that is intended to qualify as an &#8220;incentive stock option&#8221; in accordance with the terms of Section&#160;422 of the Code or any successor provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&#160;&#8220;<i>Insider</i>&#8221; shall mean an Eligible Person who is an &#8220;insider&#8221; within the meaning of Section&#160;16 of the Exchange Act, including an officer, director or a direct or indirect beneficial owner of more than ten percent (10%) of any class of any equity security of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&#160;&#8220;<i>Negative Discretion</i>&#8221; shall mean discretion to be applied by the Committee to eliminate or reduce the amount of a Qualified Performance Based Award; provided that the exercise of such discretion would not cause the Qualified Performance Based Award to fail to qualify as &#8220;qualified performance based compensation&#8221; under Section&#160;162(m).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&#160;&#8220;<i>Non-Employee Director</i>&#8221; shall mean any Director who is not also an employee of the Company or an Affiliate within the meaning of Rule&#160;16b-3 (which term &#8220;Non-Employee Director&#8221; is defined in this paragraph for purposes of the definition of &#8220;Committee&#8221; only and is not intended to define such term as used elsewhere in the Plan).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&#160;&#8220;<i>Non-Qualified Stock Option</i>&#8221; shall mean an option granted under Section&#160;6(a) of the Plan that is not an Incentive Stock Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)&#160;&#8220;<i>Option</i>&#8221; shall mean an Incentive Stock Option or a Non-Qualified Stock Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)&#160;&#8220;<i>Other Stock Grant</i>&#8221; shall mean any right granted under Section&#160;6(f) of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&#160;&#8220;<i>Other Stock-Based Award</i>&#8221; shall mean any right granted under Section&#160;6(g) of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)&#160;&#8220;<i>Outside Director</i>&#8221; shall mean any Director who is an &#8220;outside director&#8221; within the meaning of Section&#160;162(m) of the Code and Treasury Regulation Section&#160;1.162-27(e)(3) or any successor to such statute and regulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)&#160;&#8220;<i>Participant</i>&#8221; shall mean an Eligible Person designated to be granted an Award under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)&#160;&#8220;<i>Performance Award</i>&#8221; shall mean any right granted under Section&#160;6(d) of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)&#160;&#8220;<i>Performance Goal</i>&#8221; shall mean one or more of the following performance goals, either individually, alternatively or in any combination, applied on a corporate, subsidiary or business unit basis: revenue, cash flow, gross profit, earnings before interest and taxes, earnings before interest, taxes, depreciation and amortization, net earnings, earnings per share, margins (including one or more of gross, operating and net income margins), returns (including one or more of return on assets, equity, investment, capital and revenue and total shareholder return), stock price, economic value added, working capital, market share, cost reductions, workforce satisfaction and diversity goals, employee retention, customer satisfaction, completion of key projects and strategic plan development and implementation. Such goals may reflect absolute entity or business unit performance or a relative comparison to the performance of a peer group of entities or other external measure of the selected performance criteria. Pursuant to rules and conditions adopted by the Committee on or before the 90th day (or if shorter, within the maximum period allowed under Section&#160;162(m)) of the applicable performance period for which Performance Goals are established, the Committee may appropriately adjust any evaluation of performance under such goals to exclude the effect of certain events, including any of the following events: asset write-downs; litigation or claim judgments or settlements; changes in tax law, accounting principles or other such laws or provisions affecting reported results; severance, contract termination and other costs related to exiting certain business activities; and gains or losses from the disposition of businesses or assets or from the early extinguishment of debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)&#160;&#8220;<i>Performance Period</i>&#8221; shall mean the one or more periods of time, as the Committee may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to, and the payment of, a Qualified Performance Based Award or a Performance Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)&#160;&#8220;<i>Permanent Disability</i>&#8221; shall mean the inability of Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or has lasted or can be expected to last for a continuous period of twelve (12) months or more; <i>provided, however</i>, for purposes of determining the term of an Incentive Stock Option, the term &#8220;Permanent Disability&#8221; shall have the meaning ascribed to &#8220;disability&#8221; under Section&#160;22(e)(3) of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)&#160;&#8220;<i>Person</i>&#8221; shall mean any individual or entity, including a corporation, partnership, limited liability company, association, joint venture or trust.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)&#160;&#8220;<i>Prior Plan</i>&#8221; shall mean the NovaBay Pharmaceuticals, Inc. 2007 Omnibus Incentive Plan (as amended on April&#160;19, 2008, March&#160;21, 2012, May&#160;16, 2016, and January&#160;23, 2017).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)&#160;&#8220;<i>Plan</i>&#8221; shall mean the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan, as amended from time to time, the provisions of which are set forth herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)&#160;&#8220;<i>Qualified Performance Based Award</i>&#8221; shall have the meaning set forth in Section&#160;6(d) of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)&#160;&#8220;<i>Restricted Stock</i>&#8221; shall mean any Share granted under Section&#160;6(c) of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)&#160;&#8220;<i>Restricted Stock Unit</i>&#8221; shall mean any unit granted under Section&#160;6(c) of the Plan evidencing the right to receive a Share (or evidencing the right to receive a cash payment equal to the Fair Market Value of a Share if explicitly so provided in the Award Agreement) at some future date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#8220;<i>Rule&#160;16b-3</i>&#8221; shall mean Rule&#160;16b-3 promulgated by the Securities and Exchange Commission under the Exchange Act, or any successor rule or regulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)&#160;&#8220;<i>Section&#160;162(m)</i>&#8221; shall mean Section&#160;162(m) of the Code and the applicable Treasury Regulations promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)&#160;&#8220;<i>Securities Act</i>&#8221; shall mean the Securities Act of 1933, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)&#160;&#8220;<i>Service</i>&#8221; shall mean the Participant&#8217;s performance of services for the Company (or any Affiliate) in the capacity of an employee, officer, consultant, independent contractor or director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)&#160;&#8220;<i>Share</i>&#8221; or &#8220;<i>Shares</i>&#8221; shall mean a share or shares of common stock, $0.01 par value per share, of the Company or such other securities or property as may become subject to Awards pursuant to an adjustment made under Section&#160;4(c) of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)&#160;&#8220;<i>Stock Appreciation Right</i>&#8221; shall mean any right granted under Section&#160;6(b) of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Administration</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;<span style="text-decoration: underline">Power and Authority of the Committee</span>. The Plan shall be administered by the Committee. Any Awards made to members of the Committee, however, should be authorized by a disinterested majority of the Board. Subject to the express provisions of the Plan and to applicable law and other applicable stock exchange rules, the Committee shall have full power and authority to: (i) designate Participants; (ii) determine the type or types of Awards to be granted to each Participant under the Plan; (iii) determine the number of Shares to be covered by (or the method by which payments or other rights are to be determined in connection with) each Award; (iv) determine the terms and conditions of any Award or Award Agreement; (v) amend the terms and conditions of any Award or Award Agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and accelerate the exercisability of any Option or waive any restrictions relating to any Award; (vi) determine whether, to what extent and under what circumstances Awards may be exercised in cash, Shares, or promissory notes (<i>provided, however</i>, that the par value of any Shares to be issued pursuant to such exercise shall be paid in the form of cash, services rendered, personal property, real property or a combination thereof and the acceptance of such promissory notes does not conflict with Section&#160;402 of the Sarbanes-Oxley Act of 2002), other securities, other Awards or other property, or canceled, forfeited or suspended; (vii) interpret and administer the Plan and any instrument or agreement, including an Award Agreement, relating to the Plan; (viii) establish, amend, suspend or waive such rules and regulations and appoint such agents as it shall deem appropriate for the proper administration of the Plan; and (ix) make any other determination and take any other action that the Committee deems necessary or desirable for the administration of the Plan. Unless otherwise expressly provided in the Plan, all designations, determinations, interpretations and other decisions under or with respect to the Plan or any Award or Award Agreement shall be within the sole discretion of the Committee, may be made at any time and shall be final, conclusive and binding upon any Eligible Person and any holder or beneficiary of any Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;<span style="text-decoration: underline">Power and Authority of the Board</span>. Notwithstanding anything to the contrary contained herein, the Board may, at any time and from time to time, without any further action of the Committee, exercise the powers and duties of the Committee under the Plan, but only to the extent it would not cause a loss of any benefits under Section&#160;162(m).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;<span style="text-decoration: underline">Delegation of Duties</span>. To the extent permitted by applicable law, the Board or Committee may from time to time delegate to a committee of one or more members of the Board or one or more officers of the Company the authority to grant or amend Awards to Eligible Persons other than (i) executives of the Company who are subject to Section&#160;16 of the Exchange Act, (ii) Covered Employees, or (iii) officers of the Company (or members of the Board) to whom authority to grant or amend Awards has been delegated hereunder. Any delegation hereunder shall be subject to the restrictions and limits that the Board or Committee specifies at the time of such delegation, and the Board or Committee, as applicable, may at any time rescind the authority so delegated or appoint a new delegatee. At all times, the delegatee appointed under this Section&#160;3(c) shall serve in such capacity at the pleasure of the Board or Committee that created the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 4.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares Available for Awards</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;<span style="text-decoration: underline">Shares Available</span>. Subject to adjustment as provided in Section&#160;4(c) of the Plan, the aggregate number of Shares that may be issued under the Plan shall be 2,318,486, plus an automatic annual increase on the first day of each of the Company&#8217;s fiscal years beginning January&#160;1, 2018 through January&#160;1, 2027 equal to (i) four percent (4%) of the number of shares of Common Stock outstanding on the last day of the immediately preceding fiscal year or (ii) such lesser number of shares of Common Stock than provided for in Section&#160;4(a)(i) as determined by the Board. Shares to be issued under the Plan may be either authorized but unissued Shares or Shares re-acquired and held in treasury. Any Shares that are used by a Participant as full or partial payment to the Company of the purchase price relating to an Award, or in connection with the satisfaction of tax obligations relating to an Award, shall again be available for granting Awards (other than Incentive Stock Options) under the Plan. In addition, if any Shares covered by an Award or to which an Award relates are not purchased or are forfeited, or if an Award otherwise terminates without delivery of any Shares, then the number of Shares counted against the aggregate number of Shares available under the Plan with respect to such Award, to the extent of any such forfeiture or termination, shall again be available for granting Awards under the Plan. Notwithstanding the foregoing, (i) the number of Shares available for granting Incentive Stock Options under the Plan shall not exceed 2,318,486, plus the automatic annual increase described above, subject to adjustment as provided in Section&#160;4(c) of the Plan and subject to the provisions of Section&#160;422 or 424 of the Code or any successor provision and (ii) the number of Shares available for granting Restricted Stock and Restricted Stock Units shall not exceed 2,318,486, plus the automatic annual increase described above, subject to adjustment as provided in Section&#160;4(c) of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;<span style="text-decoration: underline">Accounting for Awards</span>. For purposes of this Section&#160;4, if an Award entitles the holder thereof to receive or purchase Shares, the number of Shares covered by such Award or to which such Award relates shall be counted on the date of grant of such Award against the aggregate number of Shares available for granting Awards under the Plan. Any Shares that are used by a Participant as full or partial payment to the Company of the purchase price relating to an Award or in connection with the satisfaction of tax obligations relating to an Award, shall again be available for granting Awards under the Plan. In addition, if any Shares covered by an Award or to which an Award</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relates are not purchased or are forfeited, or if an Award otherwise terminates without delivery of any Shares, then the number of Shares counted against the aggregate number of Shares available under the Plan with respect to such Award, to the extent of any such forfeiture or termination, shall again be available for granting Awards under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;<span style="text-decoration: underline">Adjustments</span>. In the event that the Committee shall determine that any dividend or other distribution (whether in the form of cash, Shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of Shares or other securities of the Company, issuance of warrants or other rights to purchase Shares or other securities of the Company or other similar corporate transaction or event affects the Shares such that an adjustment is determined by the Committee to be appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan, then the Committee shall, in such manner as it may deem equitable, adjust any or all of (i) the number and type of Shares (or other securities or other property) that thereafter may be made the subject of Awards, (ii) the number and type of Shares (or other securities or other property) subject to outstanding Awards, (iii) the purchase price or exercise price with respect to any Award and (iv) the limitations contained in Section&#160;4(d) of the Plan; <i>provided, however</i>, that the number of Shares covered by any Award or to which such Award relates shall always be a whole number. Notwithstanding the forgoing, any adjustments made pursuant to this Section&#160;4(c) shall be subject to any prior approvals as may be required of any relevant stock exchanges on which the Company&#8217;s securities are then traded or any other applicable regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;<span style="text-decoration: underline">Section&#160;162(m) Award Limitations Under the Plan</span>. No Eligible Person may be granted any Award or Awards under the Plan which is intended to represent &#8220;qualified performance based compensation&#8221; with the meaning of Section&#160;162(m) of the Code, for more than one million (1,000,000) Shares (subject to adjustment as provided for in Section&#160;4(c) of the Plan), in the aggregate in any taxable year. No Eligible Person shall be granted, during any one (1) calendar year period, Options and Stock Appreciation Rights with respect to more than one million (1,000,000) Shares (subject to adjustment as provided for in Section&#160;4(c) of the Plan) in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;<span style="text-decoration: underline">Prior Plan</span>. Pursuant to Section&#160;11 of the Prior Plan, (i) no new awards may be granted under the Prior Plan after March&#160;15, 2017, and (ii) all awards granted under the Prior Plan will remain outstanding and will continue to be governed by the Prior Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 5.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Eligibility</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Eligible Person shall be eligible to be designated a Participant. In determining which Eligible Persons shall receive an Award and the terms of any Award, the Committee may take into account the nature of the services rendered by the respective Eligible Persons, their present and potential contributions to the success of the Company or such other factors as the Committee, in its discretion, shall deem relevant. Notwithstanding the foregoing, an Incentive Stock Option may only be granted to full-time or part-time employees (which term as used herein includes, without limitation, officers and directors who are also employees), and an Incentive Stock Option shall not be granted to an employee of an Affiliate unless such Affiliate is also a &#8220;subsidiary corporation&#8221; of the Company within the meaning of Section&#160;424(f) of the Code or any successor provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 6.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;<span style="text-decoration: underline">Options</span>. The Committee is hereby authorized to grant Options to Eligible Persons with the following terms and conditions and with such additional terms and conditions, not inconsistent with the provisions of the Plan, as the Committee shall determine as set forth in an Award Agreement:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;<span style="text-decoration: underline">Exercise Price</span>. The purchase price per Share purchasable under an Option shall be determined by the Committee; <i>provided, however</i>, that such purchase price shall not be less than one hundred percent (100%) of the Fair Market Value of a Share on the date of grant of such Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;<span style="text-decoration: underline">Option Term</span>. The term of each Option shall be fixed by the Committee at the time of grant, but shall not be longer than ten (10) years from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;<span style="text-decoration: underline">Time and Method of Exercise</span>. The Committee shall determine the time or times at which an Option may be exercised in whole or in part and the method or methods by which, and the form or forms (including, without limitation, cash, Shares, or promissory notes (<i>provided</i>, <i>however</i>, that the par value of any Shares to be issued pursuant to such exercise shall be paid in the form of cash, services rendered, personal property, real property or a combination thereof and the acceptance of such promissory notes does not conflict with Section&#160;402 of the Sarbanes-Oxley Act of 2002), other securities, other Awards or other property, or any combination thereof, having a Fair Market Value on the exercise date equal to the applicable exercise price) in which payment of the exercise price with respect thereto may be made or deemed to have been made. The Committee shall have the discretion to grant Options that are exercisable for unvested Shares. Should the Participant&#8217;s Service cease while the Shares issued upon the early exercise of the Participant&#8217;s Options are still unvested, the Company shall have the right to repurchase any or all of those unvested Shares at a price per share determined by the Committee. The terms upon which such repurchase right shall be exercisable (including the period and procedure for exercise and the appropriate vesting schedule for the purchased shares) shall be established by the Committee and set forth in the Award Agreement. Any repurchases must be made in compliance with the relevant provisions of Delaware law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#160;<span style="text-decoration: underline">Incentive Stock Options</span>. Notwithstanding anything in the Plan to the contrary, the following additional provisions shall apply to the grant of Options which are intended to qualify as Incentive Stock Options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)&#160;The Committee will not grant Incentive Stock Options in which the aggregate Fair Market Value (determined as of the time the Incentive Stock Option is granted) of the Shares with respect to which Incentive Stock Options are exercisable for the first time by any Participant during any calendar year (under this Plan and all other plans of the Company and its Affiliates) shall exceed One Hundred Thousand Dollars ($100,000).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)&#160;All Incentive Stock Options must be granted within ten (10) years from the earlier of the date on which this Plan was adopted by the Board or the date this Plan was approved by the shareholders of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)&#160;Unless sooner exercised, all Incentive Stock Options shall expire and no longer be exercisable no later than ten (10) years after the date of grant; <i>provided, however</i>, that in the case of a grant of an Incentive Stock Option to a Participant who, at the time such Option is granted, owns (within the meaning of Section&#160;422 of the Code) stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of its Affiliate, such Incentive Stock Option shall expire and no longer be exercisable no later than five (5) years from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)&#160;The purchase price per Share for an Incentive Stock Option shall be not less than one hundred percent (100%) of the Fair Market Value of a Share on the date of grant of the Incentive Stock Option; <i>provided, however</i>, that, in the case of the grant of an Incentive Stock Option to a Participant who, at the time such Option is granted, owns (within the meaning of Section&#160;422 of the Code) stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of its Affiliate, the purchase price per Share purchasable under an Incentive Stock Option shall be not less than one hundred ten percent (110%) of the Fair Market Value of a Share on the date of grant of the Inventive Stock Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(E)&#160;Any Incentive Stock Option authorized under the Plan shall contain such other provisions as the Committee shall deem advisable, but shall in all events be consistent with and contain all provisions required in order to qualify the Option as an Incentive Stock Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;<span style="text-decoration: underline">Stock Appreciation Rights</span>. The Committee is hereby authorized to grant Stock Appreciation Rights to Eligible Persons subject to the terms of the Plan and any applicable Award Agreement. Each Stock Appreciation Right granted under the Plan shall confer on the holder upon exercise the right to receive, as determined by the Committee, cash or a number of Shares equal to the excess of (a) the Fair Market Value of one Share on the date of exercise (or, if the Committee shall so determine, at any time during a specified period before or after the date of exercise) over (b) the grant price of the Stock Appreciation Right as determined by the Committee, which grant price shall not be less than one hundred (100%) of the Fair Market Value of one Share on the date of grant of the Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appreciation Right. Subject to the terms of the Plan, the grant price, term, methods of exercise, dates of exercise, methods of settlement and any other terms and conditions (including conditions or restrictions on the exercise thereof) of any Stock Appreciation Right shall be as determined by the Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;<span style="text-decoration: underline">Restricted Stock and Restricted Stock Units</span>. The Committee is hereby authorized to grant Restricted Stock and Restricted Stock Units to Eligible Persons with the following terms and conditions and with such additional terms and conditions not inconsistent with the provisions of the Plan as the Committee shall determine:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;<span style="text-decoration: underline">Restrictions</span>. Shares of Restricted Stock and Restricted Stock Units shall be subject to such restrictions as the Committee may impose (including, without limitation, a restriction on or prohibition against the right to receive any dividend or other right or property with respect thereto), which restrictions may lapse separately or in combination at such time or times, in such installments or otherwise as the Committee may deem appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;<span style="text-decoration: underline">Issuance of Shares</span>. Any Restricted Stock granted under the Plan may be evidenced in such manner as the Board may deem appropriate, including book-entry registration or issuance of a stock certificate or certificates, which certificate or certificates shall be held by the Company. Such certificate or certificates shall be registered in the name of the Participant and shall bear an appropriate legend referring to the restrictions applicable to such Restricted Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;<span style="text-decoration: underline">Forfeiture</span>. Except as otherwise determined by the Committee, upon a Participant&#8217;s termination of employment or resignation or removal as a director, as the case may be (all as determined under criteria established by the Committee), during the applicable restriction period, all Shares of Restricted Stock and Restricted Stock Units at such time subject to restriction shall be forfeited and reacquired by the Company; <i>provided, however</i>, that the Committee may, when it finds that a waiver would be in the best interest of the Company, waive in whole or in part any or all remaining restrictions with respect to Shares of Restricted Stock or Restricted Stock Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;<span style="text-decoration: underline">Performance Awards</span>. The Committee is hereby authorized to grant Performance Awards to Eligible Persons subject to the terms of the Plan. A Performance Award granted under the Plan (i) may be denominated or payable in cash, Shares (including, without limitation, Restricted Stock and Restricted Stock Units), other securities, other Awards or other property and (ii) shall confer on the holder thereof the right to receive payments, in whole or in part, upon the achievement of such Performance Goals during such Performance Periods as the Committee shall establish. Subject to the terms of the Plan, the Performance Goals to be achieved during any Performance Period, the length of any Performance Period, the amount of any Performance Award granted, the amount of any payment or transfer to be made pursuant to any Performance Award and any other terms and conditions of any Performance Award shall be determined by the Committee. From time to time, the Committee may designate an Award granted pursuant to the Plan as an award of &#8220;qualified performance-based compensation&#8221; within the meaning of Section&#160;162(m) (a &#8220;<i>Qualified Performance Based Award</i>&#8221;). Qualified Performance Based Awards shall, to the extent required by Section&#160;162(m), be conditioned solely on the achievement of one or more objective Performance Goals, and such Performance Goals shall be established by the Committee within the time period prescribed by, and shall otherwise comply with the requirements of, Section&#160;162(m). Following the completion of a Performance Period, the Committee shall review and certify in writing whether, and to what extent, such Performance Goals for the Performance Period have been met and, if so calculate and certify the amount of the Qualified Performance Based Awards for each Participant prior to payment of the Qualified Performance Based Awards to the extent required by Section&#160;162(m). In determining the actual amount of each Participant&#8217;s Qualified Performance Based Award, the Committee may exercise Negative Discretion, if and when it deems appropriate, to reduce or eliminate (but not increase) the amount of the Qualified Performance Based Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;<span style="text-decoration: underline">Dividend Equivalents</span>. The Committee is hereby authorized to grant Dividend Equivalents to Eligible Persons under which the Participant shall be entitled to receive payments (in cash, Shares, other securities, other Awards or other property as determined in the discretion of the Committee) equivalent to the amount of cash dividends paid by the Company to holders of Shares with respect to a number of Shares determined by the Committee. Subject to the terms of the Plan, such Dividend Equivalents may have such terms and conditions as the Committee shall determine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;<span style="text-decoration: underline">Other Stock Grants</span>. The Committee is hereby authorized, subject to the terms of the Plan, to grant to Eligible Persons Shares without restrictions thereon as are deemed by the Committee to be consistent with the purpose of the Plan. Subject to the terms of the Plan and any applicable Award Agreement, such Other Stock Grant may have such terms and conditions as the Committee shall determine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;<span style="text-decoration: underline">Other Stock-Based Awards</span>. The Committee is hereby authorized to grant to Eligible Persons, subject to the terms of the Plan, such other Awards that are denominated or payable in, valued in whole or in part by reference to, or otherwise based on or related to, Shares (including, without limitation, securities convertible into Shares), as are deemed by the Committee to be consistent with the purpose of the Plan. Shares or other securities delivered pursuant to a purchase right granted under this Section&#160;6(g) shall be purchased for such consideration, which may be paid by such method or methods and in such form or forms (including, without limitation, cash, Shares, or promissory notes (<i>provided</i>, <i>however</i>, that the par value of any Shares to be issued pursuant to such exercise shall be paid in the form of cash, services rendered, personal property, real property or a combination thereof and the acceptance of such promissory notes does not conflict with Section&#160;402 of the Sarbanes-Oxley Act of 2002), other securities, other Awards or other property or any combination thereof), as the Committee shall determine, the value of which consideration, as established by the Committee, shall not be less than one hundred percent (100%) of the Fair Market Value of such Shares or other securities as of the date such purchase right is granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#160;<span style="text-decoration: underline">General</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;<span style="text-decoration: underline">Consideration for Awards</span>. Awards may be granted for no cash consideration or for any cash or other consideration as determined by the Committee and required by applicable law and any applicable stock exchange rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;<span style="text-decoration: underline">Awards May Be Granted Separately or Together</span>. Awards may, in the discretion of the Committee, be granted either alone or in addition to, in tandem with or in substitution for any other Award or any award granted under any other plan of the Company or any Affiliate. Awards granted in addition to or in tandem with other Awards or in addition to or in tandem with awards granted under any such other plan of the Company or any Affiliate may be granted either at the same time as or at a different time from the grant of such other Awards or awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;<span style="text-decoration: underline">Forms of Payment under Awards</span>. Subject to the terms of the Plan and of any applicable Award Agreement, payments or transfers to be made by the Company or an Affiliate upon the grant, exercise or payment of an Award may be made in such form or forms as the Committee shall determine (including, without limitation, cash, Shares, or promissory notes (<i>provided, however</i>, that the acceptance of such promissory notes does not conflict with Section&#160;402 of the Sarbanes-Oxley Act of 2002), other securities, other Awards or other property or any combination thereof), and may be made in a single payment or transfer, in installments or on a deferred basis, in each case in accordance with rules and procedures established by the Committee. Such rules and procedures may include, without limitation, provisions for the payment or crediting of reasonable interest on installment or deferred payments or the grant or crediting of Dividend Equivalents with respect to installment or deferred payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#160;<span style="text-decoration: underline">Limits on Transfer of Awards</span>. No Award (other than Other Stock Grants) and no right under any such Award shall be transferable by a Participant other than by will or by the laws of descent and distribution and the Company shall not be required to recognize any attempted assignment of such rights by any Participant; <i>provided, however</i>, that, if so determined by the Committee, a Participant may, in the manner established by the Committee, designate a beneficiary or beneficiaries to exercise the rights of the Participant and receive any property distributable with respect to any Award upon the death of the Participant; provided, further, that, if so determined by the Committee, a Participant may, at any time that such Participant holds such Option, transfer a Non-Qualified Stock Option to any &#8220;Family Member&#8221; (as such term is defined in the General Instructions to Form S-8 (or any successor to such Instructions or such Form) under the Securities Act), provided that the Participant may not receive any consideration for such transfer, the Family Member may not make any subsequent transfers other than by will or by the laws of descent and distribution and the Company receives written notice of such transfer. Except as otherwise determined by the Committee, each Award (other than an Incentive Stock Option) or right under any such Award shall be exercisable during the Participant&#8217;s lifetime only by the Participant or, if permissible under applicable law, by the Participant&#8217;s</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">guardian or legal representative. Except as otherwise determined by the Committee, no Award (other than an Incentive Stock Option) or right under any such Award may be pledged, alienated, attached or otherwise encumbered, and any purported pledge, alienation, attachment or other encumbrance thereof shall be void and unenforceable against the Company or any Affiliate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&#160;<span style="text-decoration: underline">Black-Out Periods</span>. Except for Incentive Stock Options issued pursuant to Section&#160;6(a)(iv), if an Award expires during, or within five (5) business days after, a trading black-out period imposed by the Company to restrict trades in the Company&#8217;s securities, then, notwithstanding any other provision of the Plan, the Award shall expire ten (10) business days after the trading black-out period is lifted by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&#160;<span style="text-decoration: underline">Term of Awards</span>. Subject to Sections&#160;6(a)(iv)(C) and 6(h)(v), the term of each Award shall be fixed by the Committee at the time of grant, but shall not be longer than ten (10) years from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)&#160;<span style="text-decoration: underline">Restrictions; Securities Exchange Listing</span>. All Shares or other securities delivered under the Plan pursuant to any Award or the exercise thereof shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan, applicable federal or state securities laws and regulatory requirements, and the Committee may direct appropriate stop transfer orders and cause other legends to be placed on the certificates for such Shares or other securities to reflect such restrictions. If the Shares or other securities are traded on a securities exchange, the Company shall not be required to deliver any Shares or other securities covered by an Award unless and until such Shares or other securities have been and continue to be admitted for trading on such securities exchange. No Shares or other assets shall be issued or delivered pursuant to the Plan unless and until there shall have been compliance with all applicable requirements of applicable securities laws, including the filing and effectiveness of the Form S-8 registration statement for the Shares issuable pursuant to the Plan, and all applicable listing requirements of any stock exchange or trading system on which Common Stock is then traded. No Shares shall be issued or delivered pursuant to the Plan if doing so would violate any internal policies of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)&#160;<span style="text-decoration: underline">Prohibition on Repricing</span>. Except as provided in Section&#160;4(c) of the Plan, no Option or Stock Appreciation Right may be amended to reduce its initial exercise or grant price and no Option or Stock Appreciation Right shall be canceled and replaced with Options or Stock Appreciation Rights having a lower exercise or grant price, without the approval of the shareholders of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amendment and Termination; Adjustments</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;<span style="text-decoration: underline">Amendments to the Plan</span>. The Board may amend, alter, suspend, discontinue or terminate the Plan at any time; <i>provided, however</i>, that, notwithstanding any other provision of the Plan or any Award Agreement, without the approval of the shareholders of the Company, no such amendment, alteration, suspension, discontinuation or termination shall be made that, absent such approval:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;violates the rules or regulations of the National Association of Securities Dealers, Inc. or any other securities exchange that are applicable to the Company;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;causes the Company to be unable, under the Code, to grant Incentive Stock Options under the Plan;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;increases the number of shares authorized under the Plan as specified in Section&#160;4(a);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#160;permits the award of Options or Stock Appreciation Rights at a price less than one hundred percent (100%) of the Fair Market Value of a Share on the date of grant of such Option or Stock Appreciation Right, as prohibited by Sections&#160;6(a)(i) and 6(b) of the Plan or the repricing of Options or Stock Appreciation Rights, as prohibited by Section&#160;6(h)(vii) of the Plan;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&#160;would prevent the grant of Options or Stock Appreciation Rights that would qualify under Section&#160;162(m) of the Code; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&#160;increase the aggregate number of Common Shares in respect of which Awards have been granted and remain outstanding so as to result in: (A) the number of Common Shares reserved for issuance to Insiders pursuant to Awards exceeding ten percent (10%) of the issued and outstanding Common Shares or (B) the issuance to Insiders pursuant to Awards, within a one-year period, of a number of Common Shares exceeding 10% of the issued and outstanding Common Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;<span style="text-decoration: underline">Amendments to Awards</span>. The Committee may waive any conditions of, or rights of the Company under, any outstanding Award, prospectively or retroactively. Except as otherwise provided herein or in an Award Agreement, the Committee may not amend, alter, suspend, discontinue or terminate any outstanding Award, prospectively or retroactively, if such action would adversely affect the rights of the holder of such Award, without the consent of the Participant or holder or beneficiary thereof. Notwithstanding the foregoing, the Committee shall not waive any conditions or rights of the Company, or otherwise amend or alter any outstanding Qualified Performance Based Award in such a manner as to cause such Award not to constitute &#8220;qualified performance based compensation&#8221; within the meaning of Section&#160;162(m) of the Code. Notwithstanding the forgoing, no amendments shall be made to any granted Awards to (i) reduce the exercise price of any Option, or cancel and reissue any Options so as to in effect reduce the exercise price of Options, for the benefit of Insiders or (ii) extend the termination date beyond the original expiration date for the benefit of Insiders without first obtaining approval of the shareholders in accordance with the requirements of applicable stock exchange rules; and no action shall be taken with respect to granted Options without the consent of the optionee, unless the Board determines that such action does not materially alter or impair such Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;<span style="text-decoration: underline">Correction of Defects, Omissions and Inconsistencies</span>. The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any Award or Award Agreement in the manner and to the extent it shall deem desirable to implement or maintain the effectiveness of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 8.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income Tax Withholding</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to comply with all applicable federal, state or local income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that all applicable federal, state or local payroll, withholding, income or other taxes, which are the sole and absolute responsibility of a Participant, are withheld or collected from such Participant. In order to assist a Participant in paying all or a portion of the federal, state and local taxes to be withheld or collected upon exercise or receipt of (or the lapse of restrictions relating to) an Award, the Committee, in its discretion and subject to such additional terms and conditions as it may adopt, may permit the Participant to satisfy such tax obligation by (i) electing to have the Company withhold a portion of the Shares otherwise to be delivered upon exercise or receipt of (or the lapse of restrictions relating to) such Award with a Fair Market Value equal to the amount of such taxes (but only to the extent of the minimum amount required to be withheld under applicable laws or regulations) or (ii) delivering to the Company Shares other than Shares issuable upon exercise or receipt of (or the lapse of restrictions relating to) such Award with a Fair Market Value equal to the amount of such taxes (but only to the extent of the minimum amount required to be withheld under applicable laws or regulations prior to the Company&#8217;s adoption of ASO 2016-09 (<i>Compensation &#8211; Stock Compensation Topic 718</i> dated March, 2016). The election, if any, must be made on or before the date that the amount of tax to be withheld is determined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 9.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General Provisions</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;<span style="text-decoration: underline">No Rights to Awards</span>. No Eligible Person or other Person shall have any claim to be granted any Award under the Plan, and there is no obligation for uniformity of treatment of Eligible Persons or holders or beneficiaries of Awards under the Plan. The terms and conditions of Awards need not be the same with respect to any Participant or with respect to different Participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;<span style="text-decoration: underline">Award Agreements</span>. No Participant will have rights under an Award granted to such Participant unless and until an Award Agreement shall have been duly executed on behalf of the Company and, if requested by the Company, signed by the Participant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;<span style="text-decoration: underline">Plan Provisions Control</span>. In the event that any provision of an Award Agreement conflicts with or is inconsistent in any respect with the terms of the Plan as set forth herein or subsequently amended, the terms of the Plan shall control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;<span style="text-decoration: underline">No Rights of Shareholders</span>. Except with respect to Shares of Restricted Stock as to which the Participant has been granted the right to vote, neither a Participant nor the Participant&#8217;s legal representative shall be, or have any of the rights and privileges of, a shareholder of the Company with respect to any Shares issuable to such Participant upon the exercise or payment of any Award, in whole or in part, unless and until such Shares have been issued in the name of such Participant or such Participant&#8217;s legal representative without restrictions thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;<span style="text-decoration: underline">No Limit on Other Compensation Arrangements</span>. Nothing contained in the Plan shall prevent the Company or any Affiliate from adopting or continuing in effect other or additional compensation arrangements, and such arrangements may be either generally applicable or applicable only in specific cases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;<span style="text-decoration: underline">No Right to Employment</span>. The grant of an Award shall not be construed as giving a Participant the right to be retained in the employ, or as giving a director of the Company or an Affiliate the right to continue as a director or an Affiliate of the Company or any Affiliate, nor will it affect in any way the right of the Company or an Affiliate to terminate a Participant&#8217;s employment or service at any time, with or without cause. In addition, the Company or an Affiliate may at any time dismiss a Participant from employment, or terminate the term of a director of the Company or an Affiliate, free from any liability or any claim under the Plan or any Award, unless otherwise expressly provided in the Plan or in any Award Agreement. Nothing in this Plan shall confer on any person any legal or equitable right against the Company or any Affiliate, directly or indirectly, or give rise to any cause of action at law or in equity against the Company or an Affiliate. The Awards granted hereunder shall not form any part of the wages or salary of any Eligible Person for purposes of severance pay or termination indemnities, irrespective of the reason for termination of employment. Under no circumstances shall any person ceasing to be an employee of the Company or any Affiliate be entitled to any compensation for any loss of any right or benefit under the Plan which such employee might otherwise have enjoyed but for termination of employment, whether such compensation is claimed by way of damages for wrongful or unfair dismissal, breach of contract or otherwise. By participating in the Plan, each Participant shall be deemed to have accepted all the conditions of the Plan and the terms and conditions of any rules and regulations adopted by the Committee and shall be fully bound thereby.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;<span style="text-decoration: underline">Governing Law</span>. The validity, construction and effect of the Plan or any Award, and any rules and regulations relating to the Plan or any Award, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#160;<span style="text-decoration: underline">Severability</span>. If any provision of the Plan or any Award is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the purpose or intent of the Plan or the Award, such provision shall be stricken as to such jurisdiction or Award, and the remainder of the Plan or any such Award shall remain in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;<span style="text-decoration: underline">No Trust or Fund Created</span>. Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Affiliate and an Eligible Person or any other Person. To the extent that any Person acquires a right to receive payments from the Company or any Affiliate pursuant to an Award, such right shall be no greater than the right of any unsecured general creditor of the Company or any Affiliate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#160;<span style="text-decoration: underline">Other Benefits</span>. No compensation or benefit awarded to or realized by any Participant under the Plan shall be included for the purpose of computing such Participant&#8217;s compensation under any compensation-based retirement, disability, or similar plan of the Company unless required by law or otherwise provided by such other plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#160;<span style="text-decoration: underline">No Fractional Shares</span>. No fractional Shares shall be issued or delivered pursuant to the Plan or any Award, and the Committee shall determine whether cash shall be paid in lieu of any fractional Shares or whether such fractional Shares or any rights thereto shall be canceled, terminated or otherwise eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&#160;<span style="text-decoration: underline">Headings</span>. Headings are given to the Sections and subsections of the Plan solely as a convenience to facilitate reference. Such headings shall not be deemed in any way material or relevant to the construction or interpretation of the Plan or any provision thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#160;<span style="text-decoration: underline">Section&#160;16 Compliance; Section&#160;162(m) Administration</span>. The Plan is intended to comply in all respects with Rule&#160;16b-3 or any successor provision, as in effect from time to time, and in all events the Plan shall be construed in accordance with the requirements of Rule&#160;16b-3. If any Plan provision does not comply with Rule&#160;16b-3 as hereafter amended or interpreted, the provision shall be deemed inoperative. The Board of Directors, in its absolute discretion, may bifurcate the Plan so as to restrict, limit or condition the use of any provision of the Plan with respect to persons who are officers or directors subject to Section&#160;16 of the Exchange Act without so restricting, limiting or conditioning the Plan with respect to other Eligible Persons. With respect to Options and Stock Appreciation Rights, the Company intends to have the Plan administered in accordance with the requirements for the award of &#8220;qualified performance-based compensation&#8221; within the meaning of Section&#160;162(m) of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&#160;<span style="text-decoration: underline">Conditions Precedent to Issuance of Shares</span>. Shares shall not be issued pursuant to the exercise or payment of the purchase price relating to an Award unless such exercise or payment and the issuance and delivery of such Shares pursuant thereto shall comply with all relevant provisions of law, including, without limitation, the Securities Act, the Exchange Act, the rules and regulations promulgated thereunder, the requirements of any applicable stock exchange and the Delaware General Corporation Law. As a condition to the exercise or payment of the purchase price relating to such Award, the Company may require that the person exercising or paying the purchase price represent and warrant that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation and warranty is required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 10.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term of the Plan</b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Award shall be granted under the Plan after (a) June&#160;2, 2027, or (b) any earlier date of discontinuation or termination established pursuant to Section&#160;7(a) of the Plan. However, unless otherwise expressly provided in the Plan or in an applicable Award Agreement, any Award theretofore granted may extend beyond such date, and the authority of the Committee provided for hereunder with respect to the Plan and any Awards, and the authority of the Board to amend the Plan, shall extend beyond the termination of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; width: 50%; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Board Approval:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; width: 50%; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;22, 2017</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Shareholder Approval:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&#160;2, 2017 (Effective Date of Plan)</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Annex B</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TO THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC. 2017 OMNIBUS INCENTIVE PLAN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, NovaBay Pharmaceuticals, Inc., a Delaware corporation, (the &#8220;<b>Company</b>&#8221;), established and sponsors the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan, as amended (the &#8220;<b>Plan</b>&#8221;);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, pursuant to Section&#160;7(a) of the Plan, the Board of Directors of the Company (the &#8220;<b>Board</b>&#8221;) reserved the right to amend the Plan at any time;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, as a result of the one-for-thirty five reverse stock splits of the common stock, $0.01 par value per share, of the Company (the &#8220;<b>Stock</b>&#8221;) on November&#160;15, 2022 and on May&#160;30, 2024, and Section&#160;4(c) of the Plan, the aggregate number of remaining shares of Stock reserved and available for issuance under Section&#160;4(a) of the Plan, after automatic annual increases in accordance with Section&#160;4(a) of the Plan, is 14,332 shares of Stock;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, the Board desires to amend the Plan to add an additional 1,000,000 shares of Stock for issuance under Section&#160;4(a) of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOW</b>, <b>THEREFORE</b>, pursuant to the power reserved by Section&#160;7(a) of the Plan, on September&#160;5, 2025 the Board amended the Plan as follows, subject to and effective upon approval by the Company&#8217;s stockholders at the Annual Meeting to be held on October&#160;16, 2025 (the &#8220;<b>2025 Annual Meeting</b>&#8221;). Defined terms used herein, but not otherwise defined in this Amendment, shall have the meanings ascribed to them in the Plan:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&#160;4(a) of the Plan, containing the aggregate number of shares of Stock reserved and available for issuance pursuant to Awards granted under the Plan, is hereby amended by substituting &#8220;1,021,332&#8221; for &#8220;2,318,486&#8221; throughout Section&#160;4(a).</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IN WITNESS WHEREOF</b>, this Amendment, having been first duly authorized, approved and adopted by the Board, and approved by the Company&#8217;s stockholders at the 2025 Annual Meeting, is hereby executed below by a duly authorized officer of the Company on this____day of _____________, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; width: 50%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 5%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 45%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; vertical-align: bottom">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; vertical-align: bottom">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 120; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Annex C</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTIFICATE OF AMENDMENT OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b>, a corporation organized and existing under, and by virtue of, the General Corporation Law of the State of Delaware, hereby certifies that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIRST</b>: The name of the Corporation is NovaBay Pharmaceuticals, Inc. (the &#8220;<b>Corporation</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECOND</b>: The Corporation was originally incorporated under the same name and the original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on April&#160;19, 2010.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THIRD</b>: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections&#160;141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending and restating Paragraph C of Article IV of the Certificate of Incorporation to read in its entirety as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote; <i>provided</i>, <i>however</i>, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to this Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At 4:15 p.m. New York City Time on _________, ____ (the &#8220;<b>Effective Time</b>&#8221;), each _______ (__) shares of Common Stock outstanding or held in treasury (collectively, the &#8220;<b>Old Common Stock</b>&#8221;) shall be combined and converted into one (1) share of Common Stock (the &#8220;<b>New Common Stock</b>&#8221;). This reverse stock split (the &#8220;<b>Reverse Split</b>&#8221;) of the shares of Common Stock shall outstanding or held in treasury not affect the total number of shares of capital stock, including the Common Stock, that the Corporation is authorized to issue, which shall remain as set forth under this Article IV.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Reverse Split shall occur without any further action on the part of the Corporation or the holders of shares of New Common Stock and whether or not certificates representing such holders&#8217; shares prior to the Reverse Split are surrendered for cancellation. No fractional interest in a share of New Common Stock shall be deliverable upon the Reverse Split, all of which shares of New Common Stock shall be rounded up to the nearest whole number of such shares. All references to &#8220;Common Stock&#8221; in these Articles shall be to the New Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Reverse Split will be effectuated on a stockholder-by-stockholder basis. Certificates dated as of a date prior to the Effective Time representing shares of Old Common Stock shall, after the Effective Time, represent a number of shares equal to the same number of shares of New Common Stock as is reflected on the face of such certificates, divided by _______ (__) and rounded up to the nearest whole number. The Corporation shall not be obligated to issue new certificates evidencing the shares of New Common Stock outstanding or held in treasury as a result of the Reverse Split unless and until the certificates evidencing the shares held by a holder prior to the Reverse Split are either delivered to the Corporation or its transfer agent, or the holder notifies the</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 121; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporation or its transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in connection with such certificates.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOURTH</b>: Also pursuant to a resolution of the Board of Directors, thereafter this Certificate of Amendment was submitted to the stockholders of the Corporation for their approval, and was duly adopted at the Annual Meeting of Stockholders held on October&#160;16, 2025, in accordance with the provisions of Section&#160;242 of the General Corporation Law of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIFTH</b>: All other provisions of the Certificate of Incorporation shall remain in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IN WITNESS WHEREOF</b>, <b>NOVABAY PHARMACEUTICALS, INC.</b> has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this____day of__________, ______.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">Name:</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&#160;</td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; width: 5%">Title:</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; width: 45%">&#160;</td>
    <td style="text-align: left; width: 50%">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Annex D</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTIFICATE OF AMENDMENT OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b>, a corporation organized and existing under, and by virtue of, the General Corporation Law of the State of Delaware, hereby certifies that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIRST</b>: The name of the Corporation is NovaBay Pharmaceuticals, Inc. (the &#8220;<b>Corporation</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECOND</b>: The Corporation was originally incorporated under the same name and the original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on April&#160;19, 2010.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THIRD</b>: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections&#160;141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending and restating Paragraph A of Article IV of the Certificate of Incorporation to read in its entirety as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;A. This Corporation is authorized to issue two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock.&#8221; The total number of shares which the Corporation is authorized to issue is One Billion Five Hundred Five Million (1,505,000,000) shares. One Billion Five Hundred Million (1,500,000,000) shares shall be Common Stock, each having a par value of one cent ($0.01) per share. Five Million (5,000,000) shares shall be Preferred Stock, each having a par value of one cent ($0.01) per share.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOURTH</b>: Also pursuant to a resolution of the Board of Directors, thereafter this Certificate of Amendment was submitted to the stockholders of the Corporation for their approval, and was duly adopted at the Annual Meeting of Stockholders held on October&#160;16, 2025, in accordance with the provisions of Section&#160;242 of the General Corporation Law of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIFTH</b>: All other provisions of the Certificate of Incorporation shall remain in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IN WITNESS WHEREOF</b>, <b>NOVABAY PHARMACEUTICALS, INC.</b> has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this____day of__________, ______.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">Name:</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&#160;</td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; width: 5%">Title:</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; width: 45%">&#160;</td>
    <td style="text-align: left; width: 50%">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 123; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Annex E</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTIFICATE OF AMENDMENT OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b>, a corporation organized and existing under, and by virtue of, the General Corporation Law of the State of Delaware, hereby certifies that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIRST</b>: The name of the Corporation is NovaBay Pharmaceuticals, Inc. (the &#8220;<b>Corporation</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECOND</b>: The Corporation was originally incorporated under the same name and the original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on April&#160;19, 2010.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THIRD</b>: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections&#160;141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending and restating Paragraph A of Article IV of the Certificate of Incorporation to read in its entirety as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;A. This Corporation is authorized to issue two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock.&#8221; The total number of shares which the Corporation is authorized to issue is One Hundred Sixty Million (160,000,000) shares. One Hundred Fifty Million (150,000,000) shares shall be Common Stock, each having a par value of one cent ($0.01) per share. Ten Million (10,000,000) shares shall be Preferred Stock, each having a par value of one cent ($0.01) per share.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOURTH</b>: Also pursuant to a resolution of the Board of Directors, thereafter this Certificate of Amendment was submitted to the stockholders of the Corporation for their approval, and was duly adopted at the Annual Meeting of Stockholders held on October&#160;16, 2025, in accordance with the provisions of Section&#160;242 of the General Corporation Law of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIFTH</b>: All other provisions of the Certificate of Incorporation shall remain in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IN WITNESS WHEREOF</b>, <b>NOVABAY PHARMACEUTICALS, INC.</b> has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this____day of__________, ______.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">Name:</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&#160;</td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; width: 5%">Title:</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; width: 45%">&#160;</td>
    <td style="text-align: left; width: 50%">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 124; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Annex F</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTIFICATE OF AMENDMENT OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b>, a corporation organized and existing under, and by virtue of, the General Corporation Law of the State of Delaware, hereby certifies that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIRST</b>: The name of the Corporation is NovaBay Pharmaceuticals, Inc. (the &#8220;<b>Corporation</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECOND</b>: The Corporation was originally incorporated under the same name and the original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on April&#160;19, 2010.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THIRD</b>: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections&#160;141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending and restating Paragraph A of Article IV of the Certificate of Incorporation to read in its entirety as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;A. This Corporation is authorized to issue two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock.&#8221; The total number of shares which the Corporation is authorized to issue is One Billion Five Hundred Ten Million (1,510,000,000) shares. One Billion Five Hundred Million (1,500,000,000) shares shall be Common Stock, each having a par value of one cent ($0.01) per share. Ten Million (10,000,000) shares shall be Preferred Stock, each having a par value of one cent ($0.01) per share.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOURTH</b>: Also pursuant to a resolution of the Board of Directors, thereafter this Certificate of Amendment was submitted to the stockholders of the Corporation for their approval, and was duly adopted at the Annual Meeting of Stockholders held on October&#160;16, 2025, in accordance with the provisions of Section&#160;242 of the General Corporation Law of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIFTH</b>: All other provisions of the Certificate of Incorporation shall remain in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IN
WITNESS WHEREOF</b>, <b>NOVABAY PHARMACEUTICALS, INC.</b> has caused this Certificate of Amendment to be signed by its Chief
Executive Officer on this ____ day of __________, ______.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOVABAY PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">Name:</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&#160;</td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; width: 5%">Title:</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; width: 45%">&#160;</td>
    <td style="text-align: left; width: 50%">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 125; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="proxy_001.jpg" alt="" style="height: 971px; width: 750px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 126; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="proxy_002.jpg" alt="" style="height: 971px; width: 750px"/></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 127 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>

    <!-- Field: /Page -->


 <!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJy9Ut1qwjAUfgLfIfRatC0orHddqVLmT5FOdhvNUbO1J91JWvWR9paLKWPeDDbmFgL5Od/POSfxvL43VRNZArGn+9WMFVDVJTfAVrADAtyCRSTZQ8TsuoK91IY4Gnf8ICbKcsByxoNgY+8dspUaRMT8u6E/GoYj5o+jMGD53Otd4onCnRSARvKScRQsJ1WTBMPp3CkU/KRQVWfntAbSUmHEgoHfhd9Y6AchW6iWHxW9aDabJV6v70bPm5JqaotKTwbwwmRpCZW10x37c7psto02qorydBkLkb420pzjIycRi2cbcbw5VBsgiw38MAz82P9SZXErlUIZXv5Wx9aUA0klVAtUu11y4LiHDCdc0pqXDSx3y8ZoY59B4j5G8YgtaAPXNdzc8Vp7evlRIDLMLZg6si4O3KxdGhkWB+huf5TFTfq3+Pf+fc/xT/r3DtyxRzQ= -->

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "% K\# 2(  A$! Q$!_\0
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M HT 6BD!S2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=7KRA*R/:S\;M+_Z!UQ_WT*?!\:M+GNHK<:?<!I&"@D\<UXC5G32?[6LN?\
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MA@UMIR'#2-UD^E>]:%X:TOP[:K!I]LB8&"^.6J_96<&GV<=K:QJD,2[4459
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MHV<@9PHSQ57M'4E)O1"9D_YZR?\ ?9HS)_SVE_[[-/-M=#K:39_W#1]GNO\
MGTF_[X-)2T*M470B8%AAG9A[G-*.E2&WN0,M:R@?[AJ($$D $$=013YF]"7&
M6[0O6GVZQ/<HL\A2$\2..JCVIE'KGI[4Y*ZT%%V>I]&?#VV\/6>AK%H<Z3%@
M#*Q/SD^XKL1@\_I7RMX=U^Z\-ZO!>VS$1[QYL8/WU^E?3^GWL>HZ?!=PD%)4
M##';/:O)KTW%W9[&'J*2LCD_B;!JU[X9^Q:5;R3R2R .%'5?2O&!X%\4X_Y
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M#_AG3O#5C]ET^$(#RS'JQK"MB%:T6=%'#.]Y&G%&(HUC4815VC\*F'2FX_\
MU4X5YC=V>DE96"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #V E@# 2(  A$! Q$!_\0
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M0W]K\4;BWU-6BM=9A5[16/"@ [/Q(SD>IKL=7\36VEZMI^E")Y[^^8B*)2
MHZLQ/05QGCOP;*MMI]]H$-_<:E;3*R!I7EPG7JQXP0*7Q7J]I!JGAK5]2M+S
M3;U4=C<>29/+(',90?>R2><\"MW&,K-'.I2C=,Z6S\<Z?<VNJW4UO<6T&EED
MN))-I <'[H .2?3CFK5AXH@N]6@TR>WDMKFYM1=P*[ [T/4<=&'<5PT=IHWB
M3P7K^G>&KJ:YU2X<75P)T,;R/NST. !P0!73>$IDN[>Q:?PW-9ZA;P^5-//
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MGE-QVDD=,\?Q4S^T_BI_T!M._P"^A_\ %5Z72UK[1?RHR]F_YF>:?VG\5/\
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M<B4;];'FG]I_%3_H#:=_WT/_ (JC^T_BI_T!M._[Z'_Q5>ET57M%_*B?9O\
MF9YI_:?Q4_Z VG?]]#_XJC^T_BI_T!M._P"^A_\ %5Z711[1?RH/9O\ F9YI
M_:?Q4_Z VG?]]#_XJC^T_BI_T!M._P"^A_\ %5Z711[1?RH/9O\ F9YI_:?Q
M4_Z VG?]]#_XJC^T_BI_T!M._P"^A_\ %5Z711[1?RH/9O\ F9YI_:?Q4_Z
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M'N 2><5UNC:S9:]ID6H:?+YD$G0D8*D=01V(JVVE=P1"2;LI,X3^T_BI_P!
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M /@0O^-7_L=K_P ^T/\ W[%'V.U_Y]H?^_8H]T/>*'_"4:!_T&M/_P# A?\
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M<8),XZE"<IMH\0QBO9O@G>N^EZI8LV5AF61!Z;A@_P JL_\ "E=$_P"@C?\
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M8O\ H):M_P"!S_XT67<+OL;-%8W_  CL7_02U;_P.?\ QH_X1V+_ *"6K?\
M@<_^-%EW"[[&S16-_P ([%_T$M6_\#G_ ,:/^$=B_P"@EJW_ ('/_C19=PN^
MQLT5C?\ ".Q?]!+5O_ Y_P#&C_A'8O\ H):M_P"!S_XT67<+OL;-%8W_  CL
M7_02U;_P.?\ QH_X1V+_ *"6K?\ @<_^-%EW"[[&S16-_P ([%_T$M6_\#G_
M ,:/^$=B_P"@EJW_ ('/_C19=PN^QLT5C?\ ".Q?]!+5O_ Y_P#&C_A'8O\
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ML\5?\]]'_P"_4O\ \51L\5?\]]'_ ._4O_Q5%O,+FY16'L\5?\]]'_[]2_\
MQ5&SQ5_SWT?_ +]2_P#Q5%O,+FY16'L\5?\ /?1_^_4O_P 51L\5?\]]'_[]
M2_\ Q5%O,+FY16'L\5?\]]'_ ._4O_Q5&SQ5_P ]]'_[]2__ !5%O,+FY16'
ML\5?\]]'_P"_4O\ \51L\5?\]]'_ ._4O_Q5%O,+FY16'L\5?\]]'_[]2_\
MQ5&SQ5_SWT?_ +]2_P#Q5%O,+FY16'L\5?\ /?1_^_4O_P 51L\5?\]]'_[]
M2_\ Q5%O,+FY16'L\5?\]]'_ ._4O_Q5&SQ5_P ]]'_[]2__ !5%O,+FY16'
ML\4]Y]'_ ._4O_Q5%%O,+FY1112&%%%% !1110 4E+10!F7OAW1M1R;S2[.8
MGJ7A7)_&L*X^&'A&XR?[*$1/>*5U_K78452G);,EPB]T<,/A)X3!S]FN3[?:
M&J_;?#?PE:D,NC1.P[RLS_H3BNJHI^TF^HO9P[%*RTG3M.&+*QMK?WBB"G]*
MNT45%VRDK!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \JE^-
M=K%-)'_8=P=C%<_:%['Z4W_A=UK_ - *X_\  A?\*\BNO^/R?_KHW\S4->K]
M6I]CS/K%3N>Q_P#"[K7_ * 5Q_X$+_A1_P +NM?^@%<?^!"_X5XY11]6I]A?
M6*G<]C_X7=:_] *X_P# A?\ "C_A=UK_ - *X_\  A?\*\<HH^K4^P?6*G<]
MC_X7=:_] *X_\"%_PH_X7?:_] *X_P# A?\ "O'*='&\LB1QJ6D=@JJ.Y/ H
M^K4^P_K%3N>P_P#"[K7_ * 5Q_X$+_A1_P +OM?^@%<?^!"_X5RNK>&O#VA6
M#?VA%KBW@CP"8@L3R8Z!L=,UG6?AB!=.T.YOY)=VKW/E1B,@>4G0-R.3D]/2
MLU3HM7L:.I53M<[O_A=UK_T KC_P(7_"C_A=]K_T KC_ ,"%_P *\JUG2Y=%
MUFZTV9@SV[E=P& P['\JW+/PI -.T.YOY)0VKW/E1K&0/*3LQR.23V]*;HT4
MKDJK5;L=S_PNZU_Z 5Q_X$+_ (4?\+OM?^@%<?\ @0O^%<+;^$#%J6OP7\K>
M7H\#3,(^#-_=QGH#UJ#7?"[Z?JVG6EBS3#4($FA5OO+NZ@GT'KZ4*E1O8;J5
MDKGH/_"[[7_H!7'_ ($+_A1_PNZU_P"@%<?^!"_X5Y/J45I!?/!8RM-%& AE
M;I(P^\1Z+GI52K6'IOH0\1474]C_ .%W6O\ T KC_P "%_PH_P"%W6O_ $ K
MC_P(7_"O'**/JU/L+ZQ4[GL?_"[K7_H!7'_@0O\ A1_PNZU_Z 5Q_P"!"_X5
MXY11]6I]@^L5.Y['_P +NM?^@%<?^!"_X4?\+NM?^@%<?^!"_P"%>.44?5J?
M8?UBIW/?O"GQ,M_%.N+IB:7+;,8VD$C2AAQCC&*[ROG_ .$?_(^1?]>TO]*^
M@*X:\%"=HG90FYQNPHHHK W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH "<#)K.T37+#Q#IHU#39O.MB[QAL8Y5BI_45F>-M533=!,/VG[/-?2+
M:QR!2Q0-]]@ ">%#'ZXKCOA_J&FZ/X]UOPUILG_$KO%74-/78R*IP%E0;@/0
M&@#U6BN*CUG4M,^(UUI6K:F&TR>P:\L?W*KMV'$BLP&25&"/8\U5DUG6MNAZ
M4;Z5KS6/.N#/'#&LL4" $*H.%W89>3GOQ0!W]%>4Z]JGCGP]X2U2:XNPAMKV
M!+&\FCB,EQ#(X4K(JDA2I/4 9KH[JW\0:6;5;WQ)')93WCM=7#1K#+&A3Y(8
M@ =V7[]<4 =G17E5OXVUR/P+K-X&:>XT_6&L!=R0X:.WWJ/-= ,956.>,<9/
M>M6WU?4;3QO>VT>KRWV@VNEB^D?;&Y63)&PN!W4%@.OX4 >@50UC6;/0M/:^
MO3((0ZIB.,R,68@ !5!)))KAK"]\9W]OHGB"P>6YCO6CDNK"00I;I;N,YC;.
M_<HQU)SZ"O1)88YMGF(K;&#KD=".AH Y8?$;0S>R60@U8W42"1X!ID^]4/1B
MNW('O71:9J5MJ^G6]_9LS6\Z!XRRE21[@\BN,T[_ )+EKG_8&M__ $,U9U:_
MO+GQ.?"^E37-C'!9"\FELTC,A+N0JCS. ,@D\$\@<4 =K17EMUK'C?3XO"EO
MJES%:W=WJQLKC;$C^?%@E9#@G:2!R!WJQ_;.O65QXYTPZQ)/)I%M%>6ES+!&
M6&^-F*,  ",IZ9P: /2J*\YD\4ZTMAX O!=I_P 3J6&*]C\E=K[HRQ([J<CM
M2:3=^)=5\8>)+63Q#Y-EHU] P1+1"98RF]HSZ#!QGK0!Z/17F5IJGC+7-+T[
MQ+HSRRFXF#G3G$(MC;EB"-Q._> ,YSUXQ7>6EG?0ZM?74^I-/:3A/(M#$JBW
MP,-AARV3SSTH T:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y+N
MO^/RX_ZZ-_,U#4UU_P ?D_\ UT;^=0U[J/$84444 %%%% !5G3DNY-3MDL-W
MVQI (=I ._M@FJU*K%6#*2K Y!!P128(]%TOQ'JI?4_#OBY&DA^RRL[3K\T9
M"Y!SW!.,'UQ3FN%U#1? +P#<8KM89 .=K*1D'\!FO/[B_O;S_CYNYYN,?O'+
M<>G--AN[FV5E@N)8E;DA&(S6/L>J-_:]&=7XML;SQ%XLUR]TNW-Q;6>!+(A&
M!M&"??H>GI6X;F/4='\!26YW>5=B&0#^%@!D'\LUYW:ZA>V44\5K=30QW"[9
ME1L!QZ&F0W=S;*5@N)8E;DA&(!I^S=DNPO:*[?<ZGQ7XAEA\<ZM<Z=,AB=?L
MTH(W),H4!@1W&:BO-0NHHHI+^?&J:A&D60-OV2UZ8 [%A^GUKE:?+++<2M)-
M(TDC=6<Y)JE35DB?:.[9Z'KWAS2+?3?$*1V\=N-,6W-I,O60LO()_BW?_JKS
MFII+NZFA6&6YE>),;49R0,=.*AIPBXK5BG)2>B"BBBK("BBB@ HHHH [KX1_
M\CY%_P!>TO\ 2OH"OG_X1_\ (^1?]>TO]*^@*\S%?Q#TL-\ 4445RG2%%%%
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MF&0/'-"QAD$B[2P4-D,.W/>NHBFCGB66&1)(V&5=&!!'L12NZHI9B%4#)).
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METY/VGH;Q&@%F95+3#'E^9Y/7/3.[OZUZW\3-.NM<^&NM6FFYDGD@#QK'R9
MK!B!ZY (H J6?Q-M)YM*EN]*NK+2M8D,6GWTKJ1*V> R Y0-VS^E7=7\=P6>
MO7.@Z98OJ>K6UL;J:W69(@J<?Q-U;!!P!7G/P^/@KQ#X-TBTU4W%QJ]A((QI
M[W4I=90?E9(]V ,=P,#G-6==UZUOOC)>:-';QZ7)%9L)[^.+_2KW"!A%&W\(
M.1R!D[2,T =WX?\ B)IOB3P;=>(M/M;ETM WVBU^42(5&X@9(!XY'/-<]'\<
M-%N]/M+O3]'U:Y$UT+>15A'[G.,%B"1DYX&<G!Z5QWP9N8+?X7^,XYI5C=#*
M65C@@&' _7BNE_9Z,*^ ;F$A1<"_=G0CY@-J[21^!H Z.\^),::EK=MINC7.
MI1:*O^FO#*BN&P<A$)RP&.3_ #KM+6=;JSAN%&%EC5P/0$9KY[\>:=8VVM:G
MXR\(ZW_9VN65XT-[I[N \LF[:6C'\0;()7!!Y^E>^:+-<W&B6$UY"(;J2WC>
M:,#&QRH)&.W- %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /G"X\#:J]U,PFL\&1C_K&]?]VH_P#A!-6_Y[67_?Q__B:**]-59'G>RB'_
M  @FJ_\ /:R_[^-_\31_P@FJ_P#/:R_[^-_\3111[60>RB'_  @FK?\ /:R_
M[^-_\35Q_#GBB6*..3587CC.41IG(4CT&WBBBDZD@5.(_P#L#Q7]H-Q_;$?G
M,NTR>>^XCTSMZ4EKX>\4V4,\-KJL,,4YS*B3. Q]?NT44N=CY$.70O%B7Z7R
MZQ&+I%V++Y[Y"^GW>GM6SX6\+:Y-XK_M74=0AGD6-PSF1F<DJ5'51THHI2F[
M,J,%=&)J7A/Q+<R?9[S4K:=(6.T&1@,^N-O7WI6T'Q6^F#36U>,V0&/(,[[<
M>GW>GM1134W8GD5QI\.^*2T+'5HLP?ZH^>_[O_=^7BEM] \56EZ]Y!JT4=S(
M,/*L[[G'O\O-%%-S=@Y$-N/#?BB[$(N-5BD\D[H]T[_(<YR/EZYJ6[T/Q;?2
MPRW6LQS/!S$7G<[#ZCY>OO111SL.1#!X?\5":64:O&)91B1_/?+CT)V\U"?"
MOB(V'V$ZA;&U#%A$96P">O\ #111SL.1%;_A!-5_Y[67_?QO_B:7_A!-5_Y[
M67_?QO\ XFBBG[60O91#_A!-5_Y[67_?QO\ XFC_ (035?\ GM9?]_'_ /B:
M**/:R#V43K?AOX7O])\7QW5Q);-&()%Q&[$Y./517LU%%<5>3<KLZZ*2C9!1
M116)L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)BBB@"
M.2WAFECDDAC=XB3&S*"4/J#VJ3:N<X&?I110   = !]*6BB@!NQ<8VC'TI<8
M%%% $$5C:0W,ES%:P1SR??E6,!F^IZFG?9;?[5]J\B+[1MV^;L&_'IGKBBB@
M AM+:WW^1;Q1>8V]]B!=S>IQU-2A0.0 #110!7?3[-YDF>TMVEC8LDAB4LI/
M4@XX-6:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +"!0\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V>TM$NX6=
MW;K5G^RH?[[T:42;=L_WJO8H H_V5#_??\Z/[*A_OO\ G5[%&* */]E0_P!]
M_P Z/[*A_OO^=7L48H H_P!E0_WW_.C^RH?[[_G5[%&* */]E0_WW_.C^RH?
M[[_G5[%&* */]E0_WW_.C^RH?[[_ )U>Q1B@"C_94/\ ??\ .C^RH?[[_G5[
M%&* */\ 94/]]_SH_LJ'^^_YU>Q1B@"C_94/]]_SH_LJ'^^_YU>Q1B@"C_94
M/]]_SH_LJ'^^_P"=7L48H H_V5#_ 'W_ #H_LJ'^^_YU>Q1B@"C_ &5#_??\
MZ/[*A_OO^=7L48H H_V5#_??\Z/[*A_OO^=7L48H H_V5#_??\Z/[*A_OO\
MG5[%&* */]E0_P!]_P Z/[*A_OO^=7L48H H_P!E0_WW_.C^RH?[[_G5[%&*
M */]E0_WW_.C^RH?[[_G5[%&* */]E0_WW_.C^RH?[[_ )U>Q1B@"C_94/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5EZM]^'\:U*R]6^_#^- $NE?\>[?[U7ZH:5_Q[M_O5?H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ S2%@H)8X
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MJ$ICM-0MYW'\*.": -#(HS3'8(A9B HY)/855@U73IXI9H;R%TBXD8/POUH
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MK&^D=+6ZBFDC^^$;)6@"[FC(II.T$YYZ\U5M-5L+Z:6&TNX9I(O]8B-DK]:
M+N:3('7BJE[J5A8(#>744 /]]L4RQU;3=1RMC>P3D==C@F@"]D49Q4;.L<;2
M2.%1>26["JL>K:;):-=1WD36X.#(&X% %[(H+"J]I>6U];K/:SI/$W1T.0:J
M7FO:/92>7=ZE;PMZ-( : -3-'2JUK>6U[#YEI/',G]Z-LTV[U"TL$5[RXC@#
M'"ESC)H M9XS03BHU97Q(A!5AD,#P:K7&J6%G/'#<W<,4KG"([8)H NY%+3
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M^*_#<7B;3/LKRF*16#12#^$BHO"NE:YI4<\6KZH+U>!!@?= KH\8^GI0% &
M,"@#@]4\$:G'KLVK>']5%E+/CS48<-7;6ZLMNBR/YDJJ%=CW/>IMH.,\XKG_
M !3H^L:O;QQZ3JHL&4_.2"=U 'GUQHEMJ?Q4:WM2&MD?S9U7H#7KX4* H&%
MP*YOPIX2B\.^;-)<&YO9O];,>]=/B@!O>N;\9^'KCQ+HYL+6>.%]VXLX-=+B
MEQ0!1TJT>QTNUM)&#/#$J,P[XJYCUQBEV@# Z48% &-XD\.VWB32VL[G*X.Y
M''8UR]KX4\7VR+:#Q,JV*\#:/G5?3->@X]Z,"@#@)?AV8M>TV_LKA MO\UPT
MN2\S>M;OC#P_<>(M&6RMIEB<.&W-TKH@H%&!0!2TVR>RTJVM9&5WCC",1T-<
M=J7@"\@U.34/#>I_8)YB2X/W3^%=_BD*@T <"? 6H:E:R'7=8:^N50B$'A%;
MU(KH/!VAW'A[P]%I]S+'+*C,Q>,<'-;H0 8_.E P,4 %+110 TYS[8J"^M([
M^QFM90"DJ%3FK-&* //O"?P_N=!UPW]W=Q7"*"(0,_**[XC<"".O!!Z4[;S1
M@4 <+J7@*XAU)]2\.:BVGW,IS(#RK57'@76M7G0>)=9^UVJ$,(8^ 3[UZ%M!
MZCI1C\#0!2FL5&DR6-N%C7RO+0=AQ6-X-\.7/AK3Y[>XFCF:67>#&",#\:Z;
M:*,#KWH J7^GPZE8SV<Z@PS*5;'6N)B\%^)-(9H-#UX1V6/ECF!)6O0=HSDT
M;1G- '%:1X(NAJJ:KKNI/?7D7^KQ]P?A6]K^AVWB'2Y+&Y.U6Y5EZ@UKX';B
MC;SUH \UM/ WBJTQ;1^) EBO 50=P4]JGNOASMU+3+RRNE4V[A[AY<EY:]#P
M*38,YZ&@#,UW0[7Q#IC65V#L/(9>H-<E'X5\8V,7V>P\0Q+;KQ&'!)45Z#M
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MVH[0&#-A,]S7&7/A>R@O-4N+":33WME\V-HGR&/7I78^&KZ?4?#MG=7?^N=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC;6%\E]/=7%_<(,1/.<^6/:NFP*3 Q0 T<-C/TK.U;[\/XUJ  5EZM]^'\:
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M (]V_P!ZK]4-*_X]V_WJOT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !111F@ HHS1F@ HHS10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4AZ4M!Z4 <_XU_Y$O5C_ -.[5\UK]Q<G
MM7TIXV_Y$S5O^O=J^:T^XOT%>A@T>/F&K0[%&***[[GGK;<,48HHHN&O<,48
MHHHN&O<,4A^Z?I2TC?=/TH>P)-M:GT7\/>? NE?]<OZFNGKF/A[_ ,B+I/\
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M.Y(H01O;U;-=E10 @   ';I0*6B@ K+U;[\/XUJ5EZM]^'\: )=*_P"/=O\
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MC\RULKG<<FOF#_B:>&]6.!+:7D1SGH#]?:O6O!WQ/MM35+/62L%T>%DZ*_\
MA3A53^/0NEB.;2>C/2>U%-5UD4,IRI&01WIU=".S<*6D!%+0Q!1110,****
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M "+U_P#]?/\ 2N;%_P ,[<%_&^1Z52TE+7E+8]L**** "BBB@ HHHH ****
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MN8^'O_(B:3_UR_J:Z<=:\2?Q'TE+^'$444"BI- HHHH **** "BBB@ HHHH
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M_P!>YKYL3[B_05])^-/^1+U?_KW-?-B?<7Z"O0P?4\C,/BB+1117<><%%%%
M!1110 4-]P_2BAON'Z4GL#V9]%?#W_D1-)_ZY?U-=..M<Q\/?^1$TG_KE_4U
MTXZUXD_B/I*7\.(HHH%%2:!1110 4444 %%%% !1110 4444 %%%% !1110
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MHH *R]6^_#^-:E9>K??A_&@"72O^/=O]ZK_:J&E?\>[?[U7CT]J $9PH))P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+2'K0 E5+R
MRM]1MVM[N!)8G!!5AD5<HXH:N)V:U/$_%_PNN-/$E]HF9K;EG@;EE^E<EX>\
M4:KX8OMUJ[K&#B2VDZ'_  KZ7?'2N(\7_#NP\1(US:;;:_'1P,!_K7-*DUK$
MXJN'=^:EN7_"WC?3/$L05'6&[ ^:%CS^%=2.3FOE[4=,U7PQJ7EW$;V\Z-E)
M!D*??->D>$/BFK;+#76PQPJ7&.#]:<:MM)!2Q#;Y:FC/6J*AAGCFA62)Q(C#
M*E3D5*,XYKH3N=JL]A>]+24M PI#TI:0]* ,#QI_R)>K_P#7N:^;$^XOT%?2
M?C3_ )$O5_\ KW-?-B?<7Z"O0P?4\C,/BB+1117<><%%%% !1110 4-]P_2B
MAON'Z4GL#V9]%?#W_D1-)_ZY?U-=..M<Q\/?^1$TG_KE_4UTXZUXD_B/I*7\
M.)6O_P#CS?\ "L;O6S?_ /'F_P"%8W>MZ)SUPHHHK1& 4444P"BBB@ IT7^M
M3_>%-IT7^M3_ 'A2EL5'<Z ]**#THKB/1Z!2TE+0 4444 %%%% !1110 444
M4 %%%% !1110 4444 (:*#10!\Z?$/\ Y'W5/]Y?Y5S/:NF^(?\ R/NJ?[R_
MRKF>U>S1^!'SE;^-(****U,@HHHH **** "O9_@Q_P B]?\ _7S_ $KQBO9_
M@Q_R+U__ -?/]*YL7_#.W!?QOD>E4V7_ %;?0TZFR_ZMOH:\I'LO8Y\=**!T
MHKN6QY[^(****!!1110 4444 !Z5O0?\>\?^Z*P3TK>@_P"/>/\ W16-;H=.
M'ZDE+24M<YTA1110,**** "BBB@ HHHH **** $/7I5/4=2MM+M'NKR39$/S
M/L*N'K7/>+-'NM8L(UM73SH)!*L3?=?'8T 9.G^/K634IDNDN(;4D")I(\8^
MM=F'#*'3#HPR"#UKS6+7K1KR^M_$6D2V\<P"2?)E%]\]J[>2^L-&\/I=1.IM
M(8\0D'.[T'XT ,U3Q'I^DZA9V-PSFXN6Q&JC./K6W7EE]I\ZW6E:S?@F]N[I
M3L/_ "S3/ KU(F@"GJNIVFDV+W=[*(X5]>I/H/>L;3_&NE:A=Q6^VYMWE_U7
MVB/:&^E9_BH?;O%NAZ<^#;[C*RGH2*L>/K2-O#;W$:*DEJZNC 8(Y[4 ;FK:
MQ9:):&ZOI B#A0.2WT%9VE^,=,U*[2U5+BWED_U8GCV;_I6)?L=5\7>'K:8!
MHT@$[*W(8XJ[X_MHUT6"]B54FMIU9& P1SB@#K^@R.E.J*W8O;1.W4J#^E2T
M %9>K??A_&M2LO5OOP_C0!+I7_'NW^]5^J&E?\>[?[U7Z "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS?\ "L;O6]$YZX4445HC ****8!1110 4Z+_ %J?[PIM.B_UJ?[PI2V*CN=
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M/*3_ )YK^5'E)_SS7\J?10!'Y4?_ #S7\J/*C_YYK^5/-% 'SI\0QCQYJ@
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MLV'_ !]I^-;58MA_Q]I^-;5<U7XCNH_"%%%%9&P4444 %%%% !1110 4444
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MT^(?_(^ZI_O+_*N9[5TWQ#_Y'W5/]Y?Y5S/:O9H_ CYRM_&D%%%%:F04444
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M%  >E;T'_'O'_NBL$]*WH/\ CWC_ -T5C6Z'3A^I)2TE+7.=(4444#"BBB@
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M]:44 %%%% !3'ECC1G=PJJ,L2<8I6Y!'Z5RWCFWNY]%B$$<DL:2AKA(OO,E
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MH_LQ?^>\GYU>HI6 HC3%!_U\GYT?V6O_ #WD_.KU%,"C_9B_\]Y/SH_LQ?\
MGO)^=7J* *']EKG_ %\GYTO]EK_SWD_.KU% &:^AVDC[W1'?^\R FF_\(_8_
M\\HO^_:UJ457-+N3RKL9?]@67_/*+_OVM']@6/\ SRB_[]K6I12YF'+'L9?]
M@67_ #RB_P"_:T?V!9?\\HO^_:UJ4478<D>QE_V!9?\ /*+_ +]K2'P_8L"#
M#%@_],Q6K14M)[BY(]C!D\(:1+]^VC/_  $56D^'_AZ7[]DI^G%=/11RH'3@
M^AR"_#+PNCAUL!N!S]XUOII$4<8C25U0# 4= *T**$D@4(QV10_LF/\ YZM1
M_9,?_/1JOT55V59%#^R8_P#GHU']DQ_\]&J_11=A9%#^R8_^>C4?V3'_ ,]6
MJ_11=A9%#^R8_P#GHU']DQ_\]&J_11=A9%#^R8_^>K4O]EK_ ,]GJ]11=@DE
ML4?[,7_GO)^=']F+_P ]Y/SJ]12&4?[,7_GO)^=']F+_ ,]Y/SJ]10!1_LQ?
M^>\GYT?V8O\ SWD_.KU% %'^S%_Y[R?G1_9B_P#/>3\ZO44 4?[,7_GO)^=6
MX(1!$(PQ;'<T^EH **** &M^7H:P/$6NSZ%]DG%NDMF\OEW+\YB'K6^<Y[U%
M-;QW,+PW$:R1N,,I'!% 'GVJMX?NWU66Y>W(,6ZWDCX;=VQCWK:TZRUF_P#"
MNFK'J<EE.(\LX4,6';.:DT_P1I=GJLUXUE"5)_=+DG;^%=0JA> ./Y4 9VCV
M5_8V[)?:@]ZYZ.R@8K3'2FX^HIU !1110 4444 %%%% !67JWWX?QK4K+U;[
M\/XT 2Z5_P >[?[U7ZH:5_Q[M_O5?H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHI"<=J %HJK>W]OI]J]Q=2I'$G5F/6LNP\8Z+J-VMM#=$2M]T2(5S]">M
M &]152^U&UTRT>ZO9TAA3JS&L[3?%NCZO<BWM+K]Z>0LB%=WTS0!N451U'5K
M32K4W-]*(8^F3R2?853T[Q7I&JW)MK6Z_?8R$D4J3],T ;5%4-2UBSTBV^T7
MTPC3H!U)/L*J:9XJTK5[G[/:7!,V,['4J<?C0!M44@/-+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 444R218HVD=@J*,LQ/ % #Z*YP>.= -P(?MN"6VABAVY^O2MTW,0B
M\UG01!=Q?=P!]: )J*YZ#QOH-S=K;1WGSLVT$J0I/UZ5M3745O%))-*J1H-Q
M9N !0!/17.VWCC0;JZ6WCO"'<X0NA4$^Q-;-U?6]C;-<W,JQPJ.6)XH LT5S
MUEXUT.^N?L\-V0Y. 9$*@_0GK70*VX9'([&@!:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BFEL9QSBL&[\::'8W3VTUW^\3[VQ"P'XB@#H**KVM[#>VJ7%M(LL3C(93
MUK&N?&NA6E[):2WF98SA]BD@?C0!T-%007*7$*S1.K1,,JX/!%8EQXWT&VNF
MMY+SYE;:6"$J#]1Q0!T5%017,=Q"D\#J\3C*LO<&J^IZO9Z-9F[OYA##D+D^
MM %^BHX9DN($FC.Z-U#*?4&GB@!:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R]6^_#^-:E9>
MK??A_&@"72O^/=O]ZK]4-*_X]V_WJOT %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4UN<"G4ULYZ<>M &'KWAX:Y<6)EF46UO*)&A*Y$A'K6/XYALQ:V-I! GV
M]IU%N$'S*/7Z5H^*?%EMX;MXUD(>ZF.(E/ S[UC:%?:%;7#ZGJ6JPSZI+RQ=
MN(AZ+Z4 .\0+_:'BK0M*N5$EO&HFF1NA(XY'>IO'FGP6^DP:A;QK%/:SJ59!
M@XSC'TIOBM_L&M:3XB56DLXSLG:-=Q"GO]*K^*-<MO$EM:Z3I#_:9+B52^P9
M"J.<D]J -V[\/_VQJ>G:E=2;H8$!-L1D$D=:R?%L%I+K6DVUE$@U$2[MT:_,
MJ>]6O$OBR'P['!I<#*=0DC 3S#A4'3<35;P_>>'M/D-Q+JT5SJ=SCS9BV<D]
ME]* ->]\.B_\16VI7,PEAMD(2V*\;C_$:Q_$4=M+XLTJVL(U%XC[IC%P53WJ
MSXK\8P:3-'IEO)&M]./OR-A8QZDU'X>O/#FEG']IQ7&H7!_>3,<LQ]![4 =E
M_%TZ=Z=4:J.@)QUS4E !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !65XATJ36M(DL8[DV_F$;
MF'<=Q6K6;KFMV>@:7)?WK$1)Q@#DGL* ,C7[/2-)\)2P3V\(18@D8V\LV,<>
M]<_JJW%KX!TNPFW"2[D6-ESR0><'\*73M5TK5;Y-9U[48 V?]&M-^51?4CUK
M6\6*FN>&X[W3?](^S2"92G7 ]* +NK>'=/;PE+9QVD:".#,>T8*L!G.:R[+3
MYO%7@K3(Y[MHU0@S9&2X!Z47_C?3;SPVT5G(\E_/%Y:6X7Y]W3D5/'J=OX'\
M&6(U $7!3:$ZY<\X)[4 +XUM]+M?#:VS01B5BJ6P1?F#>HK2&@1:GH=A:ZF9
M&,2JSJ&P&8?WO6N:T?4-&DNSK.N:I#)?-S'$S96$>@'K6YX@UR[LK:RU/3QY
M]@S?O]BY.T]Z ,3Q/J%A>;=$BT]K=Q(%6XDCVHF/0UW=C%Y-E!%OW[$"[O7C
MK7&^)_$^BZIH$EK;.+RZG7$$2#+*W8D=JZC0()[;0K*"Y),R1*'SV.* -*BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"O>123VLT,4@21T*JWH?6L72]!T_P]H3Q70BE5
M0S33./O9Y.:VKNYALX)+BX<+%$I9F]!7G;^)-/\ %=V'O;]+/2(6P(2V&F/O
M[4 6-$N'T_P5K5_;JXMV9FMU/&!TXK9\+:'9)X5@62U1WN(R\I<9+9]ZLROI
MOB'PW=V.E2Q21"/R\1_P^E8WA_Q=ING^'A97\KP7MFI1H)/O-CICUH C\+V=
MQ<:-K&BQ3F(1SLD,A.2BGM6TVE:5X?\ "3VUS' T4<1#LZ_?;U^M9GAB?^Q]
M"U+7=55H$N9C.$(Y"]A6;;ZYIOB6\%]J^H10V$;;H;,M][W:@#H? \;V_A=7
ME+)&69UW\;4_PKF?$QD\26=YJ;L5TVS/EVZGI*W=JZ76II]>\-O%X:EAFWD(
MQ#[0J]Q7.ZXWB2U\*/:2Z/;06<2A69)@Q(]<4 =]HW_(%LO^N"?RJ\*PO"TV
MH2Z);F^MTAQ&OE[&SN7'!K;')!)YH =1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !67JWWX?QK
M4K+U;[\/XT 2Z5_Q[M_O5?JAI7_'NW^]5^@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "D(SCFEHH K7.GVEX0;FVAFV_=\Q V/SJN="TDL3_9MID]S$*T:* (
MS!$8?),:F+&W9CC'IBH;?3;.S8M:VL,!/4QQ@$_E5JB@"G<:78W;![BT@F<#
M :1 QJ-=#TI&#+IUH&!R"(@,&M"B@"G<:5I]T^^XLK>5O[TD88_K3%T72U=6
M73[4,OW2(@"*OT4 -*@X]!TIU%% !1110 4444 %%%% !1110 4444 %%%%
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M??A_&@"72O\ CW;_ 'JOU0TK_CW;_>J_0 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %9>K??A_&M2LO5OOP_C0!+I7_ ![M_O5?
MJAI7_'NW^]5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBD-( Q4<MO%/$T4L:R(WWE89!J044]
MF#70SAH&D ?\@RT_[]+2_P!@Z1_T#+3_ +\K6A13NR>5=C/_ +!TC_H&6G_?
ME:/[!TC_ *!EI_WY6M"BB[#E78S_ .P=(_Z!EI_WY6C^P=(_Z!EI_P!^5K0H
MHNPY5V,XZ!I'_0,M/^_2U/;Z;8V;E[:TAA<C!:- ":M44KL.6*UL-P*KW.G6
M5ZP:ZM()B.AD0-C\ZM44%7(K>SMK5-EO!'$OHB@5'<Z=97A!N;6&8CH9$#8_
M.K5% &<-!T@$$:9: CD'REJ^8T*%"H*$8VD<8IU% %!-$TI)!(NG6H<'.X1#
M.:O%0<<=*6B@!-HSG'-5[G3K*\(-S:PS$?\ /1 :LT4 06]G;6D>RV@CA7TC
M4"GS6\-Q&8YHUD0]5<9%244 5;73K*Q)-K:0P$]?+0+G\JE%M )O.\I/-QC?
MCG\ZEHH ADM8)G1Y84=D.5++DK]*)K6"X0+-$DB@Y <9J:@]* .<U?1KJ\\1
M:3>0JGV>U8[P3VQZ5L6^F6%M*9H+."*4GEU0 G\:LX[XZ]:<.E #2BD$$ @\
M'/>JD6CZ;!-YL-C;QR_WUC /YU=HH BDMH9MIEB20J<@L,X-++#%/&8Y8U=#
MU5AD&I** (I;6">#R)88WBQC8R@C'TJ*VTVRLB3:VD,)/4QH%JU10!6N=.LK
MQU:YM(9F7H9$#$?G3Q9VRR)(L$8=!A6"C('I4U% %:ZT^SO0HNK:*8+RHD0-
MCZ9IPL[=71Q"@=!M5L<@>U3T4 1S6\-Q$8IXDDC/57&145MI]G9;OLMK##NZ
M^6@7/Y59HH B^S0>?Y_E)YN,;\<XHDMH)G5Y(4=T.59ER14M% "8YS2XHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/KSO0=0@T?PEJ.KO&&O%F:*2<9/FL#PQ]J5%NYM._M!_%:KJ++YJP+,!$/\
M9Q0!V&NWMQIVF/=V\8<QD,X/]WO5JQN4O;.*ZC(*RJ&XK(T+4AXD\,&>;:QD
M5HI-G3(X.*J^ 96;07A)RL,[HOTS0!U5%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9>K??A_&
MM2LO5OOP_C0!+I7_ ![M_O5?JAI7_'NW^]5^@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@ [
M57O 6M7 &2:L4F,C!IH3U1@>5(/X&_*CRW_N-^5;P%+BM?:V.?V-S \M_P"X
MWY4>6_\ <;\JW\48H]J'L# \M_[C?E1Y;_W&_*M_%&*/:A[ P/*D/&QORJYI
MR,LS,RD<8Y%:>*.!2E4NK#C1L[E#6\OHEXJ@EC"VT <]*S_"4!_X1&T@N(B"
M8RKHPZYK>([YY/%+R!P/PZ5C8Z#R?5M&U+1O$UA86T<LVDF<2IM4GRLGD5T^
MLQ76B^+(]?BMWN+66+RIU099<#@XKKQG&,D$_C2C( SG-,#A-4OI?&5U:6.F
MVLXM(95DFGF0H..P!J]XKMI&U/01%$[B*X7+ 9VBNMR>1U-*>O\ ]:@#FO'<
M,D_AF5(HFD)=2549)YJW-X?TO6+:SEU"T69TA50'[#%;).!D4H'?OZT <UKO
MA2"[\._8-.1;=X6$L&.@851MO&D]G&+76-*NX[J,8+1H65SZ\=*[/OD?E29.
MX\\>F* .1TM]<UOQ"FI3K+8Z9&N$@+<R'U-9DFJ#0_B!J-S<6ET\$D:A6CB+
M#->A9[9XI%&WC/'?- '.V7C*ROKM;9+6\5G/!>$@53\0:;J.G:['XBTB'[0Z
MILN;?."Z^HKKR3VYXI.2<DX]J ./?Q\C6X6#2+][QN!"8R #_O58\):+=VLM
MYK&J@"_O6R4'\"]A74 DYYQ2C[HQV]: .9\>1RS>&I%BC9W$J$*HR3S6K<6$
M&JZ(ME=1YCEB ((Z'%: R5'09ZBDYZD\T >8^'[+5K/X@0VEZDCV]G&R03%3
M@KCC)J_)JG]A_$#4KBXM;EX98D"M'&6S7?@DC!'X4N<<_KZT <[9>,K*^NDM
MXK2\5G. 7A( _&J7B#3K^QUZ'Q%I47VAE79<0 X+K[5V')X/'TI,>O7.>* .
M/;Q\C6X6#1[YKQCCR3&0 ?\ >J?PEH=Y;7%YJ^J@"_O&R4!^XO85U7)/7CTH
M/O0!A^*=$?7-':")PES&0\+'IN%9%GXSGLHQ:ZSI5W'<QKM+Q(760CZ=*[/Z
MT;L#D_E0!QVF2:WKOB&+49$FL-+A4A8&;F0^I%5X)9O".OW\EU;S2Z==OYB2
MPJ6VGOD"NY/8FDYZ  "@#BH#/XJ\4VNI):RP:=9J=KR+M:1OI5N6&4_$FWF\
MIC$+5AOQP#74Y[9Y]:,Y((_EUH Y#Q=#-)XCT!X8G95N!YA R *E\?P2RZ1;
M"&)Y'6Y5L(,X^M=6?J/;CI2\[NG;F@#A?%<TUOK/AYXH/.F1@1'TSQSS3=<U
MF;Q-:'1=/TZX$LQ'FO*A58P#SR>M=)J>AMJ&L:=?K<"/[&Y;9C.ZM<EN,+F@
M#@]=T!-/O;&_DT_^T;2* 03PGDJ ."!WID#:7>7]JN@^'8P0P,LTT!7RQ[9[
MUWV>< ]^N*=GYB/:@#E+V&4_$?3YA$YB%NX\S&0#CI2>,H9I+C1C&DCE;M2=
MJY 'J:ZO!QZ8HYY["@#GO$MW?6+P.+-;O2V^6Z0KN8 ]P*YE;>TU#Q'IDOAJ
MPFLQ$^;F4QF-=O\ =(/6O1LD'GDFG9/I]: //M0,-GXPNI]>L9[FT8 6KJA<
M+^ Z4EJCR>/+*>+26M+41D(X7K[GTKT+/MQ30Q'##CVH XS5ISHGCA-2N8)W
MLYX!&)(5+;6'J!VJ>^62;QWHUU'$YMS$Y+[>!D=ZZWD9QS[4F2,@@$#IQ0!P
M]M--X/UZ_%S;3RZ;>/YL<L2EMA[Y J2V6?Q/XJMM4%K+;V%DI"/(,,Y^E=L,
MXX_ 4AR[=< =L4 <KX6CE37_ !!))&\:/.I0D8!&.HI%BE'Q)\XQR&(VI4.1
M\H.>E=6><CCGUHSSC/'TH %')YXIV/FSGM0!CMBEH X+6M-E\4^,TLI_/BL+
M)-^Y/EW.?0T_6/ %O+I<Y@U#4))T!>,23;AN'M7;_P 1Y'OQ1TX QB@#SZ6'
M4=7\/:3JL%O(;[37Q)"XVEP.I&:T;GQG<WT4=MH^G7']H2,!B>(A$'<DUV!'
MS9[D=^U&3SD=!^= '%^(7N-,UW1]8N8'FBBC,4S0KNVL?04GBLO.FD:Y96TT
MT-M,)'15PVWZ5VH!['%'(SQB@#SSQ3KD_B+P^\>GZ9<E RF5I$((YZ =ZT_%
M=M>-X9L3;Q2/'%L-Q"G5DP.*[ DX!'6C:5Z=SR30!YOK,NGWGAR:+1- =VP-
MY:(J8_P/6KGB*RN9?!FDRQ0O(UJR22(H^; ]J[O+]L?[WI0...A]0.* .)\5
MO+J^B:=JEG;3-';S+))&4(< =>*UM92/Q'X4DGMUD5U7SH0Z[2'7GD5T6?3J
M*Q_$.F:AJUL+6RU$6<;<2G9DL/;TH P?!#W6L3SZ[>)M.Q8(P/4##?K77WF?
ML<Y&3^[./RJ+3-/BTJPALK<8CC7K_>/<U<YYP/QH Y7P##+!X9"SPF-O-<[6
M7!ZUT\@<Q.JD;RIP??M3UP1TH/'- 'FVBM8V=S<0ZSI5Q/K+2,5=HRP<=L-T
M%7_!\-RFJ:Y--8M:"7F.(] /3/K7<[C@=S2$\[< \Y]* . T[1KG4O!.IV/E
MO'<?:WDC5AC)!R*NZ;XLF?2H[/\ LR[_ +31#$8V0A2P&,Y]*[)NG)/T%&7!
M(//H1WH Y?X?17,7A^07<#0SFX<NC#'.:ZL#!)SUIJ9))/\ .GT 4M5M_MFE
MW5L?^6D9%<_X5U$Q^"0Y5FGM%='0#DL"<<5U9Q@]JR['2!I^H7=U#*?+N3N\
MO'"MZT <?X>\'C5;235]0NKVWNKQB[+"Y3 SP"*=>:&WA7Q)IVI64EW<Q3OY
M=QN)<X['/I7H*Y(ZC..M(#R1TH X;QDM[I>IQZIIEO),;R(V\RH,GD?*?:KL
MOAEY/ D>F(%^T!1,0>C2=<&NL;(R0>OXTN.,8S0!YS%=:%'8B*?PPRZHHV^5
MY!*LWKN]*T=8M;A?AX\#6*P3,,_9[=>%YKM<M@\_CBC.1P<'Z4 5;$.-*ME(
MQ((%!!]=M<%I#VEC?7D>NZ;<7&I&8E)C&6#CL >PKT?CGU/7WHY+$%N/I0!P
MOA:.>#7]:N9K :?&R912/EQZDUA:?8WUV+NYAT_498YIFW26MR(XY?HOI7J4
M\0N(9()AF.52A ]#7-6OAS6=,3[-I.M)%9J3LBFAWE?;- %"%+/Q%X:O=!M;
M9[*YM@-T#=21TR>^:HPW&A6]@(+SPP1J48V&,0$JS>N[WKKM%\/KI4MQ<RSM
M<7MP<RRMT/L!V%;/)'K[X[T 8.EF73O#$DUS:Q6FQ&D\B(8"BHO MK);^'5D
MF7:\\C2X]B>*T]8TU]5T\VGGF)'(,C+U8>E7;:)(((X8UPD:A5^@H FHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K+U;[\/XUJ5EZM]^'\: )=*_X]V_WJOU0TK_CW;_>J_0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 &*,"BB@ HP*** "BBB@ HP#VHHH *,444 &**** "BBB@ H
MQ110 48Q110 8%%%% !@4444 &!1110 8HHHH **** "C%%% !1110 4=:**
M "BBB@ P,YQS1110 4444 & :*** "C&:** "BBB@ Q1110 8HHHH *,444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LO5OOP_C6I67J
MWWX?QH ETK_CW;_>J_5#2O\ CW;_ 'JOT %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4G>EI.] "9Q
M7#^.O'9\*R0VT%N)KJ9=R[N@%=R?6N<\2^#M,\4%#?>8K1C"M&<'%3--[$5$
MW'W3S$?&/7QD&QL?UI?^%R:]_P ^-E^M=4/@UX?  ^T7O'^W2_\ "F_#_P#S
M\7O_ 'W7/RU>C.+V>(Z,Y3_A<FO?\^-E^M'_  N37O\ GQLOUKJ_^%-^'_\
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M"=_:SS:E)?Z?<2"*3[1]Y">XQ5V\U"\T_P 8VBR7!;3+Z/"I_=?M69J^H?\
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MY'I5KP_>->>'[21]ZR; IWC!R!WH V!THH'2B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LO5OOP_C6I
M67JWWX?QH ETK_CW;_>J_5#2O^/=O]ZK] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2;?>E
MHH 0# Q1BEHH ,48HHH 3%+BBB@!"H/6C;Q2T4 )M% 4 8 P*6B@+";0>O/U
MH*@]>1Z&EHH 3:,8P,4!<+C-+10 @4 8' HVCT_&EHH ;L4]J-B^@SZXIU%
M"8 Z<?2D**>H!^HIU% #6&!P!G^5<S'X=O;G7EU/5+]+B* YMX8UP%^OK73G
MD4T#:>  OI0 ^DQUH'3FEH 3:N,8&*-HQCJ*6B@! H'0 ?2@J#SW]:6B@!,#
MM2% ?;GM3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI^='VJ#_ )ZI^= $U%0_:H/^>J?G1]J@_P">J?G0!-14/VJ#_GJGYT?:H/\
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0 (P&P\#I4:$D#FBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +6!0\# 2(  A$! Q$!_\0
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MZ/[*A_OO^=7L48H H_V5#_??\Z/[*A_OO^=7L48H H_V5#_??\Z/[*A_OO\
MG5[%&* */]E0_P!]_P Z/[*A_OO^=7L48H H_P!E0_WW_.C^RH?[[_G5[%&*
M */]E0_WW_.C^RH?[[_G5[%&* */]E0_WW_.C^RH?[[_ )U>Q1B@"C_94/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS\T :E&:KVM[:WL0DM;B.9",@HV:GY)H 6BBB@ HHHH **** "BBB@ HHHH
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MUV/B;0H?$.CRV4F ^-T;_P!UJ ,'XE2K+X)EDC(=7P5(Z$5J>&9Q;> [&=\
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MZCX(\6VVE"^EN;"Y((#G)_&O4Q@'V/2@!]%%% !1110 4444 %%%% !1110
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M#.US3Y-4T:YLHG5'E0J&/053\)Z+/X?T"+3IY8Y70D[H^G-;F*,4 ,<!E9&
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MG- '%Z-X*GAU--5UW43?7R?<('RBNSQ\^0.O>EP!TI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *R]6^_#^-:E9>K??A_&@"72O^/=O]ZK]4
M-*_X]V_WJOT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !2'I2T4 -_V1Q0% /2G44 -'7 Y/>G444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4T=.O'O3J* $'TXI:*
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R]6^_#^-:E9>K??A_&
M@"72O^/=O]ZK]4-*_P"/=O\ >J_0 4F:6FGJ3[4 +FC-5;J_BM'A24C=*VT<
MU9R,G(Z4 .HH'2B@ HHR** "BC(]:* "BBC(H ***,CUH ***,CUH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHH/2@!,TH.:CDD5(FD.<*.<5%8WD5];">'
M.PDCGVH LT444 %%%% !1110 4444 %%%% !1110 4444 %9>K??A_&M2LO5
MOOP_C0!+I7_'NW^]5^J&E?\ 'NW^]5^@ JO=/)':3-",RA"5'O5BJE]<"SLI
MK@QO(L2ERB?>.* /+;>TM->FMI=0U&9M0>X*R1;RIC&>,"N_T"QU2PBGMM0N
M$N8%;%O(#\VWT:N<U.QT3Q*FGZC!;[#<OAV4[67V.*72]5F\.MK=IY\E[96
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MQ?\ GO)^= %[(]11D>HJC_9B_P#/>3\Z/[,7_GO)^= %[(]11D>HJC_9B_\
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MQ?\ GO)^= %[(]11D>HJC_9B_P#/>3\Z/[,7_GO)^= %[(]11D>HJC_9B_\
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MQ?\ GO)^= %[(]11D>HJC_9B_P#/>3\Z/[,7_GO)^= %[(]11D>HJC_9B_\
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M8@$-(Q!%;=H9VMD>Z14GQ\P4\9]J )QTI:04M !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,XRV=R[1114EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K+U;[\/XUJ5EZM]^'\: )=*_X]V_WJOU0TK_CW;_>J_0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(5I_UT?^==H.:\2I\;/HZ-O9Q]!:***@U"BBB@ HHHH **** "BBB@ HHHH
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MAVE\ZD/+&-P/KZUJ4 %%%!Z4 %%-9E7 + ?6C>G]]?SH =13=Z_WU_.C>O\
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MH =13=Z_WU_.C>O]]?SH =13=Z_WU_.C>O\ ?7\Z '44W>O]]?SHWK_?7\Z
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MNT4 4O[+@_O/_P!]4?V7!_>?_OJKM% %+^RX/[S_ /?5']EP?WG_ .^JNT4
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M'\: )=*_X]V_WJOU0TK_ (]V_P!ZK] !28&>G6EHH ,4444 %%%% !1BBB@
MQ28'I2T4 %&*** # HHHH ,#THHHH ,4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !K-U[_D7M1_Z]W_D
M:TC6;KW_ "+VH_\ 7N_\C36Z)ELSY=C^X*=38_N"G5[O8^:?4****!!1110
M4444 %%%% "'H:^B/AM_R(6F?[A_F:^=ST-?1'PV_P"1"TS_ '#_ #-<>+^%
M'H8#XWZ'5T445YI[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%%  ::>AIQIIZ&@71AW%?,_BW_D<=7_Z^6KZ8[BOF?Q;_P C
MCJ__ %\M77A/B.#'_!$QZ***],\<**** "BBB@ HHHH *#10:$![[\*O^1"M
M/^NC_P Z[2N+^%7_ "(5I_UT?^==I7B5/C9]'1_AQ]!:***@U"BBB@ HHHH
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
MUFZ]_P B]J/_ %[O_(UI&LW7O^1>U'_KW?\ D::W1,MF?+L?W!3J;']P4ZO=
M['S3ZA1110(**** "BBB@ HHHH 0]#7T1\-O^1"TS_</\S7SN>AKZ(^&W_(A
M:9_N'^9KCQ?PH]# ?&_0ZNBBBO-/8"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH #33T-.--/0T"Z,.XKYG\6_\ (XZO_P!?
M+5],=Q7S/XM_Y''5_P#KY:NO"?$<&/\ @B8]%%%>F>.%%%% !1110 4444 %
M!HH-" ]]^%7_ "(5I_UT?^==I7%_"K_D0K3_ *Z/_.NTKQ*GQL^CH_PX^@M%
M%%0:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'.#CK2
MT$9&#0!Q6MVVJ:7K4^JV*/>6T\.R>WW$["!U K*TU-3\36]E9FP>VL;:<3--
M*,%L'H!7I!C4H4(^4C!%1P6T5K#Y4*[4!R%H Y6\']F_$"SG88BNX3'N[;NP
MI9O!LXU:\U&UUVXMY+D_O $!P/05O:II<.JQ1K*2KQ.)$8=58=ZNQC"A22Q4
M8+'O0!Y_IOA?5H/&$\LVHW/V=$#?:"@_??[)K>GUZ_@\80Z2;(/9SIE9_0UT
MHY6JL>FVL5\]Z(_](<8+DYX]O2@#FO$NG:C#J=IKNE1+//;_ "30'JR^WO5.
MXCU7Q?J5DEQILVGZ?:R"63S>&=AT %=YBB@#CO$=CJ%GKMMK^DVOVF9%\N:#
MN5]JJF#5/%>M64MYILECI]FWF%9?O.W;BNZ"@=*7&: .,URQU/2O$*^(-+LQ
M>*\?EW$&<-CU6HX+?4_$WB*SU&[L7LK&Q^9(Y>)&?Z5VV,4,,_44 <EX@3^T
M?%6D6*<K"_GR8[5U@//3IQ6?;:1%!JMQJ)8O<2C;S_"/05HCWZT +1110 5E
MZM]^'\:U*R]6^_#^- $NE?\ 'NW^]5^J&E?\>[?[U7Z "BBB@ HHHH ****
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M10 4444 %%%% !1110 4444 %%%% !1110 4ASVI:* $/3IFDP<^WI3J* $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1["@#H]QSTX]:7=T]ZR]8UA=*2#$1EGGD$<<8/)]Z74]:LM%M%GOY/++_P
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MA6WV'=OQC\J ,J]OY[SP#H]K(Y8W4X@D_P!H UUOB#1+27PG/;16\2>5%N3
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M_</YT?V;:_W#^= $WGQ?\]%_.@3Q,VT2*6^M0_V;:_W#^=+'I]O&^]4(/UH
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M **** "BBB@ K4TO_5/_ +U9=:FE_P"J?_>K*KL;4?B+O>E%)WI17,=K%%%
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MPG1A_B.AHHHKE.T**** "BBB@ HHHH ****:!FKIG_'L?]ZKHZU2TS_CV/\
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M^X*=7N]CYI]0HHHH$%%%% !1110 4444 (>AKV_P-_R)>G?[I_G7B!Z&O;_
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MKHZU2TS_ (]C_O5='6N*7Q'H0^%"T445)84444 %%%% !1110 4444 %%%%
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MN\#?\B7IW^Z?YUX@>AKV_P #?\B7IW^Z?YUA62MH=&'^(Z&BBBN8[= HHHH
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M** "BBB@ HHHH **** "D/2EHH YKQ!X:749/MUI,]KJ$:X$J\[U]#67X?\
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M$'F1,O\ $I[5MJ"!SC/M0 ZLO5OOP_C6I67JWWX?QH ETK_CW;_>J_5#2O\
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M*EUYO<J.&IQU1SNR3_GF_P"5&R3_ )YO^5=%@>E&!Z5/M9%^QB<[LD_YYO\
ME1LD_P">;_E718'I1@>E'M9![&)SNR3_ )YO^5&R3_GF_P"5=%@>E&!Z4>UD
M'L8G.[)/^>;_ )4;)/\ GF_Y5T6!Z48'I1[60>QB<[LD_P">;_E1MD_YYO\
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M 8Z]:=10!4N;**XGBF<-YD)W+CO5D#YL\\TZB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***0]: %HIIZ]?P H_' H =12<9S
M2$XQ[^M #J*:,?E0W/:@!U%-!SS_ "I<XH 6BD''O2T %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6/B+P]:6TT7E0]65AR?4T =_W&.U+3%977<C @]"*?0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !67JWWX?QK4K+U;[\/XT 2Z5_Q[M_O5?JAI7_'NW^]5^@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5EZM]^'\:U*R]6^_#^
M- $NE?\ 'NW^]5^J&E?\>[?[U7Z "BBB@ HHHH **** "BBB@ HHHH ****
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M;BSME@GCN%"O'P2/>@#LYM0M;>9(I[A(Y)/NJQP35:#Q#I%S=&UAU&%YP<;
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MINKZVLU1KF98@[;$WG&X^E+<3,EG,ZD;U0L,?2N8U%4USQ=86RG=!:)]H?N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "LO5OOP_C6I67JWWX?QH ETK_CW;
M_>J_5#2O^/=O]ZK] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %)2T4 (**6DH$'6C%%% !BC%&:,T
M &*,449H ,4"EI* %HHHI#"BBBF 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5EZM]^'\:U*R]6^_#^- $NE?\>[?
M[U7ZH:5_Q[M_O5?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.U8^L6\6L:!.(G#JT>^*1#W[&D\*ZB=3T&WF;[Z#RV]RO&: -JBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "LO5OOP_C6I67JWWX?QH ETK_CW;_>J_5#2O^/=O]ZK] !1110
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M33+012@B42_.?4#UKIM:\.VNMQQF4O%/"<PS1G#1GVJC!X0W7L-SJFIW&HF
M[HEE 4(?7CK0!2U2&.?XCZ6LL:NOD.0",]J3QK%&+[0W5 KK=J%8#H*WI]"B
MF\00:P96$T$9C1.V#1J^AQZP]HTTKI]GE$H"]R.U &;XGTN/4;RR,-^EMJD)
MWVZN 1)BLJ6^OK76=,3Q/IENSE\6]W;MD[_0BNEUOP]:ZVD32N\5Q"<PSI]Y
M#5.U\)D:C!>ZEJ=QJ,EOS$)5 "GUP* ,^:X:7QA<?V-IL$]]%&%GN)Y" H]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M12@Y&:8/8$X]:<,XYH 6BBB@ HHHH 3(I<TT^G3THYST_6@!V:*:>.O6G=J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"LO5OOP_C6I67JWWX?QH ETK_CW;_>J_5#2O^/=O]ZK] !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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I_1/RHHH /[4G]$_*C^U)_1/RHHH /[4G]$_*H9[J2Y9=X'RT44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>proxy_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 9R!/L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH X[XJ_\DSUO_KDG_HQ:J?!O_DF
M&F?[\W_HUJM_%7_DF>M_]<D_]&+53X-_\DPTS_?F_P#1K4 =Y1110 4444 >
M,Z'_ ,G'ZU_UP;_T".O9J\9T/_DX_6O^N#?^@1U[-0!6O[*/4=/N+.4LL<\;
M1L4.& (QD'L:\-'C'5-!\':OX*N)99?$,5Y]AM&R2\D<I/S ]>F<'_;2O>ZY
M2_\  >GW_CRP\52/B>UC*M#LR)''W')SU7)[=ATQR <7K-C<>'/$?PWTA;R9
MRLCK<-YC'S7S&6)]1DG&>U<\SP7?C_Q7'J5CXHU&.&\Q"FC;G$0RV=X##&<#
M'T->L^(?"']O>)= UC[=Y']D2M)Y7D[O-R5XSN&W[OH>M8@^'NNV7B'6-6T7
MQA_9QU2;S98O[,2;&"2!EF[;CT H&87B0R^$I/"7BRQ&I0Z;$%M;VUO&;S%C
M;)!D7/W@"PY[A:YV;QAK+>,F\>1O,?#4-^-/V!CM,6WEMOT^;/J0*]AU#PW)
MK7@V;0=8O_MDTT)22\\@)E\Y5]@.!@X.,]JK1>!=.C^'_P#PB1;=;F QM-LY
M,AY\S&>N[YL9]J .:\ W%QXL\::]XL>:4Z;&_P!CL(RQV$#&6QZXP?\ @9]*
MH_%NXUJ'Q7X5CT*XDCOG,QB57PKL-F 1T.>1SZUZ)X7\/V_A?PY9Z/;OYBVZ
M8:3;M,C$Y9L=LDGBJ&O^$/[<\4:#K7V[R/[)=G\GR=WFYQ_%N&WIZ&@1XWXP
M\<>)/$]C:726L^E:;:74=M<!7*F2Z()8>N%"GCMGGD\=Q\4M1FU37=#\'V6H
M?87N7-S=7'F;/+C (&3D=<-QZ@5U7C7P:GB_1[?3TO!8^5>+=%Q#OW$!AC&1
MUW9S[50;X9Z=J'BS4]=UZ6/5/M858+>2':MNHX SN.XX YX[^M S \#0V_CS
MP?'I6M75V+[1)VMY#;W)1F'\))'48!'_  $FLSX9>%[77O[4NKZ^U)Y+#4C%
M#B\<#:N" 1GFNXT3X?VWAOQ?<ZQI%TMM87, BDTY8<KD8PP;=QR/0]3ZU;\&
M>$/^$1AU*/[=]K^VW;7.?)\O9G^'[QS]>* /)F>"[\?^*X]2L?%&HQPWF(4T
M;<XB&6SO 88S@8^AK6^(CK::/X'@MX]9BM)9L/:EF%VR'9E",Y+X) &>M=0/
MA[KMEXAUC5M%\8?V<=4F\V6+^S$FQ@D@99NVX] *T-7\#W>N-X:FO]<\VZT:
MY%Q)-]D"_:2&4XVA@$^[CC- '"^!KNZGE\9OI]SJ$>AP6;I%:ZA-NN(IMG4C
M)*]'_3J0<7M!\3RZ#\ 5U62=WO&$T4#NQ9C(TK*O)ZXZ_1:ZJ?P!_P 5;JFM
MV6I_9HM3LVMKJU\C<&8KC>#N&#T/3UYYK*'PG$F@:!HEUK7G:?I=P\\T0M=O
MVHLY;!^?Y< D=^IH YWX;W]YX9\7PZ%J6I&[BUBQCN(F,WF>5, 24SDX/WA^
M"UT/A:YGD^,_B^!YI&A2&(I&6)5>$Z#M5S6?A1HUR;*XT$1:)?VEPLZ7$4)D
MSCL5W#O@]>WO3;GX?:TGBW4O$&C^+!ILU^%$B#34FP  ,99O49Z4 5?BVFOF
MWTJ73X[^;28Y6.HPZ>Y25UXQR,G&-WMZ]JM_##4-"OK.^;1-3U6=04\RSU*7
M>UL?F^[['ZGI6E<>&?$D^FV:#QI<1:E;F3?=I91A)@Q& T6=ORXP#GN?6G>$
M?!2^&;O4=0N=1DU'4]1<-<7+1+$#@D\(.!R:!'%_&'7EL]5TBT:\N9+-%DEO
MK&RG,4I7@(S, 0!GUKI/AOKL3Z'8:+>:P-1UA;7[2^PM+LB8_(&DQC(! P3F
ME\0?#N;5/$=SK6F:Z^FSWEM]EO(VM4N$ECX&,,>. /7I3_ WP]_X0:ZOOLVJ
M"YL[H+^[DM0LBE>G[P-R.3QC^N09R9\1R?#+Q7XCT^_EEET^Z@:^TSS&+#?S
M^['H,Y'_  $>M9,,_B#3-!\-Z3_:5Q;:EXKNS-=7A<EXHR5"JGH2&W<8P3BO
M3_&7@6P\9_V:;R0QM97 D)"9\R,_>CZC&<#GMBK/BKP?I_BO3H;:Y:2WFMG$
MEK<P':\#CH5]N!Q[#T% '">,=!N/AYHT?B/0=;U,S6\R+/!>7)ECN58X.Y3W
MS_7&*R_B9HMM8>';#Q%I]UJ<-SJE_&9$:[<JJRH[D =!R!78O\.+_5I[8>*?
M%5SK-C;.)([/[,D",1TWE2=W\^OK6OXX\'#QEH]IIXOA9"WNTN0XA\S.U67;
MC<,?>Z^U '(^/?#EMX0^&VLR:7=WXDGDM]SS73.5Q(/ND]/O'-1^ ;?36UG3
M9H]'\8P70A+?:;]6%J28R"<EB"#DXX]*[OQGX:_X2[PQ<Z-]K^R><R-YWE^9
MC:P;ID>GK6?H/AKQ1I5Y:?;/&7V[3[==AL_[,BBWJ%(4;P21@X/OB@1U]>6>
M//\ DKG@?_?;_P!"%>IUX_\ %+5+;1?B-X1U.\+"WM@\DFT9. PZ"@#V"N,\
M6?$O0_"S&UWM?ZF3M6RMCEMW8,>B_P _:N3;6?&_Q+)CT.%] T!N#>RY\V5?
M]DCG\%X[%J[+PG\.M!\)*);:$W-^?OWEQ\TA/?;V4?3\2: .-3PQXS^(TBW'
MBFZ?1M%)W)IMOP[CMN!Z?5L_[HKTG0?#6D>&;(6FDV4=O'_$P&6<^K,>2?K6
MM10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% ''?%7_ ))GK?\ UR3_ -&+7S;IWC'Q'I%DEEI^LW=M
M;)DK%')A1DY/ZFOJKQ7H?_"2>%]0T@3>2US'M60C(5@01GVR!7A)^ WBO)Q=
M:21Z^=)_\10-'*_\+$\8?]#%J'_?VO2O FD>-_&&AMJT_C6^LH&=DA5?WC-C
M@D\C SQ^%<__ ,*'\6?\_6E?]_W_ /B*ZKPQX+^)OA*REL],U+13;2,7$<SN
MX1CU*_)Q_+VH \_\1^)_'/AKQ!>:/=^);UYK9P"Z2G# @$$?4$5E_P#"Q/&'
M_0Q:A_W]KL]1^"_C?5M0GO[[4-,GNIVWR2-.^2?^^/TJM_PH?Q9_S]:5_P!_
MW_\ B* %^#M_=ZG\4'O+Z=[BYEM)"\KG);[HY_ 5]'5Y+\,_A9JGA+Q!+JVJ
M7=JQ$+111V[,V=Q&220,=/UKUJ@&%%%% @HHHH **** "BBB@ HHHH ****
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M:67_ !+D)F1;TF1F$2R81?+Y&6"Y)'.>.U7M4UJ:P:5(K6&5H;1[N8R3F-4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+25+22&>Z>5Y&<F11L*AB<!<=, @#Z52/ART8%WFNGNMZN+II3YJE0P&#T
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M)PGF>9)&3&"%?8[)N ). =N1R>#WJ!O#=FT8_>W0G\TRFY$Q$I8KM/S>FWC
MX';!YK3MK:&SMHK:WC$<,2!$0=% & * ):*** "BBB@ HHHH **** "BBB@
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M,DGG#Y-@W8..0>1@J>M<VGPQNAHUEIS^0_V>Z\YY6O6W3(553$W[G[NU$'_
M:W-8\+7^L^(M-UB:ULD>S^]$+Y]LX&=F[]S_  EF(^M %VZ\=Z7;6]]<B&[F
MM[*"WGFEB12 LWW<989P/F/H/6F77Q!T>TN]9MWCNF;28Q)(RHI$V=HVQ\_,
M074'..2*SM#\&7NC>'=0T4VUI=0WP997EOGW;-@C51^YZ*J@"J$7PYO$M]'C
M<6\CV$[S2R->MF[W2+)M?]STW(GY4 =EKOB2W\/VUE-=6MW*;RY6UBBMT#OY
MC*S $9']TCZD=N:RI/B'ID-GYTMCJ23B^&GO9^2IF68H74;0V""%X()ZCWQE
M>)- \6:G'8(C1.\>LK>I+'=C-M&$8!1NB *@GT8G/0CH^#P5JD;PSSFVN+P:
MHFIS3O>$&5U0H%P(0 H![4 :U[X]T^QEG22PU)TM(XWOI(X0RV>\ @2?-G(!
MR=H;%/G\=:;!KHT4VUXU^\D2PQ(BGST<$^:AW8* *<DXQCI61JO@S5=2O-2D
MC>*TMM4""_MHKW(FVC;P3 2F0,''6F3^"-3EUE=906T>HPS1M;2K>OM@A12O
MDA?*Y4@MGN<T ;L7C73II4@6WN_M#:FVF>057>)%!8L?F^X%&[/IVI+7QOIM
MT;15ANDEN+J>U:)U4-"T()D+_-@* !T)^\.*P=/\/ZV_Q!OO$LNCVUNOE^5%
M#+?Y5Y,!3,NU#C**HY /)JW:>$;RU\4:CK?V.RD-ZC*;9KY_+C+A1(P_<]6V
M+F@"_8^/-/U":W2*QU%%O$D>QEEB55O-@)(CRW!(&1NVYK-TSXCQ2:!'J.I:
M9=02S7<EM;PIL)F*LP^4E\# 7YBQ49Z9XJ/2O!FJZ;>:=)))%=VVE!QI]M+>
MX6'<-O)$ +D X&>E5V\ ZDU@+/-J8X+Q[RRWW ?[.SEBZD& AU.\\'VH [31
M]>L=;T<:G;.RV_SA_,P#&5)#!NW!![XK(B\>Z?)H[:J;'48[)W2.U=XES>,[
M;5$2AMQR?[P7KFHK/1->M+>SML6+6\2S"XA6<1K<[^FX+  NWH,?CFLN/P3K
M*Z(FD27,<EI;21RZ>3>8DM&1LJ0WD?-CISVH V)/'^FP6DTEQ9:A#<0745K-
M9M$IF1I?N' 8@@^H)J.W^(>GS7<=L^FZI QO5L)&EA0+#.WW58ACUXY7/49Q
MFLW_ (0K59?-GNFM[B^GO;>\GN6O""_D'Y$"B$ +U]^34TGA#4I)9G,=H/-U
MB+5CB\;ATVX3_5=/E_6@#H]:\1VVC7%I:FVNKR]N]WDVMJ@9V"C+-\Q  &1R
M2.M9C?$#2RFF?9[34+F743,L,,,(,BO$5#JP)&TC=],*>>F;^M^'!JU]8ZA;
MWTUCJ%EO6&>)5;Y7 #*RL"".!]"*IZ;X(L]+O-)N8;J=WT_[2S-)@F=Y\%V8
MC'.5[4 7-?\ %%IX?N+"VFM[FYN;YG6"&W"Y;: 6Y9E'<=\GM0?$]NWB%]%M
M[*]N;B$(;F2%%\NVWC*[R6')'. "<4SQ7X83Q58)8S7C06W/F*L$;E@<="P)
M4C!P1ZTR/PI]DU]]4T_4[FU%PL27<&U76<1C:IRPRIV\$@T 1+XYT\:E=6$U
MI>P300RSKYBIB58_O;<,2#R.&"T_0O&MCK][#:PV=];//:"]@-U$JB6+(!*X
M8]"1UQUR,CFLFP^&=II\D134[AUBM[BV0-#&#ME&"690"S#U.<ULZ9X3@TV^
MTJZ2ZD<Z=I@TY5*@!U&WYC[_ "#\Z ,[6?%U[9^*)]$@TNX*#39;I;H;#AA@
M!L%ON#.#QG..".:C\)^.([_3M+@U2*[AO)].%T;J>)4BGV@>85P>V<]!QTXK
M6U?PN-3UF+5(K^6VF%I)9RJJ*RRQ.02.>AR <BH;?P7:0_V*KW#RQZ78R6(1
ME $J.JJ2?3A>WK0 OA[QOI?B2]:UM$N(Y/(^T1^<JCS8LXWK@G')'#8/(XJG
M<ZGKVK^*=4TG1;NTL8M*CB\V6>W,QFED7<% W#:H&,GKS5SPUX/A\-2'R;MI
MXDB\F%7MXE9%R.KJH9CP!R:CUKPG<W-_=ZIHNLW&DZA=0"&9D17CEV@["RL.
M",XR,'% ')WWQ"OY++PW.VH6FBK>B\2]EDMS.B20%5^49!P3GOW]JZ_0]9U*
M_P# $>L7T*07SVDDVU5(7C=M;!Y ("MCWJMI7@B"WM_#WV@)&^E6\\3P1L9(
MYC, ')9@"<D$]/XC6II'AQ-)\+#05NY9H%C>*.1P-RHV<#WP#C\!0!QW@CQG
MJVLZK9P75];WT4^GFZG5+0P/;OD85<G]X#D\@5O#XB:4MIJ4\]K>V[:?$DTL
M,BQERC-M##:Y'7J"01Z56T_X<QVZ6\=[K5[>1VEE+8VBA$B\A)%VL05&2V ,
M$FH4^%]H--OK-M3F;[79)9%U@C38B,&7 4 9ZY)Y.: -=_&ML'LH(]*U66\N
MT>5+185$JQ*V/,8,P"J>,9.>>F:;<>.],M[V:%K:]:UM[D6D]^L0-O%,2!M8
MYSU(!(! )Y-6M7\--J&L6VKV6I3Z?J$,+6_FQ(CAXF()5E8$=0"#6=<^ ;:X
MN+I#J5VNEWEX+ZYT]0FR24$,?FQN"EE!(!Z^E %#Q#XZ;[1#::1'>)Y>L06$
M]X85,+$N!)&"<G.#C.!['-:O_"?:/_;W]D[9]WVK[']HPOE^?_<^]NSGC.W&
M>,U6N/A_%+?O+%J]W%9OJ::HUF$0H9PP).[&[!(Z9Z\U8@\#VMKK\NIV]T4C
MFNC=R6[6T3YE/)(<J74$\X!Z],4 :7B'Q%#X=M4N)[.ZN(SN+& )\@ R2=S+
M^0R3V%<W<^-I8/%JBWAO=0TJ;0XM0C@M(59OFD;,A)(.-H'&?H,UL>)/!UOX
MCO;6ZEO)H&ABD@*K&CAD?&[ <':W'WAS6>W@!XY;26RUZ[LY+?28]*+1Q(V^
M),_,=P.&YZCI0!:E\>Z9LMFLK6^U%I[07NRTB#-'">-S;B,<@C R>#Q3?^%A
M:*;'4+Q5N7BLX8)QM09G2;[AC&><GY<'&",5&? %O;+;?V3J=YISQ6(T^1XP
MCF6$'/.X<-DD[AZT2_#K26O-"FADFBBTE%C$0Y$ZH0R!_7#9;ZDT 37/C_2+
M36CIDJ7(9)HX)I@$\N*1\;5;YLG[PR0"!GDUU5<K+X'M6\0RZM#=&(7$R3W$
M#6T4@=EQT9E+*" ,X/TQ754 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ')S^([P3:T\
M,EN8K#>(H&M9-TI6-?\ EINV_P"L)7&,\?B"3Q/=FUT:*"*!K^ZDB%VI!V0K
MNVR8YSG*OMR?X&/.,'5C\/6T:31FXN7AEG^T&)G&T.9?-..,XW=L]#BD'AK3
MAYFU)%,EQ)<LP<YWNK*?H,.V!T!.: ,&/Q9>/H<&HFZM$^URQI$IL9?W2MER
M6^?+XC5C\N.1Z5=A\0ZBD-D9[-)GOHG%J(D9 \BL=I;).Q6C(?GE0K Y.!6K
M:Z';VJV@,T\PM"3")6!V?)LQP!V)'XFI;?2+6U6Q6/?ML8C# &;.%( Y]3A<
M9]S0!E?VW>117%M-]F;4([H0!E1A'M\M)&D(W$X56/?DX&>:AL?$E[/X9U+5
M)H(5EMH5,<:J1ND,*/M//]Y]OX&M:;0+&>>_G=7\V^@\B5@YX4C!V^A( R1U
MVKZ5 WABV,%S +J[6">7S3&KC"/O#Y7CU X.>.* (KW5KN/7K;2X9[>)C LL
MS/:R2Y+-M4#:P"_=?DYZ>QK2U:_.FZ>UPL7FR%TBC3. SNX103V&YAD]A54:
M"T5Q+=0:E=BZ>(1EY"KJVW=M++@9P6)P"*NRZ=#<Z:+&Z+SQ[%5F<X9B,8;(
MQALC.1C!Y% &9>7VI:9:YNKFQFN;AA%:QI T8$AR<L2YRH +'&#A3WP*0ZY-
M_P (=!K&R+SY(8C)U\N)F(5F/?:I))YZ*>:M)X?LS,);LR7SJI5/M9$@0'&<
M#&.<#GVJ:+28+?3C8VLDUO%O9U,38*%G+$#CIDD8].* .;D\8R+H^J/;M:WU
M[:/(L3P*1%(JQI(9,;B<#>%X8Y;@$9XLKXEE.JO;RS16]O;R^1)(]I(ZRR!-
M[A7R%3'( .[H?;-^?PCH=U ([C3X)VR"TTR!Y6^;<<NV203G(]"14O\ PCFG
MFZ,Q1RA8O]GWGR@Y786"],[>/3OC/- &(_B?48(-\T5L)+B"&>")8V+1"23;
MM8!LR,%RV%QG8P'K6[H%_/J6EK=3F)MSL(Y(U*!T!(#;225/L3D=\=!!'X7L
M(HD"27(FC=7CN#,3(FU2B@$]@K,,=/F).22:T[&RAT^T6V@#"-2S99BQ+,2S
M$D]2223]: +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%4;_ %'[#>:9;^5O^W7+6^[=
MC9B&23/3G_5XQQUSVQ59_$%K;W]];W96!+9HE5RV3(SJ6P% SG@\#- &O16;
M+K^EP- LM[$C3*'0,<?*3@$^@)X!..>*LW][%IUC->3[O*A0NVT9.!Z"@"S1
M7./XNL5FTMW=8K.^M)KA7D!# HT0VX^DC$_[N>E:4^NZ7;/"DU] IF57C^?(
M*L<*V>P)X!/!H T:*@O;G['87%SLW^3$TFW.,X!.,_A6;'XHTH) +F[B@GDB
MCD:)FSLW@$9..!SC)P* -FBLB/Q)ISWVHVKR&(Z>H:>24%4 QDG<>.*<WB31
MTM%NGOX5A:7R022#YFTMLQU#8&<=3QZB@#5HK..O:6NH&P-[$+H.J&,GD,P#
M*#Z$@C'KVI6US35O7LS>1_:$SF,')R!N(_WL<XZXYQ0!H45GZ+K-MKNG+>V@
MD$99EQ(I4@@XJ"/Q)IS:AJ%H\AB-@@>>24;4"GJ=QXXH UZ*IV&J66IB3['<
M)*8\;U&0RYZ9!Y&>WK4$^N6EOKUMH[B3[3<0O,I"$J I48)]3O\ TY[9 -.B
MLI/$NCRV(OH[Z-[8MM$B98$XSQ@>A_"EN?$>CV;JEQJ$"%HEF'S9'EMG#Y'\
M/!YZ4 :E%4O[6L?M_P!A%PK7/=%R<<9 )' ..<&J*>+_  _)%YJZK;%-H?(;
M^$_Q?[O!R>@P<]* -NBL74?$5KI,5W/<E7B@,8 A)=_GZ9&,#VY-:;7D"6;7
M;/M@6/S2Y!&%QG..O2@">BJ4^K6%N',UU$@2)9F+-P$8X4_B00/6DAUG3[B%
M)8KJ-D>7R1SSYG]TCJ#[&@"]16=/KVF6Q FO(D)E,(!/)<8RH]3S5NYNH;.'
MSIY%CCW*NYNF6(4?J10!-16?<ZWIUFSK/=QHZ.(RO5MY7=M ').T@X';FJ[^
M)M-%[I]M'*9C?AC#)$"R<<<D>_'MWQ0!L45C_P#"1Z?;VMO)>W=O$\X=HPC%
M@P0X8KP"<9&>.*FO/$&E:?'&]U?P1I)'YJL6R"G][C^'D<].: -*BF12I-$D
ML;!D=0RD=P>E8Z>*-+BM;9[R_M8I9K:.Y(1RRA&!PX) .S(/S$#WQF@#;HJB
MVL6"W<EK]H5IXUW.B@MM&-W.!UQSCKBJ-GXMTF[TZWO3<>0EPYCC692K,PZ@
M#OZ\4 ;E%5/[3L\9^T)_KOL_7_EI_=^M59/$>F)#=R)<B86B,THB!;[IP0".
M"0>/;O0!JT5D6>NVU['%<+)%';26GVDF5BCJN<$D$8"CUS^G-21^(=)DM)[I
M;Z'R+?!E<G&P'H3GH#V/0T :=%9JZ_I;V<EVM[&88W$;GG(8XPN.N3D8&.<B
MKT$T=Q"DT3;HW4,I]0: )**S?[>TS-U_ID8^RQM+-G(VHOWF]P,=12V^NZ7=
M1W$D-]"R6Z>9*Q; 1.<,2?X>#STX- &C16/I>O0:KK%[:6KI)#;V\$OF+G.Z
M1I000>G$:G_@5,O]=6V\16&D+L#3Q23R/(K854*# P,9._J3@;?<4 ;=%9<7
MB/2)XIY8M0A9((C/(P;I&.KCU7W&15VSO+>_MEN+65986SM=>AP<<4 3T51A
MUG3KB_>QANXGN5+ QANZ_> ]2.X[=ZS].\46,VDZ7<WUQ!;7%]:Q7'E;ON[U
M!_ 9. 3UH WJ*I/J]@E_]A-RAN<9,:Y)7C(SCID>O6L^V\7:1<:>;U[C[/#]
MIDM5\Y2I9T+# ]<A"0.O;KQ0!NT5GMKNF)??8FO81<;Q'LW='(R%)Z!B"..O
M--A\0:5<7OV.*^B:X\QXM@/\:YW+_O#!XZX&>E &E162FOV,=M;R75U;I)."
M46)B^X X)' .!QDXP,UI3SQ6T#S3R)'%&I=W<X"@<DD]A0!)16%9^)[&ZU#4
M(UN(19V=K#.\Y;;M+M*"&STP(U/_  *I)O$%N\5I)8R1SK->);/R04)!/(Z@
MXP<'U% &S169:ZS:R6K2RW%NK)"9Y-CDJL8)&[) X^4]NU/CUO39;X627D1N
M3P(\\YQNQ_O8YQUQS0!H45G6^O:9=[?L]Y%(&E\D%3P7P3MSZX4_E5RWN8;I
M'>"175':,E>S*2&'X$$?A0!+16<-=TQKM[5;V)ITW H#DY498#U(P<@<BH/#
M>L'7=->^VHL9F=8U4,"%!P,Y R>_''..U &Q1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E:U
M87-Y]@N+,Q?:;&Y^T1I,2J/F-XRI(!(^61N<'D#@UE2Z'?SK=W=S:V<M[<W"
M2+&EY)$L 1"H*RJFXMR>=HX8CZZ^J7/D:AHL>PMY]XT>0[+MQ!,V< X;[N,'
MCG/4"N=B\2:O>:)'*\%K;S7VD2:A;-&[-Y>T1Y#=.?WJD8Z8(YZD 23PE?SR
MLU^Z:B+JUC@N\W\]L,KN!XC&'!#=PO(/KQU][ ;JQGMPVTRQLF?3(Q7+:->Z
MG'81V%A;6;O9VL<LS32NHD:0%@HZD<#)8YY/2FQ>+[V[TS4=4M+* V5LD+0B
M20B21I(HI #QA<"7&>?TY -/3])O8[S1[F[6V5K*PFM)%CD+Y9FAVE25'&(C
MGIC('/6L*#P3<Q6MO;W"QW<3Z=;V=U&-1GMU!C0JV @PZD'HP!Z\\\:,OB'5
M[6:\6XL[,QV,D0F:.5LNLF/N@C@KGOU]L\/B\2SW.N?V?;K#(DPF6"812[ Z
M>K%0K]\[3P1CGK0!O:C ]UIMU;1D!YH7C4MT!((Y_.N>?PS=MHNM68>W\Z^T
MY+2-LG 98F3).,XR<]ZH67B.[M=%T74-1075S+HLEV6C<IO/^CX!7[N29!EL
M<8., D5>U+Q%JNDR):W-G:2W<XC:W\J5@AS/%$RL2,C'G*0>_/ QR /U?P]>
MZA+JJ(\*P7?V>5'\UU<21,K!2%'"G;]X-D9Z=Z+3PY*EU8W36\4,L5]]IG!O
MIKHNHMY(U(:0 Y!<<<# ZYXK5TG4+JYN;ZSO8X5N+1U!:$G:ZLH8'!Y!ZC'M
M[U#JTTFGZOIEZ9G%I(S6DZ%CL!?!1R.F0RA?^VE %:XT&YF.I%&A!NM6M+U"
M2>$B^S[@>.O[EL?4<CG%:R\+RVVL-+-&MQ;"]EO(Y3J$ZE&<LV/(QY9P6(SD
M<<XSU;INJZE<.BVJH\]^LFH W3L$B@W*L2J!T)7:3Z')Y)JHWBR^28ZH8T_L
M]=,^TFT )?S-Q7&X=?FXSCISB@#I= LKG3=,%G<B+,4C^6T;EMZ%B03D#!YZ
M<_6LW4M!O;R[U$Q-;K%<_9IHV=CD2PN&"LN,%#M&3G/7BK>@:O=ZE+=0W=G)
M$80C+-]GEB20-G( D522I7G&1RO3.*Q](U;4K6("2*![2XU>\M8W,C&16\^;
M:2,8VY&W'88.>U &UI]A?-K,^J7Z6T,C6Z6Z0V\K2# 8L69BJY.3P,<<\G/$
MMY973>(=.U" 1-%#!/;RJ[E2!(T3;EP#DCRL8..O7BJNB:])K$T<8@5/+M5>
MZYR8YBQ4QC_=*/G_ (#ZTR(7*>.+A&O9Y(9+ 2)"Q^2(A\< =^O)YYQT H I
MKX?U6#0M!T^":,I968@N8H[N6W#N$0!PZ#<0,-\O&=V3TIVF^&;JST^2WDDM
MW=M$M=-5@3_K(Q*&/3[I\Q<=^#Q4WAO[>EK>1-=M=R1:E)&\MTQ)*#&<8X'L
M!@"J-DMYINI.E[#?_;;RYNQ9SR7[R0,2TDD:&+?A<1@8^7^$]#0!<M]%U*WU
M2SE@%O;Q(L8NI8[EV-P%C"D-$4VYR  ^<X4?2H]/\,W5I86D#O;EX=$73B5)
MQY@ !(X^[Q]?:J6AW=Q#KNE6I_M;S;BTE-^M\9"OFJ$Y3=QP21^[^3YA[4FH
M&_N?%6HQ67]I-<1/:F%X[AEMXE/+[TW!2",_PDGMS0!>;PW>_P!F:A;B2W,L
M]O;)'EFQNB49R<< D=<'Z5TF\_9-]TD:'9F50Q91QR 2!D?@/I7+:W?75AXS
ML[E;F46,-L/M,.X["KR;-Y'3*DJ<]E#4[2+VZOO&UY,UQ(;)[4BWAW'8 DFP
MOCIEF#G/==M %/1O#]U-H;3I(K3)>1O9^>"H:W@;;"K<$\J&;.#R^<=JT7T+
M4Y3/?M]D6_>]AN5@65C%B-0NTOMSDC)SM]!CC)M>,I98O#V83<;FO+2,K;2F
M.1U:YC5E5@RX)!(ZCKU%4KS67T+2HEM[:XCGV23&UO7ENIMJ^K1F3 /]XG R
M..U $FG:#J$>HV][>&TWI=W%PRQ,S!1(@4 $J,D=">/Z5NZG8QZGIEU8RDJE
MQ$T98=5R,9'N.M8T6OW=QJ44 BAM89XU:V:X5SYY:/=\K ;<@Y&W.X[2>F*R
M++Q5JL6GV,,L275]/%).TB6\SKM5MH4B-6().>>  .] %^TT'5K1K+4BUG<:
MJGGFZ1I&2.0RE#E6VD@J(T497D9Z5+::%?VES8W8-L\RW<\]S'O9542GG8=I
MR1QU W')XS4$OBG4?L>IWJZ>D,%CIRWC1W!99=[1%Q&5QQ@C!S6MI^I7S:M)
MI^H06Z2>0MPA@<L "Q4J<CJ"!R.N>@H J:5H-S97FERS-"PM+6ZA?:226EEB
M=2..F$.>G4=:Y^]L;S0-(BM4:UN+N70XM.>(^8?FC5P#& AWY,C?*=O1>1S6
MU_9L?_"<;/M6H^7]D^T^5_:$^SS/-Z[=^,?[.,>U9\'BF^AT1+FVL8&MK30[
M;4YA).Y<AED)0$Y).(S\S'KUSG( .PT^%[?3;6"3AXX41L>H !KG=,\,W=GI
MTEO*]NTC:':Z:"I)'F1B4,>1]T^8N._!XIE[XJO],N387=G$U](T/E>0))4
MD$QY"J6)40/T'.1TYQHVWB!QX:O-7OK.:#[&DSR1F-T+K&"=RAP&P0,C([X]
MZ *]EHVH6NL6L\?D06Z1JMTT=P[&ZQ$$&8RH52"%^<')"@'KPFFZ%>VSZ4+@
M6VW3Y)\,CLQ='!"G!48/)R,GZFH-3\2:MH\ :\L;1Y9H6D@6&9B%92N48D<\
M-]X>G3I6OIFH7DNIWFG7\4"SP113AX&)5DD+@#GG(,;?7CZ4 9DFAZI]O"1F
MS^Q?VF+\R-(WF$=TV[<=<G.[VQWJQI6EZA9Z&=#G6U^S16QMX;F.5B[C&T%T
M*@ XZX8Y/UXS)%FO-'UG6GU*ZM[NTFNA $G98H!"S*NZ,':P(0,=P)^;C'&-
M6QU?4-3O)8[>WMXH;8QI<&9CO+M&LA"@= %=>2>3D<8S0!0D\-7][8"&Y>VA
M?^R_L1\MVD7>&!!Y5<J0!D<=2/>GWN@ZGJWVV>[6S@GFMXK=(HI6D3:LF\EF
M* ]\ 8XYYYXBTS6M8-K#!,;6>]NM0NX(G(94C2*60$G')P%  XXZG@FHQJVI
MW_B+3EMH;=+J."_@G225C$&22 ;A@9;/;IC<?3D T;_1)Y[C4IE@M[@7+0M$
MK7+P%"@(W;U4E6SC&/TK7TJ&[M]+MH;^<3W21@2RC^(_Y[\9KEY?&US)%!]B
MTUY)C9+=RQB*67DLZB-3&AP28W^9L#IP<G&SI6JWFI:IJ,9MHXK.T=(E+$B5
MF:**3E>@QYA'_P"J@#GF\):U<P78N[F&2XFTFZL3*]W+())9=F'VLNV)?D.5
M4<9'7%;6L^'YM3GNS')%%'-8?9DR"<.'W#(_N_CZTZ47,7CVS!O)VMY].N6^
MS9Q&I22W ..[?.W)]<50\)K-I[VNFZI%J*ZJUB'>2XOWN(YBFQ9&4%R%.YE[
M#AN.] &GI-CJ2:[J&I:A':1?:;>WA2.WE:3'EM*222JYSY@[>W;)-<T*36+K
M_7"*!]-N[)V'WU,QBPP'3@(W?TK3OXX9+*5;B9X80N7D24Q%5').X$$=.N:X
MZR-U<_8;-[J^CTV_O9I+<O<2"<P+%E5,F=XW,&<<[MN >XH MZIH&L:U9317
M2V%O(FG7%I#Y$KL'>5 N6R@V*,?=&[MSQSURJ$4*H  & !VKA[F1I/#]U&]Y
MJ#WD%W/9:?Y-VZ/,^3Y8)4C?MZ$MD85BW>IM8CO+"_DU/4TO[C3K>PA,DEG?
M/"L;HTAE<QJZ[A@H>AX7'M0!/H_A>33M1B:>-9H[>:6:"X.H3D@OO_Y8'Y =
MKD$@^^!GC/@\$W,5K;V]PD5W$^G6]G=1C49[=08T*M@(,.I!X# =_7CO*\_F
MUO4U\+ZB%L]28IJ-U&M\LT>U5%XZ@#,F_ &%QMZ# XH Z:QLM0T[5+SRX[6:
MQN[@W#2-,RRQDJ 5V[2&Y48.X<'';FG;:%?1S6(E%L8;35KF^5@[%G243D#&
MWA@TP'4C )SVIESXGN%UM+"TCAN!-++;Q,(Y0JRI$[X:3;L/,94J#D?@<5Y_
M&K&.WDM+4R+<"!$.QW*RR(\K*50%CM1 2 .K#IR: )Y- U)K:XTM3:?8)[UK
MHW!=O.4-+YI4)MP2#D!MW QQQS/%H-Q'9VT6Z'?%JTU\Q!/*/-(X'3[VUP/P
M/-3VNKW]WX=N;U=/=+V$2A()$>,2E<X(#@, PQC(XSWQ5)?%4M_>1P:7##+'
M<.J03RL0O^J\UV..H"L@ '<GGB@!NFZ'JNC30W%LME<NUJMM-'+,T84+([JR
M,$;.?,((('0<\5MZYI[:KHMW8I((WFC*JS#(!ZC([C/7VK-L?$%Q/JL>FW%O
M&DZ3RP3E&++E8TD4K[%9%X/0Y'.,U'IGB"_U.^LX(K:W6*2!IYG9SE0)"F%'
M<G&: *MYX=U75I-6FO#9VSW4-FL*6\\C8:"5Y/F?:I )8#(Y SZ<V+?P[,JP
MR^1'!/\ ;H[B;-_-=;U1<#YI #GG&,8XZU+JNMZE::E?6]G:VLL5E8QWCF60
MJ6W-*-@P#CB/KV]#GBO<>*+M)KJ2"SA>UB%LL>^0J\DDY54!X(4!F&3SQVXH
M BE\*7;Z=I=N)H T6Z"]Y.)+=W#LHXY)VJ.<<,WXR67A>6VUAI9HUN+87LMY
M'*=0G4HSEFQY&/+."Q&<CCG&>LEYXBO]*-W'?6UL[VL*7;-"YP\)8JX /1QC
M('.[IP>C)/%5Q;V,-S/:Q?Z99-<6:))G>^X!(B>F2)(^G?=V% #+_3Y-*\"_
M924:^@/F6PB4L&N _F1@< \L #]370:/8?V9I%M9L^^2-/WC_P!]SRS?BQ)_
M&J^IZC=6DEC9VT4,EY>,RAI&(C0*I9F..3TX'OUX-9M_XEGT_4+>V=89F\Z"
MWN5ACE;8\KJHR^THN-ZG#')'U&0!+70=0B:QLY#:_8;*\>Z2=9&,LF2Y"E=N
M%/S\MN.<'@9XV-#L9=-TB&TF9&DC+9*$D<L3W^M8T?B'4Y5&VTM0;G4IK"T+
M2-C]VTNYWXX^6(X ZGN,\6_"LMS-!J9NPHF74)5(5RRC&.A/:@#?HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDFAD7[,0%P@<_)(IYQMY&#US0!>$6C^'DO[W=*\MK:^=.TMQ)<2K"-QX+L2
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MIB^6-E<H!YF#R!\O' (W;JVO8_ \=NL]Q=W2QQ8E\ITD?YEY*DE@<=<\\'-
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M-2V&B:?IGE_8[<1>5%Y* ,Q 3<6QR?4FJN@6LD-I?6DJ2K EW*D*R9_U1P0
M3_#R<>U<M!#JES:3B4W;PZ9-%ISB)F,D\229DD&WDED\K..?E<#DT =-=^&;
M74M<N;^]W212VD5L(TE=,A6E9@VT@,IWK\IR.*ORZ/83K=K+;*ZW859@2<,%
M&!QGC'M7*PBYM;J&\M[?4%T>#4A(D1AE,BQFV=&(C(W[/,9>,>IQBC3;2YU+
MQ';W%U;W\=HLE],@E#Q@GS(/*W#CJ-Q /H>.#0!T<7AS3(CN\F21_,20O-/)
M*Q*9*99F)(!)(!X!YQGFJT_AR"2ZTU(XXDL;*Y:\6,[F;S3NP!GA5!<M@=P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@"O>7?V.#S/(GG.<!(4W-63+XNTV-(G1;J826WVK]U
MS%8@<%F'48[CK[5/KVB'6EM1YL 6"0N8KF#SHI,J1\R;ER1G(YX]*IZ=X4&G
MVBVZWFX+8-9 ^4%ZL3NP#COTH 9KOBJ&TLKG[%YLDL0CS,L)>)"Y&T,?4@@^
MV1G&16AKFLMI'V+;9S7/VFX6']WCY<]_K65-X0N3:3V=MJJ0VUT(6N UMO9G
MC1$RIWC:"L: @@]."*VM8TZ748(!!<)!/!.D\;O'YBY7L5!&003W% $">);"
M2Y6("?RGF-NER8CY32 D;0WU!&>A/ .:GO-9M[.[2T$4\]RR>88X(RY5,XW-
MV SG'<X.,X-9T?AF=$ALVU!6TN&Z%RD'D8DRLGF*IDW8VA\'[N< #/7-RZTJ
MZ.KG4M/O(H)9(5@G6: RJZJS,N,,I!!=^<GKTH B;Q18"6>(1W3O#-]GPD+'
M?+_<7U..?0#DXP:D?Q%:+I_VU8+N2)2XE"0$M$4X;<.V/U[9JG?>$HKZT:*2
M6&1QJ#7T?GVXDC#,"NUD)^8;68=1U![54O/ Z7=M##NTR-5BEC>)--'D@N?]
M9''OPK@#&X[J +X\40+JM];RP2):6MG%=F[QE&5R_0#G^#CU.1CCG0T[5H-1
MDFB2.>&:$*7BGC*.%;.UL'L<'\B.HK)N?"0N8IX'O!]GN-.BL95,.6_=ERCJ
M<X',AR"#G _&]H>B)HZS'R=-227:&:QL1;;@,XW#<V>I_,T 5M0U?2A+++J%
MM.C:?#+>(9HB R1XWN@[XR.O/((K0T[6+?4I9H8TGBEA57:.>,HVQL[6P>QV
MM^1SBN;B\ ;(+J-KZ#?/IMQIYF2SVR/YNW]Y*V\F1QM]@<GI73Q:?Y6MW6I>
M;GS[:&#R]OW?+:5LYSSGS>F.,>_ !77Q#8OJ M!YW,QMUF,9\II0"2@;ID8/
MMD$9SQ69IOBV :%IUS?^:TTEA!=7<D4)*0AU!W,1]T9S] ,].:DL_"-O9:R]
MZD>G21O<27.9+ &X5W)8XFW=-S$CY<XXS5*+P%;PK: _V==>79P6DWV[3A-O
M$2[=R?,-A(ZCYAP/?(!NC78)+B>&WMKJX\@LCR1193>HY0,< GMQQGC.:H:;
MXMM[NPT>6>UN(;C4[?STB";@JC9N8L.BCS <G''Y5=T_2KK3;N98;R(Z?)-)
M/Y#P$R*\C%VPX;&-S$X*D\XS5/3O"YM(=.AN;M;B*RT^73P%A*;XW\K!/S'D
M"+!QUW=L8H GB\5:=*JOMN8XI(FE@DDA95G55W$H3[<X."1R.*B;Q39W%C++
M"TUNRQQS(T]NWS1NV P7(R.W4$<9[9A_X1>ZFMK:UO-46:"SB=+8+;;'#-&T
M09SN(8A';H%&3]*FN_#'VJ-$^V;=MFEKGRL_==6W=?\ 9QCWH OP:Q!=7\EK
M!%<2"-S&\ZQGRE<=5W=R.G'&>.M))KEE$TR.S!XKE+5E(YWLJL/PVL#GT!]*
MCT_2KK3;N98;R(Z?)-)/Y#P$R*\C%VPX;&-S$X*D\XS4-WX;AO-?_M&68F$P
M&-[;;PSX91)G/!V.Z_B/2@"*3Q=9"U,\5O=N'A:6VW0E!<A1GY"?;GG!QD@$
M"FIXH@2TCOKP26\1LA=/ 82SJ"P&<@\]>F,]_:DC\,7$D=G;WVI"XMK)&2W5
M+?RWR8VBW.VXAB$9AP%&3G'2FOX5FFLTAN-01I%LEM-Z6Y4$*X8-@N>P QGW
M]J +G_"3V*Q3M+'<PRPM&I@DA(D;S#B/:O?<00/H<XP:MZ7J]OJRW)@2:-K:
M;R)4FC*,K[5;&#[,.:R]<T8R7-QJB2R^=LM1$D4'F%'ADD8-C(W ^:01P< X
M.>DOA>UOH8]2NK_/FWMYYZYC\L[1%'&/ER=OW. 23C&><T 00^+["*RMWG>>
M8FPAOIIX[9@B1.#^\89.T?*QQDD#UP36D-<ADNKFW@MKJ<VQ*R/''E=X ;8"
M3UP1[>]9<7@_R]$NM-^W9\_18=)\SR?N^6LJ^9C=SGS?NY[=>>+AT.9_$::J
MUQ;($)^6"V*22J5*A9'WD.HSD#:.0/?(!!H_BR#4K?2M]G<Q75_:I<B(1E@B
MG&6+#C;DCDXSD<5;/B734T^ROI)6CM[NW-S&[+TC"!R3Z'!'%0:'X>ET@V?F
M7J3BULELH]L)3**1M)^8\X'/K[=*SSX*FFM+2QN=5#65E;/;6ZQ6VQPI4*K,
MQ8@LNU>P!YR* +U]XF-K;VLJ:5?,)[E(-KQ[& ;^+!_EQ[XJ4>(+>%Y(G:6Y
MG-S)#'#! =_R $]SP,C+' Y [C)<Z3J5[8Q1W.HVINH;A)XI4LV5/E/1D\PD
MYYZ,*A/AN>&^-_9WZ1W@FF<-)!O39+LW(5# GF-""".E $K^*M/'V98H[N>6
MX65EBB@8NOE,JR!A_"06'7\.V4US73:^%'U;3E-P)(E>!U7<,/C:Q!(XY!I=
M.\._8-1@OFNS+,J7(F/E[1(\SQN2.?E \O '/!'/'+E\/X\(6V@_:O\ 4VT5
MOY_E]=@49VY[[>F>] ##XCM+)1%=&Y9X40W4WD?+"6 (\PCA3SD@9P#DX'-+
M-XJT^ 7C,ET4LYDMY76!B/,9U4*,?>.77IGK46H>&I;Q]2BBOUBLM4Q]MA,&
MYV^01ML?<-N450<ANF1BIY/#^^UN(/M./.U&*^W>7TV2QR;.O?R\9]^G% #8
MO%=A)<>2T5W&RS);RF2!@L,CXV*QZ9;<N,9^\O3(K<K%G\/^=]N_TK'VK4;:
M_P#]7]WRO(^3KSGR.O;=T..=6W29(B+B5)'W,=R)L&W<=HQD\@8&>Y&>,XH
MEHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $(# @]#4-G9V]A;+;
MVL2QQ*20H]2<D^Y)).:GHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]SS0!IT5 ]Y;QR&-YXE<=5+@$<$]/H"?PIG]I66QG^V6^U0&8^:, 'H3]>U
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M'*B-U /J2S*?PK%LM$U2=M'GU*(&>&1$E&\$111HQ!'/)>4(QQV"@_=KLJ*
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M!10!XGJ]CJ%YX:TC2EMH7$.BBV9E6$O%<8 (9I%8A.!S'SD=1P:T[NU2^7Q
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M@T;J&5AW!Z&GUYU)?7RW6EQ0)=026\EC#M\R8^=&QC\QM@_=A0&92S9.5/3
MJ2ZFUX6M];0/>%]*'DF3+DSI),IW C)9D@'49.YSCD4 >@U6NM0M;**62XF5
M%B56?N5#' ) YP2#^1K'\*>>;:[9[P7%N91Y(\R60Q_*,C?)\S#//?&2/88/
MB:Q7^V-=*M=K-=:;;"$K)(5)$LN_:N2N5!0XQQNSW.0#OZ*X;6%U'39=1M-/
MEO7M0EE*[232R,@>259=K\N!M1,[>0"2,5N^%1/_ &;,9KL7,;3L8"'D?8F!
M\N]_F;YMQR>Q [4 ;E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEU4+CRP,[5'?('.>?6@!VAZO8200FRCFMEN=1G@<7<<Q>5T$G(9QG.(@>>%
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M8)Y&OIS"K11.X3",V3M!_NXQZ$GH#531O$UO?RO:SMLN_M=S;J%A<(WE2NH
M<C:6V(&(!SU. *N:O83WDVFSVTD:R65UY^V0'#@QO&1QTXD)_"J=OH,L/]G_
M +Y#]EU2ZOFP#\RR^?A?J/.'Y&@"[9Z]IU_=?9K:9FD(9E)B=5D"G#%&( <
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MUMY1()(^;[_U'I[UR=IXXUJ3Q4;,7]M*IUV73OL+6A0K K$>8)LX+ #[O4T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:O<Z9!O5?$"JJLO\#KA)FSV/D[2/=#59]3F@>98]2>+5HK_R+?2@5"F$2[5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+U
MG5+G3GTZ&TM(KF>]N3;J)IS$JXBDD))"L>D9&,=Z?-J]O80P?VI+!:S2#E5<
MNBG_ 'MHXYZD"J7BC1I=833/+M+&\2UO//DM[UBL<B^5(F/N-R"ZGIVK)USP
MWJ^JZ=)9VXM;6WDL#;);0WDL45NYW L B#S%(*C#  ;3P<T =!=>(--M?M8:
M??):(7E2-2Q& #CCC/(X]ZC3Q/I/V&TNYKM($NH_,02Y4A>Y([ 'J3Q[U3?1
M;Z35[V2+R;6RN8I$E5)WD\YV "N8RH5".<E2<]_;-E\+:A-]GEFA@E<V"6,]
MNFISP)A"V&#(OSA@YR&7CC!ZY .BG\1:1:SW$,^H01R6^WS@S8\O=MV[O3.]
M<?7V--M#IVJWPU.VN#.]N&@"[B%B)P3\IZ,1CD]NG7G.?PW+Y.H0Q>2$N-3L
M[J,,Q.(H1;@JQQU_<MCKU&3R<:UE82V^KZE=L4\NZ,10*3D;5P<T 9MMKFKR
M7]_;W.FZ? ED@:647[OU0L,#R1QQSR,>_2K7_"3Z/$?+N-1M8YE5?,&_Y4)0
M.,D@8R"",XS3)-(N&N-=D#Q8U"%8XN3\I"%?FXXY/;-4(_#-TMA=0,UN7FU"
MRN@<G&R$6X8'CK^Y?'U'3G !L_V_I?V(7?VV+R3)Y0/.=_\ =V]=W?&,XYJU
M'?VLMB+U+B)K4IYGG!AMV]SGTKF=1\,7=SJ$]]$Z,QU#[3'$+J6#<AMHX2"Z
M#<K90GC((X[\7VT 2>$IM'C5;5I4<X\YYU5V8N26?#."Q).<9R: +:^(](:T
MENO[0A$$+(LCL<;-QPN<] 2>#T-6[*_M=1@,UI,LJ!BI(ZJPZ@@\@^QKG;O0
MM3U2Z:\NULX)=]HJQ12M(I2*X69B6*#D@$ 8X]>>-K3;"6SOM7GD*%;R[6>,
M*3D*(8H^??,9_ B@#+_X2BY^P?VO_9B_V+][[1]H_>^5G_6^7MQLQ\WWL[><
M=JUI=9T^&\:T>Y7[0J[FC4%BHQGG'3@< ]:P/[ U?^P?^$:W67]E^7]F^T^8
MWG?9^FSR]N-VSY=V[WQVK4L;+4-.U2\\N.UFL;NX-PTC3,LL9*@%=NTAN5&#
MN'!QVY &VGBW2;K38;XSF&.9F5$D4AV*]<+U..#D=,U'/XJT^VU.**6[MUM)
M;07,<X?(8;L9&/X<<Y[52T_1-8TN2VGACL9I;>*6VV23NH>-G#J^[8=K9&"N
M"#Q\W%,M?#^L:7<QW%I_9]Q(UO,DJS.\:J\DS2G;A6^4%B,<9 '(Q0!T$NN:
M9#=Q6LE["LTH4HN[KNX7GH,G@9Z]JBM[C3-3U<W%M<++=6*2VSA&X3<Z[E/O
MF(?Y-<Y:>"7L94MR/MMFRVP<OJ$\!4Q1I'GRTRK_ .K#<XY)&:Z;1-/DTVRF
MAE*%WN[F?*=,23.ZYXZ[6 /N* *LWB%X=5O[)M/D5+6S-TLK2 >;CJ .<#MD
M]\\=S/H>I7FJ6@N;FVLX8W163[/=F8\C)#91<$<>M-FTZ9]=DOU$+Q&Q-N(Y
M"?F;=GG@_+_G%9EO8WND37VKKI=G'*\,<$=C82$K(P8X9VV+_>Q]W@ G)[ '
M0WLEW%;YLK>*>8G 2:8Q+CU+!6/Z5BP^)KB\MK-;/3D:_N6G!AEN-D:"%]DC
M;PI)7=MP0O.X=*O>(8=5N=,\C2&@2:1PLCRS-&5C_BV,%;#=@<<9SVK/&E:C
M;C2[NRL["&XLH9;;[)]I?RC$Y0\2>7D$&-#]WU'O0 MSXGNHM";68=,22U@2
M1KI'N=LD;1L5=% 4AR"K#JN:L'6[R7Q#/IEM:6;1P>7ODFO"CD,,G:@C.<#W
M'X5DG0=;B6RMUCT^[LXGDNYXY+EX?-N7E:3G$;912V0.YQGIS>UG1;G5;E%6
MPTV-?,BD-\9";A-C!OE79UXP#O'7IVH Z2L-?$6[P]:ZK]E_U]S#;^5YGW?,
MG6'.<<XW9QCMCWK6@,Y\SSTC7#D1['+97L3D#!Z\<_6N3B\#VT6CV:+8Z:NJ
M0WD%P]VL(#$)<+(V'V[LE 1]3Z<T =!)K^EQ2SQ27D:/ C/(&R-JK]X^X&1G
M'3O4EUK.GV3.ES=1QNFS*D\Y;.T =R=K<#GBN=@\,:C-JRSZI+'<0!;B.0FZ
ME?S4DX $1 2/ XP,Y]?6!/".I?8K.>XN([C4H;@R2[;J6!95\OREQ(@W*=JJ
MQX(R6'?- '6?VG9FP2^%S&;5]NV4-E3N( Y^I J*YUO3K-G6>[C1T<1E.K;R
MNX* .2=O.!VYJB=,LK3PE<6%VGV:V>.7S@LSS[3(6+$.PW,<L3G'6LK2-&U>
M*UTO6&$$NK,DTEW#<,8E8S;#U 8JR"-%Z'@$4 ;MS)IFO6L5G]K$L-TC2!89
M.)HU(5P2/X<L 1[XJ6'7=,GN+:WAO(GFN85GA13R\; D,/8A3S6+;Z%JMC=6
M^H6YLI;L_:_.B>1DC3SWC?Y2%).TQ@<@;LD\=*L^&M N=':%KAX':/2;.Q)C
M)/SP^;N/('RG>,?0\"@#0N-?TNTO3:7%]#'.-N48_=W?=SZ G@$]Z)=?TJ"X
MN8);Z!);4!IU9L>6"%(SZ9W+CUSQ7/:AIFHZGJWB.QMX[=;:^MX8))Y697C!
M1@60!2'."<#*X/?FKUUX?NI7U*>)X!--J4-_ 'SM;RXHEVOQQDQMR,XR#STH
M U8-<TVY5#%>1G?+Y(!."),;@I!Y!P,X/6A-<TV2WEN$O(S%%&LKN#P$;.UO
M<'!P1UQ6!?\ AJ_UIKW[<;6W2_$$4Z6\A<QQ1%V!5BHRY9L9P, #&2!44^F7
M5SK>BVLK0B6.$?VBL"$1O'$P>$C@!?G'W?1G'(&: .JOM2L]-C1[N=(@[;4!
MY+'K@ <D_2J=SJ6G7CIIXU!H9YPIC,3%6/&X '&,D#..N,\4FJV%X^J6.IV*
MV\LUM'+$8;B0HK+)L)(8*V&!C'8\$CBLB;0=8N]:AO+F:(QQW<=PN+V4JB!0
M#&(MH0D'/SGD^@[ %[3]4T#3[.9X-0616GQ+*[EWDE(Z9ZEL+T'0+T %6-+U
MI=2T.;4T,.Q9;E48/\C+'*Z!LC/!" \>M9\.@W]E9:2UN+62ZL)97,;R,D;B
M3=GY@I((W YVGN.^:L:;I%Y;>%KK3KAK?[5.]V^8B?+!EED<#D9X#CM^= %H
M>(M+26*WFOH$N7$>4#$@%\;><=#G )QGZTNM:S'H\NF^<46&ZNC [L3\O[J1
MQCU)* 8]ZRF\-W9L-2@#V_F7,5LB'<< QJ <\>H./Z5L:GI\E[?:1.A3997;
M3R!NI!AEC&/?,@/T!H )=?TN&RBO'O8A;R@E) 200.IXZ =\].]$NOZ5!>"T
MEOH5G)4;">F[[N3T&<\>M<[=^&=7DM'M8KB,PR/>L8UNY8 K33.Z.=@R^%;!
M0D#.>3UJS_PC5W_9VH6_F6_F7,-M&C9/6-0#GCU!Q0!?U?Q+9Z?*EM'/#)>&
MZMX#"6Y'F2(I_P"!!6+8ZX&>E:<M_:P2O%+,B.D1F8$]$'5OH*YR\T#4WGEA
M@^Q-9RZI!J#2RR,)%"/&S(%"D$_(<'/0XQWK0U[1KC4;JPGM9(XS&YBN=^?G
MMF(,B#'<E%_6@ U7Q+966F6U[%<021SM ZL6PIADEC0R9] ) :M+K^EM9R78
MO(_)C<1NQ."KG&%P><G(P.IR,5S]IX1NK?3IK5Y;=PM[ ;8<X2UBN1,$/'WL
M%EXX.%J?5_#-W?W\UW%(F1=17$48N)(=^V)HV#.@W+]\D$9Z#- &M+XET>&*
M"5]0A"3J[1$$DL$(#X Y^4D9]._2KKWUM'!%.TZ"&9D6-\Y5BY 7!]R0!]:P
M]+\/O9:G97GDQ0B."Z69!<R7!,DLD3 AW&3Q&<YQR>_6F3Z<-/\ AU%IE[*%
MEMK"*'S(5+XE15"LHQDG> 1QZ4 :UQKNF6C,LUY&K+(8BO);< &( ')P&!..
MF:DCU:PF1WBNHI$2!;AF1LCRVW;6R.QV-^1KG].T35; 6.HQ):S7[6\@O(IY
M&C7S)7$C%6"MC#9&,<@#D8Y@C\-:O86]XMH]C+)?VC0SF5W00N99I,H IW*#
M.PP2O"CGF@#IKV]M(],:XFNQ;V\B "8-@_-P-ON<C%4[?4]&TG3+2-;E8K8K
MB-I-W0'!+$CCGJ6[FF7FDW<FFZ0+<P-=Z;(DJI(Q$<A$;1D$@$CAR0<'! XK
M+\1Z#KNOVMQ#O@B2XLF@\I;^9$AD.\%SM0>:""O#8 VG@YH TO[=E_MG[#Y*
M;?[4^P[LG.W[']HW?7/'TK2O=6L=.9!>7"0[^F[./J3V'/4UE?V'=?VY]MWP
M^7_:WVW&XYV?8OL^.G7=SZ8[YXJKXKT#5=<6Z@M;A/LT]DT"(]W+"(I#NRY5
M!^\!!488X&WH<T ;0U_2C??8A?1?:?,\HIGH_P#=)Z ^W>JMQXEL_P"V-/TV
MUGAFFN+IX)5#<IMBD<X]2&0*?3/-02:#<M9W42M"'FU:&^!R?N)-&Y!X^]M0
MC\N:K6N@ZI!>:1$WV(V.G7DUP)?,8RR*\<J@;=N 091GYCG&>.E &EJGB*UT
MZ_&GE7-T]K+<I\AV?)MX)]]WZ'IQEVE>(].U&R69;R#>MNL\PWX"+CDY/50<
MC/2H]:TN\O-1M[FU\@J+.YM)!*Y4CS3&0PPIS@QXQQUZ\8K/U'PM<7]C:6HF
MBB6'2I;%BI;[[&$J1C'R_NFSR#R,>P!KCQ)HYMC<_;X1$KB,L3C#$9 QUY'3
MU[5=L[VVU"V%Q:S++$20&7U!P0?0@C!%<W!X:G\V*XDMXH;@7,$DC-J,UUO2
M/>0,R#@@N< >O6MO2;"6Q-]YC(?M%V\Z;2>%;'7WXH T:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .<\7K=RV^G6]N\0CGO8XY5DW?..2!\I'&1S3(_$5ZT,&HM:P#3)[M;5
M0)#YHW2^4KD8QRQ&5[ YSQBM^YM(+OR?/3=Y,@E3DC##H>/K5)/#NF1W@NE@
M<.)3,J><YC60YRXCW; V23G&<DF@#D-%U>XLF=E!GFFM+*&%))"%WO<72Y)Y
MP,#GC)P!6XWB.ZLM4%CJ4-N@C>/SIXV.P1RK)L;GH=\14CG[P.><5I#PWI(A
MDA%K\DD<<;#S&SA'9TP<Y!#.Q!'.3UX&&OX9TF73[FQFMFF@NBIG\V9W>0K@
MKERQ;C QSQ0!GZ/XFGU22TMWM%ANI9)&FC+']W"$5U;ZD2P@CU9O2J'B2\U1
M?^$M@\^,6<&A>=$J@AU=EN!D'UR@_(8[YZJ/2[.+5)=22!5NY8EA>0$\HI)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_@K7[CQ!937$^IZ3>E0GRZ?&Z^42"2K[G;)Z=,=#7,VGQ"U>?Q4VF@Z3,O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME)SP#C QR,_A0 W0_AR-$&E,NJM/+874MPTDD',H:'RD7[W 50OKG';-5O\
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MD@(&<!@7V'ME3QVJ2UUO49'L+R2:%H;V^DM/L8CPT04R#(;.2PV98$8Z],4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH R=:U*STV?2WO8X-DMTR+/,P46Y\F5MX)Z'"E>HX<\]B/<Z!:
M6=O>//IL-J96F@G9XU0R,&RZMTW$,^2.3N/J:75]/>^OM%E5$9+2],\F[L/(
ME0$>IW.M8K:1K4-K#;P']R;J]DECBG$;$23L\1W;3A0K'('.2.N,4 :ZV7AV
MW2[9;72XU,1^U$1Q@>6_)W_[+8[\'%3&71[Z^GLVDL;B[\HQS0ED>3R^ZLO7
M;ST/'-<[!X8OX[?0("8_+2SM[;4_F^]Y&UTQZC=O4^SU)HOAR[LM2@^UB:5+
M6XGGAF%P-A\S?R4V[LD.<Y.,\\\4 ;OE:=HLUW?S7$<'VED#O-(J*H5<*HSC
M X)QZDU7FF\-$Q:Y-)I)).V*_<Q]0#PLA] &Z'L:@\7K(;?2_*ACFD74H66.
M1L!B,GK@X/''OBJT&A7DE];7MQ!$F[6&U!X ^X1+]E:$<XY;=M8X[L>N,T .
MU;3-&U6XM](%[IT+0Q;$M%BA:6-<=8P>4X Q@<8%:%Q)H]OH\SQK820S6K$*
M\B!)XT3H6/!0#@DY !K+_L34=WV'R8?)_M7^T/MOF?-M\[S=NW&=V/W?7&WO
MVJO/X8OWL_$%L/*:.2SN+;3!NQ@3;G?=Z#<44>R#UH V_$&MZ;IUG-#=/:S3
M,G_'E)*H:52<'Y3G(Z]NU/BC\/V5W'IT2:9!<DB1+5!&KY&2&"#GCGG'K6+K
M6B:E.VL06UI;W$>HSPSB:27:8M@C4KC'./+W+CNQZ=U_X1V[_MZX>8336DU^
MEZCI<*JJ5"$!EVY)!3'!P1QQS0!>O[W0IM1M]):'3KV6]O"ES"2C,C+"[AW3
M!R<1*O..W/&*V%2RTFR;:MO:6L>YS@+&B9))/8#DDD^]<Q::)J4%_HT+VEO]
MGTZ^N+A[OS?FD61)@,+CJ3(-W/4<9[;FOV,]_8PBV"/)!<Q7 BD;"R;&#;2>
M<=,@^H% $+-X:?&MDZ2V6_X_SY9R1_TT]1CU[5:MM/TBS5KVTL[&!70LT\42
M+N5L$DL!R#@'\*Q#H5[=W37D]O#%YVI071M]^[8L:!=Q.,%B0#QZ#FNCU")[
MC3;J", O)"Z+D]R"!0!BRCP<=.@\X:$;&*1HX=_D^6C]65<\ ]R!5VYUVP_M
M*32%OX(;_P"SF8;F4[1CK@GG YQZ<UAW7AR^C_LF2V5REMI_V.2""98RN=G0
MLI!!VX(XZ#K5Q=#GM[BW@@C_ -$.E_8"[2[FB(^Z3G[WIF@"W#9:+::)%I]U
M):3V@B>X;[3L*R*#N>4@\8W."3T&X5'<3>%!ID,%S)HW]GY;R8Y&B\K*G#;0
M>,@G!QT)K%NM$UO4-/:VELX(3'H5UIZ$3[M\L@B /087]WU//J!713:5N\0Z
M;=)#']EM;*X@Q@?*7:': /3",/\ ]= %VVL[.$(]M;P1@)M1HT PI.<#';/-
M86K7^CZE-IVG:C<6RR2WC^7 9$D67RV9-K9]<8QV/R]16KX>LYM.\-:78W./
M/MK.&&3!R-RH >>_(K)MM)O[2;3YA$DGDZA>RR*) "(YI9&5AZX##(H T-0E
MT7PUIB74\-K:6UL<1;45 A;J%Z8)YZ>]([^&[:]CO';2HKJ]7]W,3&KSJ<=&
MZL#QZ]JF\064VH:%=VML%,SI\@8X!((.,]NE8^I:7J=Q+J;Q64$PU6R2W832
M@?9R P(/!W+\^>.^?7- &IJVGI'HUQ]A@6*>.U:*+R(EWB,#/EID8&<8 Z X
MXXI+74;*VLM%M[",O;W:*EL%X"1"/<&/L  /JPK3MHC!:Q0M(TAC0*7;JV!C
M)KE(?"]XT>K6DDRQ0&UFL]-D0Y:))268X[8)10/2,>M &C)=^%G>[U7S-)GF
MMXS]HN%,;.BX(PS=1GD8/TIMG/X4ATZUN(/[)M;:\*-"/W48D96RH&."RL>W
M0^]5O[*U&_N+=I[.VL%MK*:V'E2[PY<*,# &$&W///3@8K/G\.ZI/Y$DL$A2
M33$L)[>*Z5=NTMDY*D%6#<XY&T<'L =;<Z1IM[<+<76GVD\RC:LDL*LP'H"1
MFL;3O$UOK%G#_:-@+2VO=/-\AGD1XW@PN_=Z8$BY!XYZ\&NB@A6"".)2Q5%"
M@L<D@#')KC[7P>;3X?RZ:D1;5IM&^Q.TMPT@#F+:54L3M3=V&![4 :\<WA:P
MM87BET>VMY)#Y)5HD5G4D?+V+ Y''(J?4/[!C5;/4O[-5;J3>L-SL'G/QR%;
M[QSBJ=]IU[!JTMW965O=PSV*V8ADDV"+:SGT/RL' ..?D7@]H-*TC4-!NX=L
M2Z@CV=M:O.9-KH8@020>JG.[@YSGCF@#9LKG28)GTRRFLDEARSVL+H&3)R24
M'3);)X[^]57O/#D^DS%[G2I--,A$NYXS#O8[CN[9).>>23FL73/#-U;7*I>Q
MRW$=O+<2Q.;E?+?S-XY7;NR0YSDD9YYJ2+2=3&F&&6VG=8+A7L$6[436RA"N
M?,QANI #9X8Y)Z4 ::MH*11Q>5I26%JL5S;N&CV(SLX5E'1<D<,.I)QT-.MQ
MX:(EUJV_LG"N6DOH_+X;!!)D'?#$=>_O61-H&K7H=M0^SS2RQ:8LQ!^5S#<O
M)+Q@?PL.PR<\"GZWITEO)J.HRR6L4 N[2Y7SY1&C^7M!#,> <XP3W"T ;^GO
MI-Y!$^FM93Q6O[J)K<HRP_*/E7;]WY=O [8JTJ6]C;D*L4$" L< *JCJ3Z#N
M:Y;PYJ$BG4+L689-3U<>3]G<.FWR(PS[@,$ QODC@D8!/6MOQ#I\VIZ-);0&
M/S-\<@60X239(K[&Z_*VW:>#P30!4NKS0?[$DU*"*RO[>UE,T0@V2#SR<C:1
MP'9FZ]<M[U?:_P!*N;U;&2YLI+V-@XMC(K2(P&<[>H(]<52G@O\ 5IM.%U9B
MVMX9S<31F4.6*#]V./\ ;.[_ +9CUK-BT34EMK;2VMX!%!J O#?"7YF E,GW
M<9WM]UNV&8Y/2@#8U>6VT;38;B/3XI3%<11V\2A4VR2R"($''R_ZTY/H3ZU!
M_:FF:GIUVFM6]O;QVT_D7$5ZR-&'"K(.3\I&&4__ *JD\5:?-JFA&U@@6=OM
M-O*8F?;O5)T=AGME5-8UKX:NDMUC^R0V]M_:<5VEGYOF")5P6.2.I;G R!ZT
M ;QO-!6XAMVN-.6:9Q/%$73=(QZ.HZDGU%-5= AUTA!IJ:Q("3C8+AACG_:(
MQ6/?Z)J4MOK>G16\$D>JREQ>-)AH<JJY*XR63;E<>@Z8I;O2=:N_$,,\K;K:
M&^6>,B<*BQ!,8"!<E\DY)/3IZ  FUN;1]2U[2+&9K.^D%S)!+:LZ/LS"[Y=.
M?^>8'..N>U6W;0-5@LK:.+2K^T\WRD3=&Z1GRRX"KR"=H' YVG/05F6>B:E!
M?Z-$]I;^1I][<3O="7YI%D24#"XZDN-WN.,]K&FZ%<V>D>$K7RXU?3"K7(4\
M9^S2QL1Z_.X_,F@"5[K0)?$MG%;V^FW5_ET::/8TMOL4X!P"1W&,C%31KX6U
M6XFMHET>\F9S--$HBD8LO!=ASR,@9/3/O6-8^'M40Z-9S6\$46FVLUL;Q)<O
M)N0*' QQG&XY/7UZUFV$+ZY-%I]J]DB6^@7.GF[LIQ*JNYA"G*C@?(Q //!X
M'< Z6XL-+\16T4.G7FG/!:L05BABG$;'N,Y",.>W?I5JYT?1[+286ETVWN(]
M,M\0>;$KLBHO !(XZ"LK3K6YT6*;4;JRN7NA%#:I&MPL@?Y\ * HPH+<$]B>
M!74W*"2VE0Q+*&0CRV. _'0^QH PIYY]=\+:@E[82VMO=63*ODN)I&5T.<*!
MU (XJ31;;2-5T%9H]&M;>WO/GEMF@3#,"1\P P3D>]1:!I$ECJ5S=)IUOI=K
M)"D8M('!5G!)+D* H."!QR>_05?\.V4VG:';VEP%$L>[=M.1RQ(_0T 47OM+
MTSQ)8:*FFQ1--$\L,L<:JJ-C&WCH2JGGVQZ4VPN-%@\57NGV>EVUO<6\'FS7
M<<2("6(++D#/38Q_#TI-;T2[U#4Y;NWV*Z6:BW=CTG23>N?;( /L2*S9O"FH
M7-I=HSQ)<7FG.DK[N//>0NR],[.=N?0=* -V[NO#6K6'VB\GTF\LXG(\R9XY
M(T;&>IR <5++/H0=+::73@]]"L2Q.R9N(N0J@'[R_,<#D?,?6L*/P[<SNEQ/
M;R^<;NV>47%PLN4B+$$84#@L?<\=,5JV]K?6&OW\Z6J7%O?R1R&82!6A"HJ%
M2".5^4L,=V;@=2 7+>ZTFXU*=K>>REOXD\N8QNC2HH).UL<@ D\'N36583^'
M+C5;FVT^TTJ2)[?S[BXMQ&0Q#]&P.<'GDUD6/@^]_LM]-NI)EEBL)[.&[^T!
MDS(NW<$"@C/#')ZCOUJ>[T'5-7.H;[.VL#-I8LX]DNX%@Q.#@<)SCIG!/':@
M#:^T>&)6.M^=I#M&P0WVZ(E6QP/,['!Z9[T_1]&TNU4WMK%;3S3233K>*BEF
M661I,!QR5^; YZ 5C#0KDQRW<EE>-?,\>QOMR;X]BN RD*%_Y:,,$<@\CC%=
M-I2WJ:9;KJ,B27@0"9DZ%OR'\A]!0!ST>LZ+9#2]4ATF*&YU:012R1Q(KQ%F
M"MYC#KB0HI]R*U+C5M)>6?\ M)K6&*RN52.:[=57S=@;*%NX#8SUZUB7'A:]
MN(_$%N6C6&5'.F-NYCD=O.<GT_>A3]%JQ)I>MK8V"1G!?SI;Z."<1GSI&# !
MRI.Q27''.-OIB@#9==&6VO$<6 MV'GW:G9M(8??<=.0O4]<5<L[*UT^ 06=M
M#;P@DB.&,(H/T%<.FC313^&M&,T)G6PAAU2)6R3'!M9&_P!TN&3GJ)#Z5VFG
MWIO[=YC!)"!-)&H?JP5BN[Z'&1[$4 6Z*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*)IMT28P(D"J H_$$_5JHW7A?3+S3/[/FC<PBZ>[4AR&61I&D8@^Y=ACT)%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK]C$J_- OF/O(/,JMV X%3P-J6MWM^+?59;&ULY?L\9ABC9YG"J69RZD8RV
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MO8]:UZ5X)!((YKXLC$=F&.10!V5%0W=NMY9SVS.Z+-&T9>-L,H(QD'L:XO\
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M_P"%6:=_T'_$G_@Q/^%:OA_P5:>'=0>\@U35KIFC,92\NS*@!(.0,=>.ON:
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MBCQNW'VQS5/3O&_AC5;I;6QURRFG<X2,2@,Q] #U_"N U7_D<OB;_P!@$?\
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M'+L'&#S\H/7CFI;7P_H=OXXOBND:=&D&GVLT>+9 (W\R?+#C@_*.?8>E;?\
M8$(U.XOHKN]ADN)%EE2.;".RJJC(QZ*HJ6[T6TO9+V27S UY:K:3%7(S&"Y
M'H?WC<^] '#:-XATYO$EGK$>J6LDFMS26TMLMPK/&G_+N2N<CA"#Q]Z:M_2=
M)L/$'VZ_UBUAO;@7MQ J7*!U@2.1D554\+E5#$CD[L^E;U[I=K?Z<;&9,0?+
MM"?*4*D%2OH00"/I5:Y\/6D]W+=1S7=I--CSC:SM&)"!@%@#C. !G&< <\4
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MC?#/XR5UR6$*:E-J #?:)84A8YXVH79>/J[5FR>%--EED+?:!;R2^=):"=A
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MX69DN2%1O4?.S8[[!7:M80OJ4-^VXW$4+P*<\;7*%N/JBU3D\.:?+9_9F64
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M =517*_\+*\&_P#0PV7_ 'T?\*/^%E>#?^AALO\ OH_X4 =517*_\+*\&_\
M0PV7_?1_PH_X65X-_P"AALO^^C_A0!U5%<K_ ,+*\&_]##9?]]'_  H_X65X
M-_Z&&R_[Z/\ A0!U5%<K_P +*\&_]##9?]]'_"C_ (65X-_Z&&R_[Z/^% '5
M45RO_"RO!O\ T,-E_P!]'_"C_A97@W_H8;+_ +Z/^% '545RO_"RO!O_ $,-
ME_WT?\*/^%E>#?\ H8;+_OH_X4 =517*_P#"RO!O_0PV7_?1_P */^%E>#?^
MAALO^^C_ (4 =517*_\ "RO!O_0PV7_?1_PH_P"%E>#?^AALO^^C_A0!U5%<
MK_PLKP;_ -##9?\ ?1_PH_X65X-_Z&&R_P"^C_A0!U5%<K_PLKP;_P!##9?]
M]'_"C_A97@W_ *&&R_[Z/^% '545RO\ PLKP;_T,-E_WT?\ "C_A97@W_H8;
M+_OH_P"% '55%<P)=6TMO)GRY4*-CT(P:YK_ (65X-_Z&&R_[Z/^%'_"RO!O
M_0PV7_?1_P * -"S\+Z;8^%6\-PK(-.:&2 J7RVQ\[N?^!&H[GPAI5UX07PQ
M*LO]FK&D84/AL(P8?-]0*I_\+*\&_P#0PV7_ 'T?\*/^%E>#?^AALO\ OH_X
M4 7/^$0THZM-J124W$UA_9[_ +PX,/''L>.M5-(^'V@Z-JD>I0QW,]W$I6&2
MZN'E\H'LN3Q2?\+*\&_]##9?]]'_  H_X65X-_Z&&R_[Z/\ A0!JZ]X>L/$=
MK;VVH+(8X+A+E-C;?G7./PY-2:YHMGXAT>XTJ_#FUG #A&VG@AAS]0*QO^%E
M>#?^AALO^^C_ (4?\+*\&_\ 0PV7_?1_PH OS>%=,FU32M2*RI=:9&8H'1\9
M0C&UO48_F:S]4^'7A[5M1FOY8;B"XN/^/@VMP\0F_P!\*<&E_P"%E>#?^AAL
MO^^C_A1_PLKP;_T,-E_WT?\ "@"Q=^"=$NO#<7A\6[0:7&X;R('*!\'.&/4\
M\GU-6-2\*Z9J=]I=[)&\5QIC;K62!MA4<?+QU7CI_C6?_P +*\&_]##9?]]'
M_"C_ (65X-_Z&&R_[Z/^% &KJ7AZPU75]+U.Y60W.F,[6Y5L %P <COT%:M<
MK_PLKP;_ -##9?\ ?1_PH_X65X-_Z&&R_P"^C_A0 R_^&_AV^U&:_6&YL[B<
MYG-G<O")3_M!3BM/3O"^FZ9K5SJ\"RF\GACMV>1RVV-  %&>G09]<5G_ /"R
MO!O_ $,-E_WT?\*/^%E>#?\ H8;+_OH_X4 3W_@C1]1U'4;Z9)A-J-K]DNMD
MA =..WKP.:?+X.TF4:&=LROH@5;-UDPRJ%"X8]P0HS57_A97@W_H8;+_ +Z/
M^%'_  LKP;_T,-E_WT?\* *EQ\+/#=U>WES.+YQ>SM<7$(NW6.1V.3E01W-=
M;8V-KIME%9V4"06T*[8XT& HKG?^%E>#?^AALO\ OH_X4?\ "RO!O_0PV7_?
M1_PH LOX+TB276I&6?=K!C-V5E*Y*9V[2.5Z]J30?!.C>';V:^LXYY;V5-C7
M-S,TK[?0$G@57_X65X-_Z&&R_P"^C_A1_P +*\&_]##9?]]'_"@#?U/3K;5]
M,N=.O$WVUS&T4B@X.",<'L:YZ/X=>'XO#]MH:PS?8(+H7?EF0_O'_P!L]Q[>
MPIW_  LKP;_T,-E_WT?\*/\ A97@W_H8;+_OH_X4 :GB'PYI_B?3EL=21S$D
MJRH8WVLKCH0>W4_G6/J7PZT;4]:N=6EGU&&\N0@E>WNVCW;5"C@>P%2?\+*\
M&_\ 0PV7_?1_PH_X65X-_P"AALO^^C_A0!-'X'T>.349/](9]1LEL;AGE)+1
MA GYX'6L^Q^%GA>RGMY6@N;L6Q!@CN[EY$C(]%)Q^E6O^%E>#?\ H8;+_OH_
MX4?\+*\&_P#0PV7_ 'T?\* .JKC;KX7^%[JYFE-K/%'.^^:V@N7CAD/J4!Q^
M6*L?\+*\&_\ 0PV7_?1_PH_X65X-_P"AALO^^C_A0!H7WA72K^'2H7@,4.EW
M$=Q:QPG8J,GW>!V]JBNO!VD7?BNU\221.-2MDV(ZO@$8(^8=SAC^E5/^%E>#
M?^AALO\ OH_X4?\ "RO!O_0PV7_?1_PH K2?#+0WU&[ODN-4@ENYVN)1!>.B
ML[').!]:W8O#MA#XFG\0()/M\]N+9SN^78"#T]>!67_PLKP;_P!##9?]]'_"
MC_A97@W_ *&&R_[Z/^% '55SF@^"-$\-MJ)T^!U&H?Z\.^X8^;@>@^8U!_PL
MKP;_ -##9?\ ?1_PH_X65X-_Z&&R_P"^C_A0!=\+^$=*\(64UKI,<BQS2>8Y
MD?<2< =?3BDT[PAI6E^%I_#MLLHT^:.2-PSY;$@(;G\35/\ X65X-_Z&&R_[
MZ/\ A1_PLKP;_P!##9?]]'_"@!M]\.]#U"PTBSD-Y&FDHR6K0W!1U#8SEAS_
M  BI8_ FDI:V-N\M].ME?+?PM/<L["5<8R3_  \=*9_PLKP;_P!##9?]]'_"
MC_A97@W_ *&&R_[Z/^% %NZ\':1=^*[7Q))$XU*V38CJ^ 1@CYAW.&/Z5<US
M0K/Q#8"SO3.J*XD5H)6C96&<$$?4UD?\+*\&_P#0PV7_ 'T?\*/^%E>#?^AA
MLO\ OH_X4 .L_ &@6.D:CIT,$NS45VW<SS,TLH]V//<U+J'@;0-4TBPTV\LS
M)%I\:Q6L@=EEB"@ 8<$'H!^50?\ "RO!O_0PV7_?1_PH_P"%E>#?^AALO^^C
M_A0 :=\/=#TR2[FB%W+<7=JUI+-<7+R/Y38RHR<#H.U27O@30]0\*VWARXAD
M>PM2IA^?YU(S@[OQ(_&H_P#A97@W_H8;+_OH_P"%'_"RO!O_ $,-E_WT?\*
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M;_T,-E_WT?\ "C_A97@W_H8;+_OH_P"% '545RO_  LKP;_T,-E_WT?\*/\
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M.>U32ZYIL-]/8O=QBZMX/M,L(.66/^]@=J .$_X47X0_O:C_ -_Q_P#$T?\
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M$+7<CR1I%GEFC.' ]Q@YID_BG0[:TANIM3MTAG9EB);ERI(; ZG!!S0!Q?\
MPHOPA_>U'_O^/_B:/^%%^$/[VH_]_P ?_$UZ1%*DT22QL&1U#*PZ$'I3Z /-
M/^%%^$/[VH_]_P ?_$T?\*+\(?WM1_[_ (_^)KTNB@#S3_A1?A#^]J/_ '_'
M_P 31_PHOPA_>U'_ +_C_P")KTNB@#S3_A1?A#^]J/\ W_'_ ,31_P *+\(?
MWM1_[_C_ .)KTNB@#S3_ (47X0_O:C_W_'_Q-'_"B_"'][4?^_X_^)KTNB@#
MS3_A1?A#^]J/_?\ '_Q-'_"B_"'][4?^_P"/_B:]+HH \T_X47X0_O:C_P!_
MQ_\ $T?\*+\(?WM1_P"_X_\ B:]+HH \T_X47X0_O:C_ -_Q_P#$T?\ "B_"
M'][4?^_X_P#B:]+HH \T_P"%%^$/[VH_]_Q_\31_PHOPA_>U'_O^/_B:]+HH
M \T_X47X0_O:C_W_ !_\31_PHOPA_>U'_O\ C_XFO2Z* /-/^%%^$/[VH_\
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M_P!_Q_\ $T?\*+\(?WM1_P"_X_\ B:]+HH \T_X47X0_O:C_ -_Q_P#$T?\
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M$/[VH_\ ?\?_ !-'_"B_"'][4?\ O^/_ (FO2Z* /-/^%%^$/[VH_P#?\?\
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M3_A1?A#^]J/_ '_'_P 31_PHOPA_>U'_ +_C_P")KTNB@#S3_A1?A#^]J/\
MW_'_ ,31_P *+\(?WM1_[_C_ .)KTNB@#S3_ (47X0_O:C_W_'_Q-'_"B_"'
M][4?^_X_^)KTNB@#S3_A1?A#^]J/_?\ '_Q-'_"B_"'][4?^_P"/_B:]+HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PGPE_
MR</K/^_<U[M7A/A+_DX?6?\ ?N:]VH **** "BBB@ HHHH **** /.?C=_R3
MF7_KZB_F:U_A;_R371/^N+?^AM61\;O^2<R_]?47\S6O\+?^2:Z)_P!<6_\
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MQTCBB55DD+.<*,*2,D^AH WJ*P[/Q5I]_A;=+@S"Y6VFADB,<D#E2P+JV#C
MZC.>V:U%O[1E5ENH"K,%4B08)(R /?!H L450U'6M-TFWGGOKV&%($\R7<V2
MJ^N!S^E6%O+9VB5;B)C*NZ,!P=X]1ZB@">BJQU"S5&=KN *IP6,@P#DC!_$'
M\JDDN88B@DFC0O\ =W,!NZ#C\Q^8H EHJ$7=NRRL)XB(CB0AQ\A]_2D6]M6,
M0%S"3*,Q@2#YQ[>OX4 3T56.H68+ W4 *?>S(/EYQS^/'UISWMLDOE/<0K(/
MX3( >F>GTYH GHJ'[7;[8F\^+$O^K.\?/]/6D2\MY)3$D\32#.4#@D8.#Q]>
M* )Z*RD\0Z>^K2Z>LH+16PN7FW+Y04N5QNSURIK0:Z@2W^T--&L.,^87 7'K
MGI0!+149N(0B,94"R$!"6&&)Z >M1O>VL:LTES"JJ^PEI  &]#[^U %BBJ,>
MLZ=-J-SIZ7<1N[9%DFBW<HK9P?T/TXSU%.O-4M;+2;C5'D#VEO"\[O'\V44$
MDC'7@&@"Y17/?\)C8"RM[A[:_1KE]EM;M;-YL_R[LJHZC'.>@IDOC?24M[26
M)+RX:ZED@2&&W8RK)&"75DZ@@ \4 =)15&RU>QO])AU2"X0V4T8D25SM&T^N
M>E9VK^+M/T:219HYY1'9&]W0A6#1AU3@DCG+#VQWH WZ*AGNK>V ,\\4602-
M[A<@=>OU'YTK7,"2QQ/-&LDGW$+ %OH.] $M%5CJ%F"P-U "GWLR#Y><<_CQ
M]:B75;?[5<P2GR?(95+RLH5R5W?+SV&>N.AH O45";NW B)GCQ+_ *OYQ\_T
M]:7[3!YCQ^='O1=S+N&5'J1V% $M%9FIZ[9Z7H=QJ[L9[6!=[&W(8D9QQSC]
M:EBU6VD\_P P_9Q#.8,S,JAVP#\O/O['VH O45GVVNZ7>?:O(OH&%I)Y4YWX
M"-QP<_7K3-9UVST.Q-U<L6&Y (XR"[;G5 0"1D L,^U &G152YU"*UO(;>56
M ECDD\W("($QG<2<_P 7IV.<5/%/%.&,,J2!3M8HP.#Z<4 245SNB^-='UTJ
M+=YH6>$3QBYB,8DC+;=RD\$;B!UZD5N)=V\CHB3Q,[KO50X)9?4>H]Z )J*@
MBO;:;=Y5Q$^T;CM<' ]:3[?9_9Q<?:H/))P)/,&W/IGI0!8HJI<:E:V\<[&5
M'>"(RO$C OM STIVG7T>IZ9:W\*NL5S"DR!P P5@",X[X- %FBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** //OB!\3O^$%U*TL_['^W?:(3+O\
MM/E;>2,8V-GI7(_\-#_]2M_Y4/\ [77M;PQ2'+QHQ'=ES3?LMO\ \\(O^^!0
M!XM_PT/_ -2M_P"5#_[71_PT/_U*W_E0_P#M=>T_9;?_ )X1?]\"C[+;_P#/
M"+_O@4#/%O\ AH?_ *E;_P J'_VNC_AH?_J5O_*A_P#:Z]I^RV__ #PB_P"^
M!1]EM_\ GA%_WP* /%O^&A_^I6_\J'_VNI[+X_?;+^VM?^$9V>=*L>[[?G&2
M!G'E^]>Q?9;?_GA%_P!\"O#OBW&D?Q2\,A$504@X Q_RW:@#W>BBB@04444
M>$^$O^3A]9_W[FO=J\)\)?\ )P^L_P"_<U[M0 4444 %%%% !1110 4444 >
M<_&[_DG,O_7U%_,UK_"W_DFNB?\ 7%O_ $-JR/C=_P DYE_Z^HOYFM?X6_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7A7Q?_ .2J>&?]R#_T<U>ZUX5\7_\
MDJGAG_<@_P#1S4 >ZT444 %%%% 'A/A+_DX?6?\ ?N:]VKPGPE_R</K/^_<U
M[M0 4444 %%%% !1110 4444 ><_&[_DG,O_ %]1?S-:_P +?^2:Z)_UQ;_T
M-JR/C=_R3F7_ *^HOYFM?X6_\DUT3_KBW_H;4 =?1110 444UY$CV[V5=QP,
MG&3Z4 .HHHH **** "BJL6I6,\_DPWEO)+S\B2J6XZ\9JU0 44Q9HVF:$2(9
M44,R!AN .0"1Z'!_(^E/H ***9%-'.I:*174,5)4Y&02"/J""#[B@!]%%% !
M15=+ZTDD\M+F%GV[MHD!./7'I4JRH\8D1E:-AN# Y!'K0 ^BJ\=_:2[#'=0.
M)',:;9 =S $E1ZG )QZ U8H **1F5%+,0% R23TJ-+B&1MJ2HS<G 8$\8S_,
M?F* ):*BEN(8"HEEC0MDC<P&<#)_(<U+0 4444 %%%% !1137=8QEV"C(&2<
M<DX _.@!U%%% !137=44LQ 4#))/ J,74#>5B:,^<,Q88?.,9^7UXYH FHHJ
M(W$*B0F1 (O]82P^3C//IQS0!+1110 45##=VURSK!/%*4.'".&*GT..E34
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1O!%(P9
MXT9AT)4$BI** "BBB@ HHHH \)\)?\G#ZS_OW->[5X3X2_Y.'UG_ '[FO=J
M"BBB@ HHHH **** "BBB@#SGXW?\DYE_Z^HOYFM?X6_\DUT3_KBW_H;5D?&[
M_DG,O_7U%_,UK_"W_DFNB?\ 7%O_ $-J .OHHHH **** "BBB@ HHHH RI=
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MQQGK36T> WL]RLL\?VC_ %T:/A)#MV;B/7: ./0>E:%% &/'X9L(H9K=3/\
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M,, )@DG'. ,\GBO29_"]O<>*Y-=EG<M)IATUH,?*4+[RV>N>U9&D?#U-*O\
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M]LC@ G<[-V_WL5L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >$^$O\ DX?6?]^YKW:O"?"7_)P^L_[]
MS7NU !1110 4444 %%%% !1110!YS\;O^2<R_P#7U%_,UK_"W_DFNB?]<6_]
M#:LCXW?\DYE_Z^HOYFM?X6_\DUT3_KBW_H;4 =?1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >$^$O\ DX?6?]^YKW:O"?"7_)P^L_[]S7NU !1110 4444
M%%%% !1110!YS\;O^2<R_P#7U%_,UK_"W_DFNB?]<6_]#:LCXW?\DYE_Z^HO
MYFM?X6_\DUT3_KBW_H;4 =?1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(UCC7).U0, 9//04 34444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXM_Z&U9'QN_Y)S+_ -?47\S6O\+?^2:Z)_UQ;_T-J .OHHHH **** "BBB@
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MH7,D]W/!'+*TB*FUF4$J H& #GKS[UK4 %%%% !1110 4444 %%%% !1110
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MI/\ 9%C+&X033SO/($8LJEC\J@D#A5"J.!]WH*DNM-D,]Y=V=P8KRY@CMP[
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M*> 12/.5#7#CY@"#,Y=CT[$\>F!UI]KH$-OJ OWNKFXNLMNEE*Y8%0N"%4
M <8 ZGK0!)>ZH4T/^TK&(W2NB21A0>58CYL $D '=@#.!P,U0C\3)%+:I<>7
M-!+:S73WMLV846,J#U.>C<^A_33@TP6NCP:;;74\*P0I#',NTN H !Y4KG ]
M*H'PK9O'LDGN9-Z3I.6*YG6;&\-A>,[5^[MQCZT 2?\ "26>X1&&Z6Z)4+:M
M"1(P8,00/3"-R2,;2#@\4:5K@O[Z\M&0^;!,0553^[3:I&\YX))/'MTXIA\,
MQ-.+MM1O6OU*[;LF/>JJ& 7&S:1\[]5/)SV&"QTRPL]<G>"ZF-](/-N5R,2
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M/>O0:* ,K0M+738;IFAC2XN+J>:1U RZM*[)D^RL..W-:M%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5YQ/JQ\&_$+Q!J&I:??R6.KQVK6]Q:P&50T2%65L=#SGZ
M5Z/10!Y9XI\40^-]+AT'1-,U22ZN+J%F>:T:..)%<,69CVXKU.BB@ HHHH *
M*** "BBB@ HHHH **** "O.]6U!_"?Q'NM9OK"]FTV_L(X4GM83+LD1B2K <
MC(_SUKT2B@#ROQ=XPM_%_AFZ\/Z)I>K3W]]LC026C1HOS@EF8\  "O4($,<$
M<9.2J@9^@J2B@ HHHH **** "BBB@ HHHH *XW6['4+K5YH8DO9K:6:V9G#N
MBP!9H2=GS;6X#-D+N4@\D$"NRK"U+Q/;:;J0LW1'=D<@),I<%8VDY7J 50\^
MN/K0!@ZQ#KT5E<VEC%?,R-<-:3^=([9PI13\ZY&2V"Y(&,8-/O-/UG"2"XOU
MCDNKLSA7ED*CS&$&U4D0A=F>AQRN1QQKKXH=GBMSILJWDYC,,)D7#*ZR,"6Z
M# BDR.>@QG-0)K>HKX5M-06W6:ZENHX729@FT/.(_P"'C(! _7GN 2:'#J-O
MJTR7;W5TAA4O<S!HP' 4;53<5P>3E0,8P2<YJJJZA$C221:DU['>!Y]LCF-X
M?-X\M=VW&S' &< YR>NM!KZS7L41M9%@FN);6*?<"&ECW[ACJ!^[?![[>V1F
MN_B2;^T7LX-+EE;SG@1_-50S*H<]>0,'KZC\: ,9[/6[NQU&<G4X9OLEX;6,
M3LI$C2R^7P#@D(4QG(''H,/NM.UJ+5;M;>\O5@1#]E'[R4.GDX*LYDP&\PL<
ME2WW<''2W?\ C&W6UB-OM#75KYL+>8ID0M$74M'U XZ^OMS3E\80QZ1979A,
MGVH[82TBIY@5<LW/W1D$ =<XX H I76D7@,2O_:,]O";.<_Z3(S^9N<2X.[/
M0(<#@=A2Z?!J-OJEAIP>5(I]]Q.@DP8A%*Q]>CEX@0."%;UK?DUO<E@+2UDF
MFO83/'&Y\O;& N2V>F-ZC'7)^IJA<^)K>R6XO6T]_)!GB6<%=TKP+(S+CJ!^
M[D /MVR,@$.N)JL^N0):17,<2/ #)%(^UXR_[S.'"KA<]0Q/;&,BA/%XA?2W
M66.[-P6%LLB2N"!&A DVHZ_ZQRW)(&-N>E:MQXL-HTXNM.>'RFCC)>9<;WP5
M7/TR2>V.,TP^-(!:S7'V.0)%:2W.'<*9/+W[EC_O_</([,IZ&@#.,6N+>S7<
MMI<3O]G= /,*[=Z68;:5.1@K,V%QDJ<<FJ8L=9WR23PZJ[K!<1VDD,C(P8LI
MCW9D+8Z_?) Q\W85TQ\22"__ +-;39!J+!76$RKM,9#'<6[?<88]<=N:CA\6
M)/(C1V$WV?,"R2,Z@HTK[%7'<AN#V],T 8MUI_B WLP2>:UBDDD998(G?$I"
M ,561<C@XW97@Y'2N@UK3I[K5-,N;?S/,@,I#"1@BDH=NX X(SCJ*SI/%%S-
M?:9+'!)!8W<0DC)*L90\]NB-ZKQ(W'HP[C LCQ<JHK2:=,OG;A;@.I,K"9(<
M'^[EI$P3V))QC% &;%9:K.L,2G58H6^SK=>;<MO,@8^9M8-D+CKMPO(V]#6O
MKUO>O/"MM-=Q6XM)@[P;F._S(2N0""3@.."#@M@@\U-'X@"V&I7-U9R0O82^
M5)$K!R[;$8;3P.=X SCWQ5&ZU^_L-1F:YL6%M#9?:)HTE4^6H8Y;. 2<#I['
M\0#/,>N,DIC@OUEDLL[&G?$#J%PJL7VN6P>HW DY;'0U236[N'4?LUIJ$:S7
M#M:N7=63$$04!%=<!G\P_,< @Y'-:UYXNM[2^N;00>?)#&7"PS*S'#HA!'\)
MS(N ??I1)XH>-Y+<:;*][#YK2P"5<!8UC8D-WR)8\#CD]L4 9S66O8:YMY;H
M7TEQ*H$LS&)4-LVSY,[0/-"\XS^%5[ZVU*9;9;%]7M;?RY!(9?-FE6?Y=I.)
M5R,9QR4SG(Z5IQ>-K6:<QQ6<\I$9(6+#.7$7F[0O7&. >[<=P3:O-=G'AL:I
M906\LA=5">=N09<*?F Z^W8_2@ UJ*Y,MCYGVR:S5'%P+)VC<R?+L/RD-M^_
MP#U*YZ9JOX9TV]MKRYNM0\_[3+;P*[/,6!8 [N,[<CC.!USCK5R'Q#YMS$K6
M;K;27+VBS[P1YJ[@PQUV[E9<^HZ8YK/OM=U2+5)+:*U3RXKV&%-CC=*K(6(.
M1@=CD<\=Z +9$>D:[K.JRP>7:M8VY:1$YD=6GW=.2V&3\Q5%K2[35?+-G,2F
MIM?&Y !4Q^45P#G.[G9CKCVJ9O&MHMS#;FVD$I($R;AF,^:T7 _BPR/T[#/H
M*E\0Z_+80ZC;0)Y5Q%82W$4SL!E@C$;%(^?&WGTR/6@"K;6SZIHFM37-A*MW
M>J6-O/#@)A,1J,]2, D_WCQQBM);U8+ 6.+D74-I$SBWC#O&&RH(!!!.5;C!
MZ=*CF\2_9XYQ<6JP7$3JOE37**&#*6&&]>",>H].:J'QM;F)9DM'$$CQQ0R2
MR*@=WA68 ^F$))/M@9S0!G3V&HOX5GT\17YN;IYV \N/%R'<X$YQA-P/.TJ0
M#Q@\#:1Y+SQ7NFM;F*.S1X[=C$=LC, 6<MTQ@!0/J?2K!U]7T[3[FWM9));]
MQ'#"Q"D-M9CN/8 (W//3C.:IVWBP7!FS8F%;>)I)WFG1%C(DECP2>.6B/M@_
MF 4M>L]0N;O48($O)XKBV*CYF583A<;/FVMGD_=W YYQ@"+5K?6(8+^SLX[Y
MXS.[6LWGRNR?N8]J\."07,G+-M&WITJZ/&L;PRRQV+RK;Q2S7#1RJ518R-VT
M_P 7!!'3WQ5ZWU.]G;74EACA6QE,<#H^XL/*5\D$=?F'YX[9(!@W5CK;1F<S
MWR^9>?O@'D;;%Y7R[4212!O)SM.>F<@5IZ5#J5OKBK<RW5VAM5$L\H:)$<(@
M.U-Q0[B&/ RISR014%MXKFBM?WEM+=2A=SE2J !;>*5C^/F''OQP.:FG\3S%
M(Q'9O%<%^(G<$.I@DD7)'3[ASCN.XYH IW=GJ=S<31%=0\][B;S'6=E@-L5?
M8% ; .-@X ;<">G6_-IDX\):=:QP/,]O]GDDMW?+2!&5F7+'KP< G' ' I%\
M5>1#IHNH(1<7<<):-+A=RM(=JX7KMR1SVSWP:@L?%%S)#;O=6H^T7$2&.")@
M59F<J/F/3@9/L._2@"WJ5Q/?Q6DB6VHQVBSD7,<>Z*4KL."-I#;=Q&<<\=QF
ML>'3-:FBDDN9M26036RPJMTPQ"9R'#;6P6\H@,>3D9!SS6I-XN$*S?\ $NF+
M6T4LMT/,7]TL9PV/[QP01ZCKBM/3M6&H7=[!Y/E-;2%"KO\ .1DC<5[*<9![
M@T <S+INLR07 $VI*T,<HMMMRX)(N'V$\_,?+V_>SD=<U+-::A!J-S%*NK3:
M8CN+86]R_F;C'$1EMVXC<90,G .<\8JYI_BHW%O:NUG*T3+:B6X+*,-.%V_*
M/=@#Z9[TFLZYJ-I=:E!!;J([:WMIHY$8%V,DC*5P>.0I ]/QX (+"RUJ.ZCN
M;V:Z>Y^UPK(%F;R3']F0.0F=N/,W'.,YJ[J,4\>N)+I\5UYTYBCN?E'DO$&(
M)+=5=5+$8/)P,'J(KSQG#8%H;BS=;M&D#PB1>B*C':?XB1*F!ZGMC-7=?O;N
M#21=Z?.J3D#R(7BW>?(WW$Z\ GJ>PYX - '-6^GZC::8+98=6!CM6CMA#<.-
MMSN;)8EN5(\O&[*\-Z\SWMEK%SI]U"1=?VP;N-XYF9FMA&+E&0JN=HP@&>-W
MRMUSSI_VM??VCYWF1_9/[0^P^1L^;&W[^[/7=^&WWYJ2SN[ZYTW47O+^.V>U
MN9%::*,;510#T;/0'K[=J -32=PTV$21W$<@&'6X?>X;/.6[\]".,8Q@<5=K
M.T)[R;1;::^8FXE7S#N0*5#$E5('&0I /N#6C0 4444 ><3ZL?!OQ"\0:AJ6
MGW\ECJ\=JUO<6L!E4-$A5E;'0\Y^E4_%/BB'QOI<.@Z)IFJ275Q=0LSS6C1Q
MQ(KABS,>W%>IT4 %%%% !1110 5YWJVH/X3^(]UK-]87LVFW]A'"D]K"9=DB
M,258#D9'^>M>B44 >5^+O&%OXO\ #-UX?T32]6GO[[9&@DM&C1?G!+,QX  %
M>H0(8X(XR<E5 S]!4E% !1110 4444 >=ZMJ#^$_B/=:S?6%[-IM_81PI/:P
MF79(C$E6 Y&1_GK6?XN\86_B_P ,W7A_1-+U:>_OMD:"2T:-%^<$LS'@  5Z
MI10!' AC@CC)R54#/T%2444 %%%% 'A/A+_DX?6?]^YKW:O"?"7_ "</K/\
MOW->[4 %%%% !1110 4444 %%%% 'G/QN_Y)S+_U]1?S-:_PM_Y)KHG_ %Q;
M_P!#:LCXW?\ ).9?^OJ+^9K7^%O_ "371/\ KBW_ *&U '7T444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF-XIB\SL75\;LDG.3@<]:M+IMLDUW*J,&N\>=\[88A0N<9P#M &1CH/2K=%
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MYVCD29Y#(TD4[QMDJJGE6!P0B<=/E!ZT[4-'L]3FMYKD3^9;[O*:*XDB*[@
M?N,,\#O[^IJ_10!GC1+ :C]O\IOM&[?GS6V[MNW=LSMW;>-V,X[T]])LI+:Y
MMGAS#=.7F7<?G)QG//0X''2KM% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'A/A+_DX?6?\ ?N:]VKPGPE_R</K/
M^_<U[M0 4444 %%%% !1110 4444 ><_&[_DG,O_ %]1?S-:_P +?^2:Z)_U
MQ;_T-JR/C=_R3F7_ *^HOYFM?X6_\DUT3_KBW_H;4 =?1110 4444 %%%% !
M1110 45S5SJ=QI6K:_/-,]Q;V]A;W,4!PJQDM," << [%R3G\ABMVS^U>1_I
MAA,N?^6(.W'XT 6**** "BJFIQW4NFW$=C*L5TR$1.W0-^1Q]<'Z'I7-'Q%-
M86TEO!;3272K)&L5U+N;[2-A$>X9R"L@8$=@>F,  ["BN.N/&O\ Q*_[3M8T
MDMS#]IC38[-)$$5F.5&%Y8KD\97OVT;'6KRXU"-)X(5MI[BYMXBC'>#$[+DY
MXY"GZ<>O !T%%<AK5[=Z/+J-Q=RW#))#,UB8I0L8V0L^QEQD-\CL&Y^HX%;&
MCW-]/J.M1W4L3Q6]VL< 1,%5,4;X)SS]_P#//;  !KT444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5Y]>'7/%'CC6=(L]=FTBQTB.WS]FC4O,\JELDGL ,8
MKT&N(\-''Q1\=#OC3_\ T2U &5KUIXB\$6<&MKXJO-3ACN8HY[2[C7;(CL%.
M".0>1S7IE<3\5SCP+*/6ZML?]_5KMJ "BBB@ HHHH **** "BBB@ HHHH *X
M+6)=:\0>.YO#]AK,NDV=E9I<226\:M)*[L0!D]  /\]N]KB-._Y+%K?_ &"[
M?_T(T 9'B33?$G@W0Y_$$'B^]OS9%'>UNXD*2H6 *\<CKUKTN*02Q)(!@,H;
M'UKD?BH0/AGK63C]TG_HQ:ZNT_X\X?\ KFO\J )J*** "BBB@ HK%\3I"VDG
M?!'-<LPBM5D&1YKG:IQZ#.3[ U>TZ.WM+:/3X)A(;2-(R"^YP ,#=WR0,\]:
M +E%%% !117%Z[%%8>(3>00QB46RNTC@E8R9T5I2,_PJ2WT% ':45C:-J;W%
MG>RR3+=0VTQ2*YB7B= BMN '!()9>.I7\*Y>V\7W%S<Q1OJ4-K:23#_2IEC.
M%,3,!E6* [E[GO@\T >@T5PD/BC49)4$EU;I/LM6CM/*PUQYCE6*Y.<8&X8^
M[WR*?_;^IQ6$,]UJ-M;F:VEN(V>$;9'4@+$.>>.2!\QSQC% '<45Q-WXDU:&
M.[1856:SVO<9481973RSR0,*C29)XS%SQ6I#=7]]X/NY_/47)CF\J>V97) S
MM(VDC=Q@X[YZ4 =%17"Z;>W4,LU]#J"7,+36,3DJ&\WS-D9;</3=D8[@YS6E
MX3UK4-8$LEYY 'E([1*Z;X)"3N1E4D@# 'S8.0?H #J**XE->NH+KR1=6D0D
MDO%BC8CAUFG :4$[A'A%^9>X;/&,1OXODATF[G>\C#K8S/;O*$Q+.A880KPX
M^[T]><<T =U17#WGBJ\_M6]M;*5<(D@'FHA\MTFBC^Z&W8.]C\V,X!'%69=:
MO+?4'T^[U*&UABGDC:_DC5<D1PNJ<G:"?-;ZB,\<Y !U]%<MX>UO4-3U6>.X
M\E8T$F^'>GF0LK[5&T$M@C.2P'(&.#5'6?%5U:ZAJ4-E(";>UN"$E5,))'%O
M5L!MV"?4 'MZD [>BN0N=8O[*]:QN=1@AB2X"M?21 !08MX4@G );//H,=>:
M2WU&;3OAIHEW%-% YM["-I9$RJ*[1(Q(^C&@#L**X*_\7W-G8SF*[2X>%I6M
MYU6,1W:(J'J6&?F9E^3)^4GBKDFM:O)>264<B0O;7*6TTIAR&,DGR%?<1 $]
MLN/2@#L:*X:7Q!K-G;.[RQ7#$72C$041B&Y2'S.O]UV<Y...PH?7M8^P37*7
M5MMM[&XNU9 DHF\MOE!*G XR#COTQTH [FBL/1)9CK&O0SWSSF.[3RXG(_=(
M88R, <X)+#ZJ>^:YC4-8O=2T66 WT9DN+1WN[>.-=UFP*CRVSG^\RG=R2,CC
M(H ]#HKE_%@CL]&TZ-OLWDI=Q(PGD\B(J >&(!"CIVJA+X@FMYHHH+VRMT6Y
MLX(+2/$@GBD:,.Z-P2!O900,?(<]> #MZ*X>3Q++<G3;430O.Q3[7&!S&XN[
M>, CL<._'TI+;5]3L[80B]-Y+<WUU9HSJ&:&;SSLR!_"(P[X/91C@B@#N:*Y
M_P 0/"NHZ>NHS>5I127S69RD9E^3RPY_NX\S@\$@=\5G7^N&Q:1-.N[9(8;:
M.2Q@&'^W,2V41L\] HV]"V3Q@4 =C17&MK.K(LLAO+11+)>QQ"90B1>3,40E
ML]P.<]\>AS63Q)+)?P$7B6MM-!#YM[<*GR_-<\9!V<F, -T(Z=10!W=%>=Z!
MKVH;["RB>W",58;RJ"X5Y7WLH9MQP.@ /(YZ\32>*K^UTG3)I;I9+RXMHKMD
M$<:(ROCY!EMS$?-]T$C()P, @'?45P$6KWUDS#[8+J>-[Y7>8!C;J+N) S 8
M^548O@]@,8%7[;5M1OM22QM-2ADMS)(%ODB5O,"HC8&#M)#,02..W4$T =A1
M6=H>I#5=(M+HM&)I;>*66-#G870-C'4=>]<]%XAGEL+::35+>&2>94O%*K_Q
M+@5<X;)X.Y53+<9.<=J .RHKAUU[6;@%HKBWC5/LR*?(RLHENI(!)UZ%%5P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<3?J]G\1;2:QMIKF:X@E\])(&"I@1 ,D
MI&!T (R1R> 6.>VKF-1\17=MJ,UK%83%89[= XV'S1(2" -W'U..^<4 8*6&
MIKJEU/?Z5<%9%LI[QE D$K++*6"A<E@NY,*,D*@SDD9T67=H5U9);RKYUT;M
M+/RF#M:B=#(-N.-PWX4X)W8QUK0E\;:5!)!',)(I)"0Z.T8:+$ABY&[YOG5A
M\F[H3TJ#Q'KUSI.JQ0VWV;<]ON59+=W:9]X58PZL F2V,D$ F@#/%NBZG->W
M&EW,ND2O<B&W^QN6#-'  ?*VY7)2?D@?>Y^]4>FZ=>006UG>6<[ZR+RTE-YY
M)*[$2,.?-Q@?*LB8SDYZ<YK4O_&EEF]M+*0?:X!(%8LA!:-@KC:&W#!SU !P
M<9JS!XSTNZGN88-TCPH\F!+$-ZHX1CR_RX+#[^W.>,T 4M5AN[?Q)>7,'V_R
MY[>U5WA5W 02R>8$ !&X IP/FPS$<U/)-K \*7+VXN&G%QB%I4(F-OY@!)&,
M[MF['&[@<$U+#XTTR:,2A95A$$EQ)*6CVHD;.K]&^?!C;[F[J#T(J]HWB"SU
MN.=[8[3 P613(C8R,@Y1F7]>QH YJ:\UV."SCC2\ED#AUF$<H!4S8*,ICY*H
M.2^W(((R>1*T%YJ!MDN7U-;T7^9\1,L<: OC8VW;C&!D'.#SS5W3?%@EAO)K
MM$*@QRVB0<M+#*VR(<G[Y8<C@#<N<5,WB^VCFEBGL+Z%X?-,X<1XB6-8W9R0
MY&,2KTR3SQTR ,>34U\/*&-WO2]>*5TC)F^SK,RA@ ,DE IR!D@DCG%5M+M;
MR;Q#8WMQ]M,4<%XD33!ERGF1;-Z\8)&[&1DA03R*E_X3W1_LWF_-O\WR_*\Z
M'.=N[.[?LQC_ &LYXQFIT\7VUQ*B6EA?7*R2+%%)&(PLKM")@!N<$?NSG) '
M!&<XR 9<FE32>(Y%!U!$;6!.9!OVB,V3+E6(P!ORIQR.!QQ264WB*74[!;E[
MB)!'#\S0OM<9/F;PJ;0Q _B*XX([UJ1^-M(EO+:W1VS<"':Q9!M,H!0%2VXD
MAEZ*0-PR>M0OXR$NGP7-MI5Z6F-J\<<AC4M%-(%##Y\=^AP<D9XR0 5=2TZ\
MD\3RW?D%[)+BS9PMN3*V"<,C^BMM+ #[N[D=*HP7'B(Z;)/=S7BSJ$,UJEO.
M2\GS;E1UC^53QRNX#:O]XY[+3-6BU4W/DQ2(()6B8N5Y8$@\!B1T_B /(J_0
M!P6I76IV\.H3S'4;2V6.XDB:"(EA*$0IN(!X'S<GY>N3P*G<:UY#S^9?2/)-
M+$8BA*B+[,S*0,?\] O/J<=\5UMUIUE?/$]W9V\[1$F,RQ!RA..F>G0?E5F@
M#B;C_A((TNKBS>[:Y6=8[>!U_=;3:*>1CIYN>>Q&/45H>'+F236]1@%QJ,MO
M':VSJ+Z-D82,TP<@, >=J^W'%=(Z+(C(ZAE88((R"*AM+"ST^,QV=K!;(3DK
M#&$!/K@4 >=V-AK6E:1HEK9V=QF/3VGB/E\V\IA >-@>AW'<H;J6(Z+6U"NH
MW>KQ6\%QJRZ26&9)D:.3=L?<"64,%SY9!/<D XXKLJ* .,OSK=UX1M7NX4:0
M_8)7 MWDE#B6)I"\2@9 PQ('.!VI;G^UK@32VUQ>1+';6YA%O:-"K.9I!(?+
M<$Y"A>#G@@^AKLJ* ."NKG4H-2N+)KG5ML<,YM?)B+L[ IL+$*<C)(!/R^IJ
M5/[2AN9_MHU"""2260M8PLY,VV/'12=OWL?PG'/:NT\B/SA-L7S0NW?CYL=<
M9]*DH X(W?B<V]Q;MO\ M5I'%+,8^=_G,A8+@$Y0"<  $_<QDTC2^(_,A07$
MZPM&3;R^1,=K[VXD'E[B -H&X*""3DGFNYAMH+<R&&&.,RN7D**!O8]SCJ?>
MI: .7UA8!X@D:\TV>]@EL/*5$M6E5FWD[20,*>1U('O6?;6NOQ26MJ\ESYD:
M1B5U!VRNMN.KXY!D')_"NXHH X.QGULP0-?3:@+1W072Q6\IF1MC[L?(#M+;
M!\@(&.#@FI_*N;2^OS&=5%O<7\<DSK'*SF VR@%."<^8 I"_,!Z=:[6B@#B8
MAK4R7<L]YJ$"QVR?9_W#-OS/,,LJKNWF(19P,KNS@&K]Y>WO_"/Z<5LKY)9R
M!( \A>+Y2?F*(7/('\(Z\XZ5T]% ')^'KG57OK8:B+N22:QC>7?$\:6\GEQ[
ME.5"L2Q8Y!R#D8P.(FGU C]^^JK+]K9;P10.0D&7V>5A<'_EF"5RVTL3@CCL
M:* .'8Z[):WLRS:B!;VDTMFIC(:5@[^6'&,DE0HVGD@C(S4$T>J6,TL-M_:"
MP/>7#S.%F8Y.#%M*HQ*X+$X&,@ ^A[^B@#CHK;6I[^,7-[?!7O$AE,*%$\K[
M&'++D94&88SUR2M4]/O]8N+J 2RZA]N46)>+R2(@&5#/O^7"G!8X)&"!CO7>
MTQ(8XY'D2-5>3!=@,%L# R>_% '!V$FK)#H=DEI?P+%;VT$QQ( 4,0WG 3:I
M!.,EMP*] .K=,76K>'1+.%KR"&*TMT)EBE;]\&(E5_D/RX"@%B!@D@\9'H-%
M ''Z$+V77[*:\%^TZV$RW1GA98DF9X251L $?*<8)&%!]:S[4:K;6;+:-J$<
ML(N9ITN(BD7RR;XU5B,?,..#]UB3SBO0*BN+>&[@:"XACFB;[T<BAE/U!H I
M:%)<7&DQ75R7\RYS.$?K&K$E4/N%(!]P:TJ** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \)\)?\ )P^L_P"_<U[M7A/A
M+_DX?6?]^YKW:@ HHHH **** "BBB@ HHHH \Y^-W_).9?\ KZB_F:U_A;_R
M371/^N+?^AM61\;O^2<R_P#7U%_,UK_"W_DFNB?]<6_]#:@#KZ*** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/"?"7_)P^L_[]S7NU>$^$O\ DX?6?]^YKW:@ HHHH **** "BBB@ HHHH \Y
M^-W_ "3F7_KZB_F:U_A;_P DUT3_ *XM_P"AM61\;O\ DG,O_7U%_,UK_"W_
M ))KHG_7%O\ T-J .OHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG*\DMJL<<0 &'=41@0".%.0/1>..:D>Z\-2'SF%C(UM)N1O*#,KNQ.4XR2S
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MB@#PGPE_R</K/^_<U[M7A/A+_DX?6?\ ?N:]VH **** "BBB@ HHHH ****
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M\J!@/FP3@GBMO1+?36T"U6RMP+.2! JR1X9E"@#<#U. .M7Q:P*NU88PN N
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M21JTD:L&"L1S@@D$?B:E>TMY8WCD@C='.YU9 0Q]2.]2(BHH50%4#  & !0
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M2[NY)F-N)V>.,!Q(^&*J(C]T$\[E P,[CG-6TNM1M;6R N;ABL7EW5R\"M+
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MJ$5]8Z+&ES$=T;O-))M/8@.Q&??% '64444 %%%% !7#6$B1_&76$=@KRZ5
M44G!8!CG'K7<UA>(/!V@>*/*.LZ;'<M%PC[F1@/3<I!Q[9H R?BO+'%\--8#
MNJET1$!/WFWKP/4UUUJ"MK"",$(H(/TKE;'X7>#--O8KNVT2,3Q,&0R322 $
M=#M9B/TKKZ "BBB@ HHHH X:PD2/XRZPCL%>72H"BDX+ ,<X]:F^*\L<7PTU
M@.ZJ71$0$_>;>O ]36MX@\':!XH\HZSIL=RT7"/N9& ]-RD''MFLVQ^%W@S3
M;V*[MM$C$\3!D,DTD@!'0[68C]* .JM05M801@A%!!^E2T44 %%%% 'A/A+_
M ).'UG_?N:]VKPGPE_R</K/^_<U[M0 4444 %%%% !1110 4444 ><_&[_DG
M,O\ U]1?S-:_PM_Y)KHG_7%O_0VK(^-W_).9?^OJ+^9K7^%O_)-=$_ZXM_Z&
MU '7T444 %%%% !1110 4444 <[+X8DFW0M?*+59;B>)!#\ZR3"0-EMV&4>:
M^!@=N>.9)O#2S,V^Z.UC;Y 3'$6>^>^?P]ZWJ* .9E\+74UG8P2:C$S6'RP,
M+=URFW;APL@R>AR"HXZ<XITOA7&GW-K:W$$'FS)+&WD,3!M@2(;,."&&S(;/
M0D8/6NDHH SO(OKFPOK:6?R'<-%!/%RZKM #GMNSD]NU8\/A&>%6*ZB@F>[%
MR9A#(9$^2-"J,921D1\[BP.>G%=310!@ZUX>GU-KTVU\EL+ZS%I/O@\SY07(
M*_,,']XV<Y[=,56N/"'VE3$UZ$AD:X\YHHBLKI,\C%-V[&T>9T*GD9&">.GH
MH YZY\.W=_Y#WFHQ--;QLL316Q0;O,AD5B"YSAH1D#&0V.*9)X9N9;L7CZA"
MMVTZRR316S(P4!!L3]Y\H(3YMVX'/3@"NDHH Y2Q\%_V>EJ8+R+S[(K]EE>%
MV(4*R;7!DPWRL?N[>>?:M"#07CT6.PDNP\BWHNVE$6T,?M'GD;<\?W>OO[5M
MT4 9&GZ']@ET]Q<;_LEM+;XV8W[WC;/7C&SI[TR'0GCU;[8;I6C%P]PD?E<@
MM'L(+;N?4<#T]ZVJ* .7TSP<FFW-K)]I2=(DA#*\;Y+QQ+&&7#[5X53@JW?G
MFM"3P[:S:I>ZA*D+W$\:QQR-""\.%(.&Z\[O:MBB@#G)?"\C6TEK%?*EO<6D
M=I=*8,LRH"N4.X;"0Q'(;'!'O4O?#%U!I][':7+R75].D[21HJ>5/NR91D\+
M@*-HR<#N237744 9EYI32:5'IUF;2.W5!$8[FV,R% , ;=R^W7-9S>&+E(C%
M;ZM(BF&WB9G1B[F+C+,KJ2&'4#!SWQQ7244 <H/!A%BUJ-0^5H8D8^4<[XIF
MF1@=^<9<@CJ0."*F_P"$24V\D?VB-'E@>)S'$V"6<-N^9V/\('7_  KI:* .
M9U'PB+[49KT72!Y9')22-BFQXX492%=2>85.<XY(QWJT/#:*D4:W&U([N6YP
M$ZAXW3;U[;\Y]NE;E% %'2[2YL;2&VGN(9DBA2-2D)0Y7().6/!&WCL0>3D
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M+^%:5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVX%:UYK/V74C:?9BR);FYEG:542-1D<Y]Q].O/%/.A6!\C;')&8-WEM%/(C
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M/%22Z%ILT @DM@\8:5]K,QYD)+GKW+-],\8H H0>(X/[#NK^*S8_9I1$T43
MAV.T_*W /WQSQSD=JK2>-H(;IX);-\Q/Y<Q20-Y9 #.2/[JKN^;N5([C.X-*
MM?L1LW\Z6$L&(EG>1L@@CYF)/4#O3&T6Q:>XE,;YN5*S)YK^6^1M)*9VY( &
M<9H RIO&=I%>"W^SR,0Y#$,,[?,:,,HZM\R,<#LN>X!DB\3F0VI:P>&*YF>)
M)990%^5@O7^\Q)VKU.#WXJ^FA:?$;4Q1R1&UC6*,QSNGR+T5L-\X_P![/4^I
MI9-#L)((8&CD\F%RZQB9PI);=\P#8;GGYLT 4M%\56VMI,]O!(46%9XRI#>8
MC9QTZ-Q]T^H]\4QXMD,L$[6L2V'V.YNKAA+NDC\HID8QU&_!4\Y^G.Q%8V&D
M6SHC20P2,L85IW*J6.U50$_)RP "X[>@IB^'-+4Y,#NQW[VDFD<R!PJL')8E
MP0BC#9'RCT% %4^))%O5TY]-D747V,D!E7:48.0Q;MCRV!'/.,9!S1HNM2WV
MJ:E8R(6>UG(D.0!$I52J_P"T<[N?;KT%*-'T?[8;+RIS<*JW E-Q*9% W*,2
M;MPZL, XPQ]35^#1K&WNA=11,LX))D\QBS9 !W$GYAP.#W&>M &:_B@_:S:Q
M6#/.;HVJ1&4*^=LC;V!Z(1&2#SD'(]*I#Q!)?:B\7DDQ,(8Q;2!2!,)+E'!.
M#QNA SSTR.M6M6T+36O[&YF>X61[P'=YTC,Q*2@*K;LQ@%RWRX'&,>ENQTS1
MG=7M82)(A&Q#%PZXWNNX-SN_>N3GDECF@"?P_?W&IZ!87UU$D4UQ DK)&V5&
MX \5I57L;*#3K1+6V5E@C&$5G9MH] 220!V'0=JL4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!X3X2_Y.'UG_ '[FO=J\
M)\)?\G#ZS_OW->[4 %%%% !1110 4444 %%%% 'G/QN_Y)S+_P!?47\S6O\
M"W_DFNB?]<6_]#:LCXW?\DYE_P"OJ+^9K7^%O_)-=$_ZXM_Z&U '7T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;9:
M'9V&M:GJT ?[5J7E?:"6R#Y:E5P.W!K2HH S=2T.SU6]TZ[N0YET^8S0%6P
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M?/&)/KP>/2K$7@[28;;1;=%EV:.^^TS)T.,<^O6N@HH **** "BBB@ HHHH
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M4 %%%% !1110 4444 >$^$O^3A]9_P!^YKW:O"?"7_)P^L_[]S7NU !1110
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M;?*D<%&( ?)C ^7/7W%/MO$EJ^I7=I/OB,<ZQ1,T3@$-"D@W,1A3\S#!(/%
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MS(Y'X=':-6B_>-%R"V6^=&'R;OND^F0#I**YFZ\7HFFWES!IMV7AMI[B$2;
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M'>@#4C\*+')+*;I6:0R9C,"^5\X /R=.<9/J2:OZ/I]SID;6K3B6U1%$.?O
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M%I>0-%- 2IYD"D'GD$$\5=T_6-.T'XI>+AJ]];V O(K*2W:YD$:R*D;*Q!;
M."<5#\1O$FB:QX833-+U:QOKVYO+=(H+6X65V/F*>BDXX% 'I5%%% !1110
M5YS>:-8>)_BO?6FLP?;+6QTV)K>"1CL1G8[FP._'^<"O1J\]?5;#0_B]J4NJ
MW<-C%=:7#Y,MPXC1RKG(#'C/M0!2\?\ @KP]H7@R^U?2--BL=0LO+F@N+<E6
M1@Z^_N:]+MV,EO&[=60$_E7GGQ)\4Z!J'@+4K"PUFPO+RY"10P6MPDKNQ=>
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MHUD0$'#[1NZ<=<UJT %%%% 'F\6@Z;XJ^)WBA-<MA>QZ;%9QVL<I.V,2(6;
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M^2<R_P#7U%_,UK_"W_DFNB?]<6_]#:@#KZ*** "BBB@ HHHH **** "BBB@
MHHHH BM[:"TA$-O#'#$,D)&H51DY/ ]S4M%% !1110 4444 %%%% !1110 Q
MX8Y7C=XT9HVW(67)4X(R/0X)'T)I]%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% &?J&A:1JSH^I:797C(,*;FW2
M0J/;<#BFV/AW1-+G,^GZ/I]I,1M,EO;)&V/3( K2HH **** "BBB@ JCJ&BZ
M7JP0:EIMG>A/N?:8%DV_3<#BKU% &79>&M!TVX%Q8Z+IUK.!@206J(P'U S6
MI110 4444 %%%% %'4-%TO5@@U+3;.]"?<^TP+)M^FX'%0V7AK0=-N!<6.BZ
M=:S@8$D%JB,!]0,UJ44 %%%% !1110 53U#2=.U:-(]2L+6\1#E5N(5D"GU
M8&KE% &3:>%_#]A<I<V>A:9;3I]V6&TC1E^A R*UJ** "BBB@ HHHH ****
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M/+#%T>9$91GIPQYQ],=:LG2+ P&$VR&(PM 5[&-NJ_0U9N+:*ZC$<R!U#K(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.UQT/T]1[U/63X7LWT_POI=K(LB2QVL2R+(Y9E;:,C))Z'/';H*UJ "BBB@
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M_7%O_0VK(^-W_).9?^OJ+^9K7^%O_)-=$_ZXM_Z&U '7T444 %%%% !1110
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MGA>.75Y9Y+&U:"75!=2 HOSQBUV#<._[PDX/J3WJ@?"M[):I ;2"-UA\NZN
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MX0X$<;SR.JE3M#;L2XZD L<=C5JZ\)6M]'+]LO;R>:0%6G8H'VF*2,+\J@
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M4%Q9V[W<<D4TVT+B(A7)E6+*Y[!G4'ZYZ5=GT"VEG,R330R;HG4Q[<(8P0,
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M&%<, R0?9MO3/"CD==P_"BW\+VEJ+3R;FY1K40B-\J3B.-HQG*XY5V!^O&*
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M64N)+Z"%!*F64JC-N4@\#.5!R.00.G%  =?6.PNII;21;BVN$M7@# YE?9L
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M*UCNB"_:F1#&9E\Q&9_+'R=2-W!/3ZU>MO#^FVL\4\<4AEB8,DDD\DC+A64
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M5.TL,*1D#CG%:USI=U=^%;.UGFNKF9;R"0N"\+[!<*>?G+?*GJQ/RYZUU-%
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MS,-O..04//<$=* ()O#-X[2?:%:Y0K,"4=0[EFMBIPV5/^J8D'(/0\&I-/\
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M',:%67*@\Y/2J?B_QKH?C72(M \.7,NH:A<W<.$CMI%"*KABS%E   %>K44
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M1<7<#M+*EO),D?DR<%<C#_+\GS*5^;'(/I5_4=9M=*GB6[<(CQL^0&9LAXT
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MD4$@;\8R0,XSG':MBPO(]0T^WO(@P2>-9 &ZC(S@^] %BBBB@ HHHH ****
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M- %;3/"H7>D.H%]*E2!DV!")@K,XP0, $D=.".F*=:^&&^P6<.I7YW1 I#&
MHVDN'(S_ !?=P/;/4\UF0Q:[IF@:9#:_;65K&W^T*Z-F$@J&50%)!VG! !.!
MD<\UHWFFWFJZ9H$%U),\JWSR&=(F5H0(I_+<A@""I\L98#)QZT :4>BVYO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#PGPE_R</K/^_<U[M7A/A+_ ).'UG_?N:]V
MH **** "BBB@ HHHH **** /.?C=_P DYE_Z^HOYFM?X6_\ )-=$_P"N+?\
MH;5D?&[_ ))S+_U]1?S-:_PM_P"2:Z)_UQ;_ -#:@#KZ*** "BBB@ HHHH *
M*** ,)KG5O\ A(&L([JR:+R'F;_17W0Y.V($^9\V2&[#.P]*73=3O#:ZG=7T
MEO-!:RND;V\+1[P@^?@NW1@R]?X:T%MK>RDO+PL5:;#RR,?NA5P /0  G'J2
M>]5+"SA?3].6QFD2PB4DQR1$-.I4@;MV#U.XY&2<4 9*Z_JPNK+3Y!9"[U!8
MY()%B;9$&61V##=EL"/@@KDGH,<L/B?4&MKV=$M0-+@>:\#(Q\[9+-&1'\WR
M_P"H<\[OO >M:L?A;3XHMJO<[UV"*4S$O"$SL"GL!N;USDYS2MX7TUDC0"95
M"[) LI_?KN+XD_O?,S'_ ($W8F@!NLZG?6]U]GL!;AX[62Z<SHS!@I "#!&,
MY/S<XQT.:RKGQ=<6]E+K'E1-IB.\8BV$3';$7W;LX^\-NW;TYSVJ]-8:??WC
M65YJ$LUZ#*&\EBA$4AW>4V. -H7N#QD8S5Q_#>G2733/&Q1B6-N6/E;BGEEM
MO3.WCT[XSS0 VPO[^/4)K+4S;R2+;I<*]M&RC!+!EP6;)! P>^>@QS0_X2MI
MIK&XMK&YEM)K6XF:-#$S_(T6#G?@ !F!&<YXQ6GI6E6=M&UQ;S7$IGB11+-(
M681C)503T W$^O/.:CCT*PL6FNW>5I&27SI9'R6#B,,3VZ1(./3WH AO?%^G
MV,FV5)2IMVN$9&C.]5C,APN[</E4\D <=>14,OC;3K>\-I<0W$4ZCYHB8RZM
MM+A=@8L25P> 1\P!(/ K6>C^'-662&UN99%,98P^8R\-$8=^T@'E#@'IZ=ZT
M+HZ5;:VZO?S6MU<*IDC1R%<L#&C'C 8[<#D9*CK@4 6EURW.BKJACD$3D!$5
MD=G+,%4 JQ4DD@#GOSBL^7Q#<7&KV-A!9W,#M<%+H2",E $W@??(P00<C/0C
MK6BFA6:Z;+8MYCQRR&5W9SO,A;=NR,8.0",8QBJ^F6&G27#W,$EQ-/!</YD\
MN[YY-NQN2 " !M^7@$'OF@!WVO4+W5+N"RDM8(+-UCE::%I&D<JKD !EV@*R
M\\Y)/'',5YXLL[*.>>6UNC:PM*GVA54H[QABRCYMV?D89( R,9Z5=GT>&:]-
MXDUQ;S, )##)M$@'3<.GX]?>JUUX7T^[$Z2F<PS&1C )#L5W4JS@=B0S>V23
MC/- #8O$L3WOV673KZ!A*D3O((]J,XRN<.3S[ X[XJKI_BNRDC@\G2KVWBG$
M,VXI&JJ+AR$<@.?O/NS@$@Y) ZU?%MIMV)[\2'8+CS)')VA7A)0]>P*GVXJI
M8V&B36L"VTS&,"VMHMS%2WV<F6,#.,GJ>.HH 5_%]I';K<-9W@AEC\VV?:A%
MPN5&4^;/\2D!L$@^QJ:.]_XEFISZ;IABOHG;S+9U56:;:K#<5)#$J5.<\Y S
M2KX7T\ *3.T:+MAC:0E85W!L(.PRJ_0# P.*L0P6DD^IPP32I/+(KW!0D%6,
M:J"#_NJM &2GB<V_V4SE;F!TFDN+F*'R1 (P"0T;N7! /(Z^U7#XFB25+>73
M[V*\D*^3:L(]\H8,<@A]HP$<G)!&/<99<Z+I%M"6NY7)/FS2M))N:8% K[AW
M&T*, < #%/C\.V$T:3^?=22X1H;EYB9(PH;;M)]G8'/7<<YH 32M=:\UG4=/
M>&7S+>5,IA?W"-#&X#D'&2S.!C/3T&:TKBZAL[JU1T)DO)?(5E ZA'DY/IA6
M_$^]9_\ 8=L+BZEL[MXM39/FN-P=@3&$4NO&1\BM@XY!QC)J]=Z9%>06Z22S
M*]NX>.9'PZMM*YSTY#,.G>@#+B\76DV62RO?(1HUDG*ILCWD!<_-GJ1G ./I
M0_B^T2&*8V5[Y=QM-JP5#]I#.J I\W'+J?FV\'/8TRR\(6EK<2_O9S:DPE(/
M-8@B,#;OSUY&??OFK2>%]/5HN9V2!E,$;2$K"%=7 4=AE%_ 8&!0 EYK_E>'
M=1U.&SF,UDDA>VD*A@R#."0V,8P>">/?BJ]OXC>/4+V&]M+B*%+I(4E(3;%N
MAC?:Y#$D[F;D9'(YK2DT^R,5W82!F74!(\J$GY@0%;GMP1^=-70K3RW61I93
M).EP[2-DLZJJ@G\$'% $&C>*-.UR.X>U<@0(DK[G0_(V=K?*QQG:W!P1CD"D
M3Q()5M_*TN_=[E#+!&/*#21C&7Y<8'S+][!^8<=<7K#3(M/M3;1R320!0BI,
M^\(H& H]L>N36:^B6%F;*#[9>1.6,%F5E)9!L+&,''W=J9^;/W1SD"@!(_%M
MI.0T-I>20YB4S!4"JTF-BD%@<DD+TX)YQUID_C72X(H7(D(FCC>/+1IG>I;;
MEV !"@$@G^)<9S5J+1-,@7[%$K("89@@8_\ +$J4Y/NJY]:$\,V$28MS-!)]
MH>Y$L<A#*[#!Q[8P,=  /04 51XSL7B\Z&UNI;<M$JSCRTC8R1K(HRSC'RN.
MN.>.I ,C>)8X9[J$VUS<20,[.L,:@QQJ%R3E^>O;DX.!Q3S9:;>_:K**[E)N
MP+B8QR9\Q=@B^]@C!" >N1FG/X7TYM^SSXMX97\N4KN1@ 4/M\H]QS@C)H 6
MV\26UU?);1VUSY;S&".X(7RW<1^9@?-N^Z"<XQQBB[UNUANY8&LYY5CD2VEF
M54V+)(%VQG+ \[T[8^89(YQ"5T6TU%+8.RW$$QNPBJQ",8V3G P!M)P*MOHM
MG<WGVPF7#R).\8<B.21<;'*^HVK_ -\CT% %32=:E?PT-5U".16<EA%A<G+8
M5%"DY). ,G))K&G\6:K!I<$LR6<5RS7HDQ$\J@PRE%7 8%00.9#\H(YQN%=-
M%IFFRZ:-.:&"ZM86VF*8"0!ASR#W&<UBQZ+X:CN6TVR<V\Q:42)9L4SYAWNC
M%1@=L#@@ 8Q0!IF]N9-?M]/FAMC975C+*1DNQ96B!![;<2'USCMTJC?V4%M?
MV&G)8:3+8W$Y(LOL8W)A3NESG;QP/N_Q 9R16I!;6E[#9ZC8/MQ9M':R;3M$
M<FQ@=IP?X$X.*KP:+%;:K'<MJ-X]X\**^YAB18P!SQP"3D@$<L30!E6_B"_2
M$6\GV>&\DE6&"U>PEA$:F39NRS8D4+@_+CD@9&:M&]MEAO;[5[*VGN]*N! 9
MXH0#R$=67>3L&)!G+8&"<XJ]+X<L[AWDN9;J>0@".1YCNAPP<;,=/F53GJ=H
MSFK$&DQ6UE+;0SW"-*YD>??F1G.,L2?H!TQ@8Z4 9D?B-DU26.:UG^RD6P61
M=A$32DJH8AN<MM'R[L9]*?)XNLX[FXM1:W$ES#(D?E1-$[.78JN,/@<C^(@C
M-*=(TC35M[+$JF>2$1HNYR3"V]2< X (Y)XYJ)M$T318_/EGE1+6+S55I"VR
M*$[N%')"[N>IY&<\4 -'CK26:Y51(S0!B0'C)8+(L;'[_P H#,,E]HQST!-=
M%;S>?;QR["F]0VUB"1D=,@D?D2*H1Z+%!'/'!=74,<K%@B2<1DMN.W(.,G/'
M3G Q5NQLH=.L8;.W4K#"@1 3DX'O0!8HHHH *Y/6O! U#6GUC3=:O](OIHUC
MN'M2"LRK]W<I[CIGTKK** .'7X=S75U;MK?B?5-5M8)5F6UFVK&SKT+8'(]J
M[BBB@ HHHH **** .3UKP0-0UI]8TW6K_2+Z:-8[A[4@K,J_=W*>XZ9]*IK\
M.YKJZMVUOQ/JFJVL$JS+:S;5C9UZ%L#D>U=Q10 4444 %%%% !7+:_X+35]6
MCU>QU:]TG4EB\AY[4C]['G(5E/!P?\]*ZFB@#A)/AQ<:ALAUOQ7JVI6 =7DM
M)-J)+@Y ; R1GM7= !1@=*6B@ HHHH **** ,#Q-XKM?"YT\W<$CQ7D_DETZ
M1 *6+M[  D^PJ"7QG AEABLIY[L:BVGP01LN9G5 Y;)( 4*223Z5?UC08M9O
MM,GGD7R;-Y6>%DW"99(GC*GGCA\]^F*YVP\ ?V180Q0ZV_VR#46N[.ZEA!*A
MHQ'Y;KN^<;!@G()Z\4 6;[QT;/1K^_\ [&N"^FR&._MVE17AX# @Y(8$,""*
MEN_&-S9:E9Z;-H^R]N('G,;WD:JBJX7&X\$G(.!3;CP4UWX>URPN-2+WVLG=
M<7GD8 (554*F[A0J@8W9]ZFUSPK/JGB*UUBWN[*-X+9K?RKNQ^T*07#;A\ZX
M/RXSSU- &_:WUM>M<+;3+(UO*89@O\#@ E3[X(_.J%OKR3M?2O$(;.R,BRS/
M(,J4/S94<@8!()ZC!QR*OVL5S$UP;FY697E+0A8MGEI@84\G<<Y.>.O3BL>]
M\.2:E=7DMU=PJL]K-:K]GM]C['X&]BQW[1TX')- &G<:M8VI<37"*R.$*\D[
MB,@ #DG'.!56T\0V5UJES8%T2:*98HP6_P!9F))0>G!PQXZ_*3]*@\.WWVUM
M0;4X#?><)586A\H#R_+*E=^3D<YW=?;BK*Z$WVEYWN5+O?)>-MBP,K"L6WJ>
MNW.??'O0!H7E_;:?&KW4HC#MM4<DL<9P .2< GCL#65?^++"S2;RR9VCM1=A
MEXC:,G@[\$>]7-3LI+FYLYK>ZC@NH&<Q^9'YBL"N&!7<I].0:S7\*'[*MO'>
M@(;3[-*7AW%CNW;AA@!R3QSU[8H TSKNF"V^T&[01^9Y70YWXSMVXSG'/3IS
MTJ6'5;&YNS:P7,<DX02%4.<*<$'/3!SQZUDZAX6^V7<MTEX$E:Z^T*&1BH!A
M2(J=KJ3]P'.1Z8-7=.TR#11<2"2)(62-0H78L:QH% R2>./PH )M?M+;7'TN
MX=(G$,,B,S?>,CNH'3CE ,D\E@/K8?5K&./S'NHUCS(NYC@9CSOY]MK9^E9V
MH:!+J.HS7*7R1VUS!!#-%Y.YF6.1W!5]PQG>1T/3BHV\-3FX_P"/V![57N9$
M@EM=V3-N+!SO^907/&!QQ[T 7VUVQ1?,DF6.#RC(9)"4P P7D$9 R>M*VOZ6
MEL+A[V-8BQ3+9!! R<CJ,#DYZ#GI68OA20VXCFU$R'84R8B0H\U9 !EB<#;M
M )/]*-1\)_;;^:\6[59))7;9)&Q38T<2,I"NI/\ J0<Y[D8[T :TFM:?$TZM
M<IF#'F8!(!. !GN3N7@<\CUJW'.DL*S(?W;+N!(QQ^-84WAEWGN6BGM4@EB$
M8MS;,4)!3#N/,&YE"8##:1GG.!6E%I\\>ABP-_*TX@\K[7CY]V,;^<\CKR3[
MDT ,&O:8T8D%TI!D\K 4[MV,XVXSTY^G/2K=Y>6]A;&XNI5BA4@%V/ )( _4
M@5S8\(7 MKA!J48GFE647'DR%XB$VY1FE+!O<DCD@@CBM_4K'^T;5(/,\O;/
M#-G;G/ER*^/QVX]LT 16NNZ9>RF.VO(Y'"LQ4'D!<!OQ&1D=1D9I8M;TZ924
MNX_E5V8-E2H0*6R#TP&4\]B#5)O#K^5MBOVBD!O&65(_F4SN6!'/5<_CCM65
M-X2F6!+8RO.;F_%Q/,N0J1^4L;H=[L[!U4CJ>3GC H ZF>_MK6R-Y/,L5L%#
M&1S@ 'N?3K58:]IA2%Q=QXFD,*#G)<=5QC.>^/3GI3?$5G<7^B3VUJ/WSE-N
M<<8=3GGC@#-06N@217Z7T]VLMP;E[B39#M5B8EB 4%B1A5'<Y.: +'_"0:3Y
M<\GVZ$) -TC%L #.,Y[C/&1QFE;Q!I:VRW!O(Q&SE!USN')&,9&!R>.!S6%>
M>%;M-)2WANUG:UMEM+-1"%*Q^9&27)8AR!$O]WH>.:GG\)2W%Q]M>_0WS2O)
M(WDNL9#)&F JR!AQ"G.X]_7@ T;KQ#90DI!(EQ,LT$;HC?=$KHH;.".D@8>M
M7K?4+6[,8@F23S(A,NWNAZ'_ #Z5EQ>&XX;2:WBF6-)+NVN%"QX""$0@(.>A
M\GKVW=\<KX=TM[%K^XEC>-KFX9HXW*DQ19)"_*2,;FD8<\!L=J -"35;**[-
MJ]P@F"[F7^X,$Y8]%X!Z^E0#Q#I1@,_VV/RPXCSSG<1E1CKSV]>U5[G0)+B3
M5(Q=JMEJ:D7,1BRX)B$64?=@<*O!4\@^O#5\/SR7ZWUY?1RW(>$_NH"B[8_,
MP,%CSF5B3GTXH M0^(=)GCDDBOX&CC3S&8-QMZ$Y[X/!QT/'6KEI=P7L GMY
M!)&21D>H."#Z$$8(K!N?"*W-I! UX1Y,<JJPCQEFFCF4\-T!C (SSGJ*U])T
MX:99>1F,N6+NT:LH8D]<,S'T[F@"IIWB73[ZW>1YXH7C$C2(S\*J,58Y( ('
M&?3.#3;GQ+:I)IT=J!<->W7V8?>41D*6.[Y20<#H<=1T&35!_!SW%JUK<ZB'
MA5)U@\N#8R&1PV6.X[L8P  /?-7K/P]]F-HYFB\R&[:ZD:.-P)286BYW.Q!P
MPYR?N@8H M?\)!I7ESR?;H0D W2,6P ,XSGN,\9'%/CUG3Y;F*V2Z0S2J&1#
MD$Y!('L< G'7 )K'3PD_V6"VEOU>*TMQ:VV(,%8]\;'>=QW'$2#(V]^.:M#P
MV@\0RZIYJ,DLJS-$ZN2L@C$8*D.%'"CJI/7GG@ OWVK6VGW5C;3B4R7LIABV
M(6 8*6Y(Z#C_ ",D5-.\3:??V!N7GBA9$,DJ,^=@!P><#.#QQWXJWJ%@]Y/8
M31S+&]I<>=\R;@P*.A'48X<\^H'!K(N/"*W%A:6QO"OV:!XE81XRQEBD5N&Z
M Q#(SSGJ* -ZTNX+V 3V\@DC)(R/4'!!]"",$5GGQ1HH8J=1A!!.<D]CAC]
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M44 %%%% !1110 4444 <5>:)J-TUS$UK(TCR71EN&F4I/"RR>5&%W9!4M%U
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MEC!3Y?G^:)CSMXQW.*TM7U.:WOY41W2.V@BD8(0"[22[!R0> $;(Q_$.G!H
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MI8G?MSVQ]W.>PYQ0T;5;S5O$5P7C$5K!:J/+$Y.)?-EC?C: W,1 .>@!Q\Q
M ,36K?\ LFYNUNE+6#B86%N+Q8V5C'%\Z@N"</Y@XRP)X'S5TMQ:WLOA.WMX
M@_VD1P>8@?:SJI4R)NSP64,N<CD]14%A?S_V$?$=[?3F'[,]R]G&D>R-0"=O
MW=Q90,'YNH/ Z42^)+^'4+;3I-*@^VW++Y:K>$H%*2-DMLR"/*(Q@]1@GD4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'A/A+_ ).'UG_?N:]VKPGPE_R</K/^
M_<U[M0 4444 %%%% !1110 4444 ><_&[_DG,O\ U]1?S-:_PM_Y)KHG_7%O
M_0VK(^-W_).9?^OJ+^9K7^%O_)-=$_ZXM_Z&U '7T444 %%%% !1110 4444
M <4MQJ\^N)"+^V+IJ$T:;H&(1!#D J'^;KZCN:6#Q;=WLVEK;_9U^UK$DJM#
MGR99(?-'/F L!E3@+T_B!Z:UCKFDW,MQ)(;:WN8I9UD+$ XB=D+%B!_",X[
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M6]PTR3*"\[')(!/& !SDG/&2>M0ZAKVC:;I,]Y$;>0^7)<K$HV^8R>O'RG<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH \)\)?\G#ZS_OW->[5X3X2_Y.'UG_ '[FO=J "BBB@ HHHH ****
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M9A#:8. I. [2#Z\'C(K>G35+FQT"*>2>&>21?[0-MQC]Q(6!(S@;PHS].>:
M)3X>9[AI);YVCEGBNIXUC $DL>S:P/51^[3(_P!GW.6#PO"-+:Q^TR;6TP:;
MNVC.T*1N^O-8\-]KC7FD1O;7H91$MQ(ZL%D4[@Q*A-H(X))8'/08ZLLHM=CL
MH9I+K4WF2RLIF1T^],[L)E(V]E497MG/!YH T;CPG;01ZG);VT$\EVLQ53"B
M2!Y22W[W&[&23[>^!6CHEK-:6\4*74,]G';JHD3EI)MS>8[$<<G'3N6K+\+R
MZS+=,VIR2JWE'SXI(Y !+N'*,4"[1\PPI.1@^YR[/^UK:T<6K:A&\*7,TR7$
M12/*R[XU4D 88 CY2?E8D\XH V4\%V49N44PB&<N&(MD$I1VW.AD')4C*^N#
MUS@TJ>#+(74<TIBN=J)&WVBW21MJ$[-K'E2!@$]]H/!YI3>7P\*+>M#<RSW3
MB7RT+!XD=\J#M5F^52 < G@_6L>WU#78M,N?M$6HM-+%LM0EN[$%;B89)VY'
M[LQ'+8)'OF@#<&BR0)86W]L$36N1:LT:;R@0J01T8X(Y '('N"R/PFD,%M''
M?2J;>UMK='* G= 24?\ '<P([Y[5EVND3OK8BWZE$JW5T[R_/C:P4IAR,8/L
M>V#W%.LKO7)C:27(ODO7:T*Q" B'RF2,SESC 8$R\$@C:N.O(!K0Z*]C=7=[
M!=K-JD\+D^< J,Y"A20.0HV(O?@=S5K5-&_M6WMHY;C!A;<P,8:.7Y2#N0\'
MKD9Z$#K7,;M4M=*LI;E=4N+B;3T:0JDFY9V*<-L&Y57DD=< ]34ENVO)J20P
MW-U)'&B^0]S#*!.OE?-O^3"L7S]X@C"X&#R 7[3PK!:I%I]MJD@B@-I/+!M0
MLYB"*C'N PA X[J<=Q4Y\.VMEIICEO"D,=E;6[R/@!4@+,&)Z#.XY],56\*K
M<-J]]//_ &@V^QM%9[R$IF4-,7"Y SC<#QP,\<5EW$>K:AI$MO-_:3R/9$WJ
M-&R!;D,F%B.!E<>9]W(P%]>0#8ATC39#J%O%J:227R#*JZDJ&EFF! ]#YK8]
MES4__"+QFYBD-TP6.2>3Y8P'/FN[,I?KM_>=/50:R9K'5+&^OY=-2YDF?46:
M/SRS(P%@=IR>@\S"Y]1BHKZ?4RMLMA/JRP-')OFGMYMZS_+MRHC)VXR< ;"<
MCT% &XGAC&G36K7TA:6.",R! .(CP".X(X8=QGUJ%?!ULEE#:+<NL:)<QMLC
M5<B>02': ,+M8#''08.:M:&UW# [ZC)<R7%Q>3QJK1L515>3;C ^52J@ACUR
MHSR!6W0!BP>'RNK1ZI<WCSW:@+N\L*NP*P5<#TWL?J?3 J:33KB_TF"&]G5+
MV-DF,L RJR*=W /4=N>H]*U** ,BQT%;34O[0>Y>:Y82^:Q4 .7\H9P.@ A0
M ?G23Z LU]+-]JD6":XBNIH H^:6/9M.[J!^[3(_V>V3G8HH Y\>%D-C/:->
M2,DEG+9J=@!5'.?Q(J,^#;+S;UE\E1=-(^_[,GFHTC;F_>=2,YX/K["NDHH
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MY"QS)SMX&?/)[\CMG 8/ MDL-NOF)-)"KH7N[=)@ZL1C(8=5"JH/H.<UU=%
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MB@#PGPE_R</K/^_<U[M7A/A+_DX?6?\ ?N:]VH **** "BBB@ HHHH ****
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M'-$WWHY%#*?J#4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >$^$O^3A]9_W[FO=
MJ\)\)?\ )P^L_P"_<U[M0 4444 %%%% !1110 4444 ><_&[_DG,O_7U%_,U
MK_"W_DFNB?\ 7%O_ $-JR/C=_P DYE_Z^HOYFM?X6_\ )-=$_P"N+?\ H;4
M=?1110 52GU2VM[HVSB=I519"(K>20!22!RJD=5/Y5=JA#_R'[S_ *]8/_0Y
M: #^U[;_ )Y7O_@#-_\ $4?VO;?\\KW_ , 9O_B*OT4 4/[7MO\ GE>_^ ,W
M_P 11_:]M_SRO?\ P!F_^(J_10!0_M>V_P">5[_X S?_ !%']KVW_/*]_P#
M&;_XBK]% %#^U[;_ )Y7O_@#-_\ $4?VO;?\\KW_ , 9O_B*OT4 4/[7MO\
MGE>_^ ,W_P 11_:]M_SRO?\ P!F_^(J_10!0_M>V_P">5[_X S?_ !%']KVW
M_/*]_P# &;_XBK]% %#^U[;_ )Y7O_@#-_\ $4?VO;?\\KW_ , 9O_B*OT4
M4/[7MO\ GE>_^ ,W_P 11_:]M_SRO?\ P!F_^(J_10!0_M>V_P">5[_X S?_
M !%']KVW_/*]_P# &;_XBK]% %#^U[;_ )Y7O_@#-_\ $4?VO;?\\KW_ , 9
MO_B*OT4 4/[7MO\ GE>_^ ,W_P 11_:]M_SRO?\ P!F_^(J_10!0_M>V_P">
M5[_X S?_ !%']KVW_/*]_P# &;_XBK]% %#^U[;_ )Y7O_@#-_\ $4?VO;?\
M\KW_ , 9O_B*OT4 4/[7MO\ GE>_^ ,W_P 11_:]M_SRO?\ P!F_^(J_10!0
M_M>V_P">5[_X S?_ !%']KVW_/*]_P# &;_XBK]% %#^U[;_ )Y7O_@#-_\
M$4?VO;?\\KW_ , 9O_B*OT4 4/[7MO\ GE>_^ ,W_P 11_:]M_SRO?\ P!F_
M^(J_10!0_M>V_P">5[_X S?_ !%']KVW_/*]_P# &;_XBK]% %#^U[;_ )Y7
MO_@#-_\ $4R37;.)HU=+P&1MJ#[#-R<$X^YZ G\*TJH:A_Q^Z5_U]-_Z)DH
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M 9O_ (BC^U[;_GE>_P#@#-_\15^B@"A_:]M_SRO?_ &;_P"(H_M>V_YY7O\
MX S?_$5?HH H?VO;?\\KW_P!F_\ B*/[7MO^>5[_ . ,W_Q%7Z* *']KVW_/
M*]_\ 9O_ (BC^U[;_GE>_P#@#-_\15^B@"A_:]M_SRO?_ &;_P"(H_M>V_YY
M7O\ X S?_$5?HH H?VO;?\\KW_P!F_\ B*/[7MO^>5[_ . ,W_Q%7Z* *']K
MVW_/*]_\ 9O_ (BC^U[;_GE>_P#@#-_\15^B@#-EUVSA0-(EXJEE7)LINI(
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M !1110 50U#_ (_=*_Z^F_\ 1,E7ZH:A_P ?NE?]?3?^B9* +]%%% !1110
M4444 %%%% &?KO\ R+^I?]>LO_H!J]']Q?H*HZ[_ ,B_J7_7K+_Z :O1_<7Z
M"@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 4)O\ D/V?_7K/_P"A15?JA-_R'[/_ *]9_P#T**K] !1110 4444
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M_KU@_P#0Y: +]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4-0_P"/W2O^
MOIO_ $3)5^J&H?\ '[I7_7TW_HF2@"_1110 4444 %%%% !1110!GZ[_ ,B_
MJ7_7K+_Z :O1_<7Z"J.N_P#(OZE_UZR_^@&KT?W%^@H =1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %";_ )#]G_UZ
MS_\ H457ZH3?\A^S_P"O6?\ ]"BJ_0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!0U?\ X\H_^OJW_P#1R5?JAJ__ !Y1_P#7U;_^CDJ_0 4444 %%%%
M!1110 4444 9OA__ )%W3?\ KVC_ /016E6;X?\ ^1=TW_KVC_\ 016E0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A/A
M+_DX?6?]^YKW:O"?"7_)P^L_[]S7NU !1110 4444 %%%% !1110!YS\;O\
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M ,*NU?\ Z*'XB_[_ +__ !='_"KM7_Z*'XB_[_O_ /%UZ510!YK_ ,*NU?\
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MH_X5;JW_ $4'Q#_W_?\ ^+KTJB@#S7_A5NK?]%!\0_\ ?]__ (NC_A5NK?\
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MN* ,B7X;:C \*2_$?Q K3/Y<8-P_SMM+8'S]<*3^%2_\*NU?_HH?B+_O^_\
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M*#(YW'O5_128]7UVV3_41W2.H[*SQ*SC\SN^KF@#D/\ A5VK_P#10_$7_?\
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M9U-=2-O']M6(P"?'S>63G;GTR,UXI_PH[Q%_T-$?_D3_ !H_X4=XB_Z&B/\
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MXB_Z&B/_ ,B?XT?\*.\1?]#1'_Y$_P : /=:*\*_X4=XB_Z&B/\ \B?XT?\
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MJ--)LK:&%+6T@B^SJP@ 3"INZ\#U[UXS_P *.\1?]#1'_P"1/\:/^%'>(O\
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M0^Q&/Q /:F'0M+.G)IYL8/LB-O6+9PK9SN'?=DDYZY->-_\ "CO$7_0T1_\
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MBO"O^%'>(O\ H:(__(G^-'_"CO$7_0T1_P#D3_&@#W6BO"O^%'>(O^AHC_\
M(G^-'_"CO$7_ $-$?_D3_&@#W6BO"O\ A1WB+_H:(_\ R)_C1_PH[Q%_T-$?
M_D3_ !H ]UHKPK_A1WB+_H:(_P#R)_C1_P *.\1?]#1'_P"1/\: /=:*\*_X
M4=XB_P"AHC_\B?XT?\*.\1?]#1'_ .1/\: /=:*\*_X4=XB_Z&B/_P B?XT?
M\*.\1?\ 0T1_^1/\: /=:*\*_P"%'>(O^AHC_P#(G^-'_"CO$7_0T1_^1/\
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MXT?\*.\1?]#1'_Y$_P : /=:*\*_X4=XB_Z&B/\ \B?XT?\ "CO$7_0T1_\
MD3_&@#W6BO"O^%'>(O\ H:(__(G^-'_"CO$7_0T1_P#D3_&@#W6BO"O^%'>(
MO^AHC_\ (G^-'_"CO$7_ $-$?_D3_&@#W6BO"O\ A1WB+_H:(_\ R)_C1_PH
M[Q%_T-$?_D3_ !H ]UHKPK_A1WB+_H:(_P#R)_C1_P *.\1?]#1'_P"1/\:
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MFZ%H.G>&]*BTW2[<0V\?..I8]V8]R:TJ!!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>proxy_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 9R!/L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#D-<\(W&K>.M"\01W44<6FA@\3*2SYST/XU%H/@
MNYT>?Q9))=Q2?VW<231A5(\H,7X/K]\?E7:44 >>1_#N[3X32^#OM\!N'8-]
MHVG8/WPDZ=>@Q7-^+])O8_'G@72[.\6"]@LBD=QLW*'1>"1W!*X(]#7L]5)=
M,L;B]AO9K.WENX 1%.\2F2,'KM8C(_"@#BM"\%:U+XT;Q1XJOK&XNHX#;VT%
MFK>6BG()^89Z%N.?O'FJ%GX&\8>&(K[3/"VM:<FD74C2(+Q',UON&#L(!!.,
M=?3H.:]/HH \SN_A2!X$TWPY87R+);7ZWT]Q*A_>L%8' '3J /85V'C#P_\
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M@#B+'P)Y6M>++N^N8Y;/7D"&- 0T:X8')/?FO,];M?[%^'5UI\?CVTO]'/\
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MK@1J08T??D'/4X?]*[:B@#R'_A6GB^X\('PK<Z[IJ:7"^Z QQ.9)/FW .3C
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M:JZ1K%AKVF1:CIEPMQ:2YV2 $9P<'@@$'(Z&C6O^0%J'_7M+_P"@FN'\'?\
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M[YP.<C!/&<4 =M17$:<?$>I:KJ^DR:X8$TN5(UO(K:,RW!=%D&\%2H"A@#M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/$\-U(R*R2;.0RJV""@XQSD]*U-5LO[2TB\L?-:'[3 \/F+U3<I&1[C-7**
M.'_X1OQ!<:9H^FSMI5K:Z9=6TW^C,[&<1.IQ@J G )P-W..:Z#2]*GL]?UR_
MD>,Q7\D+Q!2=P"1!#NX]1VS6Q10!QS>$KQ]*NHUN88KU=8DU2SDP6127+*''
M!Y!*G'KP:<^C>(M1\3Z)JNHOIT$&G22EK:VE=]^^)DW;F4<Y(XP,#/)XKKZ*
M ,WQ#82ZKX:U338&19KNSF@C9R0H9D*@G /&35C3H'M=-M;:0@O#"D;%>A(
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MB@QA=K,HX!W <#(J[IOAC^R=;TN6U9/L%AI3V 5B?,+%XV!Z8Z(<^YZ5TM%
M&-I.E3V.N:[>RM&8K^>*2(*3D!840[N.N5/3/%+X6TJ?1= AL+EXVE229R8R
M2N'E9QU [,*V** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HK.US1;3Q#H\^EWWF&VGV[Q&^UOE8,.?J!7'?\ "F/"
M/]R__P# MJ /0J*\]_X4QX1_N7__ (%M74^&O"^G>%-/DLM,$PADE,S>;(7.
MX@#J?910!LT5S/B7P)HOBRZ@N-46X,D*%$\J8H,$Y[5A_P#"F/"/]R__ / M
MJ /0J*\]_P"%,>$?[E__ .!;5WMO EK;101YV1H$7)R< 8% $M%<+??"3POJ
M.H7-[<)>F:YE::3;<L!N8DG ^IJO_P *8\(_W+__ ,"VH ]"HKC=$^&/AWP_
MK$&J6"W8N8-VSS+@LOS*5.0?8FNDU?2K;6]*N--O-_V>==K[&VG&<\'MTH O
M45Y[_P *8\(_W+__ ,"VH_X4QX1_N7__ (%M0!Z%16%X9\):7X2MIX-+$P2=
MP[^;*7.0,=ZB\3^"='\7/;-JBW!-L&$?E3%/O8SG'7H* .BHKSW_ (4QX1_N
M7_\ X%M1_P *8\(_W+__ ,"VH ]"HJO8646FZ=;6-ON\FVB6&/<<G:H &3WX
M%<AJ?PI\,ZMJ=SJ%TEX9[B0R2;+EE&3UP.U ';T5Y[_PICPC_<O_ /P+:KNE
M?"OPUHVJV^HV:W@N+=]Z;[AF&?<=Z .UHJIJ>GP:MIESI]SN\BXC:.38VTX(
MP<'M7$?\*8\(_P!R_P#_  +:@#T*BO/?^%,>$?[E_P#^!;5T7A?P9I/A$70T
ML3C[5L\SS92_W<XQGI]XT =!16!XG\'Z5XNCMH]4$Y6W+%/*E*<MC.<=>@KG
M/^%,>$?[E_\ ^!;4 >A45Y[_ ,*8\(_W+_\ \"VKMM*TRWT;2[?3K3?]GMT"
M)O;<<#U/>@"Y17%ZQ\+O#>N:M<:E>K>&XG8,^RX91D #@=NE4?\ A3'A'^Y?
M_P#@6U 'H5%<-I_PF\,:9J-M?VR7HGMI5ECW7+$;E.1D=Z[*]M(K^QN+.;=Y
M4\;1/M.#M88.#VZT 3T5Y[_PICPC_<O_ /P+:C_A3'A'^Y?_ /@6U 'H5%<U
MX9\#:-X2GN)M+6X#SJ%?S9B_ .>,U9\3>%-,\66D-MJ@F,<+^8GE2%#G&.U
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M  .![ 4 =A17GO\ PICPC_<O_P#P+:I;;X0>%;2ZAN8DOO,A=9%S=,1D'(H
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ML[7-%M/$.CSZ7?"0VT^W?Y;E6X8,,$>X%<=_PICPC_<O_P#P+:@#T*BO/?\
MA3'A'^Y?_P#@6U=1X:\+Z;X4L);+3!,(9)3*WFR%SN( ZGV H VJ*YKQ-X$T
M7Q9<03ZHMP7@0HGE3%!@G/.*PO\ A3'A'^Y?_P#@6U 'H5%>>_\ "F/"/]R_
M_P# MJ[VVMTM;6*WCSY<2*BY.3@# H EHKA;_P"$OA?4M1NKZX2],US*\TFV
MY8#<Q).!V&35?_A3'A'^Y?\ _@6U 'H5%<;HGPQ\.^']7@U2Q6[%S!NV&2X9
MEY4J<CZ$UV5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M =517*_\+*\&_P#0PV7_ 'T?\*/^%E>#?^AALO\ OH_X4 =517*_\+*\&_\
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M_P!]'_"C_A97@W_H8;+_ +Z/^% '545RO_"RO!O_ $,-E_WT?\*/^%E>#?\
MH8;+_OH_X4 =517*_P#"RO!O_0PV7_?1_P */^%E>#?^AALO^^C_ (4 =517
M*_\ "RO!O_0PV7_?1_PH_P"%E>#?^AALO^^C_A0!U5%<K_PLKP;_ -##9?\
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M5X-_Z&&R_P"^C_A0!U5%<K_PLKP;_P!##9?]]'_"C_A97@W_ *&&R_[Z/^%
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M_P"^C_A0!U5%<K_PLKP;_P!##9?]]'_"C_A97@W_ *&&R_[Z/^% '545RO\
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M2!V3. .3@53_ .%E>#?^AALO^^C_ (4?\+*\&_\ 0PV7_?1_PH O:)I$NBZ
MEM%%:F^2-LL.%=LDC)QG'/I5*XT+4]8N+NXOFM=/DDT^:QC^Q2M*W[S:=[,5
M3[NW@8XRW/-)_P +*\&_]##9?]]'_"C_ (65X-_Z&&R_[Z/^% "6NBZK'?6U
MX;72;1[*UD@A2U=]LQ(&T-\@V(",[1N^O',N@V&MZ>L[7MKI\EW<9DGNUO'=
MI),?*-IB7:@Z  \#U.28_P#A97@W_H8;+_OH_P"%'_"RO!O_ $,-E_WT?\*
M+4&GZI=:[!JFH16-LUM!)$B6TK2F3>5^\Q1<*-O3!YYSQ0EAJ]_J^GW>IQ6-
MO'8L\B+;3/*TCLA3DLB[5PQ..<G'/%5?^%E>#?\ H8;+_OH_X4?\+*\&_P#0
MPV7_ 'T?\* .JHKE?^%E>#?^AALO^^C_ (4?\+*\&_\ 0PV7_?1_PH ZJBN5
M_P"%E>#?^AALO^^C_A5O3_''AC5+A;>SUVQEF8X6/S0K,?0 XS^% &_1110
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M"'][4?\ O^/_ (FO2Z* /-/^%%^$/[VH_P#?\?\ Q-'_  HOPA_>U'_O^/\
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M1?A#^]J/_?\ '_Q-'_"B_"'][4?^_P"/_B:]+HH \T_X47X0_O:C_P!_Q_\
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M \T_X47X0_O:C_W_ !_\31_PHOPA_>U'_O\ C_XFO2Z* /-/^%%^$/[VH_\
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M_P!_Q_\ $T?\*+\(?WM1_P"_X_\ B:]+HH \T_X47X0_O:C_ -_Q_P#$T?\
M"B_"'][4?^_X_P#B:]+HH \T_P"%%^$/[VH_]_Q_\31_PHOPA_>U'_O^/_B:
M]+HH \T_X47X0_O:C_W_ !_\31_PHOPA_>U'_O\ C_XFO2Z* /-/^%%^$/[V
MH_\ ?\?_ !-'_"B_"'][4?\ O^/_ (FO2Z* /-/^%%^$/[VH_P#?\?\ Q-'_
M  HOPA_>U'_O^/\ XFO2Z* /-/\ A1?A#^]J/_?\?_$T?\*+\(?WM1_[_C_X
MFO2Z* /-/^%%^$/[VH_]_P ?_$T?\*+\(?WM1_[_ (_^)KTNB@#S3_A1?A#^
M]J/_ '_'_P 31_PHOPA_>U'_ +_C_P")KTNB@#S3_A1?A#^]J/\ W_'_ ,31
M_P *+\(?WM1_[_C_ .)KTNB@#S3_ (47X0_O:C_W_'_Q-'_"B_"'][4?^_X_
M^)KTNB@#S3_A1?A#^]J/_?\ '_Q-'_"B_"'][4?^_P"/_B:]+HH \T_X47X0
M_O:C_P!_Q_\ $T?\*+\(?WM1_P"_X_\ B:]+HH \T_X47X0_O:C_ -_Q_P#$
MT?\ "B_"'][4?^_X_P#B:]+HH \T_P"%%^$/[VH_]_Q_\31_PHOPA_>U'_O^
M/_B:]+HH \T_X47X0_O:C_W_ !_\31_PHOPA_>U'_O\ C_XFO2Z* /-/^%%^
M$/[VH_\ ?\?_ !-'_"B_"'][4?\ O^/_ (FO2Z* /-/^%%^$/[VH_P#?\?\
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MG:W5X=/0,EU(44)MAR<COG;^9H ]*\+>+])\864MSI;R9A?9+%,FUXSVR/\
M#T-9VN?$?0_#_B>TT"]%R;JX\O\ >1JICBWM@;R6!'KP#P:YOX52V]I=>*Y-
M2=H==-T9M3B9 L<0RY&P@G*Y+\_3ZGSN74=%\3Z9XSU?4]0@@U2[F5]/BE/S
MA8^0!]5POX4#/?\ Q/XCM_"NBR:K=VEW<6\; 2"U569 >-Q!8<9P/QJ&[\7Z
M39^$?^$FDF+:<85E4J 6;/10,_>R<8SUJCX,U6#QIX M)KM5F\^ V]VC<[F
MVOGZ]?QKRS2/"^H7/CK_ (5[>7@ET'2;AM1*'K)&=I53_P!]C(_VF/I0(]PT
M;5$UK2+;4H[:XMX[E!(D=PH#A3T) )'(YZ]ZY'4OBQHVF:S?Z9)IFL3/8-MN
M)H+=7C0>I.[('U%=XJA5"J  . !VKP^RU;5M+^)WC5=(T&35YIW"%5<*L?H6
MR.1S^E 'H.H_$G0-/\*6_B1&N+O3YYA OV9 75\$X8,5QC:?TK;\2:_:^%]
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MB@ HHHH **** "BBB@#PGPE_R</K/^_<U[M7A/A+_DX?6?\ ?N:]VH ****
M"BBB@ HHHH **** /.?C=_R3F7_KZB_F:U_A;_R371/^N+?^AM61\;O^2<R_
M]?47\S6O\+?^2:Z)_P!<6_\ 0VH Z^BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHJ.<R"%S"$,NT[ Y(4MCC)'04 >->)A9^.?BI
M=:1=W4,6GZ3I\L:M*X5?/=<9&>X++_W[K=^&7B&:[^&UW;/)MO\ 1DD@/()
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MN2V^W8DDD*.I!8X[<#I0(;X/\5:WK'PNO=6OM;M+>_2Z,:WUY&BQQJ"F<A0
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MBATD1@RLI&001P01WJG;:]I%[=M:6FJ6-Q<KG=#%<(SC'7*@YKS+QAJTVE_
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M_P!^YKW:O"?"7_)P^L_[]S7NU !1110 4444 %%%% !1110!YS\;O^2<R_\
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M3A99#P5!/H-N">NWMFNV\,:_KFKRO%JWAF;2O+C!,LDRLKOG!"@<X[YKIJ*
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M<-NOVYX;B.)IGW$LN78?+WZ=^<XKJ/",OB.PLVTR;P;#I%C:VK&VV7T<OF2
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M;7;:!$6UED7:3O&[+!@.%)/WNU=;97]GJ5JMS8W4%U;L2%E@D#H<<'!'%6*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /"?"7_ "</K/\ OW->[5X3X2_Y.'UG_?N:]VH **** "BBB@ H
MHHH **** /.?C=_R3F7_ *^HOYFM?X6_\DUT3_KBW_H;5D?&[_DG,O\ U]1?
MS-:_PM_Y)KHG_7%O_0VH Z^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7E&K>&I-(0('B=KM)A)GM\H&#[&O-]!TRVLO!OB&#Q3H&IRV=QK+,L<=L_F
M$#$JC@[1CJ/7O6C\+8-3@\1:JEH-6'A18@+0:FI5O,ROW0>V-_3_ &<\T =A
MX[\8KX(T:VU%[(W:37:V[*)=FT%6;=T.<;>GO6/!\398M=TZQUGPW>:5:ZFP
M2RNII5;>3C&Y0/EZCC)QFL_XZACX-TT(H9_[5BV@]"?+DZUF>)=0O_'^O>'=
M*M-"U*S:SNUN+Z6Z@*+#C&0&Z'H>>_&* .DU;XES6'BO4O#EGX>N-0O[7RO)
M2";F;<@=B?E^0+D#//45/JGQ"FCUZ30]"\/W.L:C;QA[I4F6)(<X^4N0<GG_
M #S5+1-,O(OC?XFU&6QN$M);.)(KEHB(W.R+(5L8)RO;TK)M;B[^'OQ \1WF
MH:5?W>F:RZSPW5I"9=K L=IQT^^1^ H$=;H?CD>(M&U*6PTN4:OIV5GTRXD\
MMPXS\N[!ZX(!QU'.*PH/B_;7VF:9_9^DM<:U?71MCIAGVF$CJS-M/'(YQZ^A
MJIX175+*]\6>.+O1KZ-;X@V>GB)C/*!G&4 R,_+SCU/3FN;L/#OBCPWJ>E^/
M7TV>\O;ZYD?4-/@MB9(8Y/10,@XSGT. >IH&>GV/C-I_']YX3NM.^S2PVXGA
MN!/N$X^7H-HQU/<_=-2>&/%Y\3:KK=O#8>59Z;<?9DNO.W>>PSG"[> ,#N>H
MKB_BRUQH>H:#XWTV,B:WW6TF]2I*NI*Y!Y'5^O<BNN^&NA'0/ VGP2KBYG7[
M5<$]2[\\^X&T?A0(H>(KS3(OBCX8MKC23/?RQRFWO/M+((  V1L PV>>IIB?
M$74-3U?4+3P]X5N-4MM/F,-Q<?:TAPP)'RJPR>AJ+Q/IU]<?%SPE>PV5Q):0
M1RB:=(F*1DAL;F P/QKB_%MM;-KL]SX.TSQ'8>)6O")!#"R0R_,<N>VT]<]/
M44#/=99%AB:1SA$!9CZ 5PN@?$+4O$US'-I?A2XDT9K@0-?O=HI49&6\O&2
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M9E<1K:QD*ZMG!#$\#'<^G-<#X0UV_P#AUHEYX<U3P]JEQ>Q7#O:/:6Y>.Y#
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MP=<0VCVSS6DLMX@^T,!E$P1\N[LQR.]<3-X2L=?\(^(V\-Z?K<=U((2)-4+
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ML7V[/G>5@?>SSCT_'MBN^H$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'A/A+_DX?6?]^YKW:O"?"7_)P^L_[]S7NU !1110
M 4444 %%%% !1110!YS\;O\ DG,O_7U%_,UK_"W_ ))KHG_7%O\ T-JR/C=_
MR3F7_KZB_F:U_A;_ ,DUT3_KBW_H;4 =?1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SOC'PG!XPTVULK
MBZDMUM[I+D-&H))56&.>WS5T5%% !1110 4444 <;X@\#7'B;6HY=1UV9]%C
ME28:4L"A2RC'+YR03DXQWKL0,4M% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5S'B[POJ/B>%+2W\03:;8NC1W4$=NKF=3VW$@KQQ^-=/10!4TO3;;
M2-+MM.LTV6]M&L48]@._O5NBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PGPE_R</K/^_<U[M7A/A+
M_DX?6?\ ?N:]VH **** "BBB@ HHHH **** /.?C=_R3F7_KZB_F:U_A;_R3
M71/^N+?^AM61\;O^2<R_]?47\S6O\+?^2:Z)_P!<6_\ 0VH Z^BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \)\)?\G#ZS_OW->[5X3X2_Y.'UG_ '[FO=J
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M].?!D6660*YA8<YW$DHP/0X(K44?:/B2\D?*V>E>7*1_>EE#*/KB,G_@7O0
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M_(\DS+L55,TZ D?PC+*/;-=+J5_;7'Q)\/6L,JR2PVUV\@4YV!@FW/UVG\J
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M%&DV+JVH-NXGDX*P#V'#/^"]S0!KW/B72K2PL[V:X817JAK95A=I)05W?+&
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M]];7:(=K-;S+(%/H2I-5[#4$73DFO=0LI2\[Q+-"X$;'S&54&3]X<*1_>!H
MGO\ 2-.U5$34=/M+Q4.56XA60*?;<#BK%O;PVL"06\210H,)'&H55'H .E4H
MM?T>>&XFAU6QDBM_]>Z7"%8O]XY^7\:LV5_::E;"XL;J"Y@/ E@D#J?Q'% $
M%[H>DZE.D]_I=E=31C"23VZ.R_0D9%2WNFV.HVPMKZSM[J $$13Q*ZY'3@C%
M3RRI#$\LKJD:*69F. H'4D]A6%H'C'2O$-W?6MI>6C2VT[1HD=RLC2H I\P
M?PY;&>1QUH T[S1]-U&W2WOM/M+F"/[D<\*NJ_0$8%6(;:"WMUMX(8XH5&U8
MT4*H'H *J2:YI,-^MA+J=DEXQ %NUP@D.?\ 9SFM"@#-MO#^C64\D]KI-A!-
M*I622*V16<'J"0.14[Z982V4=E)96SVD041P-$I1-N-N%Q@8P,>F*EN+NWM
MAN)XH1(VQ/,<+N;!.!GJ< G'L:A35].DT\Z@E_:M9#.;E9E,8P<'YLXZ\4 3
MPVL%NTK0PQQM,_F2%% +M@#<<=3@ 9/H*;#9VUO;FWAMXHX"6)C1 %)8DMP.
M.223ZY-10ZKIUQI[:A#?VLEDBEFN$F5HU &22P., 4R/6]*FOOL,6IV3WF,_
M9UN%,F.N=N<T +8Z+I>EN[Z?IMG:-)]\V\"QEOK@#-3)8VL<4T26T*QS,SRH
M(P [-]XL.Y/?/6F7>J6%AN^V7MM;[8S*WG2JF$! +')Z9(&?<4R[UG2[""&>
M\U&SMX9L>5)-.J+)GIM)//X4 -M=!TBQ,9L]*L;<QN9$,-NB;6(*EA@<$@D9
M]":+S0=(U"Y6YO=+L;F=>%EFMT=A]"1FK,U[:VUH;N>XABM@-QFD<*@'KN/&
M*CL]3L=1MC<V-Y;W5N"098)5=0?J#B@"7[);_:ENO)C^T*AC678-P0D$J#UP
M2 <>PJM=Z5%=ZA:WI.V6 /&WRY$D;CYD;VR%/U7ZT^QU?3=3\S^S]0M;ORSA
M_L\RR;3Z'!.*AG\0Z+:LJW&KV$+,[1J)+E%)=3@J,GJ#P10 ^RT32],,CZ;I
MME9R2#YF@MU3=]=H&:=I6FQZ5IZ6L;%R"7DD8?-)(Q+,Y]RQ)_&L_P 3>*M/
M\,:>ES=SV_F2.BQ0R3K&T@+JK,,]0H;<?85KVEY;7]LES9W$5Q;R#*2PN'5N
MW!'!H 66V@FFAFEAC>6!BT3L@)C)!!*GL2"1QV-(;6 W2W1AC-PJ&-9=@WA2
M02N>N"0#CV%.GGBMH6FGE2*)!EG=@JJ/<FJ]AJVG:K&\FG7]K>(APS6\RR!3
MZ':30!$^@Z1)?B_?2K%KT'(N&MT,F?7=C-7$MH([B6X2&-9Y559)0@#.%SM!
M/4@9./3)JD_B+18I(HY-7L$>8D1*UR@+D$J0!GGD$<=P:N75W;6-NUQ=W$4$
M"<M)*X15^I/ H K7VAZ3J<J2W^F65W(G"/<6ZR%?H2.*EGTVRND5+BSMY45#
M&JR1*P"G&5&1T.!Q["L2#71?^,[.VL+^&YTV;3)YR865U:198E!##T#,,9QS
M72T 4([*#1].DCTC3;>,*"R6\*K"C-^ P/KBJ7AO2I[".^N[U(DOM1N6N9EC
M;<$X"H@.!G"J.<=<U!IWC71M2\17>CP7UDTL(C\IEND8SLP8LJJ.I7;SC/7M
M6I>:WI.G3I!?:G96LTGW(YYU1F^@)YH O$9K/@T#1[5W>VTJQA=V#NT=LBEF
M!R"<#D@@'-: (89!R#WJ.:ZM[>2&.:>.-YFV1*[@%VP3A0>IP"<#TH YW3/"
MUL\VK-K&G65T)M2DNK?SHEEVJ40 C(X.5-6O$>DSZC;:9%:HF+?4+>=U)P!&
MCY./P[5KO=01W,=L\T:SRJS1Q%P&<+C) ZD#(S]15;^W-)_M'^S_ .U++[;G
M'V;[0GF9_P!W.: '66CZ9ICR/8:?:6C2G,C00+&7^N!S3;S1-)U&=)[[3+*Z
MFC^Y)/ KLOT)'%9FL>,]'T36K'3+N^LXY+AF$IEND3[. A8%@>S$ #..M:U[
MJNGZ=;K<7U];6L+'"R3RJBD^Q)Q0!,]I;RR02201O) 2T+,@)C)!!*GMP2..
MQI8+:"U#B"&.(2.9'"*%W.3DL<=2>YIT4T<\2RQ.LD;@,KH<AAZ@T^@"H=+L
M&T_^SS96QLMNW[,8E\O'7&W&,57N-$M9+>RBMDCM/L4JRVWDQ@"/'!4 <8*E
ME(]#5VYNH+.!I[F>.&%.6DE<*H^I/%1V&IV&J0&?3[VVNX@<&2WE61<^F030
M!#'H6D0Z@U_%I=BEZQ)-PMN@D)/7YL9IVG::FGFZ?>9)[J=III2,%B>%'T50
MJCV%);ZWI5Y>/9VVI6<]U'G?#%.K.N.N5!R*OT 07EE:ZC:O:WMM#<V[XWQ3
M1AT;!R,@\'D U!8:+I6E9_L[3;.SW<'[/ L>?^^0*6]UC3--DCCOM1M+627B
M-9YU0O\ 0$\UF^&-2N+^WU22[F#^1J5S A("A8T<A1P.P[GF@#3O])T[5%1=
M0L+6[6,Y07$*R!3ZC(.*G@M8+8,((8X@YRP1 N3@#)Q[ #\!4%CJ^FZGYG]G
MZA:W?EG#_9YEDVGT."<4R/6]*FU!M/BU.S>]7(-LLZF08Z_+G/:@":WL+2SL
MQ9VMK!!:@$"&*,*@!))^4<<DG\Z;+I>GSZ>NGS6-M)9*H1;=X5,84< !2,8%
M1:?=,\5V\]Y:SB.XD7= >(U!X5N?O =:9;>(M$O&"VNL:?.QD$0$5RC'><X7
M@]>#Q[&@">UTK3[%E:SL;:W*Q^4IAA5,)DG:,#IDDX]ZFNK6WO;9[:Z@BG@D
M&'BE0,K#T(/!JO=ZUI>G^9]MU&SMO*V^9YTZILW9VYR>,X./7!JQ%=V\]JMS
M#/%);LNX2HX*D>H(XQ0!0L_#&@:==+=6.B:;:W"9VRP6D:.,C!P0,]*O6UG;
M68E%M;Q0B61I9/+0+O<]6..I/<U7L];TK49)(['4[*Z>(9D6"=7*?4 \5F:/
MXTT?6]9OM-M+ZRDDMW583'=(YN 8PY9 .H&2#C/(- &OJ&EZ?JT"P:C8VUY"
MK;UCN(5D4-@C.&!YP3S[U7M?#>AV*3)::-IUNDZ[)5AM402+Z-@<CZU,^L:9
M'J"Z?)J%HEZ_*VS3J)#]%SFGWVI6.EP>?J%Y;VD.<>9/*L:Y],DT 16VB:59
M1"*TTRSMXQNPL4"J!N&&X []_6J:>#O#$;J\?AS2$=2&5EL8@01T(.VH=(U>
M34/%>L6R723V$-K:2V_E[2N7\W<0PZYVKW/3BNAH HR:+I<U^+^73;-[P# N
M&@4R#_@6,U,MA:*UNRVT*M;*4@(C ,2D $+_ '1@#@>@JO<ZYI-G=I:76J64
M%R^-L,MPBNV?12<U9N;VULR@N;F&$ONV^9(%W;06.,^@!)]A0!/5&31=+FOQ
M?RZ;9O> 8%PT"F0?\"QFGV&J:?JL32Z=?6UW&IVLUO,L@!]"035N@#.N= T>
M]2%+O2;&X6!0L(EMD81@= N1P/I5]$6)%1%"HHP%48 %<]IWC71M2\17>CP7
MUDTL(C\IEND8SLP8LJJ.I7;SC/7M4&B^)[=8[_\ MG5;2!UU2YM[<7$B191'
MPJCIG _&@"5/#<5YXDUJYU2QM;JQNTMA$DZ+(-T8<$E2./O"MQM.LVLELFM(
M#:KC$!C&P8.1\O3@@$?2I);B&"!IYI4CB4;F=V 4#U)-16.HV.IP>?87EO=P
MYQYEO*LBY],@D4 37%O#=0/#<11RQ.,-'(H96'N#UJM::-IEA;26UGIUI;02
M?ZR*&!45_J ,&KM4AK&FM=1VRZA:&XD=T2(3+N9E^\ ,Y)&#D=L4 /?3;*2Q
M6Q>TMVM%"JL#1*8P%QM 7&.,#'IBL>TTV]O/%3:SJ-M#;I:P-;6D:R>8S!F!
M>0G QD*H Y[^M:KZQID>H+I\FH6B7K\K;-.HD/T7.:GCNK>:>:".>-YH<>;&
MK@LF1D;AVR.F: )JKFRM6O5O6MH3=(AC6<QC>%)R5#=<9[4G]H6?E3R_:H/+
MMV*S-Y@Q&0,D,>Q&1U]:2QU&QU.#S["\M[N'./,MY5D7/ID$B@!PLK47K7HM
MH1=L@C,X0;R@.=N[KC/.*6.SMH?.\J")//8O+M0#S&( );U. !D^@J"'6M+N
M91%!J-G+(T7GA$G5B8_[^ ?N^_2BQUG2]39UT_4K.[:/[XMYUD*_7!.* $M]
M$TJTB2*VTRSAC27ST2.!5"R8QO  X;'&>M6I+6"6XBN'AC::(,(Y&4%D#8S@
M]1G S]*KQ:QID]^]A%J%I)>1_?MTG4R+]5SD5=H *STT+28Q<!-+LE%RX><+
M;H/-8'(+<?,0>03WJ2_U;3M*5&U&_M;-7.$-Q,L88^VXC-17%X6NM,-O>VBP
M7#,2KMEKA?++#RSGD]&/7Y0: +DUM!<F(SPQR&)Q)&74-L< @,,]#R>?>JM]
MH>DZG*DM_IEE=R)PCW%NLA7Z$CBENM9TRQNHK6[U&TM[B7_5Q2SJCO\ 0$Y-
M9WA/5)[_ ,-"^U"=6<7%RK2, H"I/(HZ8'"J.?:@#=1%C0(@"JHP !@ 5SB>
M&XKSQ)K5SJEC:W5C=I;"))T60;HPX)*D<?>%;5AJFGZI&\FGWUM=HAVLUO,L
M@!]"035N@"*&VAM[=8(8HXX4&U8T4!0/0 =JJV>B:3IT[SV.F65K-)]^2"!4
M9OJ0.:6^UK2]+=$U#4K.T:3[@N)UC+?3)&:R_&/B6#P]X8NKY+NUCN6A;[()
M9% D?'&T$_-C(.!0!MR65K-=PW4EM"]S &$4S("\8;KM/49[XZTAL;5KU;TV
MT)NE0QK.8QO"$Y*ANN,]JJ:!*DVE1R1ZRNL*Q/\ I:^7AO4#RP%P#GWIOB+7
M[/PWHMSJ-Y+"@BC=HXY)1&9G"E@BD]6..!0!/?Z+I>J%#J.G6=X8_N&X@63;
M]-P.*F^P6@-N1;0YMO\ 4?NQ^ZXV_+_=X)''8XKF]0\41W-IH%YI5_;O!=ZE
M'!<-#(DJA3&[,A;G!! ]#6_8ZOINI^9_9^H6MWY9P_V>99-A]#@G% %VJESI
M=A>W$%Q=6-M//;MNADEB5FC/7*DC(/TJ&PNR8+R6YO;25(KB5=\+86)5/W7.
M>&4=:EL-6TW55D;3M0M+Q8SAS;S+(%/OM)QT- #+S1-)U&=)[[3+*ZFC^Y)/
M KLOT)'%7@ HP!@#M2UF+XBT5YH(5U?3S+<*&@07*$R@]"HSR/I0!->Z/IFI
MO&]_I]I=M$<QF>!9"GTR.*S/$&BM>6^GQV,,*B+4X+N8 !055\L?<X_.M>ZU
M"RL<?:[N"WRC./-D"95<;CSV&1D]LBHI]9TRVL8[Z?4;2*SD *7$DZK&P/((
M8G!S0 MEH^F:8\CV&GVEHTIS(T$"QE_K@<UB:-X5M5BNCJ^FV5S,=2NKF!I8
MED*))*SJ02.#@BMS^UM._L_^T/MUK]BQG[1YR^7C./O9QUJ2YO[.S9%N;J"$
MN&*"20+N"C+$9ZX')]!0 ^>VAN8&@GBCEA<8:.10RL/0@U#8:7I^E1-%IUC;
M6<;'+);PK&"?HH%/DO[2*R^VR7,*6FT/Y[2 )M/0[NF.>M6* *D>F6,*VRQ6
M=NBVI)MPL2@0D@@[>/ER"1QZFI3:P&Z6Z,,9N%0QK+L&\*2"5SUP2 <>PJ:L
M]-<TF34#IZ:I9->@D&W6X0R<?[.<T 2QZ780W\E_%96T=Y*NV2X6)1(X]"V,
MD<#\JFN+6"Z5%N(8Y51UD42*&"LIRK#/<'D'M6/I^H74_C+6["27=:VUM:/$
MFT#:S^;N.<9.=J]?2CP;J%UJOA#3;Z]E\VYFBW2/M"Y.3V  H V);:"::&:6
M&-Y8&+1.R F,D$$J>Q()''8U7ET?39[66VFT^TDMY9#+)$\*E7<G)8@C!)/>
MKA(49)P!WJC9ZWI.HSO!8ZG974T?WXX)U=E^H!XH GLK"STVW%O8VL%K .1'
M!&$4?@.*BO\ 1],U4(NHZ?:7@0Y07$"R;?IN!Q7,3^)[>]\>1Z/;^([2V@@A
M1WCBDA9KB8R,IA);)! 3E5PWS=17:4 5I-.LIK'[%+:0/:;0OD-&#'@=MN,8
MJ.TTC3=/,?V/3[2V\M61/)A5-JL02!@< E02/85DR^-='A\4IH3WUDLIA+%V
MND&V7>JB+;_?.[..O'2H[?Q'%::_X@BU;4K:VL[6:".W-PZ1JNZ%6(W'&<DD
M\DT :PT#1Q<0W TFQ$\ "Q2BV3=&!T"G&1^%.O=#TG4ITGO]+LKJ:,822>W1
MV7Z$C(JW'<12P+/'(CQ,NY9%8%2/7/I5>QU?3=3\S^S]0M;ORSA_L\RR;3Z'
M!.* )+NPL[^U-K>6L%Q;MC,4T8=#CIP>*2'3[2WD62"U@B=(A"K)&%*QCH@(
M_A'8=*LU0N=;TJSO$L[K4K."ZDQLAEG57;/HI.30!)!I6GVMU/=6]C;0W$_^
MNECA57D_WB!D_C4$/A[1;9G:WTBPB9W61C';(I9E.Y6.!R00"#V-9:>($L_%
M6N0:GJ$%OI]K;VCQ&=DC5&?S=WS''78O4]N*Z"*[MY[5;J&>*2W9=RRHX*D>
MH(XQ0!%<Z787MQ!<75C;3SV[;H9)8E9HSURI(R#]*BO-!TC4+E;F]TNQN9UX
M66:W1V'T)&:=9:UI6IRR16&I6=W)']]()UD*_4 G%*VL::EPMN^H6BS/*85C
M,RAFD !* 9R6P0<=>10!6ET19O$]MK,DVX6MJ\$$&SA&=@6?.>I"J,8]?6M4
MC-4WUC3(]073Y-0M$O7Y6V:=1(?HN<TM_JVG:4J-J-_:V:N<(;B98PQ]MQ&:
M (H- T>U=WMM*L87=@[M';(I9@<@G Y((!S5R.V@AFFFCAC268@RNJ ,Y P-
MQ[X''-.BECGB26)U>-U#*ZG(8'D$'N*)98X(FEE=8XT&6=C@*/4F@")+&UCB
MFB2VA6.9F>5!& '9OO%AW)[YZU7M=!TBQ,9L]*L;<QN9$,-NB;6(*EA@<$@D
M9]":?8ZQIFIJ[:?J-I=K']\V\ZR!?K@\5S&C^)H-=\9W\%MXCM3:VK(EO9V\
MD+_:LQ;F?/+$ MCY2 -ASF@#LG19$9'4,K#!!&014#:?9OI_]GM:0-9>6(OL
MYC!CV 8"[>F,<8Z59JC?ZSI>E;/[1U*SL]_W/M$ZQ[OIN(S0 ^_TRPU6$0ZA
M8VUW$#D)<1+(H/T8&A=+L$M8K5+*V6WA<21Q")0B,#D,!C (/(/K2W&I6-I9
MB\N;RWAM2 1/)*JH0>AW$XHMM1LKVT^UVMW;SVV"?.BE5DXZ_,#B@"6YM;>\
MMVM[J".>%^&CE0,K?4'@U6M=%TNQM9;6TTZSM[>4$20PP*B.",'( P>*;%KN
MDSW<=I#J=E)<R()$A2X4NRD9#!0<D8YS3[/6--U":6&RU"TN983B5(9E=D_W
M@#Q0 V+1-*@OC?1:;9QWA&#<+ HDQT^]C-9EUIU[JOB>QGNK:*+3],=YH6\S
M<\TK+M!QCY0H+=SDX]*T9=?T>"1(YM5L8W>0Q*KW"*6<'!4 GD@\8J3^V--.
MH_V<-0M/MV,_9O.7S,?[N<T 7:HW>C:7?W$5Q>:=:7,\7^KDF@5V3Z$C(J6^
MU&RTR#S[^\M[6'./,GE6-<_4FDCU&REL3?1W=N]F%+FX653&%'4[LXP/6@!Q
ML;5K5[5K:$V[[M\1C&QLG)R.AR22?K4%IHFE6'E_8M-L[;RBQC\F!4V;N&Q@
M<9P,^N*(]<TJ:^^PQ:G9/>8S]G6X0R8QG.W.>E7Z *3:1IS7SWS6%J;MT\MK
M@PKYC+TVEL9Q[5(VGV;Z?_9[6D#67EB+[.8P8]@& NWIC'&.E-O]3L-*A674
M+ZVM(F.T/<2K&"?3)(K(USQIH^B16,DE]9.+R:-$S=(O[MFP9?=5Y)/3WH V
M;[3K+4X/(O[.WNH<Y\N>)9%S]"*:-+T\:>=/%C;"R92IMO)7RR#VVXQBAM4L
M%T\7[7ML+)E#BX,JB,J>AW9QBG6.HV6IP>?87EO=0YQYD$JR+GZ@T 27%K!=
M*BW$,<JHZR*)%#!64Y5AGN#R#VK,G\)>&[J>2>X\/Z5--(Q=Y)+*-F9CU))&
M2:L3Z[I%K>I97&J64-VY 6"2X19&)Z84G-4-*U.XF\1^([:XF!MK*2 0@@ 1
MJT*LW/?DD\T :4^D:;<V$=A/I]I+9QJ%2WDA5HU &  I&  .*:=%TW^RI=+2
MR@BL949'@BC"*01@\#&*M6UU!>6Z7%K-'/!(-R21.&5AZ@C@T]W6-"[L%51D
MDG  H RSX=TVZBM?[4LK34;FWC5!<W-LCN<=\D'![\58&F1G6!J+MN>.#R(4
MQQ$"<L1[MA?P4>]%CK6EZH[II^I6=VT?WQ;SK(5^N"<5S,_B>WO?'D>CV_B.
MTMH((4=XXI(6:XF,C*826R00$Y5<-\W44 =I1110 4444 >$^$O^3A]9_P!^
MYKW:O"?"7_)P^L_[]S7NU !1110 4444 %%%% !1110!YS\;O^2<R_\ 7U%_
M,UK_  M_Y)KHG_7%O_0VK(^-W_).9?\ KZB_F:U_A;_R371/^N+?^AM0!U]%
M%% !7(^+K*#4/$GA*VN8Q)"U],S(>C;;>1@#ZC('%==56YTZUN[NSNIHMT]F
M[/ VXC8S*4)P#@_*Q'/K0!S_ )4=O\3X!#&L?GZ/*9=HQO*31A2?7 =OSKES
M;QW?PXTNVF&Z*;Q#Y;C.,JVH."/R->D-IUJVJ1ZD8_\ 2XX6@63<>$9E8C&<
M=57GKQ55?#VEK80V*VV+:&Y%W&GF-\LOF&7=G.?ODG'3MC'% '/ZQI-@WQ"\
M-#[+$%%K=L4"@*VSRMF1T.TL2/0U;T*-(/''BB&)52,K:2E%&!O97!;'J0J_
ME6_-IUK/J-M?R19NK9)$B?<?E5]NX8S@YVKU]*(=.M;>_NKZ*+;<W2HLS[B=
MP3.WC.!C<>E %DC(P>E<CX:5XE\5O;1J9UU6?RQCOY4>!^==?6;#H.G6^KS:
MI#"\=W-S*5E<(YP!DIG:6P ,XS0!S'AK3=$N_AA;O>I#)!=6?GW\T@!8RD9E
M9F/.X-NYZC'M6WX*GN[KP3HL]^6-R]G&79_O-\HP3[D8-$_@S0+BXDFDL<B5
M_,EA$T@AD?.=S1!MC'/J*W54*    . !0!R?CNTBOE\.VTZ[H9-8B5U/1E\N
M3*GU!Z$>AJGXOAF3Q!X6L+*RLI;=I;B06]Q(886E5 4SM1N0"Y QU&>U=?>:
M=:W[6S7,6\VLPGA.XC:X! /!YX8\'BF:II-CK-J+;4+=9X@P=02058=&4C!4
MCU!S0!Q&JZ3J]II'C+4;VWT^TM[S1Y 8+.X>7,JQR9<[HTP2I4?\!%&O6=A!
M\*;>YL$C\Z**WGLIE WF<LA5@W7<S'D]3DUNZOX=AM/!VOV>EPSR7%W8S(!)
M/),\C&-@HW.Q/4^O>I-,\(:/ +.Z:Q(N(0LBQM*YCCDQRRQEMBMDGD#.: *6
MIV%MJ'Q.TM;J)94ATNXF5'&5W"6)02.^-QK.5=2G^(&OBUTW2[LV\-O#"+VY
M>,QPLF3L41N,%MX)X^Z/2NW;3K5M4CU(Q_Z7'"T"R;CPC,K$8SCJJ\]>*J:G
MX<TO5[F.YNX'^TQKL6>&9X9-N<[=R,"1[9Q0!S=OX1U3_A%;6PEFLHKJQU!K
MRTB&Z: )N8I$V0I*@/C( Q@$=*S_ !%K<][X4O[)["&SNX-2MK74HO.Q"R.Z
M$GS N=C*0"=N0"01Q7:S>'=-GTV#3VCF6W@;='Y=Q(CJ>>=ZL&SR>_>BV\.Z
M3::9/IT5E&;2X+&=),R>:6ZERQ)8GU)- &%;Z-KC>*-*U*73]'L(+6.6&;['
M=.[21LORI@Q*,!@IZ\<XIO@_2;&XB\1R3VT4S7.KW<<ID4-E Y&WGMU./4GU
MK<TSPUI>D3^=9QSJX0QKYMU+*$7CA0[$*.!TQ5VQTZUTY9UM8O+$\SSR#<3E
MW.6/)XR>W2@#SW)F^"VDO*=[*]DH9N3@748'Z 5Z6JA1A0 /0"LS_A'M+_L'
M^P_LH.FA-GD,S'C.>I.<YYSG-7+&RATZS2UM_-\I,[?-E:1N3GEF)8]>YH S
M/%&J)IMA;QFQ2^FO;E+6"WD(5&D.6&XD' &TG.#TK TW[?'\4$2^BT^&671I
M&9+-F.0LT84MD#.,L <=S77:GI5EK%I]EOX!-#N#@9*E6!R&!!!!'J#FJVG^
M&]*TR[%W:VS"Z$;1F>25Y)&4E2068DG[J]?2@#E?#&CV$_P_U-IK6*1KN:^,
MQ=02V)I%'Y!1BH+<_P!HI\.$U ^=;S61G<2<J]P+="A(/!.#(1[BNYM-)LK'
M3FL+:'9:L9"4W$\NQ9N2<\EB?QJ";P[I5QHUOI$MH&LK946!"S9CV#"E6SN!
M [YS[T <]';65O\ &%3;JB3R:)*\Z)QG]]$ Q'J<$9]%'I7:UCZ=X7TC2K_[
M=:6K+=F-HFG>9Y'=6*DAF9B6^XO)R1BMB@#EM&B0>/\ Q+A%!$-F1Q_LR55\
M%6=I?:5JEQ?0137]QJ%S'?\ FJ&.5D950Y_A"!<#I@UT,N@Z=-K":LT+K>HH
M3S(YG0,H)(#*I 8#)QN!ZU6OO"6BZC=RW5Q:N)9@!,8IY(A* ,#>$8!^./FS
M0!0^'SD^&#&CE[2&\N8K-R<[K=96$?/<8&![ 58\;6\C^''O8%+7.FR)?P@=
M28SN8?BFY?QK=M[>&TMX[>WB2*&-0B1HN%4#H .U2,H=2K %2,$'O0!PSW4V
MJ7'B;7]-)D-GIQL]/9?XG\OS7(^K-&OU2D_LS0O^%3;MD/V3^SOM'G\;O,V;
MO,W==^[G/7-=;H^CV&@Z;'IVFVX@M8R2L88MC))/)))Y/K6=_P (7H'G^;]@
MX\SS?)\U_)WYSN\K=LSGG.V@#$)GN=0\ S7Z?Z7+'(T^X<[S:DMG\<TR\.I3
M_$N\6WL=.NGMM.A-LE[<M$$5V?>R 1ODDA03Q@ #G-=;JNBV&M10QWT3/Y,G
MF1/'*\;HV",JR$,."1P>]1:AX;TO5/LYNK=S);KMBFCF>.5!W =6#8./7F@"
MGX0TF_T?3[RWOEM8Q)>236\%K*SQPQO@[ 2J_P 6XXQCFNAKGM8\.O+X8?1=
M)E-JDKJ'D:9RRQEP9"&.26(W8R>IZUOH@C0*HPH& * ,/Q-J8L_[/LH]/BO[
MR_G\NWAF8+&&52Y=F(. H4G@$^E86D17C?$#5K6]%G!+/I,32+8,V/\ 62*&
M)('S8)YQTQ76ZIH]CK5ND%_!YBQN)$*NR,C#HRLI!4\GD'O5>S\-:38/*]O:
MXDFB,,LC2.[R+_M,Q))]R<^] &#H1G\,7VE>&M0M;22-XFBL+ZV7:7\M,E9$
M/W6*C.02"?2NTK'T_P +Z3IEX+RWMY&N54HDD]Q),T:GJ%WL=H/MBMB@#C_#
MMK;WGB7Q9+>PQRW@O4@Q(H;%OY*% ,]%)+GW.:Y%2EO\.-1@TXQO8OX@:!B\
MI5#;FY"D,X!(4C"DX/!/!KT?4?#&DZK=B[NK9OM&SRVDBF>(NG]UMC#<.O!R
M.:DMO#VDV>F7&FPV,*V-PSM);D;D8M][@]![#@=J ,&WT;7&\4:5J4NGZ/80
M6L<L,WV.Z=VDC9?E3!B48#!3UXYQ4&E1S>#;G3-%O;:WN+&XG:&ROXAB59"&
M8"53U) ;YU//<#-=#IOAG2](G\ZSCG5PAC7S+J64*IQPH=B%' Z8IEEX3T;3
M[R.[@MI#/$"(FFN))A%D8.P.Q"<<<8H XF\^;PCJT4AQ:3>)VBO#G&(&NE#Y
M]L<'V-;/B^QTZWUKPA)'##%=+JBQQ;%"GR_+?<..P(7]*Z"YTRQL=(OXHM,:
M[AN7DFGM5(8S,YR_WSCG/3(%<M9^'X;W7=+FLM$O[&VLIO/EN-0F+NV%94BC
M#.Q"Y;<<8'RCK0!HV%C;7/Q-UVYFB622"RM%C+#.W>9=Q'O\HYJA8:C:^'M%
M\72R6OG6=MJSQQVJ 8;S$A^0 \ %Y#[<FNTATZU@U&YOXXL75RD:2ON/S*F[
M:,9P,;FZ>M5VT#3'MM0MWM$>'4)#+=1N2PD<JJYY/'"KTQTH Y&<:G%XX\)F
M^M-+LS(]S&L=I(SOL\AB5)*J"H(7H.H%:_AV-%\7>+<(HQ=V^..G^C15?L_"
MFCV-U!=16SM<0,6BFFGDE=,J5P&=B<89ACIS5C^P=/&MG6%A=+Y@%=TF=5?
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MMT;61))G\R58KB6-)&]616"L?<BKNKZ+I^NVB6NI6RW$*2+*J%B,,O0\$?\
MUZ //[^RO[31/"=I-;V\TM_J+7-]%=2F..2=T>4([!6.-YX&#DHHKI-'TG68
M?%D^K7EKIEG;SV8ADBL[EY#)(KY1R#&@X4L,\GI70:EIEGJ]D]G?VZ3V[8)1
M_4<@@]01V(YJ#3-"L-':1K19]TH =IKF29B!G R[$@<F@#D/"/AFSU+X616B
MX@FU"U=);E5!?YB1R>X  &/08JQ)J^HV%KJVD7%C:PZS;Z5+=6D]D/W<RJ"!
MA3RA#%?EY'/!KJ(M"TZ'15T>* I8JFQ8Q(V0,Y^]G=U[YIFF>'M,TB:6>T@?
MSY5"O--,\TC*.B[G)./;.* .'T_1-9U#PMH:Z?I^AV\<#6]W!>)?2-)P59F(
M\D9+KN!R>=QS7IE8=MX0T2SNEN+:UDA*2>:L27$HB5LYR(MVP<^U;E '+ZYI
M.H1:XOB#3(K6\E2U^S26=S\N] Q;,;\[6YP<C!XZ8S5"74K76-1\":C9(4MK
MB:9XT*X*C[++QCVZ5T&I^&M,UB?SKV.=GV>6PCNI8U=>3AE1@&')Z@]:L?V-
MI^_3V%LB?V>2;4)E1%E"G '&-I(P: .;\+65I>R>)Y+^"&:XDU2>&?SE#'RE
MP(U.?X=FT@=.:Y2V+?\ "K?#UO9"*YM+C6WB<7$I5)8OM$Q4.P#'#,$!X.<^
M]>B7_A31M2O7O+JT)GD4+*8YGC$RCH)%5@'';# U-'X=TF/16T8641TYBY-N
MV67YF+GK_M$GV[8Q0!C6&D:V/%MOJUQ9Z58P+:O;SK9W+R--RI3(,2#Y2&YS
M_$:ZVLO3/#VG:1,TMHD_F,NPM-=2S87T&]C@?2M2@#C_  E;6]Y?^);B\BCE
MOSJ<L$GFJ&985 \I>>B[,''0Y-<Y.B+\,O%L$.#8VU]/%9=U6(,O"_[(8N!]
M*[O4/"^D:G=F[N;9Q<,H1Y()Y(6D4= Q1AN'L<U/+H6F2Z(=&:T1=.*>7Y$>
M47;Z#;@B@#055084 #T K#\:J&\"^(,@'&FW)&1W\IJW:CG@BNK>2"=%DBD4
MHZ,,AE(P0?PH XKQ-8V]YI'A&UFC#02:E;;T[,/*<D'U!Q@CN*O:A!%:?$'P
M^]O&D336EW%(47&Y%\IE!QZ'I]36G;>%])M+6UMHH)3%:W N8%DN)'\MPNT8
M+,3@ XV]/:KTVG6MQ?VM]+%NN;576%]Q&T/C=QG!SM'6@#CM-T?^WO#'B/3?
M.\DS:S=%7*[@"LVX9'=21@CN":V-!U6=M5N]'U*PMK;4[>&.8O:G,4\1+!67
M(RN"&&T].Q-:#>']-:QNK/R&6"ZG:XE"RNI,C-N+!@<CD9X(I=+T'3M&,S64
M#+).099997ED?'3+N2QQV&>* -*O,?#6G:/-\#]\L<3Q/8223RL 6$B@\YZY
M4@ >F!BO3JX;PIX'TT>%M)&JZ:RW:01F>!I7"-(H'+QAMC$8')!Z4 5VM3JN
MJ> 1JT?FRFPFEGCD&0T@CB/S ]<-SSW K0M[>WG^)EY%>11DVFFPG3XF VJK
M.XE91T!R$!/IBNGFTZUN+^UOI8MUS:JZPON(VA\;N,X.=HZ^E5]4T'3M9,+7
ML!:6'/E2QR-%(F>NUT(89]C0!S5K!80>,?$]D$A&CO80S7\9XB25O,#9'09C
M"D_@:SO (%SJ4ZZH9Y)UM NEBZ49;3RQVMCNYPN[/. F:[!?"VC)I,VEK9@6
M<[[YD\QLRMD'+MG<V<#.2<C@\5:N]-LY[JUOI8"UQ9;S R,05W###@C((QP>
M.!Z4 <#9%KA-+\$.2S6.HN+@$\FT@VRQ$CT.^!?SKTRN7T#3WN?$VJ^)+BPD
MLWN8XK6!)@!(8TR69@"<98XZ]$%7_#.EW6E:6Z7\PFO9[B6XG=6++N=B<+G!
MP!@=!TH U9YDMX))I#A(U+L?0 9->9:]?7VH>#[;6(]+TS3["6YM;FV/F$W'
MS3(58 *%#'.2,G@GFO4" P((!!Z@USZ>"/#T:[%L"8@=R1-/(T<9SG*(6VIS
M_= H BTG_DH?B3_KSL?YST?#S_D0='_ZX?\ LQK<ATZU@U&YOXXL75RD:2ON
M/S*F[:,9P,;FZ>M&G:=:Z380V-E%Y5M"NV--Q;:/J230!S_Q!<KX8$;N4M)K
MRVBO'!QMMVE42<]A@X/L35;QK9VECI>EW%C!%#?V]_;1V'E*%/S2*K(,?PE"
MV1TP/:NNN+>&[MY+>XB26&12CQNN58'J".]9-CX2T73KN*ZM[5S+""(3+/)*
M(@1@[ [$)QQ\N* *,,:?\+0OOD7_ ) ]N>G?SIN:ZFJJZ=:KJDFI"/\ TN2%
M8&DW'E%9F QG'5FYZ\U:H Y:2-#\4+<E%_Y \IZ=_.CJ#1-.M9O'_BN\EA62
M97MHU9QG:I@4G'IGC/K@>E;VH:#IVJ7=M=74+FXML^5+',\; '&02A&0<#@Y
M'%6+?3K6UO+N[ABVSW;*T[[B=Y50HX)P. !Q0!YK>M+;^ =3L[9(Q:+XA>U:
M-W,<:VYNAE"P!VH<[3@' )XKH[?1M<;Q1I6I2Z?H]A!:QRPS?8[IW:2-E^5,
M&)1@,%/7CG%="FB:<EG=V?V5&MKR226XBDRZR,YRQ(.>OITJ#3/#6EZ1/YUG
M'.KA#&OFW4LH1>.%#L0HX'3% &O7$:G'/X0O-3UN2WMK[2+J=9[O<,7%N<*F
M5)R'08!V\$9.,UV]8D_A/1KJ^-W<6TDKF02F-[B1HBX.0WE%MF<\]* ,JPL+
M:Y^)VNW4T2O+!8V:QEAD+N,N3]?E'/U]:HV&I6OA_1O%TLMKYUI;:L\<=J@&
M&\Q(?D / !>0^W)KM(=.M8-1N;^.+%U<I&DK[C\RINVC&<#&YNGK5=M TQ[;
M4+=[1'AU"0RW4;DL)'*JN>3QPJ],=* .1G_M.+QQX3-]::79F1[F-8[21G?9
MY#,5)*J"H(7H.H%7_"FG6LGB#Q3?R0H]R-5,2NRY**(8CQZ<L>GMZ5KV?A31
M[&Z@NHK9VN(&+1333R2NF5*X#.Q.,,PQTYK0L].M;"2[DMHMC7<QGF.XG<Y5
M5SR>.%48''% 'F.B:7KOB#P#+%%INC&>^:622\EO9!,EQO;YR!"<,K#@;N H
M&:ZO5-(U6'4X-?M([.]NX[(6UQ:3_*' )8F)\?*Q)(Y&#QG&*T9?"&B37LMT
M;61))G\R58KB6-)&]616"L?<BI=3\-:9K$_G7L<[/L\MA'=2QJZ\G#*C ,.3
MU!ZT 3Z%J5KK&AV6HV2%+:XA5XT*X*C'3'MTK"\:*D^H>&K.\ .F7&H[;E6^
MZ["-VB1O4%PO!ZD"NHM[>&TMX[>WC2*&-0B1H,!5 P !Z5%J&G6FJV4EG?6Z
M3V\GWHW&0>X^A!YS0!S/B*""T\6>%[BR1([^6Z>"0( #);>4Y<-CJ%(0C/0U
M/X<C0>+O%I"*,7=OCCI_HT5:>F^&]+TJZ:ZM8'-PR;/.GFDF<+UVAG8D#V'%
M7+;3K6TN[RZABVSWCJ\[;B=[*H0'!.!\J@<>E %JN/\ "4%O>:IXDN[N-)-2
M74I(',@RR0KCRE&>BE2#[DFNPK'U#POI&I7OVVXMY%NB@1IK>>2!W4= QC92
MP^N: ,>Y@@G^)EG;7<:&WM]*,ME$X^42^9M=E'3<%V#V!-5IXHK3QUJ\-BJI
M#/HK37B1C"^:'(C8C^\5W_4**Z:^\/Z9J-I;VUU;ETML>0PD99(\#&5<$,#C
MN#S2V&@:;IEM<06EOL6XR9F9V=Y3C&6=B6)QZF@#@+G2+)/@MHVR!4=TT^4R
M+PX>22(.P;KDAV'T-=)JMG;6/C+PG]E@C@R;F#]V@7]V(2P7CME0<>U;CZ%I
MSZ+!H[6^;"!8ECBWM\HB*E.<Y."J]^<<YJ>XTZUNKRTNYHMT]HS- ^XC864J
M> <'@D<T <1I&EV4WA[QC+-;1R//?WZR,ZY)4%L#V Y./4D]ZANK&VM?A5HM
MU%$HN5?3[GSR,N97FBWN6ZDG<V3[FNY@TBQM[:[MHH=L5W))+,N]CN:3[YR3
MQG/;\*;)H>GS:/#I+V^;&$1".+>W C*LG.<\%5[\XYH P(XHKSXGWJWZ*[VN
MG0M8(XR K._FNH/?(0$^F*R-3CBM-0\=6E@JK9MHOGW$:<*ERR2@X'0$H%)]
M>#7::IH.G:R86O8"TL.?*ECD:*1,]=KH0PS[&FV_AW2K72KG38;0+:W0<3KO
M8M+N&&+.3N)(XR3F@#D]9TVSL/AII\MM B36S64T4H7YQ(98\MGKDY.3WR:]
M JC<Z18WFEKIL\.^T4(!'O8?<(*\@YX*COVJ]0!S>OZ-?RZO9ZWI@M9[FUAD
MA-K=@A)%8J3M89V/\N,X((/-8VJ:E:ZYX:\.:A;6WDQR:Q:KY3 9C*S;67CC
M[P(XZUU.I^'].U>5);M)RZKL!ANI8<KZ'8PR/K2S>'M*GT9-(>RC%@@79#'E
M FTY!4J0001G(.: ,/6(H;GX@Z#9WRJ;);6XGMXW^X]PI0#CH2J%B/3DU#?I
M]A^(<)TF-!<W.E7#W<2# ;8R>2S =]Q=0?3-=#<^'M,O--AL+F!IH(2&B+RN
M9$8=&$F=X;D\YS3M+T'3M&,S64!66;'FRR2-+(^.FYW)8X]S0!B^ ;.PD\%:
M;<I''-/<Q+-=2NH9WG/+EB>20V1STQ7+ZF[+XYUU=2++X;:YMQ?-'_?\A-@E
M](B>N.^,\9KN#X1T;[>UZEM+#*\GFN(+F6)'?.=S(K!6/U'-7TTFQ2>^F%NI
M>^V_:=Q+"3"[!D'C[HQQ0!:B5$B58@HC  4*. .V/:N6\>[7L-)MYSBPN-4@
MBO,G"F(D_*W^R7" _6NBT[3K;2;&*RLT9+>(;8T:1GVCT!8DX]!VI]Y9VVH6
MDMI>01SV\J[7CD7*L/<4 <KXMMK>SO\ PU<6<4<5^-3B@B\I0K-"P/FKQU79
MDXZ# JQ#&G_"T+[Y%_Y ]N>G?SIN:T=/\+Z1IEV+NVMG-PJE$DGGDF:-3U"E
MV.T>PQ5Y=.M5U234A'_I<D*P-)N/**S,!C..K-SUYH M4444 %%%% 'A/A+_
M ).'UG_?N:]VKPGPE_R</K/^_<U[M0 4444 %%%% !1110 4444 ><_&[_DG
M,O\ U]1?S-:_PM_Y)KHG_7%O_0VK(^-W_).9?^OJ+^9K7^%O_)-=$_ZXM_Z&
MU '7T444 %<WXK\7)X5ETSS;)[B&\F9)71\&!%7<SXP=P"@DCC@&NDKD_$\:
M2^,?"$<BAT>XNE96&00;:3(- &KX@UQ=#T)]42$7*B2% HDVAA)(J9S@]-V?
M?%0ZMXC>SU.+2=.L'U#4Y(_.,0D$:11YQN=SG )X  ).#Q7%:_(^D^%M2\+W
M#$_9)[2:P=CDR6INH\#/<H?D/MM/>NFT,JGQ!\51R\3R+:21 ]3#Y97CV#A_
MSH MV?B2Y75X=*UK2SI]U<*QMG2<30S%1DJ'P"& YP0..E7/#^L_VYI[SO;_
M &:XAGDMYX-^_P MT8J1G SD8(XZ$5D>-BK3>&X$(-T^LV[Q ==JY,A^FS=G
MZU&UU#X8\7ZJ]PWEV&H69U $\ 2P@++CW*>6?P- &Y9:Q]NUW4M/BM_W5@(U
M>??]Z5@6* 8[+M.<_P 73BL^R\71WGBVYT3[(R1('6"[,F5GDCV>8@&."N\=
M^<-Z51L+J3PS\/[C6;R(M?W >^EBP26GE.4C^N2B#Z"N8NM1ATKPII$T&GZT
MVHZ1,MY+(^E7""0L3]HRQ0 !@\AR?:@#N=>U^^TW6-+TO3M,AO;B_29P9KHP
M*@CV9Y"-G._]*?HWB":_U.[TK4-.:PU&VC28QB42I)&Q(#HP R,J0<@5B>)#
M=7WC7PF^DWT$#R6MZZ3R0&9"I$)^Z&7J.^:?X=\ZP\6:S'K=PMQJGV2*;[8N
M%C^S;G 54_@PP8D$MG.<T :.J^+8]+\2V.DFT:6*8HMQ<A\"V:0L(@1CG<RD
M=1CCKFKNO:W_ &#%:W4UMOL7G6*YG#X^SJW"N1CE=V >1C.>:X"/4;;6_#.N
M27&GZT+S69&GADCTNX<1JN!;D,$P0 J-QW)KN="OH?%?A&WGNX 5NH#'=0.N
M,/RLB$=L,&% $^O:V-&M8#%!]JO+J98+6V#[3*Y]\'"@98G' %:H)(Y&#7">
M"--FDU749K^[:[.BS-I5B7'*1@*Y8^KD,BD^B>YKO* .&L?'FHR:!:>(+_0(
M[?1YPK--#?>:\*LVW<R&-> >N"3CG%=)9:U]L\1ZII'V?9]@B@D\W?G?YN_C
M&.,;/4YSVK@O">C:UX@^'.D:9<3V$&BRPKYAC5VGDC#9V\X5<XP3SQ6M''K4
MGQ&\1_V1=6$&+6R\W[7;O+GB7&W:ZX[YSGMTH Z==:W>+)M#^SX\NQ2\\[?U
MW2,FW;C_ &<YSWZ50U_Q;'H6K6%D;1ITF*M<S"3:+6-G6-788Y!=L=N 3VK+
MT=-3C^)UZ-5GLYI_[&AVM:PM$H7SI, AF8YSGG/I61!JFGZW;^(YKVPU>5-6
M+6\$D&F3RH+= 5C965"#DEGX/\5 '=>)=:_X1[PY?:O]G^T?98C)Y6_9N]LX
M./RK/C\1ZE::I96>MZ-%9I?2&&"XM[SST\S:6"ME%(R%..#TKFM5UB36O@?J
M-Q<AEO8[1K>Z1U*LLJ,%;(/()(S@^M:!34V\;Z3;^);BVFB"R3Z=]CB,41G5
M<,'5BQ+!&8K\V/O<<4 :=IXP6X\=7_AJ2R,0MU!BNO-R)FV([+MQ\I ?U.<&
MM'Q)KB^'M#GU#R#<2*56* -M,KL<!<X./<XX )KBKZWE.N^+]2M4+WFEW]I>
MPJ.KA;9-Z?\  D+K^(K4UBYB\0WSFW<2V&G::]YN'1I9HV$?Y1[S_P #6@#I
M--UF*]\,VFMSJ+:*>S2[=2VX1J4#D9P,X!ZX[53\*>)3XELIY);%["Y@D57M
MI'W,%9%=&Z#JK#Z'([5R5W?HGPU\):08KB4:E:6J3I;0O*_V=8T:4A4!.",)
MT_CJY%KMO%\0K*Y@M-1MK;4X/L4YNK"6W3S4RT1RZ@$D&1<?2@#HM3\1O;ZF
M-*TS3Y-1U$1B62-9!''"AX!D<],X.  2<=*MZ5>:M<-*NJ:5#9;0"C0W?G*^
M<Y'W5(QQV[UC^%F6/Q+XLAF(^V&_27GJ83"@C/TX<?@:ZN@#D?#_ (F\0:_I
M]CJ4?AZRBL;H!MYU-BZH3@G;Y/)Z\9_&MG3=:_M#6]9T[[/Y?]FRQ1^9OSYF
M^-9,XQQC=COTKDOAS%XB_P"$-T)TO=+&G>4I\MK20R[,\C?YF,^^W\*V/#O'
MC?QBIZFXM6Q[?9T&?S!_*@"_>:[/#XA&C6UDDT[Z?)>1L\^Q25=4"'Y3C.[.
M><8Z&LA?%'B5M>DT8>&[#[4ELMT3_:S;=C,RCGR>N5-3R<_%BVQSMT.7=[9G
MCQ^>#^1HB_Y*Q=_]@.#_ -'RT :%AKYN=8U/3KJV2V;3[>WFED\[<O[P.2.@
MP%V=>^>@JE;^)M6U:/[5HGA\7%@W,5Q=W?V?SE_O(NQC@]BVW-<YXBBN)KKX
MBQVH8S-I-K@+U(V39 _#->@:9-:W&EVLUB5-H\*-#MZ;"!C'X8H EM9)IK6*
M2X@\B9E!>+>&V'N,CK]:P?#OBV/Q!J%]:BT:W$/[RV=I-WVF'>R"0# P-R'C
MG@@]Z/'.JRZ7X8G%L)3>79%I;"*-G?>_&Y57DE5W-@?W:YB[UC3]*U/PW>6%
MAJMM;66-/G:XTZ:%!;. H+.R@?*X0_B: .V76MWBR;0_L^/+L4O/.W]=TC)M
MVX_V<YSWZ5#K&OR6.H6NF6%@U]J-RCRK%YHC1(U(!=V(.!E@. 22:SXO^2L7
M?_8#@_\ 1\M:.N>'AJLUO>VM[+8:G:AE@NH@&^5L;D=3PZG X/IP10!;TNYU
M&Y@<ZEI\5E*K858KCSE88ZYVK^HJ_7/^'-8OKR[U'2M5B@74=/,?F26Y/ERH
MX)1@#RI^4Y!SC'4YKH* .1U'QL]EH6O:C'I9GDTK4%L5@$^WSR3$ V=OR_ZW
MI@].O/&U;:Y;WOAS^VK52\)MVF",<$$ Y4^A!!!]"*\_U/\ Y%;QG_V,L'_H
M=K6WJ7_%-W^IVI^73-9AFE@](KH(2Z>P<#</]H-ZT :Y\6P)X;TG5'M97N=4
MAB>VL8#OD=W0/M!.!@#.6.  ,U-8ZCX@FNXEO= M[:V?.Z1-0$CQ\=UV =>.
M":Y/PZ5BU'P&]SCRI/#IBMB>@FV0L?Q*!OR->D4 %4=6U6#1M/:]N0YB$D<>
M$&3EW5%_5A5ZN-^).EV%]X:$]U9P3S0W5LD;R1ABBO<1*P!/0$<'UH V=0U6
M>V\3Z/IB+&8;V.X>1F!W QA",<X_B.>#6S7#:[H5B_BOPII<4*V]@D5YFW@&
MQ67$9VX'\)/)'?IT)J6Q2Q\+^+]5MK94L]*72X[Z2).(XV5Y%9E4<#*@9QUQ
M0!VE45U6!M<DT@*_VF.V2Y8X^78S,HY]<H:\[N?L\,VAZOI7AJ;35GU*V07\
MLJ++-'(X4AU#%F#!CPW(X/%;-OX>T=?BI>2KI=F)%TZ"Z5A"N1,TTV9,X^\<
M#GKQ0!VES<):6LMQ)G9$A=L=< 9-85]XB86?AZ\LHU\G5;J&,B93N6.2-G['
MAN!ZCK5OQ/86>H^';Z*]MH;B-87D594# ,%.#SW%<-)HEDG@OP3;VD*V8O+V
MSDG:V C9V,#;B2.<D<9ZT >H45QHTNR\/>.M(BTJW2TAO[:Y6XBB&U)"GEE6
M(Z;AEN>O-<S;P7'B'3]3U"3PWJ-YJ<UQ<);7\=S OV4H[)&(]TH9-NT9X&3D
M\@T >L453TEKQ]'LFU!!'>F!#<("#MDVC<...N>E<1HFFV6B:E;6'B#1XFU*
MY:2*+5^)%O6(8E78_,K%=WRMQP<&@#M=.U6WU-[U( X-G<M;2;AC+A5)Q[?,
M*O5YSH>GV&@Z?XSU73=+M8[RQN;I8&CA4$*L*,$&.V>U3?\ "+:9_P (-_:V
M]O[6^P_;/[6WGS_-V;]^_KMS_#TQQB@#T"L;5M5GL=<T*RB6,Q7\\L<I8'("
MPNXV\]<J.N>*Y;3"/&>MQ1ZY'NMX-(M+H6+G$<DLP8N[+_%MVA0#D#)H\91G
MPU+X:.@Z9&SP7-RT5K$N%!-O)DA1UQDG Y.,#K0!V6NWLFFZ!J-_"J-+:VLL
MR!P2I94)&<=N*FTZ=[K3;6YD #S0I(P7H"0#Q^=<G)8V,?P[UO4;6[_M">^T
MZ:6>_/WISY;?]\J.@7^'IUS6=?Z%9:-X*T[6[9#_ &O ;-_MI)\U]TD:LK-W
M4AB-O0#H.* /1ZQ_%.JSZ+H$U_;)&TJ20H!("5P\JH>A'9C6&FGVOB;QKKD&
ML1+=6VFK!%;6LO,8WIO:0KT)). 3TVFL'5E-AIWBK0X7=K"SN=/EMD=BWD^9
M*A:,$\X!4$#L&H ]2K&T+59]3NM:CF6-5L=0:UCV @E1'&^3D]<N>F.U8<6E
MV?B3QOKR:Q MW#IPMX;6"7E$#Q[V<+TW$G&>OR\5S@EGT?PWXEM;&:YE,OB1
M+,21RCS5C=8%*AV(^;;\@8GKR3WH ]8HK@M(TR[L?%&G2Z7X8NM'L&26._WS
MP%)!MRC%4D8EPPQNQG#')K/T31HD\":OKD49EU8)J*VTK$DQ 22@*GH"1GW)
MH [G0]2DU>UEO@J"TDE86A .7C'&\_[Q!(_V<4:YJ3Z1:Q7Q5#:)*HNB0<I&
MW&\?[I()S_"#6%J&D2ZGX'T6#2XXIX(%MY6M'D,:74*I_JRPZ9RIY&.!GBBR
MET2;P?KEI:Z;_9D<$<J7UB\80PL8^<@97!7!!'!% '8U6L)+J6U#7L"03[W!
M1'WC:&(4Y]UP?;.*I^&6G?PKI#W6?M#64)ESUW;!G]<UQ-AI-WJG@K36M[:.
M^@MM3O9;C3Y9/+6Z7SY@!GH2"0P#<''- 'HUQ<16MM+<3.$BB0N['HJ@9)_*
MJFAZC+J^B6>HS6IM6N8Q*(2^XJIY7)P.<8..V<5QEW=Z9JOAZT\.Z+:-8C4;
MXVEU:%/+:W1/GG! X'R@#CCYQCK6IK[:5?ZLFE'P\VM7=M")&B^00P(Q(4MO
M(7)VG& 3Q0!U]%>4_P"D77@:*Q=I;8Q>)$LXAYN]X$^U !0W<KG /L*U?$EC
M;Z5>:!X>T[29IM-NY+B>XL[654,Y15P&+NN02VXC/.WO0!Z#17'^%+*^L-:U
M!$T6XTK1I88WAMY98F"3 L'V+&[;5(V'' R#5;Q?-+=^*M*TB33+G4K$VLUU
M+:0R1H)F5D5=^]U#*NXG;GDD<'% '<T5Y=J-MJ&G^"O&4;Z5/IFEFW66QMYI
M8W\LE2) H1V"KD*0/]HXK6UO0+'P]_8VHV$9CU#^T[6":[!/F7"R2!'$A_BR
M&)YZ'&* .M758&UR32 K_:8[9+ECCY=C,RCGURAJM=ZR^D:/?ZEJMOY<5L[D
M+"V]GC!PK=L$^G:N=M_#VCK\5+R5=+LQ(NG072L(5R)FFFS)G'WC@<]>*PM7
MT^SO?A[XKFNK6&:2WU6\:%Y$#&,F7!*D]* .]U;59['7-"LHEC,5_/+'*6!R
M L+N-O/7*CKGBMFN/U/3[/2_$7@ZUL+6&VMUO+DK%"@11FVE)X%<O;P7'B'3
M]3U"3PWJ-YJ<UQ<);7\=S OV4H[)&(]TH9-NT9X&3D\@T >L5CV.JSW/BK5]
M+=(Q!9P6TL; '<3)YF[)SC'R#''KUKFOLLOB'Q1INF>(X Z6^BQW<UFY!C:Y
M9]KE@.&V[<#J/FJSX5L(-,\>>*;6V<^0MO8E(BQ(A!$QV#/09R0.V<#C% '3
M:GJMOI26SW <BXN8[9-@S\[M@9]JO5Q?C_1]-OET::[L+:>4ZI:P;Y(@Q\MI
M!N7)['TI+S3;34/&EKX>G@4:/9:8+F.R4;8I',A0;E'!"@=.GS4 =K17'Z5;
M1Z'X]FT;3P8M.N-.^UFV4_)#(L@3*#^$,#T'&5JSKB?V=XLT/5QPDQ?3;@^T
MGS1G\'0#_@= '3T5YG<2S7ED;])I(8_$6N1VAFC;:PM$W(H!'(W>6>1_SUK3
MUK1K#PO>:)>Z);)923:C%9SQ0\+<1R9#;UZ,1][)YX- '5V>JP7VH:A91!Q+
M82)'*6'!+('&/7AA5ZN \/Z-I.D^)/%MW9:3:1RV,L?V?RX54H#:HQ52!P"2
M>GJ:P;&TU*_\+6>K:?X:U"7Q#,D=VNK&YMQYCDAB"3+N\L@E=A' [ T >NT4
MV218HVD=@J*"S,>@ [UY7J\UH^EQ^(M&\-S6N;J":+5I)$2216F49QN+E&#$
M8;'#=* /2&U6W77$T@A_M+VS7(./EV!@O7URPJS<W"6EK+<29V1(7;'7 &37
M%S^'M'E^*D,DFEV;2-IKW)8PJ291,F'Z?>'KUKHO$]A9ZCX=OHKVVAN(UA>1
M5E0, P4X//<4 5-3\1/'H>D:G8QJ8]0NK2,"93D1S.H)P#PP#>_/K715YC<Z
M/9P?#/PU#8PI9->76F-+);J$8NS1@OD=6]ZVKC2+#P]XO\.MI5NMK]MDGM[D
M1D@3*(6<%_[S H/F//)YH [2BO)[>"X\0Z?J>H2>&]1O-3FN+A+:_CN8%^RE
M'9(Q'NE#)MVC/ R<GD&O3-):\?1[)M001WI@0W" @[9-HW#CCKGI0!C^*/%L
M?AJ2T4V;7/FDR7&V3;]G@#*KRG@Y +KQQGGGBNC!!&1TKSJ'6;#4M8\0W-]I
M^JW-M< Z; ;?3IYHV@3(<AE4@[G9^G]T56;59;[X*:O%/YHO-.MI+2831E'R
M@&UF5L$$H5;D=Z /3Z*X36] L?#W]C:C81F/4/[3M8)KL$^9<+)($<2'^+(8
MGGH<8I;30-/UKQOXI.IP+=PQRVPC@F&Z-6,"Y;;T+< 9/3''4T =U17F=PSI
M\-M6M#([Q66K_9H2[%BL:7:;02>3@<?05TOC!@+KPR"1DZS%@>O[N6@#IZQM
M0U6>V\3Z/IB+&8;V.X>1F!W QA",<X_B.>#7*Z^-,UR75Y+3PU+J,UKOAEU!
MI$C$,B+@B-F;<"O<J ,]ZFTZZFOM1^']W<.7GGTJ:61CW9HH23^9H Z3Q3KC
M^'/#MQJD5G]LDB:-%@\SR]Y>14'S8./O9Z=JMZ-J<6LZ/::C"I5+B(/L/5">
MJGW!R#]*P_B-_P B5<?]?5I_Z4Q55CU*/PE=>(;2928$0ZI9H/X@YP\:^_F]
MO^FHH T+/Q:M[XYN_#D=F?+M[9I3=^9PSJ8PR!<=O,'.>H(Q725P&@Z;)I7C
MO2[>=@UTVA7$MRX_CF>XC9S_ -]$_ABN?L8+_7O"[ZO#X:U&?7[H230:H+FW
M'ER;CL5<RAE1<!2N.@.0: /7ZHZMJL&C:>U[<AS$)(X\(,G+NJ+^K"N#N&FU
MOQ;J<.J>&[K5X[&*WCCMTEA$4+/'O=MKR+EB3@,,XV\&H-8T627X=(-?TP&[
MM-0BBM6NRDTJ6[7<84%@6&2A"GGG'.: /2)I+I;ZV2*!'MF#^=(7PR$8VX'?
M//TQ5FN1O+*UT[QIX5M;.WBM[>."]"11*%5>(SP!6'H/A?3-2\%WE]>P^==F
M:],,S$[[?;-(%\L_P<C=QW- 'I5%>=6[-XIN?"-EJQ,UI/HO]HSQ,?DN9L1
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MIYB+* & ]P"1^M4K/Q;IE_XFFT&U,LMQ#"TSRJO[H;6560-GE@7&0!@>N>*
M+NEZ/;Z3+J$D#RL;ZZ:[EWD'#E54@8 XP@ZY[UH45S-UXWL;:6Z*V.HW%G:.
M8[F^@A#0Q,/O9.=QV]RH.,'/2@#6T/1[?0-%M-*M7E>"U3RT:4@L1[X 'Z46
MNCV]IK6H:JCRF>^2*.16(V@1[MN.,_QG/)[5#JGB&STNWMI"LMU)=MMM8+50
M[SG&?E&0,8Y))  [T:/K]OK#W$*P7-I=VQ GM;I LB9Y4\$@@X.""1P: &7O
MARVO=1O;XW-S#/=V'V!FB91L3<S;ER#ALN>>1TXK2L[2&PLH+.W0)!!&L4:C
MLJC 'Y"IZ* .?O?!]A>VFN6KS7,<.LE6N$C90$8*%+)D<$A1G.>E7]7T>WUB
M.U$SRQO:W"7,,D1 974^X/!!((]":T:* ,ZST:WL=3U._C>1I=1='F5R"H*(
M$&WCT49SGFJ>D>$].T32+S3+,S""Z=V<NP+ ,H4*#CHJ@ #L *W:* ,72_#-
MGI-Q:312SRM:6$>GP^:P(6->_ 'S-A<G_9' JUK.CV^N6 M+AY8PLJ31RQ$!
MXW1@RLI((SD>E0:_K\7A^&S>2SNKM[NY%K%%;!"Q<JS#[S*,84]Z;I/B.WU2
M\FL6M;NQOH4$C6UV@5RA. P*DJPR",@G!ZT +JOANSU6ZBO/-N;2_B78EW:2
M>7(%Z[3U#+GG# BI=+TB336E:75M0OVD &;MT.W&>@15 Z^E:=% '*Z5X*;1
MK6VM+/Q+K:VMM@) Q@*[0?NG]UG'XU?U/PS;:AJ"ZC#=WFGWXC\HW-G(%9TS
MD*P8%6 ).,CBM**Z>2_N+8VTJ)$B,LS8V2%LY"]\C S]16+I'B6[U738]271
MW%E<RHMJ8I@\C1LQ4R.N $ &&P"QP?48H NZ1X>M-'FN+E);BZO+G'G75U)O
MD<#H,\  9/  '-2KH]NOB&36@\OVF2U6T*9&S8KLP.,9SECWK1JO?7+V=G)/
M':SW3(,B&#;O?GMN('YD4 5K;1K>UUK4-41Y#/?1Q1RJQ&T"/=MP,9_C.<D]
MJS!X-M[9W&EZKJFEP.Q8VUI*OE GD[5=6VY]%P*KP^.'GO[FQC\+ZZUS;*C3
M1[;?*!\[3_KN^T_E7107<DUY/ UI-$L:(PE?&URV<@8/5<<_44 5/[!@:\TR
MZEN+F:33D=8O-<'<S *7;C); (S_ +1XJSJNFV^L:5=:==@FWN8FB?'7!&,C
MW'45<HH YNZ\(+/J<6HPZYJMI=)9I9M)"T69$0LP+;HV^8ECG&/I4LGAJXDA
MA7_A)-:26+<#,LD09P3GYE\O:<=CM!K?HH YB[T&XT?PYJJZ"9Y]8O%_X^IY
M097D("AV8X'RCD 8'' KHK:%K>VBA:5Y61 ID?[S$#&3[FI:* .?G\'Z?<6&
MIV;S7(CU&^6^E(9<K(IC("\?=_=+UR>3SZ7M>T.T\1:1-IM[O$4N"'C.'C8'
M(93V((K2HH Q7\+Z;+X=LM$G226VLXXXX)"^V5#&H"N&7!##'48IMCX=FL[N
M.9]?UBZ2,G;!<2QE#QCG:@9NO<FJQ\9VTLLPT[2M4U.&%RDES9PJ8PPZ@%F7
M?CI\H-:^DZO9:W8+>V,OF1$E2"I5D8<%64\A@>H- #XK$Q:E<7GVNY<3(J"W
M=P8H]N>5&."<\\]A4>LZ3;ZYI4VGW32+%+M.Z)MKJRL&5@>Q! /X5?JM87]M
MJ=HMU9RB6!F90X!&2K%3U]P10!1CT",7>FW<]]=W5S8),B2S%,R>9C.[:H'&
MT8QC\:=<^'[*\U*YO;C?(;FR^PRQ$C8T>6)[9R=Q'6M6LS3M7^WZMJ]AY'E_
MV=-'%OWY\S=$LF<8XQNQWZ4 9:>"+0I9QW.IZG=PV,T4UK'/*NV%HV!7&%!;
MIC+9.">>:T+K0(KG78-8CO+NVN8XUAD$++LFC#;@KAE/&2>1@\GFM>B@!DT2
M3PO%(H9'4JP/<'K6!:^#[:VM-/M6U'4)X=/N$GM5F=#Y>Q2JID*"5PQZ\\#F
MNBK(\1>)=/\ #&FM>W[.0 Q2&)=TDFT9.U?8 DGH!R2* +%UI,%WJ]CJ3O()
MK))4C52-I$@4'/&?X1CD5FR>$H1>7,]CJNIZ<MU(99X;65 CN>K896*D]RI&
M:V(;V&73TO2WEP-$)2TA VJ1G)].*QK+Q;'J,L)LM'U:>SF<*EZ(%6(@G&[Y
MF#[>^=O2@#H N%VY/3&>]8-OX4B2_M;N\U34M0-HQ>VCNY$*1L05W855+'!(
M!8G&:Z"LO5-:.FRQQ1Z7J-_+(I;;:1 A0/5F*J/IG- $=KX>AL]6O+Z&[NA'
M>,9)[,E3"SE0I;!7<"0!_%CVK/\ ^$%L?LWV#^T-2_LG.?[-\Y?)QG.W.W?M
M_P!G=CMBM+2/$5CK%E<7,1D@^RNT=S%<KY;P,HR0P[<$'/3'>L^U\;V-S+:E
MK'4;>SNW$=M?3PA896/W<'.X;NQ8#.1CK0!=U/PU:ZC=V][%<7-A>VZ&*.YL
MV"L$/\!!!5ESS@@X[4+X>C,VF3W%_>W4^G2R31RS,F7+HR$-M4#&&., =J-2
M\0-I]TUO%HVJWS*H=VM85*J#_M,R@GV&343^+M+7PE-XDC,TMC#&SNJIB0%3
M@KM.,,#Q@T ./A6R":M#%-<0VNJ1.D]M&RB-68$-(@(^5B#SV)YQFI[[0;;4
M-"32)9)EMU$0#(0'_=LK+SC'51GCUJ*PUZZO;Q()/#NK6:MG,UP(=BX&>=LC
M'GITK:H Q=1\-P7VHKJ,%Y>:??>7Y33VC*#(@.0K!E96QDXR,C-0GP?IQT6X
MTWS+DBZF2XN+AI TTLBLK!F8C_9 QC ' Q7044 8NH>&X;W4O[1M[^]T^\:,
M122VCJ/-0$D!@RL#C)P<9&3S5>S\%:1::/J.E8GFM-0G-Q,)I"S;R%&0W7.4
M#9SG.3FNBHH R-,T.73I_,DUK4[U0A18[J1"JCCGY44D\=22:GTC2+?1M-^P
M0-))#YDLF92"<R.SL. .,L?PIF@:O_;FDK?^1Y&9IHMF_=_JY6CSG Z[<_C6
MG0!SECX?N8=)_LE;^[LH;2<FSGM73>82,JC!E887<5P1T534-QX31--ETZ"2
M>==2N ^IW=Q(#)+& ,C@ <A53   !-=310 @ 4    = *PHO"Z6NEQ6-CJNH
MV:Q32RB2%H]S&1V=@=R%2,L<<5O44 <_I/@_3]'U/^T89;J:Y*.K//(&W,[!
MGD/'WCM4>F%  %2WWAJ*ZU5]2M]0OK"ZDB6*9K1U F522H8,K#(R<$8//6MN
MLS7-7_L:WM)?(\[[1>P6F-^W;YD@3=T.<9SCO[4 48O!NFV^FQV$+W"0QWZ:
M@/WFYO,5P^"2#D$CGN>>:OZSH=KK<4 F>:&:WD\V"XMWV21-C&5/N"00000>
ME68+IYKNZA:VEC6 J%E?&V7*YROTZ'/<59H H:9ILFG+)YNI7M^\A!WW3)E<
M=@$50/RJ'6-!MM9:VE>:XMKJU8M!=6SA9(\C# 9!!!'4$$' K5HH PY_#,=Y
MX?OM(O=2U"ZCO5*R32NGF $ ?+A0HZ?W:NZKI,&KPV\4[R((+F*Z4QD EHW#
MJ#D'C(YJ_10!D76@17.NP:Q'>7=M<QQK#((679-&&W!7#*>,D\C!Y/-1GPO8
M-H^IZ7(TSV^HS333;F&X-(<G:0.,'I6W10!BQ^'$$NF37.HWMW/ITKRQ2SE-
MS%HV0AMJ@$ ,>F#GKFH)/"4(O+F>QU74].6ZD,L\-K*@1W/5L,K%2>Y4C-=#
M10!D:KX>@U.>VNENKJSO;966*ZM7 <*V,J=P*L#@'!!Y%1Z+X8L]#U"_OH)[
MJ>YOUC%Q)<2!BY3=AN@Y^?'I@  #%;=5K"_MM4L(;VSE$MM,H>.0 @,/7GF@
M"OK6CP:Y8"UGEFAVR)-'+ P5XW1@RLI((R".X-5;SPS#>I9R27UZE_: B*_C
M9%FP?O _+M(/'!7' XK;HH R=)T"VTF>XNA/<7=[<[1-=73!I& Z+P  !D\
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MBDEM'4>:@)(#*ZLIQDX.,C/6I;SP_!J'A]M'NKFZEC8#,[2?O=P8,&W8QD$
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M.3G.<\FH;KPI!/?W-U;ZCJ%C]K(-U%:2JJ3$#&XY4E6P ,J5/ YK?JGJU_\
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MIHGM;.[N]3%PX9TM=,:422+P-Q\KY@H]<@<U#X%U">]L=4AG>[=;+4'MXC>
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M^ZF@A,L+@@D0)G:P[@X^AJ])X6U*_C@L]8U[[;IT3JYA6U$;S[2"HE?<=PR
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M7,N!)RAY'IT]0:Z&0_8/']BUS<//Y&@W)DF<*&?$L.20H S] * .O50JA5
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M"#][SBN>/W?.W/7VH ]!HKA]!\3QR>*8M'C\1VVNP7-L\RS1^5YD+H5RK>6
M-I#9'&?E/)JCI>I^*[GP+_PD1OC<7,EN!':1VJ-@;PK2\#+/M#,%&!T&#UH
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MH)B6,%IQ@@CC:4^K"@#LJ*** "BBB@#PGPE_R</K/^_<U[M7A/A+_DX?6?\
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MQ0FH7<!FUR+9F%3MB_<^7CGJ!QSWZ\9Q6YH4>IPZ7%#JL=HEQ$ @^RR,ZLH
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M+MK"UT_3S<0B1(&"RJGD1 $;^?O8P!@<\US?B#P]J%[XI@:UB#:7J A&IMO
MV^0Y=.#R=^=AQV'- %W3]4U"3Q!I5CJ%O:I<SZ0]U<-'&0R2!X@44DG"_.>/
M4"J?AO5_%/B31(=37^RK**:+]V)())&+AL%B XPIPV!G/0Y[5JRZ?=-X\M=2
M$6;2/3)H&DW#AVEB8#&<]%;G&.*7P;I]UI7A#3;&]B\JYABVR)N#8.3W!(H
MY7PYJFK:+\)['4GEM)R([86Z^2X*J\BHV\[SN.&ZC;]#77Z]JL^F3:.D"QL+
MS4$M9-X)PA1V)&".?E'K7,V6A:Q/\.'\-367V6\LXXT@FDE1HKAHWWJ1M)8
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M4MP[$]5'E$G'U(^E '->&-3\0Z?\-K;5+:"P%C96SR&WF5S+.B$EB'#80\'
M*MGC.,\=3?Z_>7.IV>E:)';FYN+7[9)/= E(82<*=JD%F)S@9'0\U3T_1=0@
M^%;Z+);[=0.G30"'>I^=E8 ;LX[CO0VEZII>HZ9K-E9B[D73DL;RT$BH^%.Y
M61B=I()8$$@$'K0!6U;6+\Z3XDT/5X[<7B:1-<PSVP81S1%64G:Q)4@X!&3U
M'-68]7U)GT?0M'6U6Y.FI=3W%TK.D4?"J JD%B3GN,;35>\T;5]:;6]4N;(6
ML\NDRZ=8V9E5G.\%BSL#M!+!0 "0 .M3G3-4TG4]-UBTL#>L--2PN[5)421=
MIW*REB%."6!!(Z@B@"MH>H7%IXM\7W6L1Q1-9V5HTKPYV.BB=MZ@\CCL>A!&
M3UJ5/$^M6UE8ZSJ$6GKIMW+$C6\>[S[=96"HS-G#$%ER HQD\G%)I^B:MJFI
M^*Y-8M19VVKV<-M"JR+(44+*K X/WAO!/;YL G&:JZ)X<BM5LK.^\ Z8;F':
MDFH1QVWEMM_Y:#_EIDXSC;U/6@#5TW6=<U7Q#J5K!%8Q6&G7OD22R*Y>5=BM
MM4 X##=R3QR..IK-A\4>))O#E[X@%MIJV=B]P7A97WSQQ.P8JV["'"D<ALD'
MIFN@\.:?=6-YK[W,6Q;K4VGA.X'<ABB7/!XY5N#SQ63;Z'J,?PRU71VML7\\
M6H+'%O7YC+)*4YSCD,O?C/.* )/[?URU.E7]]!8KI^HW$< MXU?SH/,^X2Y.
MUCG ("C&>"<5-/K6KZAJ^H6FBMIT4.GL(I9;T,WFRE0Q10K#: &7+'/)Z<5)
MK.EWMWI&AP00[I+6^M)9AN VHC L>3SC':L:Z\+QV?B+5+N;PE9Z];7\JSI(
MR0&:!]H5E/FXRIV[A@\9/% %X>,)K_2M%;3K>%-0U4NJI<-F.#R\^:6Q@L%(
MV@#&21TJ>RU;6+J[U#17ET^/5;:.*>*Y6%V@EB<D9\O>&!!5AC<>QYZ50UOP
MJEU;:%=VWAW3Y%TXR>9H[K'Y>V4#>%R-FX, >P///-;'AS3K2V:>:#PM;Z$S
M87Y$A#R#KSY1(P/J: .5\-7^IZ=\._#D]PUE=1W%S901*T#!HTDD"DL2YW.,
MY! &#V-=!/J^NW7BR_T73$L8X[:WAF-S<1NX7?O&TJ&&XG;QR,8/7(K'L=&U
MH>$=&T272WCETJ_LRTOG1E)HXY@S.N&R %&<$ \X -=+I^GW4'C+6[^2+;:W
M-M:)"^X'<R>;N&,Y&-R]?6@#+_X2^[M_#M_/<V<3ZK9WPTX0Q.1'-.Q0(5)Y
M"D2*3GISUI+S5_%&CZEHL%^NE7%OJ%XMO));Q2(8<JS8PSG=G'#<=.G/$,_A
MG4;FRUX(D<5TVM)J5@9&!5S&L)7.,D E&7GD=<5!KM]J^HZSX7CN=);3XEU1
M6*2S1R/(PCD/R["?E #$DX/3B@#N+R[BL+*>[N&VPP1M+(WHJC)/Y"L'2+SQ
M+JT5KJ+KIUG8S[9!:O$[S"(\@EPP4-CMM./6M"ZAFUF'5])O+)H+*2+R([CS
M5;SU=,,0HY7:21SUK,T*ZU^PMK/2M0T1YF@"P-?P3Q>2Z#@.5+!P<#)&T\]Z
M (+/6?$>NV4FJZ/'IL=@6<6L-TKF2Y521N+A@(PQ!QPW&#43>,+_ %)O#HT:
MTA!U>*<O]JS_ *.T>W.<'G!+C'<@<CK1I47B#POI/]B6NB_VA';EELKI;B-$
M\LDE1*&(8$9P=H;.*-+\+WFD7OA=!B>.QAN_M<ZD >9*5;@$YP6W=/QH ?:Z
MQXGN]7OM$5-,2[L0DDMZT3F)T<90+'OW!LA\_-@8'7/#SXLG7P1?:K+ B:C;
M22V?DQG<K7*R&)0N>H9\?@:T=-T^Z@\7Z[?2Q;;:ZBM5A?<#N*!]W&<C&X=?
M6L#3_#VJ/J=K!>6OEZ?%J][J;L9%.\F1C , Y_C+^VT9YH Q;KPK-;^(]&TZ
MRF U+3M#DN+>8GAK@3QEB?9RS@^SFMO5]6BUNT\&W\2M'YFM1AXF^]$XBF#(
M?=6!!^E;4FG79^(5OJ@AS9II4MNTFX<2&6-@,9ST4\XQ6'K/AG5%\8Z9<Z9"
MLFE2ZBE_>+O5?(E1&0N 2,APPR!GE,]Z ,:QUO2+'2O$EOJ.CW5Z#J]]N_T)
MC"P,K8#2D;%'J2>*Z&'PU>3> -&MTNHVUK388YK2Z#;E\U5^[N[HP)4^H.:@
MTL>(](AUBRA\-O.USJ5U/#/+=0K 4DD)4L Q?&#R-N:Z?PUI+:%X:T[2GF\Y
M[6!8FD[,0.<>WI0!S>E7K^.M6MKR2VEM],TI@7@E7!>^QR#ZB+./=CG^&M;Q
M/#H>F:#J5W>Z?;2+.I#H(5+W$C#"KTRS$X I_A/3;O3;;5$NXO+:?5;JXC&X
M'=&\A93P>,@].M84XUZX\62ZAJ'AF]N[6RD*Z9%#<VXC'8SMND!+GMD?*/<F
M@"%]/N8M&\#>&=4;S?.D47BMR'$,+2;&]1N5?KMK5U*W@TOQ]X>GM(DA:_2X
MM;@1K@2*L?F(3CNI0X/^T:GUJTU+5]/TO4[6Q-MJFGW/VE+2XE7+##(T9=2R
MC<K$@\\XSWIEK:ZKK7B>RU74=..FVNG12""&29))))9 %+'82 H4$#G)W=J
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M_0VH Z^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O;2.^M
M)+:5Y4208+12-&X^C*00?I6;8^&K*QOEOFEN[NZ12D<MW<-*8U/4*"<#/<@9
M/K6S10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A/A+_DX?6?
M]^YKW:O"?"7_ "</K/\ OW->[4 %%%% !1110 4444 %%%% 'G/QN_Y)S+_U
M]1?S-:_PM_Y)KHG_ %Q;_P!#:LCXW?\ ).9?^OJ+^9K7^%O_ "371/\ KBW_
M *&U '7T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU&W2$6Y3)7:J#G/!^X?SK5G\5:+;ZGI^G/>JUWJ*>9:QQHTGF)_>RH( Z\G
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M83 JW[O"\C.,Y/3;6QJWC/P_H6I#3]4U*.UN3!]H"R*V/+R1G=C&<@\9S[4
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M@>)RZZ/J<5T\8RR ,C@>NU@#CWQ5.?XC>$[?5_[*DUF'[;YGE>6B.XWYQMW
M%<YXZT ='/;07(43PQRA3E0ZAL'U&:EKG=<\=^&O#=X+35M5CM[@J&\O8[L
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M>^0#0!ZK1110 4444 >$^$O^3A]9_P!^YKW:O"?"7_)P^L_[]S7NU !1110
M4444 %%%% !1110!YS\;O^2<R_\ 7U%_,UK_  M_Y)KHG_7%O_0VK(^-W_).
M9?\ KZB_F:U_A;_R371/^N+?^AM0!U]%%% !7D_QP-L+;PV;P$VHU#]\!W3
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MS7MQH.GR7#-N9V@7YCZD="?K0!Y9J4>JZ;\4-*275-/@N!HT45K>7\9:)V
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M[,;3K0Z?P/LA@7RN#G[F,=>>G6B[T?3;_3QI]W8VT]FH 6"2(%% Z8';';%
M'G_AW3)X/']SKU]XBT6YG-@PNH;!2I,8((=@"?0<FN\T/7M-\2:<-0TJX,]J
M6*"0QLF2.N P!K/'@G0[;2;^PTRQAT[[; T$LUM&!)M88/)K0T#1+7P[H=II
M-GN,%LFU2V,L<Y)..Y))_&@#RWQ'H-GXC^.J:??&80'3 Y\F0HV1G'(J7XF>
M%%T#P/I;Z3'//;:5?BYE61R[;6SDD^F<#VS7JATNP.HC4396WVX)L^T^4OF[
M?[N[&<>U6719$*.H96&"",@B@#A_$'Q#\-'P1>7\&J6LS7%JZPVZR RL[*0%
M*=1R><]*\]U72KG2/V=K6*[1HYIKM)S&W!4,Q*_I@_C7KD/@;PM;WHO(= T]
M)P=P80+\I]0.@/TK7OM.LM3MOLU_:6]W 2&,4\0D4D=#@\4 >)W>C1^!?&OA
M/5[NZN=2TR[58B^H/YIM9"!RIX  R"./X37L^M?\@+4/^O:7_P!!-+>Z1INI
M6L=M?V%K=6\9!2*>%752!@$ C XJTT2/$8F16C*[2A&01Z8]* /#_AS\/X?%
M?@JSGU+6=2.G>>Y.G12;8B5;J?K^?H16SKVD6-W\=_#MA/;1/:1:2"L#*"GR
MF;:"/0$ _@*]1L=/L],MA;6%I!:P DB*",1J">O XI'TRQDU%-0>SMVOHT\M
M+DQ*9%7GY0V,@<GCW- 'EETUCI_QZWZX((;,Z<JZ:TV%C1AMZ$\#GS/Q-5;>
M6UNOBQXEGT$QMIXT>07CP$&)I-H].,Y'Z-[UZOJVA:7KL"PZI86]Y&ARHFC#
M;3Z@]OPJN- L--T&\T_1[&WM%FB=0D2! S%2 2>_U- 'C7A*]\+Q?!+68+N2
MT%^RS>9'(5\UY"/W14'D\[<8Z$'WJMIP-I=_#:;Q( -(%O+M,_\ JU<O(4)S
MP!@PGGL*]$\&?#FPM/"MA:^)-'L;G4+9I/G91)@%RP&>XYZ&NUOM)T_4['[%
M?65O<VO&(I8PRC'3 /2@9YAJ4]C>_&_P\_AYX99HX'-_);$%-F&^\5XSC^:^
MU8DMS<_"Z;S='U72M:T;4+[+6?#7 )]""<XQC/3...:]CTCPYH^@HZZ5IMM:
M;_OF*, M]3U-5;;P7X:L]0%_;Z'81W0;<)!",J?4>A]Q0!Q%WXEO]3\;:_I\
M&IZ/H%MIRJDMQ=VZR37 P>S, 5'Z9'7-<=ID@?\ 9^\5[7#H-5780NT8WVYX
M7M]*]OOO"VA:EJ,>H7VDV=Q=QXVS20AFXZ9]<=LU,- T<64]D-*L1:7#^9-
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MO+"UN9K=MT,DT*NT1R#E21P<@=/04L&EV%K>3W=O96T-S<?ZZ:.)5>3_ 'F
MR?QH \O^'M]X?OOA==Z7KT%I:06DYMK])/W:EF8;78]B3@9]5[8K%M%M_!?Q
M&T+3O"/B!]1T_49MMU8B83+$I(R25XZ$L#U&WG(->P2^&="FCNXY-'L"MXP:
MY'V9!YS Y!;CDY).3WIFE>%- T.8S:9I%I:S$8,D<0#8],]<>U &Q7A7A)+R
M3]GS7EL0YG,LO"=2F$W_ /CNZO=:JV&FV.EV_P!GT^RM[2#<6\NWB6-<GJ<
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MDV_7!.*\0T?P[?>*/#?B[PSHMZ!I]EJJO8>;(=CJ#)E-W/& C?7![YK>\/\
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M+:(8CC3HHSG^M '+?\+*T+_A,&T W5JJ)"9&O6ND$6_('ECGEN3QGM6?X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A/A+_DX?6?]^YKW:O"
M?"7_ "</K/\ OW->[4 %%%% !1110 4444 %%%% 'G/QN_Y)S+_U]1?S-:_P
MM_Y)KHG_ %Q;_P!#:LCXW?\ ).9?^OJ+^9K7^%O_ "371/\ KBW_ *&U '7T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'A/A+_DX?6?]^YKW:O"?"7_ "</
MK/\ OW->[4 %%%% !1110 4444 %%%% 'G/QN_Y)S+_U]1?S-:_PM_Y)KHG_
M %Q;_P!#:LCXW?\ ).9?^OJ+^9K7^%O_ "371/\ KBW_ *&U '7T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'A/A+_DX?6?]^YKW:O"?"7_ "</K/\ OW->
M[4 %%%% !1110 4444 %%%% 'G/QN_Y)S+_U]1?S-:_PM_Y)KHG_ %Q;_P!#
M:LCXW?\ ).9?^OJ+^9K7^%O_ "371/\ KBW_ *&U '7T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'A/A+_DX?6?]^YKW:O"?"7_ "</K/\ OW->[4 %%%%
M!1110 4444 %%%% 'G/QN_Y)S+_U]1?S-:_PM_Y)KHG_ %Q;_P!#:LCXW?\
M).9?^OJ+^9K7^%O_ "371/\ KBW_ *&U '7T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'A/A+_DX?6?]^YKW:O"?"7_ "</K/\ OW->[4 %%%% !1110 44
M44 %%%% 'G/QN_Y)S+_U]1?S-:_PM_Y)KHG_ %Q;_P!#:LCXW?\ ).9?^OJ+
M^9K7^%O_ "371/\ KBW_ *&U '7T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'A/A+_DX?6?]^YKW:O"?"7_ "</K/\ OW->[4 %%%% !1110 4444 %%%%
M'G/QN_Y)S+_U]1?S-:_PM_Y)KHG_ %Q;_P!#:LCXW?\ ).9?^OJ+^9K7^%O_
M "371/\ KBW_ *&U '7T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO4: "BL.[\9^&K'4/L%UKEA#= [6C>=05/H?0_6KE_KNF:7]E^W7L,'VMQ'
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M **** "BBB@ HHHH \)\)?\ )P^L_P"_<U[M7A/A+_DX?6?]^YKW:@ HHHH
M**** "BBB@ HHHH \Y^-W_).9?\ KZB_F:U_A;_R371/^N+?^AM61\;O^2<R
M_P#7U%_,UK_"W_DFNB?]<6_]#:@#KZ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!SC&< X)QWQFGCPGH(TV[TX:9!]CO)/-N(<';(^0<GWR!^5 SR?QMH>FZ/\
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MPLN/M5Q:Z1KFB7]]N68J#=*3SP3Z8SQD9],U[E!#';01P0HJ11J$1%& H P
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M* "BBB@ HHHH \Y^-W_).9?^OJ+^9K7^%O\ R371/^N+?^AM61\;O^2<R_\
M7U%_,UK_  M_Y)KHG_7%O_0VH Z^BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \)\)?\G#ZS_OW->[5X3X2_Y.'UG_?N:]VH **** "BBB@ HHHH **** .+
M^*VD3ZS\/=1AMD+S0[;A4 R6"'+#_OG-87P8\7:??>%;?0I)TCU&R+*(F.#*
MA8L&7UQG!^GO7J->5>*O@CIFKWSW^CWATR>1MSQ>7OB+>J@$%?PR/:@#U6BO
M"O\ A1WB+_H:(O\ R)_C1_PH[Q%_T-$?_D3_ !H&>ZT5X5_PH[Q%_P!#1'_Y
M$_QH_P"%'>(O^AHC_P#(G^- 'NM%>%?\*.\1?]#1'_Y$_P :/^%'>(O^AHC_
M /(G^- 'NM%>%?\ "CO$7_0T1_\ D3_&C_A1WB+_ *&B/_R)_C0![K17A7_"
MCO$7_0T1_P#D3_&C_A1WB+_H:(__ ")_C0![K17A7_"CO$7_ $-$?_D3_&C_
M (4=XB_Z&B/_ ,B?XT >ZT5X5_PH[Q%_T-$?_D3_ !H_X4=XB_Z&B/\ \B?X
MT >ZT5X5_P *.\1?]#1'_P"1/\:/^%'>(O\ H:(__(G^- 'NM%>%?\*.\1?]
M#1'_ .1/\:/^%'>(O^AHC_\ (G^- 'NM%>%?\*.\1?\ 0T1_^1/\:/\ A1WB
M+_H:(_\ R)_C0![K17A7_"CO$7_0T1_^1/\ &C_A1WB+_H:(_P#R)_C0![K1
M7A7_  H[Q%_T-$?_ )$_QH_X4=XB_P"AHC_\B?XT >ZT5X5_PH[Q%_T-$?\
MY$_QH_X4=XB_Z&B/_P B?XT >ZT5X5_PH[Q%_P!#1'_Y$_QH_P"%'>(O^AHC
M_P#(G^- 'NM%>%?\*.\1?]#1'_Y$_P :/^%'>(O^AHC_ /(G^- 'NM%>%?\
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M?"@Y_#UKW>LW0M!T[PWI46FZ7;B&WCYQU+'NS'N36E0(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cik0001389545-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +KIpo7xRiXgen8uAZHZcOaaOKbPtxZ976ekhsmR9bSlqbykq/+W7SCAH9QAGkdMA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:CIK0001389545="http://CIK0001389545/20241231" elementFormDefault="qualified" targetNamespace="http://CIK0001389545/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://CIK0001389545/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cik0001389545-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cik0001389545-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cik0001389545-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="CIK0001389545_PEOAddEquityAwardAdjustmentsMember" name="PEOAddEquityAwardAdjustmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CIK0001389545_NEOAddEquityAwardAdjustmentsMember" name="NEOAddEquityAwardAdjustmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" name="PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CIK0001389545_PEOTotalEquityAwardAdjustmentsMember" name="PEOTotalEquityAwardAdjustmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" name="PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" name="NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CIK0001389545_NEOTotalEquityAwardAdjustmentsMember" name="NEOTotalEquityAwardAdjustmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" name="NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cik0001389545-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cik0001389545-20241231.xsd#Cover" roleURI="http://CIK0001389545/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://CIK0001389545/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOAddEquityAwardAdjustmentsMember" xlink:label="loc_CIK0001389545PEOAddEquityAwardAdjustmentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545PEOAddEquityAwardAdjustmentsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOAddEquityAwardAdjustmentsMember" xlink:label="loc_CIK0001389545NEOAddEquityAwardAdjustmentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545NEOAddEquityAwardAdjustmentsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:label="loc_CIK0001389545PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOTotalEquityAwardAdjustmentsMember" xlink:label="loc_CIK0001389545PEOTotalEquityAwardAdjustmentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545PEOTotalEquityAwardAdjustmentsMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:label="loc_CIK0001389545PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:label="loc_CIK0001389545NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOTotalEquityAwardAdjustmentsMember" xlink:label="loc_CIK0001389545NEOTotalEquityAwardAdjustmentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545NEOTotalEquityAwardAdjustmentsMember" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:label="loc_CIK0001389545NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:type="arc" order="70" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cik0001389545-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOAddEquityAwardAdjustmentsMember" xlink:label="CIK0001389545_PEOAddEquityAwardAdjustmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CIK0001389545_PEOAddEquityAwardAdjustmentsMember" xlink:to="CIK0001389545_PEOAddEquityAwardAdjustmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CIK0001389545_PEOAddEquityAwardAdjustmentsMember_lbl" xml:lang="en-US">P E O Add Equity Award Adjustments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOAddEquityAwardAdjustmentsMember" xlink:label="CIK0001389545_NEOAddEquityAwardAdjustmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CIK0001389545_NEOAddEquityAwardAdjustmentsMember" xlink:to="CIK0001389545_NEOAddEquityAwardAdjustmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CIK0001389545_NEOAddEquityAwardAdjustmentsMember_lbl" xml:lang="en-US">N E O Add Equity Award Adjustments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:label="CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:to="CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_lbl" xml:lang="en-US">P E O Periodoverperiod Change In Fair Value Of Equity Awards Granted In Prior Periods That Vested In The Period [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOTotalEquityAwardAdjustmentsMember" xlink:label="CIK0001389545_PEOTotalEquityAwardAdjustmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CIK0001389545_PEOTotalEquityAwardAdjustmentsMember" xlink:to="CIK0001389545_PEOTotalEquityAwardAdjustmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CIK0001389545_PEOTotalEquityAwardAdjustmentsMember_lbl" xml:lang="en-US">P E O Total Equity Award Adjustments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:label="CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:to="CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_lbl" xml:lang="en-US">P E O Periodoverperiod Change In Fair Value Of Outstanding And Unvested Equity Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:label="CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:to="CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_lbl" xml:lang="en-US">N E O Periodoverperiod Change In Fair Value Of Equity Awards Granted In Prior Periods That Vested In The Period [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOTotalEquityAwardAdjustmentsMember" xlink:label="CIK0001389545_NEOTotalEquityAwardAdjustmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CIK0001389545_NEOTotalEquityAwardAdjustmentsMember" xlink:to="CIK0001389545_NEOTotalEquityAwardAdjustmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CIK0001389545_NEOTotalEquityAwardAdjustmentsMember_lbl" xml:lang="en-US">N E O Total Equity Award Adjustments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:label="CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:to="CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_lbl" xml:lang="en-US">N E O Periodoverperiod Change In Fair Value Of Outstanding And Unvested Equity Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Pay-Versus-Performance Relationship</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="ecd_AwardTmgDiscLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgDiscLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgDiscLineItems_lbl" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cik0001389545-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cik0001389545-20241231.xsd#Cover" roleURI="http://CIK0001389545/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://CIK0001389545/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOAddEquityAwardAdjustmentsMember" xlink:label="loc_CIK0001389545PEOAddEquityAwardAdjustmentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545PEOAddEquityAwardAdjustmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOAddEquityAwardAdjustmentsMember" xlink:label="loc_CIK0001389545NEOAddEquityAwardAdjustmentsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545NEOAddEquityAwardAdjustmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:label="loc_CIK0001389545PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOTotalEquityAwardAdjustmentsMember" xlink:label="loc_CIK0001389545PEOTotalEquityAwardAdjustmentsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545PEOTotalEquityAwardAdjustmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:label="loc_CIK0001389545PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:label="loc_CIK0001389545NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOTotalEquityAwardAdjustmentsMember" xlink:label="loc_CIK0001389545NEOTotalEquityAwardAdjustmentsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545NEOTotalEquityAwardAdjustmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0001389545-20241231.xsd#CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:label="loc_CIK0001389545NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CIK0001389545NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEF 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NOVABAY PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001389545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance Disclosure, Table</a></td>
<td class="text"><p id="xdx_80D_eecd--PvpTableTextBlock_dU_zVK71DJ6giP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Pay-Versus-Performance Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In accordance with the SEC&#8217;s rules, the below table sets forth the following information for the fiscal years ended December&#160;31, 2024, 2023 and 2022: (i) the total compensation paid to the Company&#8217;s principal executive officer, the Chief Executive Officer (or &#8220;<b><i>CEO</i></b>&#8221;), and the non-CEO NEOs, as provided on the &#8220;Summary Compensation Table&#8221; provided in this Proxy Statement (and, as relates to the fiscal year ended December&#160;31, 2022, the &#8220;Summary Compensation Table&#8221; provided in the Company&#8217;s 2024 Proxy Statement filed with the SEC on April&#160;18, 2024 (the &#8220;<b><i>2024 Proxy Statement</i></b>&#8221;)); (ii) the compensation &#8220;actually paid&#8221; to the CEO and the non-CEO NEOs, which reflects certain adjustments based on SEC rules and as described in the footnotes below; (iii) the Company&#8217;s total stockholder return (&#8220;<b><i>TSR</i></b>&#8221;); and (iv) the Company&#8217;s net loss. The &#8220;Summary Compensation Table&#8221; and the compensation actually paid amounts do not reflect the actual amounts of compensation earned by, or paid to, our NEOs during the applicable years, but rather are amounts determined in accordance with Item 401(v) of Regulation S-K. The Compensation Committee did not consider the pay-versus-performance disclosure when making its incentive compensation decisions for 2024. For information regarding the decisions made by the Compensation Committee with respect to compensation for 2024, please see the &#8220;Compensation Discussion &amp; Analysis&#8221; provided elsewhere in this Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" id="xdx_30D_zheUtsSgpCRk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure">
  <tr style="vertical-align: bottom">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="color: #1F4E79">Fiscal Year</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="color: #1F4E79"><b>Summary<br/> Compensation<br/> Table Total -<br/>CEO<sup>(1)</sup></b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Compensation<br/> &#8220;Actually Paid&#8221;<br/> Total -<br/>CEO<sup>(2)</sup></b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Summary<br/> Compensation<br/> Table Total -<br/>Non-CEO</b></span></p>
        <p style="margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>NEO Average<sup>(3)</sup></b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Compensation<br/> &#8220;Actually Paid&#8221;<br/> Total - Non-CEO<br/>NEOs<sup>(4)</sup></b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>NBY TSR<sup>(5)</sup></b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Fiscal Year</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Net Loss</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>(in thousands)<sup>(6)</sup></b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; width: 28%; text-align: left">2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98A_eecd--PeoTotalCompAmt_c20240101__20241231_zJ6vdCxufyJ4" style="padding-right: 0pt; width: 9%; text-align: right">365,177</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_980_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_zpRSHvfe2j9h" style="padding-right: 0pt; width: 9%; text-align: right">366,461</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_zMPRL4EDpmJk" style="padding-right: 0pt; width: 9%; text-align: right">220,196</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_zDT6vn4AmlOb" style="padding-right: 0pt; width: 9%; text-align: right">220,295</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98B_eecd--TotalShareholderRtnAmt_pp2p0_c20240101__20241231_z20OrPK2GR1c" style="padding-right: 0pt; width: 9%; text-align: right">0.13</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231_z7f8Gca9NlIh" style="padding-right: 0pt; width: 9%; text-align: right">(7,223</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_989_eecd--PeoTotalCompAmt_c20230101__20231231_zTgkfwAXnSY2" style="padding-right: 0pt; text-align: right">364,146</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_982_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_zAB2JBikIvC" style="padding-right: 0pt; text-align: right">358,857</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98F_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_zFion8p2wFR8" style="padding-right: 0pt; text-align: right">190,840</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_983_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_zm1HBvnVBCPd" style="padding-right: 0pt; text-align: right">189,734</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_988_eecd--TotalShareholderRtnAmt_pp2p0_c20230101__20231231_zLfXdsLmYs02" style="padding-right: 0pt; text-align: right">0.84</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231_z4XtUCUnjFo8" style="padding-right: 0pt; text-align: right">(9,640</td>
    <td style="padding-left: 0pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left">2022</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_984_eecd--PeoTotalCompAmt_c20220101__20221231_zxzEfROoczb5" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">364,954</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_984_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_zdJlkvkoL43j" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">111,489</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_989_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_zUWcFU6a7df" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">259,285</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_98F_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_zvlPcLzB31dj" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">108,806</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_988_eecd--TotalShareholderRtnAmt_pp2p0_c20220101__20221231_zFewj2blZiUj" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">7.99</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">$</td>
    <td id="xdx_98B_eus-gaap--NetIncomeLoss_pn3n3_c20220101__20221231_z1MkfTqtxoIg" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(10,608</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></td>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(1)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Reflects compensation amounts reported in the &#8220;Summary Compensation Table&#8221; provided in this Proxy Statement and, as relates to the fiscal year ended December&#160;31, 2022, the 2024 Proxy Statement for our CEO, Mr.&#160;Hall.</td> </tr>
  </table>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></td>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(2)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Compensation actually paid (as defined by SEC rules) to the CEO for each period presented reflects the amount set forth in column (1), adjusted as set forth below in the Reconciliation of Compensation Actually Paid Table.</td> </tr>
  </table>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></td>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(3)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Mr.&#160;Law, our Interim Chief Financial Officer during such fiscal year was our only non-CEO NEO in fiscal year 2024. Mr.&#160;Law, our Interim Chief Financial Officer during such fiscal year, Dr. Kunin, our former Chief Product Officer, and Mr.&#160;Jones, our former Chief Financial Officer, were our non-CEO NEOs in fiscal year 2023. Dr. Kunin and Mr.&#160;Jones were our non-CEO NEOs in fiscal year 2022. Mr.&#160;Law was appointed our Interim Chief Financial Officer effective February&#160;16, 2023 (and subsequently our Chief Financial Officer effective August&#160;19, 2025) after Mr.&#160;Jones resigned as Chief Financial Officer effective February&#160;15, 2023. Since his resignation, Mr.&#160;Jones has continued to serve as a consultant to the Company pursuant to a consulting agreement. Dr. Kunin was appointed our Chief Product Officer effective November&#160;5, 2021 and resigned effective November&#160;5, 2023. Amounts in 2023 and 2022 for the NEOs other than the CEO are weighted-averages based on the number of days applicable NEOs served.</td> </tr>
  </table>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></td>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(4)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Average compensation actually paid (as defined by SEC rules) to the Company&#8217;s NEOs (except the CEO) for each period presented reflects the amount set forth in column (3), adjusted as set forth below in the Reconciliation of Compensation Actually Paid Table.</td> </tr>
  </table>



<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></td>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(5)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Reflects the TSR of a $100 investment in the Company from the beginning of fiscal year 2022 through each of the fiscal years ended December&#160;31, 2024, 2023 and 2022. The Company&#8217;s TSR includes share price depreciation, but does not include dividend reinvestment as the Company did not pay any dividends in the 2024, 2023 or 2022 fiscal years.</td> </tr>
  </table>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></td>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(6)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">Reflects &#8220;Net loss&#8221; in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss included in the Company&#8217;s Annual Reports on Form 10-K for the fiscal years ended December&#160;31, 2024, 2023 and 2022.</td> </tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">$ 365,177<span></span>
</td>
<td class="nump">$ 364,146<span></span>
</td>
<td class="nump">$ 364,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="nump">$ 366,461<span></span>
</td>
<td class="nump">358,857<span></span>
</td>
<td class="nump">111,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote</a></td>
<td class="text"><p id="xdx_84F_eecd--AdjToPeoCompFnTextBlock_dU_zLX3LaMsXai7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Reconciliation of Compensation Actually Paid Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table details the applicable adjustments that were made to determine compensation actually paid (amounts are weighted-averages for the NEOs other than the CEO in 2023 and 2022 based on the number of days served):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" id="xdx_30F_zwDGAMaCsm51" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure">
  <tr style="vertical-align: bottom">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="color: #1F4E79"><b>Reporting Period</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Reported Summary<br/> Compensation<br/> Table Total</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>($) </b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="color: #1F4E79"><b>Deduct: Reported<br/> value of equity<br/> awards</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="color: #1F4E79"><b>($)(a)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>Add: Equity award</b></span></p>
        <p style="margin-top: 0; margin-bottom: 0"><span style="color: #1F4E79"><b>adjustments<br/> ($)(b)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="color: #1F4E79"><b>Deduct: Reported<br/> change in the<br/> actuarial present value<br/> of pension benefits</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="color: #1F4E79"><b>($)(c)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center"><span style="color: #1F4E79"><b>Add: Pension<br/> benefit adjustments<br/> ($)(c)</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center"><span style="color: #1F4E79"><b>Compensation<br/> actually paid<br/> ($)</b></span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"><span style="color: #1F4E79"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td colspan="9" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"><i>CEO</i></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 34%; text-align: left">2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_989_eecd--PeoTotalCompAmt_c20240101__20241231_zbGJVPU2tWZ" style="padding-right: 0pt; width: 8%; text-align: right">365,177</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 8%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--PEOAddEquityAwardAdjustmentsMember_zqTAdmBGRjAf" style="padding-right: 0pt; width: 8%; text-align: right">1,284</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 8%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 8%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_zEzH0bzp5ysk" style="padding-right: 0pt; width: 8%; text-align: right">366,461</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eecd--PeoTotalCompAmt_c20230101__20231231_zb6BD0UGmu41" style="padding-right: 0pt; text-align: right">364,146</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98D_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOAddEquityAwardAdjustmentsMember_z8YfLYHU56Ve" style="padding-right: 0pt; text-align: right">(5,289</td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_zdg4jM5klEEe" style="padding-right: 0pt; text-align: right">358,857</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2022</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_987_eecd--PeoTotalCompAmt_c20220101__20221231_zf21MH2Ehqzc" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">364,954</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_984_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOAddEquityAwardAdjustmentsMember_zlpFhXVcWVV3" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(253,465</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_988_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_zEnH7X0Xgnpb" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">111,489</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td colspan="19" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"><i>NEOs (except the Chief Executive Officer)</i></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2024</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_z852ZOUARH0f" style="padding-right: 0pt; text-align: right">220,196</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98E_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--NEOAddEquityAwardAdjustmentsMember_zw2GPfpQ7mf9" style="padding-right: 0pt; text-align: right">99</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98D_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_zsYMwFmHDqrd" style="padding-right: 0pt; text-align: right">220,295</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_z9D9wnn5Pywd" style="padding-right: 0pt; text-align: right">190,840</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98E_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOAddEquityAwardAdjustmentsMember_z7LtCpKsyzv4" style="padding-right: 0pt; text-align: right">(1,106</td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_988_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_zyAX1Gvdve25" style="padding-right: 0pt; text-align: right">189,734</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2022</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_zyV2SflyV4N2" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">259,285</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_98E_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOAddEquityAwardAdjustmentsMember_zuYVTguDNjV3" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(150,479</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_z3phWdgUELs9" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">108,806</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></td>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(a)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">As provided in the &#8220;Summary Compensation Table&#8221; provided in this Proxy Statement and, as relates to the fiscal year ended December&#160;31, 2022, the 2024 Proxy Statement. No equity awards were granted to any NEO in the 2024 or 2023 fiscal years.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>





<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></td>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(b)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">The equity award adjustments for each applicable period include the subtraction of the following (amounts are weighted-averages for the NEOs other than the CEO in 2023 and 2022 based on the number of days served):</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" id="xdx_30F_zQ1JJDczYUCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure">
  <tr style="vertical-align: bottom">
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="color: #1F4E79">Reporting Period</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Period-end fair<br/> value of equity<br/> awards granted<br/> during the period</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Changes in value<br/> of prior years&#8217;<br/> awards unvested at<br/> fiscal year end</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Fair value as<br/> of vesting date<br/> of equity awards granted and vested<br/> in the period</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Change in value<br/> of prior years&#8217;<br/> awards that vested<br/> in year reported</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Fair value at<br/> the end of<br/> the prior period<br/> of equity awards<br/> that failed to meet<br/> vesting conditions<br/> in the period</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Value of dividends<br/> or other earnings<br/> paid on stock or<br/> option awards not<br/> otherwise reflected<br/> in fair value or<br/> total compensation</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"><span style="color: #1F4E79">&#160;</span></td>
    <td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>Total equity award adjustments</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: #1F4E79"><b>($)</b></span></p></td>
    <td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"><span style="color: #1F4E79">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td colspan="8" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"><span style="font-size: 10pt"><i>CEO</i></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 30%; text-align: left">2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_981_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zLAEag9WlLml" style="padding-right: 0pt; width: 7%; text-align: right">1,284</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="padding-right: 0pt; width: 7%; text-align: right">-</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98F_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--PEOTotalEquityAwardAdjustmentsMember_zdHkWb9fRMI8" style="padding-right: 0pt; width: 7%; text-align: right">1,284</td>
    <td style="padding-left: 0pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_zzufJCWS94Ea" style="padding-right: 0pt; text-align: right">(2,974</td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98F_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zoBlt3R53zh" style="padding-right: 0pt; text-align: right">(2,315</td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_984_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOTotalEquityAwardAdjustmentsMember_zlyDt8wZHzF6" style="padding-right: 0pt; text-align: right">(5,289</td>
    <td style="padding-left: 0pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2022</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_zgbLfrvl1M5" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(236,113</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_980_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_z1tMKdp6DQPl" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(17,352</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_986_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOTotalEquityAwardAdjustmentsMember_z7aCWywn4v95" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(253,465</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td colspan="18" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"><span style="font-size: 10pt"><i>NEOs (except the Chief Executive Officer)</i></span></td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2024</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zEwIfdRqd8Gg" style="padding-right: 0pt; text-align: right">99</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_986_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--NEOTotalEquityAwardAdjustmentsMember_z9F3sGC5wqw6" style="padding-right: 0pt; text-align: right">99</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: Gainsboro">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_z09B9dZovWOh" style="padding-right: 0pt; text-align: right">(83</td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_984_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zIbf4Gs9mizg" style="padding-right: 0pt; text-align: right">(1,023</td>
    <td style="padding-left: 0pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="padding-right: 0pt; text-align: right">-</td>
    <td style="padding-left: 0pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_987_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOTotalEquityAwardAdjustmentsMember_zWgAdfI9kx5d" style="padding-right: 0pt; text-align: right">(1,106</td>
    <td style="padding-left: 0pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">2022</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_98A_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_zGEBBUQOJdvb" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(134,736</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zsxtw1BaC56i" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(15,743</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">-</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid">&#160;</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left">&#160;</td>
    <td id="xdx_98F_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOTotalEquityAwardAdjustmentsMember_zWBWYRKTtyY3" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right">(150,479</td>
    <td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></td>
    <td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><sup>(c)</sup></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0in">In the periods presented and consistent with the &#8220;Summary Compensation Table&#8221; provided in this Proxy Statement and, as relates to the fiscal year ended December&#160;31, 2022, the 2024 Proxy Statement, the Company did not have: (i) a change in the actuarial present value of the accumulated benefit under any defined benefit or actuarial pension plans or (ii) any service cost or prior service cost related to any defined benefit or actuarial pension plans.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="nump">$ 220,196<span></span>
</td>
<td class="nump">190,840<span></span>
</td>
<td class="nump">259,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="nump">$ 220,295<span></span>
</td>
<td class="nump">189,734<span></span>
</td>
<td class="nump">108,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock', window );">Pay-Versus-Performance Relationship</a></td>
<td class="text"><p id="xdx_844_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zO74glgJuvp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #1F4E79"><b><i>Pay-Versus-Performance Relationship</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company believes the table above shows the alignment between compensation actually paid to the CEO and our other non-CEO NEOs and the Company&#8217;s performance. The charts below show, for the past three years, the relationship of the CEO and the other non-CEO NEOs compensation &#8220;actually paid&#8221; and (i) the Company&#8217;s TSR and (ii) the Company&#8217;s net loss.</p>







<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img alt="" src="img_003.jpg" style="height: 300px; width: 550px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsNetIncomeTextBlock', window );">Compensation Actually Paid vs. Net Income [Text Block]</a></td>
<td class="text"><p id="xdx_84D_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zqmvdVCgeie" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img alt="" src="img_004.jpg" style="height: 309px; width: 550px"/></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">0.84<span></span>
</td>
<td class="nump">7.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">(7,223,000)<span></span>
</td>
<td class="num">(9,640,000)<span></span>
</td>
<td class="num">(10,608,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=CIK0001389545_PEOAddEquityAwardAdjustmentsMember', window );">P E O Add Equity Award Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="num">(5,289)<span></span>
</td>
<td class="num">(253,465)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=CIK0001389545_NEOAddEquityAwardAdjustmentsMember', window );">N E O Add Equity Award Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">99<span></span>
</td>
<td class="num">(1,106)<span></span>
</td>
<td class="num">(150,479)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember', window );">P E O Periodoverperiod Change In Fair Value Of Equity Awards Granted In Prior Periods That Vested In The Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="num">(2,315)<span></span>
</td>
<td class="num">(17,352)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=CIK0001389545_PEOTotalEquityAwardAdjustmentsMember', window );">P E O Total Equity Award Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="num">(5,289)<span></span>
</td>
<td class="num">(253,465)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember', window );">P E O Periodoverperiod Change In Fair Value Of Outstanding And Unvested Equity Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,974)<span></span>
</td>
<td class="num">(236,113)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember', window );">N E O Periodoverperiod Change In Fair Value Of Equity Awards Granted In Prior Periods That Vested In The Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">99<span></span>
</td>
<td class="num">(1,023)<span></span>
</td>
<td class="num">(15,743)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=CIK0001389545_NEOTotalEquityAwardAdjustmentsMember', window );">N E O Total Equity Award Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="num">(1,106)<span></span>
</td>
<td class="num">(150,479)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember', window );">N E O Periodoverperiod Change In Fair Value Of Outstanding And Unvested Equity Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
<td class="num">$ (134,736)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsNetIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsNetIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CIK0001389545_PEOAddEquityAwardAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CIK0001389545_PEOAddEquityAwardAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CIK0001389545_NEOAddEquityAwardAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CIK0001389545_NEOAddEquityAwardAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CIK0001389545_PEOTotalEquityAwardAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CIK0001389545_PEOTotalEquityAwardAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CIK0001389545_NEOTotalEquityAwardAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CIK0001389545_NEOTotalEquityAwardAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure [Text Block]</a></td>
<td class="text">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_901_eecd--AwardTmgMethodTextBlock_c20240101__20241231_zkumahoDFW6g">The Board, upon the recommendation of the Compensation Committee, determined not to grant any equity awards for the 2024 fiscal year or 2023 fiscal year to any of its NEOs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_906_eecd--AwardTmgHowMnpiCnsdrdTextBlock_c20240101__20241231_zMaUyqNiQDwb">In connection with the Investment Transaction, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90A_eecd--AwardTmgPredtrmndFlag_dbF_c20240101__20241231_zTaXnd4h7ZB4"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90A_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20240101__20241231_z6V9AxSHXQNc"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90E_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_zDo4dVZl1X6h">no</span></span></span> equity awards were granted to any NEOs; however, as consideration for the Release Agreements, each Resigning Non-Employee Director is entitled to certain Equity Consideration subject to stockholders approving Proposal Seven (Director Equity Consideration Proposal) at this Annual Meeting, as further described below.</span></p> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMethodTextBlock', window );">Award Timing Method [Text Block]</a></td>
<td class="text">The Board, upon the recommendation of the Compensation Committee, determined not to grant any equity awards for the 2024 fiscal year or 2023 fiscal year to any of its NEOs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgPredtrmndFlag', window );">Award Timing Predetermined [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock', window );">Award Timing, How MNPI Considered [Text Block]</a></td>
<td class="text">In connection with the Investment Transaction, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90A_eecd--AwardTmgPredtrmndFlag_dbF_c20240101__20241231_zTaXnd4h7ZB4"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90A_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20240101__20241231_z6V9AxSHXQNc"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90E_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_zDo4dVZl1X6h">no</span></span></span> equity awards were granted to any NEOs; however, as consideration for the Release Agreements, each Resigning Non-Employee Director is entitled to certain Equity Consideration subject to stockholders approving Proposal Seven (Director Equity Consideration Proposal) at this Annual Meeting, as further described below.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgHowMnpiCnsdrdTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMethodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMethodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgPredtrmndFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgPredtrmndFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>25</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>8</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="novabay_def14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://CIK0001389545/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="novabay_def14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="novabay_def14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="novabay_def14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cik0001389545-20241231.xsd</File>
    <File>cik0001389545-20241231_def.xml</File>
    <File>cik0001389545-20241231_lab.xml</File>
    <File>cik0001389545-20241231_pre.xml</File>
    <File doctype="DEF 14A" isProxy="true" isUsgaap="true" original="novabay_def14a.htm">novabay_def14a.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img_001.jpg</File>
    <File>img_002.jpg</File>
    <File>img_003.jpg</File>
    <File>img_004.jpg</File>
    <File>proxy_001.jpg</File>
    <File>proxy_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="60">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>22
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "novabay_def14a.htm": {
   "nsprefix": "CIK0001389545",
   "nsuri": "http://CIK0001389545/20241231",
   "dts": {
    "schema": {
     "local": [
      "cik0001389545-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "cik0001389545-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cik0001389545-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cik0001389545-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "novabay_def14a.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 8,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 25,
   "entityCount": 1,
   "segmentCount": 8,
   "elementCount": 100,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 60,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 3
   },
   "report": {
    "R1": {
     "role": "http://CIK0001389545/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "novabay_def14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "novabay_def14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "novabay_def14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "novabay_def14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "novabay_def14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "novabay_def14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "novabay_def14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "novabay_def14a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r51",
      "r61",
      "r86"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r54",
      "r64",
      "r89"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r82",
      "r90",
      "r94",
      "r102"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r100"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://CIK0001389545/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://CIK0001389545/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay-Versus-Performance Relationship"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://CIK0001389545/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://CIK0001389545/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://CIK0001389545/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://CIK0001389545/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r51",
      "r61",
      "r86"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r48",
      "r58",
      "r83"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r82",
      "r90",
      "r94",
      "r102"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r106"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r106"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r106"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "CIK0001389545_NEOAddEquityAwardAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://CIK0001389545/20241231",
     "localname": "NEOAddEquityAwardAdjustmentsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "N E O Add Equity Award Adjustments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://CIK0001389545/20241231",
     "localname": "NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "N E O Periodoverperiod Change In Fair Value Of Equity Awards Granted In Prior Periods That Vested In The Period [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CIK0001389545_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://CIK0001389545/20241231",
     "localname": "NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "N E O Periodoverperiod Change In Fair Value Of Outstanding And Unvested Equity Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CIK0001389545_NEOTotalEquityAwardAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://CIK0001389545/20241231",
     "localname": "NEOTotalEquityAwardAdjustmentsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "N E O Total Equity Award Adjustments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r107"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r53",
      "r63",
      "r88"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r56",
      "r66",
      "r91"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r56",
      "r66",
      "r91"
     ]
    },
    "CIK0001389545_PEOAddEquityAwardAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://CIK0001389545/20241231",
     "localname": "PEOAddEquityAwardAdjustmentsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "P E O Add Equity Award Adjustments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://CIK0001389545/20241231",
     "localname": "PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "P E O Periodoverperiod Change In Fair Value Of Equity Awards Granted In Prior Periods That Vested In The Period [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CIK0001389545_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://CIK0001389545/20241231",
     "localname": "PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "P E O Periodoverperiod Change In Fair Value Of Outstanding And Unvested Equity Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CIK0001389545_PEOTotalEquityAwardAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://CIK0001389545/20241231",
     "localname": "PEOTotalEquityAwardAdjustmentsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "P E O Total Equity Award Adjustments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r38",
      "r48",
      "r58",
      "r83"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r49",
      "r59",
      "r84"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r50",
      "r60",
      "r85"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r47",
      "r57",
      "r67",
      "r92"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r42",
      "r52",
      "r62",
      "r87"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>23
<FILENAME>0001829126-25-007608-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001829126-25-007608-xbrl.zip
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M6W/B-A1^[TS_@]=]-N:2;#=LZ Y+DAVFR2:3D+1O&6$=0(V0J"1S^?>59)M
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M$D:-R#E9;&*S>=K-GUAW^X[]7/W$_KB)"&2__!=02P,$%     @ VX,W6T=
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MU"][,*#<,>)RD+W[Q0'K TKTZ7X0O7\O#MCHV]6+8]=/ ^^3[ ?]>_CBJ)G
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MP_<]Y[V_WUKWG+7><_^ZD[6SYC,S:U:>V?N9_>PD5]-7?P&W-53450!$1$2
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MWXB?%B>S^*T"&'0[Y6*\$'/V$*(SU[!\(C"M_1AHUH/_.2HG&. I%10%PL.
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M+?#!.4*?Z#N3S+X' C'F72YU:NF7^9:#?V.;[B;>- X*RY^M OQJ4?(9](Q
M\6,0,KZEQ6_\0>C/:QPZ%#]PHI5JJCE!KBPG0\H>K6+H6-RS_:D%,\338OT9
MCBHKY6W3P814QZ/Y/SUA1%)"CYTVP'=]4YOUEOD;GI$UV[SS/88+3)9*6^PJ
MFX*6[@H/O:,F4F:GS[*&[H][NOEQ?D-K$I1F<R[=N(9:FB$Q@717@$\GA0<
M@M<>=F4Y)&;8CN8"%%BS?/#O[\[A_SUG^W_W@<IE0L=?J:B^0.4'WHVTQ4@L
M9I2L])]7B$./,F?1J(\'@<"0^VL?W.621<;XMJ"&>6LWGY>]UROUJ3I&UR#W
MG)DOT0+G''5.OM&7-8Q+5NB&YN?@M5G4(:@-W7"AM'#=D]@(,D)XC.$GZ?_
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MW.Y.12\+3QOHS\.OE+S^+\2M"G%ZK8:>^:0_&RMY5GX\?1@2.7O9=M.ST"A
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MWA=0@[UY]X,5X<Z2*O;N[+'(GJNIX?AONV"TTQ(WG8;Q [9#%=T@C+Y UPB
MK_>\.%_A1?R:E0%.J@UNFSV6-=,L'%B6W<HXQ6Z]';NEAP.!3%G@84DX<*)X
M5+I8/,8'*U%J/@J"EGH_+A=\>L/=T5TO3!" O*N_;^2NVN[:@EV>/CJZXA&C
M+=3^EOK9*JF1E\:=QP2QDPUY(->XBD6HMW43!ZC!Y;-= I,3)?G>-$R\J1__
ME#?4E\2JA7[R<:Z;EQMI$'>TF;FKGTCV0H7H?\K"5!/OZ1#P9K5 W#'%$HIA
MTIRRE+;;DEBH56ENG&0FMEUG! <8*^$ FN9]1Y(9"0<V,I;U"3[<8IHNH]KF
M5#;4?YYC#,+%]H]^@^6I7B1N;_4XGJC=S4+5@!]:<Y6\*S/V31"?W)4\YV/V
M%<6/YJAZ++Q;X;%;[?PN+P\/%]P>@K@B;#U3_@/AW82(;*(%*7G+>O'>JS$\
MD^;&7YP4?:G20'?WT X.<-W+<G@]R!F\,X$Q%*"9)]"2KAL]_R-[K#!CVZ!5
M+SK0EV(;AC-.UUC9V!#_-;S//"["E'_H0</.4@DM0RUN0YR>4>Q]"E9P_YZ'
M1]$1-8,$X?N;/?W<64O7\298)_@'9^L4),['Y\0&646?\$K0,UYV4)\A-;PX
MF, .HC1($;(-HX>HG?P>KZ5;UTX[UX-?,\B=A/QER%X>@)DG&$>&-R=*SKAC
M7VOKG%+;'&<O?',8(BQ(F'DLN.,Z,WWT(]*.:LZ=^'Q!/-<XP4(0W94FZ!:4
M?+09M#I>#.&.5+"H'7T79.9,P55RUS6T?#6EN1Q-K%AZ5RD.I9+B8K.C]BA.
MD;4AH@P^.\L)VM_W1:>Y?M?-;U)W->_PZ>3BEEVOH(]QWC;J:S;=X/#)S4VC
M;A)*Y=AJ5:!B'R]G/<4^NQ ,4!<XQ2*=%0-GNMNI1LTC%7C[ZQN_(?)5_H'<
M>E)LAVFE)%:BUU,\+Y&KKRO1@.U9]T#<G8:\;@=YM#92HM^)2.Q$:T0$N[K\
MTLFG</Y1K,K"%_N>.XH-(D/Y::%K32R#KKM/9AGHA^^ZFVV$6*AEISH.GLX]
M7FB6685"2)&?D9I\C:B'[ B4K]=F5BE+V)K\7EOW6Q^Q]+E[*==1W]E,#OO$
M2UTF0QFOV9:C4F?<_)EY(X2[=X,H#LE%WVBR,LP\%;#O.ZF?5I; WR /^6L7
M*&\^EV,6$6$/HH9A3[=NT1:!EYSN1PAN8\$4+@W>6^IR\+"<QOV8L?G[F$$6
M#@O0J84ABUZ.51PPM70/XM_'-LJ>X2G.1.L1/QRXGV"D3.XC/J'D?A(:@G%I
MNZ'_#^A_0/\#^@LH^C?0*YB)#N2W'!J1[:\[N"'!]U^5)]Q=P&DM4\+X*@P%
MMS1%KX<M9GW8._ O*J*@,@H0(Z0.N%\-JRY3EK,SW=/E0E2?:J[U/T5&6^QL
MS1"-='#9%Y=5WI#Z1%_7^"(KC#$4K?;KCEN#Q+&!EAX7 1K*XY;@?)&L0F69
MH@/4Z;%QESLIM01M6[,0F1>=)7A,1!\]V1&3WZ:5[!"KJ7: 7CS1PY#'""'G
MO2Y8J=P:9%4'X0\<.LDWO2KX7CBSHZ)W4%?%M&;^4KIMZT$4\!7D.;'16M#R
MQ;OWK3T!2J/ZRRV@^';4S'.D+[:.G[<^/_W9>.Q+'VP+Y;Q&6\O;\M1-42^(
MLG:<LCQ-#:[-P7T-8_]M XG .9)'WU2K<NP+LL] $;F4D6=&F]G4!,\D=$:G
MR^Y)I\.SU^1^&&C'BN_3B4U.+L.67P O9M9<8"=8ZU=399I)81E<]9JO1CK$
M1QIW[GDZIE'^E^>M\0VNKV?E*Y+/C\V#9AZR,4>.X+D\]V-65M^#[',SJ364
MUP=MS'=K:.D)9'2JAP'TI>@KBITRMZAY.5#+2OTD/<G8QL /_$3?OLVY(]>N
MZAK00LUK YM(Z$+8/M9)?RR6MM>?)53>_GZ;CYB=U00'Y* ;7[!"3R-Q.S4F
M[;\7SZ 7\=L0E44&O%$@*>B!/L;*]7P$_'G7[P]2&S_4E!\].$QR8VEB85!>
M1.2#I)3>VJS(#4HOIAGL,/#:JH6)Y[\?9GOC ]K&E"\.RA#8P>G!+PY1D?S4
M'H']_COD2=.E3"GZ@)6*SH*6M!-^3RK2D]/>PYZO( C&$N2'XPK>?+VBYA%;
M""V4+="F&CWPP2H+7J,D@CD?C8_GE(S>X@>N72Q,JQ=;V(MBW'LOOW,417:E
MQ+B>/6B0W4RK3ZOA#;Q2O[CO!3++_L&6VS_<AD/O2B>IA4J^Y\G@>:K8^K#N
M)DJ (L]TWY!K<5IOV^UD>N&U29U_F$"&X1&D>#?XTG])^E;U+6L)3T]A>YVD
M$*KF3>0=EO5.Q^2:-\0TN9G5Q:7^9!V?9;#JW(U#5Z_S: C7QGW.J""_:$QH
M*:^+^:-L3.<LS:MZW>$QAJ.0&??.']^QC<CB'5\>O#Q\269;R8I]JXAHHR\^
M_CHDTYCNI@+#%7@@==/^M9'=THUGI"-GR,O"Q<B?P/TX=RZ#TZ?=#>G[;C=3
M8FO]AP[,R-28[U:(@D6]C7*5Y+JV"GR BE31CH/5?EY/OEYNBHN?M#A%>_F:
M*_>FIL#=TY_O=;3G.\A_<GGD:F5%,VIBJ,^E0S(4/N.G%"[.O5K.P&)FPB$I
MDL&Q*:?G\&< R(6!8K[J$@V4Y2@RR0TN/_Q0#?$'B.-8UN8_BO(-Q# (>&/Z
M\41W1GZ(^PC3*[DU4@B4MY9TV'GDS!MNCU5TX&VQOF/%Q=$I[T50=-F]TF32
M8&4[9)VRZ1J(B3CH(,\;O\XHT2RA2I9T=#.6P%/'P:]=5L28NRS2C>H&-+!/
MYN2BJ!7NA],MQM+@+XN7P:I1'8H?OC,Y#OCN@>8_G^.?V@4*L9DORU.^*Y&\
M(ME(-^&/;_9-#ZC?G532T$T9R=DX..=F9K8YG25DWC?%GFWSIU:>1JN4P%\G
M__S//D6I>\V&Z^HRY#7'T.^;BH\VY3Q4/U#P4@^+LC2M"\U*YHJA(S1S>:3E
M^<1S&/G3PK<\ZXNOF\L+L04=WIV;JN7@\I^X.\M!/Y%''ON 1KWYD>KM<G)\
M*9NJ&EN1-V(FJ8E7H4(9WEBY(,9 I4( , ($5(:1HV$CAL=4T^!I,=%3Y#QO
MAR K$6P=(8^?>.?[S\A3I"D*\&?=6]L:["+W5VHF2NTDFA0WF)6D\QO+(S+B
M8L<G<QHP<Q?\KEE@-[N\X7T.#@$#=3TT"$/-@/MA^)?DS15P!TWMP]:?7[RC
M#P)013]R'TP,6L)01D]])#'%S!H;&VIJGB:,ZO<W?7L"PULRW7'TV<W]QV-=
M*HP6Q$M<&P$Q\M":U1&-Q?.XDD2F(\_9*#\]Q ,UR&?K:%G7OM MZTDH:;NV
MR%O6#X(<-7;Q7L_?K=!^DCD@EQCL?HR.(^BI+GJI9L $!])=12^QX< D1(4S
M)RO6\H06K50^YP>-GA[+U$R"A\2/_05[IU:W4L^I,5_L"9I);[JO.[ADH_TH
M)UA%CU%ON]RG;AG9\.' D"#%+0H<V-4LN<25:AWVIK/YND/%+L0,!W9F[6>T
M/@VM:IE8H$HX5KX3LB 2S,[-"F,*V?]WCA/_3NP2> C?W7O:/-W"GYT0AOM(
M(%'7*T_]#'8PP()<@M2/)A9_GC&9^&7$J&_PBP1?NT *K)OW(TNSK<]K$Z!#
MB!%<CJQBI6'JZYB\DOCT##NU(F^RFE,Z19%*+-A$ EUM4E/OTKTK?#''?:LW
MKEL#;E]E":(/LIH2PX%^+:G/P5"*R<9E'=R?J9RY? <1Q R</[ >NB EU'#\
M+AN#J62"&*GT*/]6/H?B$E/A2 OI98HV9<*W$DK1X\G=-0J_'3!CDBS[?%S6
M>@6_[(XWPY*P;I=*<4C03!M%^H[8-XJ]Z!717$]PL C.UK4J;7=.CTJ]@6M=
MIZQ/8NNJ04!(>586O;JR7^$+H%3@<^E'@8+E]&,.;\'E$MX. ?NJL2^SZ6;Q
M]1XD$Y'OE"7L:V8;!55DM.\746GC7]8Y[O<V@@Z-I&_+7=V+8%Y;<.!BQQ#&
M^"'0R3&LX^<*Y.HP&PXL%H O"WG^?#^MJ7UC'3^XLLOP9%$*#K2JP &HVCNH
MYNW%"!PX'&^]57]Z@IX2IT$^A \>\J& W<G]=OKO5[CN *NMLI:7D#H<$#X%
MWYRQP0%\R5_P=B_JZR6,]_[,EN07N,3_96+4ROUS!+O>7%;9^9\=%9G.>)_+
MUZ)WUXEP("QKP1A,_4\=&^X1]7^51?]-,80W_P#@_<Y6 B_HKUU87)42DOEA
ML+.-U/,3N<K/Z;G+>AG=9:4BA.Z2JW0W]*\5W7-=8-73RFIYM)6T[6S.]AW+
M=!^^#?TL5:R=(8;,>O,>Q1=@-' I=#05#UWCANWDY^T_OP[_V5$NVR\S5K4<
MSD0" KMGH8%E&R7P"=[E%-^_%/'?KI#_+Y-0H6&D:[D\#7C:#=D4?VB&H/Q:
M%;SLI@,'AM%6?]\I9.HM;5T]!E]O+0Z,<^_<Z628#EQW*6R6PX'V@^K[.0>_
MY[>M7F4X@-XP!?/3I+A\TKILP"]!H9$W;:A5,'<N>JD_V7KZH.X_-BS11']E
MWD.?O3-^@SS)Z"8<#2-P@=P!I:)'E.#VZ$O]\S\]!>US=FBJH'$HL"(+*(Q:
M.Z*_KA;I^$V,LK\7H^6O8NB5EBQ#L"PU,.^^/*VK#1!Z8(*.^SW*OWR,.\UB
M.81 8?C ;BW1%>*T+DG]S$-FF)<Z-G9LM%)MJ]J+6"!>M?K'X3^1Z+C$0BY1
M8M*VZN=GSMEZ_3:C%WM@QKG*HQS$W]G&\?S&MORC4,Y>#W6,HIVL;21>J6R1
M>B/9T"WKKN$U@A[XMPW;0(JCQGWPUB.'W[>/\=MG+U]V%8".#/L6#*(1W[2+
M8"S.=WLB3F9.>;->^Y;DZ6A5ON%&P;%4;SD^V$$])6^)8U2S,VZ(CZG?$OTS
M(SSPGXVB&;NCK"/F?:35-R9!B&)N&_/BIM.3U5-=MCKXZ_43*#Z!ZC0<^,4M
MOWUPG0?!@9=,T;<H]VTY:59TD>H>6[':@1?%WXI?\I_BK\8IGUG[O-_%%TSO
M^24>I'YYR'T=ST<GP_C.),]IL8D!RK'8);"R'9K;_ZZ;YZ/T:!"I:81)8]_5
MO4@4M]&?P%-5K:,M?J7$1TII6:Y**:FV[6'TQ9C_ZM0RD(J1_&.$NQ_KR7:V
MTMC;DY+P)N/R*/6PC'$-B\AJM3%G7*P9WR'NTW 0J;\<'N;%-("Z_(JBE"GJ
M$IQOU2 :[=**:54![BR%:BJ-39E2%;1I*]DB#A,#9SI,8=':XU5#(5,Z&B4%
M06-T9:!^BKG"_6D'JDJ$&#6C:--!]5CMR9HM3^66> AWM,#2$"E[<?E+OR>%
MCPE<B3SX#[L MU/-N-V9O"AOX646%5!X6=#,^</RIF2^B,0GO<NRO872*CEG
MP-L&P2+P$ZNW$W;>,J0)J@N"^GI<((SR+XHQA'[(KH:M>DK(%A(>ZJV1U;VW
MZ,4+2%8'7'?&Q8_F/BYGURYD#SHC$JF;IK-W*WI.U$Z<D2B2+,Q*%?7[9,YL
MFUQ+S9+$Q]*\8T5V>>2W>ZF$G*F.::I=.5QUWM+,@?*JT(1O($([!'BD)$.3
MO%S,YFT!MLMR#_BV7A]UEAVSTRZ&IIO;&+'!\^.NCWT\]1KM5,8XRB;=A.F=
MT>ZGX:@@/WYC*,DKW@IM%&Y3%QQ4<H2OBLU*IR:-CLC-SCIO<VV*MB<OSM\-
MV@D@1U3$TWB][RWEO!\\8M9+P=/$BW#@%;>%1FM3/93_J"6>>S#"7AO]>VZE
M],"'QH^%0C^ 7IHCQ6<.+\E*\-=K=7HB3R^;&.P*];I ;FY%)$R1Y=174*/X
MCTMI.?Z]9#L]YS^:S1U6TU[LXB@^_V2#OYX[4":I91?Y.1L J!FV4XF!TT*F
M'V90A:H:<J")P H.X!88AYV+TKJV;/7C"!;T[LODS%\FJD.#0UG,H%BQYMF&
M+[_AC* F<*3,<&Z]<$BO0M@ZU4S2L4[GF.)J%NQLX.QGJ/O,/Y8JSA)9;X(R
MIW"WA+$I[-[EEI#@-KPS-:6Z(R^<LRP4_@HGO[:MPSB8)79(F!Y1\E\$,E;,
MP7WY784U\)YP8\J[P &*6#@P)0ESP?3*AQ+^=8Y*XV==&]^/Z7";)7Y).?-2
M\,8HN42V6/T] V/;VA-[B><HI_ILG9X%/HH=+:R2,105?3_&((-$Z!^=YG C
M*/14DY==, G:V( YDT8M,\2TXAPSBK:W3; 5V/D)3,1V,R7"%]KOL#W(0]*8
M8FX>L*(57T])&#$ITE/(>]Y,-'%9TWW2:< \Q>;<Z.1@8^'/'"*)-!+@<TV>
M'E]G:SKN#$:0L77ST#0A F!/ 3.*?NY-UX; _3C5+I +%_L<Z\]X$H2>+U]?
MN3F]RS6J2Z"UE99\1NP[^).U_3QL_T(@ _\R2,O;J4AO>XPR=&IO-("7I@\/
MZ:$;43Z$&ST_*TSN"EIHC9VCC6CWD\73Z'%7\/99J48&<\6<[*@\M0RUBP7_
M\P)5#>D,RX.?6YX7P5SA/KR=#&1-KJMO=)VL.,X^5ARCPE@6884GR<ERC05?
MM,SKXU?>V$@ZONQ18"2V#P^;"'-4\7R6%<;8^\>B*0CY #X6D8 #!J-P0/;Z
M00OX\KY)H5XS/-MG.X5D,@UT@9^<EBW>>P:_SSGP7YRA)G3<FCJ^+,74/EP"
M25-:9E7S;#H^[=[$:CPD11C+M;C,:-=LV&C.VCG7R=$@(%:MS"8QI?SXHH.)
M;'6=NMHE3@F9>R4:E2TTZ..QG@?GM#[S(!6&742$#$69<=>K55$4Q16^/=;3
M08FJ0<,W<?T6CKB.$1$<90<YFFH#V'+L $*,HO67N\8<\+#&?<E^@'MKB1@W
MWH1;NKM E*@XT22%EUB+*T%329MW,&)JU)>?$L1/&AOC-!LV/.7-6[@C\,._
M6&=QIF3CLQD6Z7!YD!C5/C,>SZO'<Q>E60S9Z;0)1#C2T^;ZA$^DRO%*=\*T
M0]01:6+]Z!'[SO1Q#ML]G^;:N4&848M!<D)NX78?/M1C++@J\)#5]1#U$FU4
M<[$72!3H3G>L8!+HCMGRELPW1X9UK%.JGAQ(&8\CO)_B7L3&'">DI V2. S2
M0#ZE*@CEBL1_2%E<C'^%&A?"V\(W"#@LD!_1A7 1:<HIXA$)<6*D+%>_\+UE
M=:0ZX6S?'(OA6^7>XG[4O%X]]U8.%/)6;"+;OLV7*L4N_Z>^],CL_.S ;C^S
M8Q'V&3",+&BQK"\^V^/F^]Q'9;YKHF&6NZR:^IVUXXO9ZYO5HT(8XY%K=OYN
MC2_5T4%IP]MR.^Q:UQA1#H:5'ZX--^02KLY*R/A>2\V:2L2DM3K7<FYY!G<-
M,N1C5%;LD9G()$\0_?A%SCC<.9;/%K$-YW:4A8C7*V;ET'3QV0N+&#_.1BD0
M;E(U7-,C_E@Y>MHP24Y873?YSF^854,Z65#C;H<J7O^G7?/[V>@2VRV#IXVC
M0J]*K6-WGLQ]A5#)T#"]4^UG;)1\?/(IJDE340+P.(A>(O,2:XQ5'+M5,#WJ
MD#77?05P=J-^CS3;R[G8O=TMKWJO%JW>&K-SL" O?.X3A1=2U.5_<O#N]J<P
MD^1?_FOJG] 5ZRY,E X.E$;>#KY2U0?WK,&!LY'6I'S0O%3([ZMV YFJ[%C)
M+6_.XLPWI_.T5[[J7S%PK7H 5@50>FF1]EO%AY?RX_'\&0\=;DTJ4R:(Q2Q_
M^%0-BN%H@DCBM5YRQ&*3()R=YE16IN_W2U@Y.)!Z]U&J2%/H.1@$,E=\AXJJ
MA:ZY&NYM(X@KL*^]']O56S]K'A!Y?+1V;9>RUBA]PL4/!Z(CIXEZO$WQ&;,]
M\;9S"U0[DYE=1>@2Y4>7TE]C=_>F-J9FTEU-*H\=2HSID@A&5[$MA/<+!H]K
M9N_6Q.KK7\8O58-2)N0DW=]S5$J4V7;/X?[@8 P./B.3/>P2$)C7\8GKLN!2
MQDKQ#L%;=5V-?=\V^,9:1"6->\!^3&M!5PQOZFEL%UXV>].G>,UKW,G$/8)6
MTQO#Z<T;WMOSXQ]#/QKD.:Y!K2B[GZPK95C*ZORZS4U<^PPW$(5%]-8TOI8_
MS\MV3U1ZFBS>;^.$2"4[2"T^N>XN[!J!<*GN)>6%W5OB%!8M.VY.3SUV\+DA
M48G2+DG*H4<V"!T47O"!YTB&*^^26J7GN/3G@>U#.(#5EJSG(2LUX'%W($K.
MR+0K14P19EXN>3*ER< 7X=W_6,N_AV\^NB_:$@Y =+%^0G:'>Z!(GVSRM+>&
M[# ['>=G*P=B4LOL9QTB'$Z+"ZIV;]Y&6E341>;" 0UR*MX[8= PB[%7XR(J
M[?3SY:KO'T0<J#EN9_G/ML.^Z0[J3(X*\]BPE#R3%V? B.$*G-2?;D\0ONK%
MR^8M6W_DE!:KT!K&8![3MTP=6M,[2(2 ]>6TP-8YI5^>9^;:79NR?GY]S061
M].XQJ+H^0=O;>#4_;7Y86_$8]U/W*-]Y,:;5YTO!#D/.)RK>)[!Y;IX96 /.
M4@QX2C4E*XS)]-EOWZ4;?JW:FW#@U[+>-* )Q9+#/+JOTGIYTO_T1-U?_EU!
M2KO,1U6RN2S*CK+4V-)[F$/MQ3?JQ8=389>;RU@?[MN]D.XT.S=6B(>0AH:D
M7(";['[$1[XE,QC^(?ZW'<;[Q3W<T_P3A@T7B49+;!2QA\AKBH"U863#G.WA
M;6+A]!3;+\;5@90OD?B4PX[AP,R# 8A_X/7\?$ZX$ZFOCD([1P[INA1RYJZ^
M19@OY;3[?5CSA+N8NW U9!N;A8II'7^3FHH==L;O]QWF5:((WC6C576^^,31
M_EC+CX2./ YA\9(W^J&EZ#G6>S@@4:)\Z;^T:T=\J;$K'\,'FR3PR1EHZGFV
M/63D26&J(83I\FC*__35PX)G<H3*-:G[1GY/?#"=,;ZIQ=@#WY_["7$N+489
MCPIQ%[J[:8KA'WP<&'F-1&ZDB_1"L,PI^O+)*>3-\.FL*+IE;4--3L+DA=-A
M\[B%!,#0+?O^;@) V(VX@) V)BHHSGB2=%H^2HJ7>\.^?I6NJ'?ZXP!6O0O&
MY=HM<5HNK;;ZNB&SYB<$HGC^LIC0?_<C2B9: AC7ABY%-N%0MJ%BM#H40\?G
MM#1']N<2!V(<YJQHKO[$K=NC]&:GS.T$MH*=R<GN'9!+$A5:*AC7Y=T3^T<>
M0QVK2Y GE[S251/R7=T0XV<15H<N#"YQ%/$QPM.(9&UMF]P6^E,E=BT<!I8C
MLSVYW_%34 ]7P^\8+U ()4C */RD_K%5$</(;LMP("39+E2(Q&6%161R?728
M=X;%5YD*GR2$Z!DY/^F)WBF8E$NW663T4''D#/2)>[CVDP;V3>KJHQ :LTW_
MU%3R^!YOHOJ Q65PQ&JR>N1PG[;6DI]QVYU[:>*YYPN(GZTQI41;JZLS]0:B
M]3Z-+Y*?@.!0*/O7W))9JP;N'[E/PUJW(1CYI23(E$]2RPCO:[# /HN%;A&?
M+9ZQ>:0>UDM)T&8KN=4DS\QDWBH;RB[XY\QZ_.HKK[Q&O^/OC5:6]UG>2VLO
MMKEM<)4UZ.20I27O@1*T(^>^8-G6W<.(2K@_"!C\.UL_F^C1B-80%T[4XB,S
M4UAY,W@^_WZN>SC1NEF=>'<+ACT/8QI3-_-8Z*.$ RC/B^" <''KX2H8R@5N
M1RV$ T,@MIO+Q5MY/.5],_+_P)3\%</M<,N_$FH2Q<^M9<#W0YG8@E+ZE,0]
M*TPAQU\U! [L8>'?9<Z!WTEM<NQS>!S61;_9WY8!+1_B_7PEQ--0_**+?R _
ME@_#QW<?3V73=.U5HCC4Q##W>!<[/$<_G"W]"GW[PM-+8RBPB:54?J5U7U]*
M*<CC*2_&AJ0%38'RA)0L?2Y#(T?V(V<3:P-<*,M AD73>$F>M-8^DB2B2-WL
MU$)\%05^RV>NR8E5GI>FO9PM<YX^"^GCRO+RT^D2#GD=+0PLZ&0ZS-]@^5>'
M-ZT7O@8,-J=8^#H&S6O$5<ISO2^.BP_K>UK[!_%4G5P?O^99[?"E;WP2'JG!
M(!3;(#S6VNN4&IU8:JW;C-55.]K!,EE).H3,3I#VHV-'Q*#E5%E*\/'K%^[@
M+G$K<^(F$VU)&K#P\>IP6M,X77L+%0^%L4!@>36&UFOS=P\\X0 FGO*/CD_X
MK?=^ ?_N%SO8\T38$WE-F)<V>+$;#JQ89F54?VR.>_7K'^_K):XZ'$B?-+R
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M^H;&SJ[NGMZ^_B\#HV/C$PCDCY^3"ZC%I>65U;7U#?3>_L'AT3'FY/0WOT
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M>=Q&M_3,5E1<3Z6\7Z:9?.)8#:6LQA"(-]J,G>K1=_I%#H6O5@WMY&1$W=T
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M74@P;2]JF]"W+N)9 G^Q]@0\T AMEWF)=H(7VTHZVI,X>?BG>!T.>H<]9N"
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M >-<HUC:,V.'"L.(%COC="FWI<S]?X+ C!^SZ"<O4'WQZ2=I4]MKMQD0'*<
ML7[%"ZO_W%"O CGH'#2/LLN!LW!9K#@T[P^SNQUU'']8C#52=?V;1A\]9QV7
M$U!#!:?P2'!%7YAY@D%"+^S<\@8I_2$P+SV* )5QX*7^RJ"+S7[Z:7F[;>M8
M>VT\\<#K!T6L':</K.@R_%A%]*^P?.R/A47^PNW1%Q7;AVC3+D5TO^?A;@1D
MC>(4D*S%@OUCJ,_Z=T-%P8?IO(_.E@&7!?[@B[1/9SO8GB_SH]+9HE=N4U!Y
M\AAGGX/L)YU@G8V< GY/.EBN_[<,_:3OP3/R32'&^5D4L*L_I].3O:'+W(*W
M+6*;>Q^7KG-X26=T)7[/%(5_V-'0]@Z#CYQWO^P-C1+4=0PZ715_.1D-F][?
M&U/TWY"*6;FZ_R46'V;V\120X^9"G75.(3<;[F;0.%)=K,UPY33DQ\NA,TTO
M(#9@*9@K7JAK"F+)LL&83I*?,&K^'D"",;75JA'C!"_MD/N&+(RXP-\ZKA:G
MN<=UD]EJJB_:]?*4_(5@?ZQ)9T'FKP%/^,]Q/SCU_ 7!WBH\$AUD/8;BUWXY
M0 F2 *S^F'\Z/(44<1VB^UEF(P6J ZC75UCDL:;(T#.'$^2ESBG G">Z2W+,
MKHYJFI=KD(YK=T;'85D_ #U*!N]\JFSGO3 4PA]*%6NS-?;ZVVP\8(Y'K88?
MD15H]3+IYMUGDM:HEX#\R^ZOEH7B!GE/^!4][\X@ABR_J.V+E2V+V\:# 0N6
MA>E(L5A'LSVM-;5W;4^^5!1";1'J=3E.+HVEVHG4T^LW.IJ0(>EAX\,I:TO=
MH+I[0MNM )MJ3C]CL>L-/HHWK<HN<DD#*R=\39;03(.EH;2+^T*\ Y--F2SQ
MO+<9>A?*7"[IS,?2":80:8L/K-<*3YN]B.'DV^U48#+W#-C+GHU#V7P;W1\[
MB3<>SZ.Q]=?SJ[9(D*RNB,!S5+7Q5OV&MHN)N:^ES7255?7IARV/^E*LIL89
MRZ<<-,=WW.D7CB4-MW!R(ZG6:GB=G)0]#R2 ']_CN"8+/)OE'*8JZ,46[B?'
M]1!,(09&MAPEMH6>O*OF'72)!'WW0SBP+B4..6PT14)P&C.;U HMB[F.N'=O
MU3RQA;_C9 ;ZEP&<3]H#>47U04+R]:'V%.FW C),E!F?MOA,UM 1RU-+!5L8
M5G(_?L_DR)OJLR(7!%"0!8NSFOZG&D6Q!+OP!%9\I%@8>;#(BMI%%&B+_:6N
MLTQ<<78,$:.X%!*+P+_,J5[![+-3J'XYS"_26C [BI'7V$1(,1O&.+?"\4AU
M$YYA].9[654(:MH/J]V ?13%B+S5KDN"F"(OJV^7$@'VPK."W$@S#^*QC27H
M/C/<[1#L:8 Y>0:X<>0ZZ6U;]C\(1FN-9RF@RVR/=R83:(&U:3M##'+W7,)L
MY897]&Y^.P4$[E,KAK5K3/!F3[\ .N/M%KXH&K2T9U>M+HW#^&6/6 L"!I6%
M6>&ADJE605;K)Y+WG)?47W*0&6/8(0/Z6Y$4WN\2L*7_J2(IA<F_#J]PGQ5)
M,;W^7)QC+$)L[K6L/AO:=:@\=0IH3X]OSWLK&+*L9L,'+'V&1J*RT;T^Q^U;
M^2[L"D8AT<XT#(C[GDYH54_3QI/90W51,E<FH#6CX;$4\09#!V3M.K!V*MJP
M#_118NW[R_,YRL$'5%ZXWX_5>87$7BAD9RPQ^5-WU=#AF>L-)F9WV28:_+UH
MR:\C2M$TA3A1[ ^)SX$_%6B-IF\R+K![4DM(DJEG2OS2?'^(W\S^,;JC,](P
MG5C).>L&D<WL1,/J_1+E8T^TW:]@/#6]=C$A)?$E24<.B"CJ[&8W?I&C*+L+
M\<$^Y*1/DQEJ+8$1L,A30#4[]031!Z"R+%@6O"!T5J_Z_*^2.S<%TG\4 .XW
M?H).'.Z1_8AJSF)D#DL&,PY/0E4[#" 49/K2YXWX,Q=;<:*T2,RI_ST]WO]2
M8:IR/WTI(%IYJV-*J<+"M?*:YH>K:GZ2.NE!U)6)\8-(("7J7N5 2RSBCG'Y
M7-+%N=@EG5C_6J7< X-C^[SJ-B*F\LC44P#!D2ZROQ)"B1(N0E[C[<H<LT#V
M??KD";.5C02WS.3Y.\Y#JSR;)OD'1.2NJMK[K1+'4XB@R0?#GEK,K8&>#+D]
MR'%V)*FK71R5N?@PV6TXP^G13'QYYQ7[HG:"V.O?3LS:8*7OE%OX#LU->\!I
MJ7Y.\[Y&@2T!S6RJWU73!>:K2:L0^7N4=1RW.7#^CT3NHPM/ ;-=&#"T;6CS
MGP*0\Z< 7T-'V.*'78P2AY%X80#]Z4<0I<\3IK#ORY=(>31X"G!2CFD%V::(
MLJ3LI%5"0"G*_<K_L%@?FYJ%1Q&O._GJ*>"[^WDM>(_Y4OT?>&BU[X!D.[HA
M%$/=["J_D?B?(OO(H-\'_@M>ZF]VCU,BZT%0E1>G /6I1T_/F>>'49),QY)B
MEU83TYZ$/KO=U5]T0Q]=AX=R;4<OYI/V5Z2< B!.IX )\E K_Z<,.;<QB+!-
MO(EYY3]7Q&,1ZT4K* W"2FM U;611H^VQ9H*Z,MZG$I U?"[C-H:"D*7</-(
MW8?;#<6IA#PA,*/!3+F,2K_!=[?,&-O$RD;]"5,'B$*X\$4MN@R&8=1;1U,M
MX,?ER*_8,ELO**=$\RHBCIJE-H]T'R];WH1<?6=;T^O! ^A2:7'QB,S6&AGG
M3@B.:3%/%SB"3SB_V$L6FC #=QW<V5M?>HKQ4^\.B!#LWC+%3LK+09CQ<3JZ
MLH21[RXKI.SG6P+;JM53'<GKQQ(<8T\T$(P(FB4M-!N#%=+*/TOL2OTL.^NB
M=!Z]6&EH+=\^25I&3$%!R$7\A3* E3FB-2;0U*HP ]_'%R=B2D(+H1]BUR6[
MQJ%VCV,N\D0S230!'1WHT:Z&=/2'96*E2^.NPCX;!M7,'IL.2WKOW5:-1]@;
M/;L/$D@A:DCYO/0T&S925_IT0M;G2+44<!X#L5#^^,=>JZ/4GSF3Q?_*%@__
MZ,B IGD1/,!0!UQYI+&]CD;!LR-1$O!B18C.K\X(7NU;W4EC)_"=06<XT*EB
M>C)U>C]B?DB^-5!4_(O$AAZ&.T,&F,21JS>XDE)"X+:9&<_5O;-K>Y)$V&?K
MY)I5F.[.NW)YF.HL,,CNT^&T'%D'P'#A*MB?W)"DVZP[O*T'S=/N=<M?G--8
MO&VW>8!-"V.3M06LN]97S$<U(OJW&+V%<-"\WE$Y-78"4<N*L7>C^W:OOIP-
MXM9S/M/UY?&?PGI4QRQ<>_DWZUP(*NT),\@9;P0MA425BUY7#1D:8)"6QWXW
M,%+^[$_ASOI(9!8JT*7AQ!7CQ_THX!<0RPI_[Z9$$<12,-O]6SKL+/1)QC\.
ME%5XYLJ]6/@'[?UWT]HP3XP^LCY0YW<9Q6@X"#^*G:;.^O%" <8K, W!#F+)
M_"$;G@:?F'O6LI8N-L"SCINBRMF$$[&6)/&@Y"TNHM@Q$3'_,$]WM4\BS4O,
M[D_%T/*_SR46&D,^03[ 4&88;P0<]UM$UQ78"#FDQ(B^E84CC9"?+I#+*0!=
M[PFU-3@%^#E\:PC=$F5+X#PJ/Z*VY]/?M=SAG6,<=:4]6)+$@9*/EXOL(\_N
MY/U;!@ZV")R=!.Y+/DOZ3;Q8V F].I%A-6.U^+"$>=\WOG\N[A9G3AH?%IR)
M*[.0MN0L;7.0SNAJ8>/294\'PIBM3'&Z;B/E?=>ZTZW)2X>Y==OGVHEC([+H
MGIKOU%,,O^BW"[B9-$615ZUITGW986E)U[X\SMK"E7?P&444ZE/VH4>TVS,B
M/&POD9Z6HH.\-2%K1&@D"0O)^S>?Q&!KNL8Y!3W3:[<0EE)X58GC[)>?AVM_
MS1X9SYUHDS*UEU*D4_/7?V_L)4A,(2%VPMW"%[,E:QE@QJA?5[2;?V*K#VF%
MQQRI1Q*N;E?'Q;WS"A+RV= ]U+OTS0<1;AC&=ZBDFBR)[2700XJ0SYA:HAZ\
M*L/C(,N8:$@ES%90DI\5XIL4"P6Q,W;0ST@]Q&99P)NL^8;U^5/C\:=^J8 X
M]FNI8EZ$O=AM]:HL/FE>;!(R$/#_;'VT?#/JQ>Z3"9>2LA&_+'GCF8M2..;W
M'2D;*2D6+-/,]>O,/-888V&9E4O4]'/*A;3(5S]RN5:TKOWS7@2L7/_0/WAR
M=NMX+NZS.YIV 3C(XM)Y"&8P0]SB.F!6?@)^0N,WP9B'<4O9GFU+^*//YD?_
MQH\DW-G54J9_,V^+0SN@Z:*2G7)]W$8'P\ANS!B;?Z35\>JU-UNR/H19*[K$
M/+ZV:RHL.59W"O)[$FKEOG5I-%/B=3WB*'\=2Q(&I$9L0EHZN^@BQI2-JXN7
M:D]V]H\T*B? CYRM>G4>1[0T$^9S77%FP/@E,E@1QX_HC?2=80D8K]H1434A
M*#G)G,Q&%%E+K#K JRUJT&?ULH!"<\2(9&Q%@Y_VV_#7:K&Z/"=#14X+=LE;
M'V1P3@9VR=>22)'KB3/20U2^9=^NFV:(*I29$7Q9[%HR(.T'<\O]C9X*S]_<
MA>!]\1WLNI<,*L'W#](XR)1T>VS/)$SB>PPG2/^OI&/9,39 >P*:/'2RW/HO
M-DR?X J&S<",&+2QGADO )6T4P X>8/ 4HAS-P>]">4("EL0=U&26)*TH8>(
M0S/^<?\(+L__^ZU]C/GUS,4N'><L\G&?I14S%'2FZ-Y?;[V'$:*$9T#Z._IX
M]E>)'G))_%*O1]GG%3&!HJ+:L,E)X]=,+5##<<!.E[T&2=RSF/NM<JF*("OV
MSDF96K[-I>JD]VU,E5P)V9&.[S/V]U.(I8L&.7CE;&S-[MNM8RWMDNNK(R_&
MIKZU.(:&QGG[TA8S(W*<S.R$?6MJ^P+U2_DW%#]8 M?W"DS:)FF+!NR*/7 C
M)F1>>]7":@!)@UB+IBM,LK,"-I7N[-@K[=3DL($QT9:0O@^"85P=#2KJ]@F9
M'S??[I-$UG'XC;M\4P->,J/(F=;$C4'RQ.*#E3LC#G=3B+PG9RZ_O^9T&^3K
M]^T3,J@QH5V(D%+!RB0\Q+(LD?$VUM'P@^?V]\*G%4@0&?X4)60!IP ;!?-E
M-]&TT?9I=J<KM9;SS;&W7VLF[6#57&A1:2IYV($4Z*C^,!](-&3B@(7'S P@
MFJ^R]F]-[]]X&1=\63M+DKEH)T]/J"IBJJF"7L723,N >633%(NF'4PP2>-9
M6G-US&THY/TI8*,@NO[>K:M4J"$2RXG:B@Z\ @OJX8?%]*1R6!;7I2H:#T$Z
M]D?#U-8F^GXKIIKK%NG6$9[^ O->0I]1SBF=#C>TX_"-$;>W>F*3]ZLU)&ZW
M*&DG!-Y6"]2P<4-6P(L+>(0O;D9J<I3*,8Q^ G"ZV1=P61P'0_SA%"'M;L.W
M1@-%5:D!*Y:U-BGCX]!J'6FN$2UZKJO),+O<1RPWOM-+D/=84)-'U9/&=W&D
MJX719EZ\+]XMD2-"9\\Q['O7**Y"FM0,^$B<9E#Y1V,6MZ*"/5VY2)/S#AF6
M*+G<L?+84,-&/+",HTX;?9ARN52-<TW.6OT44&^*'BS?M3Z>][K7I]IP?CK]
MYVQ C:3RS[.07[.QUXQ6)F\,U/(;<]JS:MV\>Y5<9UO=\_RZ IR9M:_\8F0^
MSX'(G;K<:7HSS>[\#\\0O)[3Y@>*(0E5_G!&F5/ 98VF.(Q=4N6YT5=X8=EV
M\"B>O6$Y7"0K+,=H1W353643@XK8T8:-OG0T198O<&'+^GC'HI$E:U=RG%X,
MMB>Z\9=A4XS/E#.M<(A*0)]0;\JR'*6M<Q8.K;I.H3@4"#Q[OD_M+_9A'JC2
ME+Q]R']RQ/LM2@ES%[$&C>*=.\E(TN;X@O0+H=!!B VWI22+E+R]VX[(<-?D
M)7L%6C/"YHS)I*$=;G/U]ALQW[XA=>QSC@4U=^X/)6I6<'2ZX\GJ2Z@VE*X%
M?:= Y4*'AA/N/Q"^@/TQ:+YW4GDNM"N>':<K%NW"OP!*X$3M6'>7[MWM'&N9
M2BL2&?5<2/>P<_YX"NB10BWNW16ME3_ZTV2(03-F;IOIDB:]7<,V9@%"(DL_
MKG*EH)_DXZ]1\9=M*:]ZT$T8\>")";F3><S(\M1^EPE+97R3N?1?X\Q<[I]%
M[7^23J:7I*5LEY;4@+^?RX9C^QYI[66W0=+2+Y6&V#]X(3&\+#P<9$%-GS>=
M^/CVN"5A@"WM2N_)%?=;]NPJ@Q5SJO;2.Z$&7;#"Y]N&C#CLGX^HV^RBPL"5
M]ASJ"^%C**FDE6:-:K&"S$=W+S"&*S =#^/[X..EM#K0<VS>C6=U[1*,M[CJ
M> W$(E;6CK/X6I@!/' EV"Z6*?;K5IY4UAB=)!59K4;=I3:;:L&W&+UU_/6'
M?7S>P7 R$-G&*OIFM2<-_2=+^]TF^<[] QH90H6C0@67Q5- &4?)&2"0;&Z@
M?F4T+6CJEX(LG-!_)%J31IILH\I]$#\9V*.#<>G[KF,T[Y,?BNZG4Z]BIN3]
M.6,']X=SGRK*DFNB7/']VKBK\A7EP1V.0PU247I?!!AZDF-YAFD&1,PD[!3@
MUGL!P1:[!ZW(\YSB\337=JDXV1:G-,W5_WFZ[^=T@&Y:SL_3H)^SL1R"_H,W
M>]6G>@:"'Q1C[C ).U3$\_J3HLXX\%IA#BN34NF+/=3@[]'[IV,.Q#[[-MJ+
ME#,/G:MZ<!"_NB=!V0/G40<U8.E:G?96:AF-,XEW3#>Q^5;X:EU(:G_017Q<
M4I]_J,J!@;.(TIE!RWX>*8YW]='G40B/F#^MCK?;+O:OH8#S+W-4">$7$8/'
MW0,KXM=^1$,D,M:6,"8KSS5;*06X%YWD':?Y,Y=+A,#,^CUA+TYVIM_NIR.5
M-UW_Z*-/3CN_^@X]O-CT.3HUN\MAY0O/612>#"=WS93Q85R%^<5"&/3K\HI7
MAS $O%/=.5AJ(2]K^B)>8/_Q:.>-VW6A %LTJ60]D@B:#_ZTJ?DD]]8%!W_1
M;M93  D$I1).:')RFWA%UURJ.#0[596(C!!+ANE!1XU1*!->8@$7"X[87N>Q
M7+.U,1$AO%$"Q1ZU>0H(?ED*(ST&*E]K=C:%79?2,]II=>P,L?'"PTZ)Z(9K
MN7VQ3'&DTWI'*D[[-#AU0O] 3LTUZD%/CF"<DO\-AXNQ4DAH*,2_OV-5CB(=
M^SK*3R7F^0#Y).$S0UJ[O6SJ[FZ9QX66.+*"DX:X:#NLKTYJ=_K<>.VSIS(2
MLL(+J$4;[E^,54KBI'%B<WY)WLC\FIV0KK.;/;/FS;KE[3<,G??XUMM>L5UA
MEP^6^:BM*8@3T6)HDT*D/-7.Q]CL-_$V+Z>=,LJRPVWN4RO&R,.?F$*QAQ/U
M#R>@ATIWF07;X35OS,SF#S/A6*R"XX94/?!\#]I>O$O,82_O; Z'X[]?EF)@
MT7YYV&Q(3K[@;Y5VX&E&T;3O$'*/#U+K_(4!O.X;G=NY<%D3-]$QH&VC&TK%
M^"&YR4M >X-F5._ )K5$BT$IY@'EJ'=BAP(>[X"3Q5-W]N9RA]>G@/S'A_59
M\?7EZCFLT1S/M8#UC "T_3.[%-P-.0PE&<1_+MR/8CC;0=,D*GF[RY--!".H
MDBP.5193+CICU*W(\%9ZA\+A?$.TV+\R9;LGA"3WX"EV;LI)CJM&ND8BRA##
MT;+$1X?@_MBVD <,3>$S/(I"!.R(J4<+JH86FAC!)HTQ@57.V S'LQ%'3* ?
MN%*Q4YA>F]%S5+;20[X->7,*^.Z,T6=GPQDUPW'!!SV&.)M\4@80AN7AK?PZ
MB8?CTZ\$EL#S'^T9#HX8UN%D]>QT:FAL*,9I 7_ \+%2-D9R2J5@>.)2G2\T
MF(*->ND10$H8WA#-@-K6[_CX$CB+Q/AF!>!DD@G0--4<\]DHA!6X$(]6/6+G
M?IZD[-G#B\K>BD0[%\XII'G]:08+UG]N0OHO"..C,'[?V<EZ5<\SP+K?7!*G
MW0\99/;AU<VN%6^'NHWD;7$":!T*H6Y_KI/3M6-IRP!'B(1X1.@9VCR]&)-0
M0=[)9G]_'>D((@HE2HN_(J"1Y=_2EF]9<CL%(TESEBJ]O06 LBS6E1Y1B6>A
M:))--(_8A?[709[V2^L6F5OI&%R@\A(.7#%/NA-Y"M!IR"GX8%]XS9-D)ZK!
M_QITU91#YZVB1W0XI+N<\Z=SU_ZWG+MTJFBQM(2?420Y@_2JRG,L0G^LW.Q0
MI4>6/6#'A? G()0/S^DL2[D7YR?U*9V#+ED2P'U.?/0_0)>SH_C?F0&: _TD
M=<@/Y)W'Q=M$G',! *JS'HYEF_Y_KN#/X\JM"O_"?1;@DFA[F=/0'V):?)P'
M)E:7#Z88^W[A?911@O0YV2L7@ICSH-:9B@KS;-#[VS%RHS>-L,I;C["O!3WM
M0Q03RT[ZH$5G3P%VZKS5= (>:8=*&,,1LT"WGQR<8_%AZ<\T>+WG_*^?K)W5
M)TYX3J^@<]9V)P/\G#&')04 N!" ?\;9P3F>GI:98-ZA\3>,>@N':IDK [P]
M3A72E7"[1?C7U,J*=[+9)S1TH8 7FD[H?EUES?6WFXC(@$G-O3>[!07'RJ4#
MJV#TO+V</=74R$(F>\_SX9??:^K*D/3O-B7Y*"1*V-YO) W!=0\\FK4&=A:?
M5;XHJ6!G,FW@^EQ7@G$NR0O#2A,2HGS[E\>E;6@C6\OT%RVR"#.P\1L7+2#(
MP9BNS-9,ILNWQ]?3\/L\7K2KK.E*ALA?3+8F_?Y1*F6AP$:<9#D>FAEN,.Q8
M@I^FAZYO*MZ9HC$3BAY7;[3BF%0)J.^C;V3N+ZG5O+ 1S"/*)TZ/W:;^J/>=
MZQ"$0:MMDMIL%C]"6[J0ANU; ;&$. VBO/!%FM9)[I$2M0E.F.810=> B ET
M64/&LGP&H04<"@[8LSY2IT]EWBL,VKDL4\ST\$+<[/-W3X6&&@(H<N-%ZU8E
M#)/@+QX4T<X*M (<G--2*VQOESYU'O=*[H#BD '*_L=*9-8'!_U]XI=*2>,?
MR$D"[K"T<I !WI-9XFX/G,43GMCM98S<MVDS&U3$>7AAJ3\6^VS0!AY+V_<_
M?$%RP?,Z1@XK^Z#K-8Z&TWXGV/57P,H'?7Z,!\HBC^W(SF3[F#ZIF&N1DB0Y
MRZ^X\<53P)^D>%<]'N;Z!0QO%4SUUT=LZ!ESSH**WZ!IKL*?8GB?X=$) LX;
MB>&%]MY3@$,1%)FH5O]#HH.N_BZGR-':6_(<,]OL #YD,.+9CO#@+=,9\F"L
MAC1A7MKHY3_L9OFKI@2'OY6_X\WZD;^[N&9[5FD<EHYYA2ZI?9.DFV2)K(-O
M-6(#&L6L+>1L,FERS-XW9EW\TBK%0-.QIFIY^8<[$%Z_=*21"_U:%=,B&K>C
M__=+D?<+*7X*T[)3 ,JY85IS8L7X%( 6F=K,M]JM(TVJQ, S[3X!2]K['^'H
M\^A8YL#/:)GR2/:Z'1Z4C#Y*@V1QAP L"_X_V>#PLF%Y;-%L<-1SJ*)W. KR
M8M5V%DI&%*7Q>F1[ZJP9"OM71@#G=PD];Q?U'0;D!L-Q6C&L=ZEYEPF: 2VP
MS<"\[L4_HXZW:I:W^R!W5OUC4/_QT[M]S7>LGDM$+.G2&+\GLV(*D_[NTHN7
M(#>3R+?E+BN0$N%<R+C53TIU]_H1/.KH:Q+>IF]H;1\59Z)#VK-WR3H:&I90
M;?"4O%U0#50D--U'/9[)T"]$8"4&T(N7O!@_Y;\*M7RD6.L:JNP9-Q$>UK@H
MRIX#%Y$GBLP:TPLV*V!,],+F7<"KLW"/']^RG,$8\!=$PPG61C(XQ4'87@*G
M  K)LY \17F_+,=[*D:E;6>32%7>J:N@F1IIGD1ZUKB%<#>XT0VINFV]-V^\
M[PO2":L:7.]EN,>D IE6Y!:G=0R$&?=9ER::X].;Y@\^XFKC>N@R)&^M%=S&
M89:Q1-+)8D:A]9U-/!0T7.?X'9M(G/'ZC7XFI9LGX^99]4/87A0\6^F:[8\5
M66?#N^@$4A2QX?^U5%ZA\$$[QCZ(8MC=:H#77:O=F&5 !2EZ#G=@2/0WXX\Q
M)>U-KY(>XB!N>\([B"5''(//,ZKVXD<1GP(8NR&G -T&J/OMR7K+32 *(@0\
M<4!'[\2Z;#_PI!8-(=X<\?MEY17G)X+08O['9;Z<(<NP37(,H2P+>/\E%IQJ
M=<\W@?C@6*&M/(^B&2TV@(3ESN<AZ08]KF)L'L9G_S"[*,IJ1BP+^/2G?)L[
M\ZS"X;5=SZ-]WFT#]]8C@IW[[@J,/^/C[1_.2!,/RA.BLBVC,[19E%]X,Y.'
M6B_%B\MFN-^;-9][ZX-OFPSYW#:\61AD$ -CD$(!;SA1RMQ8V-<?');_$#(<
M[@8\"#1Y86B=MBQ[4Q.M^6(5E%H(#C*=#Q!Y285_5H *,:.JV14]XF5D03#Q
MM_-9'ZB+6DQ^&"VB-?[(W6:C:Z=2'';K+DL*,D@8GL.;X_M>258P8T,2Y?V5
M);WP(4M6MN;/N@!^D5^2(T[O_V^5 7_W.%>J<.B_O,/A38'Y=TGBS/$ ^_^I
MA\=YJ@UX2(9YU<+HPL>_8Y@R&&?H=0-/7\86D,19PG*-,S!9= 1#TE%GU1S/
MSBC+^H !#4ID0-=XRA[)U;F-??,\I"_U/%H[85^ZMSLW@^9QO<XP77S%:!F(
MW %.P RUA&)1[L3[DH9RLT)Y;A=D6=*JPV[\;KG+=)?Y&)![R:&6ZAS^* _F
M66VU3HT985,4!F;JQHW_@ :PI%V4^\1I3P%_KBY; E)CZ.!G+4S\P)DN3?59
M=A;8=7Z,@8SNUVWUW.GS>RAE*5VX*="S;]/%P8C1D]D?5-.-U;H2DB\M*R[R
M55>#%L#=-9W9/3%L4_ZU[C G%^([DTJBY<Y:SF,[A4:;A#9?-D\!<F&/U:7\
M+TA_%HG/\MQL:*X8MK3Y+D-*FI@]HM]1_QI*\Q0IJCD]=SU'Q:4DR#J$<NO>
ME[N,+W9WTX#!^!<99##:U>&)^L1&$]WMY^&S5=%/G7K,/T=./U9 %ZJRG@(
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M9^I,Y!,\?E\E ^@@&;35W2:<#0F:M[>^L(1(2B<? #\6>]GE+74*Z/#B%N'
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M__^T]YU1335KVQM!L%"D=U! BA2I2B\B7:1)2PA(44J B$!H!H(TC1":@()
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MP"TLM'%T C"($4"[!0+? EVU W0  $('_7( OQT@-/ -= Q,K)O8.-<,%80
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M,&V!MFS)]UA[-K6%7)QG-J<O=U)O1MY<?(G'X)NWPJ=&LS,U=%0(+_ UDSB
MH]VD2.QEZ8\]P2"20 H!?:UWU*3<4I2G7],$J/EDQ1XJF.J$!\K<[<Z*</ =
M:0 $==/\!*-UL$)XGQV2TA1<9!R:*2L'9TF/=C;[ZAIQ4>P6()G>4ZP9J<XG
M&JVTNL26&:!J9;?53)(3)G93"!R[<T<@VMHG=ZT$1A5%+R:_%ZL./NWN863/
MP<T'W7 46);@U+H" I)3>4"E\V1W,@!WPXX?#>E&5NU?B0@0#KY/@][R:XX\
MK9 \'M06:C?@]N?&Q[#KHL@GN(F2W%W.60BEZLECM<Q0Z9WJOA[JI)E9)IXW
MR^L";45.K?$X9RXRWGB_FFFW9;6KE6LNXMP+"OBRZU5.612T'#ME@MH+8A9P
MCOXNB[@"T!]5E;PJ9, 'X\L@?$04?BBFZ3(]7VV[]\T>*\-<ZT8) (I6A1P,
M!(G4%U,EXT,X9&?*$GTC=\^P)_:VFR["4^K5KX"N'W/;B"<KXA;@M,K131M3
MUZW"+Y]&=NX)*N3I%BHW&U&IX,A$Z*KA3/DVZH@_@>:+1;A[J*&;CG&PU KF
MN. \$>FD-O4FA3(E0W95M$4G/2VS(>[VG^%-\>M!G_&/-I-H)CCKI=-EO<!H
M'5).-$_/!S'"^WXT?#:RZOU*!'/K1Y>@"BYDT'T19?I+[PET>:IUH1CB;A2Z
MD0L4S3>GM9R] .?3QP,SUT[!DQ/-XI&'%5O3:N"1WM=FG\SSU^)].S(.^:J^
M"*H Q@,/TNC#QD0O'@ZH!/76UT7,$&";/EBNAF$AI[9NQ[\;K]"'W67IJ./!
MB;DL!ZU^ZJ @[Y/%+3%XR!(HZSH7XR2,D20NO29%*)AE&@>UF%#'"3POL3Z-
M7-#.ZZEXA+DH&*\4^8$(WRMOE WDH*! XYHNZ7K4][1^]'4YLFUV1A8M^71U
M,@7G#<)'.G]#W$%IU'1_\PC';8FN->)F > FSK<FA1//R_.TZ$A%4E7]>*K[
M.>;Y3HA58%$FA$*?:O+.%6"W_]/IT)13-8I)<$+@T7[3).W/L"&.R!WH R#J
M\450#Z@'8?0X0OA=F%]X?'*T!<CBG_B([-S:Y[N7 CFZ[E5S07LI-QU_<]W5
MAIL69YIF\PX!=5F2?T2@!,1-/1JTHY$=K(13'9K=:.;KJ=W=K9DJR0S78\]P
MYJ*XKCAI^@KH><1^IA/O*39*_'#<!B7N[OF^OEP6B2=%F^8[0?*5(?#5=PY+
MQC,1OWM2TBV8$D?=R+F.K+;**)9/BC:FMF3T]A9@%YU&0Z9'=76/U.C#2K/)
MEZL);B*UYSJT[3>2Z ^LX3]"Y8E+0+*.M8>WW>-\,H6 T/<$\5K>B??H EW4
MIY'WA@5@LS(Q41[^\4#[GK&_E:=X%HUY6\OF<A7#-#LU:6%/VUGJ.(K'QG/.
M^]F3*Z! <^]H5'L6?Y1,>_G9\;V5: @="-Y0Y6>%:I:.Y6U1?1$"(,184KX6
M0N/3>0WJM6]U>TZ^6^Q=&:\4,Y[GI%+=157!M4HJ:_R79_/M(:J!69=W*.<Q
M(_G.)M079:X DI@KX#PQ&_QA-RM(<H%MF'Y43-J!!6'UG80E&!NS4&3<)L21
M71(+ZJYR'(:7;]_SEDESO(X@2(H '>[C<" D$+"GDQF3U&A# IJ&/&;9O>B)
M7/2I6C-Z-:^*1V/?/S]K('1L_T2Q2C.\:SKD,*'IE'2)_ J(NP9SRL2=W5S7
M!(6& ,/'><+?S..!H YO8#B?7]$)CY+)W.&U6%]W%V?$V"!2WM!+M?66L0%U
M#ZZI@JH]NMZ>U[2@-UE3M+86K3HV@<.:P82OXVG"PE'W:4RA/Z\7CQ1YO/!0
MO6:V$:21>92D*%Z#2I$.$D"S;DQDV4A6,C)[!;2=[,+7"5_XM=V9/4Y'>J5:
MZ'7$S#2FF9;.MK%C3"LP.'0XQA>]03&DK47/&JS=7>KX"GQ.'O?A=Q17KVC"
MY%Q*.XG$87^_CJEWL -&6E6LV01T#.EC+3/,RX1? 7J'G)3Z-U',^Y;.?5:0
MH<IV<;N(B@%/+@3>4]PKH'!'BK3>9-Z03F47%7<FV_2=BYXA-(U0H;"N=6)_
MG9:XO#8J]-N0T[;M/3KJE4O"\\U=YY>IN_Q^=&B3W7-.)G<BRD%M2"]'*Q/#
MINL!7JIF0_2P1%Z4](9Y<:&_SBZ'\P%\SE4K('^#GO=>T[<-G1'EW:X(#?WJ
MK:!$G ^\$11Z-8D.4HV[1!VY:WKI^YW#Z-'"4V(>V,"AE6+1%5#"0I;;9,TS
M#YY<K+"GQ/39C!\J$GOLA[B48_Z4O!TROH?YEK5T5VILZT-!^Y!?>F2MRBL+
M;VP5LWX\'?U1+AN6:JESF7=IDDI UQYI>.2;>NG,V56BTY>6#U5N6+V3=9KE
M'.0O,)%-4*\O)S*0!;E.?B9]4'BG2T0B)GT=+D;IAF9RGQ=MZ9VH3OJ& 5+I
M8&*SZU0-DV#WO%6$MF!APTONN.-5G2X^,W-$XKV!]D,M+YJ'83>EP%,"&;ME
MR>BML+4TF,@ ,JT]7OH*R&P['<0TS(<83UZ2QR/Q7_K<.NJPH[VU&U[UE@.C
M H$V46H0;:)C$D!Q6!C763G@,*\?$\GRACZ !IF.]'"BZ?+G2 N/ZPUP%HG(
MM0#'[]F\V:KG-A48( @LAYI\4B=?"!JN"Z?3N)S8;=?)VE$&<1YUO$+)UD00
MH!NS%^/18Z<D9?'O8$R)9_DN$*'A/-+'+.X ;!L)!IDG*F@>*=OO/>OB.:!_
M(M8/M>EH! V]=KQIPY_W NI T,\L)YSER<,\ Q7O2NQ:,90,"]S!-@Z;_Y""
M@62\-)1OC77H[4@'<NXTLG\I5%UHN0)"N ;=R2@*2WW89W7UC5L9:]^:2CD$
M'F4:6E;&A1(FD=K=POUT2:R]R@\:<&W3IKP3R%4H?S8<0(B?'M^/A'W!4<7,
M_H3E,=B_4+N0EXP,=7 H@![3TA3;,O?OS_@>"H@9D>UM\N3;;1PO$+[0P0P!
MQ#!%+699QL1$N;3 L;ZJ=AN&\N$568/U N*]\L1"W4&#\0=>2EWMM,1[7(D%
MD"J[&67VX-[L!SAS A.>3X+GD.Q;]W]\T2A]X?[. JTJT!/]1;:E^MS&7D)/
MCV\35Q?PE#(HD-N3!R%*-8 W-2T0*G3VZ!:U#WO%[MBH4"-5<2PK;J-23DL_
M%JFQT9Y*7)"U%:):D3EZK?@M':L/+\IEX8+K_&'M6"$GJ"$0MW-I/[,4A;F
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MIB$+G@0+Z@A.-L4< [Y)>:9[\(C;>X7K"UO&S?L-Z:Q4)M9*<K WVJJMFU=
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ME%&_4M,>N&_MX<J/=\:>Z,%"F%1-0I7<H!]?2UV\6R>'/)&:I8??VQPK@I^
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M\*>JNR[J7/WY%M.V]9=^U42!M/$.R5D[5E+>@NI8]E\!\SOAO@2,^Q*PJE\
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MEIS836CQ8G,P:\F!W6KI<-!FWDS>>V;%?DUHU=WN=51.^IIC7[8\9D/^/JF
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MZWWUW-[+-Y#+\=F9[Y\ X3O!'5^XYEN4#W)6 @69N#Z V4A+9XUK^"^.7#N
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M3X)0+>87GU=S(&@MX6RM,\?1"6A]>TM#A,=(6_W"2F6A DXZR[J><&!KZ\$
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MTD9_4!OX9:-JQ%_.+ML<]]/+\@1!]W*NE%>S4X[G ,Q'%%)K2U^=*\+ZZ2%
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M4EU<9:.*S[&?*,(F<L-6X(FFVBQ#T2OT@.&M TK5)F B,-KP99#JM_(XSW-
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MMZT7BP@^48Q6+!WB/'E?5<)KZ?,FNG>IM$H@5<[I85:FN48R02;W4ZG\&5?
MROS@HRV\49;92(A)R.TC]:3^KZ_=V5)6HVGFN]MI(D"WAJM_QR>-LHK=JU2Z
M(OV)R(%S0 90A+&WF1 MX2SC'*#0[ZD& IX#!HH3(LV41>^< \9!^YL7!LB$
M,P&9(PW?BWQI%_E4**4$/>(5.XIMI"7-B(H?<R6/IP>X/2^LX&J2?/S=!,-
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MOHVN3G[&RZ0QZ% =FG^=&C5'PA-M*JJ!@GPN&8<S9??R)?TO=:XM\<A]M,'
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MO)^F#,"CM,9F/ MW<@*S+T,6JLWY#VX \O5]/NC"B1#Q0(!/J<6D['SC08S
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MU_!BO!KF1OLJ< R:XFCQ<%J/44M?M\Z,\^4$8T 49Y^->9*.[SY6>8S4?XR
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M;Z*U9A<WD)B?>#248\D=^.X5 ?68$VHC/H82/!77,$()HK>7[0P!U7E$*_[
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MALPQ/NJ^)*K.]4G1GEE/YH6!N1/VGPJ_LCK7(>A=T4C)M#DLVM@4:^]'N4$
MD2^N.Q,YS,NR8/WWGZMOU2$!?O1L7KG<$]5(_^.)&K5]3CG,VIIL_6K]Z%V(
MD^2;FJAB\WYITS(+3ZD;0&ACZNU!L JE9RUG[+UJP>2?G-2F.YT9);]?53B+
MPAHG^JRIP3%T7P3*)VS>ICG6YK+,CQ%J-_V8H+W=_>40V?(UB5=_=%V@S"UH
MD[<P, U3-;PG4,F3RB=Z8,*9;M-D?-^83[T_C.QVVT6<YGI_73&Y%8%=<N;
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M]03B+B,RTZ@EJ(Z<X*>9&>"*IOXI67D"PAGZH_SNLVI-D\X;-(2W@3G"?]8
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MO@CNY*D('B/]=7TUPX(RCY<KU_ZMG7L#6.$8#][FA=X @I58#Y*VVXZI:VX
M;3FMKV_U#'WS&P"">>OJ,O>:0LO[.L0[ZVPOP46@XZ3A!L!S'/R'TT_PZHZ+
MW/YV[C6E#.UU6&W6V;'1".M!M'/6,5[SWRN$\%3< /[VUO'=_!^R=7(;LO&R
M'.-N-X '?TV2YQ![\:R"4N;Y](]C8C;.V>&EV\%MMX/[@A<FUP[JWN-'OYR
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M.0P4ZAV>3@*  .?CUG$<NN]T0WCE(!,V,\?%?/FIN2J]YGZQ3#.)$.M8,G5
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M5;(W4 GF0EC^0-[OEL282'.#A[N%G2Z:4;$Z3QQS;(FH(SWBD9/Q= X)&]H
MT@_6(?]4E-M_)_POXRUG@E)[FFSP-DN7_ZH+JP3@!W[0^7?COZ[Q=_?S&JR@
M8>^YQ[X\]4I3\IP)N2 WF&U:0(;JZ%;IDD-R'_^5H$KMZM_HO]%_H_]&_R71
M;#A&(\U\.:!&5Y[U9NY_ %!+ P04    " #;@S=;_:]2VV5+ @#BOQ( $@
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MX=FG4VI:?7S2_6@Y8)DF/C.;E=DE_>&P<VOEX!BCF\X=066OLQ"YF'7Y2$1
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MSF-X.1$Q9\WF%MSX_L-M#F;O3'@XNQ2>QVO =3T!R.D+A^UM;C=V[VGNR@
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MKU_)L+-(F5$JVC[;,N*&]W8Q4/L!],4G5A*_7^?+S5.PZ3V9CM5*=:Q>,@'
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MWJ 7U(P8K8(B(]//=8!4FO]B6J%JE+SLZ[PO69DQ-,U(/H]O+4N3QJ9+GRR
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M/4PI@;K6BZIF4B9)A9'-(AO%$B4W%"$QC&RYBK9]CA/<6(O$1*S7# Y5EXG
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MTF:5$VPE;) W(E%"[A?[UM#&I*8?)IXBG3):/Y;)"\2>_!D#RD^4SR"G6:0
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MA**O>S/ T@J>).FQD0O741(Y[,M\.#(I&A\(IL(G;U.^*6&ZL%SP-8Q:P[[
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M*U-*P+]SHIZ,-' Q@D^RHJPZ1PI1Y%A!,AIG6T B;P"MEG/XHT\=B341=]B
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MO%/)0D?>92X.93;K*;6AKGPEID&1H(9HW7!IZ\!&DW(]XULZMAS=>F#COOJ
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MI /Z^UJOWYZ&HG?_*M[WK<;6J]@=5;';,K8E.W4;!K9;*O955N6;N4D_A,*
M2R4H:VK:<4UQP >_Q>6TFEW.X#___2+/KN%F[\]U9RBWB7VN)D@:3'61U1#4
M<Q".",9&P.LXM_6A8W"=03TC2!I<0AK 2U!TEEGA])@![YLYL[WW?,/3_Q6\
MY[55>^E29S/W,T/@-!11^A=P_T8"6*:]'?"MZ-I-'EMO!VR2'8 NYF;N4A,8
M!^GFM R03I\I:>D\,FT(\ D,W>5Q/CT^W0OWZ6+\Y]#P26CJ_Y^Q6=@ $3;3
M'X*]>)\K*C1U?PM)RM.GJYI"$#TN04\_JWP4,[?14KX1*6F6I@$6$?TJSL%A
M/I<&T? 2F[E&O4FQ0R9%>[2@I?[J-JT5GO8%SV[!\\G1-A<\[Q3H_=ZT\@Y8
ML: 7UU",CTZ_5#%>-!0CEUB;,I^Z=L2.GJ(=-W/FML&4W=B!;9R/NM91=M'=
M-YIG#^__H/O4+239NB$_VZ0A=V[L+]\5QYLQWDUT?-=4L9?QY\W4$N+CDD9%
MTFVFH^4^DR='QT^#=[,T'E9%\%ZXO+UVK;J$V?(J<MTK?M?\-3A0QZOT-!.G
M"#=+"(;D9RJ[;#2_LRT5_?Z KI4 #SLY'IQVLHIJYI!9^ E3P#D6YV<<5>=.
M?X4F'V':V0G1LR3Q3-+GIO2X\:J;N=:]K[SSOO(V62M?VQ+<9/-YD\>VY:;]
M-EL1V")U,[?DF<.^970P"O]YN)@)YS=^=_%GA2KF7 !7DF2G^BG/J;_"4!W^
MZ"^/N!,R*@WLYHS,^W,E1!C"U"AL&$3?(:HL_Z1*N7J/PO?8M-;R%A$QQ]D,
MWG(4IOL:*!=).$&_P(#Z'#G491\4]>:E#DWIP<5LGF0+I8*74N]58*8 ^9$5
M?!,ZC_N@N.F,I1+=S%7L+83>0N@MA*W0PIL\MMY"^%H6P@5VC-C,+=D5::",
M^+*N\Z669*)*6UK*BR//#KJ.1H0N?>B++,SI&MT=@%FND2BKR!+EL&5QA9OI
M2EO@$P(:2HW7B2JY83*"/:06+)$,>G\SIWZ)6@_;E#K&5[ EY;9HX<W&P-\&
M*!?T6GLG->,FCZW7VE]+:[^--Y5#:%EZ8)72]C(%-H#O) N6=!PC]M3CQT<F
M7P W/!X\/C(?;.9\]9IVVS1MKVAW4IEM\MAZ1?NU%.W'30^?/X2>G1N@6\'=
MH^9A+O'VOQP='AT/6/D^]E3OKNA=G("6OHU] /I>1];KUUW389L\MEZ_?K7P
M<[(=&6JO%_MX@R1]GY[]1K3CW82%M[DUU>L2F]7$,P1F2-]- H^2:68ZK2+(
M _ND%$I](GNMG:Z(4T#85P5_X'&5T[,C[&Y*%O,/_!3LF_W=3W!G8287EMVP
M^.1L<YT,:F]/&NP9VE^_6'(:7M&]$C#+(T2FJ)1(E!(%)VM_T*AF65J?*?VU
MJ2V\=T<N2-D/A!JBXX;-NA8YNUX%BWU*$2P4>Q[8#8DK7;%SS_ /:5M%0@1F
MLAC;/N4CN<L(T;/2Y*0((FK@,.SF>=P_A)DM2GBE@==^U;2 H-K@/0^K8[[<
M'^CMH;<&]<!Q*:SJT]*! O;J>ZA."-X#DXP.F;G]:>="Z29C<J.V:1ZTWZNQ
M1E1QK'N1X4^X-9+M2W09?T:JZ:R:3 /P::4/9*Y%A^:,AF6;Q67)*[!^W]U[
M:$:SK##S65^8Z15F'F]S8>:7;Y6^J^9M[?$[[*IY:KIJVKX>:+)P>^UM[Y6Y
M5A.Q2\?2@+?G_N@@N%AZ?["<32!;?T?5@P>YUFQL:YNLO1X;8RKT;"Z8B9P[
MQ:-I($WLR%A"J*M*U'R:@0F+[?RNI!#H-8K,%*P*^'"XT):0L$I( SRCO]GI
M&(5YY#>\(Z9&?);N>K<-#>S6VF<O;'O(=]@>LF.+$6H9=AB'-%](3\ 7TCOQ
M'1D(;[FKRDYNPD8736?_Z;:)R_I*2L<9=**FB!+/&KTE!](K%"PBL?RNIXI^
MN\9MN9EM*7RBI,):'A$PZ1NUL=0W;\#1X2(UDSZ$(8KY"MM_F^:";*Z&'7TG
MV0 \E U2\'"+QG@Q[9P&TCLTSMUFD7K8<O\JU;.K(OT0<R;]CK;:^#36Z(I>
MF:99[[ J:1WK-^SN+2J/.@S^9>H-;9M-;#V<S^%U0O9%4'>Y$SQ8?6//F*;W
M02\<[&GT3DO8A%AX:$&).<(N:9;G>7P5)VK"!K[+'3O@_J=@T<,P)OR!(UA-
MR\F!Z:-,MXA,;<$>QM;0P\"IHBJ#@OW)=JK>8"].1TD5L:!=6 I#]ZD2/TJ[
M[H'3V<HBO/X]]MDW'X'%$I(;PLDK%4Q00Z3DG+DO+R\),@3,2W)-BFK.U1N'
MP1E1+L$K)8O!.L=R61_9E0UO^Y;QNVG</C+&+9NSP1N0Q%FTHRW@18L2Q5?H
M<HUZ9ETJX&HR[5Z&R#&.OS*Q1_?L2&CC*LY+#/\V>KM?7Q_*=_0#?L2,OSX$
MT?#]VQ>_(TGI0,JW4)9AG+:]9?/O,@SJV]P8BV=UHG4)HID"6B7L=)19S,TF
M!M2_#B\/Z7"?@W2)POW@^.#9T='!D^?TOU/ZRFD-;&/H7F-F#,(%W)U9%WB%
M%>Q^JOC*YEC5EH$*_A>&DD#FQJ6^F<P!K,40/B4K68^7NJK OP]PI.:%$L*I
MT_*)90&2<C875AJ*1?!L'#\YB.))S'HASQ*- S!]KF6X,**:F7W(S@NH>9#N
M]9^'.!4%V F$,\!M!=N,C;*BYAC@U-$@54HR#B^"'Q6@$G*5+!CF=E^]CA_J
M*&E/AB+49I5DCXQ!BB>PV/!49")P=;_C-NF%M+0%)X_ (L7.\V$042$CC(L<
M(CAGQR<_'!T'X>'L,'@?<D$"O@:NXZ6"?6"9?T].F?GW,%@^2GH^]=^1O826
M##SH^(?'SX,Y/N@B1 &1F@?]IJ)4%3"T0? .+!'SQ./'^HEG8VH]O_2Y],C"
MV<Q9FBP:MO(0!U,*M7$SQ03'*81# 18&'"$&3L*SY FM22EN]UV["QAQ>5G(
M:Q\=\?SNN1-,):'^VS[QWU8+AB*09D91E;</VGGG- N2+ 7CC^/YW+8^IA:"
M;=Z"IGTVQ2C69'%,Z_;WWMY#YGI]'>HJ-#E/1V/17L +O#D$>3K+<IQKL !P
M/XXKM&FUH0A&/,Q_R#%R$PR_4J"8$E?TZM:-A0*?C J495O#T!1Y!+Q<5"U,
MACXE3:4;14SI/1ZJ#:1TPY_AM'/!\!!;T^=T/I)L@IM2#P .CWD>O5*,.5QR
MAC+!%,.PV3:G,>A)=9.YW=CCK=\_>L%8TZ%NSFF1AOA'G. .B/65Y/.#LXUU
MY:-L'MN4>NW7O"'0==;2BNY%_\T_T5F/0C[SNE!\:8Q+!W;@4)?@[1S,PQBS
M[5<J 3/B,'A5Y;1)/>NC%L#08\"E98=/&9?-U?+O4-S:#V13D!BB="*.5T4T
M?OP/R7!8"_@1CUY%3K>4*F43Y%KNA&&3+*]FK6B!K=]*G$9KK!V%&LH@RN"Q
ME*(F*;W@U;%Y/A=5@:NI4,?QD=:Q3(H\N4NF9YJ^;6D,2T6(M7[+-E# WK1E
M'^#:1V9F,KG5=VA9MM_9S:&:ZS]>9^;ZC[]\N+@(?K\X^W"I?X>RR%Z+[9-X
M#S6?8+.[.)\ZBVD^90C1ZN0Q*W9W.= _H K0PIE)D;8VOA5B$P>&QCI:ET(=
M"]$)PZH N[MP C\XHRI/*'B-YV7,&J5I;/RF^$AQI!K> _X!FIO7 I]0BZ7C
MB\',3<5\XORW!N>$K0&B!Y/7?:QB V(5CTVLXH.ZR@CG@ <!5-0N1RMLJ '.
MV50E) 7H<^PL:D,3.<X)^]%$V,;7:(@:GC?48=T'%D\E$J\+4(+U-0L!%A\H
M%P*D<LF%'"9M2VE99V>/O!H:1<(MQ]Q+[75\=XO/F.=QEFMX36V,-;6[_R-S
MXB[UD\A'0F>IQ4]R'!4=D-@KXMD\J?M>.L S<P<"TS/ =X[+0B7C@5X"JQSW
M'WC'K(TS>=[C3#R<R<DWAC.Y[9ZZ]3.7+EM'PAC%!!QO.-]PQM U19%$5@1C
MV/"X<6LJO+)%;K$=[QI&3*[E2C'ZA'U.G8RY5&@?@7$T"-[DA_S^?\=!I<&;
MP^ 7\"4'P47QYR'Q</%9!V\CGL/>KK=YIL#*"18.O<\(Q'99@CD(4N.RPJ#G
M,5;U!A<SE2^N0*" -#^'28#=E(*X>O[HR=$SS.HE:'^!0<?B)1IT6=38H!&]
M[3DK19R4MI"M;U"W6E D(M%G=L#AG-(#YVP.0EL^:(.+'VJEK-MKL@\V5-,P
M&>N?L!GNCZ391<2QY6GD$YC8^T#D]=;=!EAW3XQU=^FT9=U-RTYZQ.L#$')H
M$X,%A!0H"&,F=I$S&8/ IK$I20)7%GPI1L(HUA(6A9H-$_HWRB5SG#$RPC]L
M.I L4MZ29!W4PB4L"RAISH!F..I>XUP;3QIC9*>8<KB#A)03]S\$">N$DPKE
M_% + N\&PU6P#;RQ4[?(\:.8[6('>6'1,F#5(5Z&)"7=B\0J_&-!%C3(W6MB
M1JJ-#E,W*%?KL)L"\PMF6@B#S89X/!M6R,O$TIAJ2DP .\;:DA ^(9F#C172
M@@<OC]>+VS'',K,M8\$8 'CRD[BQ0K*98F5#?D(3B7""A+: N.7^#['RA88/
M=Z3,Y BWBK;<!YCF 6LY1L6E="31Q@YF*DSIB:@C34AF(*HQIR55PAL)XP=3
MS-EB'O3"9/PP)L@S4&"(#VRD.*ITO)EB"CCEA<JO4/DVUX<"$BJ=@!45!9=9
M!(<U^*]P!I+L/#LDBDLX/W%1ZF!DUS02FR?G$V$YF=\2025"]!FG8[1U]6EA
MS,9A\ H':5_1N2H(AUE5\MGDX?&QG'/HNU &+\3Y>0E'X1EV1F@P1$C^V>O)
MW=233XV>9*#C&T9F[::B?">PP)"/H\WYU6*BJEVCL9D9<TPZO$9M0!USVJ.;
M%E>@+6J4*B.7GK<KL?K:O:O&RA73K$HB02IPS-3>NMWN%BEV"[.;)6!KIW;1
MZ%S;B,K13!K*'VMJT/M3P,A8 'XQDJ [)%[LXBFF\4QBMX,V.]X)[0XQ$/1'
M%4VXX#35@66":O8B:R=%UC,G<(LM+<P6_O<2M,)N"K3W8"V Q42I%W'.<YD3
M@X9)TZR"H].%9O"-FC&9>QVWHA;:9$]3!Q%I%"(,X'CX7J$ >';P#U-CRIV^
M\$B/P:S3>+$Q6G![C_:MP(S"!5A!A/YXD 3,DF#FZ5$?S/2"F:??6#"S%_E?
M+O)G<10ERI7Z7=?(\&B(=R<T^5RT:)H?@F*&6- 13&EP_&CU U9JH^=&&[W1
M10T$/SA? 2.KEQ'=YRP,6U3N59C'H3\A=N?+L(;W/[1[7Z#3([- +D+CAX><
M__MXR0L'I&*Z9-1>:I=(+=ZMXFL3!T*"-\$HP=@+ 438;R//JV"_".U%!+#O
MG>[SA<JO"!H$Y_AI\-K\XS6#V^4/^)S@@>2.(,!LPJ58^J8'"XK"JGQ6' 9G
M#%%$6VJ C5; 6))U0SO(SUT0](A%!CT@9)DQ<XRU]=D&#*MZ.)]G<5IJ4AZ3
MAOHU_$^8,^!<OWH7GX''PR$Y(S#::V\1%H8S+V*NNX(P1WM/]QT4%0+LL:PK
MV'OF? P3)2$KG#P,/AT__;%H('XI4BV6)TZP:?VNE\9Y$*/F/\\Q#D[U5E4-
M/&Y]5($?\ HV[V7#Q(+5)^ 1!<:"]S6?%OX>34.W)\V@/N4"H;2U6XR01:8@
MKG>C*"#%;AV2?5W58<"((<)N#PB(0>4%L.PX5W0/_"7B8F=(>DCPW#W0[C;(
M*6J*WBO4T0F#? ME*1H5*#0 ?@"NMN[Y2^'>YDORTXFY)9XAJH&>(L]L]!!H
M?^CV@AS_I3LCFYD(75CA6PH5G_],^&0$JR@OGSEP#E9AY )F3YAN*PI>YEB[
M4"7!Q6'P"O,$H&7V)+#+%=!XA7RC2Y<EJKO?V)-XZS=P"B^OX3:7<5F[%7T5
ME_7;H/0P9\/?0D7KF6Q?9"YHR:^42&][LK681J& 18QXFATO_^3HY%DC[#4.
M+KV 504G-C'I$BJ")<1Y-1J!]YE)46I4)8O G>@_*TR?XTG/<N\>,)0D5G0O
MV 4&,Y"K&8([L<X##HDNE$3FGQ E061?,A[K!QT&;VPYYI0F4S(Z?$#A.41>
M:JC';+X*5$YLDQE5JLL]Z!&D*B@->$6 QY8;2.RNJ/\47R52(ZR0*NR',M\D
M;%I#AFZFSY.OIB_X*JCHF'$7<*+*"JN9-%B!XJ#7,>5H=,%TY].\B&-,F :1
MM8S9G75 <VO3$@[AB&VOZ#%G^TW\1QP&>R^RX7[P6U4_T_JJWZKFN4Y9P/RN
M4L0$[OU=C<?[P?^=*@2U-80,?LM?-FYD@?"1'!><7B,<7'4]Q=HILIJ,UC:G
M_,F*4VXP_0.28G^OX.0$/^-!_91=M<@R_=42N=B&TNF:0;RB>2N2J?J2W[-T
M\AE\+IB_2Q6F[9-IKL9+;C>C:T_ITU53NK7;O\-,]LGD*.M:L]UXIDP%5+VW
MH+,Y?B% DQC8*[L7[CF:F#>HWG_\UV7L&HEP4+V=8_?"OJ-*6/MTADWI%I4V
M03XXJNKBBFQ2'_WAL]811QWI6;;XR,+.9G/4(QS4+2R5G11#D)TYEDP0GD54
MH'G)<'PN\/-%A4FEK9H_9B2)([J::W/!G<GHA[4E:GL&#UCJLC+$L%2NMDM=
M$]1,9F/"Q *@G/IR_=_GG38B"'G'>:?38Q-(.A?_T^E."AM4.()V-'>.>""&
M0HG+WW2-R<6FG+5VT)V BL^["$9TB$PN>Z'0-?H5UR=<$<Q6R##.)GDXG^+:
MMJ)<P*:CFM9"& :V0G&U,UA1-DGS5_G;[\1N/^-6V0U(\1(P93^2 KMH>DF/
M&_'G>Z:R8IFU5%"=/IB@:I4-34;O20NC-WR%,_0_WSWZKB:\*(_5+;G6%G%K
MQ8S; _:P46H1@$'P?GKX\C"H2Z$6[O-6^N3F>Y_6WWO5&]U53@<N/:)7/)^&
M(# 86?<Z9:8O5_[>;:;"//9L CL*[_W\F/..+?35:R^R7(C$U>ON!2,I[NZ]
MND31\"=C:X']-Y+W?A,N1" ?'9W<[01W#\1$PPH>Q+G'O$5; 3RK,[!<P88U
M,314%)=8)HQ%LBZ3-/_@P08OBN\=&,;SD%FQ\27<7?M^&H(&&ZF*#A]"S<:J
M*!C$J=&C*68+X+2;?7?[X_N(!G:I UMFG?_)T2TN>2DD'W:+)[61N[>(KW$X
MBY/%#\%O(/E1^A=-BPMN]/3QCZ[0:K[-B1%&K4MP\;F$O8+!/;#3X2UIAC^E
MV76BHHD2BT'P\@--)TY^0,2TFB=''&DD(HQ4U8V=8B!Y)J),"9.*E)Q),*%K
M$9>+[9_'?^M78](EWIR,18[@FIR]0'B;@C,KX(5AQ& :P]'Z%"<(H<;L#Q=?
MTJ4QHD8*3C:-IK$:-ZJ;<M=&#$%@XJ3.E.ZZA/HOJXI@[A^?$7FE5+5[FV-R
M4\VVI)/!VO=X@$6]E>WAG"*]8$3R J(HGF,KA=&?%9%N@;P8<+#_<XB4L\&D
MXA-QN0#KY;,I?B,![(6W^()&1$MS%6"3+OL0#"Q\R$:,+ W^\OCP%'R!)(FE
MM>!MUUK,3P<MI3_QB@C%T#PZ/''K%EO6_<;W>[SBAJT^V<V><OSLK_?TB/:&
M.M:S70:M.^ZA=1ZT[M$V0^N^<CS"":A2WHSBX>@N.Y96357,74N+F%.-G<56
M;_#W$%SDW!J]SP^#7Q0ENHD#I:F4SD%PI?'GX$6<S51$3WF=C@X)YY''5PA4
MF65@>1'1<!2'DS0KD-B,0ZG2#Q ?)-'%&,G3? GX+AUEHT6I/*D*8OD,'I#H
MD9X<<^!39L2@)^H*6&,'"JYJHKXLDBU3!4$;>&(Z%#3R_:HJSX8Q:*<)O>Y'
M-9JF]!<N*+Y\L/?NX_D/P=N/KU]S "=T)@Q?D"?18^"E>7#>Z/CY\Z<R);P,
M:[T<+5+7&V+<2!&=19SCIEGQGJ+*N%OR\V?/J5?C\^>/:$?@$N:PWJ62(O 9
M%HJ99E'Y)V'#XP2SO9T9.MI+N!^C"FO@WH;PSV*1<L((MQMFJ1&OA"88*K]9
M=J4#]?(K"K]?811BJ@Z8P +58%A6L P\!,X*G2'MCS>!VN"%+\ULR-C-TM R
MEUAHXBSJBQ<@E']]]>N^WK?'I[)(9]4$#JO>C<=/UGG>>Y5>8_E&S1\ZSP[-
MRA\?T8QH SWUQVBW#_SQKBRJ3Z'3S<:[J]Z:>#?_2OG"//$8ED-E].OZ5T="
M<)HLYG <G2/OGDR^NA[0K.]AWJIM[^5R2]OYVM<+5)NL#ZH ;X6 8A$B"2KL
M'53EF T_*XH,W&&-.)'7I>T[U0+-#B!T^IL:&[\,BT^X_=!P!T4R#2)XY8*>
MG"PL(7@J#D*R\-_19-[#X 72PV)+-![^@C?0*]#WTW 6_"N-J2M0N9#RX&":
M@=I&E$"4X0JC'*5?4)HK3Y&*D%WE-^ 5J.!R-+T.\_(_L!()4H33]I)'W5LZ
MI@]MWG=H\R7XYQ'&-@FAM&D13<\R;-J%7E1M281RG=M@)!)O$9P^WKA(9*O%
M=I.Y<2..OAXY>=PQ9[=^9CVX^#9+U9T_HR,&>$[&QH4Q-MXY1A5'I/IHWRVC
M5/<0C!JL&8W"FKA1LC@H\Q AN28<Y>(K-!>IK[NUFNT#5_<4N"HQ#R#I8N2$
MMFD!XI'H7+H[CBZY@:35(96;W._Q;6ZX9NC'!I+N[1&WB"X]-'R2H=$"9P";
MEPQF$APBLHU'UR'=V:5#@]LZ05V*@&,0=15H,5P^?,U M [K2&[PY:]0..GQ
MTD,-7&.I%_4JOKC0#A\[S'"3-W$:BS.T'^R]/;M\>?;/'X)7KR\N]K'7$A%)
MLC_1^F3"CG6\,CE4]!WBSU+NU27?D=!^"3Z$ZT>=G*+C^TH-<S=0@]BRVB38
MYY./$L^6CL%RKHW-.)Q@P/EBE(#@3CJ\2C,GY[^?G^]+5,>/)3&@Q02Z:R]@
M&/ [7V+9),( /\9ET^?EP25(\TX^WMNPB,(_[6@_?GS[7ESYVJ8[P4GV TR/
M!K6UMF-SJH<(K\/9,.WIM]^?W62O#P N;F,&:H^BZI^N[%$:=<<S_%C!_&>5
M>L&J=^]_?BM3\0;]:?O:-!/^Z!^M,TH_H.:&P+K']>L_/P2_9-@[S-]6O_]R
M+H.K3]BCYD(][AW>K75X=>W--KJZ-P3FW,CM??1LM]U>K>4PROC\OGU>@<Z<
MU[O1:2S-0_G#[H9YH9E >NC+[:$OKN\SS)FET=26D1:*Z'4*@G_V3N==.ITE
MEZ<)Q^P$S+'$\S\Y"&]<3&,(<F5H/E*]T_G-.YU<!^1XFR&6V:"![:>U#6V2
MD[_&&DHO)*7=&LI!FWUWJ*N-').UJ-GPL$\OHHFBV-=[S==YC@A[70&TATU?
M?P@NWH-9RDYK(]]U<@2/83.XW2/\-[);OC=&,@9!ST!"\\DYET,!CYUS&R^*
MJ!DM\4ZCTKCHX)(9.DTY5O/>/R?9$.ZK[__&I&CQN?$GG>34:<UG.)^HBY%^
M6OH',/UJ5@A3EI['56]5>S+U.[]*1.5>)/%_PJ$JI\$92*"T-HK',HJGYL6L
M[_?26:W+$A-D$TZ>O4]"ZG$WP+Y$,2,8L7;C AV8D]/3'U7P:UAAVY-S&ZJD
MQ^HW&F)0H;"[K($>H%8'[3+.N;9.!NOH(MFW-,I5BLJ.BU >59R4.$&@!I1&
M<&!:WPOKCO(,QZU%ZR#(9FF,?2Q2E0R"638DCEG,WH:#@+*D\'$XG^LFQVEV
M%>H:=AT"QBC")*=22_0UZ.D&'.F<*YOT3(,W+\YX,<^SI)H-X]#NX,O1-,L2
M\0U?')Y1=O0"7B>;Q2,)6/\2YE?H)MKTZ -3H9WT>"T/K_5XF_%:?17B5Z]"
M?,**_@OK$$\MM;W3Q.I,MQ;;S?+#LV">5'E(#3TEAL8=&-V>>-C*I[/O(H*V
ML"%AG O9C=N,C<B6:NW>3&'C4B(*D]SCKD9(%$+7-NDMXH*P8MAT:=#1<(.#
MFM)D!-V$U>WJ8MV5#HE'SH8%MCHSAA&3WL.+I <T6P-D'B'@(:'6A N%B]^9
MQ]]I84?/EIYK@1J/X<JO7MK\<%'&]>_?##W^W!)ZO)]PXXY1-';*/M?'B[#;
MJ\21J/4BFKG?_?2A0;+T3O,G>82&#T_Y5W\K,RYDWDGC&;M'AB3*Z2I+<J-Y
MZEUIM8RK3%(_FLMFRWD!V\NB']7+HF]2%%TGE;%%T7T&93LS*#[?$;CIA^1<
M;6-"Y<ZS*(^/=CN+(AEW#)D\N>\D2DNM\4/E38@P#N68&P,ZG\9I&/P#/BY!
M^3E\H BG_[6,#C5"O/G32VSP.0WCX%S5?NM0T^G;]%F9FV5EWF%1\?%C*2HF
MX*"+633Y&H:=Z'X_>@7ZHM9[3--XM0M2,M-G8;[U+,PE%P)6J3*E.\]\:C93
M;8B;Z);"> ]+@,;8A90BRA3$6#1_>E84RA7#FH"7"GB")(,9+,J0&7:9,A@D
M)^*>R;T7B.+^(1%G(\VP-!<[F(<Y/$Y3)-20L:J\UF^G$SX"TW-&1H2I]:Y)
M<GFM0(][K1:6AN_RXAS;]Z4FT35 4)F/D>R<VQMIJ^!5"VCJF""$M5)/I)QJ
M(MNXCV%ZT)YW>0_SI122\)HD%]W$1<:YU__KQ65P]O,@^ 76+?@'_M\+F'@B
M=,8J1T[S-#-(+]Z^#]Z#N3N$&]J?ZLI121(=/?%+52G^1<WG,#M8NRDX0&<O
MW@9G;SZ\"UZ$Z2=D28'%W>>V=31Q^O8G<OO'7#B6)1&E(\6L%L <O ,L BBZ
M6GICX%9V(?&XN7*@"[WLS+JW/)^J2K_HSWD85=1(EU,F."/RF![IMK5^6@NM
M[*8R5ZWEJ]TG^NW)\]WVVPQXX$'@;X8RRN>2LG\V@'%?T==SU8<1KB_5E4JR
MN6[G<)Z'XQ*1$@)M,%KPUU_/>W?M9N[:)=+0XDLA)03#*L ^\EVUD6GM+K4"
M6.F?)16;3Z2_,)FB.3!=?H*2RZB7K9CL.##0$ H,RC$G\ NHP:R:#\0'[YW"
M.W,*-5]8"F9OEG]BE![U)BY,+U[J7R=+/0AP;5*5:XIEZ<=KV@3W+N2W[D+6
M&*B;CLT:4ET,9"H]Y20NND^#Y:*C XMW_+R-%9O<! =KZ&,,33*)O+8W&+PZ
M<WAID/'"P<9APFI0?\:-WWF%V#.XN)::G.8K&B>TC?S&<OAIL->5<BJ_K#1W
M6((T4R"><<(/Q"D,$6F%&&^9C<<L%"@G>8WC%PEAXWG4?%ZH/32P;+DZH>D/
M2>;$S"(TSD85<A.20XZ-RRVH6)=ZH<NEPJ*QZJU@S-!Y<6PZ7J#+#O_3<-)S
MV&,1V/#Z/>WC#!KPA^"]T'&\#_X-KUDAM(%+F#Y>_I^#?\/W[_]]^(M3+6@?
M7Z^3TAOOQ^!E.,.WE*V..\[<[N79FX[;=143UF_.3"YIB?1-H^!R 1,WJXWY
M_.-EZR-JY6Y4<J:SL2&9DB-M<C96P*%$86>'.%$6A<'\O4KP%,)I\SWGRZQ"
MD"C6BX,$"A\8!WC:XP ]'."3;QL'^$"9_<<-PO.;I/;KS4WZU/ZVAXQJ+7WZ
M,%$]O?]HM\-$-KU_TD5&OI6\0)TU(UZ5"A;@O/S<QW-ND7X_<=+O]5".E(\8
MSL;M?V4;TE!NQGNJP@0=R*$**^'94PLUPCR>,$KZ35K@)VSF2M<DGB>G,$>:
M,G$94*1F^.=$I5(1T\>H[BQ&]:NEL[)48:: E'SKBP]OSI@I$<XS.ILQ^F"T
M0F=7"CU<224[W_9QJF\]3N6VH6OE.%I:T=BBG9#V&,G78HXUC&+D6J8ZNQ%6
M(MJHAO ?<RR#R6FPWZ@0BT8QAE(0$Q%2I\]I/)D>(&Y*B10CJ>6$W#$(A;F9
M>8)Q>]2MB)UB[QPNG9 GO:(>E0,'4GCJ1@X(<Z#R) .?]D6<%2.N,L1W'<99
MJ>F/%\'YA]>7[S]HEN?2A$H6.G!U(LGTDT>&Y[=]AKVI_3D/XV2 \;WF(ZG&
MMZT?@C>UV*YN 3.1XNM$JI2VB'I41S*JDT.O,2'%+;/E^M.HS5IKZ@;Y,L^N
M?2\SN7G X@T]MY\_G+W^=4![_&S"TNMR&GY*E/(T4Z%2##M:FF5=E$O-A3]D
M$8ASCD:1&PPK]6X83F)P!(FM%QY0P?X&K7CY"5[A(ZQM.(^E?=E9DJA\$J:\
M6>+"-)+GG0F[##:R4W8*#M\G\+%!\V59!$,+$[F1'1VS$6(G3O*ZX%KJD-8L
M7,71O\]!BBO=Z^CG<#;$2M6_9],4.P+SI_HOJO95\R(^SPS)6*34W-?[E'!Z
M8.7?LI'"X$4XFBK0HB8P&RELVFAY??V(USE:HUF>8HGN"Y7#+A!R8-A%B""I
MWP:&;,+*9]$,A GE[\Q&-R6X]UI-V\<"'BH6T-*:=QLC CU3TLV" )SV(;6U
MVS& MAS9(/B99"QF0ZJT4,P?<&X22)<*^ZMCC*3G%/YR]]FV#;.S:;2.P<YF
M/A6)DM[%H)>XR3!"0>".VAW33<*,8:#].@<_V_O.]P?Z[^!@%M[H"7Y4%!4:
ML'!244O&U)2Z8_$U1TKO2W_SOK37%WX=PN#[$_F'M2[U/@#E=N/H(B<6E,JZ
M@RP:U17'W&.IU2]?DV-9^':]FSK=VMTN[4QC@+^53*''J5R?N%J$H%;=\%IX
MA=]["(:E8_2X98^IIU!MV#*?;<^[9+^WCN6'']1G?ZA@_Z8,;VDP*!\_]H [
M<5&K66A[-+4K F-F2N2TH[;'U"F9CT^=Q_R1Q72=<^]!;:X1?"<0#K-OS&XJ
M@S-DNPX7B-#07T<8#\D1F\(%_^F(@R*FN9;4RBAZ/%>IU$I!CIXXK,8,"E*(
MZ!M2V00N'^L$Q,7 K%.?G&&>P63D8<J& 3XM49_EPED(!F1N8#L&J\-F 1]H
M"_BAW\88EQF(<:"_F6#@A2H":WOR%LVO"-EE$$@:X@-S>HG8L3#_I$DW8Z>L
MY$B7E0@0#:1H-OHD4#3X+9\; 6HM@G_#0_X1%G.]T8^?/Q<.M:/C^JGRV@(Q
M\567YVYJ5AGCMD:HX!(&\C)6DTR/^^^(LNGXH7.Q+2[Y-;Q^8'C-HQY>X\%K
MGG[;\)H^AO1 )4A9.OD,WTR"O4N%+=88HM='D7X*'C_9[2C2KD))M"'(.M.@
M4ITBV9<*H<0:<"T5K%L0(^K#&VWGY VH.@3?I\')4\[1B7U8S].I?()F*9E$
M?A?OJLF^&L^PH.5[N 76M>@81U_9TD<YC"&/"K.SO.6F4HB9!40621.;X)<L
MH=@;57ZT=&<^II8YCUJ<S)6W:W%X6ZD&_GFJ<\88":&ZCSU-/[!O.0;(N7@+
M#IO'?WV,0VIV+VH9KWV,XQ.[$PS&)@SWBN;4"1J;M+?;:J[U15YD2.7XJO*]
MJ;U?_N%6_+?S RT+:5#%3@Z;]"#XO_$?F([C%T*9@KXYOF 97'%!"$L:32[A
M74\U/E+WB+=KT%X$O[X7*@>B26!6[./VV6JMTX"1OD3B"BQCJ=_\L'W2-9$"
M]Q4/SE^=8:5'#C8F9O"9<Y6W)9,OM-UD(M0%$>^1#RH%[[;NO-)NA8_!93[A
M/#Z3+'#/7)O=1KLBB_!7EPQ!H;B9<:8QTF7XIINN+HH!+B+YC3 *3#G!#P2]
MD9([/FO-K",?O&6RIN%>5-@9FB-@AD&GSFV]=W[Q^L7E/C_J^.BK<X?VA,0-
M0N*G=T!'_,24:;PBXPBVN26B*7:3C?@CQ0P1/I-F =N$'O\.'-]91B@9.GQ9
ME=M&7X,6HDZ*Y-7ZF=T'N\FR*-3C/@KE1:&>]5&H7K;> :ERV[[M(EINB&(W
M:!4</UH]HI7B^JFMJC/9AI]-MN&!Q76_R3:BH\ S9T]$;/"54RQ)1NO0;<V&
M2-'=U.B6DYLL_RB;$W-VL,:$!'MH;@M+-Q>R^K_2I:="W[TOB<EP/D^H%5@6
M8%K,,1"T!1#L6<<.;0C;I;:E7?F2%K;NE^$(T[<"+C<@;(0EY1F"GP?XYYS:
M/A7X7^SM0Y0$,5@Y2#]0I4P4N._CG0ZIR]"X@C?!^=5F3VW^$%%]%<*-\-QG
MFC6P*8? C1MI&G>\S;4:@B=#6?NU">&OKZ\/L?1E&"X.1]E,]NQA\!M3?Z;$
MZQ+%Q2C)"APYE\P@ SM1KQ+T67@3*35<$,C+0+7<]])T=HO@.B2O"[]:]2/;
MC8);5^BA1/P2](N\0F=-?GYY@24 C%LH8*!!DHUT[MN=I=[3VE5!_=P(:A.@
ML17%#ZZ]OXIHQOH5E$AX;+!-@NZ%@$0;KW(5TT/=\@/;J@W/:)VC!LY/,>:&
MC$H?2#[^6%4D0CUVYECW8*"AC#6NA(A"?[^\",YF\**C,#74J3]7<:18.,*=
M0XYX.;(>ZT+8D2Q= A[P$C/ZC"J%,'R'?U!PBV HZ<*RC!@!P;,$(TLR4WJS
M:+M[+R$V3T+<02SFT9&1#[P5;"Z2P[M,A;&C01E?3I13C%WNG>X'AB'9'A@W
M8HXA86+M,9,U(+O/(8$TWVC66L,A>6Z9?LX*8FGRSJ()I;J]IFJY$(=5<N"<
M8O@:EB(NIF2&ME!0.J-R'WD87#C=8?Q1+)T3*=-"XBHPCG2PFX4LH2BO8G5-
M?0V15B5AR#1^6DBX'5\1[$PPY& RX,;SA>FLU7R<&9-^S@98AE];*&YB<RL1
M.;[PNZ.V5AQ"/+XQ9.0+1V\F[1'.V3KA&1XPR5L,$QH0PP/,0N/;+W[Y]I>S
M.^EQZZ0P/HCDY-^&^?<_6>GSS<Z&IR+Z2>%),9KQ7B8DCR?3I:)A>R=.:WB>
M-Y=JNF,B@Q8DSIT9N_<OFM<$EOZOBZ<73RZ>=."?WH=5$EPXCA^1*O[O=5!?
M][8UNO; FN^V4@<MZRSX7__K^9.GS]O!9]_0-)QOX@3<9(.OU49R_<7>&+&Y
M,9MB%X5GJX3T21,WZD#HQ;_)"J^/ZNU?XPNWD)9!J\>Z\>+EEDNSBT+BIA96
M&]'*1NW;.U8A&W@R=_\-;V,:[8!8NOL%W46)U2J67H97<82>WZ_A?\)\HS;S
MCM@#._(:O5GS30B)FYHUE]?89B8N-VJO]I&B?AKZ>%%O.=VKY?0F_B,.@[T7
MV7 _^*T:2-O=C=KY.V)Z[,AK]!;4[?3(+DJ4FYI92[H\__=&;?)O/CO5&UWW
M8W2ML]@;+R:_TJ:X5PGZQ<1%]V&<M5-2W2$/T]:8-_W[;)'=MG6+]2!EK?6"
MASKV]Y:/6UKM[@&"U^+RZ^9?<_:%IE:*T^^^[_Q2>)?<&^*Z?[DQT.['$K%.
MIY[8R'==:@RT#NX<FPMOUTO^]XU?LE9^X71O9OKV[7K__WV[1?8J-G:H*@<+
MWZ0,0B79=5!,LVNNMDLK/,',3T5U:ZE3L!3,I%:)Z:^(0PC9OO!VRXMAL*T6
M%BUS89Y+KWWR^%X[_KAU''<EZUEQAE69+:GNL$6F6- @OQ0=CC]=I0>T@ERV
M6=<W'KX&DKO[-AU ;2JMNU8\B&&6=)#)OJTL>ULV9B2V+J(+?H&-N2XE8K<G
M]7,+<^[7**KIJHEAB<<GE&C4I'+UX1S:E6,^::_C^>ZG9U^^/+]-XU+=6SBN
M.=$U7;@)L]PVLX\>8N/?_>RV5W5NZB0?/]3VO5,29[RVR6%ZC%Q6S;+9K^"%
M?M$:W(LEMHR5[4G/RN:QLCW_MEG9'LAH-UJ>R".02YI8O9&IJ"3F'+8'M(T^
MH$IL+@P/J%$($Z0:-FJYD$Q\-/V-<2].CTMED0H]$G%7$.'%8?":S?\!TBT:
M]D0>"I*KJFLN5$^#IX__JN\93B:YFF#Q^)J.AD^B0>U8FJ.""Y!*WA ('P:O
MP K/KNGM$E/?#T^N$FJ[6XRF*JH2&"8U_JU/'%[L$'-89A"X!BD[D&W DCT5
MJBBHO^K+*L<G\J0XU"<._6W3J_PZ_4X?CNKCQNF+.S*YNR_46I USZE+[DV/
MH$]6*\_3>3WHX)'1KYA,ET:$A)?;I*!.!7+/$[),$Q\WY\U.TCU/B=[4RTC[
M&^T\[GJ7B,&SQC9ID,<_P$Y!_G N2/[2!BEY=LTS>OS83.FM3DIKHY!;"#6X
M]&AEG.]+)Y(\NQ^\R6MM"K*1X^\&<@P"B5%OW3NU%X]OX8M8,+,9^C)9?G/A
MVQJU_EK"]];2\OZDQ3W,R1JD=S.ES5JT\.I)E+CPZ>2:?'4>0QT9O!_ 3H7G
MGQV<.A24%Y]'4VIV>#8J#^O\>7]R>Q]52*-!(<P+:3#&?G882:DO3>F0Z-'[
MX-OAB&LC9/9+YIE">YK;++O,6,.%9L9\B(-[_WM_J\;.A*]"!\O[$-;0KKHT
MHQP$PZHT+(1)#-^2+_E#75Y]84^H57+MZTFQ9<F_G1E :R>L%0-JD^4//DO]
MMMNL 3B]U=;88B?'3S9MB^EH%S4!QLC8S.^OAA^Y,1]0;G'!C87F%6BVD4O2
M/8Y!-6(OMXQ:1"4+XJ4&@1MK!1U&"M3PB D938-K8B@WO4>(61KYK87HF[7J
M/,]&*H*/"V=<U-(G,1?V1V5G!M!+Z'[;]1(:9R17V-J2Q2L1TQ9.Q![DJPF9
M^T3!"_!1BDJ)TQ+F<:%8R(,$Q12)_BEY1=AWC>7I))<F;"A@K2L$;DS)7..<
M/['=X/FFW%$>[B'.3Y8O/(;R@4FG2)L&^BDU\'3XRO5S;Z1P^M.W,P/HA7Z_
M[7JACS.BC6:=B)[GZH!YV77REL-6^%V:I0?\%R94J?4K-VG)483F''GJQ>HN
M[>]>K/;;KA>K-Y\1$*'8YSG&C*"Z"I,JE'^G$^XEC?)4)S#P;P'\6"!F-@8#
M&+MF*:6_O\[R3_1YB*VDKZ?8@]GVE\ 6JL4,;''=&*V7PKMR''HIW&^[7@K?
M)J*![7E,U/E+(\[4,3++T>B5"W*5J+!0@\X@AMNL4J"@^.@_*^KODRS:?X3-
M%26X'7!41EO:XQA!D_0VDN+=[X_0S@R@E]S]MNLE=XODOGER4&#G,4C. @89
MC['_9&DCVQ%CQ5&(+E28NR%MZB0+PKB2AK4PE S^S9&/7"&4 X;!N!O;X]9]
M2I6&$4X*8L[I5U$\'L-HTY'J4X>[,X!>7"_'2CKXZPW8B[L[JON7]E]C[JP*
MH%A)7(PJCFW<B2W/(!'[V1RV[BC66<Q9N$!K6S?W+()1'M/Q&)@&GZU#JRL"
M!HF204_%8"W/T_K#^0X_LGZ!3<MBJ"<KPL09Y#2\@M?PGAG/YN&HU-W/Z_>Y
M4_VSHM:CI7RA6=:CR]6?_?5A#]YZK]!:7Z(+L;9NQ$==_=8W>] G=SKJVVCM
MF^WWS=#MMBI[62GUT[Z4VBVE/CW:YE)JIR#U/L'X&U[A>K<::YW2U,W687=9
MX;3ARN]F[["QZO"FK[%*0=ZM@W![9?C@172Y@M$0D@6,]'"2*PFP#U5YK53Z
MY5X$DBGDD6 FZP;[G9C::QC17V4+][&G/O;TD+&G_AQLXC;L<Q?-&8E3A*,3
M"F?L:!BFM3F?QFKLD+F^&X_CD4*>H.C[+)<29"HR2E0^N&V>.AQF5>E%A?*X
M^%0@;EY]GE/1DT2>"F+/,5D/-2]<I8AEUF7X"31EF06(5)K!>P9%-9KR#7_$
MF_2G>WL.UY8-H-=R_3G8@&W8:[GFC!C""<E,Z)K9L6BQ7(U4/ >MEZL25 E"
M6JDR*U=A2;H%E",5=X4Q>F1T^167$%2%XU=9W3:P=;B.PO-J=RG;CI_.D <O
M+P[[,[G!!#7;+)579D0W=EML6![\AF1&#SGJ%]GMH$=4;"J2RH:%YB"/LC15
MB5-5BZ0(""J]"DL%?QI<9YVW"&])J=XJ!1E;YC$QC\*#D<^ ZFM=CIDODWJ&
MB.[Y#:G]=I^MSF7*WE;2NG:"M^TEK&OA>=N6H7?S!ZY)6O> B9]-YQ7M"?!:
M"?#:N?UORH/7T\A]91HYU/_%*)L3<458E=-,LV<L6^3UF>;N?6)</$./>]ZX
M >Q4-&(0. 0&'EH3#PO6U&)QP"C+YUF.3/@:BCD()EDH@81L^ <SAMF 1JTZ
MEQR#\XMW?#E<D#N4]!E']0N2K-<*610*J?\",]\6!#>(:M:\+TKI!&?7]@K0
M;]/V#H-&N3$%2\PLW?;U^EJ&G1G -Q=I[[==KTI:9\2CE?21_K/P$_ZS5@/F
M<:-A/!I$8ZI)&)":K%PX4A2L,@R'7]4D[CP)L9K,KT)+E?27P8>!_(T+K@/
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MHH0A8.$C<Z+G52)A569&])(EEQ?GIEZ3*RB3$('1\WD"9P&AEC"FJH^O[LX
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M MB)N\@>S"RG%7T\RY!ZRE$^L_@SG>!IB- +6"=8"V0%;Y5UA0D7.#DP#CO
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M[L37,"@0%)5@6,<L U.011M;DWT]2.';Q]T"57VV;N8H^\1TT;<DVX#K*N-
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M!SP)N-IW8!8J? 9<!)UVMNQ+RTVI4EL[;6>;M?O,)Z\=:W,O,\>^@VWP$JU
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MIS-:-]4Q=IXO%&K(7TAU)9DL^7B6;;.TUVE/Z09)\+M # G+ZX._RZ]X;_]
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MK';L=02LDJ81>]2%#2IOC%29EUQ7",?:SN@R&=6A:.4D3=)<_Z=VDWY-X(O
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MI+-&8,.VEBV]T61Z!)I,>U:3Z4,="1MC[24K<,0I:(ZQG[HN4Z>0-9B@QFT
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MC?$-NXE+D4&'2%]XIOB]!J_Y#EZMZITH+?.KRTY%:T9W<EMJ9[[8]MAO@3#
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MU+AG/((]O,:^\5R-=W3&<,':C&&J!&&T$"'8&--]3[</:*_?.#E-88?Y^R5
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MKCU6V1R40Z$:*P](1Q-W/;4W4AE+7E"O^QR("@1Q$$-!K*^M=\N96^+N\K9
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MML9S2&($M(DK2B\,)T.\!$4+2 Z?NZLR/8C'+0U R%-01E[(<V[W>T=CBG0
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MTEE6IT!S.8T4P*/U]J/X&1LT8?E=TP$(N@FT0ZF;%= =( ^?9Z5YT\BYNJP
M5\+MBI:3EYKLW-_&TJC-#=A0! ?'3Q 0\I-1>AU/+'&R].3P?5(']B ).O;3
M%B4KJ/TZ*0JH])SU?N]_1I@7P+*<_V[?LJ7/G<*/><TM,?<Z7O(:4>I0#KE#
MZ']&U5!FC3#&"]JI+HG:"E&6=4A3ITRO1@814&K!1W![[R2ODX]Q$A=:PQ[Y
M#D(> JAR###!ZG58SZ-LZP>S\ETY[>6NE-..L%UO5."Q+=*1S3CXV!ZHBY!H
MGY2GB<8_3;^1-Z!>K\I%Y^TN:J([# 7*I$+KICV1*"&!V&SE5C3SH>M]NYMZ
MGU?OV_^QZWT_3E;ZKE+/KVWJ^=!QKK^'TXJ6CDW1/,\.P)OH7J"W^@'+,L;4
M^].&^6DJCOH$P0T\="(8!<?(NJP&Z^5$Y>S7?0)UQGC,O(ESE2[-(DT7+,\.
M13@^7\Q_@*Z:2$*. ,/)!>'61T!OK0LAZ%JT9G%V)N?K3+-13IE#O]-=? !-
M+K/V=+S<\>:A6F,B.O G]GL'=:ZQ2+ZX2ZJKQ2O(:X0I7G+5"ST(VKD+E$0K
M!B\Y,"^5&Q#.O7O51OYR([:V/M6'_.Q@77-Z_5FB&C'C\$- ET[!4JO$$GB.
MO%R>+>72! .<UF;W7,S/ S%_917IDG-5L9XH%X^19 8L-/Z9A<"9*3!6$+K\
M*B&.RNJ@-'[I7+A'X#PZR,7SR"YU,.DB]P([[I\VMZ879,QJ=W?UM9O<J!B[
M$ JJABV!6Q'LU[*^R.]@C2,X15+8I#%R+KVZE7$VL7LNGV1GE)\56#',&9Q&
M!(=HADR0RGB9*5JG> 6I%A!* M@L;H0WPNVBBQJ^K?9E/67^3R%92JEM>%E!
M@@*YCL(4N>MA:<O"A[;S/)]*)A_-Z""?<%>M;$D.:(<%B8'",[5LS6>]Z8Y5
M_A7M]L?46$F"M^KJFL2:_3#MAU?IR:>=DFEUN$]#L5SO9_EKU3N&OO.3_ JF
MQH332>\0%F?2^V2\ /S9*0"\RLSG(FK=\)>9]5<T<R( XBAO!Z@0BFT@06QL
M?5$N,&\S1-TCJ'&8:-TFE-DYJ6!\9NEMO=G9MNDF!!5Q?RG\MS^@/GFBC7&^
MRG+8DK-_\P U32U20"0!)YQKP&PEBHH===0X#I@LV& -YM%2)K*;XO%O^57I
MJ">A)R926MARI%E$C6P>;62,P[;N/G00;3L:M-/LF!)+HVU4K ]L5AM)\';G
MDV4%</"=/>KIE+F&M4! ^N '7$GC)E9+L-'Z!K 4-43F2)ULLJUU8?\UO!YH
M^B\7JEW$&E"PU#/'[J"H%*ZUJ5<C;(7[;0!MCR!U\,:AUO+JFS'<*(3^/#,"
MGTF_'=TEV- .!^4_N^O:4A L#TA%I(HHZ\J5"("UE#DV)5;?UNU9;7<Y-_OD
M$>R3MW:?*(M[- /5OO3YYM!.XRX5'V??!VOHV$/2&[10VGT*'#\MBITKR"33
M0.W1^_)[U* $O4@\_,V#@VJCZZQK)5=HN.IAZU6#<JFU/C&MT;[R&0 / ^&3
M\6K876^>0N\NL.Z[SU[G"6G^HGV!;2JJ=CJ!1Z81/6OKQBX::++S4*H=@*&'
MPBJV@)_G@WQ1K;#K'\WL]-Z^^-] RJV[B?]$K-J_BV7OO;GPQQR\.Z@Q>W9D
M]>DSR";%Y3,)*-$@C]-I/KG^N?UF?_W'T?@O.I&.Z8P6BF!;_W6ZPEMU\)=P
MM'I@.0Y,(+F %F;@P[&OKO]BW\:V#?K -T:;1TD"]*+7%SAH-@Z8DR9(!N5;
M_M*L:.!G2\QI]BL#<"\:<$_79E%*N!LH.DBVIGG!_V7+DK+YK#HBS(5D(Y9^
M9[L5"U.?%F9B.,<$E;H@S<(VHP;_TAE;$P59JYM<9PL',V"J,X4QK(%1:J7V
M[?Y?CHC(+<1TUI$# >3Y&E(%(>N>?K*&F-FKI02 U;^LM0(1(=D"1T_BUZI-
M<_]><5UM>(*]#9[ PQ.\VN )GG^P\[KI<+U)M//.1CNQ].USC74 )3;.T1&C
M"AR)A)BK_:<H(?O/=I1K<W.D[/=MJY1$S<D\-\:70(:V4DI^RQS=.03C*8\!
M;Y?&Y&FIY,0)9<G8K4@9]+[.4#X&'=W+'!7EJD6Y'"Y<J9W&8:ZWI.\R@2M5
M.7 X>85)7."/3>0)@X?)D!,*]3&**S@'Q!N""]CP[^/Q%W%J<;!S'JR)1085
M)Q4K/'BHH;9&9*-^HP2TL ) T U\43AHON7!;P='GTY.O=L&<_1K67S+@%]V
M]@*K-RL&$![<=ABS@D?QW3,U+^_=>%F;56NG_2TU2\S\OOAKDX'#4Z/9NCTW
M"?9&7?4.:I[08S@U;O8H%2_SV/B%V%EA+>_WD20/G\J."^EP<,S0GY?.\BEQ
M=V)M#L(+O3L]@Q!:LQ:!DG4E\[P"45MTU2SP&8B?-37RM73Q/:R2>IMG_'+C
M&7N>\>N-9_P\/>/@2*#[KW\B[-^M[41__"(M\Q2N7IE=,7DQ-!-@'?/Z6<$>
M^9L=ZY%;-^0DO_JY\RGP/9_$0@^,*3T2A6/N#SVPDA/@V5JXK:.$V]O9?=,[
MGL[RP;*"TO8L>.0'L:D/U3?= "_A'%%:?9/NQU!906ACH.<?CN &I2X]C]",
M1%^LZ6DS7K V]? '8%.U,M4J\K&ZKZ.VEP<APVZRL[,#_[^9TP!06*PQF)*,
MP7):E^1U^+/46T7:>S WV]M-7K[<:\2W:J8K*#/@U(="W.CA6""$$ZJHM6P?
M&B,#59 9A L7.3HI6YA''A.""! 6-J>,F7Q%"(N=0<8AA-"C(*^%- ]MQ8$P
M*6<EW%)WMO,XZQ..VVH&FQB"6IK@8Y&]^)*9H##'H-!EH&L??IU!R0.>(DM!
M(C KIQ :RB.UO.YMI&4,6 Q?"3$C.G-ES=,5%RJ;5:E/\IBX=^'W%Z>CPBL"
MQM=YTL1JQJR4]OW6I8_K"*O3QMNXQB]\G<@G33U9_JNLS=;3+>D<AR;)6(*S
M' N,_HNJKT\K7&/^$.0]?/0@":4G] /X/_F4%T3]HKE9L=2\K\Q2&%C4=!Z3
MM^^:S$3;(G<D,+0RA9U'W=JG8ME]E^SO[ZB;KW]/S^[ [NQD=RQ0ENQ.O_>G
M!O%B+L-G:=G=;S&=35:W=:JHRL*FW,1@T%10\1Z&)4:%W&DZRF(*[;LOS)U>
MO'R%''=EQ?6_7C6?4!-KC%7?;.XZ->N>?6>K+DDPW_IE_TA9;>KE#DE%U:KP
M=75A\PDH35WP]%QG:5DY/2/;FN)-!1R!2%^!<VN_?*-SAA^G;GAZ?\IU;;-W
M<$J[$]&]WB8KZ\Y<20;>?*4$K2;!\GS3)]UA>$&OS6!?)6_VW]GE&@6'*O8F
MJE[Y#+M[W!+\9$UQA'01#9]R:)1AXJEJLS2NO9\*HMT8"Q%:W;Q(A"^@*GBQ
MTPY GN3*RZE'?)V[=VG@/K)SFCRI;18A ^R1I.'-?.J!+:B!'-1B^;QQ/FOG
M27=/1ELS)*_I-OGJM7G>^IKOOJ@YT QV]T;A7N8@4S #+QAI]5_MFV\;S!9J
MSN#\6XN&LCV,!:G%!VX*:B:(!@#_!?%,PV+BWAGU2NN3@3#NP'H'(8276C1C
M766ZZ=%\9]4>"#T]"8U.OPTHUMD-#_>T(<'P>D_W=&USE\86B/5MNP6@0N+-
M:;6)"O=_O)2(P+A6<W![)T]U;@21ONU+:3@45'<M3@312N/U%OE$E SE 4:*
M5[\M"=%P,UAX"Z20,A= .9LJL:(PYC]A$1?7&??(801G+-TY<LD 7 _%;?(A
M=U$L6121+0F,]5L&Q-BH?K $D.'BO"R69^>R8Z"BN[@F2Q1T;NIN"G0JI<Q*
M(3-X.[9?.=:!8:4CV^F6O=ZY!K#A=R]I/J6L\SV!S]_L.O"Y7;Z_I[.S97KV
MY.F$6\ 8H>_0X)LJHJJFOFA4WUG!WQ97IFSWF[&_D$J>#^*P OBQ(OPU$!]4
M/S_9H] KH^Y#$;4I.#7C03W#>WWJMJ+I_J9HZA5-W_S81=,'VB"P)3K#1<)B
M&A\(_=Y)%R\[V(M#NQ<I$8-^HLU5NBCK1$59W$\K^&/K>]$&QL#"_-D&%!Q)
MI+.60((1YV,$E ,[C;DE!NL-+-9CX\J8WU-2;9"9"4>9#%]8'K([NV^M*U;_
MX]X;U_ +H>$8:?*R<H@%M?V_V;FI19NAXZS33_PLD]0]"AXNBM9F#@W9I*KI
M'J2' 2HJ!9H'!Y0>X-56W1DI"^T+'A-_;<W@HF!RI=7.M;Y+W[[>HOG%\EMG
M+2IU/ Z6"_-=_A%?R SC1""$+Y@"F.4'LPGYG_#BE^5UWQS-U][R@F-UR124
MQJ<5Q2I:RDBE@ZJBR-AKU47K4KJ8X)28BYJW-4<*A >7J&U#4Q;+HX7@_T5Z
MY='/QJ]'.R ]@T[1>"X"?H)?KGI;W.($;['!:]@.W@1JK4B^66",,H-#2#CS
MW/&(L&6BX!2K_9#:QBK;!^+DC\%](OW=L7G9&<_06%W/XDQI->%U8-+,+C!+
M; (]Y==4=)%Q*9J4FDT90EP'JP-F3)*#S2;(S6>P0$,<)VXC?B<^@P0/#;_
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MD\HC*3]P),0X*.AAG>08@&^YDB"J0A#4CR4$,;XU@4=EKIF6I+\$Y4T@.\@
MEN<R0DUH7)"XE7DP0Q'A!/#E,"O04B0.<"V2V(-A4JT3+A2IR^+@9P4<*5RE
MP;%R.3-UL]4TMC TCXS,D8M*1H"+M')6(3RQ=6YZ*"ZOD>+/>C?4FCD^FC=
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M9V(KG'EW.&>S!=2>'/"3<@,7F34I(4ZYION)00C3<)H[,9T*@%(O[R/&:"N
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M7KKI4RQ55/"PBPI:4<'M+BKX-(UJNL-YOT^Z_#?>8S1O1YOE1-<\"3XJ5AW
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M5,[(^BNIJF"2]Y[KEO!B Y=X2QQN'LQ_,)4;"@DY@ZOAGF;7"Z-;XME=5.'
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M?B:]+QY59V5,4ODF+\8Y&JUB@Q5Q%15,.V;,VPWYGZ:$T1>^):T#_9R-+[P
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MXJL*?D52^&9%!3B8G;IU']Z0L ;B7,X&KNN&BZ>B-1BH4]77^I-EK(ZC>NE
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M)&.HXL@(+:$HBPR'PM=U$A[2$%C3U]@(J#\"\.=";RG*%C,D%?U:^4'D39!
M*:Q&0[?@QW#G!*M/@LN\A#M4P^P E"=N:>-MFC4;*IZOO#$:*@*L)2@9=E&6
MLQ\A/X7K8TC\<9U[L,37G)*(S.:>K7,L7W%SE6-[KD75!8H6P@\3<][T-_
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M5<I*NGY8"[NMO.+ I N[;C"(*R8D?&$7#UL"G;RE=/)G[!+RAW GWHB_OTV
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M*W?MI:D%3=08!MDSE.="_TG:\#::-REA9A($,Q! 2"(9M+^J0KCP3?@L[0S
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M]<H\!7N#R[4;4FIN$_13L8L'N+#8WJ](2HHW(W.J>2U$D,>Q^"HA%O48NU+
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M"RRVBGAM+<1!MF,?Q+UJA>R.J<#%PPZC:&,4MSN,XFH9J5&3F\54ZV>H\Z<
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MFYOPGW6E-V>' ?W)'#L4N!Y*&T<;U\Q)6D5?<1]!;LD[V4H7\'2'P4#L4<F
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M]TI,S5:&K76WVYF'7"+Z"VB"Q  2PX:1[[U%L0*>^TU=UTKBLHZIB3G4G4F
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MQ R[1V69RT.?Z&"DTW <1ZD0HA "N1M2%AL>EK+15?&:35)HR-\=SG<G"W.
MP#&64%I..3F^=4;]6W0<!+HC&16];:%[.W#2K><#0X(E*0NMJ2:2*+G7=6O/
M'T#3J'8<35\F6N^6\F$AA0@WJ6@=%:_77!Z9T=#\WGO"F?W7I@PJ9%<9O6J+
M)<E*6<AT16_=-7+PL))N^+PST?Y6^5+(BP"3G_&V3LX?-*%,<3.Q=-<(8;OR
M-/F>*NQH4]!#9$,PTFP^UCJCT=\K\=C56>FIF*W]#K-E8[8.GQEFZPZ9:QY=
M+;B&#)U_JO^[MFAD5)]S"YE"1:MJ>2YST8D260='D4Y@1@Z$CZQ\[3+'U"!B
M.^H4".Y^#-:.UAU+RGXO(+N*:TX0*0YZ\8Q3@O:65N: 1T1]V:G524M'4<Y!
M8 ;3&*+]<O'*M=?KZOHY7AU*1$P$!L$+[#DOR;7QM&_[3CUD,<I%!KE"\=O5
MBW@MW';1CGA-);2!F!=QC#-47=/?A@IBZ,:/Z%TAQ0$,D6"22F&+X1X53Z6Z
MX2*NBCSB7_BAD2K! KG/)),%M%DSYM5,JT-J>=&XW:V&3B44&-6B.#59)-'@
M6NQ#N"'"_*FG!H3YHJ4IS6\SPW=0)6!0D]K(='5_816B,%X"TIMV/+$B;I;X
M,D>(G*\J$B;-O_ MB^ZP".&$$P%]):NKC?F<20VJ:C@CLT=(SK@' \D* X7?
MB[%AZ7<\E?8XN O:8\. ;)U;GMHLUS'4T@V&$M9%GD>:419<($[W6?@7U=\2
M;I.E-% YB,D[/M!0'1M7E/I$@Q)+DL"I3^?[0I6Y)YE"V5.G"IPZX#,A\^U
M8<IDV!==Q%X\R?EON9"9)(L8MVA<,^T=4OZ'20$UE;V*NQA,#65[2D?);6S'
M/WAX*%[))&KD=(6HHB_BM'8+L.0:RBF?LG-SO 1[=&3LF,L$@\)_ET8E%0]
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MRG/P1)0QE?2KON"Q)4_)4&58\K'0OW1N]7.(G:9*Q>H:&6+S,N&KG(;ECYF
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MZ:HM_EM0MCE"F?K\-!1AZ'?@GCB:IK RH(C\+H^"Y.^?5Z?(0D-;1\=)&Z\
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M,=:')E/=-#0.$6O>;\ .&X'&?FL)32P=1*IQ,.ZA%)\*DKW__BC3].3G!'<
M1GW2*?/J[+E-:2GOG99U,]$@M2?S>/=B-@^J5O1#"BQ1+)+?-2QL;6BQ'SN
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M"JIQ=PBYB#B)F7%>_:AE7V6\'1VM2PR6>K!RW)1GL3[5</0[C?9CHP]2\,Q
MZQ-E8UC#TT7*OS6FI>W4W6,HCV8-)+%Q*RL@8ERN[/[(QFULJGMDF+V^_H..
M+H,V./18:,[L'$(B M1K5$;=2Y0D>7LWY3DMVUM=S)EZLY\B;GU!L+VB3[R7
M+*N72>F)E016AB&55DCQ:"\NE38RF'L7&-5*J.)%A9@Q/\9*;@6/VD1C+=B
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MPY[X^60B9Y0[(YX+-YFU_FDMPZMKPZ-[M_ZD,J^N,6)IC8N<B_J#U*0D,7P
MP[_LI_@_!0)3KW"P]=)7>_)H\D0]>;3:@;8 ;0<:)Q?I4#'LC^/33W+0]=NR
MVR+K@D>:<$V!9'HTD@4>9CTAUAG+&*%*>Q7EY(>_ =+\%FC_+@D8ZS4DIYQ&
MD?KBGOF"U[AH9_J#=R+<4ZR7E3EN\'$U3!!P.K0%,(LR"6#1\\H<+]6MI]W%
MY!#A\7,5U!YB<:Y1H&\4C'N+=!P8<^T/QI>R2GBNZK]!53,U#TDBV<:"\BTW
MA#WV8N!BTT4D.V(M*T/*Q@8Y<B.P5TL,V4W9/E<3;S2+<:D-;7:["Z\8K %%
MH0J&'EUEA$QK9<B.&8C90&H/  !>!4\*G7O$TBV:<+P>WE3"DCT*J>?"24K$
MTPCG2-TK&WHZ+9.].[S=XQ2, XCH7@W[C$Q7!!56%_B>*]P+V?C]8:SV8P*H
M/&LX3VY.-##$0.B@GT?+G>S-C$DH4WP27;;0(,(9OM$&>%V2ZG? >X>&\F@J
MS:88J&+KLJ((58->BSSQ DD,ZF.GF]P31F)K7E>E4)N,+>81Z%Y#N.# D7X$
M8J*P(UW-WG0Q,O&69UPFZ$@JXH2/P3OGA1$CVQ+AFRI2]['3^NUD4=_F LUL
M0;L&.EM"6AKEJD[P5MTU@NBS[U8$(+B7M'TLI]1:%62WR-9:Y8GQ<N0CYWQP
M^;%8/,*F,0\J1 TC5Z6/'RA:ZN--22!@T_X9)/T*:#$0?4@>4+754)O8FC$X
M6?.4RYX^'OR,O>H"-#[+ZKP=+)OR4A]3^,3.%B(^;-\MR,2VN223C<[SAHD.
M,0( ?J*_*:M#M:^B39?@?,O_>WR7$#6Z0IX!5$K<S820'F2()YI"Z*1[ .%6
M9)^6$B:,Y;)7VGY^(@\J,(H?K\:_/>_%7613)P/S,>+1#5A%-*-]1E*.>C\Z
M/Q_EK$DSD8Q>3O8M"><D^8MYS)L/<4+JRLC2_ #L(C\K^'2O,H*$3=RYF^.!
MO8]KNG)Y=#%R49G))"-TILT49:!U@L4ET,I*8</J:'L%K6^:D6SO1RVGL5W$
MK"8[@!/*N*Z=.$$$!??%'_UAI=F$Q;8FL@"XBYZ5-(J.HA(;7;Z3V=G5PDP!
M59UU%3Q]'F\#$,LWS25/(KA\R:;E^0F+ &%KSLJ-""$.<T7P>\R?EFBN!_.5
M:K/5#OWYYH4+O,YZ^O0)]5.,,'+G8\R0P1$\6K@QX6SGX'QG:WL/?#TI_&YE
MK3^2"^+Y?%H:4Z&Y-Y<#SNR5JS6,[Z" .)2>=XAO/V^8^<*_E^2%R[*N!BUK
MKXBFQ]YDUHS]"@E]F^#X]<TG,XS$;"_BHVF^/--R]BM/2=T565>[9?/&%(OS
MCZ'DH2PN*-VKL8.S<)O!M"M#KB6C#-M3?=QC-67W]E2K2TW]PGM"8TI6UNF&
M"Y2[W@ZDT,.#GA%69K7?(0"X"8"$AB2)KF-$0<NT/4/*QQ8!B!)GBBU.K"LM
M.<]VQT0^BQ#U]M6!%L=7H*WC9MKU)F9OXX3<&;U:R:66,4T_*@*+U+A8M!11
MJ,&B_=*R6H+02;H:8K9Z5HV"#*^=1)CYY[W@KMO1IJNDV@E#%4BTP^WWRS=_
M,D2GZ0CC:M"<@!:B6,\E""R.8:1LI"'7^7ZYSS&]Z[QYR,G[!'IEF1>/^EA<
M3S+IYF>]%#PJ=1W9NV//E*/VBY5/]=S />Q$H]7@&*EMH](CO:6O7"VD?,F9
M+S+/V4=CWKK7D$\A7SXI/>:T-KP%=]FZ:I\WO-1!V06TT^>&*,?//G#FV&U8
M6IRM_"U,+?XND(@<VCP+ET'K>F$.NY#:H#7OPG#\@#J_%?-0)W'3?3'K%,.W
M;KZ*[1:K6RT64Z:X"L,1'Q:7^ ?&_TBY(PMN1XQ-/)'XYGMYJDXJ-13."'0G
M:R7?W]HMT'VA:MXORT7+(^K)Z(5,;CD[TBTH7RK2&30ZW"K4VH-7KE;"[_]6
M\E5W">L]-W,:^KJKPXX<FG/,E1,B]U$573CQSU/B!1Z[M05WWXMD+/<434OI
MH7?69Y;;I6D6S/IR$PO4(1M!/K%?S;T2)6$6Q11!=!_.*&LAI6R>IOR3WXSP
M'<+@<W/DF,10]N]$"<KDSL>%&IO:2'_:N"K??B/15\W50Y%$@SN1))WO$)L^
M-L^B_S63Q4X7?580\W;$L@T>,8??!6YHB0S__LF]J+LJ&G_9@.]Q"+<'ES9'
MC!QO-V\U*.#=D&"_L*9<^<:HEGK;3$$TM+YQ%A[]T:K:A7&)__P38I%D]X"N
MV0O*S,Z<EHZ4/64^QF1#?;G/HU$(?G4"T?". GOV'B]<*U&TVT&A N':V0EF
M:6/:-H$^5/9-)%7&Z1NRNH.EA/G^!_O)^B^A!PQ-+=FS/]U5)^JIT]"?%M
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M&;%&W?:,/,'ZT>O2085I/'RU"7:?V\TE@H];,CXM?:Q,RL7.=>1*K-.?T9(
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M%/T >G"<[S*3,HD'7$V)??;=D?O@[<X1OX 27_(W("SG=U1S>N0@["A^F[Z
MQ9%LT^J%19M'\EN#%^99\,5^HE\/Q'V7@+]'2.2[.YB;MEC&]:&Z.K]#7%^'
M"C4M^MQ/]$+[?-<[XE@5L+E)-ELGX+NR^ZD_K:XOT/&R@/I3FD5_77<_6\YN
M-),( CX_UNYQ>GIR8KQF0*_7$3FE1U0_ F3CPG.UEF*VT0P3E@<]A0$./7W1
M<M>]LN2_U3A58ICB9?B0? X^ ^%$,-ZDG/N?9?DSHFL3PD#>X!D1_G['H/+[
M[\NU."+B5Y+ I_A'"D<0/E/3! KG@#-3"T)O%^\G,N!1(@\KMO!P.H5P+C[
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M$DE&?+5\K/![NUH1^GBT44'4)TI&39DX\G  H*&DU[+()W#0%4U8MJXA<7&
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MI;G+?46UH2=/^[LFXV:B9#59V%Q%*"C:D;$L?A[[2$,XM[?>K4E+WW_F8+X
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M.F^L["_ PSV=XDY# TPYS&5'*K,OM_&%!5'B^OOQPD_,WL27V8$#10A+JH;
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M^1_K-?"Q:;*L2XU]OC3Y<^42V[7',1IH05(/V>2X3DBG+#$KDB)#9[)7IFR
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M0YUS,PKWVM%/'I2?,%G[6&J4IOJ(H_^6%;6>^FNF$!O@L4L%X%--?)#@E3M
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MQ.481"0C#*0O#6 EW/<7>!P0Y=P+U^,7]<A*]R2#P)F!BBB4N*=&*[W YPS
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MH'+0AUG !?(5%]9Z]6]A8HN_1!L0B0L.=U!Z,TYEV1G%/X =:U7]SCA+'@2
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M8\+"I^7,5?R38Q\(#E+#R&\\YZ_.:23^TPWSU>6P[&AM^-IM^$4I>S++(LX
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MP-N'14#=G(L?&FAI6=3<UIQT]$O/<.B21WY;9?4^) EK'=\C9Z?;;BBSR-C
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MF7<_/4]N;^YJUK2ZXE7G3IT87*+?6K:BKTLCAP.@@R[08_@\^4FTM^![?R>
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MA .J$!M .#"JQE"%\WJ(BR.!=_]'>MH^3\P,S!^PRCBA4E=[DM[S^0JGGLI
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M+=\ QS+?RB"O:1)YI 15Z@T_W'*,LRZL_/1N2&.&IB-%:Y;<X]M[?J_)N"J
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M\5G02[ Q,!VC$^$6)_Z2S;^KXD^L<,K7G@$OM8'NBE[]G'+:>VGL!+)#=70
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MNO'V&(_-JAVAMF?1B.>L]LC$+4CX @\Y5QMIR;/==R0=T<SA>X0NEHC9UAQ
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MMBB]9^X*#A_);$?T]GE_>4>/T/>$Y=:EU!1WW=DXT;2L!?_9\J,>0^VTM-
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MKNYF]TOYJLUW-^7++O\?X%M%_R,O$5S[]/H9V"QT,W_L$[EPU&R<"?3Z] Q
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MK]Y K]Z#$$U_+;*WNOE^0Z7<:V"^GLP9O,RJEK7P./QA5'$@ZZ&)FHK.,H*
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M%V][SG "L0'>]F?/S;6B:CBXLFK5=-:+CH9'Y^J9#C42-U8@:OY5)HZX"DN
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M>XW]P'B8^J28K78GODA@<\"&\GK#NFYWGK^\ *:2T?0Z4=6Q]NLFUP"3&Z7
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MM;ER\J-IVDQG'[Y)2?SZN[EHH,CX6"A!/3.<MMTL3'E'= !)E@COFPF=Y84
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MMSF'0P,43!D\@3HE!#@N>SAJJORAOS//65EMY=#4YFMH?H9RQ973#X0+_=0
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M),[NV,UTPZS$"28&2JVY@<,O^62B0,MPZ,/V$A'%?NH!Z*NY&KDEKPD*"NL
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MO%[Y4$T,"$"58N$!5Z4,Y.;.PX#R8UO+WM0;$.H_)Q,XH\PU&^UHWY%NK,
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M15QR8804BLF3B5(LNA6, EG>P(OFAJ[RJP>[E^<SV#/"$:@.G.<J8@^U3[W
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M;L>,PWA37ITP3*!-)%3=^T<AQT![4V=/\KD.4<<'L_J5.T;>FI1%VJT(+60
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M[6*7?>  HVB<*ZXC7[ZZ>"&5;N!9+[SA-#_1(\R4VL1&$P.FKN7?79C@.WD
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M_[&KRQ_,Z^/X(ZB;C1KTR''L:XJ$TMH]"P@8YER8<STW]$OZ$^D#-)'*="1
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MVD*,2CJ*M+J>)>IZT[:#7G43G GO -0[O]'8I("V@[XK;1<TC%:?>F\,>?#
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M:K/XY(_B[*C?0P3M>D?HC':(T/?6MC"'JNU76F=8-=LZFQN#C US2@R7T=F
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M&'8-6;$)H,/AF$MPF/\B28?C2(=TJ)(OV4W6:[[DHI,[?)]"I(ID0J>+5SE
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M@9%#&Q@)DJ6U)TU;K:;,E[:64B)O,.C6:S?IH[=QECRL>]H7F(E'AE(F!&$
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MGQIZ_V45)@BV'%?&OH"/SA=X\4VC!M7Y.\\5'Y[F(6\;8X!-P4M8Y)8 JQX
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M7]=1OG:$3P752#3D'?\ @GX[TSZ@3_Q, Y.P#4&K/%K'&BWK(^D,T]DTJ7V
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MQ..<.0N)E%I>!,UQNU<U1RS 3ST_??.="'Q1)4@EOTKF&+%V<A'<$"#9%!X
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MV%#8?JQ)86@^BN%SH7JIQB\M.TJ,/4;\D8/6\<Y,@S0E[N++H/70[*I#\E%
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M<V"HOG/$75^=8IU$L/Z W,_N"K7*]0%KLL5THA3.@8^S8^TC^'[3+0"=BS^
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M%!+]EREW61.#E:@673K,6SQ:!1.<W1I,N%,%>AVT&#%1F&#+IL<:JJOPU1H
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MVQTA-M+@4N2D$-O.XDSY(I?45D\AN45M5^#L_(ZAI6V-5M+%EJ**7D?28J
M%+4$]N#7DHPB#2-W[NQMEFMC[$LG@;A S3]_0799U]?Z?;N/+ZE4SO0T'YLQ
MP['T_Q25A/J(R)G 1*^0\,.#%>/&"U K<%U?X)H/.)*ZA^#$=>E$&Q7[#(8
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M_3)3-PWUEV[06>DF[?,0O P!; [[<6;;)Z(M'MX'.-;[$ZN+)X608=1U6L$
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MAP[SZJ=.QI"<;YKMMY_)U7O5^W;J_K;I8_YBQFLUU-VZ\'"Q*3043%X>A[6
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M1!P;&J?+>G/R]@)P ;Z:AUN\M<=12F)C*.[$6RE*0;$':H5OM! JP$ZSQ\H
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MIBT);^?**S *XR DQS:/<(FVO7P:OFBFQHB](87B= (=6 MGU*4&&2[FU-R
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M0?F_KF.-0EVN?O:IXI5)G 9_JSI/*4-J#!'2]6^O"-H7FC#"/=J7(,[,D7'
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M&??8EKRX16?Z!D5'_]9%(UPC\F9D$;HAGA\+GK]QY\\=SAT;5ZUJ?S(0$QB
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M\CQ?M U+Q0_N:I3R@\1+!G\+S/RR+Y3-\W8],GJCWMH>B4G=&(/_OI_$; P
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MFGXVG]/ <N;$H-B *0(FQ/+(R79SC%V2?=??MWOJPN/9X/X".]\ F.C'!XP
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M$ILZK?4[;OVA1$9;-0[2--E_'(_J3G LVM*+1#;Y&T!UV5+]U&*!XVZ*:X,
MHR?UJ*PSRZOFOEYCEY^>4&0N7Y*?U<9^>T5AJF*GTI_Q6\$JH0A08QP>@]60
M9-[P&Q._!?FI"*NVQDO0+^TLGJ5OFK(O1JV&-W-IFGBB?;.KER.*SW%,=HMU
MDI51#*FVQ8?=+*>^JTE,H]FHX_7:_!AV+AZE8/:&712_:\-5\C)Y]I1.!V9'
MIKM"R^P;#3CR#&BT45DNKVC*UN]Z-<3>>!*]1YAB.V!R4K',?=QL#E:D>=X@
MNM8-#RX\>2-(N0*!#E/5J*KT7Z[EB"9X)H#!HC$BC+DJWR@5'S&CDM>%  T.
MRR],'%#EX? G\AX!(S42DA(K#@/]&R=KG*->>K;L-[A+_=S%#?8D7^N6&5:*
M+8.E_ZR7^4VF]L[B6.;QP!&TS$E6*;S\K1*=%'+8P':7WT/B98:^_-P\WA68
M<\078>XBYN;8GP&=K:V 0VAO[Y0AH"L[*G+_W;?4)W%FJSA%=\YWHJA4E6&Y
M<8 5.I]A/V/%)\Q#MF.3Q[[54TV6>-GPYG*<RSG.2/QV5E=Z=7*,C"@>BZ[9
M4Q>6D.SYKT!&,4E&&(_@T1[:/<TH#<47BPM[V.'K!/"82D6)G1(VDR\"=VE(
M9$CL$ =$MP/PEG IP,PPI\^K'_BX$[>=H@R\& :F#F$).WP-F[B,*F@:/VL2
M^^U@^)_N+/]W]O]-K8135&]F9[[&9'JU6:2)65Z" ]68RBQ8?76;6?JF1!Z@
M2*J4\XP0W8TVS:!5-#^[J?AO'OGKA("PAQOT#CL7]&@NUV9R!6W/'8;"JGIA
MU%^M\$?R+@KXEEW 7KO <Z.BI*"@R(:8-=?.=JG,=77.1>4J7IM@.;65?W$V
M/RUV.*W590P?%9=Z^G3JE8B?^Z?3WB)U?-%'>S X_4J$T@(E4@8O9%*4G%H*
M17Q;" 7\X;S<^("PT/1].J/5(G%T:)-8+QJ 5%$-^R#&JRZ2]IC"[5!OWU.F
MF#^XR)Z'+NXO@'*UYW;J'QSWEJ*SU([&2N2[L[4C;5 S9Y$-*6ZD#HHREGTO
MX$5(\I1P$;1TS:'#)@1C+A54%7!)/?-:-QR[['(E$A!:-D9M)N!^)$/S\5?K
MWE_ V)/WDV^MR;'!IMK22^#.#3*#.U'K)YVNQ?U;91Q[XDYXOI<!,6UY4<Z$
MIN(YW NW$OM8?$(++*5Y2"_W4'/*U2)8*4]XGW1%.^R*7YU?T2\F%8/J1V(X
M-,,M.* ;6P96ZH6)L<37Z!>[5[8N*+M',(MQIN9>H^\$&\<(SU_'CO$'8=)U
M,!N(26M#);'H;T,*!OSG)7EQD7WGF2[3V#QQ^X@(XJH=TAC%5:U@W#OZ0 =X
M! ]/=0 E998C\ZKATCN,MME=.*0/Y"3YYV%D2 %#$U[_4RASIXGOP=GO]A+A
M;G7">Q;P:\''0L-Y)3X7(JT@A#)]*$W3.A?Q,W<C:R_&C$'82U<&,)J/+;;S
MTF35(>(N8AF/E2;@ EGUH&!7%,$<WZK\G?FI'3%5UX"HU"(B-EQ"L%1GS*JM
M.\5KZHSH*/.3T 6>A#'^6P9C)Q&NF-UK[^;C;EGY'$L6#$,EH1'WQ!]^K8DI
MCD6W%2S\9I-,&:@K$5Z#"HS%]Z?$9=!.NUK/[&%8>_[AM7&D HM?^NJCV,9Z
M0H$02(=IO:)R"7\1' 2:9^G\'LK9VAZKE7(B5\TW2%MM8J!#&\9!D@QCK;*B
M(PRM8+X/=9;>TWR,479U]&+IJ!2Q2C:]DSG5F!@&D*1(A,G0]K\-4VN'MSDK
M(AI:VF%[8O0Z.B8RFR&N'T8&")>&06;&V#CQ(UTI>\@3 C]8KQ[^<;&ESQUT
M4LI_.\98AT+*;^;R<@:<(Q3R ]1&X\JAJ3C^4184%[<=1S($+?*2^@M KA_W
M_2;*<;VE*H*;XX2'K^\%M&G]J2=>9,3HF=+ 6Z/^<7KM+P^'*8U+ZSO9>CR$
MM\HZ0<C1'8@"RX0Q"L*^M'2 PWPOW^._:X]_*SW$A0?7M<Q7?HZP463H@*U!
MV^>R=5H,!IQRJ0/Z+[==[]Q$_DA!BUOFO*1^IK[]7>*M";Z&"41H<(R/4<*0
M2D"49\D$P20EU&#AV@"F1N3:(.$7+M0;EIB-<-V51& *0' 64X]AXW$CGD!=
M/E&KJZ4-FD6S3@5 )62),=W'?AE=:XA69TP]7SQG_F\RL@25#S9X*'&DOZB_
MV60 $MP4&76'$MTKIFK5'2&GC"WJ8JG/-D8"=<^ :$PI$0V,G'B1!7U>S\UR
MJ,?:!QZ12)2.BJ&U$K65EQI*Y4)_ ?C#7\;VETVQ/\2W6O,5*F*,80 L7?#J
MJ?[<B8M54M@<#FW-K#H)^OVL=65)&5*\(L_\<V%#I?/@3W<NMV%)3J>7W75^
M,-TENN;$;\B]E+(:+!"]14JLU!_P95*1:H<&,!LE)_)U<H9 NQK&_B>RA@:F
MU-!<1;1%Q2$XO$H/'=L^KR8&-[NMOJ_+- 8RDC((*%DN[J0F#VO%Z?%W&N%G
ML'6DF@2F"'7;,[J1C%?M??YLHB!XY]$S>C7A]<@]UIWF[>-#P'(&FQ$]7:52
M, ZUA83EXD-06)0+\:L2L9&K?/"V>08#@^*\Y!\X#[G\UJ:;O3U31NZY5WK[
MYRW=$VTAIRRX#+O];( PH<@/B7?JZF7"X_UEAQ2WJ0@'+Z'VYL9._EVCC$SE
M=JQQ:3,W/DQ9Q!$XVRA[()^EG=*52:Z.[W)9=/''*8.!+K*>SBR7GY4[>1A
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MJW\!P#W3Q\?8A^R?]_^<9H _W_WS?=Q_ 5]:K +^US,LP1*/_Y-;ONQ]W;^
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M^J41EHGX(@'M5RB'?A8IIM0JKL*C8\6C".=V!J6XN*_RJ@,N_!'(@C01C]R
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M_B#DAXE2::\"N]%05._O'GO&-/B'A$_;HX9* (^EI:P6YRKB^X(3<):A;:E
MD<-B-"?V6Z 4O=SQ"">[[Q=25&-&C\'A61QG7U\DHTC_:F9P"Q0$"KF2,26=
MT0I1 G@RN%V3FV1^;EXO_=0=/8KD_^2 4DT%--'+;@$F$]%79YSJIGXE5]D[
MXZQ=[!LZ&_/^!<RE$?9\<8@-M" _CMB+A$HUI4=X'PEI8VJKT<8/B*SO-RGO
M IG+_C>/_O\4_F_5>OAO.$">RJF%J.ZW"ZP4:V89\D8I;DH&UL!++^V/Q,5'
MG&57'7[HFK[,<F;9P,S5!E*F\HI\H;T.CY"PCA]?E'H=%/JK>)2NK%34KV5
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M.0!N<4E_A3%(;[-QY"@O U]SD6"+GY!OI8IIO!V<YFEKJR]P=J5* T30M!?
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M O^6-#S<_ED?6/P!;&@PRGBU'N,ER&%__2[='3?M("\C\QX_4#2<4A1&XX5
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ML%8%G@EU&1=G-U>@Y]A)X9MK].E&K(?42#@:';C_Y1,(]J8%^Y;>J&=^W)T
M:JFS+LXD!AH9Q$$PDHDST@@92'^*X^:S?@OLO)69Z2!F6+7ECA],W'X/]Y#(
MI[7+WN!<,#@!QF6KL/8LY.12Z24J]IL*L.PS0G&E<?OW$L-<YXRY=LP$RI+Y
M!#V%H+A+E.V9-N/4C]%>V&CB++3T <*A-S?X^-:>'OO6F'S/C*": ( -5!6
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MA^0IOPVU\SV0SL'8D[K=9"0@0ZM2LJF(\ZEBBP<A_!PI1729TAUNB9Y[NPY
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MLI-J7RX9_:WD(,W:M_KHS>/B_\;O^RX;?K1E\K*8W<@B*:-.N@(C\C%[)Y4
M.NBQ.3_3%EYQM$DTOJ1V/V9%4.:E=!N^.H<6[^&\L(2*^Q[==@F5YX5! 8^O
M\/Y-TM>B$35SVP<MND.2C"6S,>N2#(4R;IK'X,T+D+Y^:K0T!J"3F)5S"T<'
MA6" ;594']^D=616UO(A+'%_5>OK]OOSU<\(:$%2OC'K!CQ8:]UN,=SEE\,
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M1GKV#!GY\:K/XW4 &>\9_@M.210"51-4.D="KH"$/#1ZJ=H>(K7I,P9N4Z=
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M\ZF_)>)BBMWJ-X[:[9+5I.WBV[/.T#\\ELWUNJ]TP.U_3G3RS0!$6>$6I [
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M7AP2WOLV%)AMM8#OC*&B1J!ZD(_ILV 9_[#H9QA*H+K'@I"-&R;&&M6K34U
M/I%&G)#*.4:)NS^6NAXV"5C.,B*1#=A"@KJU;W*"[H1+EHTEB4OR/=@(ZUZ?
MKR=(_9Z+];_@_4FH@IISV(D+(SK^D02E +_OQ270E9D:]2Z^Y9E.[&<7.P,X
M[VXUX1=QQ#;I[$V64,R_'*Z7&:OZ V84?QR)M=3ZF[Y[QHI6U/YOP9"T=,?C
MA]'P'2RLJPC>#Q%VVO[JN(CD?J##WX5]NMGC2SW+9G\<6I2OO-]_GO=FU)VX
M#Z?Y8.E"K.% X]$./3A_O[N1P(RW:M5A([[BIT29A<9:KL'RX;%@AMV_OQ+]
MBA1RX6\-SCK#*GJ*-I<:\SQ\[?(\IML;U&0T_?=S145![8\^>4S_8NCSQW?6
MSM JWWTEDL2WNU6=&12LWCNL"D[*5+\OH:UQ1%;GD* ^\M DP@K"-%72^35S
MC@Y;50E*OHJS/ZY^8:WV8:_:ST\N+J)[7,DST?$<,UU[1AX NF_LWGC024*#
M@REXF]:L^2RK!8$''^=74"@2T/(1./3TS!9>+'Z<)CMC6_"7+SU(C!'T>84"
M3A]A IQ(E0<Q7-PC_5G4E29$Z+'J?+[H+;X#UE:I[:H%TVBT\//CO8_99\$?
MPHP5JMW-SBKSYM\2KL+=7BC;_F)OD@J:R]*R4"/R[E_A$H(MM(TR(4TRPAUY
M-A"G+Z3GM*C4Y=,F&]K?O7P7$'%P,/D#X:K*AWAU2'S%0:S-K\ G].7'Z:7!
MVQ\"W:S&)2*P@W]$7<".(O%MOQ%)VXPM>T%#XC[:^3 Z G>BP.6@6/""3UR?
M,<:J-?&5NE6C^@@E"\7$5,R)8^#R4=)"ZPT3TJCZ]J?2+MR3.^:5CK;!Q2A'
M>Q9Z[ZAUN9O?\/2#=MUMS#@\&MS/U?EAM^S'[#2>2>WL J0WVB;2@).G??!^
M+3RF$IY5;69EOQ7[,ABI!:,<*VD6CKNOZ6*,*!H%Z6 _F9$3D>2I1K:1C*'Q
ME9Q4#_O+TOBXKF'W1"51)R*TWBS.U0=E1;VWN9S]/^3%P-V" MW(28.>."!+
MM3.^)I1O>2!/HI.<OWDE.B^C$S;I/W^1H'=8'1;GO+BYK)%^G @ZMGU5G9;-
MU-8U?WQBQSN&TLA.Q[+7HM@R="TKN0EH:V_]Q3'&AJOUR::;IRN8,YM+2-C6
MBE@>Z3\>"1@Y@O?](AS@I0:#M KT-A][UI24!0\VZD3HSZ:]N7<490WX5<>0
M\Z7K_5^C$+FOW^"($QB%/6;Q^XBS)3T(A>[90A$DL;C Y1I1)SF.XP7?F6?\
M,+:P_'3G"QUIBQ*%2JNJDE5"=8<7\6LB[V5')?\X20QZWB[Z2 ,.VO=X,)0,
MZ-CI<XC2?2_?')'T>G%NK-DGU3[$S/V:'SX@Q0ML,YVS3T6%\""5IL2K2\-W
MC;4)E!(!]8 '+5ZVAV!U^6.K^L>7!IZF!O?VYBBST;-Z+B*U(&?FB\=]_3LZ
M$_Q36%NR#"(%O1W,IE[4.GP9]3ZB !*9-1DOBPJK[HT$=@K/]->\)=M@6+_[
MK]R%/.J\;*GZ*<WW9Q';9U5FD_HZT>=_@47\K,7"QQA3+,CSLG9%Z2><4'[9
M#=F><8$V6;*IGYV5=MQ:7J'D[)^LMPT;6%8[SHJ' ,[D*&%0]'M"B-ND_%Q7
M78VV[8S<2-8TW^\FZMOD>Z(#0O_'IO#_DS<30%^E69W]N1RXE1[36Q@\8/OG
M?BQJFHJN.7*AI4(KUI:9 +61$A?W916F,9ZNT:'6PIN7@[<9NNS3A<&#B/3E
MS]^:!(SAH!WHIB_>)=MC^BU6/0#GH>4@56-E&*-BZ."6/O>!-J)N(XJY,A]]
M"FK,<O<^?:*#%5)#?G,-7*Y&1!PWHF"N6BGO;X(]U9PZ%ZL]W7!-,#B7W?T%
M&> @2_0%O(-;MVG]K%V_Y/!\TV ([&R&FA(>G8D293\>8HO4W"AY+$$=(3*]
M*LEPWKBTH_;+,1/@LJE.J-0!K9CKQ7YQ:").W#?WQ\NDI$9#IHP-C0'=2^B%
M_?52> !RT[?OJ![;CO6<L(R3 \_UD*]B"49HVC22=-%^[06W<PCK2S9:Z>E*
M5XE_HI!/[5^LR"P_/S89_B5KE&+7OJ,T7UW?0:(2VRU[=?0 $!CJKM87,$7/
MU++*>C/7#GEK#>RN#(76N(RP-[C/5=;8)4Z8\. 5])_V"A&J<+8!H9-&[2JH
MVE3]7&.LJJ,Q#._0B73P@Z/]9>T$2RLY\N8J3=N:-O?>\[-?,/L]]R :AJ@K
MM@<-BKVR=JT82XG\@4<G3TG[0;'>G'C%/Y +6 WHGO H=7D \([(0P.V,W3L
MS,B+JQ-%TIQDT&(%_KBAO<%TRL7)W+W(Q;F)W'']*W/=*R34,=C*F'IUR*)C
M9[\3@;_4J""X5(Z&@=YS@LJ+$P2%[,(^Z(GXTC<N?FQI]$BUNJOA(I%JT3KO
MII"SC>4^SU8$W":.R$G<,,JY=#(!41#YT,#*JP(/HJJJ;>M7DXEZ9'BOAAC'
MW%1JAL1?\S)&G+"RW?'[\O(G@%^%Y/HQX1^WVV+DNIKJ(VTT_T7;/.2_,<J"
MDLXJ);V-L<L+#FC]B<ST<OBE!I-9BZ2 '7Q00I2ZY7:2W,J-/&0\9J ?ZF78
MZ3LFF$4_&DJ1I5*Z%;30X-(AQ:;_OG[NHSP^1:F6U8($TC.3A'CNI44BRRHJ
MCL%[CAB7#ID_N\V-S&RT&]Q7YJ2L<ICP=.#DN-JDK2D6NJ&12D8H)!>38B&*
MQLOF,9#2%<ZC8(\)<5HY%!:TVVGW2L2S>.X]1HN9,**RAVKG)(E$5$NY,EA1
M;?CSZJ8_]>N!ZKLT?FOD3Z"(+'<7"Z9<=O3>2[NE7)S.2&B2"HRP%B2DP:\J
M7W& +\WC%#ZO=4[\+%! Y+6PKKS!1W\9(0VW](5OT"P2S85Z^8V%U5\#/$O9
M+]D8QL:$S6F@U#K4_=>DP(F-<%0X&+S;W)Q"%\K+>BYLHH%3F/Z#II_K,!%B
M*LINS''[P:?.E)!3WT5"5TER4#?!>3%)+YMQ.BY<1-B]F+67Y/-K699F%"TL
M+N'H4F3/3_YD)9 :N7F[F94)CZQ=Y +>RM)88'+T5YXR=6A#07.HKD6DH&IA
M> !=!:)*0CS:\1#OI'4G0\XQS)I\+\AZ)3GW#WM,)V8T5@[;7\>)!6!GX9O(
MZ^(-R1T: I[6^;W1 6>T!(;8YZ]>K7!A@B4DR0!P]Y:ER!2JHRI%N'1W$U=)
MMD9SG,.:QG/T(0/S6)^C@ 41Y;])SE=1?L32/CSNCD/LF5\'U<WD"*OW#$>[
M^3SL"HKT<A0[_"+CZX[<PTL4/:30\KHEN7Q/DR=FCZX[?B*UY+</[@P^ #9!
M:G-TL$]9)2-@UC+K8CE3,:OH>)'U33&#LL&9-VA'^KB5AZT;+?GZ!VE=IM_F
M7%([4]KKW24_GVD[#)YFXCB]428; -SFM/%*:/ .]:IK"D>J20D44NCUAZL*
MN-9(I./MG[WWS_,7EIAL9*Z_YVU61O^99&"DN[1QR(\+8MMMQGN[EX9+B^68
M],U?68L0X2>A-FHAI%"A_%!(L[/+OHK9^M@#>\W7"+ZLM""[A)C]/J'[T#F]
MDI<#?Q6.L3K01-[M@3_#4L;:.4F3PF".Z.38+*BF) D0S#Y.Q>%(Z#R$^3Z*
MU3]9JIL;(3I>>(?^=QE+Z*++ZH@O_4\P=9,'D+IRG*#&)!?.D91B."R//;?/
M&(M6O96I@CAMY"4>T=E3?@#='$BPJ1*]TTI:8>7\\U'8=K0.*[ P*' HKXIT
M=]'5C^BHU5NO;6EIJ5U,71K9_@4'?JUQEMP*CK*4T@G:HVMXI:ZU H=49VT+
MY<D-I;0CZ7)-WA<(KD]^>'V0[6B0<\>PTG1'_[6;&JE2H8(OGOV#WZL]-Q3#
M+_?0I*9BGS*.8UY]#@KX>Y8.^09,]^9F$X9:.KE8ML*=78"(-GN9]-"Y&Q7D
MY8&29>+HY7)OV-&NR%H3Z)8?G10PLN56624\T*I4X4K4\:7#,AD_5%$,RD-/
M=OLK0!9I,5W$^K%Y90SW^T7F_ #DIY?#+?5;6NMFCXTEY]F2?@V+S?(G[9T%
MW=81[S?1I  N<]HD10HU\ +Y^]6&A<X>JIY/=0WZD UQ5GS"41UBAAU&:X-/
M97'X(+V#LU[KWR^##AT-V9;/%R0)^C4X53SCWR*L_D#>)\W%E<AO7MXT2AN8
M_JERQ$'4[FG@/.Y$&STZXQ%;Z*]MQ1:0C4:ZY9R D[CQ:B&T! D49;-B,;LB
MRZ,U7=OR$0DE_@TM%E<TNR#R?CR ZJB[TME1;/6FC[W$+?6()Y"I!SG-U $
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M?0IM"Z1 /C>%Q/VL5.N9DXQV8/L^K[K<(F^5@FZ41$J_=KKZR7RU%F__R /
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MX!"D_L''=<_^6(?GIQGF>91NMM3XH3O=EI?S994>$Q)]?SHW*%VN*71+?VV
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M'O>:<XXQ9K*R[F WY/>6O^W9IAJ8DH%NV<)@RIW'/"HJ0&LVD4TY]2F*,_2
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MPC)G$ AQ@?.,9$2^\("W=$#X;4"Y'W.3=/EX)(#V5\><G@;NPG6@8Y8(Z(;
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MW@\2R_H0R-6,V2I/L\SKHERO+_M94\-WWLD>I!M[]B,.CA'1\=V):J0H6]U
M,VE,Z" $'W4UU!O<-)X9>!;MP7BTCK=F1!YW=L\%G<9 5WV:5S,F,-G5E9=
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M ]U/B)9,^6J?FE2>:UO<N?V-RX7F8^NS5CB[A7F"MZ!D&8J<TA[I%-J=ZU;
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MK'5E-+Y7?$OB.QBG"=B_Q$(2=>HA7RT?Z*0*E>WHFF\N+%?VMXO;B1A[-79
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M9B )0:]H^C9JO2Q$17RHG#S<<KZZT6!*ACYVU+.,*1T%PG[RNTR<MP(N7VX
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MLU N]^Q4J< DRD9LRL3[-S"62?/*]PC_Z3>*@S30>EN/#="%CS L-? $ZY4
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M9G:6,+;I7?555I;3,] N/-_C?>>2=R<:7=Z-3F-KM$N KH9XT6C>-U7)5T+
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M.0V*-I4F&Z,T6RHL)F__R+(00FN E>XM%Q6FG--L4;8"K [) #6$G(P^5*H
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M2,@3-D8E/LD%?MEB$VB=3"]QU0QP8$JR/ P3D-2I8OYFXT96KWY<YZJ[A!&
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MK&#HXX4F?') SOO&G_7\5J.]J=/$L"\]6<T%K:KJHI=RXP2UXB^ 9#O6.O,
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M(^U@:2CYXXM-)7%?;5'<T5 5<4(+L8O>Y/4ST/+1$VV-A(,H:6AJF)P> U2
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M(O%Y923_:YAX :[![HY'-_0G!XYZA+P9#0NV886385]<(E]>1\YJP%Y&B6_
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MN>1/N[B?B[OBU(,B[*8QU$'?81Q_ =A-O? ;6;8LU3CPEIO;>]TTKH:/NF*
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M*=;?*%>-3=.$.%BC:8*A#\7>9?2EJ81 O?VB$0PU6;OS>'2<4^T!+UG$NLH
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M:W4/"@E!Y8ZP%U/]\1UVCHY<;E?(,NJ#-]1[O7=)]$FW/=6SC8?N<-*,#=.
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MUU"61,?[>V'QG=,.U^=8W&=YJT,:QK8YSX4_C%,K1J8C,8Y6/\3C*'ETZ*$
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M>REEBQFC;^VO]T!YPAKHTRF4<=;CW-_"@4.YJJ XHL!25(;32;Q*2@3%55X
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M7$Y=;XJJ)#)EK7,KL7M9,R^XSKC8SPW/*%<WUP^P6IC;:!"AU58"HT>!&"6
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MJW/^0DX>9!";AC'2T20+3=_;?G53Z/,W4'2CS-$&(\FA!;9B?3_K9R,JRYM
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M'!U,\E<&$ _8_Y+Y[NN4FZ2P+KA&N$)@IJ85HJ3!8EC\HRZ%41771):YA"F
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M_=]/HF+4*(7O/\0__0C8+UBYX2LACD)B?X%,=G"BU-3;ONLR!IG!O]:*X@,
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M7;_"JI;NLQ78?^N^CH^Z2UT6BREH![A"(1A9)80#+\V"&31_QZI<E%'*END
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M0PBHLY\>>Z3\FS!VA>49YD>?9?)++/1;3=K9T"+$S0"80!E]4J&D<\FRD;'
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M!8>_?#N &*7!:?"N<9G_^CC>04KH\>V[FNSUS/I8[!%Z?Y.!!HR0] 5J%'M
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M)?*Z9$DJA,N-A.+VH\AGECBWA:&^V%$Y-V.!:5A]=8A70TCF9W%O;\P8(=H
MBJHG%J'R:]:4T$Y89SXN=)7Y=[B%QNIO4WE/J2QE%Q#&=EORE<8@D)AG/N*?
M;0=L()$TG0#\2A4NJ"-&>P=95[4!@>LRC@@$1''J3J$I?4WZX^%^K]\)<F)?
MH,,A0>;)&N$[V4K#Q_B3L9><,TSPL%#3--:PWA:5+P68"LKLW5IOT G;J#JM
MB_9O?)J(%Q>6#)2^+.UZ?/[(W\3&);WUQ 2+ X#^O2DMG:$/O$,MQSGDF1U,
M*M>:[^FD>%T98K:#<;W:/T;V5$.KOV>+-85]:*_)9L(UL4[Y/-3GQ$([?UIM
MUSKE"GOKP=;VJZ$Y?:7I_]F_HZ$)G)[0ZBY:T%]5_PJV!.&-#M[L%X1K;ST"
M/ .&_RG #W1K'GZW&VZK*=4RMK88A3N0>Y9[2+(5M5'L9S5,7]U&3O))T-T+
M!/7;Z39F*-:,Z[T\J$F'R8R_KS J03?FVR\)^=4O>-[H'903Q3'';P2]49NB
MJ+9\T[ RN[;(-Q,3U-2]K)(V5-%D4T>+;<F3ZXC^/0 -O34P^SUTOR6<JB^>
M&1L0[KAPM;%II:H^ I#'!U?ZY6;%"_ON3WEQ^J@2QK!L,-(4;FZ870) 20<@
M1E9D>Q36!77V66,A?L-4WV5,! T1OS=/K-W5?"5^<OOU&/0A-<TKY/^>6K+%
MJ%5T-E\;P+NDHKWR/3A[^0Z8[@6Y)1R#P<38+T(O!E5NYXK&,LR]G<'.;I9@
MX.5?_6>LX7KY;)0<BG^RL=1EI(=!L-SZ$+.F4-'/)BWQI=KTTIS]@H\ O%&H
M282D0&.L7L>TN=Z+T5MF$'_9INWE(X#JZGD99HJ9O:?$2GM2O8@(_6%Q#*MN
MXOT.&ALB5R'A3@,^EK51'0J1C"WA+/H]NSDB8+D8]<4R_.(1\#P#*IE38K/*
M"-<?M<7K#&-L8;+XB,H*3L$8E.TZ61#RJKS,,/_Y+MYD<6EE((;E8S9K'"=^
M% K-DX0];YHC3\\J@)@8R+HX/@*\7L7QYW1-8"5YU.ZJ=2!+UL>1"A9-Z?<O
M7^[#*'@)+3T^M_E.LJW['A#@K=@DYU#>&=[4)T^JJ'&O;O]@IP$#FB@'I'#G
M2_8E*28%R;].U;<:*#B'>A2@?/\'.%WF(B36&,(_XK403'+J4&W&,D;9\@M-
M4&OS(#S;!NU/54$V&!.YZDMI<$O4D!KE]ZGG6J9P3*(Y[+QJ$*I]%?I:DGY?
MPT;=EG53%7L:VL!AJ:X9.'3./$][.,]UGB6E/MT?4O2#4"] (2X^X!M=,^W9
M:MT1D'ICE.<6UBC&&O6"8=M"49KSX:1D0WH<B'#,\,P[K$/VJLR?_V[P<- $
M.X"?)RS(Q+5MD4-X18=/1E_027;.<K<QDC54910;'H2S1'_UIMN#72:4C*!'
MD2\-J"-0UH3VTF.#[\3+UWR;-">/CAT]_B;T/1-=MYY'E%/%AKF"]/]PBM_S
MST%7Z2\TVV2)+J]]I9ZC>X8%[E@AYRO*[>9N,AX!5D2LHVTXS\7#(FL3GE$.
MN!SJKZ%V;N4,/P),IOSW.(VVLX,+;:>YYO2-DMI&Z'_4RJ&6HS\<2X])_+3'
M$QY\WW0KF6,)ML6$KAJU*5-M78@"<">PF!'^#TJ.=8\ !ZES'[</1H^ !'S_
M(SR"AX"D56,]_0/A:GOOIZ!NW?3Y($]+C<7, /<$3%M,5VS_ND5/CI/([J9?
MA/":+XCQK*9N%@$\JB-<1SC!BU?R"9PV4[);RFWL8U=8SN,=J@X>/7_6/B*+
MUB,-AOHFAM$$"J+"(#BF,9L,NL6C!;8I5%]LS_;G$A8& ,K6@?I"@RJO*"A*
MAHOVSXRZOW)'URTO!3&FY6LAT!8-*.E# )XOPHE/U)&CX$OO2G'5#R7HOY(O
MN7K:3LN#4!N_^OE!?]JED]V7A-RY>((J;>?/5@;15F2+7^'0T7,I#J-QMN4,
MM,=J3YRW?UDQG>7B/F'^D$0B3VU[@=6TH52T1Z46[GAY8Y4#LB4-XZF1?RK"
MU=6;TG0B]VEN4/KG-LZ/@)X/&^7>-E0OZCY!7PE^<4)U&SO*EG\#G*\[U ^<
M<A6_?_?.2KCQ5(69UL0N,7:0+(L@"/@:[/<Z;\+UO%EGM8J!GM-MB!;E1N>,
MW50&$-R-&2#IB1"N]"R_XS98&K67"^4,,ZG;NW2/;.;=1#8Y:@%8$+#5%EM8
M[HR? /*=D7Q=Z42"H>@0%WHA_7CZN:(/V4:DB_/V'I7-"YKW>+5QO0R;Z.:4
M@,T9G8 IP>VV4(0#M]P,T;6F"J,1HD2*HY$?BRUP4!!E._GR5 ZA"\5HS,PV
MK"X,)I;GN^TEM:#Q.F9Y$ K.L\LFC5S7OH]>;K0O2TH5Y-$=M1V6_( RL^ZP
MVXCG7>AE&27V;1ZAMU1TU,75A$,<3H-K*F#.XB1V\_RO)"Y\<H:E$T2@;I\F
MT"'?]*%50HEB0$U-W6<"TZ2G\_JE%]O]%_][O/+O+?"5L A)X&&C6&#FVW0?
M%P(FK3"G3PJ:2[CV"Y5<L KN!,C8*J>WQP QNP93M1]@_:-2T8)"Z7#IH*5#
MRE3Q,(\.*[$8HMO!(@:+KB< 6 Z5#\I^,7W'7+HH!X2XA_AV:/PU"JHKV,KY
M&9_CQ.D]*"D./_1 T[Q]66;KQGU?WHW.ITBYT +;5F"F'![CB]4_V0D5_Y[]
M*MXBNEM' 1"*58-5^5D/R=9+Y;O7UC!1P?3[0[.1J6'9A8GZT]-B!\14!V+A
MKWMN?"'U+I4WXF4;<2U_D9+?'/MM:)FD4'P,)XU/=S:U:F;,>;O=2CLSN(C/
M-SJ*Y'UI;G1_F>PG4U6\PL^S!'TE%G53_IXLAXL"")#931QO9[U,*CD(8BS]
MI+_R/</U,Y0LT>R"DH8*\Y\QK(3_''1N2!(_ A+#YOS7FJO=J_]C#\K_9WBC
MY_A_-L.TG/D_N5MD!F5^4HX4H$N H.]/;PK)GWJA&#JF=W+<,1Y9]+E ='#%
M+$:]_2O9M@E5LK4)+G=;) VL#(7ZUY#.)GK,W01F5?"F+PAHDTV*D,^P!?L"
M7]I['JU$?0$\VUN4(&M]!!"\/X1=P)A.CI[2V:R#U:V29?#(;_DSQ8,76#O,
M'9Q)\$= H! V4.\1\$SJ^T5>F9TM42@*#9-@N)H"Q27;KP.O>1)XB6PC'=H,
M4+'Q$6 SQPV\J'5GN38P'WHN]N7O6A; &_?F,M;>@^M8R(#",5;1XK><RR,
MA4U(:+7(W!3.O;W=WFHH&D,D^#-47H+LBZ=D3]O7[@XJ^%@-//M*=]8L%/H@
MX\PZNU7"W[?>B&T^) KQ/5MM'GV_ U+>B U2JP1&OKA,[-VMN?[&6)-YBQOX
MI/<FA+WF4DK56<CUH[/^3OI7Q%#.+DKFTK%WS+FV<\>[X;T?F^A<>4%2X=V1
M\7W44S?"U9>S5XH82+A*VQ@QY;E[NANS%C!Q+#=,+^_GO0G)6L]B4T&81/F8
M.4/%;:K!&VV\A2+,3A$,?S$G_ *L&[&J&6+U19)[YF'R4$9PDW^ZH</287;J
MSTNQU:2RZYS%FZ2LM921^VRW1/ \.K1-5@$.NXH BD!/</>:<FTO]7^VAV4P
M+AS@IJDN(P*B+[I/TE>?%CU"$(8'E"T^6"6IGVK@%NO]VVP R',T7T>)G\@Z
M'&8[H7\/.-\#RN:O&/LFK.G^2M\M2:3]\R27UQAVFGUE^Z@*Z2D%*U'%*ULL
M;ES46>CTL\;3/%>B>X]C!&(X1]H,0$!)K&FA/:!$KDW<L*#68GM%E.,U1@H+
M.U[7.)O0RJ&-Q7VNH 6^1F/4.N]!V^@HFO@9%(\2W!\X6X&Q <I?7BY)RU%M
M'K.;/:H$FP.'4&PVK0#G0Y35A%,.K$C[<MM+/Q;X<88_QBS\5KB&"-/2)XK.
MSU%4=+/S97OUQT= G/;NO9/_/?H$\ZC/*VCG]PZNZ<\S,&Z@:*/JJ^BF\"0D
M<-V1J9WI$: [[5JD,^.&HRQD'B)"PF5Z+T)D+ //Z9F_20F!N5$ 5<OTI%-4
M,T0-KD -H2X7)[H^$L7[#^S(:N@&5)2Y-7LTF5/<.[!9A^;7T(=!U; 'C.QS
ME /HP\1" [PE^"@B5%8J%?BK(&&IQ7PU#V2M8B1PJ]I +5,"]YNS-N%,C.W,
M=-NLUD? <+DSI4@%07QIY_;>2G^Q*6H'=D0P=$^9'U!?@:MRU1<32/EY]M_*
M!TM\,CQF/@QA@^<2F/I:J\0HFOO*3QI[_)WD5,L="K"HC3K]O<L<I1UIT.I]
M:-%<G_UJW4_K4Z98DR/V^GSD88N#V&#$ ^W^/&O'N',QQY^?_5]S59*&=K$H
M) ?:4]2G88+E%!45IHK<^10Q@GL%;Q[J44;\>_Y,=&[P@@ K^C]97LJWVQ<2
M@8?H/NTF;R&R9W,V'@$O#)NBVXQL*P[BY(IMI^0;'_Q3B =;W?T<<,^/53_+
MY>V=((YWQE1Y^I9H1<8(&UH<SOA+W)?-OQI[S1A3PW=2JGWT$!EVR?$KA<3L
MBD74B=S9S@> ]<OA7 )=L:* Z;%<,"@DSFA@=]3D-;CJ:),TS@[B.[.JVGY1
M,77]%A3_MV)5;P^)=9P9X^5B_&ICW0PIOADI9W7*?;RC^",31J'&(6&O%"F#
M9+;]:8OXU3DS1=K1NJQ<K_)L*7LD+C+V/>"RU<A;L:/9WEY"9P"ZX7>NL<S\
M^R; 12M:K>^ 3>U%\L[UA[_"/=IGJ(\ ;T>76*]3^N\==/#=,!^<8KL6=$W]
M-5G!EV,':.$OA\:4'GC>C#?8[4^_05YT;+]S4<[GT4"<^10&7M/_"9#@P%,;
M.#CP-O >\:SB'B*1I?DY3B0APOZ&/EH'3+07SH40KBFI^(4ZS=@L;8Y69I;-
M=V*L6K+V)WVM7WE%^.U4(<O GB>&;)#"--9I14T!4OV!5&DFR,#?#K:SZ736
M!D,N'48YQZ3NK@9(8/4_<+37(A2"\J;<L!\!=1?*822I/8IU#'R;N#)=O70?
M8QH6]>QN' NGN$/S;-TG:109T@SSKKJA;1_T:\(^3#\0+RRCFF8!FP&B7(6R
M\3G._>#B)/.-D]ATRZI$$&U6^]B/<2Z-Z)^#_$]Z*N UE)UR3Y)SUGKBCK/L
M(+F,>MP>[7TD.ZL272ZA,W*><:/2!<K3;E]\ ++?Z)_FB6B%G7W+!]XM4']?
MB8*VT'_/.547.KDY\]\V!/?FX"\_ LQL]-,0OC>]-2:WXG_I=/C]5*R+4$7R
M$)BECP!*'D',EK'4%ILLT]/YL#]GK=2MV0)&']./X_&0-2D?:Y5[G+@A&^C?
M'@&MF?.9R\."4C0->J 4U_W<.OG?8Y] 77>'4?#Y,+?7)![X+J -&,>E=QD+
MOUWB"G2;9=GS#:6ADW.V ELEF@32+AE+4\RIHU&D^VN&&?]UGJ_[KNA5KIT[
MV].O[4VW3NJ\2Y[E.Z"'R^5=NHNM58;&#OC?#BR$VUFY(03[2.B5YE58="!*
MW5K0W4V\=@5;ZXR@.KW'\<+O]&UCR!^97I9G 9_\N]P?.&R(#FOL6]Y=#0QP
M:_U1[A<5WG<*E?9?&;.]HNK(L/UZJ9SU=HHZAVMD:YB__(CR^I>:<_=N"68;
MSTB/5V/UNJJP*EOOC43]]YIEN?*B';9E?"7S6$.X.M:^$<'W\U2A\>@'NKK9
M/#US$ ,0OLMQ5&P>?"""\D\[=$-HB=G/MU;3)Z J*):MMZ>.'-8TP^S/TQQL
M?<B>"270H&210W]_WY:T0^NNM,3!03T7S=M7P#C+VM>^U" RDC/5T8PED(4?
M2TO!6($4Y?._&E?_[[+_G]I]:R]R\/?U;_6%2^QW,]Z\F_!#I)C'/ )>4=[9
M:T4 . 7>PB]3-K* "[;D:U:-/!:+.P)W@Y1O/JN;Z;MJ8)%YP@MZ1)JFC"1S
M6#[KK''QCNV39+>5BM*'<@I 7X<4=\;V-.H;)[/6U'>JBU'$.<30H0R=#]A/
ML>?BZ\HAW3;:T70>IFOK_!O8.:E'!)2V4?E"T!&#I.DGO=5X__3HO#V=>M?J
MW*@$VK;Y&SSYR\E7PKX\/^!-$YPM;*EW<D]3KZ$]ZLNS'S*<S"?T?9]H$B]>
M9A1Z8/6V"%4>D5]*6B_%#;I>X4\!?WH3JZL7<Q;G!XBF=I!X2'!#GKGN6W^_
MGTW?D=V.VL4Y\RG8GV]W)?&P5_H];S:WW<!=VHO2% /F&U@8.^;+]"=QB3K3
MG]' HBVYXX5W9)0NK2G8 Z>6>.W=?O_V)&82(]-R'NRPKTIFR6:+D/GAQM$[
M0U=_PXXF(COANH:WWZL^!>H8MZ/X'>LMQ5;-I511Z=]%1X=@/5@ST6]9Y8#=
MOB.N=^R=B)]'5&5' (8F??@*D/[O02*JM3'4NN.I)5P6+*;);(F#E2X('Q:X
MPUM+$-]6S%O%Z&,63CKGK$X16BP);UVP',!<),35:D9P9-/Z(;%8;EM?*OTI
M#:F84XP1T#57IC\M.=@8SA,(57V/)ZO9X-X2XOZ,*:F J^VNQ):2)F>LG@LH
M7K2?7OE08@O:7C6)<[0XH[C^YKJ>B5^22U8F!S#M7A]%75*:$?Q=(;QX0$S)
M4W!6*&E.8['KKB S$=$B2,MKHYQ/_<Y7R(PPTI-_TW0=-]N?KJ% #N"<_K5G
M_-E^^C>1N(5AYJZE7*5=3V+F ]),/\_R!T;XRV"H]\)K(4YK$0V>_G1*?6'.
M^RF9_>&[4=<?&ICXL1MX6+U@-Y[$XJ)6P_R*GU5_:=A%*3XKN$Q7>58SS;K:
MN%%31TJ0;,3DE1SJID8?LWW8DGYV'<$GKD!)@W%H?"4'<!&6Q)E^H0H_^@K'
MB6S')S/P_!:59XBQO(".EE!0*E3T.LRU^4X6LYVU$::&K4(TOL,+"0."QJ:O
M8D7'A9[>6WO&]=#(0"V[Y_*U\-S&\_<9$<<?EAB"I)YO5_J1(CG&CJG+?:DM
M)H9JY=?L4C<"AT1?Q^2WBK&C<?M(%)5\-S$Q<+ #$\1-7T?_<1Y8AAV)ZV#L
M]HP_7S4>_P)B"X/AM=A4'M.);DD>X$MQZ5K+ :Q,D-[*,^>OCY1'M%/4%N*O
MQ5-]RJ/;@K-YQ:?/1TG4)L^_GV=0?XSH)DLR8_G52ZPH'L[V1L+^;00 JKNA
M\&UJ]Z^R\K?(O\2^:8Z%1(YC+DU"D\H;*SS^A-W52J#6#T$DZ"[74<)YX]0N
M]?>;8P*C=IK2E#@;T;1ND?>?]/U+[ B_\UB>T5^%!_!%K3L5Q*% BR<%N<5[
M6^QL(=J=BS"B2"[O1;C2\':X4,'__LL"_@^_@.!_]ZO^GV#_#<=_*?MO./Y+
MV7_#\5_*_AN._U+V?P4<QOY0,/7!&CRIY-O=*TNPRT_LOA22Y<1M@S+*+8+/
M!%!,?!NT"?8J\]X:9,_JL1G4H)+#V^2UZQ=]3D[.W3B7P"BK2GWD>*]N2\"O
MQGDNUA8VNX&ZLF5?E#WUJ0 1FXHG:4BX3V5T)/SUYAOY]-]H)J[J)H[<Y#=
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MB=[MJS&BXVQ8UC=;RQ3%SY1A6V1>K0:S:F6?FMPY-5DX-1$"]9DRRO6TALH
MN_JP:Y,'R\1E]<#8E6,+HA7?OJ":)3",8;]PZWXG(71&*#AILQ7\PD;SM3X
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MJ%__"U!+ 0(4 Q0    ( -N#-UMCAO.&200  &\6   :              "
M 0    !C:6LP,# Q,S@Y-30U+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0    ( -N#
M-UN2]3@3@P0  &HE   >              "  8$$  !C:6LP,# Q,S@Y-30U
M+3(P,C0Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #;@S=;(Z%@15D1  "BY@
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M  !I;6=?,# R+FIP9U!+ 0(4 Q0    ( -N#-UN3\"5%!J<  &_K   +
M          "  :*7  !I;6=?,# S+FIP9U!+ 0(4 Q0    ( -N#-UM_<6%#
MCZ\  (WU   +              "  =$^ 0!I;6=?,# T+FIP9U!+ 0(4 Q0
M   ( -N#-UO]KU+;94L" .*_$@ 2              "  8GN 0!N;W9A8F%Y
M7V1E9C$T82YH=&U02P$"% ,4    " #;@S=;[LQZ)D?C @"S;0, #0
M        @ $>.@0 <')O>'E?,# Q+FIP9U!+ 0(4 Q0    ( -N#-UNQW)6!
M/M4! +%H @ -              "  9 =!P!P<F]X>5\P,#(N:G!G4$L%!@
0   +  L Q@(  /GR"     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>novabay_def14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CIK0001389545="http://CIK0001389545/20241231"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cik0001389545-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PEOAddEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PEOAddEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PEOAddEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NEOAddEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NEOAddEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NEOAddEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOAddEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PEOTotalEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PEOTotalEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PEOTotalEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:PEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NEOTotalEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NEOTotalEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NEOTotalEquityAwardAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CIK0001389545:NEOTotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000004">0001389545</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0010">DEF 14A</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000011">NOVABAY PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000012">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000013">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_901_eecd--AwardTmgMethodTextBlock_c20240101__20241231_zkumahoDFW6g"&gt;The Board, upon the recommendation of the Compensation Committee, determined not to grant any equity awards for the 2024 fiscal year or 2023 fiscal year to any of its NEOs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_906_eecd--AwardTmgHowMnpiCnsdrdTextBlock_c20240101__20241231_zMaUyqNiQDwb"&gt;In connection with the Investment Transaction, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90A_eecd--AwardTmgPredtrmndFlag_dbF_c20240101__20241231_zTaXnd4h7ZB4"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90A_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20240101__20241231_z6V9AxSHXQNc"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90E_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_zDo4dVZl1X6h"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; equity awards were granted to any NEOs; however, as consideration for the Release Agreements, each Resigning Non-Employee Director is entitled to certain Equity Consideration subject to stockholders approving Proposal Seven (Director Equity Consideration Proposal) at this Annual Meeting, as further described below.&lt;/span&gt;&lt;/p&gt; </ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMethodTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000014">The Board, upon the recommendation of the Compensation Committee, determined not to grant any equity awards for the 2024 fiscal year or 2023 fiscal year to any of its NEOs.</ecd:AwardTmgMethodTextBlock>
    <ecd:AwardTmgHowMnpiCnsdrdTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000015">In connection with the Investment Transaction, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90A_eecd--AwardTmgPredtrmndFlag_dbF_c20240101__20241231_zTaXnd4h7ZB4"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90A_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20240101__20241231_z6V9AxSHXQNc"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90E_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_zDo4dVZl1X6h"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; equity awards were granted to any NEOs; however, as consideration for the Release Agreements, each Resigning Non-Employee Director is entitled to certain Equity Consideration subject to stockholders approving Proposal Seven (Director Equity Consideration Proposal) at this Annual Meeting, as further described below.</ecd:AwardTmgHowMnpiCnsdrdTextBlock>
    <ecd:AwardTmgPredtrmndFlag contextRef="From2024-01-01to2024-12-31" id="Fact000016">false</ecd:AwardTmgPredtrmndFlag>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="From2024-01-01to2024-12-31" id="Fact000017">false</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:MnpiDiscTimedForCompValFlag contextRef="From2024-01-01to2024-12-31" id="Fact000018">false</ecd:MnpiDiscTimedForCompValFlag>
    <ecd:PvpTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000020">&lt;p id="xdx_80D_eecd--PvpTableTextBlock_dU_zVK71DJ6giP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&lt;i&gt;Pay-Versus-Performance Table&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In accordance with the SEC&#x2019;s rules, the below table sets forth the following information for the fiscal years ended December&#160;31, 2024, 2023 and 2022: (i) the total compensation paid to the Company&#x2019;s principal executive officer, the Chief Executive Officer (or &#x201c;&lt;b&gt;&lt;i&gt;CEO&lt;/i&gt;&lt;/b&gt;&#x201d;), and the non-CEO NEOs, as provided on the &#x201c;Summary Compensation Table&#x201d; provided in this Proxy Statement (and, as relates to the fiscal year ended December&#160;31, 2022, the &#x201c;Summary Compensation Table&#x201d; provided in the Company&#x2019;s 2024 Proxy Statement filed with the SEC on April&#160;18, 2024 (the &#x201c;&lt;b&gt;&lt;i&gt;2024 Proxy Statement&lt;/i&gt;&lt;/b&gt;&#x201d;)); (ii) the compensation &#x201c;actually paid&#x201d; to the CEO and the non-CEO NEOs, which reflects certain adjustments based on SEC rules and as described in the footnotes below; (iii) the Company&#x2019;s total stockholder return (&#x201c;&lt;b&gt;&lt;i&gt;TSR&lt;/i&gt;&lt;/b&gt;&#x201d;); and (iv) the Company&#x2019;s net loss. The &#x201c;Summary Compensation Table&#x201d; and the compensation actually paid amounts do not reflect the actual amounts of compensation earned by, or paid to, our NEOs during the applicable years, but rather are amounts determined in accordance with Item 401(v) of Regulation S-K. The Compensation Committee did not consider the pay-versus-performance disclosure when making its incentive compensation decisions for 2024. For information regarding the decisions made by the Compensation Committee with respect to compensation for 2024, please see the &#x201c;Compensation Discussion &amp;amp; Analysis&#x201d; provided elsewhere in this Proxy Statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="3" cellspacing="0" id="xdx_30D_zheUtsSgpCRk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;&lt;span style="color: #1F4E79"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Summary&lt;br/&gt; Compensation&lt;br/&gt; Table Total -&lt;br/&gt;CEO&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Compensation&lt;br/&gt; &#x201c;Actually Paid&#x201d;&lt;br/&gt; Total -&lt;br/&gt;CEO&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Summary&lt;br/&gt; Compensation&lt;br/&gt; Table Total -&lt;br/&gt;Non-CEO&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;NEO Average&lt;sup&gt;(3)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Compensation&lt;br/&gt; &#x201c;Actually Paid&#x201d;&lt;br/&gt; Total - Non-CEO&lt;br/&gt;NEOs&lt;sup&gt;(4)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;NBY TSR&lt;sup&gt;(5)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: #1F4E79 1pt solid; vertical-align: bottom; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Fiscal Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Net Loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;(in thousands)&lt;sup&gt;(6)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: Gainsboro"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; width: 28%; text-align: left"&gt;2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eecd--PeoTotalCompAmt_c20240101__20241231_zJ6vdCxufyJ4" style="padding-right: 0pt; width: 9%; text-align: right"&gt;365,177&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_zpRSHvfe2j9h" style="padding-right: 0pt; width: 9%; text-align: right"&gt;366,461&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_zMPRL4EDpmJk" style="padding-right: 0pt; width: 9%; text-align: right"&gt;220,196&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_zDT6vn4AmlOb" style="padding-right: 0pt; width: 9%; text-align: right"&gt;220,295&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eecd--TotalShareholderRtnAmt_pp2p0_c20240101__20241231_z20OrPK2GR1c" style="padding-right: 0pt; width: 9%; text-align: right"&gt;0.13&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231_z7f8Gca9NlIh" style="padding-right: 0pt; width: 9%; text-align: right"&gt;(7,223&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left"&gt;2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eecd--PeoTotalCompAmt_c20230101__20231231_zTgkfwAXnSY2" style="padding-right: 0pt; text-align: right"&gt;364,146&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_zAB2JBikIvC" style="padding-right: 0pt; text-align: right"&gt;358,857&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_zFion8p2wFR8" style="padding-right: 0pt; text-align: right"&gt;190,840&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_zm1HBvnVBCPd" style="padding-right: 0pt; text-align: right"&gt;189,734&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eecd--TotalShareholderRtnAmt_pp2p0_c20230101__20231231_zLfXdsLmYs02" style="padding-right: 0pt; text-align: right"&gt;0.84&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231_z4XtUCUnjFo8" style="padding-right: 0pt; text-align: right"&gt;(9,640&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: Gainsboro"&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; text-align: left"&gt;2022&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eecd--PeoTotalCompAmt_c20220101__20221231_zxzEfROoczb5" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;364,954&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_zdJlkvkoL43j" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;111,489&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_zUWcFU6a7df" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;259,285&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_zvlPcLzB31dj" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;108,806&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eecd--TotalShareholderRtnAmt_pp2p0_c20220101__20221231_zFewj2blZiUj" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;7.99&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--NetIncomeLoss_pn3n3_c20220101__20221231_z1MkfTqtxoIg" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;(10,608&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: justify; text-indent: 0in"&gt;Reflects compensation amounts reported in the &#x201c;Summary Compensation Table&#x201d; provided in this Proxy Statement and, as relates to the fiscal year ended December&#160;31, 2022, the 2024 Proxy Statement for our CEO, Mr.&#160;Hall.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: justify; text-indent: 0in"&gt;Compensation actually paid (as defined by SEC rules) to the CEO for each period presented reflects the amount set forth in column (1), adjusted as set forth below in the Reconciliation of Compensation Actually Paid Table.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: justify; text-indent: 0in"&gt;Mr.&#160;Law, our Interim Chief Financial Officer during such fiscal year was our only non-CEO NEO in fiscal year 2024. Mr.&#160;Law, our Interim Chief Financial Officer during such fiscal year, Dr. Kunin, our former Chief Product Officer, and Mr.&#160;Jones, our former Chief Financial Officer, were our non-CEO NEOs in fiscal year 2023. Dr. Kunin and Mr.&#160;Jones were our non-CEO NEOs in fiscal year 2022. Mr.&#160;Law was appointed our Interim Chief Financial Officer effective February&#160;16, 2023 (and subsequently our Chief Financial Officer effective August&#160;19, 2025) after Mr.&#160;Jones resigned as Chief Financial Officer effective February&#160;15, 2023. Since his resignation, Mr.&#160;Jones has continued to serve as a consultant to the Company pursuant to a consulting agreement. Dr. Kunin was appointed our Chief Product Officer effective November&#160;5, 2021 and resigned effective November&#160;5, 2023. Amounts in 2023 and 2022 for the NEOs other than the CEO are weighted-averages based on the number of days applicable NEOs served.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: justify; text-indent: 0in"&gt;Average compensation actually paid (as defined by SEC rules) to the Company&#x2019;s NEOs (except the CEO) for each period presented reflects the amount set forth in column (3), adjusted as set forth below in the Reconciliation of Compensation Actually Paid Table.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;



&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"&gt;&lt;sup&gt;(5)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: justify; text-indent: 0in"&gt;Reflects the TSR of a $100 investment in the Company from the beginning of fiscal year 2022 through each of the fiscal years ended December&#160;31, 2024, 2023 and 2022. The Company&#x2019;s TSR includes share price depreciation, but does not include dividend reinvestment as the Company did not pay any dividends in the 2024, 2023 or 2022 fiscal years.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"&gt;&lt;sup&gt;(6)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: justify; text-indent: 0in"&gt;Reflects &#x201c;Net loss&#x201d; in the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Loss included in the Company&#x2019;s Annual Reports on Form 10-K for the fiscal years ended December&#160;31, 2024, 2023 and 2022.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000021"
      unitRef="USD">365177</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000022"
      unitRef="USD">366461</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000023"
      unitRef="USD">220196</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000024"
      unitRef="USD">220295</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="2"
      id="Fact000025"
      unitRef="USD">0.13</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000026"
      unitRef="USD">-7223000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000027"
      unitRef="USD">364146</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000028"
      unitRef="USD">358857</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000029"
      unitRef="USD">190840</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000030"
      unitRef="USD">189734</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2023-01-012023-12-31"
      decimals="2"
      id="Fact000031"
      unitRef="USD">0.84</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000032"
      unitRef="USD">-9640000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000033"
      unitRef="USD">364954</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000034"
      unitRef="USD">111489</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000035"
      unitRef="USD">259285</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000036"
      unitRef="USD">108806</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2022-01-012022-12-31"
      decimals="2"
      id="Fact000037"
      unitRef="USD">7.99</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000038"
      unitRef="USD">-10608000</us-gaap:NetIncomeLoss>
    <ecd:AdjToPeoCompFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000040">&lt;p id="xdx_84F_eecd--AdjToPeoCompFnTextBlock_dU_zLX3LaMsXai7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&lt;i&gt;Reconciliation of Compensation Actually Paid Table&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The following table details the applicable adjustments that were made to determine compensation actually paid (amounts are weighted-averages for the NEOs other than the CEO in 2023 and 2022 based on the number of days served):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="3" cellspacing="0" id="xdx_30F_zwDGAMaCsm51" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Reporting Period&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Reported Summary&lt;br/&gt; Compensation&lt;br/&gt; Table Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;($) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Deduct: Reported&lt;br/&gt; value of equity&lt;br/&gt; awards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;($)(a)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Add: Equity award&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;adjustments&lt;br/&gt; ($)(b)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Deduct: Reported&lt;br/&gt; change in the&lt;br/&gt; actuarial present value&lt;br/&gt; of pension benefits&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;($)(c)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Add: Pension&lt;br/&gt; benefit adjustments&lt;br/&gt; ($)(c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Compensation&lt;br/&gt; actually paid&lt;br/&gt; ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: Gainsboro"&gt;
    &lt;td colspan="9" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"&gt;&lt;i&gt;CEO&lt;/i&gt;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 34%; text-align: left"&gt;2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eecd--PeoTotalCompAmt_c20240101__20241231_zbGJVPU2tWZ" style="padding-right: 0pt; width: 8%; text-align: right"&gt;365,177&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; width: 8%; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--PEOAddEquityAwardAdjustmentsMember_zqTAdmBGRjAf" style="padding-right: 0pt; width: 8%; text-align: right"&gt;1,284&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; width: 8%; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; width: 8%; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_zEzH0bzp5ysk" style="padding-right: 0pt; width: 8%; text-align: right"&gt;366,461&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: Gainsboro"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eecd--PeoTotalCompAmt_c20230101__20231231_zb6BD0UGmu41" style="padding-right: 0pt; text-align: right"&gt;364,146&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOAddEquityAwardAdjustmentsMember_z8YfLYHU56Ve" style="padding-right: 0pt; text-align: right"&gt;(5,289&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_zdg4jM5klEEe" style="padding-right: 0pt; text-align: right"&gt;358,857&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;2022&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eecd--PeoTotalCompAmt_c20220101__20221231_zf21MH2Ehqzc" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;364,954&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOAddEquityAwardAdjustmentsMember_zlpFhXVcWVV3" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;(253,465&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_zEnH7X0Xgnpb" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;111,489&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: Gainsboro"&gt;
    &lt;td colspan="19" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"&gt;&lt;i&gt;NEOs (except the Chief Executive Officer)&lt;/i&gt;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_z852ZOUARH0f" style="padding-right: 0pt; text-align: right"&gt;220,196&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--NEOAddEquityAwardAdjustmentsMember_zw2GPfpQ7mf9" style="padding-right: 0pt; text-align: right"&gt;99&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_zsYMwFmHDqrd" style="padding-right: 0pt; text-align: right"&gt;220,295&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: Gainsboro"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_z9D9wnn5Pywd" style="padding-right: 0pt; text-align: right"&gt;190,840&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOAddEquityAwardAdjustmentsMember_z7LtCpKsyzv4" style="padding-right: 0pt; text-align: right"&gt;(1,106&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_zyAX1Gvdve25" style="padding-right: 0pt; text-align: right"&gt;189,734&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;2022&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_zyV2SflyV4N2" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;259,285&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOAddEquityAwardAdjustmentsMember_zuYVTguDNjV3" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;(150,479&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_z3phWdgUELs9" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;108,806&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"&gt;&lt;sup&gt;(a)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: justify; text-indent: 0in"&gt;As provided in the &#x201c;Summary Compensation Table&#x201d; provided in this Proxy Statement and, as relates to the fiscal year ended December&#160;31, 2022, the 2024 Proxy Statement. No equity awards were granted to any NEO in the 2024 or 2023 fiscal years.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;





&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"&gt;&lt;sup&gt;(b)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: justify; text-indent: 0in"&gt;The equity award adjustments for each applicable period include the subtraction of the following (amounts are weighted-averages for the NEOs other than the CEO in 2023 and 2022 based on the number of days served):&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="3" cellspacing="0" id="xdx_30F_zQ1JJDczYUCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;&lt;span style="color: #1F4E79"&gt;Reporting Period&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Period-end fair&lt;br/&gt; value of equity&lt;br/&gt; awards granted&lt;br/&gt; during the period&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Changes in value&lt;br/&gt; of prior years&#x2019;&lt;br/&gt; awards unvested at&lt;br/&gt; fiscal year end&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Fair value as&lt;br/&gt; of vesting date&lt;br/&gt; of equity awards granted and vested&lt;br/&gt; in the period&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Change in value&lt;br/&gt; of prior years&#x2019;&lt;br/&gt; awards that vested&lt;br/&gt; in year reported&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Fair value at&lt;br/&gt; the end of&lt;br/&gt; the prior period&lt;br/&gt; of equity awards&lt;br/&gt; that failed to meet&lt;br/&gt; vesting conditions&lt;br/&gt; in the period&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Value of dividends&lt;br/&gt; or other earnings&lt;br/&gt; paid on stock or&lt;br/&gt; option awards not&lt;br/&gt; otherwise reflected&lt;br/&gt; in fair value or&lt;br/&gt; total compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;Total equity award adjustments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-top: rgb(31,78,121) 2pt solid; border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt"&gt;&lt;span style="color: #1F4E79"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: Gainsboro"&gt;
    &lt;td colspan="8" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;CEO&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 30%; text-align: left"&gt;2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; width: 7%; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; width: 7%; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; width: 7%; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zLAEag9WlLml" style="padding-right: 0pt; width: 7%; text-align: right"&gt;1,284&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; width: 7%; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; width: 7%; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--PEOTotalEquityAwardAdjustmentsMember_zdHkWb9fRMI8" style="padding-right: 0pt; width: 7%; text-align: right"&gt;1,284&lt;/td&gt;
    &lt;td style="padding-left: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: Gainsboro"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_zzufJCWS94Ea" style="padding-right: 0pt; text-align: right"&gt;(2,974&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zoBlt3R53zh" style="padding-right: 0pt; text-align: right"&gt;(2,315&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--PEOTotalEquityAwardAdjustmentsMember_zlyDt8wZHzF6" style="padding-right: 0pt; text-align: right"&gt;(5,289&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;2022&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_zgbLfrvl1M5" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;(236,113&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_z1tMKdp6DQPl" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;(17,352&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--PEOTotalEquityAwardAdjustmentsMember_z7aCWywn4v95" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;(253,465&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: Gainsboro"&gt;
    &lt;td colspan="18" style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.165in; font-style: italic; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;NEOs (except the Chief Executive Officer)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zEwIfdRqd8Gg" style="padding-right: 0pt; text-align: right"&gt;99&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eecd--AdjToCompAmt_c20240101__20241231__ecd--AdjToCompAxis__custom--NEOTotalEquityAwardAdjustmentsMember_z9F3sGC5wqw6" style="padding-right: 0pt; text-align: right"&gt;99&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: Gainsboro"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_z09B9dZovWOh" style="padding-right: 0pt; text-align: right"&gt;(83&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zIbf4Gs9mizg" style="padding-right: 0pt; text-align: right"&gt;(1,023&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eecd--AdjToCompAmt_c20230101__20231231__ecd--AdjToCompAxis__custom--NEOTotalEquityAwardAdjustmentsMember_zWgAdfI9kx5d" style="padding-right: 0pt; text-align: right"&gt;(1,106&lt;/td&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;2022&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember_zGEBBUQOJdvb" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;(134,736&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember_zsxtw1BaC56i" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;(15,743&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eecd--AdjToCompAmt_c20220101__20221231__ecd--AdjToCompAxis__custom--NEOTotalEquityAwardAdjustmentsMember_zWBWYRKTtyY3" style="border-bottom: rgb(31,78,121) 2pt solid; padding-right: 0pt; text-align: right"&gt;(150,479&lt;/td&gt;
    &lt;td style="border-bottom: rgb(31,78,121) 2pt solid; padding-left: 0pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 0in; text-align: right; vertical-align: top"&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"&gt;&lt;sup&gt;(c)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: justify; text-indent: 0in"&gt;In the periods presented and consistent with the &#x201c;Summary Compensation Table&#x201d; provided in this Proxy Statement and, as relates to the fiscal year ended December&#160;31, 2022, the 2024 Proxy Statement, the Company did not have: (i) a change in the actuarial present value of the accumulated benefit under any defined benefit or actuarial pension plans or (ii) any service cost or prior service cost related to any defined benefit or actuarial pension plans.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</ecd:AdjToPeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000041"
      unitRef="USD">365177</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_PEOAddEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000042"
      unitRef="USD">1284</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000043"
      unitRef="USD">366461</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000044"
      unitRef="USD">364146</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_custom_PEOAddEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000045"
      unitRef="USD">-5289</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000046"
      unitRef="USD">358857</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000047"
      unitRef="USD">364954</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_PEOAddEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000048"
      unitRef="USD">-253465</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">111489</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000050"
      unitRef="USD">220196</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_NEOAddEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000051"
      unitRef="USD">99</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">220295</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">190840</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_custom_NEOAddEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000054"
      unitRef="USD">-1106</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">189734</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">259285</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_NEOAddEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000057"
      unitRef="USD">-150479</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000058"
      unitRef="USD">108806</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember"
      decimals="0"
      id="Fact000060"
      unitRef="USD">1284</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_PEOTotalEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000061"
      unitRef="USD">1284</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember"
      decimals="0"
      id="Fact000062"
      unitRef="USD">-2974</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember"
      decimals="0"
      id="Fact000063"
      unitRef="USD">-2315</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_custom_PEOTotalEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000064"
      unitRef="USD">-5289</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember"
      decimals="0"
      id="Fact000065"
      unitRef="USD">-236113</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_PEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember"
      decimals="0"
      id="Fact000066"
      unitRef="USD">-17352</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_PEOTotalEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000067"
      unitRef="USD">-253465</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember"
      decimals="0"
      id="Fact000068"
      unitRef="USD">99</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_NEOTotalEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000069"
      unitRef="USD">99</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember"
      decimals="0"
      id="Fact000070"
      unitRef="USD">-83</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember"
      decimals="0"
      id="Fact000071"
      unitRef="USD">-1023</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_custom_NEOTotalEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000072"
      unitRef="USD">-1106</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfOutstandingAndUnvestedEquityAwardsMember"
      decimals="0"
      id="Fact000073"
      unitRef="USD">-134736</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_NEOPeriodoverperiodChangeInFairValueOfEquityAwardsGrantedInPriorPeriodsThatVestedInThePeriodMember"
      decimals="0"
      id="Fact000074"
      unitRef="USD">-15743</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_NEOTotalEquityAwardAdjustmentsMember"
      decimals="0"
      id="Fact000075"
      unitRef="USD">-150479</ecd:AdjToCompAmt>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000077">&lt;p id="xdx_844_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zO74glgJuvp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #1F4E79"&gt;&lt;b&gt;&lt;i&gt;Pay-Versus-Performance Relationship&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company believes the table above shows the alignment between compensation actually paid to the CEO and our other non-CEO NEOs and the Company&#x2019;s performance. The charts below show, for the past three years, the relationship of the CEO and the other non-CEO NEOs compensation &#x201c;actually paid&#x201d; and (i) the Company&#x2019;s TSR and (ii) the Company&#x2019;s net loss.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;img alt="" src="img_003.jpg" style="height: 300px; width: 550px"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
    <ecd:CompActuallyPaidVsNetIncomeTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000081">&lt;p id="xdx_84D_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zqmvdVCgeie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;img alt="" src="img_004.jpg" style="height: 309px; width: 550px"/&gt;&lt;/p&gt;

</ecd:CompActuallyPaidVsNetIncomeTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
